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Cellular reprogramming to pluripotency can be achieved by using a defined cocktail of 
transcription factors, converting differentiated somatic cells into induced pluripotent 
stem cells (iPSCs). These cells behave like embryonic stem cells (ES) and can be used to 
generate all cell types in the body. OCT4, SOX2, KLF4 and cMYC (OSKM) were the first set 
of reprogramming factors defined based on both their importance on maintaining 
pluripotency, and their ability to reprogram mouse and human somatic cells to iPSCs. 
Despite recent progress in refining the reprogramming technique, this process is still 
highly inefficient and often leads to partially reprogrammed cells. This is even more 
dramatic in human cells, where efficiency is low (∼0.001–1%) hindering the therapeutic 
prospects and promise of iPSCs and their clinical applications. Extensive studies have 
been focused in elucidating the molecular mechanisms by which the transcription factors 
contribute to reprogramming, but there is still a notable lack of understanding of the 
reprogramming process at the protein level. Particularly little is known about the protein 
network by which the reprogramming factors maintain pluripotency in human ES and 
drive pluripotency during the reprogramming process.  
Due to the relevance of OCT4 as a core transcription factor for both, the pluripotency 
network and the reprogramming process, the work present herein focused on studying 
OCT4 at the proteomic level. By exploiting proteomic approaches focused in on and off-
chromatin bound proteins this work described for the first time the OCT4 protein 
interactors involved in early stages of reprogramming and during pluripotency. For the 
hES interactome, OCT4 binding partners involved in pluripotency maintenance were 
identified, in addition to a new set of chromatin associated proteins that have non-
previously been described in the pluripotency context. On the other hand, during early 
reprogramming, OCT4 interactors included somatic transcription factors and other 
interacting proteins non-previously reported in the reprogramming context, such as 
proteins involved in cell death, development and differentiation. Further comparison of 
both interactomes revealed that the initial engagement of OCT4 with the somatic 
proteome is markedly different from that in ES, illustrating how OCT4 is able to change 
its chromatin-binding dynamics in order to stablish different phenotypes.  
Additionally, the analysis was expanded by applying the same on and off chromatin 
proteomic approaches to three OCT4 mutants bearing deletions of essential or non-
essential reprogramming regions located in the transactivation domains (TAD). This 
allowed the identification of a unique set of seven proteins present in all the OCT4 with 
reprogramming capacity (WT or mutant). Interestingly, these were not associated with 
OCT4 in ES nor the deficient OCT4 mutant bearing a deletion of an essential 
reprogramming domain. This set of proteins included: UFD1L, RAI1, TNIP2, ETV4, XPO6, 
FBRSL1 and MCMBP and further functional analysis proved that they are necessary for 
the reprogramming process as their depletion had negative effects in its efficiency. 
Remarkably, the biological processes these proteins can be involved are quite varied, 
including nuclear export, signalling response, post-translational modifications 
recognition, transcriptional regulation, chromatin remodelling and cell cycle; evidencing 
the versatility of OCT4 involvement in different processes necessary to achieve the 
pluripotent state. Furthermore, the mutants’ analysis not only allowed the identification 
of important proteins for reprogramming, but also revealed that removing non-essential 
reprogramming domains caused more expansive engagement of OCT4 with both the 
somatic genome and the proteome. These results suggest that different OCT4 regions of 
the TAD domains contribute to its binding properties, being the essential domains more 
important for more specific interactions with the genome and more functional 
interactions with the proteome.  
Overall, the findings of this thesis helped to get a better understanding of the protein 
interactions of OCT4 by describing for the first time the OCT4 networks during 
reprogramming and pluripotency in human, while revealing that focusing in the 
properties of the transactivation domains can help understand new biochemical 
properties of OCT4.  
Finally, applying the same proteomic approach analysis to the remaining reprogramming 
factors, can further help to understand their molecular mechanisms, expand the 
reprogramming and pluripotency networks, characterize crucial interactors and, thus 
provide a better understanding of the proteomic molecular mechanisms. This with the 
ultimate goal of improving the efficiency and fidelity of human iPSCs reprogramming.
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Lay Summary 
All the parts of our bodies start the same: from a set of special cells. These cells are 
called embryonic stem cells and they have the potential to become any cell type. 
Once the cells reach their final fate they are said to be differentiated and lose their 
potential to become any other cell type. Naturally, in our bodies, these differentiated 
cells cannot go back to their origins or transform themselves into different cells from 
another part of the body. However, in research laboratories the story is different, as 
these cells can be forced to overcome these biological barriers and go back to their 
origins or change their cell type completely. One of the most interesting conversion 
process is the one where differentiated cells can go all the way back to be embryonic 
stem cells again and then become any cell type from there. This process is called 
reprogramming and it gives origin to cells called induced pluripotent stem cells (iPSC). 
Even though this mechanism was described more than a decade ago, it is still 
extremely inefficient, limiting the potential of using iPS in regenerative medicine 
approaches.  
To try to get a better understanding of the process, this work focused in studying 
interactions happening inside the cells during their way back to stem cells. To achieve 
this, the original protocol to create iPSCs was used, which involves forcing the cells to 
express four specific proteins: OCT4, SOX2, KLF4 and cMYC. These four proteins have 
been described to drive the reprogramming process and stem cells maintenance, but 
they do not act alone as it has been described that their interactions with other cell 
components, like DNA and other proteins, are fundamental for their function. 
Focusing on the protein OCT4, this work aimed to define the proteins that through 
their interaction with OCT4 are important for the reprogramming process with the 
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Chapter 1 INTRODUCTION 
 
1.1 Pluripotency: From development to cell culture 
The development of a multicellular organism from a single cell is a remarkable process, 
owing to the unique cellular plasticity of embryonic cells [1]. This plasticity known as 
pluripotency emerges from a specific group of cells in the inner cell-mass of the 
preimplantation embryo, which then differentiate post-implantation to the three 
embryonic germ layers: mesoderm, ectoderm and endoderm [2]. The pluripotent state 
is therefore at the root of embryonic development that give rise to all the somatic 
lineages as well as the germline [3]. Pluripotency is a transient feature during 
development, which can only be captured in vitro by deriving pluripotent stem cells from 
few early embryonic developmental stages. Interestingly, stem cells derived from this 
limited time window can all be maintained and propagated indefinitely in vitro while 
maintaining the potential to differentiate to all three embryonic germ layers [2, 4]. The 
dual capacity of stem cells to self-renew and maintain pluripotency (ability to 
differentiate) define the hallmarks of pluripotent stem cells cultured in vitro, providing a 
powerful tool for understanding the molecular mechanisms early embryonic 
development. Furthermore, the pluripotency of stem cells can be exploited for disease 
modelling, drug discovery, animal engineering and regenerative medicine. 
 
1.2 Derivation of pluripotent stem cells 
Pluripotent stem cells can be isolated from multiple sources, including pre- and post-
implantation embryos, malignant tumours and germ cells and classified accordingly as 
embryonic stem cells (ESCs), post implantation epiblast stem cells (EpiSCs), embryonal 
carcinoma cells (EC) and embryonic germ (EG) cells, respectively [5-10] (Fig 1.1). All these 
stem cells acquire pluripotent properties as displayed by ESCs once cultured in vitro, 
while featuring differential developmental potentials when assessed by a range 
functional assays for pluripotency, which include in vitro differentiation, teratoma 
formation, chimaera formation, germline transmission, tetraploid complementation and 
single-cell chimaera formation [1].  The lowest hurdle for establishing pluripotency 
consists on the in vitro differentiation to derivates of all three embryonic germ layers 
where culture conditions that maintain pluripotency are replaced by media specific to 
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the target tissue, being this approach limited by the availability and efficiency of the 
differentiation protocols [11, 12]. In vivo assays are taken as more robust indicators of 
potency. The teratoma formation is the standard in vivo approach, with assays the 
spontaneous generation of differentiated tissues from the three germ layers after the 
injection of the cells to asses in immunocompromised mice. Disadvantage of this assay is 
that the histological analysis is not capable of asses every single cell type, as well as 
possible misinterpretation of masses originated by co-injection of matrices or scaffolds, 
necessitating the use of lineage tracing or markers to distinguish donor cells against host 
tissue [13]. Blastocyst chimaera formation consists of another in vivo assay, measuring 
the capacity of pluripotent cells to re-enter development into host embryos in two 
possible pre-implantation stages: aggregation with morulae or injection into blastocyst, 
supporting normal development and contribution in all embryonic tissues and germ line. 
The quality and origin of the stem cell to asses defines the level of chimaeras and embryo 
viability [14]. Once the chimaera formation is assessed, another robust indicator of the 
capacity of functional pluripotency is the capacity of test cells to generate functional 
gametes, defined by the integration of donor cells into the germline transmission, 
indicating robust chromosomal integrity and functional pluripotency [15]. Tetraploid 
complementation is used to measure the capacity of the cells to drive the development 
of an entire organism. Cells to be tested are introduced intro tetraploid host blastocyst, 
which cannot sustain normal embryonic development, therefore the embryos are derive 
entirely from the tested stem cell [16]. The most stringent assay involves the injection of 
single-donor cells into a morula or blastocyst for the generation of chimaeras with 
widespread contribution from a single cell. As genuine pluripotency is a property of single 
cells, these chimaeras provide clonal analysis [17]. Despite single cell and tetraploid 
complementation suffer higher failure rates, depending on the origin and quality of the 
cell to be tested; they are interpreted as the most definite ways of demonstrating 
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Fig. 1.1 Diversity of pluripotent stem cells. Human and Mouse Embryonic stem cells (ESC) 
are derived from the Inner Cell Mass (ICM) of the Pre-implantation Blastocyst. Mouse 
Epiblast stem cells (EpiSCs) are derived from the epiblast of Post-Implantation Embryos. 
Mouse Embryonic Germ Cells (EGSC) are derived from Primordial Germ Cells from post-
implantation Embryos. Mouse Spermatogonial germ stem cells are derived from 
spermatogonial progenitors from post-natal or adult mice. The diagram was adapted from 
[4]. 
 
1.2.1 Embryonal Carcinoma Cells 
The first characterization of the pluripotency capacity of a cell was defined when 
investigating mouse testicular teratocarcinomas, a form of malignant germ cell tumour. 
In 1954, Stevens and Little observed that these type of tumours contained a mixture of 
differentiated cells from all of the three germ layers [18]. When single cells from these 
tumours were transplanted to a secondary mouse donor, they were able to induce the 
formation of tumours containing cells from all three germ layers [19]. This particular 
observation lead to hypothesise that the tumours contained undifferentiated 
components that were able to give rise to the complex cell mixture of the tumours. 
Because of their pluripotency potential and the resemblance of the tumours to the 
embryonic tissue, these cells were called embryonal carcinoma cells (EC) [20]. Further 
experiments allowed the successful isolation of EC and their propagation in vitro. 
Moreover, the cultured EC cells were able to maintain their ability of multilineage 
differentiation and develop teratocarcinomas when injected in immune compromised 
mice. More interestingly, when injected in pre-implantation embryos (blastocyst) certain 
EC cell lines were able to form chimeras when injected into blastocyst [21, 22]. This 
evidence indicated that of the pluripotency of EC cells is functionally distinct from its 
malignant transformation as these cells could lose their malignancy and become benign 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 1  4 
without losing pluripotency by contributing to the generation of chimeric animals [23, 
24]. Altogether, these observations served as the first platform to define pluripotency in 
vitro, setting the ground for the subsequent isolation of pluripotent stem cells from the 
mouse embryos. 
 
1.2.2 Mouse embryonic stem cells 
The cutting-edge definition and characterization of EC was soon followed by the isolation 
of pluripotent stem cells directly from mouse embryos. In 1981 two papers  reported the 
first isolation of mouse ES cells. Evans and Kaufman, as well as Gail Martin,  were able to 
sustain the inner cell mass (ICM) of mouse blastocysts on a petri dish, recapitulating early 
development in vitro and giving origin to the term mouse embryonic stem (mESC) cells 
(Fig. 1.1) [7, 10]. Since these discoveries, mESC cells have been widely derived directly 
from the inner cell mass (ICM) of preimplantation blastocysts while maintaining the 
hallmarks of pluripotent cells of unlimited self-renewal and the capacity to differentiate 
and give rise to all cells from the three germ layers in vivo and in vitro [25]. Contrarily to 
the malignant teratocarcinomas generated by EC, mESC form benign teratomas when 
injected into immune-compromised syngeneic mice, and are competent at contributing 
to the three germ layers [26]. Furthermore, mESCs can recapitulate full developmental 
potential when injected into mouse blastocyst contributing to the formation of high 
percentage chimeras, a property not frequently seen with certain EC cells. In these 
chimeras, mESC were also able to contribute to the germline, as it was observed that 
progeny of chimeric mice crossed with phenotypically distinct wildtype mice were 
bearing coat pigmentation characteristic of the isolated mESC [27]. More importantly, 
mESC were able to form a whole embryo when tested in tetraploid complementation 
assays [14, 16]. Originally, mESC cells were cultured on a feeder layer of mitotically 
arrested embryonic fibroblasts in a medium containing carefully selected foetal calf 
serum (FCS). Supplementing this medium with the cytokine leukaemia inhibitory factor 
(LIF) can maintain the self-renewing state of mESC without a feeder layer by activating 
Stat3 pathways and the transcription of pluripotency factors [28] [29] (Fig. 1.2). 
Furthermore, the addition of bone morphogenetic protein (BMP4) proved substitute for 
FCS and support mESC in combination with LIF via the activation of Smad proteins, 
resulting in the expression of inhibitors of differentiation [30]. However, under these 
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culture conditions mESC are morphologically heterogeneous and show fluctuating 
expression of key pluripotency transcription factors (TF) such as Nanog, which can be 
solved by inhibiting the mitogen activated protein kinase (Erk) and glycogen synthase 
kinase 3 (GSK3) (2i), respectively [31]. Under these conditions the inhibition of the FGF4-
mediated differentiation pathway perpetuate the pluripotent state and mESC appear 
morphologically and molecularly homogeneous allowing the robust propagation of mESC 
cultures with concomitant maintenance of pluripotency [32] (Fig. 1.2). Since these 
pioneering studies, the 2i+LIF culture system has been stablished to supports more 
efficient derivation and clonal expansion of mESCs from diverse mouse strains [33, 34] 
allowing the better characterization of the molecular basis of pluripotency (Figure 1.2). 
Moreover, the study and characterization of mESC helped to establish the standards to 
define pluripotent stem cell lines, which include normal karyotype maintenance, 
immortality and indefinite propagation (self-renewal), and pluripotent capacity 
(pluripotency assays mentioned in section 1.2) [35]. 
 
1.2.3 Human Embryonic Stem Cells 
The ability to isolate and culture embryonic stem cells from the ICM was also achieved in 
humans by Thomson and co-workers, which was first reported in 1998. In this report, the 
human pluripotent cells were isolated from ICM of donated ex-utero embryos originally 
produced for in vitro fertilization (IVF) and cultured in feeder cells (Fig. 1.1)[36]. The 
characteristics of these derived hES cells were consistent with the previously identified 
features in mESC cells: they were capable of long-term self-renewal and indefinite 
expansion while maintaining a normal and stable karyotype. Additionally, they were able 
to form benign tumours in immunodefficient mice, reminiscent of the spontaneous 
human teratomas, which contained endodermal, mesodermal and ectodermal cell 
derivatives, representing the three germ layers [37, 38]. Due to ethical constraints 
regarding the generation of chimeric embryos, teratoma assays remain the gold 
standards of measuring pluripotency of hES in vivo. However, in vitro differentiation to 
all lineages have confirmed the pluripotency of hES, providing an essential tool to 
understand the human development and human diseases and their main differences 
with mouse [39]. For instance, the maintenance of self-renewal and pluripotency in hES 
involves different signalling pathways from those in mESC, as LIF is dispensable for hES 
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and the presence of BMP4 in culture medium induces hES differentiation [40-42]. Factors 
playing a role in maintaining hES self-renewal include Activin A /Nodal, FGF2. Activin A 
and Nodal are members of the transforming growth factor (TGF-𝛽) superfamily 
promoting NANOG and other pluripotency genes transcription via SMAD2/3 signalling. 
FGF2 signalling also helps sustain NANOG and pluripotency-associated genes expression 
via the pathways involved in self-renewal and pluripotency such as PI3K/Akt, MAPK/ERK, 
and Wnt, as well as sustaining expression of pluripotency-associated genes [43-45]. 
While the derivation of many hES have in principle followed the original methods and 
conditions previously described, great advances have been made towards improving the 
culture conditions for research-grade hES, such as stablishing feeder-free conditions with 
the substitution of cell feeders with coating agents (i.e. laminin), allowing the 
establishment of clinical-grade hES and stem cell banks (Figure 1.2) [46].  
 
1.2.4 Epiblast stem cells 
In 2007, two papers reported the isolation of stable cell lines from the post‐implantation 
epiblast. Brons et al. and Tesar et al. derived stem cells from a single layer of epithelial 
cells, which originates from the ICM after implantation in mouse (Fig. 1.1) [5, 9]. These 
epiblast stem cells (EpiSCs) provided a robust and developmentally‐relevant system to 
study the detailed molecular and cellular mechanisms that function to transition 
pluripotent cells to their differentiated derivatives [5, 9, 47]. EpiSCs are considered as 
pluripotent following the criteria of self-renewal and the capacity of multilineage 
differentiation. Yet, these cells display a limited developmental potential when 
compared to mESC, as the efficiency by which EpiSCs contribute to chimeras is extremely 
low and they do not contribute to the germ-line [5, 9, 48]. The limited pluripotency of 
EpiSCs therefore reflects the advanced developmental stage of the post-implantation 
epiblast from which these cells originated, in contrast to the more primitive 
developmental stage of the pre-implantation blastocysts where mESCs were derived 
from [9, 49, 50]. Additionally mEpiSCs rely on different culture conditions as they are 
unresponsive to LIF and rely on similar growth factors necessary for hES culture, such as 
FGF and TGFB/Activin  (Fig. 1.2) [9]. 
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1.2.5 Germ Cell lines 
Another type of pluripotent stem cells are derived from the germline lineage known as 
primordial germ cells, which are localized in a specific part of the early post-implantation 
embryo that will eventually migrate to gonads and give rise to the germ cells [25]. When 
cultured in vitro, these cells acquire ES-like features and termed embryonic germ cells 
(EG) (Fig. 1.1) [51, 52]. Pluripotency of EG cells has been confirmed by their capability to 
generate teratomas and contribute to chimeras [53, 54]. Spermatogonial stem cells from 
new-born and adult male gonads also generate ES-like cells, although at very low 
efficiency (Fig. 1.1) [55]. Adult germline stem cells have also been derived from human 
foetuses, but their characteristics are not as well defined [56].  
 
1.3 States of Pluripotency: Naïve and Primed Pluripotent Stem Cells 
The isolation and characterization of mouse pluripotent cells have allowed the 
identification of two distinct pluripotent states, depending on the developmental stage 
of their isolation and their growth control conditions: the ground or naïve state, 
exemplified by the mESCs and the primed pluripotent state represented by mEpiSCs (Fig. 
1.2) [57]. The naïve state reflects the unbiased developmental potential of pre-
implantation; however, as post-implantation proceeds stimuli trigger the conversion of 
the naïve cells into a more primed phase that is determined to initiate the lineage-specific 
programs, where cells start to acquire epigenetic restrictions [58]. Main differences 
between the naïve and primed states include differences in colony morphologies, better 
survival rates of naïve cells when passaged as single cells accompanied by shorter 
doubling time, and different metabolisms for respiration and generating energy [57]. 
Moreover, the key molecular differences between both cells include differences in their 
gene expression pattern and epigenetic states, which are more related to the ICM form 
naïve and early germ layers form primed cells [9]. For instance, in naïve mESC, both X 
chromosomes are active while primed have already underwent the X chromosome 
inactivation. Additional epigenetic differences include global DNA hypomethylation 
(Naïve pluripotency is associated with global DNA hypomethylation) and reduced 
prevalence of the repressive histone mark H3K27me3 at promoters [59]. 
Transcriptionally, EpiSCs demonstrate heterogeneous expression of early lineage-
commitment markers such as homeobox protein OTX2, Brachyury and zinc-finger protein 
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ZIC2, indicating early exit from pluripotency [9]. Differences in culture conditions play an 
important role in maintaining these two distinct pluripotent states. In mouse, naïve 
conditions can be maintained in two conditions: a more naïve “ground” state in 2i+LIF 
and a less naïve state in LIF/FCS conditions. In contrast, mEpiSCs, which represent primed 
pluripotency, are more heterogeneous and display very low clonogenicity [60, 61]. These 
cells are also unresponsive to LIF and rely on different growth factors, fibroblast growth 
factor (FGF) and the transforming growth factor beta signalling pathway TGFb/activing 
(Figure 1.2) [44, 62]. 
 
Fig. 1.2 States of pluripotency: Naïve and Primed pluripotent stem cells. Schematic 
representation of culture conditions (rectangles) used to obtain primed and naïve pluripotent 
stem cells in mouse and human. In mouse, ESCs and EpiSCs are characterized by a different 
pluripotent state, called naïve and primed, respectively, which reflects their embryonic 
origin. The stability and homogeneity of mESCs cultured in 2i+LIF represent a developmental 
ground state closely reflective that of the ICM of preimplantation blastocysts, in contrast with 
the heterogeneity of mESCs cultured in LIF +FBS conditions, representing a less naïve state. 
In human, hES derived from ICM resemble the primed pluripotent state of mEpiSCs derived 
from the epiblast. Both cell types are dependent on FGF2/Activin/Nodal signalling and grown 
in similar conditions. hES with mESC-like characteristics can be produced by defined 
conditions and culture media (rectangles) allowing derivation of naïve hES from either 
already established primed hES or directly from blastocysts. Image adapted from [4, 63] 
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Transcriptional and epigenetic characterization of human ESCs have established that 
they are more related to primed mEpiSCs than to naïve mESC [64]. Although pluripotent, 
when first isolated, hES were clearly different from mESC cells in their characteristics and 
culture conditions. Human ESCs were derived from blastocyst using the culture 
conditions more similar to mEpiSCs, requiring the addition of TGFB/Activin and FGF2, 
while being insensitive to LIF to culture conditions stablished for naïve mESC (Figure 1.2) 
[44, 64]. Additionally, hES share many other primed pluripotency properties including 
low levels of naïve pluripotency markers like KLF17, DPPA3, and lack of restriction 
H3K27me3 modification over developmental genes, lack of global hypomethylation, and 
lack of a pre-X inactivation state in most conventional female lines [65, 66]. Regardless 
of the similarities mentioned above, hES are not identical to mEpiSCs and are considered 
less primed. For instance, hES do not upregulate the expression of the mEpiSCs marker 
FGF5 or N-cadherin and has higher expression of some naïve pluripotency markers such 
as NANOG, REX1 and PRDMD14, which are crucial to maintain conventional hES, as 
NANOG and PRMD14 depletion induces differentiation [65, 67]. Multiple efforts have 
been trying to address the derivation of human and other species pluripotent stem cells 
that resemble naïve mESC with promising successful outputs, suggesting that the naïve-
like pluripotent state might be an early developmental stage that is conserved across 
mammals (Figure 1.2) [57].  
 
1.4 Molecular and transcriptional hallmarks of pluripotency 
Regardless of species or pluripotency state, embryonic stem cells are characterized by 
the expression of an extended pluripotency gene network that sustain self-renewal and 
suppress differentiation [1]. This is largely governed by the core pluripotency network of 
set of transcription factors, OCT4, SOX2 and NANOG, collectively known as OSN [68-70]. 
 
During mouse development, OCT4 expression is required to maintain the pluripotent cell 
population of the ICM and epiblast [71]. Carefully balanced OCT4 levels are required for 
the maintenance of the pluripotent state in vitro. Inactivation of OCT4 in mESCs causes 
rapid loss of self-renewal and induction of trophoblast (TE) differentiation, whereas OCT4 
overexpression triggers differentiation into endoderm (EN) and mesoderm (ME) [72, 73]. 
In hES, low levels of OCT4 can induce ectoderm or extraembryonic differentiation, while 
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high levels can promote self-renewal or specify mesendoderm lineages [74]. NANOG is 
also an important factor in early mouse development. Although required at a later point 
than OCT4, NANOG is restricted to the ICM and epiblast of the early embryo controlling 
the epiblast versus primitive endoderm (pEN) decision in the blastocyst [75]. Different 
levels of Nanog in vitro also revealed its important role in mESC self-renewal, as Nanog 
depletion causes these cells to differentiate into a broader repertoire of cell lineages, 
primarily TE and pEN lineage [72]. Moreover, NANOG overexpression enables mESC to 
self-renew independently of LIF [76]. In hES, NANOG is involved in repressing embryonic 
ectoderm differentiation, but has no effect in other lineages. Lastly, SOX2 is expressed in 
the pluripotent lineage of the mouse embryo and is required for epiblast maintenance 
[77]. Sox2-depleted mESCs differentiate primarily into TE in vitro. Whereas, SOX2 is 
involved in repressing mesendoderm differentiation in hES [72, 74]. 
 
OSN are members of different structural families of transcription factors. OCT4 is 
member of POU family, NANOG is a member of the homeobox family and SOX2 is 
member of the SRY-related HMG-box (SOX) family. Because of their ability to bind 
specific DNA sequences, OSN are known to target genes that maintain pluripotency. 
Studies focused in mESCs a hES have reported the genome-wide binding patterns of OSN, 
showing that OSN occupy the promoters and enhancers of pluripotency genes including 
their own genes [68, 78]. Moreover, these reports showed that OSN co-occupy and 
regulate two type of genes to co-ordinately regulate their transcription. The first set of 
genes encode important genes that promote self-renewal and include transcription 
factors (e.g. STAT3, ZIC3), signal transduction components (e.g. TGDF1, LEFTY) and 
chromatin modifying enzymes (e.g. SMARCAD1, MYST3), among others. The second set 
of genes targeted by OSN are silent in ES cells but remains poised for subsequent 
expression during cellular differentiation [68, 78, 79]. These genes include a set of 
transcription factors which expression results in lineage commitment and differentiation 
(e.g. NEUROG1, PAX6, and OTX1). The coordinated and efficient repression of these 
genes is essential to help maintain the undifferentiated state of the pluripotent cells [68, 
78]. Characterizing the chromatin state of the promoters of these poised genes revealed 
a bivalent enrichment for histone post-translational modifications consisting of both the 
repressive histone H3K27me3 and the activating histone H3K4me3. Interestingly, most 
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of these bivalent domains were also co-occupied by the epigenetic repressor proteins 
Polycomb group (PcG) proteins and by the RNA polymerase II (POLII), explaining how 
these genes encoding developmental regulators existed in a poised state, meaning 
repressed in pluripotency, but ready to be expressed upon differentiation [78, 80, 81]. 
Moreover, given that the proteins rarely act alone, one approach towards the 
understanding of this molecular mechanism is to look at its protein interaction level. 
From integrated mouse dataset based in the OSN protein interactomes, Sall4, Tcfcp2l1, 
Dax1, Esrrb, Rex1, Nac1 and Zfp281 were identified as part of the pluripotency network. 
Furthermore, interactomes using these proteins as baits have been analysed to gain a 
more complete view of the pluripotency protein interaction network [82]. Integration of 
these proteomics datasets gave a network comprising 239 proteins, being transcription 
factors one of the overrepresented groups [83]. The nucleosome remodelling histone 
deacetylase (NuRD) complex was among the most prominent complex identified in the 
embryonic stem cell protein-interaction network suggesting that the transcription 
factors co-recruit the same machinery, NuRD for histone deacetylation as a gene 
repression mechanism to regulate pluripotency. Besides NuRD, other complexes 
involved in chromosome remodelling and part of the basic transcriptional machinery 
have been reported [84-87]. Overall, as data accumulation continues towards a more 
complete embryonic stem cell protein interaction network (discussed in section 1.6.3), 
the physical protein-protein interaction (PPI) networks of pluripotency factors including 
OSN and other proteins have provided valuable information of a well-coordinated and 
multi component process, linking transcription to chromatin and signal-transduction 
pathways that are required to maintain pluripotency.  
 
1.5 Reprogramming somatic cells towards pluripotency 
The isolation of pluripotent cells and the definition of the underlying gene regulatory 
networks that govern pluripotency and differentiation processes have contributed to the 
derivation of differentiated cell types from pluripotent stem cells. However, the source 
of pluripotency is restricted to the early embryo, as differentiation is regarded as an 
irreversible process during development by which cells gradually lose potency. The 
evidence that differentiated cells can be forcibly reverted back pluripotency was first 
reported by Professor John Gurdon, who established that by injecting the nuclei of 
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epithelial cells into enucleated Xenopus laevis eggs resulted in the generation of normal 
tadpoles, which nuclei could be transplanted again into enucleated eggs and develop into 
fertile adults (Fig. 1.3) [88, 89]. This approach known as somatic cell nuclear transfer 
(SCNT) was successfully applied in mammals including primates [90-92]. Therefore, 
somatic cells retain the genetic information necessary to become any other cell type, and 
that the epigenetic effects of differentiation could be reverted by the presence of 
adequate factors. Since then, several studies have achieved the conversion of somatic 
cells to a pluripotent state, such as cell fusion of somatic cells with embryonic stem cells 
[93, 94]. However, the main limit of these techniques is that they require oocytes and ES 
cells as the principal driver of cell fate changes (Fig. 1.3). Still, these techniques lead to 
the hypothesis that there were factors present in pluripotent stem cells and oocytes that 
can drive cell fate conversion [95].   
 
Taking advantage of the resources available in the literature of the genes involved in the 
self-renewal and maintenance established thanks to ES cells, Shinya Yamanaka and 
Kazutoshi Takahashi tested the hypothesis that these genes could be responsible for 
reverting somatic cells into pluripotency. By taking 24 of these genes and overexpressing 
them in mouse embryonic fibroblasts (MEF) in ES cell culture conditions they were able 
to generate what it is known as induced pluripotent stem cell (iPSCs) [96]. From these 24 
genes, they could narrow the list to just 4 factors: OCT4 (O), SOX2 (S), KLF4 (K) and c-MYC 
(M). These four factors included two of the main factors of the pluripotency core network 
(OS) and were defined as the minimum required factors to induced pluripotency from 
fibroblasts. In the same report, they probed the ability of these factors, also known as 
OSKM or Yamanaka factors, to induce pluripotency from adult tail-tip mouse fibroblasts 
(Fig. 1.3) [96]. Characterization of the first resultant iPSCs showed that they could be 
propagated using the same culture conditions of mESC, that they were able to reactivate 
ES cell associated genes an therefore had similar transcription profiles to mESC, 
presented demethylation profiles in certain pluripotency promoters, contributed to the 
three germ layers in teratoma formation assays but were not able to produce full adult 
chimeras after injected in blastocyst in spite contributing to the three germ layers in the 
chimeric embryos [96]. 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 1  13 
 
Fig. 1.3 Nuclear reprogramming methods. Approaches for restoring developmental 
potential to somatic cells. a. Nuclear transfer involves the transplantation of the nucleus of a 
somatic cell (diploid 2n) into an enucleated oocyte replacing its genetic material (haploid 1n). 
In the oocyte environment, the somatic cell nucleus is reprogrammed so cells derived from 
it become pluripotent allowing the development to the blastocyst stage from which 
embryonic stem cells can be derived for tissue culture. b. Cell fusion requires the 
hybridization between ES cells and somatic cells to form a single entity, yielding 
multinucleated heterokaryons (tetraploid 4n) ES cell lines. By altering the nuclear ratio in the 
fusion, and hence the stoichiometry of the regulators provided by each type of cell, the 
heterokaryon is reprogrammed towards the desired cell type, influenced by the culture 
conditions as well. c. Direct reprogramming requires the introduction and expression of 
defined transcription factors directly to the somatic cell, without requiring ESs or oocytes as 
starting material. This approach leads to the formation of induced pluripotent stem cell 
(iPSCs), which have similar properties to ES. OSKM or Yamanaka factors represent the original 
reprogramming factors. Image adapted from [97]. 
 
Further works, however, successfully produced fully reprogrammed iPSCs that could 
contribute to mouse chimeras and to the germline, demonstrating the pluripotent 
identity of iPSCs [98, 99]. Since the iPSCs initial discovery, reprogramming to iPSCs has 
been achieved using different somatic cells of origin. For instance shortly after the mouse 
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study, the OSKM factors were able to reprogram human adult fibroblasts into hiPSCs and 
maintained in human ES growing conditions, suggesting that the fundamental 
transcriptional network defining mouse and human pluripotency involves similar 
mechanisms while influenced by different signals and growing condition factors [100, 
101]. These hiPSCs could be maintained in human ES growing conditions, displaying hES 
morphology, and had the ability to differentiate into the three germ layers in teratoma 
assays and embryoid body formation [100, 101]. 
 
Following the breakthrough discovery of iPSCs, induction of pluripotency from somatic 
cells by transcription factors has been a main field of study, revealing the complexity of 
this long and highly inefficient process, particularly in the human context. [102]. 
 
1.5.1 Epigenetic mechanisms of cellular reprogramming to induced pluripotency 
The reprogramming of somatic cells into iPSCs is a long and complex process that involves 
the re-activation of the repressed pluripotency gene and the silencing of somatic genes 
[103]. Thus, the induction of pluripotency could be regarded as a mechanism where the 
pluripotency network gradually overcomes the epigenetic landscape that guards the 
somatic cell identity (Fig. 1.4) [104].  
 
1.5.1.1 Chromatin structure in cellular reprogramming 
Pluripotent stems cells have a unique epigenetic landscape that differentiates them from 
differentiated somatic cells (Fig. 1.4). In pluripotency, the chromatin is in more open or 
permissive state, enriched with the active histone marker H3K4me3 and hypomethylated 
DNA around the promoters of the pluripotency genes. On the other hand, during 
differentiation and lineage commitment the pluripotency genes are silenced and 
repressed with H3K27me3 and H3K9me3, while DNA gets methylated, resulting in a 
closed heterochromatin conformation. In addition, the genes responsible for the cell 
identity of the somatic cell remain active. Therefore, to be able to achieve the 
pluripotency-like epigenome, chromatin remodelling, histone-post translational 
modifications resetting, DNA demethylation and reactivation of the silenced X 
chromosome must be successful [95, 99, 100, 105, 106].  
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Fig. 1.4 Epigenetic changes of induced pluripotency.  Turning on pluripotency genes and 
turning off genes responsible for the maintenance of a differentiated somatic cell state. a. 
Epigenetic changes discussed in this thesis during reprogramming in regulatory regions of 
pluripotency genes (top) and in regulatory regions of somatic genes (bottom). For 
pluripotency genes, reprogramming leads to acquisition of active histone marks (e.g., 
H3K9ac, H3K4me) and loss of repressive histone marks (H3K9me and H3K27me) and DNA 
methylation on pluripotency genes, which facilitates the opening up of a compact chromatin 
structure and thereby allowing exposure of pluripotency gene promoters and binding of 
pluripotency factors. In somatic genes, reprogramming leads to removal of active chromatin 
states in active genes (H3K79me) and the gain of repressive chromatin states (H3K27me). b. 
Common Mammalian core histone modifications of histones H2A, H2B, H3 and H4. Post-
translational covalent modifications include acetylation (Ac), methylation (me), 
phosphorylation (P) and ubiquitination (Ub). Effects of the modifications in gene regulation 
are shown as active (green triangle) or repressive (red triangle). Amino acids and positions 
where the modifications have been reported are  indicated.  
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Changes in chromatin structure, nucleosome composition and histone post-translational 
modification patterns are involved in the reshaping of the somatic epigenetic landscape 
during reprogramming [107]. Therefore the initial repressive state of chromatin 
represents another mechanistic barrier in reprogramming as pluripotency related genes 
present repressive histone markers such as H3K27 and H3K9 methylation while lacking 
the active H34Kme3 [108]. One of the key epigenetic blockades to reprogramming 
associated with histone modifications is the presence of the H3K9 trimethylation, which 
silence gene expression by promoting the formation of long-range heterochromatin 
[109].  
 
Genome wide binding profiles of OSKM factors at early stages of human reprogramming 
revealed that mega base regions enriched with H3K9me3 are inaccessible to the 
reprogramming factors at early reprogramming, contrary to ES and iPSCs, therefore 
named differentially bound regions (OSKM-DBR) [110]. The transient knock down of 
H3K9 methyltransferases SUV39H1/2 enhanced OCT4 and SOX2 binding at the OSKM-
DBR regions and increased reprogramming efficiency. [110]. Furthermore, a proteomic 
approach focused on global quantification of the different histones modifications at 
different reprogramming stages revealed that pre-iPSCs and MEFs were more enriched 
for repressive H3K9 methylation marks than iPSCs and corroborated that the H3K9 
methyl transferases increases reprogramming and promotes decondensation of 
chromatin [111]. Agreeing with these observations, knock down of H3K9 demethylases 
such as KDM3A/B, KDM4A/B inhibit reprogramming, whereas overexpression of KDM4B 
promotes the conversion of pre-iPSCs to iPSCs [109, 112].  
 
Genome-wide characterization of epigenetic changes that take place within the first cell 
cycles after the induction of OSKM in MEFs revealed that the ectopic factors initiate a 
gradual change of chromatin opening by first depositing the H3K4me2 mark, the 
precursor of the active H3K4me3 mark, at important pluripotency targets, prior to gene 
activation (Fig. 1.4) [113]. Furthermore, major H3K4me3 changes were identified in 
intermediate reprogramming stages of MEFs, which is followed by a second wave of 
changes closer to the pluripotent chromatin state and resulting in gene reactivation 
[114]. These studies also revealed the initial loss of the repressive H3K27me3 mark in 
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specific loci [113, 114]. The gradual gain of H3K27me3 together with H3K4me3 has also 
been reported during the reprogramming process resembling the pluripotency bivalent 
domains observed in pluripotency maintenance (Fig. 1.4) [114].  
 
Other histone modifications such as H3K36me2/3 and H3K79 methylation have also been 
associated to facilitate reprogramming. Lang et al. described that the overexpression of 
the H3K36me2/3 demethylase KDMB2 enhances reprogramming by binding to promoter 
of early activated genes including epithelial and pluripotency genes [115], while Onder 
et al. described that the inhibition of the H3K79 methyltransferase facilitates the loss of 
this histone mark from somatic genes increasing the reprogramming potential (Fig. 1.4) 
[116].  
 
The evidence that histone modifications and DNA methylation act as barriers and 
facilitators of reprogramming has allowed the identification of important chromatin-
modifying enzymes and how their modulation influences the reprogramming process. 
For instance, as widely discussed, reprogramming requires the acquirement of ES 
permissive euchromatin, which allowed to relate the importance of chromatin 
remodelers required for ES maintenance with the reprogramming process. For example 
esBAF (Brm/Brg-associated factor in ES cells) and Ino80 (inositol requiring 80), which are 
members of the SWI/SNF family of chromatin remodelling factors and are required for 
the maintenance of ES, also have important roles in reprogramming. In ES esBAF and 
Ino80 complexes co-localize with the pluripotency factors generating an open chromatin 
structure and their overexpression along with the reprogramming factors facilitate the 
binding of the transcription factors to their targets [117, 118]. Additionally, members of 
the esBAF family target and facilitate the de-methylation of Pou5f1 and Nanog promoter, 
while down-regulation of Ino80 reduces reprogramming efficiency and results in a more 
closed chromatin state near pluripotency gene promoters and reduces reprogramming 
[118, 119]. Similarly, a member of the CHD (Chromodomain helicase DNA binding) family 
remodelling factor, CHD1 maintains open chromatin in ES and its downregulation results 
in the accumulation of heterochromatin leading to reduction of reprogramming 
efficiency [120]. 
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Furthermore, complexes involved in gene repression had also been identified as 
important for both pluripotency and reprogramming. For instance Mbd3/NuRD 
(nucleosome remodelling deacetylase), a complex responsible for the deacetylation of 
histones and required for silencing pluripotency genes during differentiation of the ES 
cells [121] has been associated to reprogramming but with different outputs. Rais et al. 
and Luo et al. reported that depletion of Mbd3 and the associated NuRD component 
Gatad2b increases reprogramming efficiency, leading to a deterministic synchronised 
iPSCs generation, favouring the re-activation of pluripotency genes [122-124]. However, 
another study reported that Mbd3 is necessary for efficient iPS generation from neural 
stem cells, pre-iPS and EpiSCs [125]. The difference reported could be the result of the 
different cell context, as different culture conditions and induction methods were used, 
and further investigation is required to clarify the exact role of Mbd3/NuRD in iPSC 
generation. Moreover, WDR5, which is a core subunit of the histone methyltransferase 
complex Set/Mll in charge of active H3K4 methylation, has been shown to be required 
for efficient methylation of H3K4 in the first wave of histone modifications during early 
reprogramming [126]. Additionally, WDR5 has been shown to interact promoters 
enriched for targets of OCT4 and SOX2, which gain H3K4me2, while its depletion has 
negative effects in reprogramming [126]. Consistently, it was shown that the counterpart 
enzyme responsible for demethylation of H3K4 acts as a barrier in the process. KDM5B, 
a member of jumonji C-containing protein complexes, is responsible for demethylation 
the active histone mark H3K4me1/2/3, a process that can impair reprogramming. In fact, 
when KDM5B was depleted in the process, it promoted the efficiency, which pairs with 
the negative effects of WDR5, as erasing the mechanisms to add the active H3K4 
methylation markers affects reprogramming, whereas erasing the mechanisms to 
remove it promotes the formation of iPSCs [127]. 
 
As the gain of repressive chromatin states to downregulate somatic genes is important 
to promote induction of pluripotency, the removal of active histone marks already 
present in somatic active genes also represents mechanisms involved in downregulate 
the original somatic transcription profile. This was probed by the inhibition of Dot1L, 
which establishes the active H3K79me2 and H3K79me3 marks present in gene bodies, 
significantly enhanced the reprogramming process (Fig. 1.4) [116]. Furthermore, the 
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early removal of the heterochromatin patterns observed by the loss of the repressive 
histone mark H3K27me3 is believed to be helped by UTX, a Jmj domain-containing 
enzyme. When depleted, reprogramming is deficient and global aberrations of 
H3K27me3 and H3K4me3 profiles are observed when reprogramming MEFs depleted of 
UTX, abolishing the ability of somatic cells to reach the pluripotency state. Furthermore, 
despite it has been shown that UTX removes repressive marks from pluripotency genes; 
its overexpression has no positive effect in iPS formation [128]. More interesting, studies 
focused on another H3K27me3 demethylase, Jmjd3 (Kdm6b), suggested that the 
function of these proteins is loci specific, as depletion of Jmjd3 contrarily to UTX improves 
reprogramming [129]. 
 
Despite the somatic pattern of H3K27me3 needs to be erased from repressed genes, gain 
of this histone modification is also a mechanism used for silencing somatic genes. The 
complex that has been involved in this mechanism is the Polycomb Repressive Complex 
2 (PRC2), which is responsible for the trimethylation of H3K27 [130]. The importance of 
this complex was described when downregulation of the subunit Eed and therefore the 
loss of all PCR2 complexes, resulted in severe deficiency of the reprogramming process. 
Corroborating the fact that silencing through H3K27me3 is an important step, the 
overexpression of the catalytic subunit Ehzh2 improves the reprogramming efficiency in 
mouse and human, whereas the absence of other PRC subunits also affected the iPSC 
generation [131, 132]. 
 
1.5.1.2 DNA methylation during reprogramming 
DNA methylation in gene promoters is typically associated with a repressed state of gene 
expression [133]. During differentiation, de novo DNA methylation silences key 
pluripotency genes such as OCT4, SOX2 and NANOG [134]. This mechanism is mediated 
by the de novo methyltransferases DNMT3A and DNMT3B and preserved by the 
maintenance methyltransferases DNMT1 [66]. During reprogramming, these repressive 
marks need to be removed in order to allow the transcription or the pluripotent genes 
[135]. Demethylation process during reprogramming involves downregulation of DNMT1 
and therefore progressively diluting DNA methylation during replication and the 
facilitating the final transition to iPSCs [136]. TET proteins (Ten-eleven translocation 
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methylcytosine dioxygenase) are responsible for the loss of DNA methylation from the 
paternal genome during development [137], by mediating the iterative oxidation of 5mC 
to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC) followed by their replication-dependent dilution [138]. TET proteins appear to 
have a more direct contribution in reprogramming possibly through their activation by 
the OSKM factors, as after their induction in MEFs, TET2 promotes the 
hydroxymethylation of key pluripotency genes, such as Esrrb and NANOG, preparing 
them for subsequent demethylation and activation [139], while TET1 facilitates iPSC 
induction by promoting Oct4 demethylation and reactivation and is able to replace OCT4 
in the reprogramming cocktail [140]. Additionally, the depletion of TET2 has negative 
effects in the reprogramming, while the overexpression of NANOG and TET1 or TET2 
enhances it, possibly as a result of the reported interactions of TET1 and TET2 with 
NANOG and their co-bind in pluripotency targets in ES [139, 141]. Furthermore, activity 
of TET proteins can be promoted by the addition of Vitamin C to the reprogramming 
media, as it can interact with the catalytic domains of TET1 and TET3 and enhance their 
enzymatic activity, hence the reprogramming process [142]. Despite the improvement of 
the methylation dynamics during reprogramming has been achieved by the addition of 
chemicals to the reprogramming media, like VitC, one of the remaining issues to address 
in the reprogramming process is the result of the inefficient complete demethylation to 
that one in ES cells [143]. Mbd3, a member of the repressive NURD complex crucial for 
heterochromatin compaction could be involved in this inefficiency, as it has been shown 
that in mESC, it associates with loci enriched for TET1 and 5hmC, opening the possibility 
that in reprogramming it is recruited to these sites preventing the demethylation unless 
its release by coactivators [123, 144]. On the other hand, de novo methylation to supress 
somatic genes could not be a greater barrier than demethylation, as iPSCs can be 
generated in the absence of DNMT3A and DNMT3B [145]. Moreover, it has been shown 
that iPSCs retain an epigenetic memory owing to similar DNA methylation to the somatic 
cell of origin, which could influence in the differentiation potential of iPSCs to certain 
lineages, highlighting the importance of the DNA methylation mechanisms for faithful 
reprogramming to bona fide iPSCs [146, 147]. Taken jointly, chromatin-associated 
proteins can contribute both positively and negatively to the reprogramming process to 
iPS.   
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1.5.2 Inducing pluripotency by the reprogramming factors OCT4, SOX2, KLF4 and c-
MYC  
One of the key features of transcription factor induced pluripotency is their involvement 
in the induction of the large-scale chromatin changes that result in the acquisition of the 
epigenetic landscape of ES. Since the description of the original reprogramming factors 
OSKM, different TF combinations containing some or none of OSKM have been able to 
reprogram towards iPSCs, although with lower efficient, mixed reproducibility or the 
need of more than four factors [148-150]. Additionally, OSKM has been describe to be 
successful in a wider range of cell types. Most importantly, they are up to now the most 
used system for the derivation of human iPSCs; therefore, several efforts have been 
focused in understanding how their induction orchestrates the reprogramming process.  
 
As discussed in the pluripotency section, POU family member OCT4 and homeobox family 
SRY-related HMG-box family member SOX2 are two of the core factors in the 
pluripotency network with fundamental roles for development and pluripotency 
maintenance, so it was not unexpected that they were common requirements for both 
mouse and human. Moreover, KLF4, a member of the Kruppel-like factor family and c-
MYC, a member of the Basic helix-loop-helix family, belong to a set of pluripotency 
auxiliary TFs. Because of their transcription factor (TF) nature, they have the capacity to 
bind DNA. In fact, the engagement of OSKM with the pluripotent genome has been 
characterised, finding that OCT4, SOX2 and KLF4 are more enriched in enhancer regions, 
opposite to c-MYC, which binds to gene promoters. Moreover, the recruitment and co-
binding with additional pluripotency TFs, such as NANOG and ESRRB, in specific loci 
maintain the transcriptional network of pluripotency. [151-153].  
 
1.5.2.1 OSKM engagement with the somatic genome 
Extensive genome-wide chromatin assays, along with transcriptomic and epigenetics 
analysis from different stages of the reprogramming process had provided insights into 
the multiple synergistic or unique properties and effects of the OSKM engagement with 
the genome. Most of the recent studies have focused on characterizing the OSKM early 
binding to the somatic genome and how this contributes to the repression of somatic 
genes and the activation of pluripotency genes using both human and mouse models 
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[110, 154, 155]. The binding of OSKM to the human somatic genome have been mapped 
48hrs after OSKM induction in human fibroblast , which is considered as an early stage 
of reprogramming prior to major transcriptional changes and exposure to ES media [113]. 
In this study, Soufi et al. (2012) reported that OSKM binding profiles were different from 
those in ES cells [151]. Analysis of the shared binding sites revealed that OSKM 
extensively co-bind the same target sites. Most interestingly, analysis of the chromatin 
state of OSKM binding sites revealed that OSK, and not c-MYC preferably bind to DNase-
I resistant or inaccessible DNA, acting as pioneer factors (Fig. 1.5) [110].  
 
 
Fig. 1.5 Initial targeting of somatic closed chromatin by pioneer factors OCT4, SOX2 and 
KLF4 (OSK). OSK target nucleosome DNA in closed, silent at distal enhancer elements. c-MYC 
facilitates OSK chromatin engagement. Initial engagement enables other factors, chromatin 
modifiers and remodelers to access the target sites, modify the chromatin landscape and 
initiate the reprogramming of silent genes, enabling cell type conversion. Mega base-sized 
heterochromatin domains of the genome that are refractory to the initial OSKM binding are 
represented by H3K9me3 markers (red hexagons). Cells that achieve the loss of H3K9me3 
and transcriptional reactivation are more prone to achieve a more stable reprogramming. 
Image modified from [110]. 
 
Pioneer factors are defined by their ability to occupy DNA targets in closed chromatin, 
inducing the reshaping of the chromatin to a more open state providing accessibility for 
other transcription factors and co-factors to bind [156] (Fig. 1.2). Furthermore, Soufi et 
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al. also observed that the closed chromatin binding regions of OSK were localized in 
regions distal to gene promoters, like enhancers, whereas c-MYC was only able to engage 
these regions in the presence of OSK [110]. Comparisons of the unique and shared sites 
for each factor revealed that KLF4 and c-MYC can co-bind to actively transcribed 
promoters, but combinations with OS were mostly enriched in closed chromatin. 
Moreover, despite c-MYC was not necessary for OSK to access closed chromatin, it 
facilitates their binding [110]. Further characterization of the pioneer function of OSK 
revealed that it relies on the OSK capacity of binding nucleosomes by recognising partial 
DNA motifs [157].  
 
Differently from what Soufi et al. and further reports observed [158, 159], evidence of 
the initial OKSM engagement with the somatic genome in the mouse context described 
by Chronis et al. suggests an alternative model of the binding and role of the factors in 
the silencing of somatic genes. This work, which was focused in mouse reprogramming, 
suggests a model, at 48hrs OCT4, SOX2 and KLF4 preferentially bind co-bind to distal 
somatic active enhancers, whereas c-MYC engages with gene promoters [154]. In this 
study, Chronis et al. described that early OSK co-binding to active somatic enhancers 
leads to their inactivation genome wide and silencing of their somatic gene targets. 
Analysis of the engagement of TF bound to these enhancers such as Runx1, showed a 
combinatorial binding between OSK and the somatic TF, which could facilitate their 
redistribution to new sites elsewhere already engaged by OSK, such as transient 
enhancers or pluripotency associated enhancers. This redistribution leads to the 
inactivation, gradual loss and silencing of the TF and their target genes. Additionally, the 
OSK engagement induces the loss of active chromatin marks as a result of HDAC1 binding, 
which is a histone deacetylase that functions as a co-repressor, and the loss of p300, a 
histone acetyltransferase that functions as a co-activator, leading to gene repression, 
thus a negative feedback loop where the somatic genes and the somatic transcription 
factors get silenced. [154]. This evidence correlated to a study that characterised the 
early OCT4 binding (no SKM) in MEFs, observing the same pattern of binding 
permissive/active chromatin that correlated with subsequent somatic gene silencing of 
bound regions [160]. Moreover, despite not being the preferred binding as observed in 
Soufi et al., this work defined that pluripotency enhancer selection also begins early 
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reprogramming involving a stepwise process through collaborative binding of OSK at 
sites with high OSK-motif density, leading to the activation of pluripotency genes at late 
stages [154]. Discrepancies between both reports could be due to the lack of information 
regarding the state of the chromatin pre-OSKM induction in the mouse report, as analysis 
of chromatin state was focused in 48hrs, where chromatin is already different from MEFs 
with no OSKM induction. Moreover, a systematic comparison between both data sets 
confirmed the differences in binding preferences to distinct chromatin states, with little 
overlap of common binding sites, which results in the induction of different expression 
changes. However, the comparison allowed defining that despite these differences, the 
general properties of OSKM binding in both species are shared, like their binding to 
distant regions from promoters. Most importantly, in both species these similar 
mechanisms in molecular properties give result to the same output of activating the 
regulatory network of the pluripotency leading to the reprogramming to similar cell 
types, suggesting that the pluripotency network regulation and mechanisms to reactivate 
it has diverged significantly between the two species. [155] 
 
Overall, despite the identification and study of the OSKM factors has helped to provide 
important knowledge and insights about the mechanisms involved in inducing 
pluripotency, much remains to be learned from the exact roles of each OSKM factor 
during reprogramming and the differences between both species. Thus, further 
investigations to dissect their particular properties and functions is needed to elucidate 
the mechanisms through which these set of transcription factors lead the 
reprogramming process of somatic cells towards pluripotency.   
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 1  25 
1.6 OCT4: a versatile transcription factor  
Since its first discovery as a master regulator of pluripotency [161, 162], the transcription 
factor OCT4 has been extensively studied, being described to be crucial during mouse 
embryogenesis, in the establishment and maintenance of pluripotency in vivo and in 
vitro, and being part of the group of transcription factors that can lead to the generation 
of induced pluripotent stem cells.  
 
1.6.1 OCT4 Structure 
OCT4 belongs to the class V of the POU family of transcription factors, which are DNA 
binding proteins that are able to recognize the consensus octamer motif sequence 5’-
ATGCAAAT-3’[163]. As a modular protein with functionally independent domains, OCT4 
comprises three main domains: a central POU domain flanked by an N-terminal and a C-
terminal transactivation domain (TADs). The POU domain contains a POU specific (POU-
S) and POU homeodomain (POU-HD) separated by a linker containing a rigid helix and a 
flexible region and together comprise a bipartite DNA binding domain (DBD) [163] (Fig 
1.6a). Structurally, the POU-S domain consist of four α-helices and binds the DNA 
sequence 5’-ATGC-3’; while the POU-HD domain consists of three α-helices and binds the 
DNA sequence 5’-AAAT-3’ [164] (Fig. 1.6b), while the transactivation domains display 
high proline and glycine residues in the N-terminus and proline, glycine and 
serine/threonine-rich region in the C-terminus and are responsible for the interactions 
of OCT4 with other proteins [162].  
 
OCT4 is encoded by the gene POU5F1 in human, and Pou5f1 in mouse. In human, POU5F1 
presents alternative splicing generating three isoforms OCT4A, OCT4B and OCT4B1. 
OCT4A (OCT4 in this thesis) is localized in the nucleus and is the only isoform involved in 
pluripotency maintenance and the only one involved in the induction of pluripotency to 
iPS [165, 166]. Besides alternative splicing, post-translational modifications are 
responsible for regulating the stability, function and localization of OCT4, such as 
phosphorylation, O-glycosylation and ubiquitination (Fig. 1.6a) [167-170]. 
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Fig. 1.6 OCT4 protein domains.  a. Diagram representing the different domains of OCT4. 
OCT4 has a bipartite POU DNA-binding domain comprising a POU-specific DNA-binding 
domain (POU-S) and a POU-homeodomain (POU-HD) separated by a linker containing a rigid 
helix and a flexible region. The central POU domain is flanked by two transactivation domains 
located N-terminal (N-TAD) or C-terminal (C-TAD). Predicted post-translational modifications 
are shown. b. Model of POU/DNA complex. POU-S is shown in green, POU-HD in blue, linker 
in pink. This diagram was adapted from [163]. NTD = N-terminal transactivation domain, CTD 
= C-terminal transactivation domain, POU = POU domain, NLS = Nuclear Localization Signal. 
 
1.6.2 OCT4 in the reprogramming process: Overcoming epigenetic barriers 
Additionally to its fundamental function in the maintenance of pluripotency (discussed 
in section 1.4), OCT4 is also a central component needed for the reprogramming of 
somatic cells towards pluripotency and although its exact mechanisms are still not fully 
understood, it has been associated to multiple processes needed for the reprogramming. 
For instance, as discussed before, in human early stages of the reprogramming, OCT4 
functions as a pioneer transcription factor, facilitating the opening of repressed 
chromatin relying on its capacity to target part of its canonical motif on nucleosome-
enriched sequences in the somatic chromatin [110, 157]. However, it is still not well 
established what additional mechanisms are required to transition these initial 
engagement events into functional regulatory elements and thus establish new 
transcriptional networks needed to drive the reprogramming process. The formation of 
context-dependent complexes along with OCT4 could be one of the ways this transition 
is happening, involving the recruitment of epigenetic modulators, chromatin modifiers, 
and proteins involved in recruiting the RNA polymerase [171]. For instance, the capacity 
of OCT4 of not only recognize and bind DNA in different chromatin states, but its capacity 
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to recruit other transcription factors and interact with other proteins to establish 
complexes to drive the transcriptional regulation have been reported in mESC. By using 
mass spectrometry based studies different approaches have been conducted to identify 
the protein partners of OCT4 in mESC, expanding the regulatory network involved in 
pluripotency maintenance [82, 172, 173].  
 
1.6.3 OCT4-centered protein interaction networks in mouse embryonic stem cells 
The identification of interacting partners of OCT4 in mESC has been approached by 
different protocols and different systems, providing important information about the 
components of the pluripotency network but with the disadvantage of being little 
overlap between the proteins identified and with the necessity of replacing OCT4 with a 
tagged version for its purification (Table 1.1) [163]. The first approaches for defining the 
OCT4 interactomes depended on epitope-tagging affinity purification yielding different 
number of interactors. In order of publication, van der Berg et al. identified 54 [82], Pardo 
et al. 92, [172] Ding et al. 198 [174], and Esch et al. more than 600 OCT4 interaction 
partners [21]. When compared only 10 proteins were shared in all four studies (Chd4, 
Ctbp2, Hcfc1, Hdac1, Hells, Mta2, Mta3, Ogt, Smarca4, and Smarcc1). These 
discrepancies are most likely due to the different protocols employed (Table 1.1). van der 
Berg et al. and Ding et al. based their interactomes using cell lines derive from ZHBTc4, 
which is a cell line that has both endogenous Oct4 alleles disrupted, depending on a 
doxycycline-suppressible Oct4 transgene [175]. In both studies, transgenic mESC lines 
were established, expressing either biotinylated OCT4 [174] or FLAG tagged OCT4 [82] to 
replace the doxycycline suppressible OCT4. Furthermore, both analysis performed 
nuclear extract purification with DNase to remove the remaining DNA and eliminate 
protein interactions mediated indirectly by DNA. Pardo et al. also established a mouse 
cell line with by integrating an OCT4 C-terminus tagged epitope consisting of a 3XF 
calmodulin binding peptide (CBP) separated by a two TEV cleavage sites (Oct4-FTAP) 
[172]. For this cell line, endogenous OCT4 was not modified meaning the tagged OCT4 
was co-expressed with endogenous OCT4. Esch. et al approach, despite being the one 
with more hits, was the less described and characterized and it relied on nuclear extract 
after the ectopic overexpression of a strep-tagged OCT4 in OG2 mESC cell line, which 
harbours a GFP under control of the Oct4 distal enhancer [84]. Moreover, besides the 
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methodologies differences, the protein levels of OCT4 were variable among the 
protocols, which could contribute to the differences, as to maintain pluripotency the 
levels of OCT4 must be tightly controlled [176]. For instance, in Pardo et al. and Esch et 
al. the endogenous OCT4 was not modified, meaning cells were expressing both the 
endogenous and tagged OCT4. In Pardo et al. the levels of OCT4 were 30% or those of 
endogenous OCT4, but this seemed not to interfere with the ESC phenotype, as 
morphology and expression of ESC markers were similar to the original cell line with no 
transgene [172]. In contrast, in Ding et al. the levels of biotinylated OCT4 were less than 
the dox-regulated OCT4 but they report that it was still within the range to functionally 
maintain the mESC [174]. On the other hand, in van der Berg et al., quantification was 
not provided but they also report no effects in the maintenance of mESC [82]. Lastly, for 
Esch et al. no quantification or characterization of the cells was provided (Resume in 
Table 1.1) [84]. Altogether, these variables, along with the biases and specificities of the 
mass spectrometry instruments, could be the main reason of the extremely low overlap 
of OCT4 interactors. For instance, one of the biggest discrepancies found was the 
absence of the remaining components of the core pluripotency network NANOG and 
SOX2, even when their interactions have been previously described at the proteomic and 
genomic co-binging level [152, 177, 178]. NANOG was not present in any study and SOX2 
only in one. This lack of identification may be a result of mass spectrometry technical 
particularities, as for NANOG is has been proposed to be relative resistant to trypsin 
digestion, whereas for SOX2 it could be the result of weak interactions that require DNA 
to be stabilized [174].  
 
The latest OCT4 pluripotency interactome overcame most of the general limitations of 
the previous approaches, while achieving a specific chromatin-associated proteins 
purification for the core transcriptional factors OSN. In this study, Rafiee et al. established 
a new protocol called Chromatin Immunoprecipitation for the Selective Isolation of 
Chromatin Associated Proteins (ChIP-SICAP), which does not require epitope tagging and 
the use an exogenous expression system, as it relied in the endogenous expression of 
OSN in mESCs for the immunoprecipitation (Table 1.1). Importantly, this protocol aimed 
to identify the proteins that associate with OSN in the context of chromatin which is more 
relevant to transcription regulation. Taking advantage of traditional ChIP protocols, 
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which rely on crosslinking to maintain protein-DNA interactions and promote the 
solubilisation of chromatin by sonication, ChIP-SICAP allowed the identification of 
chromatin-bound proteins close to OSN on short stretches of DNA (~200-500bp) while 
allowing the in parallel purification of DNA for next-generation sequencing, a step not 
allowed by other ChIP coupled with MS protocols [153, 179-182]. Specifically, 525 
proteins were identified to interact with Oct4 on chromatin, including 8 out of the 10 
that overlapped in the previous OCT4 mESC and adding 312 proteins not identified in any 
of the other studies.  
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Despite the differences between all mESC interactomes, a degree of consistency has 
been observed in the cellular processes of these identified proteins. First, the interactors 
shared between all interactomes included members of the SWI/SNF: Smarca4 and 
Smarcc1 and members of the NuRD family: Chd4, Mta2 and Mta3 increasing the overall 
confidence in the biological significance of these proteins. Moreover, the classification of 
the different proteins included five main groups: transcription factors important for 
pluripotency maintenance, chromatin remodelers, and proteins involved in signalling 
pathways, transcriptional co-activators part of the basal transcriptional machinery and 
proteins involved in DNA repair, recombination and repair [82, 172].  
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Interesting associations between OCT4 and members of the pluripotency network were 
further expanded in van den Berg et al., linking OCT4 to more pathways. In this study, 
further identification of interactions of ESRRB, which was identified as an OCT4 binding 
partner, revealed proteins member of the Mediator complex, including RNA polymerase 
II subunits, and other transcription factors, such as TATA-box binding protein and TFIID. 
Therefore, ESRRB interaction with OCT4 could be linking the formation of the 
transcriptional machinery in genes regulated by OSN [82]. In fact, the Mediator complex 
has been identified along the masters regulators OSN, ESRRB and KLF4 in large enchanter 
domains known as super enhancers of pluripotency genes [153]. The mediator has also 
been shown to induce phase separated proteins condensates containing OSN to activate 
gene expression [183]. Furthermore, RNA polymerase II was identified in OCT4 ChIP-
SICAP [179]. 
 
Noteworthy, despite discrepancies, all the studies correlated in the identification of 
chromatin remodelling complexes and histone modifiers, linking their importance for the 
pluripotency maintenance to the core pluripotency network, especially the esBAF (a stem 
cell specific SWI/SNF complex), NuRD, Polycomb, LSD1 and WDR5 (part of the MLL 
complex) [82, 84, 172, 173]. What is more interesting is that this complexes have been 
associated with the reprogramming process, and their interaction with OCT4 could help 
explain at some level how OCT4 is promoting the changes in the chromatin landscape 
and transcriptional network during the reprogramming process.  
 
1.6.4 Integrative model of the involvement of OCT4 in pluripotency genes activation 
in reprogramming 
A model integrating the evidence of the effects of the chromatin remodelers in the 
reprogramming process, the interactions described previously in the OCT4-interactome 
studies and the pioneer activity of OSK could be drawn to try to explain the 
transcriptional activation of silent pluripotency genes in the reprogramming process 
(reviewed in [171])(Fig. 1.7). This model includes the activation of a CpG island containing 
promoters of pluripotency associated genes that are activated by a distal regulatory 
element (enhancer) containing the DNA motifs for OSK. In somatic cells, the CpG island 
is repressed and contains the repressive mark H3K27me3, whereas the enhancer could 
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be high or low methylated but condensed in nucleosomes with no obvious histone 
modifications that could be associated with repressors. When OSK are induced, initial 
engagement by the recognition of the partial motifs in the nucleosomes lead to local 
nucleosome breathing allowing the binding of other TFs. After the recruitment of 
epigenetic modifiers, this results in gradual epigenetic remodelling by initially acquiring 
H3K4me1 and H3K4me2 and subsequently promoting the methylation of H3K4 at the 
promoter region, mediated by WDR5 (MLL complex) in parallel with the removal of the 
repressive mark H3K27me3 by UTX. At this time point, the transcription of the target 
gene is still not active, which may be due to the continuous repressive forces by the NuRD 
complex, which inhibits the nucleosome eviction. Moreover, for the gene activation, the 
need of yet unknown factors that cooperate with OSK help the eviction of nucleosomes 
resulting in the canonical signature of enhancers, meaning the presence of H3K4me2 and 
H3K27ac, being stabilized by the esBAF complex BRG1 (which has already being 
associated to help the pioneer activity of OCT4 in mESC [184]). Then, the recruitment of 
the co-activators Mediator and cohesion complexes establish the topological linkage of 
the enhancer and the promoter, and supressing the effects of the NuRD complex, 
although it remains associated with the enhancers. Finally, the recruitment of the 
transcription machinery and additional unknown factors activate and induce the 
expression of the target gene (Fig. 1.4) [171]. 
 
While this model integrates a growing body of evidence generated by characterizing 
OCT4 in pluripotency maintenance and reprogramming, there are still some limitations 
and important unanswered questions. First, the low overlap between the OCT4 
interactome studies needs to be addressed before the function these proteins can be 
associated with OCT4 function in pluripotency. Second, protein interactome of OCT4 
during reprogramming must be defined, as it might be very different from that in ES cells, 
similar to the report of differences observed in the initial engagement of OCT4 with the 
somatic genome compared to the ES genome [110, 154]. This is necessary to unravel new 
reprogramming-specific factors that are being recruited as a mechanism to help the 
OSKM factors to reshape the chromatin landscape to acquire the final pluripotent state 
(Fig 1.4, Fig. 1.6, and Fig. 1.7). Additionally, the identification of new reprogramming-
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specific partners could lead to uncover new functions and biological processes none 
previously described for OCT4.  
 
Fig. 1.7 OCT4, SOX2 and KLF4 (OSK) transcriptional activation of silent pluripotency genes 
at early reprogramming.  Diagram representing the steps required to activate pluripotency-
associated genes that are epigenetically modified with the repressive mark H3K27me3. First, 
pioneer factors OSK cooperatively bind to partial motif sequences enclosed in distal 
regulatory elements in closed chromatin, driving epigenetic remodelling by the deposition of 
H3K4me1 and H3K4me2. Initial OSK engagement also promotes the deposition of H3K4 
methylation at the promoters of pluripotency genes, mediated by WDR5. In parallel, the 
histone demethylase UTX removes the H3K27me3 mark. A roadblock of the reprogramming 
process involves the inhibition of nucleosome eviction and stable acetylation by the 
repressor NuRD (subunits MBD3 and LSD1). To achieve gene activation, esBAF subunit BRG1 
and other unknown factors help stabilize OSK to evict nucleosomes and stablish the canonical 
enhancer signature with the marks H3K4me2 and H3K27ac (mediated by p300). Topological 
changes involving the Mediator and cohesion complexes link the promoter with the enhancer 
and directing the expression of the target gene, by the recruitment of RNA polymerase II (Poll 
II) and more unknown factors. Each step of gene reactivation involves multiple complexes 
and factors, most of which are still unknown and are represented by the question marks in 
pink circles. Image modified from [171]. 
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Third, and most importantly, since stem cell and cellular reprogramming research 
started, the main goals of their applications have being motivated by their potential for 
regenerative medicine approaches, such as drug screening, disease modelling and the 
promise of personalised cell therapies. Nevertheless, there is still a gap in our knowledge 
of human pluripotency, which is lagging behind the mouse model where most of the 
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1.7 Aims of this thesis 
 Define OCT4 protein interactors at early stages of reprogramming to iPSCs and 
during pluripotency maintenance. 
 Define the role of essential and non-essential regions of OCT4 transactivation 
domains for its proteomic and genomic engagement at early stages of 
reprogramming.  
 Compare the OCT4 pluripotency maintenance network against the early 
reprogramming one and identify key molecular interactions that are most 
relevant in the reprogramming process.  
 
 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 2  35 
Chapter 2 MATERIAL AND METHODS 
2.1 Reagents 
Cell culture 
Glasgow Minimum Essential Media (GMEM) (Sigma Aldrich #G5154) 
Foetal Calf Serum (FCS) (Gibco #10270-106) 
Sodium Pyruvate (Gibco #11360-039) 
Glutamine (Gibco #25030-024) 
Non e aa (Invitrogen 11140-036) 
2-mercaptoethanol (50 mM Life technologies #31350010) 
Pen strep (Invitrogen #15140-122) 
Laminin 521 (BioLamina #800110) 
SILAC Protein Quantitation Kit (LysC) – DMEM:F12 (Thermo Fisher # A33970) 
KnockOut™ serum Replacement (Gibco # 10828028) 
bFGF (Peprotech 100-18B) 
DPBS, calcium, magnesium (Gibco™ # 14040133) 
 
Lentivirus production  
Fugene6 (Omega #E2691)  
Opti-MEM™ Reduced Serum Medium (Gibco™, #31985062) 
Lenti-X Concentrator (Takara #631232)  
Polybrene (Sigma, #H9268-5G)  
 
Rescue and Reprogramming 
Alkaline phosphatase staining (Sigma # SCR004) 
VitC (Sigma Aldrich, #A92902) 
 
Western Blot 
RIPA lysis buffer (Thermo Scientific™ #89901)  
Pierce™ BCA Protein Assay Kit (Thermo Scientific™ #23225) 
NuPAGE™ LDS Sample Buffer (4X) (Invitrogen™, #NP0007) 
Bolt 10X Reducing agent (Invitrogen™, 10X Bolt™ Sample Reducing Agent #B0009) 
Bolt™ 4-12% Bis-Tris Plus Gel (Invitrogen™, 10-well #NW04120BOX)  
1X Bolt™ MES SDS Running Buffer (Invitrogen™, #B0002) 
Immobilon-P PVDF Membrane (Millipore, IPVH00010) 
Mini Blot Module (Invitrogen™, B1000) 
1X of NuPAGE™ Transfer Buffer (Invitrogen™, #NP00061) 
Bolt™ Antioxidant (Invitrogen™, BT0005) 
Skim milk powder (Fisher #10651135) 
PBS Tablets (Fisher #12821680)  
TWEEN® 20 (Sigma #P7949-500ML) 
SuperSignal™ West Pico chemiluminescent substrate (Thermo Scientific™ #34578) 
Amersham Hyperfilm ECL 18 × 24 cm. GE # 28906836 
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Immunocytochemistry  
Donkey serum (Sigma-Aldrich, #D9663)  
Goat serum (Sigma-Aldrich, #G9023)  
DAPI (Invitrogen™, #D1306) 
Fluoromount-G™ (Invitrogen™, #00-4958-02) 
 
ChIP-SICAP and ChIP-seq 
DSG (Thermo #20593) 
cOmplete Ultra Protease Inhibitor (Roche #05892791001)  
Formaldehyde (Pierce, #28906)  
Protein G Dynabeads™ (Invitrogen™ #10004D) 
Terminal Deoxynucleotidyl Transferase (Thermo Scientific™ #EP0161) 
Biotin- 11-ddUTP (1mM stock, Jenabioscience, NU-1619-BIOX-S) 
Streptavidin beads (NEB, S1420S) 
Vivacon 500 spin column (30K cartridge Sartorius, VN01H22)  
RapiGest SF (Waters #186001861)  
Lys-C (Wako, #125-05061)  
Trypsin (Promega, #V5280)  
Sera-mag beads (65152105050250 and 45152105050250) 
 
Immunoprecipitation 
Anti-FLAG® M2 Magnetic Beads (Millipore #M8823-5ML) 
Benzonase® Nuclease (Millipore, #E1014-25KU)  
SYPRO™ Ruby Protein Gel Stain (Invitrogen™, #S12000)  
GelCode™ Blue Safe Protein Stain (ThermoFisher #24594) 
 
Mass spectrometry 
NuPAGE Novex 4-12% Bis-Tris gel (Life Technologies, #NP0321BOX) 
Instant™ Blue Coomassie (Expedeon, SKU: ISB1L)  
Lyophilised Trypsin Protease (Pierce™ Trypsin Protease, MS Grade #90057) 
Empore Disk C18 Octadecyl (C18)-bonded silica (C18, #2215, 3M) 
Iodoacetamide (Sigma, I1149-5g) 
Ammonium Bicarbonate (NH4HCO3-Sigma, A6141-500G-D) 
 
ChIP DNA purification  
RNase A Solution (Millipore #70856) 
Proteinase K Solution (Invitrogen™, #AM2548) 
Phenol:Chloroform:Isoamyl Alcohol (Sigma-Aldrich, #P2069) 
 
Library preparation 
Qubit 2.0 HS dsDNA quantification kit (ThermoFisher, #Q32854) 
NEBNext Ultra II Library Preparation Kit (NEB #E7645S)  
NEBNext Ultra II Library Preparation Kit with Dual Index Primers (NEB #E7600S)  
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SpeedBeads™ magnetic carboxylate modified particles (Sigma-Aldrich, 
#GE65152105050250) 
Agilent 2200 Tapestation with D1000 HS reagents (Agilent #5067-5584, #5067-5585) 
 
Cloning  
T4 DNA Ligase (NEB, #M0202S) 
BsmBI (NEB, #R0580S) 
SfiI (NEB, #R0123S) 
BamHI (NEB, #R3136S) 
XbaI (NEB, #R0145S) 
In-Fusion® HD Cloning Kit (Takara, #638909) 
EcoRI (NEB, #R3101S) 
BbsI (NEB, #R0539) 
NotI (NEB, #R3189S) 
Shrimp Alkaline Phosphatase (rSAP) (NEB, #M0371S). 
 
2.2 Methods 
2.2.1 Cell Culture  
Human Fibroblasts 176 (HF 176) 
HF 176 were obtained from RBiomedical and cultured in GMEM supplemented with 10% 
FCS, 1X 13 non-essential amino acids, 1 mM Sodium Pyruvate, 1 mM glutamine and 0.1 
mM 2-mercaptoethanol at 37°C and 5% CO2. Medium was changed every 2-3 days and 
cells were passaged every 4-5 days using Trypsin+EDTA. 
 
Human Fibroblasts SILAC 
HF 176 were cultured in “Heavy” DMEM:F12 for SILAC supplemented with 10% dialyzed 
Foetal Bovine Serum (FBS) for SILAC, 1 mM Sodium Pyruvate, 1 mM glutamine, 1X Non-
Essential Amino Acids, 0.1 mM 2-mercaptoethanol, 0.46 mM 13C6 L-Lysine-2HCl (heavy) 
and 0.47mM L-Arginine-HCl (light) at 37°C and 5% CO2. Before addition, medium was 
filtered using a 0.22µm filter. Medium was changed every 2-3 days and cells were 
passaged every 4-5 days using Trypsin+EDTA. 
 
Human Embryonic Stem Cells (hES)  
Master Sheffield 7 (MS7) were obtained from Tilo Kunath’s lab at passage 17 and were 
cultured in Essential 8™ Medium (Gibco #A2858501) in plates coated with Human 
Recombinant Laminin 521 (4μg/mL in DPBS with Ca2+ and Mg2+) at 37°C and 5% CO2. 
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Medium was changed every day and cells were passaged every 2-3 days using EDTA 
(0.5mM). 
 
hES SILAC  
MS7 were cultured in Laminin 521-coated plates in iMEF conditioned-SILAC “light” 
medium. SILAC “light” medium for hES was prepared using DMEM:F12 for SILAC 
supplemented with 20% KnockOut Serum, 1 mM glutamine, 1X Non-Essential Amino 
Acids, 100 μM 2-mercaptoethanol and 10 ng/mL bFGF. After preparation, hES “light” 
medium was conditioned in iMEFs changing and collecting the everyday for 7 days. Once 
all medium was conditioned, the isotopes were added: 0.46 mM L-Lysine-2HCl (light) and 
0.47 mM L-Arginine-HCl (light). After, medium was filtered using a 0.22µm filter and used 
for MS7 growth at 37°C and 5% CO2, supplemented again with 10 ng/mL bFGF before 
use. Medium was changed every day and cells were passaged every 2-3 days using EDTA 
(0.5mM). 
 
Human embryonic kidney 293 cells (HEK 293) 
HEK 293 were obtained from Keisuke Kaji lab and cultured in GMEM supplemented with 
10% FCS, 1X non-essential amino acids, 1 mM Sodium Pyruvate and 1 mM glutamine at 
37°C and 5% CO2. Medium was changed every 2-3 days and cells were passaged every 4-
5 days using Trypsin+EDTA. 
 
Mouse embryonic stem cells ZHBTc4 
mESC ZHBTc4 were obtained from Ian Chamber’s lab and cultured in plates coated with 
0.1% gelatine/PBS and GMEM supplemented with 10% FCS, 100U/mL LIF, 1 mM Sodium 
Pyruvate, 1 mM glutamine, 1X 13 Non-Essential Amino Acids, 0.1 mM 2-mercaptoethanol 
and 150μg/mL Hygromycin at 37°C and 5% CO2. Medium was changed every 2 days and 
cells were passaged every 3-4 days using Trypsin+EDTA. 
 
Mouse Embryonic Fibroblast (MEF) 
WT MEFS  
WT MEFS were derived by Elisa Hall-Ponselè (Soufi lab) and were grown in GMEM 
supplemented with 10% FCS, 1 mM Sodium Pyruvate, 1 mM glutamine, 1X non-Essential 
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Amino Acids, 0.05 mM, 2-mercaptoethanol, and Penn Strep (10000 U/mL pen, 10,000 
µg/mL strep) at 37°C and 5% CO2. Medium was changed every 2 days and cells were 
passaged once using Trypsin+EDTA. 
 
iMEFs  
Irradiated MEFs (iMEF) were thawed and kept overnight in plates coated with 0.1% 
gelatine/PBS in the WT MEF conditions described previously. Next day, SILAC hES media 
without the addition of the isotopes was added. Medium was changed every day as 
described in hES SILAC.  
 
Cas9 TNG MKOS MEFs (Tg MEF) 
Tg MEFS were obtained from Dan K (Keisuke Kaji’s lab) and cultured as reported in plates 
coated with 0.1% gelatine/PBS and GMEM supplemented with 10% FCS, 1 mM Sodium 
Pyruvate, 1 mM glutamine, 1X non-Essential Amino Acids, 100 U/ml LIF (0.1 mM, 2-
mercaptoethanol, Penn Strep (10000 U/mL pen, 10,000 µg/mL strep), 5 ng/mL FGF2 and 
1μg/mL Heparin at 37°C and 5% CO2. Medium was changed every 2 days and cells were 
passaged once using Trypsin+EDTA. 
 
2.2.2 Lentivirus production and concentration 
Virus Concentration 
HEK293 were seeded at a density of 3 X 106 cells per 15 cm dish. Next day (~40% 
confluence) transfection was carried on using Fugene6 and a total of 15μg of DNA 
plasmids in a 3:2:1 ratio of the gene of interest vector (FU-tetO), psPAX2 packaging vector 
and pMDG envelope vector respectively. Mixed plasmids were dissolved in 90 μL 
Fugene6 and necessary Opti-MEM™ Reduced Serum Medium for a final volume of 1.8mL. 
Mixture was left to incubate for 15 minutes before adding it in a drop-wise fashion to the 
HEK293 cell culture. Sixteen hours post-transfection, the medium was replaced with 
30mL of fresh HEK medium and cells were left in cultured. After 60hrs of the medium 
change, supernatant was collected, filtered through a 0.45 μM syringe filter (to remove 
cells and debris), mixed with the Lenti-X Concentrator at a ratio 3:1 and left incubating 
overnight at 4°C. Next day, the mixture was centrifuged at 1500 g for 2 hours. 
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Supernatant was discarded and pellet was dissolved in 200 μL of GMEM (plain medium 
with no supplements). To help dissolve the pellet, it was left with the GMEM overnight 
at 4°C. Next day mixture was then gently resuspended, aliquoted in small volumes (20-
50μl) and stored at -80°C. 
 
gRNA and TetO viral Supernatant Collection - Candidates 
HEKs were seeded at a density of 7.5 X 105 cells per 10 cm dish. Next day (~40% 
confluence) transfection was carried on using Fugene6 as previously described for the 
virus concentration but using 5μg as the final plasmid DNA concentration, 30 μL Fugene 
6 and necessary OPTI-MEM medium for a final volume of 600μl. 16 hours post-
transfection, the medium was replaced with 10 mL of fresh medium and cells were 
cultured for 60 hr. Supernatant was collected and filtered through a 0.45 μM syringe 
filter, aliquoted in 1.5mL volumes and stored at -80°C.  
 
Lentivirus titration 
Concentrated Virus  
To determine the virus titre from concentrated lentivirus, a concentrated lentivirus for 
constitutive GFP was used. HF176 were seeded at a density of 1x105 cells per well in a 6 
well plate and cultured for 16 hrs. Concentrated constitutive GFP lentivirus was 
resuspended and diluted 10−2, 10−3, 10−4, 10−6 and 10−6 into a final volume of 2mL of 
culture medium. Human fibroblasts were transduced with 2mL of each diluted 
supernatants. Polybrene was added to each infection at a final concentration of 
4.5μg/ml. 16 hours post-infection medium was replaced and cells were cultured for 48 
hours. %GFP cells and the virus titre was determined using FACS (BD LSRFortessa (4 
laser)). Titre obtained from the constitutive GFP lentivirus was used as an estimate of the 
titre of the remaining lentiviruses.  
 
Supernatant gRNA 
To determine the virus titre from supernatant gRNA lentivirus, WT MEFs were seeded a 
density of 1x105 cells per well in a 6-well plate and cultured for 16hrs prior to 
transduction. For transduction, for each gRNA Lentivirus and aliquot was defrost and 
dilute 1/2, 1/4, 1/6 and 1/8 in MEF media with Polybrene at a final concentration of 
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4.5μg/ml. Cells were incubated with the virus for 8 hours before changing to MEF media 
and cultured for 48hrs. %BFP cells and the virus titre for each sgRNA was determined 
using FACS (BD LSRFortessa (4 laser))  
 
2.2.3 Rescue assays ZHBTc4 
ZHBTc4 cell lines were plated at a density of 107 in a 10 cm dish. After 6 hours cells were 
transfected 15 μg of the corresponding CAG plasmids (hOCT4 and 3XF OCT4). 12 hours 
post transfection cells were plated at a clonal density (106 cells per 10 cm dish). After 6 
hours, knockout and selection was induced adding dox and puromycin (1μg/mL). Cells 
were cultured in the presence of dox and puromycin (1μg/mL) with daily medium change. 
Alkaline phosphatase staining was performed after 10 days. Colonies were count by hand 
and the rescue efficiency was determined from the ratio of alkaline positive mESC cell 
colonies in plus dox to those in minus dox. Three technical replicates were taken into 
account.  
 
2.2.4 TNG MKOS (Cas9) MEF Reprogramming  
Previously thawed and plated TNG MKOS Cas9 MEFs and WT MEF were mixed in a ratio 
of 10% TNG MEFs and 90% WT MEFs and plated at a density of 1x105 cells per well in a 6 
well plate pre-coated with 0.1% gelatine and incubated for 16h. Three replicates were 
plated per sgRNA and per TetO lentivirus. To transfect, sgRNA and Tet-O supernatant 
lentivirus for each candidate and controls were thawed before transfection and diluted 
to an appropriate titre to achieve ~85-90% transduction efficiency in mESC+fgf2 media 
with 4.5µg/mL polybrene. MEFs with lentivirus were incubated for 8 hours and media 
was changed to fresh mESC and incubated for 16 hours. Reprogramming medium was 
added 24 hours after, including ES media, 300ng/ml doxycycline, 10µg/ml VitC. Cells 
were incubated for 15 days with change every 2 days or every day when necessary at 
later stages. At day 15 wells were washed with PBS once, and 1mL PBS/well was added 
before imaging using the Celigo Imaging Cytometer (Nexelom Bioscience) using the green 
(GFP) and red (mOrange) filters. Images were post-processed using Fiji Is Just ImageJ (FIJI) 
[185]. GFP+ colonies were manually count, taking into account three replicates for each 
condition. Significance in changes in reprogramming efficiency were determined with a 
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paired student’s t-test for each condition GFP+ colonies against the respective control 
(Zeo and No virus). 
 
2.2.5 Protein purification 
OSKM 48h for WB (3XFLAG WT, WT and mutants) - To test expression of OCT4 (3XFLAG 
WT, WT and mutants) and SOX2, KLF4 and cMYC by Western Blot, HF 176 were seeded 
at a density of 5x105 cells in 10 cm dishes and transduced with concentrated OCT4 (WT 
or mutants) lentivirus, along with SOX2, cMYC, KLF4 and rtTA2M2 concentrated lentivirus 
at MOI of 5. 16 hours post-transduction, the medium was replaced and cells were 
cultured for 48 hours. OSKM protein expression was induced adding fresh medium with 
1μg/mL of doxycycline into one dish of each factor infection. Cells were cultured for 48 
hours before collection. For control samples, Human Fibroblasts without transduction of 
the virus were cultured and processed as the fibroblasts with virus. For total protein 
extraction 10 cm dishes were scraped and pelleted by centrifuging for 5-10 minutes at 
500 × g. Media was removed and cells were washed twice with PBS. Cells were lysed on 
ice using 100-200ul RIPA lysis buffer containing cOmplete Ultra Protease Inhibitor and 
sonicated on high with Bioruptor in Cold room (6x10 sec intervals). Cell suspension was 
left for 15 minutes rotating in the cold room. Cells lysates were centrifuged for 15 
minutes at max. speed (4°C) and transfer to protein LoBind tubes. Protein concentration 
was determined for each sample using the Pierce™ BCA Protein Assay Kit. 
 
Chromatin-bound Proteins from Subcellular Fractions 
To test candidates expression in chromatin by Western Blot, HF 176 were seeded at a 
density of 5x105 cells in 10 cm dishes and transduced with concentrated OCT4 (WT or 
mutants) lentivirus, along with SOX2, cMYC, KLF4 and rtTA2M2 concentrated lentivirus 
at MOI of 5. 16 hours post-transduction, the medium was replaced and cells were 
cultured for 48 hours. OSKM protein expression was induced adding fresh medium with 
1μg/mL of doxycycline into one dish of each factor infection. Cells were cultured for 48 
hours before collection. For control samples, HF without transduction of the virus were 
cultured and processed as the fibroblasts with virus. For hES cells, 10 cm dishes were 
plated until 90% confluence. Cells were scraped and pelleted as described before for WB 
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Extraction was performed as reported [186]. Pellet was resuspended in 1mL of cold PBS 
and transferred to a 1.5 LoBind tube and centrifuged at 130 x g at 4 °C for 3 min. Cell 
pellet was lysed with 5 volumes of ice-cold E1 Buffer (50 mM HEPES-KOH pH 7.5, 140 mM 
NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, 1 mM DTT, 1X cOmplete 
Ultra Protease Inhibitor) for 1 volume of cell pellet. Cells were resuspended by gently 
pipetting up and down for 10 times before centrifugation at 1,100 x g at 4 °C for 2 min. 
Supernatant was collected in a new pre-chilled LoBind tube and labelled as the cytoplasm 
fraction. Pellet was resuspended in the same volume of buffer E1 used previously (5 
volumes) and centrifuged immediately at 1,100 x g at 4 °C for 2 min. Supernatant was 
discarded and pellet resuspended by gently pipetting with same volume of buffer E1 (5 
volumes). Tube was left for 10 min in ice before centrifugation at 1,100 x g at 4 °C for 2 
min. Supernatant was discarded and pellet gently resuspended in 2 volumes of ice-cold 
E2 buffer (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA, 1X 
cOmplete Ultra Protease Inhibitor protease inhibitor cocktail) for 1 volume of cell pellet, 
followed by centrifugation at 1,100 x g at 4 °C for 2 min. Supernatant was collected in a 
pre-chilled LoBind tube and labelled as the nucleus fraction. Pellet was resuspended in 
the same volume of E2 as before (2 volumes) and centrifuged immediately at 1,100 x g 
at 4 °C for 2 min. Supernatant was discarded, pellet was resuspended in the same volume 
of E2 as before (2 volumes) and centrifuged immediately at 1,100 x g at 4 °C for 2 min 
and left for 10 min on ice before centrifugation at 1,100 x g at 4 °C for 2 min. Supernatant 
was discarded and pellet was resuspended by pipetting in 2 volumes of ice-cold E3 buffer 
(500 mM Tris-HCl pH 6.8, 500 mM NaCl, 1 X cOmplete Ultra Protease Inhibitor protease 
inhibitor cocktail). Tubes were sonicated in the water bath sonicator in the cold Room 
for 5 min, 30 sec ON/30 sec OFF on maximum power. All fractions (cytoplasm, nuclear 
and chromatin) were centrifuged at 16,000 x g at 4 °C for 10 and supernatant was 
transferred to a new pre-chilled LoBind tube. Protein concentration was determined for 
each fraction using the Pierce BCA Protein Assay Kit.  
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2.2.6 Western Blot 
For 3XFLAG OCT4 IPs (OCT4= WT and mutants) and HF control: To corroborate OCT4 
elution in the IPs 5μl of each elution were loaded, 1 μL of input. (Triplicates for each 
sample) 
Total extract OSKM 48h (OCT4= 3XFLAG WT, WT and mutants) and HF control: To test 
OSKM protein levels 5 μg of total protein were loaded. 
Fractions OSKM 48h (WT and mutants), hES, and HF control: To test fractionations, 1 μg 
of Total Extract, cytoplasm extract, nuclear extract and chromatin extract were loaded. 
To analyse candidates, 5μg of chromatin fractions were loaded and 0.5 µg of the 
chromatin fraction were loaded to detect OCT4 and H3 as loading controls. 
WB General Protocol 
NuPAGE™ LDS Sample Buffer (4X) and Bolt Reducing agent (10X) were added to each 
sample for a final concentration of 1X. Samples were heated at 70°C for 10 minutes. 
Required volume was loaded into a Bolt™ 4-12% Bis-Tris Plus Gel and ran at 200V for 30 
min with 1X Bolt™ MES SDS Running Buffer. Proteins were transferred into a Immobilon-
P PVDF Membrane at 30V for 90 min using the Mini Blot Module in 1X of NuPAGE™ 
Transfer Buffer, 20% MetOH and Bolt™ Antioxidant. Membrane was blocked overnight 
at 4°C with 10% Skim milk powder in PBST (PBS 1x + TWEEN® 20 0.1%). Primary antibody 
incubations (in 5% BSA) were left overnight followed by 5X min washes with PBST. 
Secondary antibody incubations with HRP conjugates in PBST were performed for 1hr at 
room temperature. After 5X 5min washes with PBST, WB were visualized by using 
SuperSignal™ West Pico chemiluminescent substrate and X-ray film developer (Film= 
Amersham Hyperfilm). All antibodies used and dilutions are listed in Table 2.1 and 2.2.  
 
2.2.7 Immunocytochemistry (IC) 
HF176 were seeded at a density of 2.5x104 cells per well in a 12 well plate, cultured for 
16 hrs and transduced with O (WT or 3XFLAG), S, K, M and rtTA2 lentiviruses at a MOI of 
5. Polybrene was added to each transfection at a final concentration of 4.5μg/ml. 16 
hours post-transduction, the medium was replaced, cells were cultured for 48 hours. 
OSKM expression was induced adding fresh medium with 1μg/mL of doxycycline. Cells 
were cultured for 48 hours and analysed using Immunocytochemistry. Cells were fixed in 
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4% paraformaldehyde for 10 min at room temperature, permeabilized with 0.1% Triton 
X-100 for 10 min at room temperature and blocked for nonspecific binding with 44% 
Donkey or Goat serum in PBS for 60 min at room temperature. Overnight incubations at 
4oC were performed with anti-hOCT4 antibody, hSOX2 antibody, hKLF4 antibody, c-MYC 
antibody. Primary antibodies were diluted in 4% Donkey or Goat serum in PBS. Cells were 
washed 3X with TBST (TBS=50 mM Tris-Cl pH 7.5, 150 mM NaCl + 0.05% Tween 20). Cells 
were incubated with secondary antibodies anti-goat Alexa Fluor 488 donkey, anti-rabbit 
Alexa Fluor 488 goat, for 1 hour at room temperature and washed 3X with TBST. Nuclei 
were counterstained with 3 μg/ml of DAPI for 10 min at room temperature. Cells were 
washed 1X with MiliQ. Fluorescence images were taken using the iRiS™ Digital Cell 
Imaging System (Logos Biosystems, Inc.), using DAPI and a GFP filter for green 
fluorescence. All antibodies used and dilutions are listed in Table 2.1.  
 
2.2.8 Immunocytochemistry for confocal 
Centre Optical Instrumentation Laboratory (COIL) facilities (Wellcome Trust Centre for 
Cell Biology – Kings Buildings – The University of Edinburgh) with the help of Dr David 
Kelly. 
HF176 were seeded at a density of 2.5x104 cells per well in a glass coverslip inside a 12-
well plate. Cells were cultured for 16 hrs before transduction with O (WT or mutants), S, 
K, M and rtTA2 lentiviruses at a MOI of 5. Polybrene was added to each transfection at a 
final concentration of 4.5μg/ml. 16 hours post-transduction, the medium was replaced, 
cells were cultured for 48 hours. OSKM expression was induced adding fresh medium 
with 1μg/mL of doxycycline. Cells were cultured for 48 hours before fixed in 4% 
paraformaldehyde for 10 min at room temperature, permeabilized with 0.1% Triton X-
100 for 10 min at room temperature and blocked for nonspecific binding with 4% Donkey 
or Goat serum in PBS for 60 min at room temperature. Overnight incubations at 4oC were 
performed with anti-hOCT4 antibody (2.5 μg/ml). Cells were washed 3X with TBST 
(TBS=50 mM Tris-Cl pH 7.5, 150 mM NaCl + 0.05% Tween 20) and incubated secondary 
anti-rabbit Alexa Fluor 488 goat (1:50000) for 1 hour at room temperature. Cells were 
washed 3X with TBST and once with water before mounting. Coverslips were mounted 
onto glass slides with Fluoromount-G™. Images were acquired with Zeiss LSM 880 with 
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Fast Airyscan microscope with a 100x objective using Zen Black acquisition software with 
GFP filter. Images were post-processed using Fiji Is Just ImageJ (FIJI) [185]. All antibodies 
used and dilutions are listed in Tables 2.1 and 2.2. 
Table 2.1 Primary Antibodies used for the Western Blot, Immunocytochemistry (IC), ChIP-
SICAP and ChIP-seq experiments. 
Primary Antibodies Company and 
Catalogue Number 





Rabbit monoclonal 1:5000 (WB) 
TNIP2 ProteinTech  
#15459-1-AP 
Rabbit polyclonal 1:1000 (WB) 
XPO6 Abcam 
#ab72333 
Rabbit polyclonal 1µg/ml (WB) 
ETV4 Thermo (Invitrogen™) 
# PA5-79223 
Rabbit polyclonal 0.5 µg/mL (WB) 
KDM4B LSBio 
#LS-B13472 
Rabbit polyclonal 1:1000 (WB) 
UFD1L ProteinTech  
#10615-1-AP 
Rabbit polyclonal 1:1000 (WB) 
Histone H3 Abcam  
#ab24834 
Mouse monoclonal 1:10000-1:20000 
(WB) 
OCT4 Abcam  
#ab19857 
Rabbit polyclonal 1 µg/mL (WB) 
2.5 mg/ml (IC) 
2.5 µg/ml (IC 
confocal) 
SOX2  R&D 
#AF2018 
Goat polyclonal 0.4µg/mL (WB) 
5 mg/ml (IC) 
cMYC R&D systems  
#AF3696 
Goat polyclonal 1:300 (WB) 
10 mg/ml (IC) 
KLF4 R&D systems  
#AF3640 
Goat polyclonal 0.2 µg/mL (WB) 
2.5 mg/ml (IC) 
IgG Isotype Control Abcam  
#ab37415 
Rabbit Polyclonal Used for ChIP-SICAP 
control 
Lamin (Donated by 
Julia W, Lowell lab) 
Abcam 
#ab16048  
Rabbit Polyclonal 0.5 µg/mL (WB) 
 
Table 2.2 Secondary Antibodies used for the Western Blot, Immunocytochemistry, ChIP-
SICAP and ChIP-seq experiments. 















Santa Cruz  
#sc-2020 
1:5000 (WB) 
Goat Alexa Fluor 488 
Anti-Rabbit IgG 
Abcam #ab150077 
Ex: 495nm, Em: 519 
1:500 (IC) 
1:10000 (IC confocal)  
Donkey Alexa Fluor 488 
anti Goat IgG 
Abcam #ab150129 
Ex: 495nm, Em: 519 
1:500 (IC) 
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2.2.9 Proteomics  
ChIP-SICAP (Reported protocol) [179] (See Figure 3.1 for diagram) 
Cross-link, cell lysis and sonication- 25 million human embryonic stem cells (MS7) and 
25 million HmFb (HF) were pelleted and re-suspended in 1.5% fresh Formaldehyde 
(Pierce) in PBS. After 15 min incubation at room temperature with occasional rotations, 
125mM Glycine was added to the solution to quench cross-linking. Then the cells were 
washed twice with PBS and resuspended in 900 μl TE buffer (10mM Tris-HCl pH 8, 1mM 
EDTA pH 8) plus cOmplete Ultra Protease Inhibitor and kept on ice for 5min. Then 100 μl 
Triton X-100 10% was added and cells were incubated another 5min on ice. Cells were 
washed twice by resuspending them in 10mM Tris-HCl (pH = 7.5), spinning afterward at 
500g for 5min, and removing the supernatant). Samples were resuspended in 10mM Tris-
HCl to a final volume of 1mL and sonicated using a Covaris M220 sonicator. Sonication 
was done in 10 min intervals and 50μl of sonicated chromatin were collected after each 
10 min cycle to test sonication quality in an agarose gel electrophoresis. hES were 
sonicated up to 2 hrs and HF up to 3 hrs. After the final sonication cycle, samples were 
centrifuged at 12000g for 10min to sediment cell debris, and collection of the 
supernatant.  
OCT4 ChIP and biotinylation- Shredded chromatin was incubated with 30μL of Protein G 
Dynabeads™ saturated with 10 μg of OCT4 antibody and left rotating in the cold room 
for overnight. After beads were washed once with 10mM Tris-HCl, and once with 1xTdT 
buffer. Beads were resuspended in 1xTdT buffer, 60 U of Terminal Deoxynucleotidyl 
Transferase and 50μM of Biotin- 11-ddUTP, and incubated at 37C for 30min. 
Subsequently the beads were washed 6 times with ice-cold IP buffer, resuspended in 
200mM of DTT and 7.5% of SDS, and incubated at 37C for 30min. Then the beads were 
removed and the supernatant was collected adjusting the volume to 1.5 mL with IP 
buffer. 50 μl of Streptavidin beads were added, and the samples were rotated 30min at 
room temperature. After rotation head-to-tail, the beads were washed 3 times with 1% 
SDS, once with 2M NaCl, twice with 20% isopropanol, and 5 times with 50% acetonitrile.  
Reverse Cross-link and protein digestion - The beads were resuspended in 0.1% RapiGest 
and 5mM DTT. To reverse the cross-links, the beads were boiled at 95C for 20min 
followed by adding 10mM iodoacetamide to the solution. After 30min incubation 5mM 
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DTT was added to the solution. Then 250ng Lys-C and 1μg Trypsin were added to the 
samples to digest the proteins overnight at 37⁰C  
Peptide and DNA purification - Supernatant with peptides was collected from the beads 
and cleaned by SP3 protocol to separate the peptides for MS and the DNA for qPCR 
analysis. SP3 beads were prepared by mixing 2x20μl of Sera-Mag beads in a 0.2-ml PCR 
tube. Beads were washed three times with 160μl of dH2O. Beads were resuspended in 
100μl of dH2O (note: the beads could be stored for 2 weeks in the fridge). 2μl of the SP3 
beads were added to the peptides and vortex. Then 200 μL of acetonitrile (ACN) 100% 
were added. Samples were vortexed and spin briefly. 20μl of ACN 100% were added and 
beads were left for 10 min before putting in the magnet. Liquid was collected for DNA 
isolation and 200 μL of ACN 100% were added to the beads. Liquid was discarded from 
the beads followed by a brief spin of the beads to discard all the residues of ACN. Once 
all the ACN was removed, 10μl of DMSO 2% were added on the walls of the tubes without 
pipetting. Beads were vortex vigorously and spin for a few seconds. Beads were removed 
and supernatant was transferred to tubes with 1μl of formic acid 1% and stored at -80⁰C 
until MS analysis. To recover DNA after digesting the proteins the liquid collected in the 
SP3 clean-up protocol containing the DNA was drown out using a speed vac. DNA was 
then reconstituted using TE buffer. DNA was cleaned using Sera-mag beads and 
resuspended in a final volume of 20µL of Tris-Cl 10mM without EDTA for qPCR analysis. 
DNA was quantified by Qubit 2.0 using the HS dsDNA quantification kit.  
 
ChIP SICAP (Modified protocol) (See Figure 3.3a for diagram) 
Double Cross-link, cell lysis and sonication - Human Fibroblasts were seeded at a density 
of 1.5x106 cells in 15 cm dishes and transduced with concentrated OCT4 (WT and 
mutants) lentivirus, along with SOX2, cMYC, KLF4 and rtTA2M2 concentrated lentivirus 
at MOI of 5. 16 hours post-transduction, the medium was replaced and cells were 
cultured for 48 hours. OSKM protein expression was induced adding fresh medium with 
1μg/mL of doxycycline into one dish of each factor infection. Cells were cultured for 48 
hours before Cross-link. For control samples, Human Fibroblasts without transduction of 
the virus were cultured and processed as the fibroblasts with virus. For hES, cells were 
grown in 15cm dishes until 90% confluence before Cross-link. Chromatin fragments were 
prepared from the 15 cm dishes (hES, OSKM 48h and HF). Before cross-linking DSG and 
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Formaldehyde were made fresh. To crosslink, cells were washed 3X with PBS at RT. After 
final wash, 15mL of PBS/MgCl2 was added to each plate. 120μL of fresh DSG (0.25M stock 
prepared by adding 613μL DMSO to 50mg of DSG) were added to each plate to get a final 
concentration of 2mM. Plates were incubated at RT for 45min in a horizontal shaker with 
constant moving followed by 3X washes of PBS prior to the FA cross-link. After the last 
wash, 20 mL of PBS were added to each plate followed by adding 3mL of Formaldehyde 
crosslinking buffer (50mM HEPES-KOH, pH7.5, 100mM NaCl, 1mM EDTA, 0.5mM EGTA, 
11% formaldehyde). Crosslinking was blocked by adding 1.65 mL 2.5M Glycine and 
incubating for 5 minutes at room temperature. Cells were harvested using a silicon 
scraper and centrifuged for 5 minutes at 1350 rcf at 4⁰C. Cells pellets were then 
resuspended in 10mL Lysis Buffer 1 (50mM HEPES-KOH pH7.5, 140mM NaCl, 1mM EDTA, 
10% Glycerol, 0.5% NP-40 Substitute, 0.25% Triton X100 and cOmplete Ultra Protease 
Inhibitor rotated for 10 minutes at 4⁰C. Cells were disrupted using a tight 7mL dounce 
homogeniser with 80 strokes on ice. Nuclei were collected by centrifugation at 1350rcf 
for 5 minutes at 4⁰C. The nuclei were washed in 10mL Lysis Buffer 2 (10mM Tris-HCl pH 
8, 200mM NaCl, 1mM EDTA, 0.5mM EGTA and cOmplete Ultra Protease Inhibitor) for 10 
minutes a rotator at room temperature. The nuclei were collected by centrifugation and 
resuspended in Lysis Buffer 3 (10mM Tris-HCl pH8, 100mM NaCl, 1mM EDTA, 0.5mM 
EGTA 0.1% Na-deoxycholate, 0.5% N-lauroylsarcosine and cOmplete Ultra Protease 
Inhibitor. Samples were sonicated using a Covaris M220 sonicator using a time of 90 min 
for hES and 140 min for HF and OSKM 48h. Sonication was done in 10 minutes intervals. 
To solubilise chromatin following sonication 100μL of 10% Triton X-100 was added per 
1mL of sonicated chromatin. Before ChIP, 50μl of sonicated chromatin were collected to 
test sonication quality in an agarose gel electrophoresis.  
OCT4 and IgG ChIP – For each ChIP, 70μL of Protein G Dynabeads were washed three 
times with PBS+0.02% Tween. The beads were saturated with 20μg of OCT4 antibody or 
IgG for hES Ctrl diluted in 600μL of with PBS+0.02% Tween by rotating for 6 hours at 4°C. 
The beads were then washed three more times in PBS+0.02% Tween. ChIP was carried 
out by incubating the beads with 120μg of chromatin overnight at 4°C (concentration of 
chromatin was estimated by purifying and quantifying DNA from the 50µL of sonicated 
chromatin used for visualization in the agarose gel). Beads were washed once with 10mM 
Tris-HCl, and once with 1xTdT buffer.  
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Biotinylation - The beads were resuspended in 1xTdT buffer, 4μL ddUTP-Biotin and 4μL 
of TdT enzyme and incubated at 37C for 30min. Subsequently the beads were washed 6 
times with ice-cold IP buffer (50mM Tris-HCl pH 8, 5mM EDTA, 1% Triton, 0.5% NP40, 150 
mM NaCl), resuspended in 200mM of DTT and 7.5% of SDS, and incubated at 37C for 
30min. Then the beads were removed and the supernatant was collected. NOTE: Two 
ChIPs were pooled at this stage for each replicate, meaning 240ug of initial chromatin 
from the same sample for each replicate. Once two ChIPs were pooled, volume was 
adjusted to 1.5 mL with IP buffer and added to 50 μl of Streptavidin beads previously 
washed 3X with IP buffer. Samples were rotated 1h at room temperature. After rotation 
head-to-tail, the beads were washed 3 times with 1% SDS, once with 2M NaCl, twice with 
20% isopropanol, and 4 times with 50% acetonitrile.  
FASP - Beads were resuspended in 100μL of 0.1% RapiGest and 2.5μL of 1M DTT to get a 
final concentration of 25mM. To reverse the cross-links and digest the proteins, beads 
were boiled for 10 min at 95C. Supernatant was collected in new Lo-Bind tubes and 
beads were discarded. 91.1 μg of Urea was added directly to the sample to a final 
concentration of 8M and shake until dissolved. FASP was done as described [187]. The 
solution was then transferred to a Vivacon 500 spin column and centrifuged for 15 min 
at 13,800g. Supernatant was discarded and 100μl of 0.05 M Iodoacetamide dissolved in 
8 M urea (dissolved in 0.1M Tris-HCl pH 8.2) were added to the membrane and incubated 
at RT for 20 min protected from light followed by 10 min centrifugation at 13,800g. 
Membrane was washed with 100μl of 8M urea and centrifuged for 15 min at 13,800g. 
Next wash was performed with 100 μL of 0.05 M of ammonium bicarbonate (ABC) buffer 
in ultrapure water followed by a 15 min centrifugation at 13,800 g. Collection tubes were 
removed and the membrane column was placed in a new Lo-bind tube. To digest the 
proteins 1μg Trypsin (1μl – 1μg/μL) and 50ng LysC (2.5μl – 20μg/mL) in 100 µl 5 mM ABC 
buffer were added to the membrane column and incubated overnight at 37C. To recover 
peptides, the membrane columns were centrifuged for 15 min at 13,800g. Supernatant 
was not discarded as it contained the digested peptides. Column was washed once with 
100 μL of ABC buffer. Wash was not discarded and it was pooled with the digested 
peptides solution for storage at-20C before MS.  
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Immunoprecipitation 
Cell lysis - Human Fibroblasts were seeded at a density of 1.5x106 cells in 15 cm dishes 
and transduced with concentrated 3XFLAG OCT4 (WT and mutants) lentivirus, along with 
SOX2, cMYC, KLF4 and rtTA2M2 concentrated lentivirus at MOI of 5. 16 hours post-
transduction, the medium was replaced and cells were cultured for 48 hours. OSKM 
protein expression was induced adding fresh medium with 1μg/mL of doxycycline into 
one dish of each factor infection. Cells were cultured for 48 hours and pellet was 
collected. For control samples, Human Fibroblasts without transduction of the virus were 
cultured and processed as the fibroblasts with virus. Cells were scrapped in the cold room 
(4⁰C), collected in 50 mL tubes and centrifuged at 1350 rfc for 10 minutes at 4⁰C. Dishes 
were washed with cold PBS and scrapped again to recover most cells. Second wash was 
added to the pellet and centrifuged at 1350 rfc rpm for 10 minutes at 4⁰C. If pellet is too 
pink wash with cold PBS once more. For protein extraction pre-cold all the buffers and 
PBS. Cells were resuspended in 1mL of IP lysis buffer (50 mM Tris-HCl pH 8, 100 mM KCl, 
5 mM MgCl2, 10 % glycerol, 0.5 % NP-40 (add fresh), 0.2 mM EDTA, 1X cOmplete Ultra 
Protease Inhibitor (add fresh)). Cells suspension was transferred into a 2 mL Dounce 
Homogenizer (cooled on ice) and 100 strokes with thigh pestle were applied, being 
careful with the bubbles. Cells were transferred into a cold 1.5 mL LoBind Tube and left 
in IP lysis buffer (with glycerol) for 30 min rotating in the cold room. Extract was 
centrifuged for 10 min centrifugation at max speed at 4C, transfer supernatant 
containing the protein extract to a new cold LoBind tube. 50μl of the total extract were 
collected prior to the IP, to use for input analysis.  
3XFLAG IP- For Immunoprecipitation all steps were carried on in the cold room. For each 
sample 170 μl of Anti-FLAG® M2 Magnetic Beads (previously vortexed for minimum one 
minute) were transferred to cold LoBind tubes. Anti-FLAG® M2 Magnetic Beads. Beads 
are more easily pipetted with a cut-off yellow tip, previously washed with MiliQ. Once 
collected, Anti-FLAG® M2 Magnetic Beads were washed 4X with 1mL of C-100* Buffer 
(HEPES (pH 7.6), 20 mM, Glycerol 10%, MgCl2, 1.5 mM, KCl 100 mM, EDTA 0.2 mM, 
Protein Inhibitors 1X (add fresh), DTT 0.5 mM (add fresh), NP40 0.02% (add fresh)). For 
each sample, the 1mL extract was added to the washed beads. 6 μl of Benzonase 
RNA/DNA nuclease (25U/mL) was added per mL of extract. Beads and extract were left 
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O/N rotating in the cold room. Supernatant was collected and kept as a control of: Non 
Bound proteins. Beads were washed 3X with cold C-100* Buffer.  
Elution - To elute, FLAG tripeptide (Sigma) was prepared at 0.2mg/mL. For each elution, 
70 μl of FLAG tripeptide were added to the beads and left for 15 min at 4°C, mixing by 
taping the tube every 3-5 min. Five elutions were taken for each sample and collected in 
separate LoBind tubes. 5μl of every elution were transfer to new tubes to validate the 
presence of 3XFLAG OCT4 (WT and mutants) by Western Blot. For Sypro staining, 35μl of 
each elution were separated from one replicate. For MS, for each replicate 10 μl of the 
elutions (1-5) were pooled per replicate and processed by in-gel digestion.  
SyproRuby staining of elutions - For one of the replicates, 35μL of each elution were 
taken for the gel. NuPAGE™ LDS Sample Buffer (4X) and Bolt 10X Reducing agent (10X) 
were added to each elution for a final concentration of 1X. Samples were heated at 70°C 
for 10 minutes. Final volume was loaded into a Bolt™ 4-12% Bis-Tris Plus Gel and ran at 
200V for 30 min. After electrophoresis, gels were placed into a clean container with 100 
mL of fix solution (50% methanol, 7% Acetic acid) and agitated on an orbital shaker for 
30 minutes. Fix step was repeated once. After fixing, gels were washed for 10 min 3X with 
MiliQ. After washes, 50mL of SYPRO™ Ruby Protein Gel Stain were added and left 
overnight covered from light and in an orbital shaker. Next day, gels were transferred to 
a clean container and washed in 100 mL of wash solution (10% Methanol, 7% Acetic Acid) 
for 30 minutes. Before imaging gel was rinsed 2X in MiliQ. Gels were visualized using a 
UV Transiluminator.  
 
SILAC  
Protein extraction  
After five passages with SILAC media, 10 cm dishes of hES and HF were scraped and 
pelleted by centrifuging for 5-10 minutes at 500 × g. Media was removed and cells were 
washed twice with PBS. Cells were lysed on ice using RIPA lysis buffer containing 
cOmplete Ultra Protease Inhibitor and sonicated on high with Bioruptor (6x10 sec 
intervals). Cell suspension was left for 15 minutes rotating in the cold room. Cells lysates 
were centrifuged for 15 minutes at max. speed (4°C) and transfer to protein LoBind tubes. 
Protein concentration was determined for each sample using the Pierce™ BCA Protein 
Assay Kit.  
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Coomassie staining - 5μg of each replicate (hES and HF) were separated by SDS-
polyacrylamide gel electrophoresis in Bolt™ 4-12% Bis-Tris Plus Gel and stained with 
GelCode™ Blue Safe Protein Stain. 
For MS analysis: Equal amount of protein was mixed for each replicate in a new tube. 
Samples were mixed as follows: hES1 + HF1 = hESHF R1, hES2 + HF3 = hESHF R2, hES3 + 
HF3 = hESHF R3. 
 
2.2.10 Mass spectrometry 
All protocols, materials and training were obtained from Christos Spanos in Juri 
Rappsilber lab (Wellcome Trust Centre for Cell Biology – Kings Buildings – The University 
of Edinburgh)  
In gel digestion for MS - Used for the Immunoprecipitation protocol and SILAC 
Gel: DTT was added to the IP and SILAC samples to a final concentration of 5%. NuPAGE™ 
LDS Sample Buffer (4X) was added to a final concentration of 2X. Samples were heated 
at 90°C for 10 min and let to cool before loading in the gel. Samples were loaded in a 
NuPAGE Novex 4-12% Bis-Tris gel and ran at 190V for 10-15 min, only to concentrate the 
samples at the top of the gel. Gel was washed with MiliQ for 5 min before staining with 
Instant™ Blue Coomassie for 1hr. Gel and Coomassie were washed 5x5 min with MiliQ 
before cutting.  
Excise protein bands and Wash Coomassie stain: All these steps were done in a hood to 
avoid contaminants. For each sample, the piece of gel stained with Coomassie was cut 
into cubes ca. 1mm and transferred to microcentrifuge 1.5 mL tubes. Scalpel was washed 
with 70% EtOH between samples to avoid contamination from previous samples. To 
wash and remove Coomassie, 50mM Ammonium bicarbonate (ABC) was added to cover 
the gel pieces and incubated at room temperature for 5 min. ABC was discarded and 
100% Acetonitrile (ACN) was added to cover gel pieces and incubated until the pieces 
became white and shrink. ABC and ACN washes were repeated twice. For the last wash, 
equal amount of ABC and ACN were added to cover the gel pieces and incubated for 1hr 
at 37oC in a Thermostat with shaking until Coomassie was faintly blue. ACN was added 
until gel pieces were covered and incubated for 5 min. ACN was removed to Reduce and 
Alkylate. 
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Reduction/Alkylation: DTT solution (10mM DTT in 50mM ABC) was added to cover the 
gels and incubated for 30 min at 37oC in a Thermostat. DTT solution was removed and 
ACN was added to cover the gels and incubated for 5 min to shrink the pieces. ACN was 
removed and Iodoacetamide (IAA) solution (55mM iodoacetamide in 50mM ABC) was 
added to cover the gel pieces and incubated for 20 min at RT in the dark (cover with foil). 
IAA solution was removed and gel pieces were washed with ABC for 5 min once prior to 
shrink with ACN for 5 min. ACN was removed prior to digestion. 
Trypsin digestion: As described [188]. Trypsin buffer (13ng µL-1 trypsin in 10mM 
ammonium bicarbonate containing 10% (v/v) acetonitrile) was prepared as follows: 20 
µL of 0.1% TFA (in 50mM ABC) was added to lyophilised Trypsin Protease (MS grade). 
Resuspended trypsin was transferred to a cold LoBind containing 1030 µL of dH2O, 300 
µL of 50mM ABC and 150 µL of ACN, trypsin was made fresh and kept in ice until use. 
Once prepared, trypsin buffer was added to the shrink gel pieces until covered. Gels with 
trypsin were incubated for 15 min at 4oC. Tubes with gel pieces and trypsin were 
transferred to 37oC in an incubator, after 30 min gel pieces were checked to see if all 
liquid was absorbed, if necessary, more trypsin buffer was added to completely cover the 
gel pieces. Samples were incubated overnight (12-16h) at 37oC. Next day, digestion was 
stopped by acidifying the samples to pH < 2.5 with 10µ 10% Trifluoroacetic adic (TFA). 
Digested peptides were recovered by removing the supernatant liquid from the gel 
pieces and transferred to a LoBind tube before StageTip cleaning, this solution contained 
the peptides. To obtain more peptides from each sample, gel pieces were covered with 
100% ACN for 5-10 min, until shrank. ACN was transferred into a clean LoBind tube and 
dried under vacuum centrifugation at 60 oC. 100 µL 0.1% TFA were added to the dried 
tubes to resuspend peptides and used for StageTip cleaning. 
Stage tip cleaning – Used for all protocols: Digested peptides from ChIP-SICAP, SILAC 
and 3XFLAG-IP 
As described by Rappsilber et al. [189]. Digested samples were acidified to a pH < 2.5 by 
adding 10-20μl with 10% Trifluoroacetic acid (TFA). Empore Disk C18 Octadecyl (C18)-
bonded silica were manually cut and inserted into a pipette tip. Three disks were inserted 
in the tip for each sample. Before passing the digested samples, StageTips were washed 
by adding 50µL of methanol and centrifuged in a mini-table-centrifuge until all the liquid 
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passed through the disks. 70 µL of 80% Acetonitrile (ACN) in 0.1% TFA were added to the 
tips and centrifuged in a mini-table-centrifuge until all the liquid passed through the 
disks. To equilibrate StageTips in acidic conditions, 70µL of 0.1% TFA were added to the 
tips and centrifuged in a mini-table-centrifuge until all the liquid passed through the 
disks. Digested and acidified samples were added to the tips to bind the peptides to the 
disks. Tips were centrifuged in a mini-table-centrifuge until all the liquid passed through 
the disks. After passing all the digested sample, StageTips with the peptides bound to the 
disks were washed 2X with 100µL of 0.1% TFA and centrifuged in a mini-table-centrifuge 
until all the liquid passed through the disks. Tips can be left at -20°C for further analysis 
by LC-MS.  
 
Mass Spectrometry – LC-MS – Steps performed by Christos Spanos in Juri Rappsilber 
lab (Wellcome Trust Centre for Cell Biology – Kings Buildings – The University of 
Edinburgh) 
Peptides were eluted in 40 μL of 80% acetonitrile in 0.1% TFA and concentrated down to 
1 μL by vacuum centrifugation (Concentrator 5301, Eppendorf, UK). Samples were then 
prepared for LC-MS/MS analysis by diluting them to 5 μL with 0.1% TFA. LC-MS-analyses 
were performed on an Orbitrap Fusion™ Lumos™ Tribrid™ (Thermo Fisher Scientific, UK) 
and on a Q Exactive mass spectrometers (both from Thermo Fisher Scientific) both 
coupled on-line, to Ultimate 3000 RSLCnano Systems (Dionex, Thermo Fisher Scientific, 
UK). In both approaches, peptides were separated on a 50 cm EASY-Spray column 
(Thermo Fisher Scientific, UK) assembled on an EASY-Spray source (Thermo Fisher 
Scientific, UK) and operated at a constant temperature of 50oC. Mobile phase A consisted 
of 0.1% formic acid in water while mobile phase B consisted of 80% acetonitrile and 0.1% 
formic acid. Peptides were loaded onto the column at a flow rate of 0.3 μL min-1 and 
eluted at a flow rate of 0.25 μL min-1 according to the following gradient: 2 to 40% buffer 
B in 150 min, then to 95% in 11 min. For Orbitrap Lumos, survey scans were performed 
at 120,000 resolution (scan range 350-1500 m/z) with an ion target of 4.0e5. MS2 was 
performed in the Ion trap at rapid scan mode with ion target of 2.0E4 and higher-energy 
collisional dissociation (HCD) fragmentation with normalized collision energy of 27 (Olsen 
et al, 2007) . The isolation window in the quadrupole was set at 1.4 Thomson. Only ions 
with charge between 2 and 7 were selected for MS2. For Q Exactive, MS1 spectra were 
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recorded at 70,000 resolution and the top 10 most abundant peaks with charge ≥ 2 and 
isolation window of 2.0 Thomson were selected and also fragmented by HCD 
fragmentation of 27. The maximum ion injection time for the MS and MS2 scans was set 
to 20 and 60 ms respectively and the AGC target was set to 1 E6 for the MS scan and to 
5 E4 for the MS2 scan. Dynamic exclusion was set to 6s.  
 
Protein identification – Performed by Christos Spanos in Juri Rappsilber lab (Wellcome 
Trust Centre for Cell Biology – Kings Buildings – The University of Edinburgh) 
The MaxQuant software platform [190] version 1.6.1.0 (released in April 2018) was used 
to process raw files and search was conducted against the complete/reference proteome 
of Homo sapiens (released in November, 2017), using the Andromeda search engine 
[191]. The first search peptide tolerance was set to 20 ppm while the main search peptide 
tolerance was set to 4.5 pm. Isotope mass tolerance was 2 ppm and maximum charge to 
7. Maximum of two missed cleavages were allowed. Carbamidomethylation of cysteine 
was set as fixed modification. Oxidation of methionine and acetylation of the N-terminal 
were set as variable modifications. Label-free quantitation analysis was performed by 
employing the MaxLFQ algorithm as described by Cox et al [192]. SILAC quantification 
analysis was performed by employing the MaxQuant as described by Cox et al [193]. For 
peptide and protein identifications FDR was set to 1%. 
 
2.2.11 DNA purification 
Sonicated DNA  
The 50μL of sonicated chromatin collected after sonication were reversed cross-linked in 
150μL ChIP-Elution Buffer (50mM Tris-HCl pH8, 10mM EDTA, 1% SDS) by incubating for 
16 hours at 65⁰C in a shaker. Samples were then diluted with 200μL TE (10mM Tris-HCl 
pH8, 1mM EDTA) and incubated with 0.2mg/mL RNase A for 2 hours at 37⁰C. Proteins 
were digested by incubating with 0.2mg/mL Proteinase K for 2 hours at 55⁰C. The DNA 
was then purified by phenol-chloroform extraction followed by ethanol precipitation. 
Precipitated DNA was eluted in 50μL of 10mM Tris-HCl pH8.5 (EB buffer). DNA was 
quantified by NanoDrop and 2-3 μg of DNA were loaded in a 1.6% agarose gel with EtBr 
and ran at 60V for 3 hrs. Gels were visualised in an UV transiluminator.  
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DNA recovery for qPCR – ChIP-SICAP 
To test DNA recovery via qPCR, hES and HF samples (FA XL and DSG+FA XL) were 
processed following the modified protocol ChIP-SICAP without following the protein 
digestion steps. To recover DNA for qPCR analysis, samples were processed after the 
streptavidin-capture by washing 5 times with RIPA Wash Buffer (50 mM HEPES-KOH, pH 
7.5, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-deoxycholate) and once with TE NaCl 
(10mM Tris-HCl pH8, 1mM EDTA, 50mM NaCl). Bound chromatin was eluted by 
resuspending the beads in 200μL ChIP-Elution Buffer (50mM Tris-HCl pH8, 10mM EDTA, 
1% SDS) and rocking at 65⁰C for 30 minutes before transferring the supernatant to a new 
tube. Crosslinking was reversed by incubating for 16 hours at 65⁰C. Samples were then 
diluted with 200μL TE (10mM Tris-HCl pH8, 1mM EDTA) and then incubated with 
0.2mg/mL RNAse A for 2 hours at 37⁰C. Proteins were digested by incubating with 
0.2mg/mL Proteinase K for 2 hours at 55⁰C. The DNA was then purified by 
Phenol:chloroform:Isoamyl extraction followed by ethanol precipitation. Precipitated 
DNA was eluted in 20μL of 10mM Tris-HCl pH8.5 for qPCR analysis. DNA was quantified 
by Qubit 2.0 using the HS dsDNA quantification kit. 
 
ChIP-qPCR 
DNA from ChIP (DSG+FA and FA) and ChIP-SICAP (original method) was amplified with 
PowerUp™ SYBR™ Green Master Mix as follows (LightCycler® 480 Roche II) 50⁰C for 2 
min and 95⁰C for 2 min and then 45 cycles of 95⁰C for 15 s and 60⁰C for 1 min. Gene 
targets and oligonucleotides are in Table 2.3 . PCR specificity for each primer pair was 
measured by gel electrophoresis and melting curve analysis. Threshold cycle values (Ct) 
analysis were from three PCR replicates. qPCR results are normalised to Input DNA 
diluted to 1ng/µL and the enrichment of ChIP(FA XL and DSG+FA XL) and ChIP-SICAP DNA 
over input DNA was calculated by Enrichment=2^(-(ct ChIP-ct input)). 
 
Table 2.3 Primers used for ChIP-qPCR 
Name Forward (5'-3') Reverse (5'-3') 
2MIR_367 ggaattagtgtaacattcctgcat ctgctgtgagggcaaattaac 
MYOD ggacttatgtttgtatagcgggag agaatagatttcctgccaagtg 
2DPPA4_Prom ggagattgagcactccttcag  ctgttgccacaagttccattatt 
MIR_367_Neg cctgggtaactgcactcaaa gactacaggaatgtgccaact 
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2.2.12 ChIP-seq 
ChIP – Modified from Soufi et al. [110]. OSKM 48 hrs (WT and mutants) were double 
cross-linked (DSG and FA), pelleted, lysed and sonicated as described in ChIP-SICAP 
(modified protocol). Samples were sonicated for 140 min for HF ctrl and OSKM 48h (WT 
and mutants). Sonication was done in 10 minutes intervals. Before ChIP, 50μl of 
sonicated chromatin were collected to test sonication quality in an agarose gel 
electrophoresis and to determine DNA concentration. Three IPs were performed per 
OCT4 (WT and mutants) using 40µg of sonicated chromatin per IP. All buffers should be 
fresh and cold and all tubes should be LoBind. For each IP 35µl of Dyna G Magnetic Beads 
were transferred to a Prechill LoBind tube and washed 3X with 1mL of Blocking buffer 
(0.5 BSA in PBS). Beads were resuspended in 800 µl of Blocking buffer with 10µg of OCT4 
ab per IP and incubated for 6 hr (minimum) on a rotating platform at 4°C. Beads were 
washed 3X in 1mL of blocking solution and resuspended in 100µl LB3 (see ChIP-SICAP) 
buffer. 40 µg of sonicated chromatin were added to each IP and volume was top up to 
900 µl using LB3 buffer and protease inhibitors. IPs were incubated overnight in a rotator 
platform at 4°C. Next steps were done in the cold room. Using the magnetic rack to 
separate beads, supernatant was transferred to a pre-chill LoBind tube, supernatant is 
the no bound fraction. Beads were washed 4X with cold RIPA-wash buffer (50 mM Hepes-
KOH pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-Deoxycholate). Beads were 
washed 1X with TE+NaCl(10mM Tris-HCl pH 8, 1mM EDTA pH 8 and 50mM NaCl), 
followed by a spin at 300 x g for 3 minutes at 4°C and to remove any residual TE buffer. 
210 µL of ChIP elution buffer (see ChIP-SICAP) were added to be beads and let at 65°C for 
30 minutes shaking at 1200rpm to elute the proteins and DNA. Tubes were centrifuged 
at 16,000 x g for 1 minute at room temperature and 200 µL of supernatant was 
transferred to a new tube. In parallel, 50 µL of sonicated chromatin from the INPUT after 
sonication was thawed before adding 150 µL of ChIP elution buffer. ChIPs and input were 
reverse cross-linked by incubating at 65°C overnight (shake 700rpm). 
Digestion of Protein and RNA: An equal volume (200 µL) of TE (10mM Tris-HCl pH8, 1mM 
EDTA) and incubated with 0.2mg/mL RNAse A for 2 hours at 37⁰C. Proteins were digested 
by incubating with 0.2mg/mL Proteinase K for 2 hours at 55⁰C. To extract DNA, 400 µL 
Phenol:chloroform:isoamyl alcohol were added to the samples to separate phases by 
spinning the sample at top speed for 5 min. The aqueous layer was transferred to a new 
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tube 16 µL of 5M NaCl (200 mM final concentration) and 1.5 µL of 20 µg/µL glycogen (30 
µg total). DNA precipitation was performed by adding 0.8mL of cold 100% EtOH and 
incubated for 180 min at least at -20°C. Tubes were centrifuged 20,000 x g for 10 minutes 
at 4°C to pellet DNA. Supernatant was carefully decanted taking care of the pellet, which 
were washed with 500 µL of 80% EtOH spin at 20,000 x g for 10 minutes at 4°C to pellet 
DNA after each wash. Supernatant was removed by pipetting and pellets were allowed 
to dry for 5 min. Each pellet was resuspended in 20 µL MiniPrep Elution buffer (10mM 
Tris-HCl pH8.5, Qiagen) using a P20 pipette. DNA was quantified by Qubit 2.0 using the 
HS dsDNA quantification kit.  
 
Sequencing Library Generation 
Libraries were prepared from ChIP-DNA pooled using equal volumes of 3 replicates ChIP 
for each OCT4 (WT and mutant) using the NEBNext Ultra II Library Preparation Kit with 
Dual Index Primers with size selection for fragments of approximately 200bp carried out 
using SpeedBeads™, which comprise magnetic carboxylate modified particles. For each 
OCT4 (WT and mutants), libraries were prepared using 20-50ng ChIP DNA. Input libraries 
were generated using 20ng of sonicated DNA. PCR amplification during library 
preparation was limited such that samples underwent 10 cycles of PCR amplification. 
Libraries were quantified using a Qubit 2.0 device with a high sensitivity dsDNA kit and 
fragment size was determined using an Agilent 2200 Tapestation with D1000 HS 
reagents. The DNA libraries were then pooled by mixing an equal concentration of each 
ChIP DNA library. The concentration of the ChIP DNA library pool was determined to be 
24.8 nM by an Agilent 2200 Tapestation with D1000 HS reagents. Library was submitted 
for sequencing using a NovaSeq S1 50PE (1 lane) platform to yield approximately 750M 
+ 750M paired ends. Sequencing was performed by Edinburgh Genomics (Kings Buildings, 
The University of Edinburgh). 
 
2.2.13 Cloning 
All plasmids (donated, bought and new constructs) were verified by sequencing 
Plasmids 
OSKM 48h: pwPT-GFP, pwPT-rtTA2M2, psPAX2, pMDG and the FU-tetO-O/S/K/M vectors 
were obtained from Abdenour Soufi. FU-tetO-OCT4 plasmid mutants (O lin-min, O lin29-
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42 and O lin97-119) were obtained from Burak Özkan (Soufi lab).  
 
Rescue assays: CAG-IP-3XFLAG-mOct4, CAG-IP-GFP and CAG-IP-empty plasmids for 
rescue assays were obtained from Chambers Lab.  
 
sgRNA KO: pKLV2-U6gRNA5(BbsI)-sEF1aBFP-W (KPL474) backbone for sgRNA was 
obtained already linearized from Benedetta Carbone (Keisuke Kaji Lab). Zeo, Tpr53 and 
Dot1L cloned vectors were donated by Dan K (Kaji Lab) and Stat3 cloned vector was 
donated by Meryam B (Kaji Lab)  
 
Overexpression of candidates: Plasmids with coding sequences for UFD1L 
(HsCD00324735, human), ETV4 (HsCD00326736, human), XPO6 (HsCD00418235, human) 
and RAI1 (HsCD00329661, human) were bought from Harvard PlasmID Repository (DNA 
Resource Core, Harvard Medical School). Plasmid for Mcmbp (NM_145955, Mouse 
Tagged ORF Clone, CAT#: MR209710) was bought from OriGene. Plasmid for TNIP2 
(cDNA ORF Clone in Cloning Vector, Human, Cat: HG19965-U) was bought from Sino 
Biological. FU-tetO-ZBTB2 was donated by Dan K (Kaji Lab). Plasmid for KDM4B was 




To construct the FU-tetO-3XF-OCT4 the 3XFLAG tag sequence was added to the N-
terminus of OCT4 using as a template the 3XFLAG sequence from CAG-IP-3XFLAG-mOct4 
plasmid obtained from Nick Mullin (Chambers Lab). PCR product was digested with 
BsmBI and SfiI and ligated with T4 DNA Ligase into FU-tet-O-hOCT4 plasmid linearized 
with BsmBI and SfiI. Primers are listed in Table 2.4. 
 
3XFLAG-OCT4 Mutants 
To construct FU-tetO-3XF-O lin-min/lin29-42/lin95-117 the 3XFLAG tag sequence was 
added to the N-terminus of each factor using as a template the sequence from FU-tetO-
hO lin-min/lin29-42/lin95-117 plasmids obtained from Burak Özkan (Soufi lab). PCR 
products were inserted into FU-tet-O-3XF-hOCT4 plasmid linearized with BamHI and XbaI 
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using the In-Fusion® HD Cloning Kit. Primers are listed in Table 2.4. 
 
Candidates 
To construct FU-tetO-UFD1L/XPO6/MCMBP/RAI1/TNIP2/ETV4/KDM4B, PCR products 
were inserted into FU-tetO plasmid linearized with EcoRI and XbaI using the In-Fusion® 
HD Cloning Kit. Primers are listed in Table 2.4. 
 
Table 2.4 Primers used for FU-tetO Cloning 
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sgRNA cloning 
To construct the sgRNA lentivirus, sgRNA sequences were obtained from a mouse 
reported library [194]. Primers were order as 19-bp complementary oligonucleotides 
with the following 5’ and 3’ attachments for cloning:  
 Top strand: Add “CACCG” to the 5’ end.  
 Bottom strand: reverse complement the sequence and add “C” at the 3’ end and 
“AAAC” to the 5’ end. 
 
Oligos were annealed using a heat block starting at 95 oC and allowed to cool slowly over 
12 min to RT. Annealed oligos were diluted to 7.1 pmol/µL. sgRNA lentivirus vector 
(pKLV2-U6gRNA5(BbsI)-sEF1aBFP-W (KPL474)) was digested with BbsI and donated by 
Benedetta C. 20ng of linearized vector and 2µL of diluted annealed oligos were ligated 
T4 DNA ligase. Oligos are listed in Table 2.5. 
 
Table 2.5 Oligos used for sgRNA lentivirus cloning 































Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
















CAG-IP cloning  
To construct the CAG-IP-hOCT4/3XFLAGhOCT4 the hOCT4 and 3XFhOCT4 sequences 
were obtained from FU-tetO-hOCT4/3XFhOCT4. PCR products were digested and ligated 
with T4 DNA Ligase into CAG-IP plasmid linearized with NotI and dephosphorylated with 
Shrimp Alkaline Phosphatase (rSAP). Primers are listed in Table 2.6. 
 
Table 2.6 Primers used for CAG-IP Cloning  
Construct made  Template Primers (5'-3') Enzymes  

















2.2.14 Data Analysis 
Mass spectrometry 
Filter against Controls 
To define the identified proteins for each sample, datasets were filter against their 
respective controls, using the Perseus Software [195]. First, datasets were processed and 
filtered out against ‘Reverse’ and ‘Only identified by site’ proteins, followed by filtering 
against contaminants. Then, proteins only identified by one peptide sequence were 
discarded, using minimum two peptides as the cut-off value. LFQ values were 
transformed to log2(x). Missing values were imputed using the minimum value setting. 
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To define identified properties, each condition was compared against its respective 
control. ChIP-SICAP datasets: OSKM 48h (WT and mutants) were analysed against HF 
control (no OSKM and OCT4 ab) and hES was filtered against hES control (hES and IgG 
ab). 3XFLAGIPs: 3XFOSKM (WT and mutants) were filtered against HF control (No OSKM 
and IPed with 3XFLAG beads). t-test was performed for each comparison using a FDR of 
0.1 as a threshold value and considering 1.5 fold change as the differentially enriched 
cut-off value.  
 
Differential Enrichment Analysis hES vs OSKM 48h 
Identified proteins for OCT4 ChIP-SICAP in hES and OSKM 48h filtered against control 
were analysed using the Perseus software [195]. LFQ values were transformed to log2(x). 
Missing values were imputed using the minimum value setting. To define differentially 
enriched properties a two sided t-test was performed with 250 randomizations and a 
FDR of 0.1 as a threshold value and considering 1.5 fold change as the differentially 
enriched cut-off value. To visualize the data a volcano plot was generated, choosing the 
t-test difference (Fold change) for the x- and the –log t-test p-value for the y-axis. 
 
Cytoscape network 
Networks of ChIP-SICAP identified proteins for hES and OSKM 48h was built and analysed 
using Cytoscape [196]. First separate networks for hES and OSKM were created using the 
STRING app for Cytoscape [197]. To create each network the reported interactions 
between the list of identified proteins for each dataset were looked in the literature using 
the Homo sapiens database establishing a confidence (score) cut-off of 0.7. Both 
networks were overlapped and visualised using the DyNet Analyser app [198] for 
Cytoscape and using the fold change values defined in the differential enrichment 
Analysis in Perseus (previous section) for the nodes colouring. 
 
Heatmaps and individual protein profiles ChIP-SICAP and 3XFLAG IP 
Hierarchical clustering heatmaps, PCA plots and individual protein profiles for ChIP-SICAP 
and 3XFLAG-IP analysis were performed using the R [199] package DEP (Differential 
Enrichment analysis of Proteomic Data) [200]. For each analysis, a file containing all the 
identified proteins (filtered against controls) for each sample and their respective LFQ 
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values was created. LFQ values were transformed to log2(x). Missing values were 
imputed using the function minimum value setting in the command impute(data_se1, 
fun = "min"). PCA plots were created with the function plot_pca. To define differentially 
enriched properties a Differential enrichment analysis based on linear models and 
empherical Bayes statistics was performed using the command test_diff (imputed_data, 
type = "all"), where “all” indicates individual comparison of all conditions against each 
other. To define the significant changes the command add_rejections(alpha=0.1, lfc=1) 
was used, where alpha is the adjusted pvalue and lfc is the fold change (=2 fold). 
Hierarchical clustering heatmaps were created with plot_heatmap. Individual protein 
profiles were created with the function plot_single. 
 
SILAC Statistical analysis  
SILAC data was analysed with Perseus software [195]. First, datasets were processed and 
filtered out against ‘Reverse’ and ‘Only identified by site’ proteins, followed by filtering 
against contaminants. Proteins only identified by one peptide sequence were discarded, 
using minimum two peptides as the cut-off value. Proteins only present in one replicate 
were discarded, and only proteins present in two out of the three replicates were taken 
into account. The ratios HF/hES were used to define proteins significantly different 
between HF and hES. A one-sample t-test was performed defining the cuttoffs: p-value 
<0.05 as significant and fold change ≤ -1 or ≥ 1 (= 2-fold change). To visualize the data a 
volcano plot was generated, choosing the t-test difference (fold change) for the x- and 
the –log t-test p-value for the y-axis. 
 
Heatmaps SILAC and Microarray Data 
HF/hES SILAC ratios and RNA levels of the proteins identified in ChIP-SICAP hES and OSKM 
were subtracted from the respective datasets to generate the heatmaps using the R [199] 
package gplots and the function heatmap.2 [201]. 
 
Protein Enrichment  
For all proteomic data, to define Gene Ontologies enrichment, Panther classification 
system was used [202]. To enrich for pathways and Complexes, ConcensusPathDB 
database was used [203].  
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ChIP-seq – Analysis was done with the help of Abdenour Soufi 
Mapping of sequenced reads 
The quality of the next generation sequencing (NGS) raw data (FASTQ files) was 
measured by FASTQC tool. All samples scored QC values of more than 30 passing the 
quality control standard for NGS data. The pair-end sequences were mapped to the 
Homo sapiens genome assembly GRCh37 (hg19) using Bowtie (version 2.3.4.1) [204] and 
very sensitive parameters. Duplicated reads were then removed using MarkDuplicates 
from the Picard toolkit (http://broadinstitute.github.io/picard/) and resulting bam files 
were indexed using the index tool from SamTools [205]. The sequencing coverage and 
the insert size distribution were measured from the resulting bam files using Qualimap 
(version 2.2.1)[206]. Overall alignment rate was more than 95% in all samples (hESCs= 
95.23%, O WT=98.17%, O lin-min= 97.13%, O lin95-117= 97.75%, O lin29-42= 95.6%, HF 
input =96.90%). Average insert size distribution was 200bp (hESCs= 218, O WT=224, O 
lin-min= 212, O lin95-117= 202, O lin29-42= 162, HF input =186).  
 
Peak calling 
The indexed aligned reads with no duplicates (bam files) were used for peak-calling. 
Peaks of OCT4 in hES and OSKM 48h (WT and mutants) showing a significant enrichment 
over input DNA were called using MACS2 (version 2.1.1.20160309) [207] and a fragment 
size of 200 bp and were controlled to q-value (minimum FDR) cut-off of 0.01. Peaks were 
extended to 300bp by first finding the summit using awk and then extending using the 
slop tool from DeepTools [208] adding 150bp to each side of the summit. The peaks that 
overlapped with the human ENCODE blacklist were removed. Input signal was subtracted 
using the bedmap tool from BedOps [209] and bed files were sorted according to the 
intensity of the peaks.  
 
Coverage track and normalization 
The indexed aligned reads with no duplicates (bam files) were normalised for sequencing 
coverage to 1X genome depth (reads per genome coverage, RPGC) using the 
bamCoverage tool from DeepTools and a bin size of 10 bp and extendReads parameters 
[208]. Reads within the human ENCODE blacklist were removed from the analysis. The 
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resulting bigwig files were converted to wig format using the bigwigtowig tool, which 
were then converted to bed files using the wigtobed tool [210]. 
 
Interactive genome visualization 
The bigwig files and the peaks files were used to visualize the coverage track and the 
called peaks for each OSKM 48h sample (WT and mutants) along the Homo sapiens 




To identify unique and shared peaks between samples, all peak files were integrated into 
a single file using the tool everything from BedOps [209]. Then, the peaks of the 
integrated file were overlapped using the tool merge from BedTools [209]. This tool 
integrates a final column that indicates from which sample or samples, the identified 
peak originally came from. For unique peaks this column would only contain the name of 
one sample. For shared peaks the column will contain the combination of samples the 
peak was identified in. To extract the files for the unique and shared peaks the function 
awk was used, generating individual bed files the unique peaks for each sample and the 
shared peaks between different combinations of samples. The bed files were then ranked 
by the intensities of the peaks. The intersection between peaks mutants was carried out 
using the Intervene UpSet tool [212].  
 
Read density maps 
To generate the read density heatmap, a density matrix was first computed using the 
DeepTools [208] tool computeMatrix reference-point and the following parameters; --
referencePoint center, --binsize 10, -b 1000 -a 1000, --sortregions keep, and --
averageTypeBins sum . For the hES vs OSKM48hrs read density heatmap, the reference 
files (-R) were the bed sorted files of the unique peaks for each condition and the bed 
sorted file for the shared peaks between both, while the score files (-S) consisted in the 
normalised ChIP-seq bigwig files of hESCs and OSKM 48h total peaks. For the OSKM 48h 
(OCT4 WT and mutants) density heatmap, the reference files (-R) were the bed sorted 
files of the unique peaks for each OCT4 (WT and mutants) and all the possible 
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combinations of shared peaks bed sorted files, while the score files (-S) consisted in the 
normalised ChIP-seq bigwig files of each individual condition total peaks CITE. For both 
cases, the analysis excluded the ENCODE blacklist. The resulting matrix files were then 




For each bed file of unique and shared peaks, de novo motif analysis was carried out using 
the MEME suite installed in a local LINUX server [213]. First, the DNA sequences (FASTA) 
were extracted from the central 200 bp of the ChIP-seq peak regions using the BedTools 
getfasta tool [208]. To use as background, DNA sequences (200 bp) were extracted from 
genomic regions located 1 Kb upstream from the summit of each peak. All regions were 
filtered through the human ENCODE blacklist. Second, the 1st-order Markov background 
model was generated using the fasta-get-markov tool. Finally, meme-chip was run using 
the Fasta sequence files and the corresponding Markov model and the following 
parameters; -nmeme 600, -meme-mod zoops, -meme-minw 6, -meme-maxw 18, -meme-
maxsize 50000000, -dreme-e 0.00001, -dreme-m 20 using the JASPAR core motif 
database [214]. The most enriched de novo motifs discovered by DREME were analysed 
by CentriMO to confirm their central enrichment over the background sequences and 
compared to the canonical motifs using Tomtom. Motif central enrichment were carried 
out using the CentriMo tool [215]. 
 
Distribution of sites in the genome 
GREAT Tool (http://great.stanford.edu/public/html/index.php) [216] was used to 
determine the distribution of unique and shared OCT4 (WT and mutants) bound sites 
with respect to transcription start sites (TSS) of Refseq genes. Sorted bed files of unique 
and shared binding sites were analysed separately and combined in a distribution graph.  
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Chapter 3 OCT4 ENGAGEMENT WITH CHROMATIN-ASSOCIATED 




The overexpression of a set of transcription factors can revert differentiated somatic cells 
into a pluripotent state. Among these factors is member of the POU transcription factor 
family OCT4 that, in combination with SOX2, KLF4 and c-MYC lies at the centre of the 
transcription factor network that is fundamental for the pluripotency maintenance in ES 
cells. While OCT4 can efficiently maintain pluripotency in ESCs, the reprogramming 
capacity of OCT4 is highly inefficient and often result in partially reprogrammed cells [84]. 
It is therefore important to understand how OCT4 can regulate pluripotency in these 
diverse cellular contexts. 
 
As a main factor in both, pluripotency maintenance and reprogramming, different 
studies have been focused in understanding its mechanisms and properties in each 
process. In ES cells, OCT4 mainly functions through the activation of pluripotency 
maintenance-associated and self-renewal-associated genes, while simultaneously 
repressing genes that promote differentiation [217]. During early stages of 
reprogramming OCT4 acts as a pioneer transcription factor, targeting silenced 
pluripotency as well as non-pluripotency genes within closed chromatin for subsequent 
activation [110].  
 
In both reprogramming and pluripotency maintenance, OCT4 interaction with chromatin 
and other proteins is fundamental to regulate gene expression and cell fate decisions. 
The interaction of OCT4 with the transcription factors SOX2 and NANOG define the core 
pluripotency maintenance network that maintains pluripotency [82]. In addition, it is well 
known that interactions with chromatin regulators, other transcription factors and the 
transcription machinery, also modulate OCT4 function in ESCs [82, 84, 163, 172, 178]. 
Yet, the identification of these OCT4 partners has been largely studied in mouse ESCs, 
revealing key insights of OCT4 function during pluripotency maintenance. However, the 
interactions of OCT4 with other proteins, specifically those associated with chromatin 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 3  70 
during are yet to be defined. Because of their importance for a successful reprogramming 
and for pluripotency maintenance, the identification of these OCT4 chromatin-
dependent interactions could provide a better understanding of the protein complexes 
necessary for the chromatin dynamics and the reshaping of the chromatin landscape of 
the genome in the induction and pluripotency maintenance, particularly in the poorly-
studied human system.  
 
3.1.1 ChIP-SICAP as a tool for the identification of chromatin-associated partners 
Several methodologies for affinity enrichment and analysis of chromatin-associated 
complexes have been developed. The principle of most of these approaches relies on the 
enrichment of specific chromatin components by chromatin immunoprecipitation 
protocols (ChIP) followed by protein identification using mass spectrometry (MS). These 
approaches include modified ChIP, ChIP-MS and rapid immunoprecipitation mass 
spectrometry of endogenous protein (RIME) [218]. A common disadvantage of these 
approaches is the lack of discrimination between direct and non-direct interactions, in 
addition to high protein background of non-specifically associated proteins with the 
antibody and other reagents. 
 
To overcome these limitations one of the most recent methods termed selective isolation 
of chromatin-associated proteins (ChIP-SICAP) takes advantage of a classic ChIP followed 
by DNA-labelling and an extra purification step, allowing the specific capture of only 
protein-DNA complexes in the direct vicinity of the bait protein on a short stretches of 
DNA (Fig. 3.1) [219]. In ChIP-SICAP, cells are treated with formaldehyde as in a standard 
ChIP method to crosslink proteins that are in direct contact with DNA, allowing the 
immunoprecipitation of specific protein-DNA complexes along with all proximally bound 
proteins. The 3’-end labelling of DNA fragments with biotinylated nucleotides using a 
terminal deoxynucleotidyl transferase (TdT), followed by denaturation allows the 
disruption of all non-cross-linked proteins and the antibody, which helps to get rid of 
background noise and of the antibody contamination. The isolation of DNA-protein 
complexes using streptavidin-beads, with further stringent washes helps capture the 
purified biotinylated DNA in complex with directly interacting proteins. In the final step, 
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DNA-protein complexes are reverse cross-linked, the digested peptides are identified by 
MS and DNA subjected to high-throughput sequencing (Fig. 3.1) [179]. 
 
Fig. 3.1 ChIP-SICAP Workflow.  Diagram representing the fundamental steps of ChIP-SICAP 
protocol. DNA proteins are cross-linked and sonicated. Chromatin is then 
immunoprecipitation with a suitable antibody following biotinylation of DNA for its retrieval 
along with interacting proteins on streptavidin beads. Extensive washes are applied before 
the isolation of chromatin fragments for reverse cross-linking. Lastly, proteins are digested 
and identified by mass spectrometry. Image taken from [179]. 
 
ChIP-SICAP benefits were demonstrated as an important tool for the expansion of the 
pluripotency maintenance network in mouse embryonic stem cells (mESCs), proving that 
this method is a powerful tool to gain a better understanding of transcriptional networks 
in general, and in pluripotency maintenance. Therefore, ChIP-SICAP represents a useful 
tool to be applied for the better understanding of human chromatin associated networks. 
More specifically, it can be used to describe for the first time the chromatin-associated 
protein networks that define pluripotency and the reprogramming process in the human 
context, which is a field that has not been yet addressed.  
 
3.2 Aims of this chapter 
 Identify the OCT4 chromatin-associated proteins in human ESCs and in early 
reprogramming of human fibroblasts.  
 Compare and contrast the OCT4 interactomes in pluripotency and early 
reprogramming. 
 Quantify the levels of proteins identified as partners of OCT4 in hESCs and early 
reprogramming.  
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3.3 Results 
The results of this chapter are presented in four different sections. First, the ChIP-SICAP 
protocol was modified to identify OCT4 chromatin associated proteins in human 
embryonic stem cells (hESCs). Once modified, the protocol was applied to identify OCT4 
chromatin associated proteins at early stages of reprogramming (48 hrs after OSKM 
induction). Next, both OCT4 interactomes, in hESCs and early reprogramming, were 
compared to define the similarities and differences between OCT4 associated chromatins 
during pluripotency maintenance and early reprogramming. Lastly, quantitative 
proteomics was performed in human fibroblasts and embryonic stem cells to investigate 
the protein levels of the different proteins identified by ChIP-SICAP. 
 
3.3.1 Modification of ChIP-SICAP for the identification of OCT4 chromatin-associated 
protein in human pluripotency 
ChIP-SICAP allows the simultaneous identification of protein and DNA interactions [179], 
therefore it was employed to define OCT4 chromatin-associated partners in human ESCs 
and the early reprogramming of human fibroblasts 48 hours after inducing: OCT4, SOX2, 
KLF4 and cMYC (OSKM 48h).OCT4 ChIP-SICAP was initially tested in hES cells using human 
fibroblasts (HF) with no OSKM expression as a negative control. hES cells were grown in 
feeder-free conditions and defined media, eliminating contaminant proteins from feeder 
cells.  
 
Following the original ChIP-SICAP protocol (Fig. 3.1) (Section 2.2.9 in Materials and 
Methods) [179], 24 million cells were collected and pelleted from both conditions for 
further crosslinking with formaldehyde. Chromatin fragmentation was optimized by 
testing various sonication times at 10 minutes intervals and measuring the length of DNA 
fragments (Fig. 3.2a-b). Despite testing extensive sonication times, 2 hours for hES and 3 
hours for HF, the resulting DNA fragments sizes remained sub-optimal since the required 
DNA fragments (between 100 and 300 bp) were not predominantly enriched (Fig. 3.2c). 
These results could indicate that the cross-link, protein purification and DNA purification 
protocols reported in the original ChIP-SICAP method might not be the optimal 
conditions for the sonication of fibroblasts and hES used in this thesis but the lack of a 
reference image of the sonicated DNA used in the reported protocol was not provided 
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for comparison. Further sonication was not followed as over-sonicated fragments started 
to appear in the samples (Fig. 3.2c red box). Despite the sonication was not ideal, the 
next steps of the protocol were tested and followed as originally described (see Section 
2.2.9 in Materials and Methods). Digested and purified peptides were processed by liquid 
chromatography-mass spectrometry (LC-MS) and were identified by Mascot software 
against the UniProt human database. Only a small number of proteins were identified 
from both samples: 94 for hESCs and 93 for HF, showing a significant overlap 32 proteins 
(Fig. 3.2d). Most of the identified proteins had a low number of peptide matches, with 
high presence of keratin and common proteomic contaminants. For hES, the bait OCT4 
was identified with a low rank and only one peptide match (Fig. 3.2d). Altogether, this 
indicated poor protein recovery and hence not suitable for identifying OCT4 protein 
partners. 
 
Due to the lack of protein recovery, the original protocol was modified and modified to 
increase the efficiency of both protein and DNA recovery (Fig. 3.3a) (Section 2.2.9 in 
Material and Methods). First, an additional cross-linking step was used. For standard 
ChIP-seq, one-step cross-linking with formaldehyde (FA) is routinely employed to study 
protein-DNA interactions. FA is a zero-length cross-linker making it ideal for the cross-
linking of direct and close DNA-proteins interactions. However, this also limits its 
functionality for protein-protein interactions usually present in chromatin complexes 
not-directly associated with DNA. To stabilize OCT4 protein complexes, an additional 
disuccinimidyl glutarate (DSG) cross-linking was used. DSG is an irreversible membrane 
permeable amine-reactive cross-linking agent that cross-links NHS esters with an 
effective radius of 7Å, stabilizing protein-protein complexes [220]. This additional cross 
link will capture OCT4 chromatin partners that might not be directly interacting with DNA 
and therefore not cross-linked with formaldehyde. This two-step cross-linking protocol 
using DSG in combination with FA has been previously used for ChIP-seq analysis of 
transcription factors, polymerases, co-activators and histones [221]. By combining the 
DSG cross-link with a previously reported OCT4 ChIP-seq protocol [110], the new two-
step cross-link protocol was successful in improving the fragmented chromatin recovery 
(100-300bp) in hES, as well as reduced the sonication time from two hours to 90 minutes, 
as shown in Fig. 3.3b.  
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Fig. 3.2 OCT4 Original ChIP-SICAP protocol in hES and HF.  Agarose gels with DNA purified 
from sonicated chromatin. a. First round of sonication: 10, 20 and 30 min for hES and 20, 30 
and 40 min for HF Control. b. Second round of sonication: 40, 50 and 60 min for hES and 50, 
60, and 70 min for HF. c. Final sonication times: 120 min for hES and 180 for HF. d. Venn 
diagram showing the total number and intersection of identified proteins for hES and HF 
OCT4 ChIP-SICAP. Tables indicate the proteins identified with their respective ranking and 
peptide match. 
 
To test the performance of the adapted protocol in DNA recovery and whether the 
double cross-linking had an effect in the background signal; DNA was purified after the 
streptavidin immunoprecipitation (before protein digestion) from both the original and 
modified methods and analysed by qPCR. Two positive regions known to be occupied by 
OCT4 in hESCs (MIR367 and DPPA4) and two negative regions with no occupancy 
(MIRNEG and MYOD) were used [110, 222]. Both OCT4 positive sites showed significantly 
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more enrichment over the input in the samples that were cross-linked with both DSG and 
FA, in comparison with the original ChIP-SICAP protocol using FA only fixation. In 
addition, there was no significant increase in the enrichment of the OCT4-negative sites, 
indicating that the additional DSG cross-link had no effect in on the background signal 
(Fig. 3.3c). 
 
Fig. 3.3 Modifications of ChIP-SICAP protocol using hES.  a. Workflow of the adapted ChIP-
SICAP method, including the addition of DSG Crosslink (XL) and the protein digestion using 
FASP. b. Comparison of chromatin sonication of hES cells at 90m using the reported protocol 
for ChIP-SICAP against the modified protocol using DSG. c. Comparison of the qPCR 
enrichment analysis in hES for two positive (MIR367 and DPPA4) and two negative (MIRNEG 
and MYOD) genome regions that are known targets of OCT4 using the DNA obtained from 
the Original ChIP-SICAP protocol (Original, red), the modified protocol with only 
Formaldehyde (FA) cross-link (Optim FA, blue) and the modified protocol with DSG and FA 
cross-link (Optim + DSG + FA). ChIP-SICAP protocol image was created with BioRender.com.  
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3.3.2 ChIP-SICAP successfully mapped the chromatin-associated OCT4 interactome 
in human embryonic stem cells  
The modified ChIP-SICAP protocol was then applied to hES with OCT4 as the bait, using 
IgG as a negative control. Two replicates were analysed for each condition (Fig.3.4a). The 
enriched proteins were digested using the filter aided sample preparation method (FASP) 
followed by concentration and cleaning of the peptides with stop-and-go –extraction tips 
(StageTips) (Fig. 3.3a). Both, FASP and StageTips are widely used in of proteomic 
workflows, as they are highly efficient and convenient for processing, concentrating and 
cleaning complex protein mixtures prior to mass spectrometry [223, 224]. Briefly, FASP 
enables protein digestion and peptide purification with the aids of a standard 
ultrafiltration device adapted with a molecular weight cut-off (MWCO) membrane, 
where protein mixtures can be chemically modified and digested, while removing 
detergents and excess reagents. StageTips uses chromatographic beads immobilized in a 
Teflon meshwork (membrane) to retain and concentrate the digested peptides for 
further washes without losing material while allowing their elution with high efficiency. 
This combination of methods were selected as they have been reported to provide a high 
yield enrichment streamlined protocol for rapid and sensitive proteome mapping, 
applicable to small amounts of sample [224]. Digested and cleaned peptides were 
processed by liquid chromatography-mass spectrometry (LC-MS). MaxQuant software 
was used to process the data using the Andromeda search engine for feature extraction, 
peptide identification, and protein inference against the UniProt human database. In 
addition, a label-free quantification analysis was performed using MaxLFQ, an algorithm 
that defines the abundance of each protein based on the peptides intensities and without 
the need of a metabolic or chemical labelling [190]. Total numbers of identified proteins 
for each replicate are summarized in Fig. 3.4b. For both OCT4 hES replicates the number 
of identified proteins was significantly higher when compared with the IgG controls, 
suggesting low background protein contaminants. After both OCT4 hES were filtered 
against the controls (>1.5 fold, FDR <0.1), a total number of 308 proteins present in both 
replicates were identified as OCT4 chromatin-associated proteins in pluripotency 
maintenance (Fig. 3.4d). OCT4 was identified amongst the top hit proteins in both OCT4 
hESCs replicates (Fig. 3.4c), while not identified in either control, indicating a successful 
and specific immunoprecipitation of OCT4 in hESCs. Gene Ontology analysis of each 
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condition revealed the enrichment of nuclear proteins, as well as proteins involved in 
chromatin structure and transcription regulation, proving that the ChIP-SICAP protocol 
was successful in pulling-down and isolating OCT4 and chromatin-associated proteins 
(Fig. 3.4e-g) (Appendix Table 1).  
 
 
Fig. 3.4 OCT4 ChIP-SICAP protein identification in hES.  a. Chromatin sonication of the hES 
samples used for ChIP-SICAP. b. Total number of identified proteins in each replicate for hES 
using OCT4 as a bait and hES Control using IgG as bait. c. Identified proteins ranked by 
enrichment over control. d. Venn diagram of the intersection between both hES OCT4 
replicates and statistically significant against the control. e, f and g. Gene Ontology 
enrichment analysis for Cellular component (e), Biological Process (f) and Molecular function 
(g) of the identified proteins.  
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 3  78 
3.3.3  OCT4 shares important pluripotency maintenance partners in mouse and 
human embryonic stem cells 
When first described, ChIP-SICAP protocol was implemented for the expansion of the 
pluripotency maintenance network in mESC by analysing the chromatin-associated 
proteins of the pluripotency factors OCT4, SOX2 and NANOG (OSN). In total, 407 proteins 
were shared between OSN as part of a core pluripotency maintenance network in mouse. 
Particularly for OCT4, 550 proteins were identified [179]. 
 
The OCT4 interacting proteins identified human ESCs were compared to those identified 
in mouse ESCs to first address the performance of the modified ChIP-SICAP in human, 
and secondly to describe if despite being different species and with different pluripotent 
state, similarities and differences exist between human and mouse OCT4 interactomes. 
A total of 193 proteins were shared between both OCT4 interactomes (Fig. 3.5). Gene 
Ontology of common interactors revealed their involvement in chromatin remodelling, 
gene transcription and mRNA splicing processes. The main proteins involved in the 
transcriptional regulation of pluripotent stem cells were part of the shared proteins, 
including OCT4, SOX2, STAT3, LIN28A, DPPA4, DNMT3A, SALL4 and L1TD1 [151, 225-227]. 
Complex enrichment classified most of the proteins into complexes that have been 
described to be important for chromatin structure and pluripotency maintenance, such 
as NURD/MBD3, SWI/SNF, LARC, SNWI and the Large Drosha Complex [228-230](Fig. 
3.5). Similar biological processes, such as chromatin structure, transcription regulation 
and splicing were enriched in both human and mouse unique OCT4 chromatin-associated 
interactors. Interestingly, some of the non-shared proteins could be grouped in the same 
family or protein type group zinc finger proteins (ZNF) and RNA binding motif (RBM) (Fig. 
3.5). This evidence suggests that despite not belonging to the same family, functionally-
orthologous proteins are interacting with OCT4 to maintain pluripotency in both species. 
These differences could also be reflecting the different signalling and routes that govern 
pluripotency maintenance in each species that converge in the interaction with OCT4. It 
may also highlight the difference of the pluripotency state adapted by human and mouse 
ESCs, as hES are more related to EpiSCs and the primed state of pluripotency, in contrast 
with the naïve state of mESCs.  
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Fig. 3.5 mESC vs hES OCT4 ChIP-SICAP. Venn diagram of the overlapping and unique 
interactors identified in human and mouse ES cells. Boxes represent groups of proteins for 
each group: shared proteins in both species and unique for each species. 
 
Overall, the comparison of the OCT4 interactome between human and mouse confirms 
that conserved pathways and proteins are necessary for the regulation and maintenance 
of pluripotency and stem cell self-renewal. Moreover, it allowed the identification of 
unique interactors for each species, illustrating the different pathways that govern and 
differentiate human and mouse pluripotency maintenance. Finally, the overlap of 
important pluripotency maintenance factors in human and mouse using the original 
method increased the confidence in the results obtained with the adapted protocol of 
ChIP-SICAP in human cells. 
 
3.3.4 OCT4 establishes an expansive protein network with the somatic chromatin 
during early stages of reprogramming 
Having identified the OCT4 chromatin-associated proteins in pluripotency, the adapted 
protocol was applied to define the OCT4 protein interactors in early reprogramming. The 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 3  80 
time point defined as early reprogramming stage was established following the criteria 
used to investigate the initial engagement of OSKM with the somatic genome. This study 
established 48 hrs after the induction of the OSKM factors in human fibroblasts as an 
early point of reprogramming as they observed it was the earliest for maximal OSKM 
expression, it preceded major transcriptional changes and it preceded the time when the 
fibroblasts are changed to ES growth conditions in their reprogramming protocol [110].  
Using a doxycycline (dox)-inducible lentivirus transduction system, the OSKM factors 
were transcriptionally induced in human fibroblasts [231] (Fig. 3.6a). After 48 hours post 
dox inductions, changes in cell morphology were already observed when compared with 
HF with no OSKM (Fig. 3.6b). Western blot confirmed the presence of OSKM, with no 
detection in HF controls (Fig. 3.6c). Immunocytochemistry (IC) assays demonstrated the 
expression of the four OSKM factors (Fig. 3.6d), indicating high efficiency lentivirus 
transduction suitable for studying OCT4 in early reprogramming (OSKM 48h). 
 
 
Fig. 3.6 Induction of exogenous OSKM factors in HF. a. Workflow of OSKM induction showing 
the transduction of Human Fibroblasts with the lentiviruses, followed by the addition of dox 
and the induction of OSKM expression for 48h. b. Images of non-transduced Human 
Fibroblasts (HF Control) and OSKM induced cells after 48 hours of dox addition. c. Western 
Blot analysis of each OSKM factor after 48 hours of cell induction. HF were used as a negative 
control showing no expression of OSKM. d. Immunocytochemistry of each OSKM factor after 
48hrs of cell induction. DAPI staining is shown to visualize the cells. 
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After OSKM induction and cross-linking, optimal sonication time was established at 140 
min (Fig 3.7a). ChIP-SICAP as described above was carried out in two replicates, using HF 
with no OSKM induction as negative control. Mass spectrometry analysis identified the 
LFQ intensities of each enriched protein. 
 
 
Fig. 3.7 OCT4 ChIP-SICAP protein identification in OSKM 48h. a. Chromatin sonication of the 
OSKM 48 and HF control samples used for ChIP-SICAP. b. Total number of identified proteins 
in each replicate of HF control and OSKM 48h using OCT4 as the bait. c. Identified proteins 
ranked by enrichment over control d. Venn diagram of the intersection between both OSKM 
48h OCT4 replicates and statistically significant against the control. e, f and g. Gene Ontology 
enrichment analysis for Cellular component (d), Biological Process (e) and Molecular function 
(f) of the identified proteins. 
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Total numbers of proteins identified for each replicate are summarized in Fig 3.7b. As 
observed in hES, more proteins were identified in the OSKM 48 replicates than in the 
control. After filtering out proteins identified in the control sample (>1.5 fold, FDR<0.1), 
380 proteins were identified as OCT4 chromatin associated proteins in OSKM 48h (Fig. 
3.7d) (Appendix Table 1). OCT4 was again one of the most enriched proteins and was not 
identified in either control (Fig. 3.7c). GO analysis revealed the enrichment of nuclear 
proteins, as well as proteins involved in chromatin structure and transcription (3.7e-g). 
This ChIP-SICAP analysis therefore reveals that OCT4 engages the somatic chromatin 
during the early stages of reprogramming by mainly involving gene regulation and 
chromatin organization proteins.  
 
3.3.5 The OCT4 chromatin-associated interactome during pluripotency is distinct 
from that in hESCs.  
To further investigate the main differences and similarities between the OCT4 chromatin-
associated proteins during pluripotency maintenance and early reprogramming, both 
interactomes were compared. As both set of samples were run using the same MS 
workflow, it was possible to normalize the label-free quantification values (LFQ) acquired 
for each protein in each condition and perform differential enrichment analysis. Principle 
component analysis (PCA) of OSKM 48h, hES and their respective controls clustered the 
OCT4 interactors of OSKM 48h in a different group from those in hES (Figure 3.8a), 
suggesting significant difference between both conditions. To further describe the 
similarities and differences, the 308 and 380 OCT4 interactors defined previously for each 
interactome (filtered against their respective controls >1.5 fold enrichment) were 
compared. First, the overlap analysis between both OCT4 interactomes revealed 149 
sharing proteins between hES and OSKM 48h, and 231 and 160 unique interactors for 
OSKM 48h and hES respectively (Fig. 3.8b).  
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Fig. 3.8 Comparison of OCT4 ChIP-SICAP in pluripotency and reprogramming. a. PCA score 
plot of total ChIP-SICP dataset obtained for hES and OSKM 48h including their respective 
controls. b. Venn diagram of the common and unique proteins identified in the OCT4 ChIP-
SICAP of hES and OSKM 48h. Boxes indicate examples of shared and unique proteins for each 
interactome. 
 
Further quantitative analysis between both set of OCT4 interactors was applied to 
describe the differential enrichment of the shared and unique proteins. The analysis was 
performed using the Perseus software, which considers the LFQ values of each protein 
(non-labelled quantitative proteomics) and using a t-test with FDR < 0.1 and difference > 
1.5 log(fold) as the cut-off values. A total number of 78 proteins were significantly 
enriched in hES when compared to OSKM 48h, 243 significantly enriched in OSKM 48h 
when compared to hES and 226 showed no significant difference between both 
conditions (Supplementary table 2) (Fig. 3.9). These differences and similarities between 
the OCT4 interactomes in hES and OSKM 48h are visualised using a volcano plot (Fig. 
3.9a). Network analysis using STRING and Cytoscape show the connections between the 
identified proteins (edges) as reported in the literature as well as the colour-coded 
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intensity of enrichment (Fig. 3.9b). Colour coding was based in the fold changes obtained 
in the enrichment analysis, where green represents enriched proteins in hES and red 
proteins enriched in OSKM 48h and black no change between both interactomes (Fig. 
3.9b).  
 
Fig. 3.9 Quantitative differential analysis between pluripotency and early reprogramming 
OCT4 ChIP-SICAP.  a. Volcano plot of differentially abundant OCT4 interacting proteins 
between hES and OSKM 48h Red dots denote enriched and unique proteins in OSKM 48h, 
purple dots denote enriched proteins in OSKM 48h that are also present in hES, green squares 
denote enriched and unique proteins in hES, blue squares denote enriches proteins in hES 
that are also present in OSKM. b. Network comparison between the OCT4 chromatin-
associated proteins identified in hES and OSKM 48h. Network was constructed using the 
String plug-in in Cytoscape. Edges represent interactions reported in the literature. Colour 
coding represents the level in abundance of each protein (fold change). 
 
Most enriched proteins included the unique interactors for each condition (green for hES 
and red for OSKM 48 in the volcano plot Fig. 3.9a and network 3.9b).OCT4 interactors 
that are uniquely enriched in hESCs included proteins known to be important for 
pluripotency maintenance (LIN28A, DNMT3A, L1TD1, SALL4, SALL2, DNMT3B) [151, 225-
227]. On the other hand, OCT4-interactors mostly enriched in early reprogramming 
included proteins previously described to have roles in reprogramming, such as OGT 
[168], RUNX1 [154] and MBNL1 [232], but also included new interactors with no previous 
association with reprogramming, such as TAGLN, CRYAB, GBE1, PRRX2 and MAFF. 
Interestingly, there was a group of proteins that were associated with OCT4 in both 
pluripotency maintenance and early reprogramming (blue in hES and purple in OSKM 48h 
in the volcano plot (Fig. 3.9a) and black in the network (Fig 3.9b)) but were more enriched 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 3  85 
in one condition over the other one. For example, the nuclear export factor XPO1, which 
has been associated in the nuclear transport of OCT6 [233], was identified in both early 
reprogramming and pluripotency but with higher levels in the OSKM 48h interactome. 
On the contrary, topoisomerase II alpha (TOP2A), a highly expressed protein in 
undifferentiated cells was also shared in OSKM 48h and hES interactomes, but with 
higher levels in hES [234]. It is worth mentioning that OCT4 was also included in the 
category of shared proteins with different abundance reflecting the high protein level of 
ectopic OCT4 in OSKM 48hr compared to the endogenous OCT4 levels in hESCs. This 
differential expression could be influencing how OCT4 interacts to other chromatin-
associated proteins as well as their enrichment. However, it was interesting to identify 
shared proteins with no difference in abundance between hES and OSKM 48h, suggesting 
that despite higher quantities of OCT4, not all the interactors in OSKM 48h were also 
increasing. For example, proteins involved in the SWI/SNF complex (SMARCA4, 
SMARCA5, ACTL6A, SMARCB1, SMARCC1, SMARCC2, SMARCD2, SMARCE1) (Fig. 3.9a 
(grey dots)) were detected in both interactomes with the same abundances. This 
chromatin-remodelling complex has important roles in both pluripotency maintenance 
and reprogramming [235]. The similar protein enrichment of these complexes may 
indicate that similar amount of interactions of this complex with OCT4 are required for 
reprogramming and pluripotency maintenance, despite the different protein levels of 
OCT4. 
 
Overall, comparison of the OCT4 chromatin-associated proteins in pluripotency and early 
reprogramming reflected the functional adaptation of OCT4 and its interactions to either 
maintain pluripotency or induce pluripotency in differentiated cells. Nevertheless, the 
shared proteins identified in both processes suggests common functions of OCT4 are also 
required for reprogramming and pluripotency maintenance. And most importantly, the 
new set of unique interactors identified in early reprogramming revealed for the first 
time the differential OCT4 engagement with chromatin proteins in early reprogramming 
when compared with its OCT4 engagement in pluripotency and proposes for the first 
time the gain of new and specific interactors for the reprogramming process.  
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3.3.6 OCT4 engagement with the somatic genome differs during pluripotency 
maintenance and reprogramming 
Previous reports of the initial engagement of OSKM in early reprogramming with the 
somatic genome when compared to pluripotency maintenance established differential 
binding patterns [110]. As these studies were performed in protocols that only cross-
linked with FA, ChIP-seq on OCT4 was performed for OSKM 48h and hESCs implementing 
the double cross-link DSG+FA steps, with the aim of investigating if the addition of DSG 
had any effect in the OCT4 DNA engagement profile. To define DNA enrichment of OCT4 
in ChIP-seq, double cross-linking, sonication and chromatin immunoprecipitation were 
carried out in a new set of samples (hES and OSKM 48hr) following the same cell culture 
and ChIP conditions applied to the set used for protein identification, but focused in the 
purification of DNA for sequencing instead of the protein fraction. (Section 2.2.12 
Materials and Methods). The DNA from three ChIPs for each condition were sequenced 
and aligned to the human genome. A model-based analysis for ChIP-seq (MACS)[207] 
was used to identify genomic regions enriched for unique-mapped reads from ChIP-DNA 
over the input DNA identifying 89,262 and 169,071 enriched peaks for hESCs and OSKM 
48h respectively (Fig. 3.10a). To further investigate the similarities and differences 
between the binding patterns of OCT4 in hESCs and OSKM 48h, peaks were grouped in 
shared and unique among the samples and peaks intensity was measured and visualized 
in a read density heatmap (Fig. 3.10a). For both, unique and shared sites, the intensity of 
the peaks revealed a high binding affinity. Most interestingly, only 8,100 binding sites 
were shared between hESCs and OSKM48h, corresponding to only 10% and 5% of the 
total binding sites for hESCs and OSKM respectively (Fig. 3.10a). Moreover, OCT4 did not 
target NANOG at early reprogramming, which is activated and targeted in late stages and 
in pluripotency, as observed by the its targeting in hESCs, therefore, corroborating the 
peak calling results obtained. (Fig. 3.10b). Additionally, the peaks visualization showed 
that double cross-link with DSG+FA did not affect the quality or quantity of the data, nor 
resulted in an increase of unspecific bindings and background signal (Fig. 3.10b). Overall, 
the low peaks overlap detected between hESCs and OKSM 48h agrees with previous work 
reporting different engagement of the OSKM factors at early reprogramming when 
compared with pluripotency maintenance and correlates with the ChIP-SICAP findings of 
different chromatin-associated proteins interactions of OCT4 in both conditions. 
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Fig. 3.10 Different engagement of OCT4 with somatic genome at early reprogramming and 
during pluripotency maintenance. a. Read density heatmaps (in blue scale) showing the 
intensity of hES OCT4 and OSKM 48h ChIP-seq peaks spanning ±1 kb from the centre of the 
peak summit of the unique and shared peaks for hES an OSKM 48h. The number of targeted 
sites is indicated for each condition. b. hES, OSKM 48h and Input OCT4 ChIP-seq profiles at 
Nanog locus. Peak presented are normalized against input DNA sequenced tags. 
 
3.3.7 The distinct OCT4 interactomes are not driven by pre-existing protein levels  
Pluripotent stem cells and human fibroblasts are different cell types with particular 
transcriptional and proteomic profiles as they both require cell-type specific gene 
expression to maintain their cell identity. To identify the extent by which the pre-existing 
protein abundance influence the OCT4 interactome in each cell, quantitative proteomic 
profiles were determined in human fibroblasts and ESCs using stable Isotope Labelling 
with amino acids in cell culture (SILAC). 
 
SILAC is a metabolic quantitative proteomic method that depends on cellular protein 
synthesis to incorporate specific stable isotope-containing amino acids in each sample to 
be compared. Cells of interest are grown in parallel but in two different medium 
formulations: the light and the heavy. Light medium contains the amino acid with the 
natural isotope, while the heavy contains the stable isotope-containing amino acid. Once 
cells adapt to the media and reach an amino acid incorporation of ≈97% (after 5 cell 
divisions), cells can be processed for whole protein extraction with standard protocols 
and mixed in similar ratios for mass spectrometry analysis. Because the difference in 
mass of the labelled amino acids is known, the identified peptides can be distinguished 
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and assigned to the sample of origin. Then, the signal intensities between the light and 
heavy peptides are used to give the relative protein abundance between both conditions 
(Fig. 3.11a) [236]. 
 
Fig. 3.11 SILAC-based quantitative proteomics of hES and HF proteomes. a. Workflow of the 
SILAC protocol followed for the quantification analysis. a. Representative images of hES and 
HF grown in SILAC media and of SDS-PAGE gel used for in-gel digestion are shown. b. SDS-
PAGE analysis of the total protein extracts of hES and HF grown in SILAC media. Three 
replicates were analysed. Gels were loaded with 10µg for each sample and visualized by 
Coomassie Blue. c. Upset plot showing the shared and unique proteins identified in the three 
SILAC replicates analysed. 
 
After hESCs and HF were grown in SILAC medium for at least five passages, proteins were 
collected from whole cell lysates in three biological replicates (Fig. 3.11). SDS-PAGE 
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reveal clear differences in the protein banding patterns between HF and hES, confirming 
the different protein content in each cell type (Fig. 3.11b). Same amounts of protein of 
each condition were mixed and processed using in-gel digestion and Stage-Tip cleaning 
procedures before protein identification and quantification by mass spectroscopy. 
MaxQuant software and the plugin for SILAC quantitative proteomics were used to 
determine the protein levels ratios between both samples (HF/hES) (Appendix Table 2) 
[193].  
 
Fig. 3.12 Quantitative analysis of hES and HF proteomes with SILAC. Volcano plot of 
differentially expressed proteins between hES and HF. Red dots denote higher levels of 
proteins in HF, green squares denote overexpressed proteins in hES. 
 
The identified and quantified proteins showed high overlap between the three replicates 
Fig. 3.11c. Differential expression analysis (log fold>1, FDR<0.1) revealed the highly 
expressed proteins in hES (green in volcano plot Fig. 3.12), which were known to be 
associated with pluripotency maintenance such as LIN28A, DNMT3A, DNMT3B, EPCAM 
and L1TD1 [151, 225-227]; as well as proteins highly expressed in HF (red in volcano plot 
Fig. 3.12), which included proteins associated with epithelial cells and fibroblast markers, 
such as NT5E [237], CRIP2 [238], CRYAB [239] and VIM[240]. These results support that 
SILAC analysis has successfully identified the different protein profiles present in human 
ESCs and fibroblasts.  
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Next, SILAC data was used to investigate the protein levels of only those that interact 
with OCT4 in h hES and OSKM 48h. For this analysis, the OCT4 interactors in hES and 
OSKM 48h were classified into three groups: interactors over-represented in hES vs 
OSKM (Fig. 3.13a), interactors over-represented in OSKM 48h vs hES (Fig. 3.13b) and 
interactors with similar enrichment in hES and OSKM 48h (Fig. 3.13c). Protein level 
profiles were visualized using heatmaps, where protein abundance is reported as the 
ratio HF/hES, meaning higher values represent overexpressed proteins in HF vs hES (red) 
and lower values represent overexpressed proteins in hES vs HF (green)(Fig. 3.13).  
 
The enrichment of most differential OCT4 interactors did not correlate with the 
measured protein levels in the corresponding cell type. Only a small set of enriched 
interactors in hES interactome reflected the high protein levels in hESCs including the 
pluripotency maintenance proteins DNMT3A, DNMT3B, and LIN28A [145, 241](Fig. 
3.13a). The same was observed for a small set of OCT4 interactors enriched in OSKM 48h 
that also showed high protein levels in HF including the somatic proteins LGALS1, CRIP2, 
CRYAB [238, 239, 242] (Fig. 3.13b). These particular examples illustrate that for some 
proteins there was in fact a correlation between the enriched interaction and higher 
protein levels, but it was not the case for the vast majority of proteins that differentially 
interact with OCT4. In each group analysed, most interactors had the same expression 
levels in hES and HF (black in the heatmaps (Fig. 3.13), even if they were defined as 
enriched OCT4 interactors in either pluripotency or early reprogramming. For example, 
ANXA5, PRPF4, RTCB, IPO7, IPO5 and TPM3 were enriched interactors in OSKM 48h vs 
hES but had similar protein levels in both HF and hES. Moreover, differentially OCT4 
interactors were sometime less abundant in the cell type were the interaction is more 
enriched. For example, STAT3, XPO1, CDK1, XPOT and KPNA2 showed more enriched 
interaction with OCT4 in OSKM 48h over hESCs despite being more abundant in hES than 
HF. Furthermore, proteins which interacted with OCT4 at similar enrichment in hES and 
OSKM 48h regardless of their differential levels in both cell types. For example, H1FX, 
PPP1CA and SFRS4 had higher protein levels in HF, while FASN, RAN, PRDX6 and PEBP1 
had higher levels in hES, but all of them were interacting at similar levels with OCT4 in 
hES and OSKM 48h. In summary, the SILAC analysis revealed that the pre-existing protein 
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levels in hESCs and HF is not the sole determinant that drives the differential OCT4 
interactomes observed during pluripotency maintenance and early reprogramming. 
 
Fig. 3.13 Protein levels of OCT4 interactors in hES and HF.  Protein levels of OCT4 interactors 
relative to their expression in hES and HF. Proteins were clustered according to the HF/hES 
ratio and displayed as a heatmap. Green represents high expression in hES, red represents 
high expression in HF and black represents similar expression. a. Enriched OCT4 interactors 
in hES. b. Enriched OCT4 interactors in OSKM 48h. c. OCT4 interactors with no difference 
between hES and OSKM 48h. 
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Similar results were observed when transcriptomic profiles of the OCT4 interactors were 
determined using published microarray expression data sets of HF, iPS and ES cells [95, 
110, 243]. The analysis was carried on using the same three groups: interactors with 
enrichment in hES vs OSKM (Fig. 3.14a), interactors with enrichment in OSKM 48h vs hES 
(Fig. 3.14b) and shared interactors with no significant change between hES and OSKM 
48h (Fig. 3.14c). To analyse the transcriptomic profiles of each group, instead of ratios as 
in SILAC, gene expression levels were used for each protein in each cell type, followed by 
the hierarchical clustering and visualization in heatmaps. As observed with the protein 
levels, the gene expression was not the main influence of the interactions of OCT4 in 
each condition (hES or OSKM 48h), as for each group there were set of genes with similar 
expression levels, higher expression levels and lower expression levels (Fig. 3.14 black, 
red and green respectively) that did not correlate with their enrichment levels reported 
in the OCT4 interactomes in either pluripotency or reprogramming. Both the proteomic 
and transcriptomic profile analysis revealed that OCT4 interactions are not exclusively 
determined by the gene expression or protein levels of the interactors in each cell type. 
 
Altogether, the results in this chapter describe for the first time the OCT4 chromatin 
associated proteins in human pluripotency and early stages of human reprogramming to 
iPSCs, revealing that OCT4 does not only interacts differently with the somatic genome, 
but also acquires new protein interactions that could be of high relevance for the 
reprogramming process. 
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Fig. 3.14 RNA Expression profiles of OCT4 interactors in hES and HF. RNA expression profiles 
of OCT4 interactors in HF, iPS and hES. Genes were clustered according to their expression in 
HF, iPS and hES and represented as a heatmap. Green represents high expression, red 
represents low expression. a. Enriched OCT4 interactors in hES. b. Enriched OCT4 interactors 
in OSKM 48h. c. OCT4 interactors with no difference between hES and OSKM 48h. Raw data 
obtained from [110] 
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3.4 Discussion  
OCT4 is critical to maintain the pluripotency of embryonic stem cells (ES) and to induce 
pluripotency in the reprogramming process to induced pluripotent stem cells (iPSCs). 
Multiple biochemical approaches, using mostly mouse as the model of study, have 
focused in deciphering the molecular basis for pluripotency defining OCT4 as a key 
component of the core regulatory network that governs ES pluripotency, along with SOX2 
and NANOG [69, 82, 84, 225, 244]. Most of these studies have reported that OCT4 is 
involved with multiple chromatin remodelling and epigenetic regulatory protein such as 
polycomb group proteins [79], SWI/SNF proteins [235] and Mi-2/NuRD complex proteins 
[245]. Expansion of mouse OCT4 interactomes has also help to dissect important 
biochemical basis for OCT4 diverse roles in both genetic and epigenetic regulation of 
mouse stem cell pluripotency that could be translated to the reprogramming process [82, 
87, 172, 173]. However, since the first isolation of embryonic stem cells and the iPSCs, 
one of the major challenges of developmental and reprogramming cell biology has been 
trying to understand and dissect specific contributions of OCT4 to each process. 
Particularly in human cells, limited information is available regarding the general OCT4-
associated protein complexes in both pluripotency and reprogramming and how they 
dictate the different OCT4 critical regulatory activities. To overcome this lack of 
knowledge, adaptation of one of the most recent protocols developed that combines 
ChIP and MS called Selective isolation of chromatin-associated proteins via ChIP (ChIP-
SICAP)[179] (Fig. 3.1), was successfully applied in this work allowing the identification of 
OCT4 and its chromatin partners during human pluripotency maintenance and early 
reprogramming.  
ChIP SICAP was first described as a protocol to expand the pluripotency network of 
mouse ES cells, focusing particularly in chromatin-associated proteins, allowing both a 
clean and reproducible technique to identify the chromatin-associated proteins of the 
pluripotency factors OCT4, SOX2 and NANOG, as well as DNA purification for next 
generation sequencing and identification of the genomic binding regions of the latter 
[179]. Modifications to the original protocol needed to be implemented when tested in 
this thesis for human ES as the first attempts resulted in a poor protein recovery (Fig. 
3.2). One of the main modifications was the extra cross-linking step via DSG (Fig. 3.2). 
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This additional step was fundamental for the stabilization of protein-protein interactions, 
which, in combination with the standard formaldehyde, allowed a better capture of 
protein-DNA by increasing the OCT4 DNA-binding signal-to-noise ratio in the ChIP and 
the number of identified proteins when analysed by Mass Spectrometry (Fig. 3.3). It is 
noteworthy that, this chapter focused on protein identification, next generation 
sequencing of DNA will be discussed in the chapter 5. Overall, the modified protocol 
allowed the purification of OCT4 chromatin associated proteins involved in transcription 
regulation, chromatin structure and mRNA splicing (Fig. 3.4). In addition, it proved to be 
consistent in the two different human cell conditions: pluripotency maintenance and 
early reprogramming. 
A discussion of the relevance of these findings is addressed next. 
3.4.1 Main pluripotency maintenance factors are shared between mouse and 
human OCT4 interactomes 
A key unanswered question in developmental cell biology is how much of the knowledge 
available for OCT4 in mouse ES can be translated to human pluripotency. Although the 
main objective of this work was not to address this question directly, the protocol 
adaptation performed herein allowed the first identification of the OCT4 chromatin-
associated proteins in human ES. By comparing this information with the data already 
available of the mouse OCT4 interactome using the original ChIP-SICAP protocol; it was 
possible to report similarities and differences in the OCT4 pluripotency networks of 
human and mouse. Not to mention that the comparison also allowed the validation of 
the performance and quality of the adapted method. 
Firstly, the overlap between both interactomes revealed a comprehensive number of 
OCT4 interactors shared between mouse and human, which included more than 50% of 
the former with 40% of the latter (Fig. 3.5). Unsurprisingly, among these proteins were 
components of pluripotency maintenance and transcriptional regulators previously 
reported to be important in both human and mouse, including SOX2, STAT3, LIN28a, 
SALL4, DNMT3A, DPPA4 and DNMT3B, as well as members of the chromatin remodelling 
complexes LARC, NURD and SWI/SNF were identified (Fig. 3.5). It has been previously 
reported that along with the transcription factors, these and many other chromatin 
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regulators play essential roles in ES and are constantly identified in the different mouse 
OCT4 interactomes [82, 87, 172, 173, 179]. This evidence confirmed that, in both human 
and mouse, these proteins are part of a conserved pluripotency network with OCT4 and 
that the modified of the ChIP-SICAP was a reliable tool. 
An interesting complex that has been identified in most of the mouse OCT4 interactomes 
and that was also detected in the human interactome is the nucleosome Remodelling 
and Deacetylase complex (NURD) [246]. NURD is unique among chromatin regulators as 
it integrates the ATP-dependent nucleosome remodelling activity with deacetylase 
histone activity to create repressive chromatin structure [247]. NURD functions primarily 
as a co-repressor by altering the nucleosome occupancy to avoid the binding of the 
transcriptional machinery at the gene promoters [248]. The different combinations of 
subunits in this complex determine its function and genomic targeting, involving cell-type 
specific functions and new roles apart from transcription regulation like maintenance of 
genome stability, DNA replication and DNA repair [247]. In mouse stem cells, different 
combinations of NURD subunits and associations with other proteins had been described 
to be important for pluripotency maintenance and differentiation, being NURD/Mbd3 
the most important one [249]. Mbd3 subunit is necessary for the recruitment and 
assembly of the complex and it has been linked to roles in development, as it absence in 
stem cells leads to defects in differentiation[121]. In addition, a more recent stem cell 
specific NURD has been reported, which involves the interaction of the specific isoform 
Mbd3c with Wdr5 [126, 250]. Wdr5 is a histone binding protein that promotes H3K4 
trimethylation by binding the histone H3. It has been widely associated with other 
different chromatin remodelling complexes and with the pluripotency maintenance 
network, having important roles in self-renewal and induced pluripotency maintenance 
[126, 250]. Even though the mechanisms involving this stem cell-specific 
NURD/Mbd3/Wdr5 complex is still unclear, it was interesting to find that all the subunits 
are also present in the interactome of human OCT4, which could suggest it might also be 
an important complex in the human context, expanding the relevance and mechanisms 
in which the NURD complex and Wdr5 are involved in human pluripotency maintenance 
and stem-cell maintenance. 
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In addition to the chromatin remodelling complexes, most of the shared and unique 
proteins of the OCT4 interactome were involved in splicing and miRNA processing. The 
roles of post-transcriptional regulation and RNA binding proteins had been described to 
be as important as transcriptional regulation for the pluripotency maintenance network 
[251]. It is well known that there is an auto regulatory loop between miRNAs and the 
core pluripotency maintenance network, which leads to repression of developmental 
genes and a sustained positive feedback of stem-cell specific genes [252]. OCT4 main role 
in the regulation of miRNAs involves binding their promoters, either activating or 
repressing their expression [253]. However, findings in this work, could point to an 
alternative involvement of OCT4 in the regulation of miRNA, mediated by its interaction 
with the large Drosha complex, which is responsible for miRNAs processing and 
maturation [254]. The presence of most components of the complex in the human OCT4 
interactome here reported, could suggest that OCT4 might be chromatin-associated with 
this complex as part of a non-previously described regulation of miRNA in stem cells.  
Additionally, members of the zinc-finger protein family were observed to be shared in 
both species, as well as some members being unique for each species. Interestingly, zinc 
finger proteins have been suggested to play an important role in maintenance of ESC 
pluripotency and differentiation potential as well as proliferation and cell cycle control 
[255]. For instance, zinc finger protein 206 (Zfp206) is considered a hallmark of 
pluripotent cells, as it is known to regulate ESC gene expression and differentiation [256, 
257]. Rex 1 (also known as Zfp42) is restricted to undifferentiated ESCs contributes to 
maintain the undifferentiated state, 200, while ZFP57 was shown to maintain the 
genomic imprints in ESCs [258, 259]. The presence of these and other zinc finger proteins 
in both mouse and human OCT4 interactomes revealed an important contribution of 
these family for the maintenance of pluripotency in both species and highlights the fact 
that for each species distinct members of the same family converge in the interaction of 
OCT4 and the pathway that governs pluripotency.  
The interspecies OCT4 interactome comparison revealed that there is a high conserved 
OCT4 chromatin-associated pluripotency maintenance network between both species, 
including complexes and pathways previously reported as fundamental for pluripotency 
maintenance.  Moreover, the more detailed analysis, as exemplified with the NURD and 
Drosha complex, also suggests that there might be additional chromatin-dependent 
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shared mechanisms non-previously described in pluripotency where OCT4 is a crucial 
component. This opens avenues to investigate in more details new pathways involved in 
both mouse and human pluripotency maintenance as well as to the better understanding 
of the pathways that differ and contribute to the naïve pluripotency state of mESC and  
the primed-like state of hESCs, opening the research field to analyse the OCT4 
interactome of EpiSCs and investigate if it resembles more the one from hESCs than 
mESCs, correlating with the more primed state of hESCs.  
3.4.2 OCT4 engagement with the somatic proteome in early reprogramming differs 
from that in pluripotency maintenance 
OSKM overexpression in HF for 48hr has already been described as an early 
reprogramming time point where important transcriptional and proteomic changes take 
place [110]. Unsurprisingly, when ChIP-SICAP was applied to OSKM 48h, the identification 
of chromatin-associated proteins revealed that at this early stage OCT4 was already 
associated with chromatin complexes thorough interacting with proteins (Fig. 3.7). For 
instance, compared with the pluripotency maintenance interactome, different and new 
binding partners in OSKM 48h were discovered (Fig. 3.8, 3.9). These differences correlate 
with the differential OCT4 chromatin-engagement profile between early reprogramming 
and pluripotency maintenance [110, 260], supporting the idea that OCT4 is involved new 
processes in the reprogramming context.  
To help the analysis and visualization of the dataset, the identified proteins were 
organized in four groups: unique in hES, shared with an enrichment in hES, with an 
enrichment in OKSM 48h and unique in OSKM 48h (Fig. 3.14-3.18). Images shown were 
derived from the Cytoscape network described in Fig. 3.9b, which includes proteins that 
have been connected based in literature evidence. Additionally, for each group pathways 
and complex enrichment using ConcensusPathDB was applied to categorize the proteins 
in each group, indicating in boxes the most enriched processes and the proteins involved.  
In the following sections, the findings for each group will be discussed. 
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3.4.3 OCT4 unique chromatin-bound partners in hES are associated with pluripotency 
maintenance 
When mouse and human OCT4 interactomes were compared, the OCT4 interactome 
described in hES contained most of the main proteins of the core pluripotency 
maintenance network (Fig 3.5). As expected, when the proteins described as unique or 
enriched in hES when compared to OSKM 48h were indeed pluripotency protein 
members (Fig. 3.15, 3.16). As most of these proteins are stem cell specific proteins, their 
enriched or exclusive interaction with OCT4 in hES and not early reprogramming 
indicates that their interaction with OCT4 occurs in the later stages of reprogramming, 
when most these proteins start to get expressed (SILAC)(Fig. 3.13) [105]. 
 
Fig. 3.15 OCT4 hES unique interactions. Subset of proteins identified only in pluripotency. 
Boxes denote and their associated biological process. Green dotted box includes proteins 
associated to the pluripotency network according to the literature. Colour coding represents 
the level in abundance of each protein (fold change). 
 
Besides the already well stablished pluripotency associated proteins, the unique hES 
chromatin associated proteins included proteins which functions in either 
reprogramming or pluripotency maintenance have not been fully elucidated. Examples 
of these proteins included CERC2 (histone acetyl-lysine reader), ZFP462 (zinc finger 
involved in chromatin stability), CBX5 (heterochromatin protein), zinc protein fingers 
(ZNF198, ZNF219, ZNF281, ZNF462, ZNF532), HELLS (chromatin remodeller) and HMGA2 
(histone-DNA modifications). Interestingly, ZNF532 and ZNF219 have been described in 
cancer gene-fusions involved in the formation of unusually large domains of hyperactive 
chromatin by deregulating acetylation [261, 262]. Therefore, their presence in the 
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OCT4 interactome of hES could suggest a potential role ZNFs proteins along with OCT4 
in chromatin structure and regulation of gene transcription during pluripotency.  
On the other hand, mRNA processing, splicing and cell cycle associated-proteins were 
also present in both the unique and enriched group of hES interacting proteins (Fig. 3.15, 
3.16). Some of these proteins have been reported to have positive effects when 
overexpressed in reprogramming. For example, addition of the RNA binding protein 
LIN28A in the reprogramming cocktail accelerates reprogramming efficiency in a 
proliferation-dependent manner by mechanisms still not fully understood but that could 
be linked to its capacity to interact with OCT4 [241].  
 
Overall, the unique and enriched OCT4 interacting proteins in hES confirmed the 
involvement of OCT4 with the well stablished core pluripotency network. Additionally, 
they allowed the identification of new proteins that once characterized in pluripotency 
could be potential candidates to test in the reprogramming process (Fig. 3.14, 3.15).  
 
Fig. 3.16 OCT4 hES and OSKM 48 shared interactions enriched in hES.  Subset of proteins 
identified in both pluripotency and early reprogramming enriched in hES. Boxes denote and 
their associated biological process. Green dotted box includes proteins associated to the 
pluripotency network according to the literature. Colour coding represents the level in 
abundance of each protein (fold change). 
3.4.4 OCT4 acquires novel chromatin-bound associated proteins during early 
reprogramming 
The most interesting group when comparing hES and OSKM 48h was the set of proteins 
that were only present at the early stages of reprogramming (Fig. 3.17). Quantitative 
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analysis of this group of proteins in hES and HF suggested OCT4 new interactions were 
not exclusively determined by the gene expression or protein levels of the interactors in 
each condition (hES or OSKM 48h). For instance, there were a set of proteins with higher 
expression in hES when compared with HF, but more enriched in the OCT4 interactome 
at OSKM 48h versus hES, revealing that, for some of the novel OCT4 interactors in OSKM 
48h, their expression levels in either cell type did not correlate with the enrichment levels 
observed in the reprogramming OCT4 interactome. 
Enrichment analysis of this group of proteins revealed a lesser amount of proteins 
involved in pluripotency maintenance and more proteins involved in differentiation and 
developmental processes, as well as chromatin structure and transcription regulation 
(Fig. 3.17). This suggests that proteins involved in differentiation pathways can 
contribute to the reprogramming through their association with OCT4 and suggest 
common mechanisms for cell differentiation and reacquisition of pluripotency, with 
OCT4 as an important component. Interestingly, most of the proteins included in this 
group have not been found to be linked with OCT4 nor described in the reprogramming 
process, highlighting that the existing barrier in the understanding of OCT4 roles in 
reprogramming. A set of worth noticing proteins found in this group, are somatic specific 
transcription factors that have been reported to be downregulated in MEF 
reprogramming, such as HOXC10, RUNX1, FOSL1 and TAGLN [154, 263, 264]. The 
downregulation of these somatic transcription factors is believed to contribute to the 
downregulation of the somatic genes at early reprogramming. How the OSKM are 
regulating the repression of these specific genes is not yet fully understood, but evidence 
suggests that at 48hrs of OSK induction in MEFs, the OSK factors share binding sites with 
RUNX1 and FOSL1. These binding sites include MEF enhancers important for the somatic 
gene regulation [154]. Detection of FOSL1 and RUNX1 as OCT4 chromatin-associated 
proteins supports the evidence that they co-bind in the genome at early stages (Fig. 3.16). 
Interestingly, in the study previously mentioned also reported that OSK induction drives 
the redistribution of these transcription factors to other genomic regions [154]. This 
mechanism could suggest that OCT4 binds to somatic enhancers competing with the 
somatic TFs already bound, resulting in their displacement and further recruitment of 
chromatin remodelling machinery by OSK to close and repress the somatic enhancers 
[154]. Alternatively, these new somatic TF-OCT4 interactions do not rule out the 
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possibility of a synergistic function in which, before their downregulation, the somatic TF 
take part of transient complexes important for reprogramming, even if they are active in 
a short timeframe.  
Taking into account the most abundant proteins identified in the unique OSKM 48h 
interactome, two members of the Nuclear Factor I family, NFOC and NFIX were identified 
(Fig. 3.17). These proteins are site-specific DNA binding proteins involved in a large 
variety of cellular and viral genes. Their binding to DNA promotes the transcriptional 
activation or repression, depending on the cellular context and the regulatory region 
where they bind [265]. Binding sites for the members of this family have been identified 
in promoters, enhancers and silencer regions of a huge set of genes that are expressed 
in almost every tissue [266]. More recently, they were described as key epigenetic 
regulators and chromatin remodelers during development and cancer [265], opening the 
possibility of a new non-described OCT4/NFIC/NFIX complex involved in chromatin 
remodelling and transcriptional regulation at early stages of the reprogramming.  
 
Fig. 3.17 OCT4 OSKM 48 unique interactions.  Subset of proteins identified only in early 
reprogramming. Boxes denote and their associated biological process. Colour coding 
represents the level in abundance of each protein (fold change).  
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Another interesting group of proteins found in the unique OCT4 OSKM 48h subset were 
three proteins belonging to the Homeobox C cluster (HOXc8-10) (Fig. 3.17). Hox proteins 
are transcription factors involved in controlling and coordinating morphogenesis with 
established functions in development and evolution, including DNA replication, DNA 
repair, mRNA translation and protein degradation [267]. The Hox family in humans 
includes 39 members, with high relevance not only because of their roles in 
development, but also because they have been involved in several diseases, such as 
different types of cancer[267]. Evidence of their expression during reprogramming has 
been described. Moreover, it was also found that an early wave of gene expression 
change involved the reactivation of late developmental regulators, such as members of 
the Hox genes [264]. This suggested that these genes are somehow involved in the 
process; therefore, their interactions with OCT4 could help define their role in the 
process. Since reprograming somatic cells to stem cells could be described as a forced 
reverse developmental process, understanding the interactions of Hox genes with the 
OSKM factors and how they are involved in this transition could be of high relevance. 
Furthermore, the identification of this new group of proteins –not previously associated 
with OCT4 either in reprogramming or other cellular contexts –demonstrates that OCT4 
gains new chromatin associated proteins from the early stages of reprogramming, 
proving that the initial engagement of OCT4 with the somatic proteome on chromatin 
differs from that during pluripotency maintenance. This is consistent with the evidence 
that the initial engagement of OCT4 with the somatic human genome was also markedly 
different from that in hES (Fig. 3.10) [110]. 
3.4.5 Involvement of OCT4 in chromatin organization complexes is fundamental in 
early reprogramming and pluripotency maintenance  
The unique proteins identified in each group, helped understand particularities of both, 
pluripotency and reprogramming. Furthermore, an interesting subset of shared OCT4 
interactors in both OSKM 48h and hES (Fig. 3.18). Included in this list of proteins were 
the majority of the proteins part of the SWI/SNF, LARC and Drosha complex discussed 
before when comparing hES and mESC interactomes (Fig. 3.5).  
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The fact that these complexes are present in both conditions is a major finding that 
reflects that both processes share similar mechanisms to regulate chromatin-structure 
and miRNAs taking advantage of OCT4 as one of their subunits, either by recruiting the 
complex or being recruited by the complex. As in pluripotency maintenance, SWI/SNF 
has been described to be a cofactor for reprogramming [235], but it is not yet clear how 
both processes are taking advantage of the same mechanisms; either by using them for 
similar functions, or using them as a scaffold for additional proteins with a more specific 
role for each process to bind. Examples of the latter have been previously described 
involving the Mdb3-NURD stem cell complex. In this complex the specific combination 
involving Mdb3 is necessary for pluripotency maintenance and reprogramming [121]. In 
addition to Mdb3, there has been other reports suggesting more stem cells specific 
SWI/SNF combinations, in which the complex has the potential to interact with ES cell-
specific regulators, such as some of the unique proteins identified in the hES interactome 
(HELLS, SOX2, SALL4 and DNMT3B)[117]. As SWI/SNF is a fundamental chromatin 
remodelling complex, it would be interesting to characterize specific combinations 
needed for early and later stages of reprogramming, unravelling a more specific role of 
specific SWI/SNF complexes at different stages of reprogramming. 
 
Fig. 3.18 OCT4 hES and OSKM 48 shared interactions with no enrichment difference.  Subset 
of proteins identified in both pluripotency and early reprogramming with no difference in 
abundance between both processes. Boxes denote and their associated biological process. 
Green dotted box includes proteins associated to the pluripotency network according to the 
literature. Colour coding represents the level in abundance of each protein (fold change). 
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3.4.6 Enriched OCT4 interactions at early reprogramming include mechanisms 
involved in pluripotency maintenance 
Enrichment analysis helped to define a group of shared proteins between hES and OSKM 
48h with higher abundances in early reprogramming (Fig. 3.9, 3.19). Included in this 
group are proteins involved in the Wnt and Notch signalling. Among these proteins, three 
members of the co-repressor family TLE/Groucho were present (TLE3-5). These proteins 
are non‐DNA binding co‐factors and are key mediators of embryonic segmentation, 
dorsal-ventral patterning, neurogenesis, and Notch and Wnt signalling [268]. Because by 
themselves they cannot bind DNA, they require the interaction with transcription factors 
or DNA-binding proteins to mediate their repression activity. When bound to their target, 
these proteins can repress transcription by a diverse set of mechanisms including 
recruiting histone deacetylases (HDAC), chromatin condensation via physical tethering of 
histone tails and attenuating the transcription by polymerase pausing [268]. Due to their 
link with the Wnt signalling, the TLE family has been linked to mouse differentiation and 
development, where it is required to silence the expression of the pluripotency 
maintenance network in differentiation towards multiple lineages, which might be 
possible through its binding to inactive TCF3, a key transcriptional activator in the Wnt 
signalling in mESC [269]. Even though, the TLE family are key regulators of development 
their association with OCT4 has not been described in neither development nor 
reprogramming. However, an interesting mechanism described for other pioneer factors 
might link the enrichment in chromatin of TLE corepressors with OCT4 at early stages of 
reprogramming. This mechanism involves the recruitment of co-repressors by pioneer 
factor to establish stably silenced domains instead of the positive regulation of gene 
expression [36]. An example is the recruitment of TLE3 to specific genomic targets 
mediated by the pioneer factor FoxA. When recruited by FOXA, TLE3A causes the local 
chromatin to close rather than open, by condensing nucleosomes in the vicinity [37]. This 
mechanism suggest that pioneer factors, could be recruiting corepressors such as TLE 
keep the silent state of their targets, protecting against immediate and inappropriate 
gene activation. OCT4 could be taking advantage of this mechanism at early stages of 
reprogramming by maintaining a competent state ready for the binding of co-factors that 
promote the release of the TLE repressors to initiate the chromatin remodelling and 
transcription reactivation once required. As exemplified with the TLE proteins, the 
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remaining proteins included in this enriched OSKM 48h interactors could be revealing 
that OCT4 is taking advantage of some pluripotency mechanisms by enhancing them in 
early reprogramming to help drive the process.  
Additionally, proteomic quantitative analysis using SILAC helped to rule out the 
possibility that the observed differences in proteins and their abundances were 
exclusively driven by the different proteomic expression profiles of somatic and stem 
cells (Fig. 3.13, 3.14). 
The results presented in this chapter are the first report to define the OCT4 chromatin-
associated partners in human stem cells and in early stages of the human reprogramming 
process. Comparison of these networks offered a dataset that allow a general and 
descriptive comparison for a better understanding of the differences of OCT4 and its 
interacting proteins in the pluripotency maintenance versus the reprogramming process 
in the human context. General analysis of both network revealed that OCT4 partners 
during early reprogramming and those in hESCs are markedly different. This evidence 
suggests that, as reported for the initial engagement of OCT4 with the somatic proteome, 
the OCT4 initial engagement with the somatic proteome on chromatin is distinct from 
that during pluripotency maintenance, illustrating how OCT4 is able to change its 
chromatin-binding dynamics in order to stablish different phenotypes. For instance, 
additional chromatin associated proteins reported in the hES interactome that have non-
previously been described in the mouse pluripotency context could help understand and 
define the different pathways that govern human pluripotency and how they could be 
influencing the more primed pluripotent state observed in humans. On the other hand, 
OCT4 interactors that are exclusively enriched during early reprogramming included 
somatic transcription factors, supporting other studies that suggested OCT4 can 
redistribute these type of factors during reprogramming. Moreover, the list of new OCT4-
interacting proteins non-previously reported in the reprogramming context (such as 
proteins involved in cell death, development and differentiation) represent a new 
dataset that could contribute to the better understanding of the early stages of the 
reprogramming process. However, it should be noted that the data presented in this 
chapter represents a general and descriptive overview of OCT4 interacting proteins, 
which could not reflect functional importance in either process, pluripotency or 
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reprogramming. Thus, further assays focused in the characterization of OCT4 interactors 
that are functionally relevant for reprogramming and pluripotency should be addressed.  
 
Fig. 3.19 OCT4 hES and OSKM 48 shared interactions enriched in OSKM 48h.  Subset of 
proteins identified in both pluripotency and early reprogramming enriched in OSKM 48h. 
Boxes denote and their associated biological process. Green coloured box includes proteins 
associated to the pluripotency network according to the literature. Colour coding represents 
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Chapter 4 OCT4 DOMAINS UNVEILED CHROMATIN-DEPENDENT PROTEIN 
INTERACTIONS NECESSARY FOR REPROGRAMMING TO iPSCs  
 
4.1 Introduction 
A basic feature of transcription factors is that they are modular proteins with functionally 
independent domains. While they depend on their DNA binding domains (DBD) to 
recognise specific DNA sequences, the activation or repression of gene transcription is 
usually achieved through interaction with other co-factors via domains that are located 
outside, and act independently of DBD [270].  
OCT4 comprises three domains: a central POU domain flanked by an N-terminal and a C-
terminal transactivation domain (TADs)[163]. The central DBD is a bipartite POU domain 
containing POU specific (POU-S) and POU homeodomain (POU-HD) separated by a linker 
containing a rigid helix and a flexible region. This domain allows the recognition of a 
specific octameric (OCT) DNA sequences and is highly conserved among species. Because 
of its importance in DNA binding, this domain has been widely studied and has been 
directly implicated in reprogramming to iPSCs and pluripotency maintenance [84, 217, 
271]. Contrastingly, the N- and C-terminal TADs are responsible of the interaction of 
OCT4 with partner proteins (Fig. 1.4, Fig. 4.1a) [163]. 
The two OCT4 TADs have been shown to act redundantly in ESCs, as OCT4 containing the 
POU domain with either of TAD is able to maintain pluripotency but OCT4 mutants 
lacking both N- and C-terminal domains fail to maintain self-renewal [272]. Additionally, 
OCT4 TADs are intrinsically disordered and have been associated with transcription 
regulation activity because of their capacity to form phase-separated condensates with 
the co-activator Mediator complex MED1, which is a necessary mechanism to drive gene 
activation [8, 9].  
More recently, a study performed in parallel in our laboratory, focused in the dissection 
of the OCT4 domains that are essential for reprogramming to iPSCs from the ones 
essential for pluripotency maintenance. By systematically deleting five amino acid 
stretches of OCT4 and screening them for reprogramming to iPSCs and pluripotency 
maintenance functions in mouse, this work found that reprogramming to iPSCs requires 
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defined polypeptide stretches within OCT4, which are distinct from those that maintain 
pluripotency in mESCs. Based on these regions essential and non-essential regions of 
OCT4 for reprogramming were defined and different OCT4 mutants with deleted regions 
based in these classification were designed, resulting in different reprogramming to iPSCs 
efficiencies in mouse and human (Fig. 4.1b-c). Of interest were three mutants: a mutant 
where removing non-essential regions showed enhanced reprogramming to iPSCs (O 
lin95-117), being more significant in MEF reprogramming, a mutant where removing 
essential regions abolished OCT4 reprogramming to iPSCs activity (O lin29-42) and a 
functionally-minimum mutant lacking three non-essential regions without affecting 
reprogramming (O lin-min) (Fig. 4.1b). Furthermore, these three mutants retained the 
ability to maintain pluripotency, including the deficient O lin29-42, suggesting that 
defined patches or domains within the NT and CT regions are uniquely essential for 
reprogramming and that the lack of function in deficient mutants is not due to complete 
loss of protein functionality. Altogether, this data demonstrated that OCT4 
reprogramming to iPSCs is not only encoded by OCT4 DBD but also requires defined 
functional elements within the TADs, which need to be fully characterized for a better 
understanding of the OCT4 reprogramming activity (Roberts and Özkan, submitted).  
The discovery of defined functional regions illustrates that through different domains 
OCT4 is able to adapt in different cellular contexts. Integrating these results with the 
evidence presented in Chapter 3 that demonstrated that OCT4 initial engagement with 
the somatic proteome on chromatin is distinct from that during pluripotency 
maintenance, suggests that one of the mechanisms by which these functional domains 
contribute to reprogramming to iPSCs is through their importance in promoting or 
blocking specific protein interactions. However, these OCT4 protein partners are yet to 
be defined.  
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Fig. 4.1 Defined domains of OCT4 essential for reprogramming to iPSCs.  a. Structure of the 
functional domains of hOCT4. Red-Green bars denote the essential and non-essential 
domains of OCT4 in mouse reprogramming. b. OCT4 mutants’ structure illustrating the 
deleted regions. c. Reprogramming efficiency to human iPSCs of each mutants. Efficiency was 
quantified by counting the number of NANOG positive colonies (purple bars) versus DAPI 
colonies (blue bars) for each OCT4 deletion mutant in combination with SKM. Averages of at 
least three independent biological replicates are shown (error bars indicate ± s.d.). Images 
modified from (Roberts and Özkan, submitted).   
The adapted ChIP-SICAP (Chapter 3) would be therefore perfectly suited to define how 
different OCT4 domains influence OCT4 engagement, while allowing the identification of 
important partners that are specifically required to induce pluripotency from 
differentiated cells. These essential reprogramming chromatin-associated proteins can 
then be targeted to better understand cell fate changes during reprogramming.  
4.2 Aims 
 Define chromatin-associated proteins that interact with OCT4 essential and non-
essential domains in early reprogramming (OSKM 48h). 
 Define essential proteins required for inducing but no maintaining pluripotency. 
 Validate candidates by investigating their importance for reprogramming to iPSC. 
4.3 Results 
This results of this chapter are presented in three different sections. First, the chromatin-
associated interactomes of OCT4 mutants in early reprogramming are identified using 
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the adapted ChIP-SICAP protocol. Next, the interactomes of the OCT4 wild type and 
mutants in early reprogramming to iPSCs and in pluripotency maintenance were 
compared to identify proteins important for reprogramming to iPSCs but not for 
pluripotency maintenance. Finally, the importance of these candidates were 
experimentally validated in reprogramming to iPSCs.  
4.3.1 Defining the chromatin-associated proteins that interact with the essential and 
non-essential domains. 
In order to identify if essential and non-essential domains deleted from OCT4 result lead 
to differences in the chromatin-associated proteins described in the dataset of WT OCT4 
at early reprogramming and pluripotency in Chapter 3, the adapted ChIP-SICAP protocol 
was applied to the different OCT4 variants: O lin-min (OCT4 minimum with linker), O 
lin29-42 (OCT4 deficient mutant with linker) and O lin95-117 (OCT4 enhanced mutant 
with linker). 
The ectopic expression of OCT4 mutants along with the SKM factors was induced in 
human fibroblasts (HF) for 48 hr, all resulting in similar cell morphological changes to 
those observed in OCT4 WT (Fig. 4.2a). Furthermore, each of the OCT4 mutants showed 
similar protein levels and were specifically recognized by the OCT4 antibody, as indicated 
by the intensity and the migration of the corresponding bands in Western Blot analysis 
(Fig. 4.2b). These results confirmed the expression of the OCT4 mutants early in 
reprogramming and the suitability of the antibody for further proteomics analysis. ChIP-
SICAP protocol was then applied for each OCT4 mutant to identify their chromatin-
associated proteins. First, samples were sonicated for 140 minutes, as previously 
established, showing optimal shearing profiles with an enrichment of 100-300 bp DNA 
fragments (Fig 4.2c).  
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Fig. 4.2 Induction of OCT4 mutants and SKM factors.  a. Images of non-transduced Human 
Fibroblasts (HF Control) and OSKM (WT and mutants) induced cells after 48 hours of dox 
addition. b. Western Blot analysis of each OCT4 mutant and WT after 48 hours of cell 
induction. c. Chromatin sonication of the OSKM 48h mutants used for ChIP-SICAP. 
 
After carrying out the adapted ChIP-SICAP protocol and mass spectrometry analysis, the 
LFQ intensities of each protein were quantified and normalized against HF control (no 
OSKM) (Appendix Table 1). Considering proteins present in both replicates, a final 
number of 1207, 1065 and 684 proteins were identified for O lin-min, O lin95-117 and O 
lin29-42 respectively (Fig. 4.3a-c). Of these, OCT4 was among the top hits for all of them 
(Fig. 4.3 d-f). Even though the same amounts of OCT4 proteins and chromatin were used 
in the ChIP-SICAP experiments, the OCT4 mutants, especially O lin-min and O lin95-117 
were enriched for a higher number of proteins as compared to O WT in early 
reprograming. Furthermore, this was even more than in hES (Fig. 4.4a). These differences 
may indicate that the deletions within the OCT4 mutants facilitate or stabilize the 
interactions of OCT4 with more proteins. GO analysis of each OCT4 mutant revealed the 
enrichment of nuclear proteins, as well as proteins involved in chromatin structure and 
transcription. This suggests that the increased amount of protein number was not a 
result of contamination of cytosolic or non-chromatin proteins (Fig. 4.4).  
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Fig. 4.3 Identified proteins by ChIP-SICAP for each OSKM 48h mutant. a-c Venn diagram of 
the intersection between both OSKM 48h mutants replicates and statistically significant 
against the control O lin-min (a), O lin 95-117 (b) and O lin29-42 (c). d, e and f. Identified 
proteins ranked by enrichment over control O lin-min (d), O lin95-117 (e) and O lin29-42 (f). 
g-i.  
 
Overall, ChIP-SICAP protocol was successful in pulling-down and isolating the different 
type of OCT4 mutants and their chromatin-associated proteins in early reprograming, 
revealing, for the first time, a significant increase in the number of proteins that associate 
with mutated versions of OCT4 in chromatin in early reprogramming to iPSCs. 
To gain a better understanding of the new properties acquired by the OCT4 mutants in 
early reprogramming, differential enrichment analysis was performed taking into 
account the quantification values for each protein. First, to get a high-level overview of 
the differences between OCT4 variants, PCA analysis was performed for all the OCT4 
interactomes, including the negative controls. This revealed that the OSKM 48h samples 
clustered together, including WT and the mutants, while ES samples formed distinct a 
cluster (Fig. 4.4b). The negative controls also formed an independent cluster, despite 
different antibody and cell type being used, indicating common non-specific 
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contaminants. This analysis demonstrated that the differences between OCT4 WT 
interactors in early reprogramming and hES is greater than between OCT4 WT and the 
mutants in early reprogramming, despite the higher number of identified proteins for 
the OCT4 mutants.  
 
Fig. 4.4 Gene Ontology of identified proteins by ChIP-SICAP for each OSKM 48h mutant. a-
c. Gene Ontology enrichment analysis for Cellular component, Biological Process and 
Molecular function of the identified proteins for O lin-min (a), min32 (b) and O lin29-42 (c). 
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To further address the differences and similarities between the interactomes a 
comparative analysis of shared and unique proteins was performed. The list of proteins 
to be compared was strictly restricted to proteins that were consistently present and 
absent in both replicates of all OCT4 variants. A total number of 725 proteins fit this strict 
criteria including 256 for hES, 370 for O WT, 469 for O lin29-42, 636 for O lin95-117 and 
676 for O lin-min (Fig. 4.4c). More than 30% of the analysed proteins were present in all 
OCT4 interactomes, representing the biggest overlap, which was followed by the shared 
proteins between all OSKM 48h conditions (Fig. 4.5d). O lin-min was the mutant with 
most unique interactors (75) followed by O lin95-117 (21) and hES (13). Interestingly O 
lin29-42 interactors were all shared with the other interactomes. Therefore, the OCT4 
interacting proteins found in both hES and all OSKM 48h are not sufficient to drive 
reprogramming, since even if O lin29-42 is able to bind them, it is still a deficient 
reprogramming OCT4 variant. Nevertheless, this set or shared proteins are necessary for 
the maintenance of pluripotency, as O lin29-42 does not lose its functionality to rescue 
and maintain pluripotency in mESC. Moreover, the remaining subgroups including the 
intersections between different OCT4 mutants and their unique interactors, reflect the 
properties gained by the OCT4 mutants to acquire new associations, increasing the 
differences and specific roles of OCT4 in early reprogramming compared to pluripotency 
maintenance.  
Hierarchical clustering was then used to visualize and compare the relative intensity of 
the identified partners of each interactome (Fig. 4.6). The obtained heatmap allowed the 
classification of the proteins in 10 main groups: Group 1 included the proteins shared in 
all OSKM 48h (WT and mutants) and hES. Group 2 included proteins present only in O 
lin29-42 and O lin95-117; Group 3 included proteins present only in O lin95-117; Group 
4 included the proteins present and in all OCT4 mutants and ES but no O WT; Group 5 
includes proteins in all mutants but no ES or O WT; Group 6 included proteins only 
present in O lin-min; Group 7 included proteins present in O lin-min and O lin95-117; 
Group 8 included proteins present in all reprogramming to iPSCs mutants (O WT, O lin95-
117 and O lin-min) but no in O lin29-42 or ES; Group 9 included proteins present in all 
OCT4 mutants (WT and mutants) but no ES, and Group 10 included proteins only present 
in ES.  
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Fig. 4.5. Comparison of the expanded OCT4 ChIP-SICAP in pluripotency and reprogramming. 
a. Total number of proteins identified in each OCT4 ChIP-SICAP interactome hES and OSKM 
48h (WT and mutants). b PCA score plot of total ChIP-SICP dataset obtained for hES and 
OSKM 48h (WT and mutants) including their respective controls. b. Total number of filtered 
proteins for each condition considered for future analysis. c. Upset plot illustrating the 
intersections between the shared and unique proteins identified in the OCT4 ChIP-SICAP of 
hES and OSKM 48h mutants. 
 
Notably, one of the main differences observed was the increase number of proteins 
gained in the interactomes of the mutants (Groups 2,3,4,5,6,7. Fig. 4.6). More 
interestingly, for O lin-min and O lin95-117, although each mutant had their own unique 
set of proteins, most of the new interactions were shared between both mutants (Fig. 
4.6 Group 7), which can be the result of both sharing a deletion fragment. Among these 
shared proteins were KDM2B, SMAD2, SMARCA2, PAX6 and ETV5 which have been 
previously associated with reprogramming [115, 235, 273-275]. It was also interesting to 
observe that even if O lin29-42 does not share a domain deletion with O lin95-117 or O 
lin-min, there was a notable overlap between the new gained interactors between these 
three mutants (Fig. 4.6 Group 5). This group includes proteins involved in transcription 
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regulation such as STAT6, PIAS3, KDM5B and proteins involved in cell cycle such as 
MAPRE1, CSNK2A2, MAD1L1, PPP2CB, NUP93, CCND1. Besides, another property of the 
mutants was that despite gaining more interactions, they were able to maintain most of 
the original interactors identified for O WT in early reprogramming and for the ones 
shared with OCT4 in hES, as represented by Group 1 and Group 9 (proteins discussed in 
Chapter 3). Group 1 included proteins that were previously reported in Chapter 3 to be 
shared in early reprogramming and pluripotency maintenance, including members of the 
NURD, SWI/SNF and Drosha complexes. Group 9 (Fig. 4.6) included the interactors that 
OCT4 gains in the reprogramming process and that were conserved by the mutants and 
had been previously described in reprogramming, including factors involved in chromatin 
structure such as ARID5B, HAT1, KDM2A, and development and differentiation processes 
such as STAT1, GATA2, MEF3D, EBF1, RUNX1 and JUNB. Most importantly, the mutants 
did not gain the specific stem cell OCT4 interactors included in Group 10 (Fig. 4.6) (SALL4, 
SALL2, DNMT3B, LIN28A, ARID3B, L1TD1, DNMT3A, ZIC2, CERC2 AND ZNF532, and VRTN 
AND HELLS).  
Altogether, these results demonstrate that the removing the non-essential domains 
expand the interactome of OCT4 beyond the wildtype in early reprogramming. 
Particularly, O lin29-42 failed to reprogram fibroblast despite binding most of the 
proteins that also interact with WT, lin-min, and lin95-117 OCT4 counterpart, indicating 
there are key interactions missing. Interestingly, proteins within Group 8 included a small 
set of proteins that was not found in O lin29-42 interactomes, suggesting that loosing 
this set of partners detrimental for the reprogramming process. 
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Fig. 4.6 Differential abundance of OCT4 chromatin-associated proteins in pluripotency 
maintenance and early reprogramming (WT and mutants).  Hierarchically clustered 
heatmap of protein abundance pattern of filtered proteins identified for OSKM 48h (WT and 
mutants) and hES proteins. Samples are arranged in columns, proteins in rows. LFQ 
(abundance) intensities were log 2 transformed, centred and normalized. Red shades denote 
increased abundance, blue shades indicates reduced abundance (or absence). Manually 
defined groups are represented in the right. Each replicate is shown for each condition. 
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Overall, the general analysis between the interactomes of OCT4 chromatin associated 
proteins in pluripotency maintenance and early reprogramming (WT and mutants) 
defined that OCT4 gains new interactions when essential and non-essential domains are 
removed. This discovery could be reflecting new biological properties conferred by 
specific deletions, which grant OCT4 the ability to engage with more proteins involved in 
reprogramming, especially when deleting non-essential domains as seen with O lin-min. 
Most importantly, the intersection of the mutant interactomes with the OSKM 48h WT 
allowed the identification of a new OCT4 specific network in early stages of 
reprogramming not present in pluripotency maintenance, reinforcing the statement that 
in the reprogramming to iPSCs context, OCT4 gains new roles and engages different with 
the somatic proteome in comparison with the pluripotency maintenance one. Lastly, the 
differences observed between the mutants and WT OCT4 suggest that different domains 
of OCT4 confer different binding properties and lacking non-essential domains promotes 
different engagement with chromatin-associated proteins. 
4.3.2 Essential OCT4 domains are necessary for its interaction with important 
reprogramming proteins 
Clustering analysis reveal a set of proteins in Group 8, which included proteins missing in 
O lin29-42 interactome but present in the reprogramming variants of OCT4 (O WT, O 
lin95-117 and O lin-min) (Fig. 4.6). Seven proteins were included in this group: TNIP2 
(TNFAIP3-interacting protein 2), RAI1 (Retinoic acid-induced protein 1), UFD1L (Ubiquitin 
recognition factor in ER-associated degradation protein 1), XPO6 (Exportin-6), MCMBP 
(Mini-chromosome maintenance complex-binding protein), and FBRSL1 (Fibrosin-1-like 
protein) (Fig. 4.7). Interestingly, these seven proteins were also missing in hES, meaning 
they could be representing a set of important proteins necessary for inducing but not 
maintaining of pluripotency. Moreover, apart from ETV4, which has been associated with 
mESC proliferation and differentiation [276], the rest of the proteins have not been 
previously directly linked in the reprogramming process. Thus, these new OCT4 
chromatin-associated proteins might represent candidates with potential new functions 
in the reprogramming process, where they might be required for inducing but not 
maintaining pluripotency. 
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Fig. 4.7 Differential enrichment of candidates involved in the induction but not 
maintenance of pluripotency. Bar plots illustrating the enrichment of the candidate proteins 
across the different conditions. LFQ (abundance) intensities were log2 transformed, centred 
and normalized.  
 
To investigate the functional necessity of these protein candidates in reprogramming, 
their encoding genes have been knocked out (KO) using CRISPR-Cas9 TNG MKOS Cas9 
MEF. This secondary reprogramming system contains a dox-inducible MKOS + mOrange 
expression cassette, a GFP reporter and puromycin selection under the control of the 
endogenous Nanog promoter, as well as, a CAG promoter driven rtTA and a EF1a 
promoter driven Cas9 (Fig. 4.8a) This cell line has several advantages. First, 
reprogramming can be initiated by simply by adding dox to the media. Second, the 
expression of MKOS is coupled with mOrange, which can be monitored to help to identify 
partially-reprogrammed colonies. Third, NANOG expression can be detected by GFP to 
identify fully reprogrammed iPS colonies. Fourth and most importantly, the knockout of 
specific genes can be achieved by infecting the cells with lentiviruses encoding sgRNA 
against the gene of interest, resulting in insertion and deletion mutations (indels) by the 
constitutively expressed Cas9. Therefore, this system allows the efficient gene KO during 
reprogramming to iPSCs by the solely addition of dox to the ES media and the lentiviral 
transduction of the sgRNA of the gene of interest (Fig. 4.8b). This system has been 
successfully used to carry out a genome-wide loss-of function screen during iPSC 
reprogramming, identifying 23 genes that impede reprogramming and 1,921 genes that 
are essential for reprogramming (Kaemena and Beniazza et al., submitted).  
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Fig. 4.8 TNG MKOS Cas9 MEF Reprogramming System.  a. Representation of the TNG MKOS 
Cas9 MEFs transgenes b. Reprogramming scheme for MEFs reprogramming to iPSCs and the 
knockout of candidates. NANOG-GFP expression indicates fully reprogrammed iPSCs. Imaged 
modified from Kaemena and Beniazza et al., submitted. 
 
To knockout the OCT4-interacting candidates in TNG MKOS Cas9 MEF, the sgRNAs 
sequences were obtained from the library used in the KO screen mentioned above, which 
contains sgRNAs to target 90% of the mouse genes. Based on the screen data, the best 
sgRNA for each candidate were picked and cloned into the sgRNA lentivirus vector, which 
also included a BFP reporter and the expression of the sgRNA was under the control of 
the human U6 promoter. The Trp53 and Dot1l genes were used as controls of roadblocks 
as it has been reported that their absence improves reprogramming [116, 277]. Stat3, 
Etv5 and Kdm4b were used as a control for essential genes as they have been reported 
to be important for the process and their absence decreases the reprogramming 
efficiency [112, 278, 279]. Zeo was used as an off-target sgRNA control as it has no target 
in the mouse genome. Lentivirus for each sgRNA (controls and candidates) were 
transduced in a co-culture of 10% of TNG MKOS Cas9 MEFs and WT feeder-MEFs. After 
24 hours, reprogramming was initiated by changing to mESC media supplemented with 
dox and Vitamin C. After 15 days, whole well fluorescence imaging was performed with 
the Celigo cytometer (Fig. 4.9a). The Mcmbp and Ufd1l knockouts resulted in the most 
drastic decrease in Nanog-GFP positive colonies, similar to what was observed with the 
Stat3 control, indicating that these genes are essential for reprogramming (Fig. 4.9b). 
Moreover, gene knockout of the remaining candidates Xpo6, Rai1, Tnip2, Fbrsl1 and Etv4 
have also significantly decreased the number of Nanog-GFP colonies when compared 
with the sgRNA controls (Zeo, Dot1l, Trp53) and cells with no virus, although not to the 
same extent as Mcmbp and Ufd1l KOs (Fig. 4.9b). This therefore suggests that Mcmbp 
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and Ufd1l are essential for reprogramming, while the rest of the candidates may be 
important for driving more efficient reprogramming.  
 
Fig. 4.9 Effects of candidate genes KO in TNG MKOS Cas9 MEF Reprogramming System.  a. 
Whole well fluorescent images of MEF reprogramming at Day 15. One representative well is 
shown for each candidate. GFP represent NANOG+ iPSCs. b. Reprogramming efficiency to 
mouse iPSCs after KO of each candidate. Efficiency was quantified by counting the number 
of GFP NANOG positive colonies. Averages of three replicates are shown (error bars indicate 
± s.d.). ** p.value<0.01.  * p.value<0.05. 
 
After establishing that the knockout of all candidates had negative effects in 
reprogramming to iPSCs, their over-expression may have the opposite effect and 
contribute positively to the process. To investigate if this was the case, the candidates 
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were overexpressed using a dox-inducible lentivirus system in the same cell line (TNG 
MKOS Cas9 MEFs) but without the KO and the sgRNAs (Fig 4.10).  
 
Fig. 4.10 TNG MKOS Cas9 MEF Reprogramming System and overexpression of the 
candidates.  Reprogramming scheme for MEFs reprogramming to iPSCs and overexpression 
of the candidates. NANOG-GFP expression indicates fully reprogrammed iPSCs. Image 
modified from Kaemena and Beniazza et al., submitted. 
 
DOX-inducible lentiviruses encoding for all candidates apart from FBSRL1were generated 
using ZBTB2 and KDM4B [280] that known to enhance reprogramming were used as 
positive controls. Next, MEFs (10% TNG MKOS Cas9 MEF and 90% WT MEFs) were 
infected with these viruses for 24 hr and reprograming was initiated by adding Dox along 
the induction of each ectopic candidate. After 15 days, whole well fluorescence imaging 
was performed with the Celigo cytometer, allowing the counting of Nanog-GFP colonies 
in three biological replicates (Fig. 4.11a-b).  
As expected, ETV4 overexpression enhanced reprogramming by more than 2 fold, 
consistent with ETV5 overexpression in previous reports [276]. In contrast, 
overexpressing MCMBP, TNIP2, and UFD1L resulted in significantly less Nano-GFP 
colonies, indicating less efficient reprogramming (Figure 4. 11b). This suggests that the 
expression levels of these proteins is fundamental for a successful reprogramming to 
iPSCs, as their reduction or increase lead to negative effects in the process. No effect was 
observed when XPO6 and RAI1 were overexpressed, indicating that while normal levels 
of this proteins are needed to facilitate reprogramming, higher amounts has no 
additional contribution to the process (Fig. 4.11). In conclusion, these candidates play a 
crucial role for inducing reprogramming by a chromatin-mediated interaction with OCT4.  
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Fig. 4.11 Effects of candidate protein over expression in TNG MKOS Cas9 MEF 
Reprogramming System.  a. Whole well fluorescent images of MEF reprogramming at Day 
15. One representative well is shown for each candidate. GFP represent NANOG+ iPSCs. b. 
Reprogramming efficiency to mouse iPSCs after constitutive over expression protein of each 
candidate. Efficiency was quantified by counting the number of GFP NANOG positive 
colonies. Averages of three replicates are shown (error bars indicate ± s.d.). ** p.value<0.05.  
* p.value<0.1. 
 
4.3.3 OSKM induction promotes the recruitment of important proteins to chromatin  
To shed light on how the functionally validated OCT4 partners play important roles in 
reprogramming, changes in their chromatin enrichment were investigated. To this end, 
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proteins from the cytoplasmic, soluble nuclear (not associated with chromatin) and the 
chromatin fractions were isolated from hES, OSKM48h (OCT4 WT and mutants) and HF. 
Western blot analysis confirmed that the chromatin marker histone H3 was exclusively 
identified in the chromatin fraction while LaminB was found in the soluble nuclear 
fraction as well as chromatin, demonstrating the efficiency of the fractionation (Fig. 
4.12a). OCT4 expression was also validated in hES and OSKM 48h (WT and mutants) 
showing expression in all the subcellular fractions and no expression in HF control (Fig. 
4.12a). Detection of candidates and KDM4B as a control were tested in the chromatin 
fraction, with the exception of FBSRL1 and MCMBP and RAI1 due to the low quality of 
commercially available antibodies. When measured together (similar exposure), the 
extent of the ectopic OCT4 expression was very apparent as very high protein levels were 
readily detected in the chromatin fractions from OSKM 48h samples, while the 
endogenous OCT4 from hES was barely visible almost similar to that in non-infected HFs 
(Figure 4.12b, see figure 4.12a for optimally exposed endogenous OCT4). Remarkably, 
TNIP2 and UFD1L were more enriched in chromatin when overexpressing OCT4 WT and 
the reprogramming efficient mutants O lin95-117 and O lin-min but showed diminished 
chromatin association along the reprogramming-deficient O lin29-42 and in hES (Fig. 
4.12b). These mutants were completely absent in the chromatin fraction of non-infected 
HFs, demonstrating that OCT4 is involved in loading and recruiting these two proteins 
chromatin only during successful reprogramming. Thus, the deficiency of mutant O lin29-
42 for driving the reprogramming process might may be related to its inability to recruit 
these two proteins to chromatin. On the other hand, XPO6 and ETV4 showed more 
enhanced enrichment on chromatin with the overexpression of OCT4 WT and all mutants 
during reprogramming and in ESCs when compared to non-infected HFs. Therefore, while 
still important for reprogramming, the association of XPO6 and ETV4 with chromatin may 
also be driven by the other SKM factors and is not sufficient for the process.  
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 4  127 
 
Fig. 4.12 Chromatin enrichment of candidates in human stem cells and human early 
reprogramming (OSKM 48h WT and mutants).  a. Immunoblot detection of Histone 3 (H3), 
OCT4 and LaminB in hES, OSKM 48h (OCT4 WT and mutants) and HF control after a cellular 
fractionation procedure. TE= Total extract. Cyt = Cytoplasm, Nucl = Soluble Nuclear. 
Chr=Chromatin fractions. b. Immunoblot detection of candidate proteins and OCT4 in the 
chromatin fraction of hES, OSKM 48h (OCT4 WT and mutants) and HF control. H3 was used 
as a loading control. 
 
In summary, the results of this chapter allowed expansion of the OCT4 interactome in 
OSKM 48h taking advantage of OCT4 mutants lacking essential and non-essential 
domains with different reprogramming efficiencies. Comparison of the interactomes of 
the OCT4 mutants along with WT OCT4 in early reprogramming to iPSCs and OCT4 in 
pluripotency maintenance showed that the deletion of essential and non-essential OCT4 
domains results in and increase of OCT4 interactions with the chromatin-associated 
proteins in early reprogramming. Additionally, the analysis allowed the identification of 
seven non-previously described proteins important to induce but not maintain 
pluripotency. Characterization of these candidates demonstrated they are essential 
proteins for mouse reprogramming to iPSCs. Lastly, enrichment of the candidates in 
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chromatin suggested their recruitment to chromatin might be mediated or influenced by 
OCT4 when HF are induced with OSKM. 
4.4 Discussion 
OCT4 is a modular protein with functionally independent domains. A recent study 
developed in the Soufi lab, dissected the OCT4 domains that are essential for 
reprogramming to iPSCs from the ones essential for pluripotency maintenance (Gareth 
Roberts and Burak Özkan et al., submitted). Different OCT4 mutants with deletions in 
these domains were designed; resulting in different reprogramming efficiencies, 
demonstrating that OCT4 reprogramming to iPSCs is not only encoded by OCT4 DBD but 
also requires defined functional elements within the TADs. The interesting particularities 
of these mutants included a deficient reprogramming variant, lacking an essential 
domain in the N-terminus (O lin29-42), an enhanced reprogramming variant lacking a 
non-essential domain in the N-terminus (O lin95-117) and a minimum OCT4 lacking three 
non-essential domains, two in the C terminus and one in the N-terminus. (Roberts and 
Ökzan, submitted). 
For a better understanding of how the deletions were influencing OCT4 function in 
reprogramming (OSKM 48h), this chapter was focussed in characterising these mutants 
by defining their chromatin-associated partners by ChIP-SICAP at early stages of 
reprogramming, as it was demonstrated in Chapter 3 that the engagement of OCT4 with 
chromatin-associated proteins differs from its engagement in pluripotency maintenance. 
Interestingly, when compared with the interactomes of O WT in reprogramming and 
early pluripotency described in Chapter 3, these mutants revealed an increase in number 
of their chromatin-associated proteins (Fig. 4.3 and 4.5). This enhancement was not the 
result of unspecific interactions or non-chromatin associations, as mostly all of the 
previously described chromatin-associated proteins for O WT (OSKM 48h) were included 
in the interactome of the mutants and Gene Ontology revealed enrichment of nuclear 
proteins involved in chromatin remodelling and transcription regulation (Fig 4.3). For 
instance, O lin-min was the mutant with higher number of interactors, which could 
suggest that multiple deletions of non-essential domains provide a better conformation 
for OCT4 to associate with more proteins (Fig. 4.5). Interestingly, despite being able to 
bind more proteins, O lin-min does not have a positive nor negative effects in 
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reprogramming, evidencing that interacting with a higher number of proteins does 
directly leads to an improvement of the process. Correlating with this statement was the 
interactome properties observed with the deficient O lin29-42, which gain the same new 
interactors as O lin95-117 and O lin-min, but still was not functional for the generation 
of iPSCs (Fig. 4.5). This evidence indicates that although necessary, the shared proteins 
between O WT and the mutants are not sufficient to drive the process. Moreover, O 
lin29-42 did not gain any unique interactors but when compared with O WT (OSKM 48h 
and hES), O lin-min and O lin95-117, eight interactors were missing, from which seven 
were specific for the reprogramming process and not present in the OCT4 hES 
interactome: UFD1L, TNIP2, RAI1, MCMBP, XPO6, ETV4 and FBRSL1 (Fig. 4.6, 4.7). 
Functional assays of these proteins allowed the identification of seven new proteins not 
previously described in reprogramming that revealed to be important for the process, as 
their depletion by Knock Out (KO) decreased the reprogramming efficiency. Because of 
their importance for reprogramming, but their absence in hES interactomes, these new 
candidates can be classified as OCT4 chromatin-associated proteins necessary to induce 
but not maintain pluripotency and will be further discussed next.  
4.4.1 OCT4 chromatin-associated proteins at early reprogramming can help unravel 
new mechanisms driving reprogramming 
The identification of a subset of proteins important for the induction but not 
maintenance of pluripotency identified at early stages of the reprogramming process 
highlighted the importance of identifying and characterising the new interactions OCT4 
is gaining as a reprogramming factor. Next, the OCT4 chromatin-associated protein 
candidates identified in this work will be discussed, combining the results of this study 
with previous literature reports to speculate their potential roles in the reprogramming 
process. 
4.4.1.1 TNIP2 
TNIP2 (TNFAIP3 Interacting Protein 2) also known as A20-binding inhibitor of NF-κB 
(ABIN-2) is classified as a cytoplasmic zinc-finger protein that functions as a negative 
regulator of NF-κB activation in response to multiple inflammatory stimuli [281]. Even 
though its expression and function had been mainly described in the cytoplasm, few 
studies suggest that the C-terminus is able to translocate to the nucleus and, when fused 
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with a DNA binding domain, activate expression of a reporter gene in human cells [282]. 
Although the mechanisms regulating its translocation to the nucleus and its specific role 
in the transcription regulation are not known, it has been associated to the member 
SMARCD1 from the SWI/SNF complex [282], RNA processing proteins like YMPL1 and 
nuclear ribonucleoprotein (RNP) structures, such as NONO, SFPQ and PSPC1 [283]. 
Interestingly, most of the proteins mentioned above were identified amongst the OCT4 
interactomes with lowest enrichment in the deficient O lin29-42 and hES (Fig. 4.13). The 
presence of these proteins could link TNIP2 to different processes in the early 
reprogramming. Even when the mechanisms by which TNIP2 promotes transcription are 
still unknown, in early reprogramming it could be mediated by its interaction with 
SWI/SNF in the same genomic regions as OCT4, contributing to the transcription of 
essential genes. It might also be involved in the regulation of transcription to promote 
pluripotency through post-transcriptional regulation of mRNAs as it was reported TNIP2 
can bind mRNAs [283]. Interestingly, most of the mRNAs it binds coded for transcription 
factors, including some that had been associated both positively and negatively in the 
reprogramming process, such as GATA2 [284], and JUN [149], respectively. It is possible 
that TNIP2 regulates these mRNAs in association with the paraspeckle proteins NONO, 
SFPQ and PSPC1, whose function include influence gene expression by controlling the 
nuclear retention or the mRNA transcripts [285]. It is worth mentioning that whichever 
mechanisms TNIP2 is involved in early reprogramming, it is highly dependent on a 
functional OCT4 when OSKM are induced, as significantly lower amounts of TNIP2 were 
observed in the chromatin fractions of OSKM 48h O lin29-42 (Fig. 4.12b). This evidence 
suggests a direct role of the essential domain of OCT4 missing in O lin29-42 for the 
enrichment of TNIP2 in chromatin, specifically when OSKM are induced. Additionally, a 
tight regulation of TNIP2 is necessary for a successful reprogramming process, as 
depletion and its overexpression both had negative effects in mouse reprogramming (Fig. 
4.9 and 4.11). Lastly, the detection of TNIP2 in the chromatin fractions is the first 
evidence to demonstrate that TNIP2 not only can be translocated to the nucleus, but it 
can also be recruited to chromatin under exterior stimuli, such as the OSKM induction.  
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Fig. 4.13 Differential enrichment of RNA interacting proteins known to interact with TNIP2 
that were identified in the interactomes.  Bar plots illustrating the enrichment of proteins 
that had been described as interactors of TNIP2 (also shown). Proteins are shown for all 
conditions. LFQ (abundance) intensities were log2 transformed, centred and normalized.  
 
4.4.1.2 UFD1L  
Ubiquitin recognition factor in ER-associated degradation protein 1 (UFD1L) is an 
important component of the NPLOC4-UFD1-VCP complex involved in a degradation 
pathway for ubiquitin fused products (UFD) pathway [286]. In addition to UFD1L, the 
component VCP was also identified in all OSKM 48h (WT and mutants) and not in hES 
(Fig. 4.14), suggesting this complex might be present in early reprogramming. The 
complex main function is to recognize polyubiquitin tagged proteins and facilitate heir 
presentation to the 26S proteosome for protein degradation [286]. This is fundamental 
to restore protein homeostasis in the ER in response to stress result of accumulation of 
unfolded proteins [287]. Additionally, this complex is involved in the protein extraction 
of ubiquitinated proteins associated with chromatin which helps in maintaining genome 
stability as it was found that the inactivation of the subunit VCP leads to accumulation of 
ubiquitinated substrates on chromatin and results in protein-induced chromatin stress 
(PICHROS) [288]. PICHROS has negative effects in multiple DNA metabolic processes, 
including replication, damage responses, mitosis, and transcription, leading to genotoxic 
stress and genome instability [286, 288]. As UFD1L is an essential subunit of the complex, 
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the evidence presented in this work where its KO completely abolished reprogramming 
(Fig. 4.9) could be related to its involvement in PICHROS, as well as dysregulation of the 
ER stress response. On the other hand, ubiquitination dynamics are a fundamental 
posttranscriptional regulation of OSKM during reprogramming and pluripotency 
substrates [289]. For instance, OCT4 stability and turnover can be regulated by 
ubiquitination and sumoylation modifications [289, 290]. Evidence of SUMO and UBE 
proteins found in the OCT4 interactomes suggest this mechanism is part of OCT4 
regulation (Fig. 4.14).  
 
Fig. 4.14 Differential enrichment of VCP and UBE and SUMO proteins that were identified 
in the interactomes.  Bar plots illustrating the enrichment of VCP protein, which has been 
reported to interact with UFD1L (also shown) and that was identified in the interactome. 
Sumo and UBE related proteins are also shown, which could be related to post-translational 
modifications of OCT4 recognised that could be recognised by UFD1. Proteins are shown for 
all conditions. LFQ (abundance) intensities were log2 transformed, centred and normalized. 
 
Recognition by UFD1L of ubiquitinated OCT4 could be a regulatory mechanism for the 
degradation or relocation of OCT4 in chromatin, as it has been reported that recognition 
of ubiquitinated chromatin-associated proteins by UFD1L results in the remodelling and 
releasing of the ubiquitinated chromatin-bound substrate, which can be further 
degraded by proteasomes or recycled [288]. This evidence, and the fact that UFD1L levels 
in chromatin fractions of hES and O lin29-42 were lower (Fig. 4.12b), could suggest an 
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important mechanism for reprogramming in which the recognition of UFD1L of 
ubiquitinated proteins associated to chromatin, such as OCT4, results in their release 
from chromatin for degradation or recycling and relocation. Additionally, the higher 
levels of UFD1L observed in the chromatin fractions of OSKM 48h (Fig. 4.12b) suggest 
that this mechanism is induced by the OSKM expression. In fact, it has been shown that 
cMYC transcriptionally upregulates UFD1L in T-cell acute lymphoblastic leukaemia (T-
ALL), as a mechanisms to alleviate the ER stress caused by accumulation of misfolded 
proteins [287]. Finally, UFD1L importance in reprogramming could also be linked to its 
involvement in clearing misfolded proteins. In fact early ER stress is an essential step for 
the reprogramming process and ectopic transient activation of the unfolding protein 
response increases reprogramming efficiency [291] which could explain the early UFD1L 
induction and activation from early stages or reprogramming.  
4.4.1.3 XPO6  
Exportin 6 (XPO6) is a G-actin nuclear export transporter that is specific for profiling-actin 
complexes [292]. Monomeric actin (G-actin) is the only directly recognized cargo of this 
protein so far, making XPO6 responsible for the regulation of nuclear actin levels. In 
addition, nuclear actin has been implicated in a variety of DNA-related processes 
including chromatin remodelling, transcription, replication, and DNA repair [293]. 
Interestingly, herein different actins were also identified to be associated with OCT4 
either in OSKM 48h (WT and mutants) or in hESCs (Fig. 4.15). 
Among the actins found in the interactomes were ACTL6A and ACTN1, which have been 
both associated with chromatin remodelling complexes such as SWI/SNF, INO80, 
SRCAP/SWR1 and the combined remodeller/histone acetyltransferase complex 
TIP60/NuA4 [294].  
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Fig. 4.15 Differential enrichment Actin proteins that were identified in the interactomes. 
Bar plots illustrating the enrichment of the actin proteins identified, which could be related 
to XPO6 (also shown). Proteins are shown for all conditions. LFQ (abundance) intensities were 
log2 transformed, centred and normalized.  
 
Moreover, there is evidence suggesting that depending on the stimuli and cell conditions, 
the regulation levels of actin had different influences in transcriptional regulation. For 
example, mechanical strain conditions can result in the reduction of nuclear actin, 
leading to the attenuation of transcription and subsequent accumulation of H3K27me3 
at facultative heterochromatin at differentiation genes. This effect can be reversed by 
depleting XPO6, which increased the levels of nuclear actin and the levels of H3K27me3 
[295]. This example shows that depending on the cellular conditions, XPO6 is 
fundamental for regulating nuclear actin levels, which will determine global 
transcriptional activity. In reprogramming for instance, XPO6 KO had negative effects in 
iPS colonies formation, but interestingly its overexpression did not have any effects. This 
suggests that if the main role of XPO6 is to regulate actin levels, only the accumulation -
not the absence or decrease levels- of actin in the nuclei are detrimental for the 
reprogramming process. Moreover, additional roles of XPO6 in chromatin independent 
of OCT4 should also be considered, as even if was not detected in O lin29-42 and hES 
interactomes, it was still detected in their chromatin fractions, with more enrichment in 
hES than in OSKM in general (Fig. 4.12b). Lastly, XPO6 could be involved in new transport 
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mechanisms, for example, XPO4 was reported to participate in a novel nuclear import 
pathway for SOX family in mESC, expanding the roles of exportins besides their 
established function in nuclear export [296].  
 
4.4.1.4 MCMBP 
Mini‑chromosome binding protein (MCMBP) is involved in the regulation of the 
minichromosome maintenance complex (MCM), known to be crucial in the DNA 
replication process [297]. The MCM complex is comprised of six subunits 
(MCM2/3/4/5/6.7), each with a different role in the initiation and elongation of DNA 
replication [298]. They are involved in melting the origin DNA for the subsequent 
replication and fork progression, where the complex provides the DNA helicase activity 
necessary to unwind double stranded DNA during replication [299]. Studies in Xenpous 
egg extracts have demonstrated that the role of MCMBP in this process is to displace 
MCM2-MCM7 complex from the chromosomes after DNA synthesis is complete [300]. 
Furthermore, in human its downregulation results in increased apoptosis and abnormal 
nuclei exhibiting signs of replication stress and slowed cell cycle progression [301]. Thus, 
its importance in the cell cycle and DNA replication might explain the completely 
abolished reprogramming when the Mcmbp gene was deleted in MEFs (Fig. 4.9). In fact, 
MCMBP was al found as an essential gene needed for mESC maintenance and cancer cell 
survival [194, 302], suggesting a tight coordination of the cell cycle and reprogramming. 
Due to the important role of MCMBP for cell cycle progression [301], its chromatin-
mediated association with OCT4 may directly link cell cycle regulation and 
reprogramming. Interestingly, OCT4 has already been associated in the regulation of cell 
cycle progression in embryonic stem cells by regulating the mitotic entry [303, 304]. 
More interestingly, it was also reported that the deletion of the N-terminal or C-terminal 
domain of OCT4 resulted in a significant impairments of the cell-cycle [305]. Other 
studies have also showed that alleviating the cell-cycle arrest induced by OSKM 
overexpression can increase the efficiency of reprogramming [306, 307]. As MCMBP is 
fundamental for the disassembling the MCM2-7 complex and the regulation of DNA 
replication, its chromatin association with OCT4 at early reprogramming could be part of 
a new mechanism implemented by the cells to cope with the cell cycle changes that 
OSKM are inducing. Besides, its absence in the hES and O lin-29-42 interactomes could 
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suggest this mechanism might be more necessary for the reprogramming process than 
for the pluripotency maintenance. However, the overexpression of MCMBP also has 
negative effects on reprogramming, suggesting a tightly controlled process is involved 
(Fig. 4.9 and 4.11). 
4.4.1.5 RAI1 
Retinoic Acid Induced protein 1 (RAI1) is a transcription factor that has associated to 
several human developmental disorders, including Smith–Magenis (SMS) and Potocki–
Lupski syndromes, as well as other adult neural disorders with developmental origins 
such as schizophrenia and autism [308, 309]. Downregulation of RAI1 in cell lines derived 
from SMS patients showed dysregulation of genes that are involved with cellular growth 
and gene expression, while cells showed decreased cellular proliferation and longer 
population doubling [310]. These studies suggest a functional role of RAI1 in the 
transcriptional regulation, which may explain the decreased reprogramming efficiency 
observed in this work when RAI1 was KO (Fig. 4.9). In fact, other studies have linked RAI1 
to transcriptional regulation as it contains two predicted protein-interacting domains: an 
extended plant homeo-domain (ePHD) and a nucleosome-binding domain (NBD) [311]. 
While RAI1 does not possess a known DNA binding domain, several studies have found 
its ability to bind nucleosomes [312] and have transactivation activity; its presence in 
both the nucleoplasmic and chromatin fractions [313]; and its binding to enhancers [314, 
315] and specific loci in the genome, with strong enrichment around transcriptional start 
sites (TSS) and enhancer regions of genes involved in cell adhesion, axon guidance, and 
neuronal morphogenesis [313]. This evidence supports the association of RAI1 in 
chromatin and suggests that RAI1 association with OCT4 might be involved in 
transcriptional regulation mechanisms early reprogramming. Nevertheless, OCT4 is 
preferentially enriched at distal silent enhancers prior gene reactivation, recruiting RAI1 
may enable promoter binding and gene activation [110]. Additionally, RAI1 promoter 
contains multiple retinoic acid responses elements (RARE), which can be recognized by 
the retinoic acid (RAR) and retinoid X receptors (RXR) modulated transcription factors 
[316]. Interestingly, one of these receptors (RXRA) was identified as an OCT4 chromatin 
associated protein in OSKM 48h (WT and mutants) but not in hES (Fig. 4.16). Moreover, 
even though RXRA was also identified in O lin29-42, its levels were less when compared 
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to the rest, particularly O lin-min and O lin95-117, which correlates with the levels 
detected for RAI1 in the corresponding interactome (Fig 4.16). Overall, RAI1 association 
with OCT4 does not only propose new transcription factors involved in reprogramming 
but could also illustrate how OCT4 might promote the expression of its interactors. 
 
Fig. 4.16 Differential enrichment of retinoic acid related proteins that were identified in the 
interactomes.  Bar plots illustrating the enrichment of the RXRA, which could be regulating 
the expression of RAI1 (also shown). Proteins are shown for all conditions. LFQ (abundance) 
intensities were log2 transformed, centred and normalized.  
 
4.4.1.6 ETV4 
E26 transformation-specific (ETS) transcription factor 4 (ETV4) is a transcriptional 
activator that has been described as an important factor in tissue development, such as 
motor neurons, mammary glands, kidney and limbs. Additionally, ETV4 has been 
described as an oncogene promoting proliferation and metastasis in colon, breast and 
prostate cancer, amongst others [317]. Amongst all the candidates proposed to be 
important for reprogramming in this work, ETV4 was the only one that enhanced 
reprogramming process when overexpressed along OSKM (Fig. 4.9 and 4.11). Similarly, 
ETV5 another member of the ETS family has already been reported to be important for 
the reprogramming process, as it has been defined as an early regulator and maker for 
reprogramming, necessary to generate poised intermediates with better chances of IPs 
cell formation [318], which agrees with the phenotype observed in the ETV5 KO reported 
in this work (Fig 4.11). Additionally, ETV5 can enhance reprogramming by facilitating the 
mesenchymal to epithelial transition (MET)[279]. In spite of ETV4 not been analysed in 
these contexts yet, it has been widely studied in cancer as it is overexpressed in several 
types, such as breast, prostate, colon and lung, besides being linked to metastasis and 
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cell proliferation [226]. Interestingly, in a human embryonic carcinoma (EC) cell line, ETV4 
can act as an upstream effector to regulate the expression of the pluripotency core 
transcription factors OCT4 and NANOG by binding to its promoters. This supports the 
idea that ETV4 is involved in tumorigenesis as an oncogenic activator [317, 319] and 
suggests that ETV4, as a transcription factor, might be part of the mechanisms, along 
with OCT4, that re-activates genes involved in the pluripotency network in the 
reprogramming process. Indeed, an intermediate reprogramming populations with 
higher expression of ETV5 the early expression of this transcription factors, preceding the 
activation of the majority of transcription factors thought to be predictive for 
pluripotency induction [318], opening the question if by similar mechanisms ETV4 could 
be contributing to these transcriptional changes, therefore its contribution to enhance 
of the process (Fig. 4.11). 
4.4.1.7 FBRSL1 
FBSRL1 (Fibrosin Like protein 1) is the least characterized protein from the candidates. It 
belongs to the AUTS2 family, along with its paralogs AUTS2 and Probable fibrosis (FBRS), 
and has been associated to zebrafish development [320]. Even though FBRSL1 specific 
function remains elusive, AUTS2 studies in neurodevelopment suggest a role FBSRL1 in 
activating gene transcription via the Polycomb Repressive Complex 1 (PRC1) [321]. This 
evidence is supported by the fact that AUTS2, FBRS and FBRSL1 are co-binders of two 
specific subtypes of the PCR1 complex, termed PCR1.3 and PRC1.5 as they include the 
Polycomb group RING fingers PCGR3 and PCGR5 respectively [322]. Even though the 
canonical role of PRC1 complexes are involved in gene repression through the mono 
ubiquitination of H2AK119 through its RING1B component [323], the specific PRC1.5-
AUTS2 is involved in activating transcription of neurodevelopmental genes [321]. The 
mechanisms mediating this unexpected role require the neutralizing of PRC1 repressive 
activity by the recruitment of the serine kinase CK2, which phosphorylates RING1B and 
compromising its mono ubiquitination activity [321]. Additionally, AUTS2 also recruits 
the histone acetyltransferase EP300 and the WD40-repeats containing protein WDR68, 
leading to gene activation of neurodevelopmental genes [322]. Interestingly, FBRSL1 was 
identified to bind AUTS2 complex [321] and even though AUTS2 was not present in the 
final list of proteins analysed in this work, the remaining principal components of the 
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PRC1 complex [324] were identified in the OSKM 48h interactomes, being fully identified 
in O lin95-117 and O lin-min (Fig 4.17).  
 
Fig. 4.17 Differential enrichment of proteins part of the PRC1.5-AUTS2 that were identified 
in the interactomes.  Bar plots illustrating the enrichment of proteins that had been describe 
as part of the PRC1.5-AUTS2 complex and could be interactors of FBRSL1 (Also shown). 
Proteins are shown for all conditions. LFQ (abundance) intensities were log2 transformed, 
centred and normalized.  
 
Moreover, proteins without a described role in the PRC1.5-AUTS2 but that were 
described to bind AUTS2 were also identified in the OSKM 48h interactomes, such as 
RERE, WDR5, TLE3, ATN1 and RBM14 (Fig. 4.18) [321]. Altogether, this suggests that in 
the early reprogramming, FBSRL1 might be involved in transcription activation via its 
interaction with the specific PRC1.3/5 complex and via the same mechanisms, its paralog 
AUTS2 is regulating transcription activation in neurodevelopment. More interesting is 
the addition of OCT4 to this mechanism and whether it is responsible of recruiting the 
complex to the chromatin or it is recruited once the complex is formed. Either way, the 
recruitment could be via its co-occurrence with the co-activator EP300, which is recruited 
to promoters by OCT4, SOX2 and NANOG in hES cells [151, 325, 326]. Additionally, PCGF5 
and WDR68, which are main components of the PRC1.5-AUTS2 are dispensable in mESC 
maintenance, as their depletion had no effect in mESC self-renewal [322, 327], 
suggesting that the formation of this specific complex is not necessary for pluripotency 
maintenance. This last statement agrees with what is proposed in this work of FBRSL1 
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being required to promote but not maintain pluripotency. Altogether, the proteins 
identified in this works allows proposing a new mechanism for transcriptional activation, 
mediated by OCT4 and FBSRL1 via a non-canonical PCR1 complex capable of transcription 
stimulation of essential genes. This model is further supported by the evidence of 
deficiency of MEFs to reprogram to iPSCs when FBSRL1 is depleted and its absence along 
the main PRC1 components in the interactome of the deficient OCT4 mutant.  
 
Fig. 4.18 Differential enrichment of proteins that interact with AUTS2 that were identified 
in the interactomes. Bar plots illustrating the enrichment of proteins that had been described 
as interactors of AUTS2 and could be interactors of FBRSL1 (also shown). Proteins are shown 
for all conditions. LFQ (abundance) intensities were log2 transformed, centred and 
normalized.  
 
In summary, the evidence presented for each candidate represents new models that 
could be addressed to understand the importance of new candidate proteins in the 
reprogramming process as well as unravelling new mechanisms OCT4 is participating in 
to drive the process. Moreover, these proteins were identified as a result of the 
expansion of the OCT4 interactome at early reprogramming implementing ChIP-SICAP in 
mutants lacking essential and non-essential domains, revealing that focusing in the 
properties of the (TADs) of OCT4 can help understand new biochemical properties of 
OCT4, leading to the discovery of new interactors and mechanisms important for the 
reprogramming process and for the function of OCT4, information that could have not 
been addressed by taking the OCT4 interactome of pluripotent cells as the reference 
point. 
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Chapter 5 OCT4 DOMAINS INFLUENCE IN THE INITIAL ENGAGEMENT OF 
OCT4 WITH THE SOMATIC GENOME AND THE PROTEOME IN 
EARLY REPROGRAMMING  
5.1 Introduction 
Reprogramming initiation involves OCT4 acting as a pioneer factor by recognizing partial 
motif exposed in the surface of nucleosomes. This is followed by OCT4 opening up closed 
chromatin and recruiting other transcriptional activators and chromatin remodelers as 
well as the transcriptional machinery [110, 156]. An interesting feature of OCT4 and its 
adaptability to recognize partial motifs in nucleosomes relies on the flexibility of its DNA 
binding domain (DBD), being able to separately use each of the PouS and PouHD domains 
within the DBD (Fig. 1.3) [157]. Interestingly, targeting closed chromatin can occur by 
coordinate binding of OCT4 and the other reprogramming factors SOX2, KLF4, cMYC. In 
the two previous chapters (3 and 4), OCT4 was shown to be part of an early 
reprogramming proteomic network that differs from the pluripotency one. Importantly, 
analysis of different OCT4 mutants demonstrated that by deleting essential and non-
essential domains can alter OCT4 protein interaction network on chromatin. 
Interestingly, these deletions are within the N- and C- terminal transactivation domains 
and not within OCT4 DBD, which makes direct contact with DNA. It is therefore unknown, 
how changing the protein interaction network of OCT4 can influence the engagement of 
OCT4 with the somatic genome during reprogramming.  
Furthermore, the cellular localisation of OCT4 may also contribute to reprogramming 
beyond its transcriptional and pioneer function, which both take place in the nucleus. For 
example, it was shown that an OCT4 mutant that was actively exported from the nucleus 
was able to rescue self-renewal of OCT4-null ES cells, but had lower reprogramming 
capacity, in contrast with another OCT4 with a strong nuclear localisation, which had 
weaker reprogramming capacity [233]. This indicates that the nuclear as well as the 
cytoplasmic levels of OCT4 play a crucial role to maintain and induce pluripotency. Thus, 
defining the OCT4 protein partners in the cytoplasm during reprogramming may reveal 
new insights on OCT4 function in pluripotency. 
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5.2 Aims 
 Define the initial engagement of the OCT4 mutants with the somatic genome in early 
reprogramming. 
 Define direct protein-protein interactions of OCT4 on chromatin independent of 
DNA binding.  
 Define OCT4 protein-protein interactions off-chromatin.  
5.3 Results 
The results and analysis of this chapter are presented in four main sections. First, OCT4 
(WT and mutants) engagement with the somatic genome in early reprogramming was 
determined and analysed using ChIP-seq. Second, tagged-affinity purification was used 
to investigate the direct protein interaction of OCT4 WT and mutants on-chromatin in 
early reprogramming. Third, tagged-affinity purification was used to define OCT4 WT and 
mutants associated proteins off-chromatin in early reprogramming. Lastly, OCT4 WT and 
mutants nuclear distribution was analysed by confocal microscopy. 
5.3.1 Deletions of non-essential domains enhance the initial engagement of OCT4 
with the somatic genome  
The proteomic analysis described in the previous chapters 3 and 4 showed that the 
deletion of various regions of OCT4 caused significant changes on the engagement with 
the chromatin-associated somatic proteome. To investigate if these deletions also 
changed the engagement of OCT4 with the somatic genome, ChIP-seq on OCT4 WT and 
mutants was carried out at the early stages of stages of reprogramming (OSKM 48h).  
To define DNA enrichment of OCT4 in ChIP-seq, double cross-linking, sonication and 
chromatin immunoprecipitation were carried out as described for ChIP-SICAP (Section 
2.X Materials and Methods). The DNA from three ChIPs for each condition were 
sequenced and aligned to the human genome. A model-based analysis for ChIP-seq 
(MACS) was used to identify genomic regions enriched for unique-mapped reads from 
ChIP-DNA over the input DNA (Fig. 5.1), identifying 499,788, 379,622, 266,473 and 
159,002 enriched peaks for O lin-min, O lin95-117, O lin29-42 and O WT respectively. 
Binding of all OCT4 and mutants to genes that promote reprogramming, such as the mir-
302/367 cluster [328]; genes necessary for mesenchymal-to-epithelial transition (MET), 
such as SNAI2 [329]; and apoptotic genes, such as TP53 [277], agreed with previous data 
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reporting the co-binding of OCT4 and the SKM factors to these set of genes at early 
reprogramming [110]; therefore, corroborating the peak calling results obtained. (Fig. 
5.1d)[110].  
 
Fig. 5.1 ChIP-seq OSKM 48h Workflow. a. Sonicated DNA used for ChIP-seq analysis of OSKM 
48h (WT and mutants). b. DNA libraries of the OCT4 ChIP sent for sequencing (WT and 
mutants). c. Workflow of the analysis applied to the ChIP-seq data. d. O WT, O lin-min, O 
lin95-117, O lin 29-42 and Input ChIP-seq profiles (red, purple, blue, green and aqua, 
respectively) at previously reported genes bound by OCT4 at 48h. OSKM peaks (bars) 
presented are normalized against input DNA sequenced tags (aqua). 
 
To further investigate the similarities and differences between the binding patterns of 
OCT4 WT and mutants, peaks were grouped in shared and unique among the samples. 
To define common binding sites, peaks with an overlap of at least 50bp were considered 
resulting in a total of 81,866 peaks bound by all OCT4 WT and mutants (Figure 5.2)This 
represent a significant overlap with the occupancy of OCT4 WT (85% of WT peaks), 
indicating that the deletions within OCT4 mutants had minimal effect on targeting the 
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OCT4 WT binding sites (Fig. 5.2). Furthermore, the binding of OCT4 reprogramming-
deficient mutant to these sites is not sufficient for generating iPSCs. Interestingly, the 
OCT4 mutants, especially those that can induce pluripotency, gained a large number of 
sites not targeted (n = 106,232) by O WTs (Fig. 5.2). Moreover, all OCT4 mutants as 
opposed to O WT gained a significant number of sites (n=70,295), suggesting that these 
new sites are not sufficient for OCT4 lin29-42 to drive reprogramming. Remarkably, O lin-
min and O lin95-117 targeted far more sites suggesting that deleting the non-essential 
domains expand the engagement of OCT4 with the genome beyond the sites bound by 
O WT. This enhanced enrichment was particularly more significant with O lin-min (3 times 
more than O WT n=499,786), from which ~60% were unique (n=198,674) (Fig. 5.2). This 
suggests that deleting more non-essential domains further expand the engagement of 
OCT4 with the somatic genome. To address if the observed gain in binding sites of OCT4 
mutants was mainly driven by low-affinity DNA binding, the intensity of OCT4 enrichment 
was measured and visualized in a read density heatmap (Fig. 5.2a-b). Interestingly, O lin-
min was highly enriched at the new sites as well as those shared with OCT4 WT and other 
mutants, indicating high affinity binding (Figure 5.2a). This enhanced binding pattern is 
represented in specific genomic regions such as SMAD2 –which has been shown to 
improve reprogramming efficiency and kinetics [330] (Fig. 5.2c). Together these data 
suggest that deleting non-essential domains enhance the binding affinity of OCT4 to the 
somatic genome. 
To further investigate whether the increase in binding sites was a result of unspecific 
binding, de novo motif analysis of the unique and shared peaks was performed. Sites 
shared by OCT4 WT and all the mutants were mainly enriched for partial OCT4 motif as 
previously reported [110] (Fig. 5.2c). Most importantly, the unique O lin-min sites were 
predominantly enriched for similar OCT4 motif, demonstrating that O lin-min targets 
specific new regions (Fig. 5.2c). Although, deletions of non-essential regions resulted in 
OCT4 uniquely targeting specific sites, deleting the essential regions resulted in OCT4 to 
uniquely target non-specific sites. Furthermore, sites that are unique to OCT4 WT were 
also predominantly enriched for non-specific sites. Thus, targeting more specific sites 
may explain why these mutants (lin-mini and lin95-117) were able to drive 
reprogramming compared to the deficient OCT4 mutant (lin29-42), which targeted more 
non-specific sites. 
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Lastly, the effects of deleting the non-essential and essential regions on the binding 
distribution of OCT4 relative the TSS was investigated using Genomic Regions Enrichment 
of Annotations Tool (GREAT). Interestingly, all shared and unique peaks showed a 
preference to bind TSS-distal sites (+/- 50 to 500 kb), similar to the overall distribution of 
OCT4 WT (Fig 5.2d). Moreover, the reprogramming deficient mutant O lin29-42 showed 
more binding TSS-proximal regions, which could be the result its non-specific and loosely 
bound profile. In general, these results are consistent with the TSS-distal distribution of 
OCT4 WT in early reprogramming; suggesting that promoter binding and transcriptional 
activation of target genes is a later event in reprogramming [110]. Therefore, deleting 
domains of OCT4 result in more engagement with the genome without changing affinity 
or specificity of OCT4 to target the distal element regions in early reprogramming.  
5.3.2 Deletions of non-essential domains enhance the engagement of OCT4 with 
chromatin and its associated proteome 
Altogether, the initial engagement of OCT4 WT and mutants with the genome correlates 
to the observed changes of the ChIP-SICAP results (See Fig. 4.4 and 4.5 in Chapter 4). The 
mutants, particularly O lin-min, also gained more chromatin-associated interactions 
when compared with O WT. Likewise, most of the O WT chromatin-binding partners were 
shared among the interactomes of the OCT4 mutants meaning that, as observed for the 
engagement with the genome, the new binding properties did not have an effect in the 
original O WT partners. In addition, O lin29-42 retained its capacity to bind to important 
chromatin-associated proteins as well as important genomic regions, indicating that 
although necessary, these are not enough for OCT4 to drive the reprogramming process. 
Moreover, the differences observed in the ChIP-seq analysis between O WT and the 
mutants’ early engagement with the somatic genome, showed that deletion of non-
essential domains confer OCT4 new properties that are not limited to their protein 
interactions, but also to their binding to the somatic genome at early reprogramming. 
Overall, ChIP-SICAP and ChIP-seq protocols were successful in pulling-down and isolating 
the different type of OCT4 mutants and their chromatin-association at the genome and 
proteome levels, revealing, for the first time, a significant increase in the number of 
proteins and genomic regions that associate with mutated versions of OCT4 in chromatin 
in early reprogramming to iPSCs.  
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Fig. 5.2 Enriched engagement of OCT4 mutants with the somatic genome at early 
reprogramming. a. Peak profiles showing average read counts, which are input subtracted, 
lane-normalized, and as reads per million mapped reads. b. Read density heatmaps (in blue 
scale) showing the intensity of O WT, O lin29-42, O lin 95-117, O lin-min and Input signal 
(blue) spanning ±1 kb from the centre of the peak summit of the unique and shared peaks 
for each OCT4 (WT or mutant). The number of targeted sites is indicated for each 
combination, which corresponds to it in 5.2a. b. De novo sequence motifs overrepresented 
in the unique and shared peaks compared to the OCT4 canonical motif found in the JASPAR 
database. c. Binding profile of a genomic region including SMAD2 (zoom) that demonstrates 
the enhanced engagement with higher intensity of O lin-min when compared to O WT, O 
lin29-42 and O lin 95-117 d. O WT, O lin29-42, O lin 95-117, O lin-min O WT, O lin29-42, O lin 
95-117 and O lin-min binding with respect to transcription starting site (TSS) display by the 
frequency of their unique and shared binding sites (all combinations). 
 
5.3.3 Deletions of non-essential domains enhance the direct protein-protein 
interactions of OCT4 independent of DNA-binding 
The correlation between the increase protein and genomic binding of the mutants 
compared with O WT suggests new properties conferred by the OCT4 deletions that 
could lead to new biological functions. The observed enhanced interactions with DNA 
and protein is not due to protein or chromatin levels, which are similar between all 
samples. However, this does not rule out the differences were influenced by the 
preferential antibody affinity for the cross-linked mutants over WT, which were used in 
the ChIP-SICAP and ChIP-seq methods. Therefore, ChIP-seq and ChIP-SICAP may yield 
better pull-down of protein and DNA interactors for OCT4 mutants than for WT.  
To rule out this possibility, a FLAG-tag-affinity purification (FLAG-IP) using a different 
antibody and independent of cross-linking was implemented. This technique depends on 
a tag attached to the protein for its purification, using specific antibody for the tag 
instead of the antibody against the protein of interest. In this case a 3XFLAG was chosen 
and each OCT4 version (WT and mutants) was cloned in the dox-lentivirus system 
containing the 3XFLAG (3XF) peptide into the N-terminus (Fig. 5.5a). Additionally, the 
FLAG-IP was carried out from a non-cross-linked whole extract. This method will 
therefore identify proteins that directly interact with OCT4 in the nucleus due to the 
nuclease treatment, as well as proteins that interact with OCT4 in the cytoplasm. This is 
in contrast to ChIP-SICAP, which defines only chromatin associated OCT4 partners 
without distinguishing between the direct protein-protein interactions and those 
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mediated through chromatin and DNA. Nevertheless, comparing both protocols will 
allow defining the chromatin-associated proteins that can interact directly with OCT4. 
Prior to the immunoprecipitation assays, protein levels and functionality of 3XF-O WT 
were tested to determine any negative effects of the tag. Proteins levels were tested by 
inducing 3XF-O WT and O WT in HF for 48h, followed by WB and Immunocytochemistry. 
The results are shown in Fig. 5.3, where both assays allowed the identification of WT and 
3XF-O WT with similar levels as WT O, indicating that the tag does not affect the protein 
levels of the protein. In addition, difference in the molecular weight observed in the WB 
corroborated the 3XF tag in OCT4 (Fig 5.3b). 
 
Fig. 5.3 3XFLAG does not affect the expression levels of O WT in OSKM 48h. a. 
Immunocytochemistry of WTO and 3XF O WT in OSKM 48h after dox induction. No dox 
induction is shown as a control. DAPI staining is shown to visualize the cells. b. OCT4 
immunoblot detecting the tagged and not tagged (3XF) version of WT OCT4 in OSKM 48h 
after dox induction. GAPDH is shown as the loading control. 
 
Next, 3XF-O WT was tested for its capacity to rescue the pluripotency maintenance 
phenotype in mESC to confirm the functionality of 3XF-O WT. To this end, a Pou5f1 KO 
mESC cell line used (ZHBTc4.1) containing a dox-off Pou5f1 transgene. These cells would 
therefore differentiate upon adding dox to the media unless a functional OCT4 is 
exogenously introduced to rescue the ability of these cells to self-renew (Fig. 5.4a) [271].  
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Fig. 5.4 Pluripotency and stem cell self-renewal rescue capacity of 3XF OCT4. a. 
Representation of the ZHBTC4.1 mouse cell line with the dox-regulatable Oct4 transgene. b. 
Pluripotency rescue index of WT O (tagged and untagged) after ZHBTC4.1 Oct4 transgene 
was repressed by dox. Rescue index was quantified by counting the number of AP stained 
mESC colonies +dox divided by colonies -dox. 3XFLAG WT O (mouse) is shown as a positive 
control. CAG-IP (empty vector) and 3XFLAG-EGFP are shown as negative controls. Average of 
three replicates are shown (error bars indicate ± s.d.). (c-g) Representative mESC colonies 
and AP stained dishes +/- dox of the rescue assays for O WT (c), 3XF O WT (d), 3XFmOCT4 (e), 
CAG-IP (f) and 3XF-EGFP (g). 
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The ability of 3XF-O WT to rescue the ZHBTc4.1 self-renewal was examined along O WT, 
3XF-mOCT4 (mouse), 3XF-EGFP and an empty vector (CAG-IP) as controls. Alkaline 
phosphatase (AP) staining was used as a marker for pluripotency, allowing to define the 
rescue index as a ratio of AP positive colonies in the presence and absence of dox (Fig. 
5.4c-g). This revealed that 3XFWT-O was able to rescue and prevent the differentiation 
process to almost similar levels to that of untagged OCT4-WT, indicating that the tag is 
not affecting OCT4 involvement in maintaining pluripotency and self-renewal in mESC 
(Fig 5.4b-g). Altogether, these results confirm the expression and functionality of 3XF-O 
WT.  
After adding 3X FLAG tags to Oct4 WT and each of the other mutants (Fig. 5.5a), HF were 
transduced with dox-inducible lentiviruses of the tagged OCT4 derivatives each in 
combination with SKM, which were induced for 48 h (Fig. 5.5b). HF with no OSKM 
induction were used as controls. The IP was carried out from whole cell lysates using 
beads-conjugated Anti-FLAG antibody under native conditions to preserve protein-
protein contacts. The enriched proteins were eluted by competition with a synthetic 
3XFLAG-peptide, to reduce the antibody heavy and light chains in the purified fractions, 
which can dominate in the mass-spec identification of the eluted proteins. Five 
consecutive elutions were performed for each 3XFOSKM 48h (WT and mutants) in three 
replicates. WB analysis confirmed the presence of OCT4 in all the elutions of all 3XFOSKM 
48h (WT and mutants) and no in the non-infected HF control (Fig. 5.5c), confirming the 
capture and elution 3XF OCT4. Additionally, total protein staining of the resolved eluted 
fractions in SDS-PAGE revealed a significant enrichment of proteins in comparison to 
non-infected HF (Fig. 5.5d). In summary, these results demonstrate the specific 
purification of each 3XFOCT4 in early reprogramming (3XFOSKM 48h) and a successful 
recovery of OCT4 and its binding proteins. 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 5  151 
 
Fig. 5.5 3XFLAG-Affinity purification methodology to detect the protein binding profiles of 
tagged OCT4 (WT and mutants).  a. Representation of the N-terminal 3XFLAG OCT4 (WT and 
mutants) constructs in a dox inducible lentivirus system. b. Workflow of (3XF) OSKM 
induction showing the transduction of HF with the lentiviruses, followed by the addition of 
dox and the induction of OSKM expression for 48h. c and d. 3XFLAG-OCT4 IP of total extract 
of OSKM 48 hours (WT and mutants). Proteins were eluted (E1-E5) by competition with a 
3XFLAG Peptide and ran for OCT4 detection in a WB (c) and in a SDS-PAGE for SYPRO® Ruby 
staining of the eluted proteins. 
 
For MS analysis three replicates were analysed for each condition (WT, mutants and 
control). For each replicate, the pooled five eluted fractions from each IP were run on a 
SDS-PAGE for-in-gel digestion followed by peptide purification using StageTips. The 
recovered peptides were processed by LC-MS and MaxQuant software was used for the 
identification of the corresponding proteins against the UniProt human database. Each 
interactome was filtered against the control and only considering proteins present in 
least two out of three replicates. A total number of 568, 1065, 719 and 840 proteins were 
identified for 3XF O WT, 3XF O lin-min, 3XF O lin95-117 and 3XF O lin29-42,respectively 
(Fig. 5.6). The bait OCT4 was identified among the top hits in all IP samples (Fig. 5.6) 
(Appendix Table 3). Cellular localization GO analysis of each 3XF-O interactomes (WT and 
mutant) in early reprogramming revealed a mixture of nuclear and cytoplasmic proteins, 
as the proteins were IPed from whole cell extracts without chromatin enrichment (Fig. 
5.6). As observed in ChIP-SICAP, the OCT4 mutants, especially 3XF O lin-min, interacted 
with significantly more proteins than 3XF O WT. Thus, the differences observed in ChIP-
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SICAP and IP were not due to cross-linking or antibody bias. Instead, they are indeed 
conferring OCT4 the capacity to interact with more proteins.  
 
 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 5  153 
Fig. 5.6 FLAG-IP identified cytosolic and nuclear OCT4 interactors at early reprogramming. 
a-d. UpSet plot of each 3XFO interactome (WT and mutants) showing the intersection of 
identified proteins among the three replicates analysed by MS and filtered against the 
control. Ranking of the identified proteins and Gene Ontology enrichment analysis for 
Cellular component is shown for each OCT4: 3XF O WT (a), 3XF O lin-min (b), 3XF O lin95-117 
(c) and 3XF O lin29-42 (d).  
 
To define the proteins that directly interact with OCT4 on chromatin, the interactomes 
of ChIP-SICAP were compared to the FLAG-IP counterparts. The overlap of the FLAG-IP 
proteins was 15 to 20% of the total ChIP-SICAP interactome, being 59, 157, 161 and 216 
shared proteins for O WT, O lin95-117, O lin29-42 and min respectively (Fig. 5.7).  
 
Fig. 5.7 Proteins identified in both proteomic approaches for OSKM 48h OCT4 (WT and 
mutants).  Venn diagram of the overlapping interactors identified at OSKM 48h in both ChIP-
SICAP (yellow) and FLAG-IP (blue) for 3XF O WT (a), 3XF O lin-min (b), 3XF lin95-117 (c) and 
3XF O lin29-42 (d). Boxes represent shared proteins involved in splicing, chromatin binding 
and transcription.  
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This low overlap can be a result of the different purification conditions mentioned above, 
where FLAG-IP used the whole extract, identifying also cytoplasmic and the soluble 
nuclear (not-chromatin associated) proteins, unlike the chromatin-dependent 
interactions in the ChIP-SICAP protocol. Despite this, the percentage of overlap between 
ChIP-SICAP and FLAG-IP is proportional to the number of identified proteins for each 
OCT4 mutant. Additionally, the proteins identified by both methods for each OCT4 (WT 
and mutant) were involved in the processes enriched in the ChIP-SICAP analysis, such as 
gene transcription, splicing and chromatin binding (Fig 5.7 boxes). Altogether, the 
enhanced binding of OCT4 mutants in early reprogramming was not due to the technical 
particularities of ChIP-SICAP steps, as using different antibody and purification strategy 
still resulted in the identification of more protein interactors for the mutants. Most 
importantly, the proteins identified in both FLAG-IP and ChIP-SICAP confirmed a subset 
of interacting partners that can be defined as direct protein-protein interactors of OCT4 
on chromatin, suggesting an important role of these proteins for the function of OCT4 in 
the chromatin context at early reprogramming. However, this does not rule out other 
proteins identified by ChIP-SICAP to also directly interact with OCT4 due to the limitation 
of FLAG-IP method. 
5.3.4 Deletions of non-essential domains enhance the engagement of OCT4 with the 
cytoplasmic proteome  
An interesting observation of the FLAG-IP interactomes was the identification of non-
chromatin associated proteins (nuclear and cytoplasmic) as OCT4 interactors in early 
reprogramming. This observation correlates with the presence of OCT4 in both the 
cytoplasmic and nuclear fraction in early reprogramming (WT and mutants)(see Fig. 
4.12a, in Chapter 4), suggesting that the interactions of OCT4 with cytoplasmic proteins 
may play a crucial role during reprogramming.  
To investigate the cytoplasmic or off-chromatin proteins detected as OCT4 interactors 
and how the deletions were influencing these interactions, the 3XF OCT4 interactomes 
were compared focusing on the off-chromatin associated proteins; therefore, the 
proteins identified in the ChIP-SICAP and 3XFLAG IP overlap for each interactome were 
removed. A final number of 509, 848, 562 and 679 proteins were analysed for 3XF-O WT, 
3XF-O lin-min, 3XF-O lin95-117, 3XF-O lin29-42 respectively (Fig 5.7 blue circles). 
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Intersection analysis revealed the presence of a core interactome shared between all 
OCT4 variants and that 3XF Olin-min was the mutant with most unique interactors (Fig. 
5.8), which is similar to that seen in ChIP-SICAP. Furthermore, even when the deficient 
mutant 3XF O lin-min is able to interact with the core protein network, these protein-
protein interactions are not sufficient for reprogramming (Fig. 5.8). This is similar to what 
has been observed for the core protein network identified by ChIP-SICAP (see Fig 4.4d in 
Chapter 4). This general analysis revealed that the deletions are also influencing the 
interactions of OCT4 with off-chromatin proteins. Moreover, it supports the idea that O 
lin-min confers new properties that allows OCT4 to engage more with both proteins and 
DNA, as it was the variant with more unique off-chromatin interactors. This further 
correlates with its observed enhancement of chromatin-associated proteins observed in 
ChIP-SICAP and enhanced engagement with the somatic genome observed by ChIP-seq.  
 
Fig. 5.8 Differential abundance of OCT4 off-chromatin-associated early reprogramming 
(WT and mutants).  UpSet plot to represent the unique and shared off-chromatin binding 
proteins between interactomes of 3XF OCT4 (WT and mutants) in OSKM 48h. 
 
Collectively, the new evidence obtained in this chapter from the 3XF-IPs revealed for the 
first time an OCT4 potential to bind to cytoplasmic proteins that might be relevant for 
the reprogramming process, suggesting its participation in molecular mechanisms 
independent of its canonical transcription/pioneer factor activity. Overall, these findings 
reveal the first non-nuclei biased interactome of OCT4, implicating that there could be 
new OCT4 protein interactions outside the nuclei that could be as relevant for a 
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successful reprogramming. Furthermore, it agrees with the statement that different 
domains of OCT4 confer different interacting properties. 
5.3.5 Deletions of non-essential domains does not affect the ability of OCT4 to form 
nuclear puncta  
Recent work has associated the transcription regulation activity of some transcription 
factors with their capacity to form phase-separated condensates with the co-activator 
Mediator complex MED1 [183, 331]. OCT4 alone is not able to form phase-separate 
condensates, but its intrinsically disordered regions (IDR) of its transactivation domains 
(TADS) (Fig. 5.9a) are responsible for the phase-separated condensates formed by MED1 
in mESC super enhancers (SE), and can be observed as localized puncta in the nuclei at 
SE of key pluripotency genes [183]. Because the deletions of the mutants involved 
domains aligning with the low complexity regions of OCT4 (Fig 5.9a – arrows) and also 
enhancing both protein-protein and protein-DNA interactions, this opened the question 
whether this was due to promoting phase-transitioned protein condensation. In order to 
investigate the effects of the deletions in the formation of OCT4 puncta, OSKM 48h (WT 
and mutants) cells nuclei were visualized by high-resolution microscopy. The visualization 
by confocal imaging of OSKM 48h (WT and mutants) revealed no obvious differences in 
the formation of puncta in the nuclei between the mutants and WT OCT4 (Fig. 5.9b- blue 
boxes), and also showed puncta formation in the cytoplasm although at lower intensity 
(Fig. 5.9b-red boxes). These findings suggest that the deletions are not affecting the 
phase-transition protein condensation of OCT4, as mutants are still able to form puncta 
in the nuclei. Further co-localization of this puncta with co-activator complexes and 
nascent mRNA would help confirm these results, and could help understand more about 
the important regions of OCT4 transactivation domains in the formation of phase-
separated condensates in the specific context of early reprogramming to iPSCs. 
In summary, the results of this chapter corroborated that the different OCT4 domains 
influence not only the protein binding properties of OCT4 but also its interaction with the 
somatic genome in early reprogramming and demonstrated that by deleting non-
essential and essential regions there is an enhancement in binding, especially when 
deleting two non-essential domains, as observed for O lin-min. Finally, the analysis of the 
off-chromatin interactome described for the first time the possibility of OCT4 being able 
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to interact with other proteins when localized in the cytoplasm, broadening OCT4 
possible functions beyond and independently of its binding to DNA. These results open a 
new area of research to understand and optimize the reprogramming outcome when 
OCT4 is involved. 
 
Fig. 5.9 OCT4 nuclear distribution at early stages of reprogramming (WT and mutants). a. 
Intrinsic disorder of OCT4 calculated by the VSL2 algorithm (pondr.com). Domains deleted in 
each region are denoted by arrows (O lin-min three deletions are denoted by the orange 
arrows) b. Representative confocal microscopy images of OCT4 IC (WT and mutants) and 
their nuclear puncta distribution in OSKM 48h. Blue and red boxes represent zooms of puncta 
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5.4 Discussion 
5.4.1 Deletions of essential and non-essential domains enhance OCT4 engagement 
with the somatic genome 
The identification of the chromatin-associated proteins of O WT and the mutants O lin-
min, O lin29-42 and O lin95-117 (described in Chapter 4) confirmed that OCT4 not only 
differs in how it engages with the somatic proteome at early stages of reprogramming 
when compared with pluripotency, but it also uncovered that the deletion of essential 
and non-essential domains of OCT4 enhances its capacity to interact with more 
chromatin-associated proteins. Similar results were obtained in this chapter, when the 
initial engagement of WT and the mutants was compared by analysing their genome 
wide-binding profiles (ChIP-seq) at early reprogramming (Fig. 5.2). Most notably was how 
theses deletions expanded OCT4 capacity to recognize more sites beyond the original 
sites bound by O WT (Fig. 5.2), consistent with how the mutants can interact with more 
chromatin-associated proteins while preserving the interactions detected in O WT (See 
Fig. 4.4 in Chapter 4). Most importantly, the deletions of non-essential domains 
preserved the ability of OCT4 to target specific sites, which is in contrast to deleting the 
essential domains that caused OCT4 to target many non-specific binding sites. Moreover, 
these non-specific sites tend to be located closed to TSS, in contrast to the other new 
specific sites, which as those original sites, are predominantly distal to TSS [110]. This 
suggests that the deletion of non-specific domains but not the specific domains enable 
OCT4 to engage more genomic sites without altering the POU DNA binding motif (DBD) 
specificity In conclusion these findings highlight the functional contribution of these 
essential OCT4 domains in reprogramming not only by interacting with other proteins 
but also by targeting specific sites in the genome. 
For instance, the deficient mutant O lin29-42 was still capable of binding the same sites 
as O WT, and most of its new binding sites were shared with O lin-min and O lin95-117 
(Fig. 5.2). The same pattern was observed in ChIP-SICAP, where O lin29-42 chromatin-
associated proteins were shared with WT O and the mutants (See Fig. 4.4 in Chapter 4). 
The interesting behaviour of this mutant revealed that although necessary, the 
interaction of OCT4 with those chromatin-associated proteins and genomic regions is not 
enough to drive the reprogramming process. In fact, the identification of a subset of 
proteins not associated with O lin29-42 allowed the description of new uncharacterised 
Initial OCT4 engagement with the somatic proteome during reprogramming to iPSC 
Chapter 5  159 
important proteins for the reprogramming process. It is noteworthy that unique binding 
sites were also detected for O lin29-42 that had the particularity of being less specific 
and bind near promoters and the TSS. Therefore, approaches focusing in investigating 
both, the unique and missing sites of O lin29-42 could lead to new essential binding sites, 
as well as roadblocks non-previously described or associated with reprogramming. 
ChIP-SICAP in Chapter 4 (See Fig. 4.3 and 4.4 Chapter) revealed that O lin-min was the 
mutant with more unique new proteins. The same was observed with ChIP-seq data, 
which revealed an increase of unique DNA binding sites, which were revealed to contain 
the OCT4 motif, discarding the possibility of them being unspecific. Besides, the analysis 
of the peak’s intensity allowed to discard the possibility that the identified were the 
result of transient and loosely binding to DNA, suggesting that O lin-min is able to target 
more specific sites and with high affinity. Further structural studies could help 
understand how this mutant is able to engage more to DNA and proteins. One possibility 
could be that as a smaller size of the protein enables this OCT4 variant to easily access 
the genome. In addition, the deletion of non-essential regions may stabilize the 
formation of protein complexes on chromatin by eliminating the competition of other 
proteins that are usually associated with these domains. Nonetheless, it is still interesting 
that O lin-min does not enhance reprogramming efficiency; however, these deletions 
may enhance reprogramming kinetics, which has not been investigated.   
Moreover, combining the results of ChIP-SICAP and ChIP-seq shows that the increase in 
DNA binding is associated with the increase of chromatin-associated proteins. This opens 
an interesting question of whether OCT4 mutants’ abilities to interact with more proteins 
and more genomic sites are mutually inclusive. Nevertheless, the correlation of both 
ChIP-SICAP and ChIP-seq allowed the expansion of proteins and genomic regions that 
OCT4 is capable of interacting with at early reprogramming, while drawing special 
attention to the importance of the characterization of the transactivation domains of 
OCT4 for its engagement with both, proteins and DNA. 
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5.4.2 Deletions of essential and non-essential domains enhance OCT4 off-chromatin 
protein interactions 
The evidence of the mutants’ enhanced protein and DNA binding led to investigate if the 
differences observed were the result of methodology biases. By defining the 
interactomes of tagged (3XFLAG) versions of OCT4 (WT and mutants) and by 
implementing an affinity tag immunoprecipitation protocol (IP) at early reprogramming, 
it was evidenced that despite using different methodology, more interacting proteins 
were detected in the mutants (Fig. 5.5), proving that the method was not biasing the 
results. Moreover, the differences between ChIP-SICAP and IP allowed to expand the 
OCT4 interactome at early reprogramming and allowed to define OCT4 binding partners 
that were both, associated in chromatin and direct protein-protein interactors. 
Additionally, it allowed defining new off-chromatin protein interactions, both nuclear 
and cytoplasmic. Despite OCT4 findings that it can shuttle between the nucleus and the 
cytoplasm, few studies have been focused in studying its spatiotemporal dynamics and 
the idea that OCT4 may have functions in the cytoplasm has not been fully addressed. By 
analysing the off-chromatin interactors identified for WT O and the mutants, similar 
enhancement for 3XF O lin-min to bind more proteins was observed, agreeing with the 
ChIP-SICAP and ChIP-seq results.  
Further literature-mining of some of the shared proteins present in 3XFO WT, 3XFO lin-
min and 3XFO lin95-117 but absent in deficient 3XFO lin29-42 suggested that OCT4 
partners could be linked to signalling pathways. As observed in the intersection graph in 
Fig. 5.9, a set of 40 proteins were shared between the reprogramming 3XFO WT, 3XFO 
lin-min and 3XF-O lin95-117 and not present in deficient 3XF-O lin29-42. Among these 
proteins, three elements of the TGF-beta Signalling Pathway were found: TAB1 (TGF-beta 
Activated Kinase 1 (MAP3K7) Binding Protein 1), phosphatase PPM1A (protein 
phosphatase, Mg2+/Mn2+ dependent 1A) and ITGA2 (integrin subunit alpha 2). 
Interestingly, this signalling pathway is relevant for development and for the 
pluripotency maintenance of human ES [44]. Other proteins identified associated to 
development were NEDD4 and PPP4C. NEDD4 is a ubiquitin-ligase and key regulator of 
FGFR1 endocytosis and signalling during neuronal differentiation and embryonic 
development [332], while PPP4C is a Protein phosphatase which was identified to be 
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required for ES self-renewal and pluripotency in a shRNA screen [333] and to be 
important for the regulation of the histone deacetylase 3 (HDAC3) activity [334]. 
Altogether, these proteins could indicate a role of OCT4 in signalling complexes, such as 
the reported complex of OCT4 with b-catenin and E-Cadherin in the membrane of ES cells 
[335]. Additionally, Heme Oxygenase 1 (HMOX1) was identified in the interactomes of 
3XFO lin-min and 3XFO lin95-117. Interestingly, HMOX1, which is a cryoprotective factor, 
has already been linked to reprogramming. Human and mouse fibroblasts cells Hmox1-/- 
demonstrated decreased reprogramming efficiency in comparison to Hmox1+/+ cells 
[336], endorsing the argument that other cytoplasmic non-chromatin OCT4 associated 
proteins are important for the reprogramming outcome. Therefore, the evidence 
presented in this chapter could open the field to understand the importance of OCT4 not 
only as a transcription factor bound to chromatin but also as a multifunctional protein 
during the reprogramming process. Further improvements to the protocol, such as 
protein identification of cell fractions could help corroborate the cytoplasmic function of 
OCT4 and lead to the identification of new important OCT4 interactors important for the 
reprogramming process in specific cellular localizations.  
5.4.3 OCT4 could be involved in the formation of phase-separated condensates at 
early reprogramming 
Phase separation is a physicochemical process by which molecules separate into a dense 
phase and a dilute phase. In cells, this process results in the formation of phase-
separated bimolecular condensates, which include nuclear speckles, stress granules, 
nucleolus and transcriptional condensates, allowing the compartmentalization and 
concentration of biochemical reactions within the cells [331].  
Involvement of OCT4 in phase-separated transcriptional condensates have been 
reported [183]. In mESC, OCT4 occupancy at enhancer elements is fundamental for the 
formation of mediator condensates at super enhancers of mESC. In this report, they also 
established that the amino acids of the transactivation domains (TAD) of OCT4 required 
for gene activation in vivo were the same required for the phase separation with 
Mediator condensates in vitro, proposing a model where the TADs of OCT4 confer the 
capacity to form phase-separated condensates with co-activators, in this case MED1, and 
regulate gene expression [183]. The particularity of OCT4, and other TFs, that allows the 
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formation of phase-separate condensates resides in the low-complexity amino acid 
sequence of its TADs, which are intrinsically disorder regions (IDRs) [183] (Fig. 5.11). As 
the essential and non-essential deletions of the OCT4 mutants involved domains residing 
in these IDRs, the capacity of the OCT4 mutants to phase separate with Mediator or other 
co-activators could be impaired or enhanced. One of the features to determine if OCT4 
contributes to the Mediator condensates is to detect OCT4 puncta at the SE where MED1 
puncta are also observed [183]. As a preliminary test to address the effects of these 
deletions on OCT4 capacity to contribute to phase-separation, the formation of OCT4 
puncta was investigated revealing that all mutants were able to be part of nuclear as well 
as cytoplasmic puncta. However, as these analyses were mainly qualitative and not 
quantitative, differences between the mutants cannot be ruled out. These results 
indicate that the ability of OCT4 to assemble chromatin complexes that are functional in 
reprogramming can be uncoupled from its ability to drive phase-transitioned protein 
condensates and opens the field to investigate if the capacity of OCT4 to form phase-
separated transcriptional condensates is a mechanism to regulate gene activation or 
chromatin remodelling in the reprogramming context.  
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Chapter 6 Thesis Overview and Perspectives  
The research described in the previous chapters focused on exploiting proteomic 
approaches to identify the binding partners of the transcription factor OCT4, a main 
component of the pluripotency network and one of the original reprogramming factors. 
This was done in order to reveal the molecular basis by which OCT4 maintain 
pluripotency as well as induce pluripotency from differentiated cells. Studying both 
processes in the context of the human system will also expand our understanding beyond 
the well-characterized mouse system. Therefore, understanding the underlying 
mechanisms of human cellular reprogramming would help to improve the efficiency and 
the fidelity of the process, which is currently limiting its potential use for regenerative 
medicine. This final section highlights the main results and proposes further research 
based on this work. 
6.1 Thesis Overview 
6.1.1 OCT4 engagement with chromatin-associated proteins in hES revealed for the 
first time an OCT4 network in the human pluripotency context. 
Taking into account the importance of the interaction of OCT4 with chromatin for the 
transcriptional regulation and the reshaping of the chromatin landscape, in Chapter 3 a 
proteomic approach that allows the identification of chromatin-associated proteins 
(ChIP-SICAP) was adapted to identify which of these OCT4 interacts with when bound to 
chromatin. Because of the lack of information about OCT4 in human embryonic stem 
cells (hES), the interactome of OCT4 in hES was described so it could serve two purposes: 
as a new resource to understand human pluripotency maintenance and as a more 
accurate dataset to compare and understand the differences of OCT4 involvement in 
pluripotency maintenance versus the reprogramming process in human. This was done 
successfully by identifying main proteins involved in the regulation of pluripotent stem 
cells. Among these proteins were components of pluripotency maintenance and 
transcriptional regulators previously reported to be important in both human and 
mouse, including SOX2, STAT3, LIN28a, SALL4, DNMT3A, DPPA4 and DNMT3B, as well as 
members of the chromatin remodelling complexes LARC, NURD and SWI/SNF. This set of 
transcription factors and chromatin regulators are constantly identified to be important 
for the pluripotency network and as part of mouse OCT4 interactomes, suggesting they 
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also play essential roles for the human pluripotency network and confirmed the 
involvement of OCT4 with the well stablished and conserved core pluripotency network 
in both, human and mouse. Moreover, beside the similarities found with previous work 
on mouse, the new dataset presented in this thesis allowed the identification of unique 
interactors for each species. It is noteworthy mentioning that the mouse dataset that 
was used for comparison was done in mESCs, which are in a naïve state of pluripotency, 
in contrast to the more primed state of hES; therefore, these differences could be 
involved in contributing to the naïve pluripotency state of mESC and the primed-like state 
of hESCs. Further characterization of this unique proteins and their importance could 
illustrate the different pathways that govern and differentiate human and mouse 
pluripotency, opening the research field to also analyse the OCT4 interactome of EpiSCs 
and investigate if it resembles more the one from hESCs, correlating with the more 
primed state of hES. For instance, besides the well stablished pluripotency associated 
proteins, the hES network included chromatin associated proteins which functions have 
not been described in either reprogramming or pluripotency maintenance. These group 
included histone acetyl-lysine readers, chromatin remodellers, transcription factors, 
histone modifiers, and proteins involved in mRNA processing, splicing and cell cycle 
associated, suggesting a potential role of these proteins along with OCT4 in chromatin 
structure, cell cycle and regulation of gene transcription and translation during 
pluripotency. Furthermore, once the importance of these proteins during pluripotency is 
established, they can provide insightful information of essential pathways and proteins 
that need to be activated to achieve the pluripotent state during human reprogramming, 
being potential candidates for a better understanding of human pluripotency and 
candidates to test in the reprogramming process.  
6.1.2 OCT4 gains new chromatin-associated proteins at the early stages of human 
reprogramming  
Having adapted the protocol for identifying chromatin-associated proteins and 
establishing the OCT4 interactome in hES, this work focused on studying OCT4 at an early 
stage of the reprogramming process, defined as 48hrs after the OCT4, SOX2, KLF4 and 
cMYC induction in human fibroblasts (OSKM 48h). Defining the chromatin-associated 
proteins of OCT4 at early reprogramming and comparing them against those of 
pluripotency, allowed the definition of a new OCT4 network specific for the early 
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reprogramming process that differ from the one in pluripotency maintenance. This 
evidence correlates with the differences observed in the initial engagement of OCT4 with 
the somatic genome when compared to hES. Taking advantage non-labelled quantitative 
proteomics the abundance of each identified protein was quantified, allowing the 
definition of four groups when the hES and early reprogramming (OSKM 48h) OCT4 were 
compared. These four groups were: unique in hES, shared with an enrichment in hES, 
shared with an enrichment in OKSM 48h and unique in OSKM 48h. Unique and enriched 
proteins in hES were enriched with proteins involved in pluripotency, supporting the role 
of this proteins for the maintenance of stem cells. Moreover, their enriched or exclusive 
interaction with OCT4 in hES and not early reprogramming indicates that their interaction 
with OCT4 occurs in the later stages of reprogramming, when most these proteins start 
to get expressed.  
Of much interest was the group of proteins that were unique in OSKM 48h. This network 
was enriched for chromatin-modifiers and proteins involved in development and 
differentiation. Some of these proteins had already been reported to be facilitators or 
blockers of the reprogramming process, but most of them had no previous association 
with the process nor their interaction with OCT4. Enrichment of this group revealed a 
lesser amount of proteins involved in pluripotency maintenance and more proteins 
involved in differentiation  and developmental processes, as well as chromatin structure, 
transcription regulation and lineage specificity. This suggests that proteins involved in 
differentiation pathways can contribute to the reprogramming through their association 
with OCT4 and suggest common mechanisms for cell differentiation and reacquisition of 
pluripotency, with OCT4 as an important component. A set of worth noticing proteins 
found in this group, are somatic specific transcription factors that have been reported to 
be downregulated in mouse reprogramming, such as HOXC10, RUNX1, FOSL1 and TAGLN. 
The downregulation of these somatic transcription factors is believed to contribute to 
the downregulation of the somatic genes at early reprogramming. How the OSKM 
regulate the repression of these specific genes is not yet fully understood, but evidence 
suggests that at 48hrs of OSK induction in MEFs, the OSK factors share binding sites with 
RUNX1 and FOSL1, thus detection of these proteins as OCT4 chromatin-associated 
proteins supports the evidence that they can co-bind in the genome at early stages 
contributing to the repression of somatic enhancers. Alternatively, these new somatic 
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TF-OCT4 interactions do not rule out the possibility of a synergistic function in which, 
before their downregulation, the somatic TF take part of transient complexes important 
for reprogramming, even if they are active in a short timeframe.  
Most interestingly, an important set of the unique proteins OSKM 48h included proteins 
that have not been linked with OCT4 nor described in the reprogramming process, 
highlighting that the existing barrier in the understanding of OCT4 roles in 
reprogramming. For instance, the most abundant proteins identified in were two 
members of the Nuclear Factor I family, NFOC and NFIX. These proteins are site-specific 
DNA binding proteins that can promote the transcriptional activation or repression, 
depending on the cellular context; also they have been described as key epigenetic 
regulators and chromatin remodellers during development and cancer, opening the 
possibility of a new non-described OCT4/NFIC/NFIX complex involved in chromatin 
remodelling and transcriptional regulation at early stages of the reprogramming.  
Altogether, the description of OCT4  at early reprogramming, proved that OCT4 not only 
interacts with chromatin-modifiers to reshape the landscape of the somatic genome, but 
also interacts with a new set of proteins, involved in development, lineage specificity, 
mRNA binding and differentiation. This evidence could link common mechanisms 
between these processes and the reacquisition of pluripotency during reprogramming, 
with OCT4 as an important central component.  
Summing up, the comparison of chromatin-associated proteins between pluripotency 
maintenance and early reprogramming illustrated how OCT4 is a multifaceted factor that 
is able to change its chromatin-binding dynamics in order to adapt its functional 
interactors for the establishment of different phenotypes.  
6.1.3 Essential OCT4 reprogramming domains are needed for the interaction of OCT4 
with chromatin-associated proteins important for successful reprogramming to 
iPSCs 
The identification of new OCT4 chromatin-associated proteins in early reprogramming 
led to investigate which of these proteins were functionally relevant and important for 
the reprogramming process. To elucidate some of these proteins, OCT4 mutants bearing 
deletions in its transactivation domains (TAD) were analysed. These OCT4 mutants were 
designed in a parallel research project developed in our laboratory focused in the 
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dissection of the OCT4 domains that are essential for reprogramming to iPSCs but not 
essential for pluripotency maintenance. Based on this analysis, essential and non-
essential regions of OCT4 for reprogramming were defined and different OCT4 mutants 
were designed. ChIP-SICAP was applied to three of these mutants bearing different 
deletions in the transactivation domains (TADs); including two OCT4 mutants with 
reprogramming-capacity (Olin-min and O lin95-117) and one OCT4 mutant that is 
reprogramming deficient (O lin29-45).  Comparison between the previously described 
networks of OCT4 WT in pluripotency and early reprogramming against the networks of 
the mutants was performed, with the hypothesis that the deficient OCT4 mutant would 
be missing important interactors present in all reprogramming versions of OCT4 (WT and 
mutants). This statement was supported by the identification a set of missing interactors 
in the OCT4 deficient mutant that were not previously linked to reprogramming and that 
were also absent in the pluripotency network, suggesting their interaction with OCT4 is 
relevant in early stages of reprogramming but not for pluripotency maintenance as the 
deficient mutant is still functional for the pluripotency maintenance of mES. These 
partners consisted of seven new OCT4 chromatin-associated proteins: UFD1L, RAI1, 
TNIP2, ETV4, XPO6, FBRSL1, and MCMBP and showed to be important for the 
reprogramming process as their depletion had negative effects in reprogramming 
efficiency of mouse embryonic fibroblast. Despite the specific roles of these proteins 
during reprogramming was not addressed in this thesis, the biological processes where 
they have been involved are quite varied, including nuclear export, protein degradation, 
stress-response, signalling response, post-translational modifications recognition, 
transcriptional regulation, chromatin remodelling and cell cycle. Furthermore, analysis of 
the enrichment of these candidates in the chromatin fraction suggested their 
recruitment to chromatin at early reprogramming might be mediated or influenced by 
OCT4 essential domains. Thus, dissecting the functional domains of OCT4 not only 
contributed to the identification of new partners crucial for reprogramming but also 
highlighted the versatility of OCT4 to be involved in different biological processes, either 
functionally or by facilitating the chromatin-recruitment of functional proteins needed 
to achieve the pluripotent state. 
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6.1.4 Deletions of essential and non-essential domains enhance OCT4 binding 
properties 
An interesting particular finding observed when analysing the interactomes of the OCT4 
mutants was the increase of chromatin-associated proteins able to interact with the 
OCT4 mutants when compared to WT. Intrigued by the fact that alterations in the TADs 
of OCT4 enhanced its protein interactions, ChIP-seq of the mutants at early 
reprogramming was assessed, showing the same pattern: altering the OCT4 TADs  
enhances the initial engagement of OCT4 with the somatic genome. Moreover, a 
different proteomic approach focused in whole cell extract and direct protein-protein 
interactions (IP) was tested to discard any methodology bias in the protein identification. 
Results using the latter approach confirmed that deleting essential and non-essential 
domains of the transactivation domains of OCT4 provides better genomic and proteomic 
engagement. Consequently, it allowed the identification of off-chromatin associated 
proteins, suggesting new OCT4 associations that do not depend on OCT4 being in 
interaction with the chromatin, and more interestingly, interactions that might occur in 
the cytoplasm. Remarkably, in all cases, the deletions of OCT4 non-essential domains 
resulted in higher protein and genomic engagement when compared with the deficient 
mutant bearing an essential domain deletion and WT. Interestingly, particularly for O lin-
min, despite higher engagement with proteins and the somatic genome, its 
reprogramming efficiency was not improved, suggesting that the essential domains are 
important for more specific interactions with the genome and more functional 
interactions with the proteome that actually result in a more efficient reprogramming 
process. Overall, these results highlighted that not only the cellular process and 
environment impact OCT4 function, as deletion of essential and non-essential 
reprogramming domains expanded the engagement of OCT4 with both, the proteome 
and the genome, suggesting that different domains contribute to OCT4 binding profiles, 
providing an additional intramolecular diversity. Thus, characterizing of the TADs of OCT4 
could help understand more about its biochemical properties while unravelling proteins 
and DNA binding sites that are important for the reprogramming process.  
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6.2 Perspectives 
Since the breakthrough discovery that somatic cells can be reprogrammed to a 
pluripotent state in vitro to generate induced pluripotent stem cells (iPSCs), significant 
efforts have been made to increase the efficiency of this technique so it can be used in 
disease modelling, drug screening and regenerative medicine. When first described, the 
reprogramming process implied the addition of a defined cocktail of only four 
transcription factors, including OCT4, SOX2, KLF4 and cMYC (OSKM). Despite the 
simplicity from the technical perspective, the efficiency of reprogramming is quite low, 
especially in the human context, and the mechanisms underlying transcription factor-
mediated reprogramming are still not fully understood. The work presented in this thesis 
tried to overcome some of these knowledge barriers by defining key molecular basis of 
OCT4 by exploiting proteomic approaches and describing for the first time its initial 
engagement with chromatin-associated proteins in early reprogramming and during 
pluripotency maintenance in embryonic stem cells. Moreover, it provided a novel 
proteomic dataset with interesting implications for the understanding of the different 
mechanisms involved in the human pluripotency maintenance and the early mechanisms 
involved in the somatic cell conversion to pluripotency. However, it should be noted that 
the data presented in this thesis represents a general and descriptive overview of OCT4 
interacting proteins, which could not reflect functional importance in either process, 
pluripotency or reprogramming. Thus, further assays focused in the characterization of 
OCT4 interactors that are functionally relevant for reprogramming and pluripotency 
should be addressed. 
The reprogramming of somatic cells to pluripotency requires the overexpression of not 
only OCT4 but also SOX2, KLF4 and cMYC, thus the expansion of the pluripotency network 
and the early reprogramming network by the application of the proteomic protocols 
described in this thesis will help provide a better insight into the mechanisms and the 
interactome dynamics involved in the pluripotency maintenance and the reprogramming 
of somatic cells to iPSCs. More importantly, expanding both the human pluripotency 
network and the early reprogramming network, can contribute to the identification of 
new proteins and molecular mechanisms involved in the reprogramming process that 
can be targeted with the final aim of improving the efficiency and fidelity of iPSCs 
generation. 
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Additionally, the identification of new proteins important for the through their 
chromatin-association with OCT4 at initial stages of reprogramming, has opened the field 
for their further characterisation, which could unravel the mechanisms they are involved 
in to promote pluripotency along with OCT4. First, their importance in human 
reprogramming should be assessed. Secondly, description of their engagement with the 
somatic genome at early reprogramming using ChIP-seq needs to be carried out. Such 
data will provide valuable information regarding the co-binding sites with OCT4. 
Furthermore, ChIP-SICAP could also be implemented in these proteins to find common 
chromatin-associated partners with OCT4 and expand the knowledge of the complexes 
they are involved in. Moreover, the list of candidates to test could be expanded by 
focusing in the unique proteins found in the interactome of the mutant O lin95-117. This 
mutant enhanced the reprogramming efficiency in mouse; therefore, some of its 
interacting proteins could be facilitators for the process. Not lastly, the unique proteins 
identified in the pluripotency network of hES could also be targeted because of their 
importance for the pluripotency maintenance, thus their overexpression along with the 
reprogramming factors could contribute for a better achievement of pluripotency during 
the reprogramming process.  
As with the majority of studies, the design of the current study presents its own 
limitations that could be addressed in future research. For instance, the approach 
presented in this thesis focused in the initial stages of reprogramming without the 
isolation of particular cell intermediates, which gave the advantage of having enough 
starting material for the proteomic and ChIP-seq approaches. Thus, the application of 
these tools to study specific intermediate populations during later stages of the could be 
limited by the starting material, in addition of the need for a ChIP-grade antibody and by 
limitations in mass spectrometry to detect very low-abundance peptides. Therefore, ChIP 
and protein isolation techniques should be improved to maximize the amount of 
chromatin and protein purification, in addition to more sensitive mass spectrometry 
approaches. These improvements will be fundamental for future research to understand 
OCT4- and other TF- engagement dynamics with proteins and chromatin at different 
stages of the reprogramming process.  
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Lastly, the techniques and approaches described in this work could be expanded to gain 
a better understanding of transcriptional networks in general, and not only during 
pluripotency maintenance or during cellular reprogramming, as transcription factors are 
involved in multiple biological processes and diseases. Therefore, the integration of the 
identification of chromatin-associated proteins, off-chromatin associated proteins and 
genomic engagement of relevant transcription factors or chromatin-remodelling 
proteins could help extend and understand their function in physiological conditions and 
diseases in an integrated workflow.  
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Table 6.1 Identified proteins ChIP-SICAP 
   LFQ Values ChIP-SICAP OCT4 (log2) 














AAMP Q13685 3 NAN NAN NAN NAN NAN 18.72 19.71 19.51 NAN NAN 
AASDHPPT Q9NRN7 3 NAN NAN NAN NAN 19.39 19.73 19.28 NAN NAN 18.93 
ACAA1 P09110 2 NAN NAN 19.27 NAN 19.19 18.56 NAN NAN NAN NAN 
ACBD6 Q9BR61 6 NAN NAN NAN 21.86 22.13 21.20 NAN 21.27 22.02 21.53 
ACP1 P24666 5 NAN NAN 20.84 21.53 21.23 21.36 21.15 21.21 20.55 20.51 
ACTC1 P68032 22 NAN NAN 24.03 24.67 23.98 23.87 25.25 24.95 26.09 25.84 
ACTL6A O96019 14 22.11 22.85 22.36 23.02 23.21 23.24 23.67 23.04 22.41 22.04 
ACTN1 P12814 36 NAN NAN 20.71 22.78 21.49 21.80 23.89 22.72 23.96 24.31 
ACTN4 O43707 42 19.29 20.79 24.37 23.65 22.38 21.96 24.50 26.17 25.30 25.01 
ADNP Q9H2P0 29 24.37 23.52 21.36 23.68 23.97 23.74 23.68 23.14 22.85 23.05 
ADRM1 Q16186 4 NAN NAN NAN NAN 18.61 18.60 NAN 18.82 18.92 NAN 
AES Q08117 7 NAN 20.36 21.17 22.09 23.47 23.67 22.42 22.14 NAN 20.97 
AHCTF1 Q8WYP5 24 NAN NAN NAN 22.25 21.69 21.58 22.56 21.47 23.09 22.82 
AHCY P23526 10 NAN NAN NAN NAN 21.26 21.43 21.88 22.57 21.42 21.71 
AHDC1 Q5TGY3 41 19.63 19.94 20.54 22.29 26.01 26.36 23.86 23.75 19.32 20.60 
AHNAK Q09666 29 NAN NAN 21.74 NAN NAN 19.89 20.49 24.37 22.85 21.26 
AHR P35869 17 NAN NAN NAN 20.97 23.30 24.20 22.86 22.92 21.69 21.52 
AHSA1 O95433 8 NAN NAN NAN NAN 21.80 22.31 21.41 21.53 21.51 21.54 
AIP O00170 12 NAN NAN 20.70 21.46 24.92 24.38 22.43 23.02 20.91 22.03 
AK6 Q9Y3D8 5 NAN NAN NAN NAN 21.46 21.49 NAN NAN NAN NAN 
AKAP8 O43823 12 NAN 22.01 NAN NAN 22.36 22.03 21.99 21.14 21.48 21.39 
AKAP8L Q9ULX6 16 NAN 22.03 22.32 22.90 24.52 24.63 23.19 23.20 22.77 22.80 
AKR1C1 Q04828 6 NAN NAN NAN 20.54 20.51 20.94 20.67 21.05 NAN NAN 
AKT2 P31751 7 NAN NAN NAN NAN 20.33 19.89 19.81 20.16 NAN NAN 
ALDH18A1 P54886 33 24.58 25.32 NAN NAN 25.96 25.84 20.65 22.78 25.58 25.40 
ALDOA P04075 17 21.78 NAN 22.72 20.53 21.04 21.33 22.22 25.02 22.92 21.96 
ALKBH2 Q6NS38 7 NAN NAN NAN NAN 21.74 21.98 NAN 21.03 NAN NAN 
ALKBH5 Q6P6C2 8 NAN NAN NAN NAN 20.86 20.87 20.97 20.75 NAN NAN 
ALYREF Q86V81 5 NAN 23.31 22.65 23.24 24.82 24.61 24.11 23.85 23.59 23.40 
ANKRD54 Q6NXT1 6 NAN NAN NAN NAN 21.61 21.65 21.09 21.04 NAN NAN 
ANP32A P39687 8 NAN 22.55 21.14 22.12 22.21 22.32 23.10 22.79 22.73 22.55 
ANP32B Q92688 4 NAN NAN NAN NAN 20.86 20.47 20.94 20.17 20.00 20.70 
ANP32E Q9BTT0 6 21.02 NAN NAN NAN 20.78 20.96 21.13 21.11 21.18 21.31 
ANXA11 P50995 15 NAN NAN 22.36 22.69 24.04 23.67 23.56 24.15 22.88 22.40 
ANXA4 P09525 10 NAN NAN NAN 21.55 21.06 21.32 20.22 23.26 21.26 20.48 
ANXA6 P08133 20 NAN NAN NAN 22.73 21.80 21.82 23.14 22.03 23.24 23.06 
ANXA7 P20073 18 20.65 NAN 23.44 23.79 25.23 25.43 24.54 24.75 23.01 23.59 
AP2A1 O95782 9 NAN NAN 20.89 NAN 19.84 NAN 20.01 21.24 20.58 20.61 
AP2B1 P63010 8 NAN NAN NAN NAN 19.21 19.20 19.35 20.37 20.02 19.89 
AP2S1 P53680 3 NAN NAN NAN NAN 19.12 19.44 NAN 18.87 NAN NAN 
AP4B1 Q9Y6B7 11 NAN NAN NAN NAN 21.13 21.01 NAN NAN NAN NAN 
APEX1 P27695 16 23.40 22.35 23.48 24.16 24.75 25.23 25.50 24.67 24.46 25.39 
API5 Q9BZZ5 8 NAN NAN NAN 21.90 21.56 21.43 22.23 21.61 21.57 21.80 
APOBEC3B Q9UH17 4 NAN NAN NAN NAN 19.08 19.41 NAN NAN NAN NAN 
APOD P05090 6 NAN NAN NAN NAN 19.03 18.58 NAN 19.59 19.58 19.84 
APTX Q7Z2E3 5 NAN NAN NAN NAN 21.07 20.91 20.40 20.44 20.15 NAN 
ARF4 P18085 7 NAN NAN NAN NAN 22.78 22.56 23.10 23.28 23.73 23.45 
ARHGAP23 Q9P227 3 NAN NAN NAN NAN 17.39 18.33 NAN NAN NAN NAN 
ARHGAP39 Q9C0H5 2 NAN NAN NAN NAN 18.01 17.94 NAN NAN NAN NAN 
ARID1A O14497 49 24.52 22.73 20.43 21.93 25.21 25.16 24.67 24.12 20.72 20.85 
ARID1B Q8NFD5 37 21.88 NAN 20.08 22.18 24.64 24.94 22.51 22.38 19.55 19.86 
ARID3A Q99856 9 22.53 21.24 NAN NAN 21.87 22.01 21.72 21.70 NAN NAN 
ARID3B Q8IVW6 9 23.19 23.35 NAN NAN NAN NAN NAN NAN NAN NAN 
ARID5A Q03989 3 NAN NAN NAN NAN 18.91 18.82 NAN 18.77 NAN NAN 
ARID5B Q14865 33 NAN NAN 22.32 24.20 24.70 24.97 24.18 23.80 21.70 22.80 
ARIH1 Q9Y4X5 5 NAN NAN NAN NAN 20.36 20.17 20.18 20.41 NAN 20.96 
ARIH2 O95376 8 NAN NAN NAN NAN 20.38 20.55 20.08 20.16 NAN NAN 
ARMC7 Q9H6L4 2 NAN NAN NAN NAN 18.12 19.23 NAN 17.65 NAN NAN 
ARNT P27540 24 NAN NAN 21.37 23.70 24.34 24.79 23.52 23.42 NAN 21.26 
ARPC2 O15144 7 NAN NAN NAN 20.76 20.33 20.43 20.00 22.49 20.60 20.59 
ARPC4 P59998 2 NAN NAN NAN NAN 19.30 19.63 19.09 NAN 19.53 19.45 
ASNS P08243 3 NAN NAN NAN NAN 19.02 19.13 19.28 18.99 NAN 18.99 
ASPH Q12797 2 NAN NAN NAN NAN NAN NAN 19.13 NAN 20.41 20.06 
ATF1 P18846 4 NAN 20.54 NAN 22.67 22.80 22.54 22.09 22.15 21.62 21.39 
ATF7 P17544 3 NAN NAN NAN NAN 20.34 20.40 19.37 19.51 NAN NAN 
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ATN1 P54259 15 NAN NAN 23.58 24.12 24.86 25.67 24.30 24.00 21.43 21.44 
ATP2A2 P16615 5 NAN NAN NAN NAN NAN NAN NAN 20.62 20.12 19.68 
ATP5B P06576 12 NAN NAN NAN NAN 17.91 18.06 NAN 24.09 NAN NAN 
ATP5F1A P25705 11 NAN NAN 21.52 NAN 20.71 21.06 20.24 23.06 20.75 20.76 
ATP6V1A P38606 10 NAN NAN NAN NAN NAN NAN 17.34 22.63 17.66 NAN 
ATRX P46100 40 22.45 22.37 22.32 23.79 24.15 24.20 23.56 23.18 23.05 23.21 
AURKA O14965 9 NAN NAN NAN 21.21 22.00 21.62 21.70 21.41 NAN NAN 
AURKB Q96GD4 12 22.91 22.55 21.34 22.27 21.88 22.09 22.36 22.26 21.33 NAN 
AUTS2 Q8WXX7 10 NAN NAN NAN 22.76 22.87 22.43 21.81 21.89 NAN NAN 
BAG2 O95816 9 NAN NAN NAN 21.02 22.58 22.54 21.10 20.75 NAN 20.51 
BAG3 O95817 19 NAN NAN 22.29 23.34 23.57 23.25 22.55 22.80 22.64 22.41 
BAG4 O95429 13 NAN NAN NAN NAN 24.24 24.36 21.55 22.06 NAN 19.94 
BAG5 Q9UL15 10 NAN NAN 21.11 NAN 21.70 21.75 20.27 20.25 NAN NAN 
BAHCC1 Q9P281 6 NAN NAN NAN NAN 19.48 19.83 NAN NAN NAN NAN 
BAHD1 Q8TBE0 9 NAN NAN 20.97 21.03 21.46 21.53 20.82 20.94 NAN 19.92 
BANF1 O75531 4 NAN NAN 24.24 22.13 22.26 22.28 23.06 23.33 24.27 24.00 
BAZ1A Q9NRL2 21 NAN NAN 21.60 22.01 20.87 20.86 22.36 20.89 NAN 20.58 
BAZ1B Q9UIG0 34 21.14 21.14 20.31 23.66 21.60 21.79 23.90 22.34 23.14 23.54 
BAZ2A Q9UIF9 16 NAN NAN NAN NAN 21.83 21.88 20.93 19.78 20.36 NAN 
BCAS2 O75934 4 NAN NAN NAN NAN 20.05 20.31 21.63 20.87 20.84 21.56 
BCCIP Q9P287 6 NAN NAN NAN NAN 19.97 19.56 19.96 19.51 NAN 19.50 
BCL6 P41182 9 NAN NAN NAN NAN 21.53 21.38 20.54 20.25 NAN NAN 
BCL9L Q86UU0 22 NAN NAN 23.65 23.95 23.92 23.59 23.97 24.09 22.05 22.51 
BCLAF1 Q9NYF8 8 NAN 20.99 NAN 20.68 NAN NAN 20.89 NAN 20.75 20.56 
BCOR Q6W2J9 52 NAN NAN 22.31 23.81 25.02 25.12 24.44 24.18 20.82 22.69 
BCORL1 Q5H9F3 5 NAN NAN NAN NAN 19.59 19.86 NAN NAN NAN 19.45 
BHLHB2 O14503 2 NAN NAN NAN NAN 19.61 19.53 NAN NAN NAN NAN 
BLVRB P30043 4 NAN NAN NAN NAN 19.83 20.24 20.30 21.46 21.53 20.84 
BNC1 Q01954 6 NAN NAN NAN NAN 19.70 20.25 19.05 NAN NAN NAN 
BOLA2 Q9H3K6 3 NAN NAN NAN NAN 20.94 20.88 NAN 19.88 NAN NAN 
BRAT1 Q6PJG6 20 NAN NAN NAN 21.04 22.35 22.76 22.33 21.92 20.20 20.88 
BRD2 P25440 15 NAN NAN 20.78 22.09 22.32 22.28 22.87 21.75 20.06 21.17 
BRD4 O60885 10 NAN NAN NAN 21.73 21.41 21.67 21.35 21.20 NAN 20.66 
BRF2 Q9HAW0 4 NAN NAN NAN NAN 20.46 20.19 NAN 19.07 NAN NAN 
BTAF1 O14981 27 NAN NAN NAN 21.55 22.22 21.92 23.45 22.89 22.25 22.10 
BTBD14A Q96BF6 9 NAN NAN 22.56 21.16 21.62 21.21 20.85 20.71 NAN 20.82 
BTBD14B Q96RE7 17 24.10 23.25 24.62 24.80 25.84 25.96 25.33 25.04 24.30 24.48 
BUB3 O43684 8 22.86 22.13 23.46 23.81 23.60 24.00 23.49 23.35 23.20 23.27 
BUD23 O43709 6 NAN NAN 20.85 21.57 22.26 21.90 21.11 20.99 NAN 21.37 
BUD31 P41223 7 NAN NAN NAN 21.05 21.32 21.60 20.73 20.82 NAN 21.14 
BYSL Q13895 6 NAN NAN NAN NAN 21.24 21.30 20.54 20.51 NAN NAN 
C15orf39 Q6ZRI6 27 NAN NAN 20.51 20.29 23.93 25.25 22.90 22.68 NAN 20.75 
C1orf174 Q8IYL3 2 NAN NAN NAN NAN 18.57 18.95 NAN NAN NAN 18.80 
C20orf27 Q9GZN8 3 NAN NAN NAN NAN 19.38 19.44 NAN NAN NAN NAN 
C3orf38 Q5JPI3 13 NAN NAN 20.79 21.42 24.25 24.08 22.35 22.24 NAN 21.67 
C7orf26 Q96N11 8 NAN NAN NAN NAN 21.95 22.01 21.30 21.43 NAN 20.46 
C7orf50 Q9BRJ6 4 NAN 20.08 21.03 21.21 21.41 21.77 21.28 20.78 NAN 20.77 
C9orf78 Q9NZ63 7 NAN NAN 21.03 21.73 20.91 21.11 21.55 21.60 20.75 20.90 
CACYBP Q9HB71 4 NAN NAN NAN NAN 20.49 20.45 NAN NAN 19.72 NAN 
CALD1 Q05682 6 NAN NAN NAN 20.65 19.54 19.87 20.69 20.43 21.35 21.38 
CALM1 P0DP23 10 NAN NAN 22.82 NAN 21.31 NAN 21.91 24.53 21.98 21.98 
CALR P27797 5 NAN NAN NAN NAN NAN NAN 19.98 21.91 20.29 20.69 
CALU O43852 6 NAN NAN NAN NAN 19.00 NAN 19.12 21.53 NAN NAN 
CAMK2D Q13557 4 NAN NAN NAN NAN NAN NAN 19.70 19.50 NAN NAN 
CAND1 Q86VP6 6 NAN NAN 19.96 NAN 19.22 19.62 19.58 20.11 NAN 19.56 
CANX P27824 12 NAN NAN NAN NAN NAN NAN 21.19 22.02 21.99 21.60 
CAPG Q9BPX3 7 NAN NAN NAN NAN 20.24 20.05 20.08 22.84 NAN 19.76 
CAPN1 P07384 15 21.24 19.26 21.45 NAN 20.02 20.81 21.26 23.01 21.28 21.11 
CAPZA1 P52907 10 NAN NAN NAN NAN 20.27 20.12 NAN 22.16 NAN 20.59 
CAPZB P47756 7 NAN NAN NAN 20.68 19.69 20.38 20.45 23.00 20.46 20.55 
CARM1 Q86X55 11 NAN NAN NAN 22.72 23.62 23.78 23.27 23.07 22.55 22.55 
CBFA2T2 O43439 9 20.36 NAN NAN NAN 21.83 22.14 21.02 21.15 NAN NAN 
CBFB Q13951 5 NAN NAN NAN 22.29 22.56 22.65 21.92 21.52 20.65 20.90 
CBR1 P16152 11 NAN NAN 21.78 NAN 21.26 21.72 21.56 22.83 NAN 21.88 
CBX1 P83916 8 22.49 22.65 22.18 22.78 23.78 23.80 23.63 23.09 23.18 23.11 
CBX3 Q13185 9 26.00 24.80 24.92 25.80 25.10 25.58 25.49 25.10 25.18 25.39 
CBX4 O00257 7 NAN NAN NAN 21.53 21.19 20.73 21.36 20.76 NAN 19.87 
CBX5 P45973 9 25.43 24.23 22.41 23.68 23.38 23.51 23.77 23.08 23.23 23.67 
CBX8 Q9HC52 2 NAN NAN NAN NAN 19.22 NAN NAN NAN 19.36 19.26 
CCAR2 Q8N163 13 21.95 21.53 20.29 NAN 20.37 19.97 21.33 20.14 21.06 21.15 
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CCDC137 Q6PK04 4 NAN NAN NAN NAN 23.45 23.86 NAN NAN NAN NAN 
CCDC82 Q8N4S0 8 NAN NAN NAN NAN 20.79 20.98 18.90 18.85 NAN NAN 
CCDC86 Q9H6F5 7 NAN NAN NAN NAN 21.51 21.12 21.44 20.71 21.20 NAN 
CCND1 P24385 7 NAN NAN NAN NAN 19.76 19.98 20.05 20.25 19.74 19.99 
CCNH P51946 9 NAN NAN NAN NAN 21.54 21.54 21.18 20.92 NAN 20.98 
CCNT1 O60563 6 NAN NAN NAN NAN 19.71 19.58 19.48 19.74 NAN NAN 
CCT3 P49368 16 NAN NAN NAN NAN 23.16 22.86 22.11 23.00 21.85 21.98 
CCT5 P48643 6 NAN NAN NAN NAN 19.00 NAN 19.12 21.53 NAN NAN 
CCT6A P40227 2 NAN NAN NAN NAN NAN NAN 18.56 20.51 NAN NAN 
CCT8 P50990 9 NAN NAN NAN NAN 20.74 20.29 20.84 22.02 NAN 20.95 
CCZ1 P86791 9 NAN NAN NAN NAN 20.42 20.16 19.59 19.80 19.61 NAN 
CD2BP2 O95400 7 NAN NAN NAN NAN 21.95 22.21 21.04 21.32 NAN NAN 
CDC16 Q13042 3 NAN NAN NAN NAN 19.27 18.79 19.32 NAN NAN NAN 
CDC20 Q12834 6 NAN NAN NAN NAN 21.17 21.36 21.28 20.79 NAN NAN 
CDC23 Q9UJX2 18 NAN NAN NAN NAN 23.61 23.85 21.74 21.72 NAN 19.37 
CDC37 Q16543 8 NAN NAN 21.64 22.70 22.08 22.33 21.74 21.39 21.93 22.22 
CDC40 O60508 12 NAN NAN NAN 21.13 22.14 22.14 21.37 20.86 20.21 20.40 
CDC5L Q99459 13 NAN NAN NAN NAN 20.36 NAN 21.07 20.69 20.88 20.86 
CDC73 Q6P1J9 5 NAN NAN NAN NAN 19.30 NAN 19.33 18.94 NAN 19.15 
CDCA8 Q53HL2 8 21.86 21.15 NAN NAN 19.21 19.50 21.07 21.24 NAN 20.32 
CDK1 P06493 11 NAN 21.43 21.71 22.91 22.39 22.62 22.77 21.86 21.45 NAN 
CDK11A Q9UQ88 9 NAN NAN NAN 21.10 21.47 20.74 21.37 20.42 20.74 20.40 
CDK2AP1 O14519 4 20.99 NAN 20.74 20.30 21.32 21.26 21.69 21.02 20.08 20.36 
CDK4 P11802 7 NAN NAN NAN NAN 20.79 21.02 20.22 NAN NAN 20.11 
CDK7 P50613 12 NAN NAN NAN 21.56 21.98 22.14 21.62 21.33 NAN 20.85 
CDK8 P49336 3 NAN NAN NAN NAN 19.76 19.23 18.67 NAN NAN NAN 
CDKN1A P38936 4 NAN NAN NAN 20.74 22.06 21.80 21.27 20.92 19.92 NAN 
CDKN2AIP Q9NXV6 13 NAN NAN NAN NAN 21.44 21.11 20.79 20.63 NAN NAN 
CDYL Q9Y232 8 NAN NAN NAN NAN 20.17 19.90 20.77 19.89 NAN NAN 
CEBPB P17676 9 NAN NAN NAN 23.61 23.87 24.23 22.58 22.60 NAN 21.25 
CECR2 Q9BXF3 7 22.13 22.16 NAN NAN NAN NAN NAN NAN NAN NAN 
CENPB P07199 3 NAN NAN NAN 21.05 19.83 NAN 21.39 NAN 21.13 21.08 
CENPC Q03188 8 NAN NAN NAN 19.34 NAN 18.12 NAN NAN 19.39 20.37 
CENPV Q7Z7K6 6 NAN 22.65 19.34 21.40 19.38 19.90 20.99 20.05 19.37 21.19 
CETN2 P41208 4 NAN NAN NAN NAN 19.89 20.07 19.34 NAN NAN 19.92 
CFAP20 Q9Y6A4 5 NAN NAN NAN NAN 20.45 20.02 NAN 20.48 20.05 20.34 
CFDP1 Q9UEE9 3 NAN NAN NAN NAN 18.52 19.51 NAN NAN NAN NAN 
CFL1 P23528 12 23.74 23.78 23.97 24.18 24.49 24.22 24.54 24.86 24.20 24.46 
CGGBP1 Q9UFW8 4 NAN NAN NAN NAN 20.10 19.69 20.38 20.07 NAN NAN 
CHAMP1 Q96JM3 11 NAN NAN NAN 21.24 21.64 21.76 21.59 21.01 NAN 20.77 
CHD1 O14646 20 NAN NAN NAN 20.32 22.04 22.24 21.94 21.03 20.84 20.67 
CHD3 Q12873 24 NAN NAN NAN 21.33 21.32 20.57 21.70 20.70 NAN 20.49 
CHD4 Q14839 70 26.02 25.15 24.59 25.53 25.53 25.74 25.72 25.18 24.59 24.74 
CHD7 Q9P2D1 22 20.32 NAN NAN NAN 21.71 20.69 19.68 18.64 NAN NAN 
CHD8 Q9HCK8 16 NAN NAN NAN NAN 20.30 20.37 19.90 20.53 NAN NAN 
CHD9 Q3L8U1 28 NAN NAN NAN NAN 23.30 22.48 21.52 20.59 NAN 20.15 
CHERP Q8IWX8 9 NAN NAN NAN 21.42 21.84 22.35 21.96 21.75 21.53 21.60 
CHTF8 P0CG13 8 NAN NAN NAN 21.66 23.27 23.93 22.13 22.53 NAN NAN 
CIAO1 O76071 10 NAN NAN 20.37 21.63 22.69 23.22 22.17 22.36 NAN 21.26 
CIRBP Q14011 2 NAN NAN NAN NAN NAN 19.99 20.06 19.63 NAN NAN 
CIZ1 Q9ULV3 6 NAN NAN NAN NAN NAN NAN 20.18 19.93 NAN NAN 
CKAP4 Q07065 21 NAN NAN 19.61 NAN NAN 20.25 20.66 23.19 20.53 22.50 
CKB P12277 7 NAN NAN NAN NAN 19.33 19.30 20.40 20.23 NAN 20.08 
CLIC1 O00299 10 NAN NAN 22.99 22.46 22.53 22.73 22.48 23.43 22.55 22.90 
CLIC3 O95833 11 NAN NAN 20.65 NAN 24.23 24.15 21.99 23.54 20.96 21.13 
CLIC4 Q9Y696 7 NAN NAN NAN NAN NAN 20.25 19.99 20.28 20.16 20.03 
CLOCK O15516 3 NAN NAN NAN NAN 19.37 19.44 NAN NAN NAN NAN 
CLP1 Q92989 3 NAN NAN NAN NAN 20.09 19.90 NAN NAN NAN NAN 
CLTC Q00610 33 NAN NAN 23.80 23.82 22.60 22.53 23.03 24.01 23.71 23.80 
CMAS Q8NFW8 12 NAN NAN NAN 21.79 22.74 22.60 22.59 22.41 23.00 23.12 
CMBL Q96DG6 15 NAN NAN 19.94 22.77 23.26 23.13 23.24 23.31 22.31 22.53 
CMPK1 P30085 3 NAN NAN NAN 19.66 NAN 19.11 NAN 21.15 19.78 19.64 
CMTR1 Q8N1G2 6 NAN NAN 20.53 20.86 20.13 20.68 20.21 20.06 21.10 20.86 
CNBP P62633 9 22.59 22.08 21.60 22.59 22.50 22.46 21.94 21.81 21.43 21.79 
CNN1 P51911 9 NAN NAN 22.30 22.78 22.05 22.50 22.85 22.77 22.90 23.08 
CNN2 Q99439 12 NAN NAN 23.55 23.03 23.59 23.65 23.59 23.46 23.35 23.50 
CNN3 Q15417 10 NAN NAN NAN 21.33 21.15 21.50 22.02 21.32 21.87 21.96 
CNOT1 A5YKK6 14 NAN NAN 22.21 21.81 20.29 20.85 20.98 20.84 20.72 20.47 
COL1A1 P02452 8 23.40 NAN NAN NAN 21.84 21.63 21.23 NAN 22.07 21.83 
COMMD9 Q9P000 2 NAN NAN NAN NAN 19.16 19.35 18.68 NAN NAN NAN 
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COMT P21964 5 NAN NAN NAN NAN NAN NAN 22.06 21.93 22.08 21.03 
COPA P53621 11 NAN NAN NAN NAN NAN NAN 22.73 21.38 NAN 21.37 
CPNE2 Q96FN4 4 NAN NAN NAN NAN 18.67 18.59 NAN 18.49 NAN NAN 
CPNE3 O75131 10 NAN 20.21 21.46 21.71 22.02 22.42 22.11 22.96 22.02 22.02 
CPNE7 Q9UBL6 5 NAN NAN NAN NAN 18.80 19.56 NAN NAN NAN NAN 
CPNE8 Q86YQ8 5 NAN NAN NAN NAN 19.22 19.49 NAN NAN NAN NAN 
CPSF1 Q10570 8 NAN NAN NAN NAN 20.26 20.02 20.74 NAN NAN 20.45 
CPSF3L Q5TA45 4 NAN NAN NAN NAN 19.34 19.80 19.56 19.33 NAN NAN 
CPSF6 Q16630 6 NAN NAN NAN NAN 20.36 20.71 22.24 20.92 NAN 20.70 
CPSF7 Q8N684 13 NAN 22.20 21.59 22.43 22.87 23.46 22.94 23.01 20.86 21.77 
CRABP2 P29373 5 NAN NAN NAN NAN 20.25 20.07 20.40 23.06 NAN NAN 
CREB1 P16220 4 NAN NAN NAN NAN 21.31 20.93 20.53 NAN NAN NAN 
CREB5 Q02930 3 NAN NAN NAN NAN 19.52 20.69 NAN NAN NAN NAN 
CREBBP Q92793 38 NAN NAN NAN 22.03 23.57 23.56 22.37 22.23 NAN 20.24 
CRIP1 P50238 4 NAN NAN NAN 20.93 21.62 22.38 20.89 21.14 21.13 21.16 
CRIP2 P52943 7 NAN NAN 21.87 22.86 23.55 23.37 22.92 23.37 22.50 22.77 
CRK P46108 4 NAN NAN NAN NAN 20.22 20.01 19.91 19.75 NAN 20.00 
CRKL P46109 5 NAN NAN NAN 21.53 22.19 21.55 21.36 20.97 20.93 NAN 
CROP O95232 6 20.62 21.26 NAN NAN 19.59 19.12 21.43 20.24 21.18 20.58 
CRTC2 Q53ET0 13 NAN NAN NAN NAN 23.58 23.35 22.20 21.75 NAN 20.13 
CRTC3 Q6UUV7 7 NAN NAN NAN NAN 21.59 21.53 21.26 20.70 NAN NAN 
CRYAB P02511 9 NAN NAN 24.41 24.24 23.41 23.61 24.15 24.00 25.97 25.77 
CSE1L P55060 26 22.91 22.47 21.36 23.02 23.25 23.14 23.98 23.44 23.37 23.20 
CSNK1A1 P48729 6 NAN NAN NAN NAN 21.67 21.37 20.86 21.22 20.42 20.65 
CSNK1D P48730 9 NAN NAN NAN NAN 19.29 20.28 NAN NAN NAN NAN 
CSNK1E P49674 9 NAN NAN 20.36 20.80 22.66 23.22 21.60 22.06 NAN 20.27 
CSNK2A1 P68400 12 NAN 21.14 21.27 21.98 22.67 22.99 21.94 21.93 21.20 NAN 
CSNK2A2 P19784 11 NAN NAN NAN NAN 21.64 21.81 21.77 21.86 20.90 20.25 
CSNK2B P67870 6 21.54 21.19 21.38 22.17 22.61 22.68 22.03 22.26 21.55 22.13 
CSTA P01040 4 22.77 21.27 21.91 22.21 20.20 19.99 20.69 24.74 22.54 22.13 
CSTF1 Q05048 10 20.72 NAN 21.44 21.66 23.37 23.22 23.52 22.52 NAN 22.52 
CSTF2 P33240 6 NAN NAN NAN NAN 19.29 NAN 19.60 19.92 19.47 NAN 
CSTF2T Q9H0L4 8 NAN NAN NAN 21.19 20.78 20.32 21.44 21.27 20.93 NAN 
CSTF3 Q12996 12 NAN 20.81 21.70 22.08 20.96 21.01 22.16 21.21 NAN 21.32 
CTBP1 Q13363 15 23.16 22.99 23.17 24.26 25.13 25.50 24.64 24.60 23.80 24.25 
CTBP2 P56545 14 24.23 24.20 22.70 24.12 24.92 25.01 24.79 24.13 23.69 23.83 
CTNNA1 P35221 5 NAN NAN NAN NAN NAN NAN 19.90 20.15 NAN NAN 
CTNNBL1 Q8WYA6 9 NAN NAN NAN 21.49 20.42 20.81 20.75 20.30 20.60 21.05 
CTNND1 O60716 11 NAN NAN NAN NAN 21.03 21.32 20.78 NAN NAN NAN 
CTR9 Q6PD62 3 NAN NAN NAN NAN 18.84 19.21 NAN NAN NAN NAN 
CTSB P07858 5 NAN NAN NAN 19.94 NAN NAN 19.34 23.10 19.42 19.68 
CTTN Q14247 7 NAN NAN NAN NAN NAN NAN 18.63 18.32 18.30 NAN 
CTU1 Q7Z7A3 4 NAN NAN NAN NAN 20.43 20.88 NAN 19.81 NAN NAN 
CUX1 Q13948 26 NAN NAN 20.36 NAN 23.17 22.30 22.27 21.16 20.62 NAN 
CWF19L1 Q69YN2 4 NAN NAN NAN NAN 19.60 19.30 19.70 19.65 NAN NAN 
CXXC5 Q7LFL8 4 NAN NAN NAN NAN 20.65 19.53 18.89 18.84 NAN NAN 
CYB5R3 P00387 10 NAN NAN NAN 22.60 20.72 20.30 22.06 21.47 23.38 22.96 
CYFIP1 Q7L576 15 NAN NAN NAN 20.24 20.45 20.83 20.41 21.13 20.13 20.25 
DAXX Q9UER7 7 NAN NAN NAN NAN 21.61 21.73 22.12 NAN NAN NAN 
DAZAP1 Q96EP5 16 22.26 NAN 22.19 21.69 23.04 22.97 23.21 22.71 22.32 21.40 
DBI P07108 3 NAN NAN NAN NAN NAN NAN 19.43 22.20 NAN NAN 
DBR1 Q9UK59 4 NAN NAN NAN 20.18 20.91 21.22 20.37 20.06 20.13 NAN 
DCAF13 Q9NV06 4 NAN NAN NAN NAN 19.27 19.71 19.12 NAN 19.08 NAN 
DCAF4 Q8WV16 4 NAN NAN NAN NAN 20.43 19.72 NAN NAN NAN NAN 
DCAF7 P61962 16 22.05 NAN 23.30 23.57 26.22 26.11 25.41 25.13 23.22 23.46 
DCUN1D5 Q9BTE7 3 NAN NAN NAN NAN NAN 19.71 19.39 19.50 NAN NAN 
DDB1 Q16531 40 22.15 22.23 NAN 24.18 25.11 25.33 24.22 23.57 23.47 23.94 
DDB2 Q92466 13 NAN NAN NAN 21.29 23.75 23.78 21.09 19.06 NAN 21.15 
DDOST P39656 5 NAN NAN NAN NAN NAN NAN 19.90 21.49 NAN NAN 
DDX1 Q92499 22 20.93 23.31 24.15 24.29 23.77 23.62 23.41 23.64 23.60 23.45 
DDX17 Q92841 26 25.70 26.87 23.90 24.92 25.15 25.12 25.00 24.72 24.65 24.67 
DDX21 Q9NR30 16 22.00 22.53 NAN 21.51 21.07 20.88 22.45 21.35 22.22 22.36 
DDX39A O00148 15 NAN NAN NAN 21.05 20.61 20.15 21.14 20.87 21.26 21.34 
DDX39B Q13838 15 24.72 25.28 23.17 24.22 23.47 23.27 24.25 23.90 23.97 24.18 
DDX3X O00571 17 22.44 22.22 21.87 20.69 21.34 21.78 22.61 23.51 22.44 22.50 
DDX42 Q86XP3 15 NAN NAN NAN 21.56 21.59 21.39 21.81 21.30 21.73 21.52 
DDX47 Q9H0S4 9 NAN 21.29 NAN 20.18 20.98 20.90 20.65 20.32 NAN 20.31 
DDX48 P38919 22 22.20 24.43 24.90 25.67 24.85 24.92 25.84 25.53 24.48 25.54 
DDX49 Q9Y6V7 7 NAN NAN 21.33 21.61 21.45 22.05 21.08 20.98 20.86 20.93 
DDX5 P17844 28 26.57 27.16 25.94 26.60 27.69 27.69 27.23 26.81 26.57 26.60 
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DEK P35659 10 23.87 23.38 22.07 23.69 22.39 22.71 23.61 23.00 23.39 23.66 
DHX15 O43143 28 24.27 24.09 23.82 25.19 24.86 25.09 25.28 24.68 25.22 25.50 
DHX16 O60231 17 NAN NAN NAN NAN 21.87 21.98 21.65 21.43 21.18 21.13 
DHX34 Q14147 9 NAN NAN NAN NAN 21.07 21.25 NAN NAN NAN NAN 
DHX36 Q9H2U1 20 NAN NAN NAN 21.04 23.61 23.80 22.15 22.31 21.20 21.87 
DHX37 Q8IY37 11 NAN NAN 20.73 NAN 19.99 19.29 19.63 NAN NAN 20.09 
DHX38 Q92620 13 NAN NAN NAN NAN 21.56 21.07 21.19 20.67 21.13 NAN 
DHX9 Q08211 42 25.95 27.14 25.50 26.60 26.95 26.91 27.01 26.53 26.77 26.71 
DIMT1 Q9UNQ2 7 NAN NAN NAN NAN 20.85 20.83 21.28 20.34 NAN 20.80 
DIS3 Q9Y2L1 31 NAN 20.60 21.32 23.77 23.48 23.74 23.70 23.70 22.40 23.35 
DLX1 P56177 4 NAN NAN NAN NAN NAN 20.18 20.23 20.57 NAN NAN 
DLX3 O60479 4 NAN NAN NAN NAN NAN 19.17 20.00 19.93 NAN NAN 
DMAP1 Q9NPF5 7 NAN NAN NAN NAN 19.53 19.98 NAN 19.43 NAN NAN 
DNAAF5 Q86Y56 8 NAN NAN NAN NAN 20.50 20.78 20.49 20.23 NAN 19.70 
DNAJA1 P31689 17 20.63 21.68 23.98 25.67 25.90 25.94 25.55 25.42 24.75 25.69 
DNAJA2 O60884 15 21.01 21.38 24.15 24.44 24.38 24.58 24.32 24.01 23.87 23.90 
DNAJB1 P25685 14 NAN NAN 23.55 23.56 25.89 25.91 23.92 24.20 23.82 23.66 
DNAJB2 P25686 7 NAN NAN NAN NAN 20.52 21.50 19.96 20.57 NAN 19.88 
DNAJB4 Q9UDY4 9 NAN NAN NAN NAN 22.31 22.47 19.63 19.64 19.89 19.33 
DNAJB6 O75190 16 22.57 21.71 23.60 24.11 27.01 27.15 24.62 25.07 23.77 23.67 
DNAJC7 Q99615 23 NAN NAN NAN 21.68 24.99 24.77 22.49 22.49 NAN 21.33 
DNAJC8 O75937 10 21.72 21.69 22.30 22.77 22.79 22.93 22.67 22.44 22.12 22.32 
DNAJC9 Q8WXX5 4 NAN NAN NAN NAN NAN 19.63 20.50 19.97 19.76 NAN 
DNCL1 P63167 3 23.47 NAN 22.20 22.81 21.83 22.82 22.79 23.28 22.18 22.86 
DNMT1 P26358 10 NAN NAN NAN NAN NAN NAN 20.13 20.09 NAN 20.42 
DNMT3A Q9Y6K1 4 22.37 22.23 NAN NAN NAN NAN NAN NAN NAN NAN 
DNMT3B Q9UBC3 23 26.39 25.36 NAN NAN NAN NAN NAN NAN NAN NAN 
DNTTIP1 Q9H147 15 NAN NAN NAN 21.79 24.69 24.75 23.46 23.19 NAN NAN 
DNTTIP2 Q5QJE6 21 19.67 19.53 20.17 21.30 23.78 23.05 21.56 21.12 21.48 19.95 
DPF2 Q92785 17 22.67 22.83 22.92 23.01 23.95 24.27 23.45 22.50 21.30 21.95 
DPH2 Q9BQC3 6 NAN NAN 20.70 NAN 20.37 20.13 NAN NAN NAN NAN 
DR1 Q01658 4 NAN NAN NAN NAN 21.62 21.72 21.22 20.53 NAN NAN 
DRAP1 Q14919 6 NAN NAN 21.21 NAN 22.27 21.47 21.99 20.83 20.89 NAN 
DROSHA Q9NRR4 6 NAN NAN NAN NAN 19.40 19.43 NAN NAN NAN NAN 
DSC3 Q02487 12 19.89 NAN 24.39 NAN 20.86 NAN 19.70 21.05 21.27 NAN 
DSTN P60981 7 NAN NAN 21.69 21.80 21.27 21.74 21.77 22.27 21.95 22.29 
DTX2 Q86UW9 11 NAN NAN NAN NAN 22.81 23.11 21.14 21.43 NAN NAN 
DUSP11 O75319 9 NAN NAN NAN NAN 21.68 22.42 18.94 18.86 NAN 18.34 
DUSP14 O95147 5 NAN NAN 20.91 NAN 22.10 21.94 NAN 21.28 NAN NAN 
DUSP23 Q9BVJ7 8 NAN NAN 21.06 21.01 22.29 22.39 21.14 21.65 20.77 21.11 
EBF1 Q9UH73 14 NAN NAN 22.70 22.09 23.54 23.74 22.87 22.64 21.17 22.55 
EBF3 Q9H4W6 13 NAN NAN NAN NAN 20.03 20.28 20.20 20.22 NAN NAN 
EED O75530 3 NAN NAN NAN NAN 19.47 20.11 NAN 19.98 NAN 20.45 
EEF1G P26641 10 NAN NAN 22.61 20.69 20.89 20.20 19.80 23.38 20.81 21.57 
EEF2 P13639 38 24.25 24.35 25.16 24.35 23.34 23.32 24.56 26.68 24.49 24.48 
EFTUD2 Q15029 16 21.15 21.15 20.64 20.79 20.48 20.68 21.64 20.64 21.59 21.31 
EGR1 P18146 10 NAN NAN 21.40 21.67 24.13 24.02 21.27 NAN NAN NAN 
EHD1 Q9NZN3 10 NAN NAN NAN NAN NAN NAN 19.61 21.87 NAN NAN 
EHMT1 Q9H9B1 9 21.34 NAN NAN NAN 20.66 20.09 20.59 NAN NAN NAN 
EHMT2 Q96KQ7 8 NAN 21.01 NAN NAN 20.97 20.26 20.38 NAN NAN NAN 
EIF2S1 P05198 10 NAN NAN NAN NAN 20.13 20.05 20.67 21.56 NAN 20.25 
EIF3D O15371 15 NAN NAN 21.26 21.60 23.98 24.52 22.58 23.49 21.03 21.49 
EIF3E P60228 6 NAN NAN NAN NAN 21.41 21.29 20.61 21.22 NAN NAN 
EIF3H O15372 2 NAN NAN NAN NAN 19.18 19.59 NAN NAN NAN NAN 
EIF3K Q9UBQ5 3 NAN NAN NAN NAN NAN 18.86 18.96 19.22 NAN 19.07 
EIF3L Q9Y262 8 NAN NAN NAN NAN 20.94 20.94 20.27 20.76 NAN 20.38 
EIF3M Q7L2H7 2 NAN NAN NAN NAN NAN 17.89 18.02 18.40 NAN NAN 
EIF3S2 Q13347 10 NAN NAN NAN NAN 22.27 22.76 22.32 21.85 21.42 21.67 
EIF3S8 Q99613 3 NAN NAN NAN NAN NAN NAN 18.88 18.58 18.90 18.41 
EIF4A1 P60842 21 23.75 24.40 23.66 23.79 24.68 24.77 24.69 25.17 24.78 24.62 
EIF4E2 O60573 2 NAN NAN NAN NAN 17.53 18.83 NAN NAN NAN NAN 
EIF4H Q15056 7 20.72 NAN 21.53 22.17 22.52 23.06 22.41 22.82 22.20 22.79 
EIF5A P63241 10 22.75 25.54 24.78 24.67 24.12 24.67 24.42 24.42 24.18 24.29 
EIF6 P56537 8 NAN NAN 23.95 NAN 20.64 21.31 20.80 23.01 NAN NAN 
ELAC2 Q9BQ52 15 NAN NAN 20.30 21.23 21.94 22.33 21.25 21.51 20.77 21.63 
ELAVL1 Q15717 9 23.14 23.84 23.04 23.73 24.16 23.91 23.52 23.45 23.27 23.29 
ELF4 Q99607 2 NAN NAN NAN NAN 18.82 18.83 NAN NAN NAN NAN 
ELMSAN1 Q6PJG2 42 NAN NAN 21.70 23.74 26.08 27.05 24.72 25.06 20.06 21.64 
ELOA Q14241 4 NAN NAN NAN NAN 19.22 19.40 19.32 NAN NAN NAN 
ELOC Q15369 4 NAN NAN NAN 21.94 20.50 20.00 NAN 20.36 NAN 20.17 
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EMX2 Q04743 7 NAN NAN 22.13 22.40 22.11 21.76 21.77 21.89 21.24 NAN 
ENGASE Q8NFI3 19 NAN NAN NAN NAN 22.41 23.17 21.62 21.89 20.56 21.15 
EP300 Q09472 40 20.61 19.71 22.70 22.68 25.46 25.67 23.80 23.33 21.28 21.95 
EPM2AIP1 Q7L775 9 NAN NAN NAN NAN 21.09 21.24 20.82 NAN NAN 20.78 
ERCC2 P18074 6 NAN NAN NAN 21.06 21.48 21.14 21.28 20.29 NAN 20.46 
ERCC3 P19447 14 NAN NAN NAN NAN 20.75 20.49 20.55 19.75 NAN 20.17 
ERCC4 Q92889 5 NAN NAN NAN NAN 18.82 NAN 19.05 18.74 NAN NAN 
ERH P84090 3 22.96 23.15 21.46 22.83 22.18 22.04 22.49 22.32 22.14 22.52 
ESD P10768 7 NAN NAN NAN NAN 22.09 21.90 21.75 21.70 NAN 21.30 
ESRRA P11474 11 NAN NAN 22.98 22.35 23.25 22.48 21.91 22.32 21.30 20.95 
ESS2 Q96DF8 20 NAN NAN NAN 22.23 24.06 24.28 23.57 22.95 20.65 21.10 
ETF1 P62495 7 NAN NAN NAN NAN 20.47 21.11 21.13 21.50 20.56 20.67 
ETS1 P14921 6 NAN NAN NAN NAN 19.93 20.81 NAN NAN NAN NAN 
ETV4 P43268 14 NAN NAN 21.65 21.71 22.83 23.10 22.00 21.59 NAN NAN 
ETV5 P41161 7 NAN NAN NAN NAN 22.07 22.31 21.41 21.47 NAN NAN 
ETV6 P41212 11 NAN 21.67 NAN 22.02 21.40 22.35 21.48 21.28 NAN 20.75 
EWSR1 Q01844 8 24.22 23.98 25.16 25.78 26.63 27.09 26.20 26.60 24.60 24.90 
EXOSC5 Q9NQT4 2 NAN NAN NAN NAN 19.88 20.19 19.54 19.37 NAN 19.36 
EYA3 Q99504 9 NAN NAN NAN NAN 21.29 21.40 21.06 20.86 NAN NAN 
FAM168A Q92567 6 NAN NAN NAN NAN 23.52 23.44 NAN NAN NAN NAN 
FAM207A Q9NSI2 6 NAN NAN NAN NAN 22.43 22.57 20.74 21.35 20.64 20.53 
FAM216A Q8WUB2 3 NAN NAN NAN NAN 19.04 19.50 NAN NAN NAN NAN 
FAM222B Q8WU58 4 NAN NAN NAN NAN 21.75 21.69 20.35 19.97 NAN NAN 
FAM64A Q9BSJ6 5 NAN NAN NAN NAN 19.49 19.69 19.54 19.25 NAN NAN 
FAM83H Q6ZRV2 14 NAN NAN NAN NAN 20.46 21.16 20.56 21.73 NAN 19.70 
FAM98A Q8NCA5 10 NAN NAN NAN 22.21 22.15 22.39 21.66 21.63 NAN 21.52 
FAM98B Q52LJ0 9 NAN NAN NAN 21.02 21.34 20.78 21.23 20.53 20.88 21.24 
FARSLA Q9Y285 11 NAN NAN NAN NAN 22.04 21.95 20.65 20.39 20.04 19.55 
FASN P49327 20 19.60 20.56 20.53 NAN NAN NAN 18.62 23.39 NAN NAN 
FBL P22087 14 23.55 23.52 24.43 25.26 25.59 25.89 25.17 25.01 23.94 24.45 
FBRS Q9HAH7 13 NAN NAN 22.04 23.03 24.92 25.08 23.63 23.67 NAN 21.98 
FBRSL1 Q9HCM7 21 NAN NAN 21.57 21.58 24.59 24.71 23.61 23.02 NAN NAN 
FBXO7 Q9Y3I1 4 NAN NAN NAN NAN 19.54 NAN NAN 19.42 19.56 19.41 
FCGRT P55899 3 22.42 NAN 21.84 22.21 NAN NAN NAN NAN NAN NAN 
FEN1 P39748 8 NAN NAN NAN 21.87 21.58 22.07 22.39 21.51 21.61 21.68 
FGF2 P09038 5 NAN NAN NAN 22.78 22.57 22.80 22.73 22.96 23.07 23.52 
FHL3 Q13643 12 NAN NAN 22.81 23.73 24.51 24.53 23.71 23.71 22.72 23.21 
FIP1L1 Q6UN15 5 NAN NAN NAN NAN 19.32 NAN 19.79 19.17 20.24 NAN 
FKBP1A P62942 5 NAN 21.04 22.42 23.19 23.20 22.95 22.57 22.49 22.80 22.68 
FLI1 Q01543 10 NAN NAN NAN 21.18 22.56 23.17 21.31 21.43 19.76 NAN 
FLNB O75369 17 NAN NAN NAN NAN NAN NAN 18.78 22.23 NAN NAN 
FLNC Q14315 58 NAN NAN 23.41 23.99 21.87 22.33 23.55 22.87 24.66 24.71 
FOS P01100 6 NAN NAN 22.06 NAN 20.70 20.93 20.62 20.17 NAN NAN 
FOSB P53539 5 NAN NAN 22.23 22.03 22.32 21.87 21.86 22.01 NAN 20.58 
FOSL1 P15407 11 NAN NAN 22.31 23.33 25.94 25.88 24.16 23.93 22.66 23.11 
FOSL2 P15408 8 NAN NAN NAN 21.75 23.47 23.67 22.50 22.62 21.18 21.89 
FOXC2 Q99958 6 NAN NAN NAN NAN 19.31 NAN 18.81 19.01 NAN NAN 
FOXF2 Q12947 3 NAN NAN NAN NAN 19.18 19.48 NAN 18.56 NAN NAN 
FOXJ2 Q9P0K8 8 NAN NAN 22.07 22.91 23.42 23.32 22.94 22.80 NAN 22.11 
FOXJ3 Q9UPW0 8 NAN NAN NAN 21.93 22.96 23.37 22.22 22.32 NAN NAN 
FOXL2 P58012 5 NAN NAN NAN NAN 21.10 22.03 NAN 20.38 NAN 20.46 
FOXO3 O43524 2 NAN NAN NAN NAN 18.84 18.51 NAN NAN NAN NAN 
FOXP1 Q9H334 16 NAN NAN NAN 22.09 23.44 23.45 22.54 22.18 NAN NAN 
FOXP4 Q8IVH2 9 NAN NAN 20.73 21.63 22.56 22.30 21.95 21.37 NAN 20.64 
FPGS Q05932 5 NAN NAN NAN NAN 20.87 21.13 NAN NAN NAN NAN 
FRG1 Q14331 8 NAN NAN 20.88 21.64 21.52 21.55 22.03 21.34 21.14 21.22 
FSCN1 Q16658 9 21.39 21.38 22.20 21.80 21.58 21.12 21.86 22.19 21.99 22.18 
FTO Q9C0B1 13 NAN NAN 20.95 20.20 20.52 20.37 20.72 20.32 NAN 20.68 
FUBP1 Q96AE4 28 25.20 26.28 25.20 25.43 25.61 25.72 25.64 25.56 24.67 24.72 
FUBP3 Q96I24 24 NAN 23.13 23.03 24.05 24.22 24.04 24.72 24.52 23.32 22.87 
FUS P35637 12 24.56 25.22 25.19 25.48 26.04 26.08 26.09 25.95 24.52 24.49 
FXR1 P51114 4 NAN 21.33 NAN NAN NAN 19.70 20.68 19.53 20.54 20.83 
G3BP Q13283 4 20.28 21.09 NAN NAN 18.53 NAN 19.72 19.87 NAN NAN 
GALK1 P51570 7 NAN NAN NAN NAN 21.77 21.30 21.10 20.66 NAN NAN 
GAR1 Q9NY12 3 NAN NAN NAN NAN 22.07 22.07 20.88 21.05 20.02 20.21 
GATA2 P23769 11 NAN NAN 22.33 22.29 22.90 23.00 23.00 23.19 21.00 21.63 
GATA6 Q92908 7 NAN NAN NAN 21.78 22.26 22.48 21.77 21.69 NAN NAN 
GATAD2A Q86YP4 23 24.26 23.35 22.85 23.82 23.64 23.75 23.63 23.36 22.73 23.09 
GATAD2B Q8WXI9 16 22.06 21.89 21.91 23.27 24.02 23.83 23.48 22.95 22.09 22.47 
GBE1 P32455 27 NAN NAN 24.21 25.62 25.78 25.96 25.53 25.60 24.84 25.16 
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GDI2 P50395 12 NAN 19.01 20.82 NAN 20.06 20.33 21.03 23.57 19.12 20.25 
GFPT1 Q06210 4 NAN NAN NAN NAN NAN NAN NAN 19.75 20.49 20.07 
GGCT  O75223 10 22.16 22.39 24.31 21.76 NAN 19.73 21.52 25.18 21.52 21.52 
GGH Q92820 4 NAN NAN NAN NAN NAN NAN 20.13 20.88 NAN NAN 
GIPC1 O14908 12 NAN NAN 21.03 22.05 22.57 22.25 21.87 22.15 NAN 20.53 
GIT2 Q14161 3 NAN NAN NAN NAN 18.95 19.56 NAN NAN NAN NAN 
GLIS3 Q8NEA6 5 NAN NAN NAN NAN 20.60 NAN 20.37 20.14 NAN NAN 
GLRX3 O76003 6 NAN NAN NAN 21.04 20.52 20.78 20.88 20.87 20.09 20.48 
GLUL P15104 15 22.84 24.23 20.00 19.89 19.10 19.62 20.62 26.42 NAN NAN 
GMPS P49915 19 20.80 21.82 NAN 21.40 22.82 22.73 22.34 21.86 22.01 22.29 
GNB2 P62879 5 20.48 NAN NAN NAN 20.21 20.60 20.15 20.35 20.65 20.66 
GNL3L Q9NVN8 12 NAN NAN NAN NAN 22.32 23.01 21.17 20.37 NAN NAN 
GOLGA2 Q08379 18 NAN NAN 21.89 22.41 21.39 21.75 22.80 21.90 21.08 21.68 
GPANK1 O95872 11 NAN NAN NAN NAN 23.24 22.52 20.82 20.56 NAN NAN 
GPATCH2L Q9NWQ4 4 NAN NAN NAN NAN 19.37 19.43 NAN NAN NAN NAN 
GPATCH4 Q5T3I0 4 NAN NAN NAN NAN 18.52 18.36 NAN NAN NAN NAN 
GPS2 Q13227 4 NAN NAN NAN NAN 19.67 20.08 19.45 19.44 NAN NAN 
GPSM1 Q86YR5 11 NAN NAN NAN NAN 21.37 21.71 20.37 20.81 20.55 NAN 
GRB2 P62993 10 NAN NAN 23.35 23.52 23.47 23.79 23.28 23.32 22.36 22.69 
GRWD1 Q9BQ67 14 NAN NAN 21.92 23.01 24.14 24.79 23.05 23.19 20.48 22.39 
GSC P56915 4 NAN NAN NAN 20.64 21.12 21.25 NAN 20.58 NAN NAN 
GSDMA Q96QA5 13 21.32 20.71 22.21 21.48 20.53 19.52 21.92 24.59 23.14 21.72 
GSE1 Q14687 39 NAN NAN 23.99 24.86 25.42 25.58 24.92 24.24 21.50 22.68 
GSTM3 P21266 6 NAN NAN NAN NAN NAN NAN 20.45 20.85 22.84 22.60 
GSTP1 P09211 13 22.63 NAN 23.25 22.56 22.48 23.23 22.54 25.33 22.83 22.64 
GTF2B Q00403 8 NAN NAN NAN 21.81 21.93 22.78 21.95 22.05 21.21 21.79 
GTF2E1 P29083 6 NAN NAN NAN NAN 20.04 20.56 19.94 19.24 NAN NAN 
GTF2E2 P29084 6 NAN NAN NAN NAN 19.65 19.91 19.32 NAN NAN NAN 
GTF2F1 P35269 10 NAN NAN 20.73 21.65 21.71 21.85 21.30 21.03 21.78 21.92 
GTF2F2 P13984 5 NAN NAN NAN 21.77 21.16 20.99 21.68 20.90 NAN 21.35 
GTF2H1 P32780 5 NAN NAN NAN NAN 20.63 20.33 20.79 20.40 NAN NAN 
GTF2H2C Q6P1K8 6 NAN NAN NAN 20.83 20.87 20.38 20.93 20.43 20.76 20.13 
GTF2H3 Q13889 4 NAN NAN NAN NAN 20.39 20.36 20.47 NAN NAN NAN 
GTF2H4 Q92759 3 NAN NAN NAN NAN NAN 19.70 18.43 18.34 NAN NAN 
GTF2I P78347 29 25.19 24.29 23.19 24.00 23.59 23.74 23.98 23.30 23.49 23.96 
GTF3C1 Q12789 24 21.55 21.62 NAN 21.32 20.96 21.30 22.29 21.16 21.40 21.12 
GTF3C3 Q9Y5Q9 16 20.63 20.85 NAN 21.04 20.53 20.49 21.50 20.55 NAN 20.35 
GTF3C4 Q9UKN8 16 20.59 NAN NAN NAN 21.46 21.68 22.23 20.88 NAN 21.29 
GTF3C5 Q9Y5Q8 8 NAN NAN NAN 20.26 20.14 20.46 20.95 20.15 20.40 20.62 
GTPBP4 Q9BZE4 9 NAN 21.63 NAN 21.21 21.35 21.79 21.35 20.17 21.00 20.90 
H1F0 P07305 5 21.50 22.13 23.20 24.56 22.13 22.27 23.66 23.81 25.01 25.13 
H1FX Q92522 5 22.21 21.09 21.11 22.19 20.71 20.50 22.11 21.74 22.76 22.64 
H2AFV Q71UI9 4 25.11 24.45 24.56 25.60 23.61 24.59 24.89 24.90 24.04 25.21 
H2AFX P16104 5 28.80 28.46 28.67 29.71 29.85 29.54 25.10 29.79 31.04 31.10 
H2AFY O75367 16 22.51 24.19 25.36 26.14 26.41 26.34 26.40 25.70 26.37 26.55 
H2AFY2 Q9P0M6 12 NAN NAN 21.96 23.30 23.07 22.91 23.77 22.66 23.78 23.95 
H3F3B P84243 4 22.96 21.85 23.46 24.34 25.81 25.78 26.39 25.35 25.29 25.53 
HACD3 Q9P035 2 NAN NAN NAN NAN 18.21 NAN 19.98 19.78 20.82 20.99 
HAT1 O14929 10 NAN NAN 20.85 21.54 21.20 21.42 22.08 21.63 21.28 21.39 
HDAC1 Q13547 15 21.65 NAN NAN 22.42 23.53 23.92 23.06 22.77 21.97 22.00 
HDAC2 Q92769 18 25.41 24.23 23.24 24.99 25.16 25.24 24.69 24.26 23.76 23.78 
HDAC3 O15379 10 NAN NAN NAN NAN 21.71 21.43 21.09 21.38 NAN 20.43 
HDAC4 P56524 5 NAN NAN NAN NAN 19.61 20.04 19.63 NAN NAN NAN 
HDAC7 Q8WUI4 9 NAN NAN NAN NAN 21.02 21.45 20.72 21.34 NAN 19.89 
HDGF P51858 12 22.49 NAN NAN 22.91 22.25 22.39 22.58 22.05 22.18 22.77 
HDGFRP3 Q9Y3E1 4 20.36 NAN NAN NAN 20.19 NAN 21.02 20.73 NAN 21.04 
HDLBP Q00341 14 NAN NAN NAN NAN NAN NAN 20.97 20.78 21.36 21.03 
HDX Q7Z353 7 NAN NAN NAN NAN 21.49 21.39 20.85 NAN NAN NAN 
HEATR3 Q7Z4Q2 3 NAN NAN NAN NAN NAN NAN 19.49 18.28 NAN NAN 
HELLS Q9NRZ9 6 21.15 20.98 NAN NAN NAN NAN NAN NAN NAN NAN 
HES7 Q9BYE0 3 NAN NAN NAN NAN NAN 19.80 20.11 20.20 NAN NAN 
HIC1 Q14526 7 NAN NAN NAN NAN 20.43 20.57 20.37 20.08 NAN NAN 
HIKESHI Q53FT3 3 NAN NAN NAN NAN 20.82 20.90 NAN 19.25 NAN NAN 
HINT1 P49773 3 NAN NAN NAN NAN 22.07 21.55 21.71 21.72 NAN 21.38 
HIPK1 Q86Z02 16 NAN NAN NAN NAN 23.68 23.91 22.24 22.58 NAN NAN 
HIPK2 Q9H2X6 18 NAN NAN NAN NAN 23.84 23.56 20.97 20.32 NAN NAN 
HIST1H1A Q02539 5 NAN NAN NAN 21.78 20.29 20.34 20.86 NAN 21.94 21.59 
HIST1H1B P16401 6 26.61 26.54 26.85 27.97 25.46 25.64 26.89 26.07 27.32 27.65 
HIST1H1C P16403 10 27.22 26.95 26.79 28.48 25.37 23.40 27.11 24.72 27.90 27.83 
HIST1H1D P16402 9 23.66 23.12 22.29 23.62 22.03 21.57 22.88 22.76 23.73 23.80 
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HIST1H2BF P62807 10 30.72 29.72 30.59 31.30 31.00 31.08 31.42 31.13 31.48 32.32 
HIST1H2BJ P06899 10 NAN NAN 27.03 28.41 24.60 23.12 26.45 26.41 26.59 27.50 
HIST1H3A P68431 5 NAN 26.07 26.16 25.24 26.07 26.37 27.37 26.30 25.83 26.48 
HIST1H4H P62805 12 30.52 29.79 30.77 31.99 30.65 30.94 31.43 31.30 31.74 32.33 
HIST2H2AC Q16777 4 20.41 27.64 29.01 25.67 26.72 27.72 28.99 27.75 29.17 28.28 
HLTF Q14527 39 20.16 NAN 23.26 23.76 24.35 24.71 23.68 23.93 23.31 24.17 
HLX Q14774 3 NAN NAN NAN NAN 20.31 19.91 19.37 19.29 NAN NAN 
HMBS P08397 2 NAN NAN NAN NAN 18.28 18.73 18.16 18.19 NAN NAN 
HMCES Q96FZ2 7 NAN NAN NAN NAN 20.61 20.63 NAN 20.53 NAN NAN 
HMG20A Q9NP66 9 NAN 20.96 NAN 21.39 23.51 23.88 22.94 22.49 20.32 21.20 
HMG20B Q9P0W2 15 NAN NAN 21.74 23.45 22.69 23.12 23.30 23.39 21.54 22.43 
HMGA1 P17096 5 23.52 23.84 23.54 24.82 23.21 23.05 23.73 23.37 24.31 24.23 
HMGA2 P52926 3 21.13 20.94 NAN 19.92 NAN 19.17 19.40 19.53 20.36 19.71 
HMGB1 P09429 7 24.46 24.20 24.57 25.19 23.61 23.54 24.49 23.87 24.16 24.36 
HMGB2 P26583 4 23.67 NAN NAN NAN 22.33 21.92 23.32 22.58 22.93 23.00 
HMGB3 O15347 4 22.72 NAN NAN NAN 21.43 21.12 22.32 21.11 21.46 NAN 
HMGN1 P05114 5 23.52 20.93 20.37 21.69 21.62 21.71 22.89 22.31 23.76 23.29 
HMGN3 Q15651 3 20.31 NAN NAN NAN 19.38 20.04 NAN 20.19 NAN 20.59 
HNRNPA0 Q13151 11 24.23 25.30 24.59 24.83 26.44 26.99 25.58 25.88 24.55 24.46 
HNRNPA2B1 P22626 24 28.40 28.86 27.16 28.05 28.27 28.44 28.60 28.21 27.98 27.97 
HNRNPA3 P51991 15 25.95 26.58 25.00 25.77 25.72 25.89 25.80 25.52 25.42 25.56 
HNRNPAB Q99729 10 24.26 24.75 23.24 23.81 23.49 23.12 24.12 22.86 23.16 23.20 
HNRNPC P07910 20 27.38 27.76 24.83 25.92 24.72 24.48 26.40 24.92 26.14 25.91 
HNRNPDL O14979 9 23.29 24.12 22.51 23.97 24.50 24.56 24.18 23.64 23.85 23.92 
HNRNPH1 P31943 19 26.86 27.56 26.26 26.89 27.56 27.80 27.38 27.36 26.99 26.83 
HNRNPH2 P55795 16 22.03 21.72 21.77 22.29 23.72 23.91 23.47 23.44 23.52 23.18 
HNRNPH3 P31942 11 24.32 24.58 22.60 22.87 24.70 24.86 24.46 24.26 23.79 23.92 
HNRNPK P14866 26 27.89 28.91 27.13 27.71 27.06 27.03 27.20 26.58 26.73 26.77 
HNRNPLL Q8WVV9 15 20.72 NAN NAN 22.13 22.32 22.66 22.10 22.08 21.71 22.45 
HNRNPM P52272 36 27.09 27.41 26.05 26.95 27.18 27.57 27.82 27.30 27.11 27.11 
HNRNPR O43390 20 23.49 24.33 NAN 22.06 22.59 22.77 23.57 22.82 23.17 23.16 
HNRNPU Q00839 27 26.68 27.13 25.52 26.25 26.11 26.21 26.45 25.89 26.01 26.27 
HNRNPUL1 Q9BUJ2 28 23.83 24.29 25.35 25.67 27.32 27.48 25.99 26.19 24.48 25.04 
HNRNPUL2 Q1KMD3 16 21.75 22.04 21.41 22.74 22.85 23.06 23.40 22.91 23.25 23.00 
HNRPA1 P09651 21 28.10 28.72 26.95 27.82 27.93 27.99 28.03 27.71 27.22 27.36 
HNRPD Q14103 11 24.91 25.67 22.37 23.60 24.68 24.52 24.93 23.98 24.25 24.21 
HNRPF P52597 15 24.95 25.60 24.83 24.88 26.08 26.09 25.97 25.57 24.99 24.48 
HNRPK P61978 26 21.54 21.09 NAN NAN 21.62 22.40 22.80 21.07 22.47 NAN 
HOMEZ Q8IX15 5 NAN NAN 20.76 NAN 20.13 19.92 19.58 19.14 NAN 19.93 
HOXA10 P31260 11 NAN NAN NAN NAN 22.66 22.85 22.24 22.13 NAN NAN 
HOXA11 P31270 7 NAN NAN NAN NAN 23.28 23.59 NAN NAN NAN NAN 
HOXA9 P31269 6 NAN NAN NAN NAN 21.37 21.42 NAN NAN NAN NAN 
HOXB4 P17483 8 NAN NAN NAN 21.00 23.06 23.31 21.66 21.17 NAN NAN 
HOXB5 P09067 4 NAN NAN NAN NAN 20.31 20.05 NAN 20.21 NAN NAN 
HOXB6 P17509 7 NAN NAN NAN NAN 22.03 22.19 21.16 21.19 NAN NAN 
HOXB7 P09629 7 NAN NAN NAN NAN 23.69 24.06 21.69 21.52 NAN 20.13 
HOXC10 Q9NYD6 12 NAN NAN 20.55 21.70 23.43 22.65 21.75 21.73 NAN 20.37 
HOXC11 O43248 10 NAN NAN NAN 22.34 21.38 21.78 21.86 21.60 NAN 21.30 
HOXC5 Q00444 7 NAN NAN NAN NAN 22.04 22.17 21.63 21.77 NAN NAN 
HOXC6 P09630 12 NAN NAN NAN 22.59 25.59 25.27 22.81 22.67 NAN NAN 
HOXC8 P31273 11 NAN NAN 20.65 21.76 23.74 24.40 22.20 22.13 20.69 21.09 
HOXC9 P31274 12 NAN NAN 22.58 23.67 24.77 25.09 23.46 23.75 NAN 21.89 
HOXD3 P31249 3 NAN NAN NAN NAN 21.09 20.39 20.23 19.99 NAN NAN 
HOXD9 P28356 10 NAN NAN NAN NAN 22.06 22.19 21.12 20.92 NAN NAN 
HP1BP3 Q5SSJ5 19 20.08 NAN 23.81 25.82 23.17 24.00 25.42 24.55 25.84 26.51 
HSD17B12 Q53GQ0 2 NAN NAN NAN NAN NAN NAN 18.65 19.55 NAN NAN 
HSP90AA1 P07900 23 22.88 22.45 22.15 23.26 24.04 24.02 23.21 24.07 22.81 23.13 
HSP90AB1 P08238 25 25.55 25.40 23.58 24.89 25.40 25.72 25.40 25.91 24.94 25.34 
HSP90B1 P14625 6 NAN NAN NAN NAN 20.54 20.20 19.72 19.91 NAN NAN 
HSPA1A P0DMV8 38 22.69 22.33 27.02 28.15 30.65 31.22 27.86 28.66 26.63 27.35 
HSPA2 P54652 22 NAN NAN 21.36 21.79 22.75 23.38 22.72 22.69 21.99 21.88 
HSPA4 P34932 13 20.90 NAN NAN NAN 20.89 20.48 20.35 21.28 NAN 20.09 
HSPA5 P11021 22 NAN 20.98 23.11 21.21 20.49 20.90 21.35 25.25 22.74 22.74 
HSPA8 P11142 38 25.66 25.32 27.75 28.57 30.56 30.69 28.70 28.83 27.03 27.99 
HSPB1 P04792 17 22.06 21.35 27.59 27.29 26.91 27.56 27.28 27.29 27.36 27.53 
HSPB6 O14558 9 NAN NAN 24.20 25.43 24.09 24.26 23.81 24.02 23.62 23.79 
HSPC148 Q9P013 2 NAN NAN NAN NAN NAN 18.23 18.86 NAN 18.45 18.41 
HSPC152 Q9UI30 5 NAN 20.28 NAN 20.77 22.66 23.19 21.70 22.29 20.96 NAN 
HSPG2 P98160 19 NAN NAN NAN 20.82 19.96 20.46 19.96 19.67 20.89 23.17 
HSPH1 Q92598 8 NAN NAN NAN NAN 20.77 20.67 20.88 20.37 NAN 20.82 
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IDE P14735 31 NAN NAN 18.94 NAN NAN NAN 16.92 26.01 NAN 17.05 
IGBP1 P78318 4 NAN NAN NAN NAN 19.51 19.88 19.26 18.93 NAN NAN 
IGF2BP1 Q9NZI8 12 23.89 24.56 NAN NAN NAN NAN NAN NAN NAN NAN 
ILF2 Q12905 11 23.21 24.14 22.88 22.96 22.40 22.45 22.81 22.97 23.12 23.10 
ILF3 Q12906 21 24.22 25.02 22.55 23.36 22.55 22.45 23.68 22.64 23.69 23.48 
ILKAP Q9H0C8 5 NAN NAN NAN NAN NAN NAN 19.58 19.11 NAN NAN 
IMPDH2 P12268 4 NAN NAN NAN NAN NAN 19.26 20.03 20.24 20.13 NAN 
INCENP Q9NQS7 14 22.40 NAN NAN NAN 20.80 20.33 22.00 21.66 NAN 21.05 
INTS10 Q9NVR2 20 NAN NAN 20.23 20.69 23.44 23.63 22.99 21.89 20.07 21.30 
INTS13 Q9NVM9 11 NAN NAN NAN 22.23 21.42 21.53 21.66 21.55 20.56 20.97 
INTS14 Q96SY0 9 NAN NAN NAN NAN 21.45 21.07 21.15 20.19 NAN 19.62 
INTS4 Q96HW7 9 NAN NAN NAN NAN 20.72 20.29 20.29 20.45 NAN NAN 
INTS5 Q6P9B9 14 NAN NAN NAN NAN 23.50 22.63 21.51 21.24 NAN 20.07 
INTS8 Q75QN2 7 NAN NAN NAN NAN 20.16 20.90 20.31 20.12 NAN NAN 
INTS9 Q9NV88 6 NAN NAN NAN NAN 20.08 20.67 20.45 19.78 NAN NAN 
IPO11 Q9UI26 16 NAN 20.83 21.44 22.12 21.42 22.49 21.76 21.08 20.13 20.19 
IPO13 O94829 6 NAN NAN NAN NAN 20.68 20.22 19.60 19.57 NAN 19.19 
IPO7 O95373 18 NAN NAN 23.70 23.07 22.30 22.15 22.38 22.00 23.04 22.93 
IPO8 O15397 14 21.17 NAN NAN NAN 21.88 22.44 21.81 21.10 20.75 NAN 
IPO9 Q96P70 6 NAN NAN NAN NAN 19.94 19.72 NAN 19.64 NAN NAN 
IRF2BP1 Q8IU81 20 NAN NAN 21.75 23.66 23.20 23.13 23.85 23.48 22.64 22.50 
IRF2BP2 Q7Z5L9 11 20.39 NAN NAN 21.08 21.08 20.93 22.17 21.05 NAN 19.97 
IRF2BPL Q9H1B7 7 NAN NAN NAN NAN NAN NAN 18.86 18.57 NAN NAN 
IRF9 Q00978 6 NAN NAN NAN NAN 21.06 21.00 20.88 NAN NAN NAN 
IRX2 Q9BZI1 8 NAN NAN NAN NAN 21.18 21.24 21.21 21.29 NAN NAN 
IRX5 P78411 11 NAN NAN NAN NAN 22.18 22.26 22.32 23.04 NAN 21.78 
ISG15 P05161 6 NAN NAN 22.92 22.20 22.80 23.10 22.95 22.93 23.77 23.27 
ITCH Q96J02 6 NAN NAN NAN NAN 20.70 21.17 NAN NAN NAN NAN 
IWS1 Q96ST2 3 NAN NAN NAN NAN 19.49 19.62 NAN 19.47 NAN NAN 
JMJD1C Q15652 15 20.37 19.67 NAN 19.65 21.74 22.55 20.66 20.09 NAN NAN 
JUN P05412 4 NAN NAN NAN NAN 22.28 22.35 20.84 20.43 NAN 20.94 
JUNB P17275 13 NAN NAN 24.24 24.67 26.39 26.47 25.02 24.81 23.57 23.86 
JUND P17535 7 NAN NAN NAN NAN 22.70 23.02 22.02 21.90 NAN 21.06 
KAT2A Q92830 3 NAN NAN NAN NAN 19.77 19.69 NAN NAN NAN NAN 
KAT7 O95251 7 NAN NAN NAN NAN 21.35 20.73 20.49 20.41 NAN 20.94 
KCTD5 Q9NXV2 5 NAN NAN NAN NAN 19.61 20.09 20.07 20.49 NAN NAN 
KDM1A O60341 31 24.11 23.43 23.14 24.43 24.82 24.73 24.79 24.39 22.43 23.64 
KDM2A Q9Y2K7 10 NAN NAN 20.66 20.31 21.28 21.33 21.67 21.13 21.48 21.34 
KDM2B Q8NHM5 8 NAN NAN NAN NAN 20.34 20.32 20.28 20.30 NAN NAN 
KDM3B Q7LBC6 5 NAN NAN NAN NAN 18.94 19.76 19.64 19.04 NAN 18.81 
KDM4A O75164 5 NAN NAN NAN NAN 20.07 20.77 19.61 NAN NAN NAN 
KDM4B O94953 19 NAN NAN 21.38 21.97 21.77 22.83 21.10 20.94 NAN 21.05 
KDM5B Q9UGL1 10 NAN NAN NAN NAN 19.91 19.63 20.10 19.17 19.96 19.70 
KDM6B O15054 22 NAN NAN NAN NAN 23.41 24.03 21.37 21.01 NAN NAN 
KHDC4 Q7Z7F0 4 NAN NAN NAN NAN 20.83 19.88 21.09 21.05 19.81 NAN 
KHDRBS1 Q07666 8 24.30 24.93 24.90 25.30 25.24 25.46 24.38 24.71 24.01 24.51 
KHDRBS3 O75525 3 NAN NAN NAN NAN 19.56 19.45 20.04 19.36 NAN NAN 
KHSRP Q92945 34 25.56 26.07 26.45 26.60 26.60 26.34 26.82 26.87 25.32 25.55 
KIAA1958 Q8N8K9 2 NAN NAN NAN NAN 18.17 18.48 NAN NAN NAN NAN 
KIF20A O95235 24 23.45 23.22 NAN 22.05 22.81 23.20 24.34 24.00 23.61 22.60 
KIF22 Q14807 12 22.20 22.53 21.62 22.50 22.22 22.17 22.72 22.08 21.25 21.80 
KIF23 Q02241 7 NAN NAN NAN NAN 20.01 NAN 20.78 20.52 NAN NAN 
KIF4A O95239 24 21.20 NAN NAN 21.09 21.26 20.91 22.86 21.41 19.79 20.19 
KIFC1 Q9BW19 8 NAN NAN NAN NAN NAN 19.28 19.77 20.13 NAN 19.49 
KLF16 Q9BXK1 5 NAN NAN NAN NAN 21.92 22.04 21.50 22.02 NAN 21.67 
KLF4 O43474 19 NAN NAN 29.00 29.08 29.56 29.75 28.98 29.54 28.82 28.95 
KLHL21 Q9UJP4 7 NAN NAN NAN NAN 20.14 21.08 19.58 19.39 NAN NAN 
KPNA1 P52294 14 NAN NAN NAN NAN 22.51 22.62 22.65 22.56 22.87 22.72 
KPNA2 P52292 18 22.48 23.29 23.94 23.58 23.73 23.76 24.12 23.40 23.39 23.40 
KPNA3 O00505 13 NAN NAN 21.97 22.67 23.32 23.47 23.12 22.76 22.64 22.60 
KPNA4 O00629 10 NAN NAN NAN NAN 21.42 21.50 22.14 21.84 22.17 22.49 
KPNA6 O60684 16 NAN NAN 22.40 23.40 25.32 25.31 24.95 24.47 24.68 24.83 
KPNB1 Q14974 15 NAN NAN 22.62 21.66 21.62 21.55 22.77 22.17 22.83 23.10 
KRT18 P05783 12 22.27 22.39 NAN NAN 21.15 21.28 19.85 NAN NAN NAN 
L1TD1 Q5T7N2 11 22.97 22.96 NAN NAN NAN NAN NAN NAN NAN NAN 
LAMP1 P11279 5 NAN NAN NAN NAN NAN NAN NAN 22.12 20.06 19.80 
LANCL1 O43813 12 NAN NAN NAN 21.98 22.76 22.94 22.17 22.54 22.45 22.12 
LANCL2 Q9NS86 4 NAN NAN NAN NAN 19.89 19.18 NAN 19.45 NAN NAN 
LASP1 Q14847 14 20.82 20.74 23.26 24.50 24.75 23.83 24.55 23.75 24.06 23.98 
LDB1 Q86U70 12 NAN 21.76 23.13 23.32 24.24 25.13 23.78 23.80 21.99 22.48 
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LENG1 Q96BZ8 5 NAN NAN NAN NAN 20.43 20.33 19.37 NAN NAN NAN 
LENG8 Q96PV6 22 NAN NAN NAN 19.71 24.04 24.12 21.74 21.69 NAN NAN 
LGALS3 P17931 5 NAN NAN 22.56 20.73 22.81 23.30 22.58 22.70 21.73 22.47 
LIG3 P49916 8 NAN NAN NAN NAN 19.93 19.98 19.81 20.14 NAN NAN 
LIN28A Q6UXM1 6 23.62 23.92 NAN NAN NAN NAN NAN NAN NAN NAN 
LMCD1 Q9NZU5 8 NAN NAN NAN NAN 20.62 20.48 20.26 19.92 NAN 20.36 
LMNB1 P20700 46 24.59 23.64 25.56 27.01 25.70 25.44 27.84 26.71 28.54 28.45 
LMNB2 Q03252 43 21.46 21.01 25.87 27.57 25.71 25.49 28.04 26.65 28.91 28.80 
LMO4 P61968 7 NAN NAN NAN NAN 20.89 21.14 20.36 NAN NAN NAN 
LPXN O60711 4 NAN NAN NAN NAN NAN 18.99 19.82 19.58 20.29 NAN 
LRIF1 Q5T3J3 12 NAN NAN NAN 21.79 22.00 21.70 21.55 21.50 21.25 20.97 
LRRC41 Q15345 7 NAN NAN NAN NAN 20.37 20.08 20.22 19.99 NAN NAN 
LRRC59 Q96AG4 10 NAN NAN 22.23 21.58 21.04 20.32 22.16 21.40 22.76 23.13 
LRWD1 Q9UFC0 11 NAN 21.73 NAN NAN 22.43 22.52 21.70 20.88 21.51 NAN 
LUC7L Q9NQ29 9 NAN NAN NAN NAN 19.75 19.39 20.78 19.55 NAN 19.41 
LUC7L2 Q9Y383 9 21.26 21.55 21.04 22.22 21.62 21.41 22.95 21.73 22.56 22.62 
LYPLA2 O95372 3 NAN NAN NAN NAN 21.36 21.12 20.79 20.80 NAN NAN 
MAB21L1 Q13394 13 NAN NAN 20.66 22.26 23.09 23.77 22.78 22.26 21.05 22.13 
MAD1L1 Q9Y6D9 13 NAN NAN NAN NAN 21.60 21.38 20.99 20.84 20.74 20.45 
MAFF Q9ULX9 6 NAN NAN 23.08 23.82 23.65 24.01 23.69 23.92 22.01 22.94 
MAFG O15525 4 NAN NAN NAN NAN 20.41 20.49 20.74 19.98 NAN NAN 
MAFK O60675 5 NAN NAN NAN NAN 20.92 20.73 21.32 20.86 NAN 20.35 
MAGED1 Q9Y5V3 9 NAN NAN NAN 19.23 21.70 22.51 NAN 19.76 19.87 19.84 
MAGED4 Q96JG8 7 NAN NAN NAN NAN 19.78 19.38 NAN 18.80 NAN NAN 
MAGOHB Q96A72 3 NAN NAN NAN NAN 20.81 20.81 21.26 20.74 21.25 20.89 
MAML1 Q92585 24 NAN NAN NAN 20.51 23.92 24.95 22.69 22.53 NAN NAN 
MAML2 Q8IZL2 10 NAN NAN NAN NAN 21.45 22.12 NAN 20.05 NAN NAN 
MAMLD1 Q13495 7 NAN NAN NAN NAN 21.57 21.65 20.26 20.73 NAN NAN 
MAP2K3 P46734 6 NAN NAN NAN NAN 19.05 19.60 19.39 NAN NAN NAN 
MAPK1 P28482 17 NAN NAN 23.19 23.56 23.83 23.87 23.24 23.42 23.43 23.01 
MAPK14 Q16539 8 NAN NAN NAN NAN 21.55 21.62 21.04 21.32 NAN NAN 
MAPKAPK3 Q16644 2 NAN NAN NAN NAN 19.15 19.25 NAN NAN NAN NAN 
MAPRE1 Q15691 6 NAN NAN NAN NAN 20.58 20.84 21.16 20.51 20.86 20.58 
MARCH1 Q9H992 12 NAN NAN NAN NAN 21.81 21.65 NAN NAN NAN NAN 
MAT2A P31153 4 20.37 NAN NAN NAN 20.24 19.98 20.19 19.63 20.32 19.99 
MATR3 P43243 28 26.27 26.37 24.00 24.16 23.26 23.52 25.13 23.66 25.10 25.08 
MAU2 Q9Y6X3 12 NAN NAN NAN 22.07 24.06 24.33 22.59 22.23 20.11 20.91 
MAX P61244 8 NAN NAN 23.23 24.00 25.00 25.29 23.58 23.59 22.57 22.52 
MAZ P56270 8 NAN NAN NAN NAN 20.01 20.21 20.25 19.90 NAN NAN 
MBD1 Q9UIS9 12 21.55 NAN 22.57 23.48 23.20 23.21 22.43 22.32 22.79 22.90 
MBD2 Q9UBB5 7 NAN NAN NAN 21.66 21.30 22.18 21.50 20.96 NAN 21.99 
MBD3 O95983 8 21.63 NAN NAN NAN 20.74 21.80 20.05 20.46 19.79 19.93 
MBNL1 Q9NR56 12 NAN NAN 25.66 23.51 23.63 23.85 23.88 23.93 22.76 22.90 
MCM2 P49736 10 21.38 21.50 NAN NAN NAN NAN 20.82 NAN NAN NAN 
MCM3 P25205 16 21.87 22.36 NAN NAN 20.38 20.43 22.01 20.66 21.09 21.35 
MCM4 P33991 8 NAN NAN NAN NAN NAN NAN 20.38 19.53 NAN 19.89 
MCM6 Q14566 8 NAN NAN NAN NAN NAN 19.04 20.83 19.81 NAN NAN 
MCM7 P33993 25 23.51 23.17 21.75 21.79 23.22 22.82 23.75 22.90 22.24 21.98 
MCMBP Q9BTE3 16 NAN NAN 22.15 22.17 21.66 21.71 21.42 21.01 NAN NAN 
MECP2 P51608 12 NAN NAN NAN 21.95 21.39 21.28 21.75 21.45 22.00 21.86 
MED12 Q93074 39 NAN NAN NAN 19.85 24.51 23.99 20.92 20.80 NAN 18.18 
MED14 O60244 7 NAN NAN NAN NAN 20.99 20.36 18.76 19.32 NAN NAN 
MED15 Q96RN5 13 NAN NAN 19.89 22.15 23.90 23.93 22.46 22.25 19.65 19.94 
MED23 Q9ULK4 22 NAN NAN 19.99 20.62 23.79 23.87 22.90 22.72 NAN 22.00 
MED24 O75448 3 NAN NAN NAN NAN 19.15 19.49 19.42 NAN NAN NAN 
MEF2C Q06413 6 NAN NAN NAN 21.19 21.86 21.92 21.67 20.71 NAN NAN 
MEF2D Q14814 17 NAN NAN 22.87 24.14 24.58 24.52 23.95 23.70 22.07 22.05 
MEIS1 O00470 11 NAN NAN NAN 21.77 23.09 24.01 21.83 21.65 19.51 21.15 
MEIS2 O14770 11 NAN NAN NAN NAN 20.41 21.48 19.80 NAN NAN NAN 
MEMO1 Q9Y316 8 NAN NAN 20.52 NAN 21.16 21.69 21.04 20.88 20.23 20.45 
MEN1 O00255 4 NAN NAN NAN NAN 19.58 NAN 19.05 18.89 NAN NAN 
METTL3 Q86U44 8 NAN NAN NAN NAN 20.02 20.23 20.26 20.03 NAN NAN 
MFSD10 Q14728 3 NAN NAN NAN NAN NAN 18.37 19.07 19.01 19.86 20.68 
MGC4268 Q8IWI9 5 NAN NAN NAN NAN 20.15 20.83 19.76 19.86 NAN 19.51 
MGMT P16455 6 NAN NAN NAN NAN 20.77 20.65 20.08 19.44 NAN 19.58 
MGST1 P10620 2 NAN NAN NAN NAN NAN 19.73 20.32 20.37 21.76 21.38 
MIB2 Q96AX9 8 NAN NAN NAN NAN 20.62 21.27 20.08 20.58 NAN NAN 
MIER1 P03971 7 NAN NAN NAN NAN 20.22 20.77 20.46 20.17 NAN NAN 
MIIP Q5JXC2 3 NAN NAN NAN NAN 19.25 19.14 NAN NAN NAN NAN 
MKI67 P46013 15 21.03 NAN NAN NAN 18.76 19.18 20.59 19.39 20.63 20.40 
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MLF2 Q15773 11 NAN NAN 22.83 23.30 26.67 27.79 23.80 24.68 22.98 23.65 
MLL3 Q8NEZ4 5 NAN NAN NAN NAN 19.04 19.21 NAN 19.35 NAN NAN 
MLLT1 Q03111 5 NAN NAN NAN NAN 20.08 20.50 19.82 19.85 NAN NAN 
MN1 Q10571 4 NAN NAN NAN NAN NAN NAN 18.89 18.98 NAN NAN 
MNAT1 P51948 6 NAN NAN NAN NAN 19.83 20.10 20.96 19.19 NAN 20.06 
MOCS3 O95396 3 NAN NAN NAN NAN 19.44 19.67 19.46 18.99 NAN NAN 
MORC2 Q9Y6X9 8 NAN NAN NAN NAN 19.52 20.05 19.08 19.40 NAN NAN 
MORC3 Q14149 19 NAN NAN NAN NAN 21.96 22.50 22.64 21.79 20.28 21.28 
MORF4L1 Q9UBU8 8 NAN NAN NAN 21.53 21.13 21.23 21.37 21.13 NAN 21.04 
MORF4L2 Q15014 7 NAN NAN NAN NAN 18.42 19.28 19.26 NAN NAN 19.32 
MPG P29372 9 NAN NAN 21.74 22.24 22.94 22.75 22.33 21.79 21.75 21.73 
MRE11A P49959 9 NAN NAN NAN NAN 20.03 19.49 20.61 19.78 20.97 21.06 
MRI1 Q9BV20 5 NAN NAN NAN NAN 20.83 21.50 20.85 21.32 NAN NAN 
MRNIP Q6NTE8 10 NAN NAN NAN NAN 20.55 21.46 19.65 19.44 NAN NAN 
MRPL4 Q9BYD3 2 NAN NAN NAN NAN 20.25 19.70 NAN NAN NAN NAN 
MRTO4 Q9UKD2 6 NAN NAN NAN 21.48 21.75 22.02 21.66 21.37 21.10 NAN 
MSANTD4 Q8NCY6 7 NAN NAN NAN NAN 22.54 21.81 NAN 20.65 20.18 NAN 
MSH2 P43246 11 21.28 21.99 NAN 20.70 21.22 21.36 21.95 21.15 21.22 20.76 
MSH6 P52701 25 23.87 22.29 21.59 22.43 22.80 23.66 23.82 22.22 22.50 22.54 
MSN P26038 8 NAN NAN NAN NAN 20.23 NAN 20.83 21.04 21.59 21.69 
MTA1 Q13330 21 23.48 23.14 21.63 22.89 23.22 23.53 23.37 22.28 20.49 21.81 
MTA2 O94776 27 24.12 22.00 22.76 24.29 24.86 24.68 24.86 23.82 23.49 23.53 
MTA3 Q9BTC8 17 21.60 NAN NAN NAN 21.34 20.64 20.97 20.82 20.61 20.34 
MYC P01106 18 NAN NAN 26.63 27.06 27.46 27.96 25.33 25.30 27.27 26.79 
MYL6 P60660 7 NAN NAN NAN 21.44 21.87 21.99 21.97 22.28 22.30 22.13 
NAB2 Q15742 4 NAN NAN NAN NAN NAN 20.61 20.66 20.15 NAN NAN 
NACA E9PAV3 3 NAN NAN NAN NAN 18.76 18.47 NAN 22.34 NAN NAN 
NAGK Q9UJ70 13 NAN NAN 22.51 21.76 22.55 22.52 22.52 22.91 22.54 22.09 
NAPA P54920 7 NAN NAN NAN NAN 19.93 19.97 20.93 20.79 NAN 20.74 
NAT1 P18440 6 NAN NAN NAN NAN 20.56 21.14 NAN 19.43 NAN NAN 
NCL P19338 20 25.81 25.72 23.82 25.77 24.74 24.84 25.59 25.11 25.18 25.42 
NCOA1 Q15788 9 NAN NAN NAN NAN 21.00 20.92 20.64 20.58 NAN NAN 
NCOA2 Q15596 23 NAN NAN NAN NAN 22.08 22.14 22.20 21.25 NAN NAN 
NCOA3 Q9Y6Q9 41 NAN NAN 21.99 22.56 25.34 25.29 24.10 24.23 NAN 19.59 
NCOR1 O75376 31 NAN NAN 21.38 21.53 23.02 22.50 22.90 21.79 19.67 19.10 
NCOR2 Q9Y618 76 20.29 NAN 24.91 25.03 26.28 25.90 25.17 25.82 23.28 24.07 
NECAP2 Q9NVZ3 5 NAN NAN NAN NAN 20.36 20.26 NAN NAN NAN NAN 
NEDD8 Q15843 2 NAN NAN NAN NAN 19.72 NAN NAN NAN 20.10 20.56 
NEIL2 Q969S2 9 NAN NAN NAN NAN 22.40 22.65 21.66 21.39 NAN 20.47 
NEK6 Q9HC98 8 NAN NAN NAN NAN 21.47 21.12 NAN NAN NAN NAN 
NEK7 Q8TDX7 17 NAN NAN 22.47 24.07 24.16 23.90 23.98 23.35 23.59 23.90 
NFATC1 O95644 4 NAN NAN NAN NAN 19.57 19.55 19.83 NAN NAN 19.32 
NFIC P08651 23 NAN NAN 24.91 24.78 25.98 26.60 24.74 24.64 23.98 23.68 
NFIX Q14938 21 NAN NAN 25.01 25.65 26.67 26.89 25.86 25.52 24.36 24.49 
NIFK Q9BYG3 8 NAN NAN NAN 20.21 20.90 21.50 20.47 19.91 19.93 20.90 
NIPBL Q6KC79 30 NAN NAN NAN 21.05 24.04 23.69 22.54 21.77 NAN 19.57 
NKRF O15226 4 NAN NAN NAN NAN 19.84 19.86 19.31 NAN NAN NAN 
NKX2-6 A6NCS4 2 NAN NAN NAN NAN 19.49 19.69 19.89 20.26 NAN NAN 
NLE1 Q9NVX2 7 NAN NAN NAN NAN 21.23 21.39 20.71 20.21 NAN 20.53 
NLK Q9UBE8 3 NAN NAN NAN NAN NAN 19.16 18.41 17.67 NAN NAN 
NMD3 Q96D46 13 NAN NAN NAN 21.88 21.44 22.01 21.28 21.53 20.79 20.96 
NME2 P22392 4 NAN NAN 22.82 20.81 20.92 20.09 NAN 22.22 NAN NAN 
NNMT P40261 11 NAN NAN 21.85 22.69 21.81 21.87 22.41 21.74 22.98 22.43 
NOC2L Q9Y3T9 14 NAN NAN NAN NAN 22.97 23.01 22.16 21.54 21.04 20.93 
NOC4L Q9BVI4 9 NAN NAN NAN NAN 21.50 22.19 20.99 20.67 NAN NAN 
NOL6 Q9H6R4 15 NAN 20.07 22.33 21.24 22.16 23.24 21.86 21.62 21.59 21.21 
NONO Q15233 28 26.76 27.04 28.59 28.80 29.64 29.65 28.63 28.74 27.95 27.88 
NOP16 Q9Y3C1 2 NAN NAN NAN NAN 18.64 19.87 NAN 18.57 NAN NAN 
NOP58 Q9Y2X3 5 20.44 20.62 NAN NAN NAN NAN 19.99 NAN 20.12 19.76 
NOSIP Q9Y314 14 NAN NAN 23.03 23.78 24.55 24.76 24.19 24.28 22.77 23.36 
NPLOC4 Q8TAT6 5 NAN NAN NAN NAN 19.65 19.74 19.46 20.35 NAN 19.87 
NPM1 P06748 9 25.63 25.27 23.10 22.89 24.10 23.61 24.55 24.49 24.92 24.82 
NQO1 P15559 7 NAN NAN NAN NAN 20.47 20.84 20.60 20.60 21.59 21.62 
NR1B3 P13631 5 NAN NAN NAN NAN 19.97 20.35 19.31 19.48 NAN NAN 
NR1D1 P20393 8 NAN NAN NAN NAN 22.78 22.67 21.53 21.73 NAN NAN 
NR1H2 P55055 8 NAN NAN NAN NAN 21.36 21.63 20.66 20.24 NAN 20.98 
NR2B2 P28702 15 NAN NAN 21.59 22.83 23.18 23.56 23.13 22.58 21.39 21.93 
NR2C2 P49116 8 NAN NAN NAN NAN 19.90 19.92 20.04 NAN NAN NAN 
NR2F1 P10589 12 NAN NAN NAN NAN 19.57 19.88 20.16 20.20 NAN 19.65 
NR2F2 P24468 16 NAN NAN 23.86 24.50 24.61 24.77 24.41 24.33 23.48 23.99 
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NR2F6 P10588 13 NAN 20.78 22.49 22.34 23.86 24.02 23.00 23.86 20.54 21.70 
NR4A1 P22736 4 NAN NAN NAN NAN 21.23 21.32 19.85 NAN NAN NAN 
NR4A3 Q92570 11 NAN NAN NAN NAN 21.58 22.19 21.48 21.68 NAN NAN 
NSMCE3 Q96MG7 4 NAN NAN NAN NAN 19.19 19.07 NAN NAN NAN NAN 
NSUN2 Q08J23 29 20.26 19.83 21.94 23.66 23.94 24.10 24.38 23.96 23.91 24.09 
NSUN5 Q96P11 11 NAN NAN NAN NAN 21.75 21.70 21.06 21.20 NAN NAN 
NTHL1 P78549 7 NAN NAN NAN NAN 20.87 20.73 NAN NAN NAN NAN 
NUCKS1 Q9H1E3 3 NAN NAN NAN NAN 20.75 NAN 21.15 NAN 21.09 21.65 
NUDT16L1 Q9BRJ7 9 NAN NAN 21.12 20.84 22.62 23.40 22.03 22.09 21.15 20.94 
NUDT21 O43809 9 21.69 23.47 22.27 23.30 23.18 23.38 23.03 22.84 21.99 21.95 
NUFIP1 Q9UHK0 4 NAN NAN NAN NAN 18.17 18.58 NAN NAN NAN 18.05 
NUMA1 Q14980 58 22.69 22.20 24.63 26.08 26.57 26.64 26.40 25.98 24.84 25.38 
NUP107 P57740 5 NAN NAN NAN NAN NAN 19.03 20.07 18.93 NAN 20.20 
NUP133 Q8WUM0 12 NAN NAN NAN NAN NAN NAN 20.85 19.53 21.14 21.57 
NUP153 P49790 16 NAN NAN NAN 21.15 NAN NAN 21.65 NAN 22.80 22.88 
NUP155 O75694 4 NAN NAN NAN NAN 19.11 19.51 20.04 19.18 NAN 19.64 
NUP160 Q12769 7 NAN NAN NAN NAN 18.38 NAN 20.27 18.70 NAN 20.52 
NUP205 Q92621 14 NAN NAN NAN NAN 20.92 20.13 20.37 NAN NAN NAN 
NUP93 Q8N1F7 19 NAN NAN NAN NAN 22.35 22.24 21.72 21.77 22.29 21.92 
NUP98 P52948 11 NAN NAN NAN NAN NAN NAN 21.44 20.35 22.09 21.34 
NUTF2 P61970 3 NAN NAN NAN NAN 19.21 19.37 NAN NAN NAN 19.37 
NXF1 Q9UBU9 25 21.04 NAN 24.35 24.24 25.51 25.83 24.68 25.07 23.28 23.44 
NXT1 Q9UKK6 2 NAN NAN NAN NAN 19.85 20.37 NAN NAN NAN NAN 
OGT O15294 31 NAN NAN 23.06 24.04 24.68 24.46 24.45 24.01 23.33 23.46 
ORC3 Q9UBD5 10 NAN NAN NAN 20.81 20.58 20.52 20.90 20.34 NAN NAN 
ORC4 O43929 5 NAN NAN NAN NAN 20.21 20.56 NAN 19.84 NAN NAN 
ORC5 O43913 3 NAN NAN NAN NAN 19.89 19.96 19.97 19.39 NAN 19.41 
OSR1 Q8TAX0 4 NAN NAN NAN NAN 21.98 22.07 20.88 21.04 NAN NAN 
OTUB1 Q96FW1 7 NAN NAN NAN NAN 21.17 21.44 21.00 21.70 NAN 21.08 
P15RS Q96P16 7 NAN NAN NAN 20.77 20.77 21.29 21.52 21.04 21.29 20.93 
P4HB P07237 11 NAN NAN NAN NAN NAN 19.25 20.04 22.71 21.38 21.67 
PA2G4 Q9UQ80 3 NAN NAN NAN NAN NAN NAN 19.37 19.96 NAN NAN 
PABPC1 P11940 18 21.40 23.21 22.34 23.73 22.30 21.86 23.91 22.82 23.08 23.12 
PABPN1 Q86U42 6 21.62 21.46 NAN 20.88 20.50 20.65 21.34 20.41 21.52 21.08 
PAF1 Q8N7H5 6 NAN NAN NAN 19.83 19.64 19.24 19.83 NAN 20.03 20.42 
PALLD Q8WX93 5 NAN NAN NAN NAN NAN NAN 19.98 19.62 19.86 NAN 
PARP1 P09874 41 25.68 25.33 23.45 24.38 24.79 24.54 24.75 24.29 23.91 24.28 
PATZ1 Q9HBE1 14 NAN 21.26 NAN NAN 22.50 23.39 21.54 21.10 NAN NAN 
PAX3 P23760 13 NAN NAN 19.86 21.01 24.51 24.11 22.02 22.29 20.87 21.21 
Pax9 P55771 11 NAN NAN NAN NAN 22.37 22.83 20.29 20.67 NAN NAN 
PAXIP1 Q6ZW49 9 NAN NAN NAN NAN 20.91 20.91 20.43 20.78 NAN NAN 
PBEF1 P43490 11 NAN NAN NAN NAN 20.61 20.50 21.84 22.56 NAN NAN 
PBRM1 Q86U86 6 NAN NAN NAN NAN 20.24 20.36 20.69 20.01 19.96 NAN 
PBX1 P40424 12 NAN NAN 21.16 21.44 22.10 21.86 21.40 21.34 NAN 21.10 
PBX2 P40425 12 NAN NAN NAN NAN 22.61 23.14 21.68 21.40 NAN 20.47 
PC4 P53999 7 23.55 22.51 NAN 23.67 23.87 23.73 24.12 23.61 24.03 24.05 
PCBP1 Q15365 13 24.83 25.32 24.80 25.18 25.39 25.56 25.22 25.10 24.57 24.76 
PCBP2 Q15366 12 23.85 24.88 23.91 24.07 23.67 23.75 23.94 23.80 23.54 23.55 
PCBP4 P57723 5 NAN NAN NAN NAN 19.57 20.34 18.81 NAN NAN NAN 
PCF11 O94913 5 NAN NAN NAN 20.02 20.01 20.02 20.04 19.50 NAN NAN 
PCGF3 Q3KNV8 9 NAN NAN NAN NAN 22.05 21.89 20.63 20.61 NAN NAN 
PCGF5 Q86SE9 5 NAN NAN NAN NAN 20.54 20.76 NAN NAN NAN NAN 
PCID2 Q5JVF3 12 NAN NAN NAN NAN 22.27 22.94 20.62 20.12 NAN NAN 
PCMT1 P22061 9 NAN NAN 21.87 21.66 22.41 22.59 21.68 21.95 21.38 21.89 
PCNA P12004 5 21.74 21.49 NAN NAN 20.89 20.85 21.55 20.95 21.07 20.80 
PCYT1A P49585 14 NAN NAN 22.08 23.11 23.34 23.21 23.38 23.44 24.27 24.04 
PDCD4 Q53EL6 4 NAN NAN NAN NAN 20.47 20.34 20.47 20.36 NAN 20.33 
PDCD5 O14737 4 NAN NAN NAN NAN 21.29 21.05 20.84 20.65 20.36 21.19 
PDCD6 O75340 10 NAN NAN 23.75 23.75 25.56 25.41 24.53 24.44 22.34 22.47 
PDIA3 P30101 10 NAN NAN NAN 21.25 NAN 20.55 21.14 22.23 22.35 21.80 
PDIA6 Q15084 6 NAN 20.28 20.99 NAN 19.61 NAN 20.31 21.84 20.80 20.82 
PDLIM1 O00151 3 NAN NAN NAN NAN 19.03 18.71 19.74 NAN NAN 19.17 
PDLIM2 Q96JY6 8 NAN NAN NAN 22.29 21.56 22.06 21.39 22.48 20.83 21.26 
PDLIM4 P50479 10 NAN NAN 22.37 22.32 22.76 22.99 22.20 22.46 22.06 21.77 
PDS5A Q29RF7 11 20.10 21.65 NAN NAN 20.74 20.65 21.42 20.70 20.80 20.74 
PDS5B Q9NTI5 14 NAN 20.81 21.30 22.44 21.27 21.91 22.14 21.47 20.38 20.98 
PEA15 Q15121 3 NAN NAN NAN NAN 19.10 19.55 19.84 19.97 22.07 20.92 
PEBP1 P30086 9 22.55 23.61 23.49 22.29 22.71 22.85 22.52 24.58 22.82 22.97 
PEF1 Q9UBV8 8 NAN NAN 22.73 22.84 24.05 24.76 23.35 23.63 22.10 21.98 
PELO Q9BRX2 4 NAN NAN NAN NAN 20.39 20.57 19.61 NAN NAN NAN 
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PES1 O00541 8 20.80 NAN NAN 20.90 20.97 21.14 21.14 20.27 20.67 20.49 
PFDN2 Q9UHV9 4 NAN NAN NAN 20.63 20.84 20.68 20.48 20.13 NAN NAN 
PFDN5 Q99471 2 NAN NAN NAN NAN 19.10 19.49 NAN NAN NAN NAN 
PFKFB3 Q16875 8 NAN NAN NAN NAN NAN 20.34 21.08 21.36 21.02 21.13 
PFN1 P07737 8 24.39 24.63 25.30 25.68 25.84 26.03 25.16 25.41 25.06 25.15 
PFN2 P35080 6 NAN NAN NAN 20.90 21.18 NAN 20.51 20.40 NAN 20.56 
PGAM1 P18669 7 22.17 NAN NAN NAN 20.98 20.57 20.17 22.74 20.31 NAN 
PGD P52209 5 NAN NAN NAN NAN 19.36 19.06 19.11 21.30 NAN 19.54 
PGK1 P00558 17 NAN 20.85 23.16 22.03 22.45 23.38 22.41 24.64 23.04 23.43 
PHB2 Q99623 4 NAN NAN NAN NAN 19.71 19.77 19.02 20.81 19.84 20.40 
PHC2 Q8IXK0 6 NAN NAN NAN 21.02 21.26 21.03 21.07 20.10 NAN 20.52 
PHF14 O94880 18 NAN NAN 21.03 22.97 23.00 23.36 22.85 21.99 NAN 21.52 
PHF5A Q7RTV0 3 NAN NAN NAN NAN 19.46 19.47 19.68 19.45 NAN NAN 
PHF6 Q8IWS0 6 21.34 NAN NAN NAN 20.31 20.05 20.42 20.60 20.81 20.88 
PHF8 Q9UPP1 14 NAN NAN NAN 20.73 22.59 22.41 21.60 21.07 20.19 20.90 
PHIP Q8WWQ0 10 NAN NAN NAN NAN 19.81 19.36 20.33 19.22 19.70 20.51 
PHPT1 Q9NRX4 6 NAN NAN 20.44 21.46 22.48 22.84 22.29 22.26 22.20 21.82 
PIAS1 O75925 15 NAN 23.44 23.52 22.52 24.46 24.68 23.63 22.78 21.29 22.11 
PIAS2 O75928 13 NAN NAN NAN NAN 21.70 21.38 20.52 20.21 NAN NAN 
PIAS3 Q9Y6X2 15 NAN NAN NAN NAN 23.95 24.71 22.58 22.12 20.82 21.12 
PIAS4 Q8N2W9 17 20.12 20.78 22.72 22.48 24.87 24.90 23.58 22.93 20.52 21.08 
PIN1 Q13526 7 NAN NAN 22.38 23.13 23.55 23.76 22.94 23.17 22.16 22.18 
PINX1 Q96BK5 5 NAN NAN NAN NAN 20.19 19.93 NAN NAN NAN NAN 
PITPNB P48739 6 NAN NAN NAN NAN 20.87 20.46 20.17 20.22 20.88 20.34 
PITX1 P78337 4 NAN NAN NAN NAN 19.00 19.86 18.54 NAN NAN NAN 
PITX2 Q99697 8 NAN NAN 20.86 21.57 22.94 23.22 22.19 22.28 NAN 21.37 
PKP1 Q13835 24 22.21 21.22 24.54 22.24 23.87 23.40 21.73 24.54 21.74 22.42 
PLAA Q9Y263 10 NAN NAN NAN NAN 20.06 20.47 20.63 20.43 20.20 20.57 
PLAGL2 Q9UPG8 2 NAN NAN NAN NAN 17.90 19.09 17.40 NAN NAN NAN 
PLEC Q15149 91 NAN 21.46 22.95 22.67 21.97 22.38 24.09 25.49 24.48 24.54 
PLK1 P53350 6 NAN 20.47 NAN 20.53 20.17 20.17 20.03 20.30 NAN NAN 
PLRG1 O43660 12 NAN NAN 20.22 22.14 22.36 22.51 22.37 22.25 21.83 22.12 
PML-RAR O15305 20 NAN NAN NAN NAN NAN NAN 21.46 21.70 22.14 21.93 
PMM2 Q15126 4 NAN NAN 20.10 NAN 20.87 20.70 20.20 NAN NAN NAN 
PMVK Q96T60 3 NAN NAN NAN NAN NAN 18.67 18.75 19.67 NAN 19.08 
PNO1 P00491 7 NAN NAN NAN NAN 22.38 22.59 21.53 21.19 NAN 19.92 
PNP P01298 11 20.79 NAN 22.89 20.53 21.16 21.21 20.82 22.20 20.50 21.07 
POGZ Q7Z3K3 16 21.20 21.61 NAN 21.30 21.68 20.91 21.66 21.10 20.70 20.71 
POLD2 P49005 3 NAN NAN NAN NAN 19.41 NAN 20.55 19.58 NAN NAN 
POLDIP3 Q9BY77 12 20.91 NAN NAN 22.03 22.90 22.86 22.88 22.30 22.02 21.78 
POLR1C Q9Y253 5 NAN NAN NAN NAN 20.22 19.87 19.61 19.68 NAN 19.90 
POLR2A P24928 9 20.45 NAN NAN 19.44 20.25 20.57 20.64 19.68 NAN 20.13 
POLR2B P30876 18 21.14 NAN NAN 21.91 21.67 21.31 21.77 20.81 20.67 21.26 
POLR2E P19388 4 NAN 20.23 NAN 20.24 20.07 20.06 20.08 19.88 20.40 20.27 
POLR2H P52434 4 NAN NAN NAN NAN 20.97 21.36 21.28 21.22 21.62 21.44 
POLR2I P36954 4 NAN NAN NAN NAN 20.70 20.85 NAN NAN NAN NAN 
POM121C A8CG34 7 NAN NAN NAN NAN 21.09 21.04 20.39 20.19 NAN 20.34 
POU3F1 Q03052 7 NAN NAN NAN NAN 19.53 NAN 19.58 21.35 21.16 20.29 
POU5F1 Q01860 23 28.20 28.19 31.63 32.03 33.54 33.86 32.47 32.70 32.23 32.15 
PPA1 Q15181 6 NAN NAN NAN NAN 20.40 20.63 20.58 21.50 NAN NAN 
PPHLN1 Q8NEY8 5 20.23 19.65 NAN 19.94 19.40 18.93 19.29 19.12 NAN NAN 
PPIA P62937 11 25.64 25.49 25.64 26.70 27.64 27.89 26.77 27.03 26.86 27.19 
PPID Q08752 3 NAN NAN NAN NAN 19.19 18.98 18.50 NAN NAN NAN 
PPIL1 Q9Y3C6 5 NAN NAN 21.68 22.14 22.58 22.65 21.63 21.65 NAN 21.38 
PPIL2 Q13356 17 NAN NAN NAN 19.68 23.05 24.01 21.58 21.49 NAN 19.49 
PPIL3 Q9H2H8 5 NAN NAN NAN NAN 20.94 21.85 NAN 21.16 NAN NAN 
PPIL4 Q8WUA2 9 NAN NAN NAN NAN 21.18 21.03 21.04 20.90 20.83 21.18 
PPM1G O15355 9 NAN NAN NAN NAN 20.94 20.70 21.06 20.54 21.27 21.21 
PPP1CA P62136 16 23.49 23.62 23.12 23.72 23.26 23.77 23.52 23.52 23.38 23.29 
PPP1CB P62140 12 NAN NAN NAN NAN NAN NAN 20.07 20.99 NAN NAN 
PPP1CC P36873 15 NAN NAN NAN NAN 19.92 NAN 20.02 19.61 19.87 NAN 
PPP1R8 Q12972 4 NAN NAN NAN NAN 21.19 21.77 21.21 NAN NAN NAN 
PPP2CB P62714 7 NAN NAN NAN NAN 19.29 19.69 19.89 21.23 19.95 19.45 
PPP2R1A P30153 8 NAN NAN 20.88 NAN 20.30 20.94 21.07 21.08 20.79 21.52 
PQBP1 O60828 5 NAN NAN NAN NAN 20.87 20.75 20.78 20.89 NAN NAN 
PRCC Q92733 5 NAN NAN NAN NAN 19.80 19.36 19.77 19.29 NAN NAN 
PRDM1 O75626 4 NAN NAN NAN NAN 19.73 20.09 NAN NAN NAN NAN 
PRDX2 P32119 10 NAN 23.24 24.67 NAN 22.48 NAN 21.50 23.32 22.98 21.79 
PRDX4 Q13162 6 NAN NAN NAN NAN NAN NAN 18.81 18.85 NAN NAN 
PRDX5 P30044 5 NAN NAN NAN NAN 19.74 20.25 19.67 20.37 NAN 19.74 
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PRDX6 P30041 11 22.09 22.54 22.28 22.03 21.76 21.68 21.54 22.51 22.62 22.28 
PRKDC P78527 85 23.50 24.22 21.98 24.05 23.98 23.75 25.58 24.90 25.17 25.26 
PRMT1 Q99873 13 23.41 23.48 23.48 24.19 24.73 24.90 24.81 24.54 24.56 24.70 
PRPF19 Q9UMS4 11 NAN 21.04 22.03 23.69 23.06 23.09 23.69 23.34 23.55 23.59 
PRPF3 O43395 7 NAN NAN NAN NAN 20.13 19.93 20.03 19.78 19.73 19.92 
PRPF31 Q8WWY3 9 20.51 NAN NAN 21.81 21.35 21.18 21.38 20.99 20.30 20.83 
PRPF4 O43172 16 NAN NAN 22.68 22.51 22.62 22.78 22.83 22.63 22.13 22.13 
PRPF6 O94906 28 NAN NAN 20.61 23.63 23.21 23.80 23.62 23.54 22.49 22.14 
PRPF8 Q6P2Q9 20 19.82 21.47 20.30 20.76 20.68 20.35 22.46 21.75 21.36 21.98 
PRR12 Q9ULL5 20 NAN NAN NAN 20.19 22.22 22.89 21.50 21.39 NAN NAN 
PRRX1 P54821 10 NAN NAN NAN 21.72 22.64 23.07 22.48 21.64 21.85 21.88 
PRRX2 Q99811 10 NAN NAN 24.15 24.67 26.38 26.35 24.97 25.10 23.51 24.05 
PSIP1 O75475 10 24.32 23.24 NAN 22.25 21.19 21.20 22.54 21.99 22.45 22.64 
PSMA1 P25786 3 19.45 NAN NAN NAN 19.03 NAN 18.56 20.93 19.54 NAN 
PSMA4 P25789 6 NAN NAN NAN NAN 20.61 20.17 NAN 20.85 NAN NAN 
PSMA5 P28066 6 NAN NAN NAN NAN 21.20 21.15 21.12 22.15 22.04 21.76 
PSMA6 P60900 6 NAN 19.82 21.30 19.97 19.84 19.42 19.88 21.23 20.25 19.81 
PSMA7 O14818 6 NAN NAN NAN NAN 20.83 21.13 20.36 22.26 21.50 20.77 
PSMB1 P20618 4 NAN NAN NAN NAN 20.96 20.67 19.65 21.34 NAN NAN 
PSMB2 P49721 6 NAN NAN 20.99 NAN 20.69 20.83 20.06 21.78 20.63 NAN 
PSMB3 P49720 4 NAN NAN NAN NAN 20.77 20.91 19.54 21.22 NAN 20.31 
PSMB4 P28070 7 NAN NAN NAN NAN 22.01 22.15 NAN 21.28 NAN 20.70 
PSMB5 P28074 9 NAN 20.35 20.74 NAN 21.59 22.07 20.71 22.33 20.98 20.87 
PSMC3 P17980 4 NAN NAN NAN NAN NAN 18.30 19.05 19.63 NAN NAN 
PSMD10 O75832 4 NAN NAN NAN NAN 20.33 20.15 20.27 NAN 20.26 20.12 
PSMD5 Q16401 4 NAN NAN 20.51 NAN 19.61 19.56 NAN NAN NAN NAN 
PSMD9 O00233 8 NAN NAN 21.36 21.86 22.40 22.26 22.53 21.81 22.09 22.03 
PSME3 P61289 4 NAN NAN NAN NAN 20.63 19.84 20.42 20.67 20.85 20.94 
PSMF1 Q92530 4 NAN NAN NAN NAN 22.14 22.32 21.65 21.03 21.48 20.98 
PSPC1 Q8WXF1 24 24.33 25.10 26.55 25.81 26.74 26.97 26.12 25.90 24.62 25.10 
PTBP1 P26599 20 25.19 26.56 25.64 26.05 26.45 26.56 26.69 26.52 25.72 25.91 
PTGES3 Q15185 5 22.51 22.39 NAN 21.79 21.43 21.79 21.39 21.85 21.36 21.88 
PTMA P06454 4 21.57 21.33 NAN NAN 20.04 20.05 20.40 19.48 NAN 20.35 
PTOV1 Q86YD1 2 NAN NAN NAN NAN 18.93 19.57 18.41 18.84 19.28 18.97 
PTRHD1 Q6GMV3 3 NAN NAN NAN NAN 21.09 21.31 20.09 20.53 19.58 19.48 
PWP2 Q15269 6 NAN NAN NAN NAN 19.77 20.18 19.13 18.94 NAN NAN 
PYCARD Q9ULZ3 5 NAN NAN NAN NAN 20.18 20.01 NAN 19.86 NAN NAN 
QKI Q96PU8 11 NAN NAN NAN NAN 22.58 22.50 22.46 21.89 NAN 21.94 
QRICH1 Q2TAL8 7 NAN NAN NAN NAN 20.71 20.24 20.30 20.47 NAN 20.59 
QTRT2 Q9H974 3 NAN NAN NAN NAN 19.93 20.21 NAN 19.37 NAN NAN 
RAB2 P61019 6 NAN NAN NAN NAN NAN NAN 20.20 21.58 21.00 NAN 
RAB5C P51148 5 NAN NAN NAN NAN NAN 20.81 21.12 22.27 21.33 21.14 
RAB6A P20340 2 NAN NAN 20.70 NAN NAN NAN NAN NAN 21.21 20.48 
RAB7A P51149 9 NAN NAN 21.68 21.88 19.99 19.68 20.32 22.59 21.94 21.72 
RACGAP1 Q9H0H5 5 NAN NAN NAN NAN 19.79 NAN 20.09 19.19 NAN NAN 
RACK1 P63244 15 24.03 23.99 23.34 23.55 24.56 24.31 24.10 24.56 24.51 24.36 
RAD21 O60216 11 NAN NAN NAN NAN 21.33 21.44 21.45 NAN NAN NAN 
RAD51C O43502 4 NAN NAN NAN NAN 19.00 19.57 18.85 NAN NAN NAN 
RAD54L2 Q9Y4B4 32 NAN NAN NAN NAN 24.26 24.25 23.13 22.86 NAN NAN 
RAE1 P78406 6 NAN NAN NAN NAN 21.59 21.64 21.20 20.88 20.69 21.13 
RAI1 Q7Z5J4 40 NAN NAN 21.31 22.77 24.15 24.75 22.79 22.65 NAN NAN 
RALY Q9UKM9 8 22.68 23.53 21.50 21.94 20.83 21.38 22.80 21.86 22.52 22.04 
RAN P62826 10 25.14 25.10 24.95 26.13 25.65 25.80 25.98 25.16 25.49 25.23 
RANBP5 O00410 23 NAN NAN 23.27 20.72 22.48 22.97 22.82 22.33 22.26 22.21 
RAP1B P61224 2 NAN NAN NAN NAN NAN NAN 18.82 20.06 19.24 20.05 
RAVER1 Q8IY67 24 20.27 22.96 24.07 24.31 25.63 25.63 25.08 24.80 22.72 23.07 
RBBP4 Q09028 17 25.50 24.80 23.72 25.03 25.14 25.34 25.06 24.45 23.83 23.97 
RBBP7 Q16576 16 22.54 21.59 NAN 23.33 22.87 23.41 23.18 22.78 21.77 22.15 
RBFOX2 O43251 6 20.65 20.49 20.77 21.27 22.12 22.28 21.18 21.26 20.44 20.81 
RBM10 P98175 8 NAN NAN NAN NAN 20.66 20.54 20.88 20.40 20.56 20.24 
RBM12 Q9NTZ6 8 NAN NAN NAN 22.70 21.88 22.07 22.55 22.38 22.15 22.24 
RBM14 Q96PK6 34 25.45 26.42 27.89 28.29 29.89 30.75 28.92 29.27 26.21 26.81 
RBM15 Q96T37 7 20.27 19.94 NAN 20.19 20.13 20.18 20.06 19.81 19.93 19.82 
RBM22 Q9NW64 13 NAN NAN 23.04 23.96 24.32 24.69 23.99 24.20 23.35 23.54 
RBM23 Q86U06 5 NAN NAN NAN NAN 23.55 23.32 NAN 23.24 NAN NAN 
RBM25 P49756 5 NAN NAN NAN NAN 19.79 NAN 21.31 19.93 20.99 20.26 
RBM27 Q9P2N5 20 NAN 20.75 22.54 23.28 24.14 24.37 23.53 23.56 22.06 22.47 
RBM3 P98179 3 NAN NAN NAN NAN 20.99 20.38 21.79 20.68 NAN NAN 
RBM33 Q96EV2 25 NAN 20.08 22.37 23.05 24.61 25.35 23.02 23.15 18.90 21.04 
RBM39 Q14498 18 22.40 22.82 22.64 23.58 23.53 23.97 24.32 23.30 23.51 23.67 
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RBM4 Q9BWF3 19 24.47 24.71 23.89 25.22 26.57 26.55 25.69 25.68 23.93 23.82 
RBM42 Q9BTD8 5 NAN NAN NAN NAN 18.96 19.01 20.18 NAN NAN NAN 
RBM4B Q9BQ04 18 NAN NAN NAN NAN 20.52 20.74 NAN NAN NAN NAN 
RBM6 P78332 8 NAN NAN NAN NAN 20.02 20.10 19.55 19.48 NAN NAN 
RBM7 Q9Y580 9 NAN NAN NAN NAN 21.71 22.25 21.29 20.17 NAN NAN 
RBM8 Q9Y5S9 4 NAN NAN NAN 21.84 21.16 21.19 21.62 20.93 NAN 21.52 
RBMX P38159 15 25.87 25.91 23.88 24.88 24.46 24.71 25.00 24.48 24.69 24.50 
RBPJ Q06330 14 22.25 22.14 21.39 23.08 22.99 23.70 23.27 23.10 22.35 22.81 
RCC1 P18754 13 22.01 21.78 23.11 23.68 23.46 24.01 24.14 23.51 24.14 23.84 
RCC2 Q9P258 23 26.20 25.74 23.62 24.78 25.53 25.77 25.31 24.78 24.13 24.36 
RCOR1 Q9UKL0 12 NAN NAN 22.04 23.00 23.45 23.48 23.45 23.04 22.07 22.09 
RCOR3 Q9P2K3 6 NAN NAN NAN NAN 19.18 18.86 18.83 NAN NAN NAN 
RECQL P46063 22 21.46 NAN 21.61 23.77 24.69 24.60 25.14 23.97 24.59 25.16 
RERE Q9P2R6 9 NAN NAN 20.78 21.28 22.31 21.51 21.91 21.13 20.98 20.27 
REXO1 Q8N1G1 7 NAN NAN NAN NAN 19.81 19.87 NAN NAN NAN NAN 
REXO1L1P Q8IX06 7 NAN NAN NAN NAN NAN 19.67 NAN 20.03 20.82 22.79 
RFX1 P22670 10 NAN NAN NAN 21.08 21.35 21.38 21.20 21.08 20.23 NAN 
RING1 Q06587 8 NAN NAN NAN NAN 22.19 22.22 22.04 21.44 21.43 21.05 
RLIM Q9NVW2 3 NAN NAN NAN NAN 18.83 19.39 NAN NAN NAN NAN 
RNASE7 Q9H1E1 4 NAN NAN NAN NAN 18.53 NAN 18.67 24.25 NAN 19.03 
RNF111 Q6ZNA4 7 NAN NAN NAN NAN 21.14 21.80 19.93 NAN NAN NAN 
RNF113A O15541 8 NAN NAN NAN NAN 21.48 21.10 21.12 20.76 20.78 20.65 
RNF114 Q9Y508 8 NAN 20.55 NAN NAN 22.35 22.56 21.48 21.65 21.38 19.92 
RNF126 Q9BV68 4 NAN NAN NAN 20.93 20.88 21.05 20.75 20.79 NAN NAN 
RNF138 Q8WVD3 3 NAN NAN NAN NAN 19.91 NAN 19.58 19.32 NAN NAN 
RNF2 Q99496 8 NAN NAN NAN NAN NAN NAN 21.09 20.05 NAN 20.58 
RNF20 Q5VTR2 19 NAN 20.10 NAN 22.54 21.64 21.58 23.09 21.79 21.43 22.16 
RNF216 Q9NWF9 9 NAN NAN NAN NAN 21.17 21.27 20.82 20.12 NAN NAN 
RNF4 P78317 4 NAN NAN NAN NAN 20.28 20.53 NAN NAN NAN NAN 
RNF40 O75150 17 NAN NAN NAN 21.76 21.18 21.15 21.94 21.50 21.51 22.13 
RNGTT O60942 17 NAN NAN NAN 22.27 23.29 23.18 22.71 22.47 22.36 22.47 
RNH1 O60930 22 19.65 21.70 25.90 26.10 25.33 25.44 25.71 25.88 25.36 26.09 
RNMT P13489 7 NAN NAN NAN NAN 20.77 20.38 NAN 20.21 NAN 20.41 
RPA1 Q15287 27 23.26 22.00 23.66 24.08 26.07 25.60 25.20 25.63 24.55 24.86 
RPA2 P27694 6 NAN NAN NAN NAN 21.84 21.90 21.91 21.23 NAN 21.02 
RPA3 P15927 2 NAN NAN NAN NAN 21.36 21.56 NAN 21.12 NAN 20.32 
RPL10 P49247 6 21.17 21.70 NAN 20.61 20.15 20.16 20.91 20.44 21.25 21.81 
RPL10A P62906 6 NAN NAN NAN NAN 20.63 21.38 21.41 20.37 NAN 21.62 
RPL11 P62913 3 NAN NAN 21.26 21.27 21.46 NAN NAN 21.55 21.88 21.61 
RPL12 P30050 6 NAN 22.29 21.60 21.79 22.07 21.64 21.73 21.92 21.98 22.21 
RPL13 P26373 6 23.26 22.87 21.41 22.23 21.60 21.86 22.50 21.37 23.63 23.73 
RPL13A P40429 3 21.57 22.21 NAN NAN 20.91 21.14 21.45 21.17 22.17 22.39 
RPL14 P50914 5 NAN NAN NAN NAN 22.31 22.60 22.79 22.03 23.47 23.66 
RPL15 P61313 4 21.55 22.08 NAN 21.39 21.26 21.58 21.76 21.18 22.22 21.86 
RPL17 P18621 6 23.41 23.87 21.89 22.24 21.88 21.64 22.75 21.98 23.44 23.77 
RPL18 Q07020 5 22.65 NAN NAN NAN 22.06 22.30 22.57 21.59 23.71 23.27 
RPL18A Q02543 7 22.89 22.89 21.70 22.27 22.05 22.31 22.51 21.58 22.92 23.04 
RPL22 P35268 3 21.91 22.26 21.36 21.59 21.28 NAN 21.42 22.41 21.55 21.76 
RPL23A P62750 5 22.07 22.57 22.23 22.18 20.80 20.75 21.87 21.11 22.59 22.57 
RPL24 P83731 5 21.77 22.06 NAN NAN 20.82 20.93 21.46 21.12 22.03 22.49 
RPL26L1 Q9UNX3 3 21.19 21.38 20.54 NAN 20.67 20.06 21.07 20.67 21.41 21.41 
RPL28 P46779 4 NAN NAN NAN NAN NAN NAN 21.65 20.31 NAN 21.89 
RPL3 P39023 12 23.99 24.58 23.18 22.82 22.09 22.13 23.21 21.98 23.86 24.04 
RPL30 P62888 2 NAN 23.12 NAN NAN 21.56 NAN 21.65 19.99 22.05 NAN 
RPL31 P62899 3 22.59 22.50 NAN 21.32 21.05 20.83 NAN NAN 22.25 22.30 
RPL34 P49207 4 22.35 21.78 NAN 21.05 21.08 NAN 21.73 19.94 21.95 21.15 
RPL35A P18077 2 NAN NAN NAN NAN 20.07 20.24 19.84 20.18 NAN 20.60 
RPL36 Q9Y3U8 3 NAN NAN NAN NAN 20.51 20.41 20.99 20.13 22.04 22.35 
RPL4 P36578 12 23.97 24.68 21.57 22.67 22.23 21.83 23.12 21.65 23.85 24.33 
RPL5 P46777 6 21.21 21.53 NAN NAN 21.31 20.77 21.07 21.40 21.83 22.01 
RPL6 Q02878 9 22.37 23.41 21.34 23.40 21.66 21.79 22.72 22.05 23.79 23.93 
RPL7 P18124 5 NAN 22.83 NAN 21.51 21.01 NAN 22.12 21.20 22.71 22.78 
RPL7A P62424 8 23.36 23.94 NAN 22.50 21.66 21.63 22.74 21.82 23.18 24.15 
RPL8 P62917 4 22.96 23.59 22.21 22.56 21.77 21.47 21.50 21.38 22.69 22.34 
RPL9 P32969 6 NAN NAN NAN NAN 21.13 21.10 21.93 22.10 21.49 21.40 
RPLP0 P05388 7 NAN 20.73 NAN NAN 20.41 20.24 20.08 21.40 20.40 20.96 
RPLP2 P05387 3 NAN NAN NAN NAN NAN NAN 19.73 21.34 NAN 19.66 
RPN1 P04843 18 NAN NAN NAN 21.49 20.35 21.00 23.72 23.21 23.61 24.03 
RPP30 P78346 3 NAN NAN NAN NAN 19.38 NAN 19.66 NAN 19.50 19.57 
RPRD1B Q9NQG5 6 NAN NAN NAN NAN 20.13 19.67 20.22 19.84 NAN 20.14 
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RPS10 P46783 5 22.00 21.72 20.85 21.04 22.77 23.01 22.43 21.51 21.98 21.56 
RPS11 P62280 8 22.60 22.79 NAN NAN 20.88 21.26 22.14 22.04 22.47 22.47 
RPS12 P25398 6 21.04 21.33 20.73 21.12 21.12 20.81 21.32 20.70 21.31 21.99 
RPS13 P62277 4 21.09 23.90 22.59 22.47 21.78 22.03 21.63 21.28 21.99 22.02 
RPS14 P62263 5 23.51 23.53 22.13 23.00 23.04 23.34 23.28 22.26 22.84 23.28 
RPS16 P62249 5 NAN 22.07 NAN 21.83 22.01 22.01 21.34 22.13 22.37 22.24 
RPS17 P08708 4 NAN NAN NAN NAN 20.41 20.68 20.84 NAN 20.73 20.96 
RPS18 P62269 6 21.85 21.62 21.22 22.08 21.96 22.04 22.05 21.64 21.96 22.32 
rps2 P15880 8 NAN NAN NAN NAN 21.47 21.64 22.51 21.83 22.89 22.79 
RPS23 P62266 3 NAN NAN NAN NAN 21.02 20.57 21.13 20.30 21.55 21.58 
RPS24 P62847 3 NAN NAN NAN NAN 19.69 20.28 20.09 NAN NAN 21.25 
RPS25 P62851 3 21.70 21.91 NAN 21.33 21.55 21.28 21.75 20.88 NAN 22.86 
RPS26 P62854 2 NAN NAN NAN NAN 20.94 20.50 21.05 20.49 21.48 21.82 
RPS27A P62979 6 26.37 25.95 27.31 27.74 28.40 28.54 27.99 28.46 28.71 28.75 
RPS27L Q71UM5 3 NAN 21.39 NAN 21.45 21.65 NAN 21.01 21.09 21.47 21.02 
RPS3 P23396 10 23.24 23.38 22.08 22.80 22.11 22.23 22.61 23.70 23.26 23.62 
RPS3A P61247 8 23.09 23.06 20.91 21.84 21.67 21.79 22.29 21.93 22.91 23.35 
RPS4X P62701 14 22.74 23.01 21.73 22.34 22.48 22.55 23.01 22.64 23.96 23.76 
RPS4Y1 P22090 10 NAN NAN NAN NAN 19.33 19.61 19.37 NAN NAN 19.84 
RPS5 P46782 8 21.45 NAN 21.98 22.68 23.19 22.95 22.17 22.30 22.17 22.74 
RPS6 P62753 6 22.32 22.27 NAN 20.97 20.30 20.78 20.99 20.52 21.64 22.28 
RPS6KA4 O75676 19 NAN NAN 20.48 21.70 23.08 23.41 22.90 22.62 21.17 21.73 
RPS7 P62081 5 NAN NAN NAN NAN 22.66 22.20 22.26 22.18 22.55 22.83 
RPS8 P62241 7 22.99 23.36 21.63 22.59 22.36 21.81 22.86 22.21 23.60 23.61 
RPS9 P46781 7 21.89 22.56 21.99 22.57 21.79 21.62 22.19 22.14 22.42 23.06 
RPSA P08865 9 NAN 23.08 22.55 22.81 22.40 22.40 22.43 23.61 22.67 22.96 
RRAGA Q7L523 2 NAN NAN NAN NAN NAN NAN 18.81 18.80 NAN 18.66 
RRBP1 Q9P2E9 5 NAN NAN NAN 19.94 NAN NAN 18.72 NAN 19.62 19.21 
RRP1 P05386 7 NAN 20.10 NAN 20.49 20.66 21.15 20.67 20.61 21.01 20.73 
RRP36 Q96EU6 3 NAN NAN NAN NAN 18.86 18.58 NAN NAN NAN NAN 
RRP9 O43818 16 NAN NAN 23.71 24.16 24.04 24.04 24.02 23.74 23.76 23.78 
RSL1D1 O76021 5 NAN NAN NAN NAN 20.70 19.98 20.42 NAN 21.50 20.91 
RTCB Q9Y3I0 17 21.64 22.75 22.94 23.53 23.31 23.16 23.48 23.00 23.31 23.75 
RTF1 Q92541 13 NAN NAN NAN 21.38 22.21 22.25 21.70 22.04 NAN 21.74 
RTFDC1 Q9BY42 7 NAN NAN NAN NAN 20.71 20.77 20.71 20.71 NAN NAN 
RTRAF Q9Y224 10 NAN 21.63 22.13 21.59 21.54 21.63 21.88 21.84 21.91 21.83 
RUNX1 Q01196 12 NAN NAN 22.86 23.19 24.52 24.86 23.29 23.67 21.53 22.96 
RUNX3 Q13761 3 NAN NAN NAN NAN NAN NAN 19.70 19.61 NAN NAN 
RUVBL1 Q9Y265 14 NAN NAN NAN 22.06 21.60 21.28 21.83 22.03 22.08 22.06 
RUVBL2 Q9Y230 10 NAN NAN NAN 21.83 22.31 22.20 22.83 22.44 22.79 22.30 
RXRA P19793 14 NAN NAN 21.29 21.23 23.26 23.14 22.63 22.23 20.41 20.80 
S100A13 Q99584 2 NAN NAN NAN NAN NAN NAN 19.22 18.80 NAN 19.81 
S100A16 Q96FQ6 6 NAN NAN 20.23 NAN 20.99 NAN 20.78 24.85 20.34 NAN 
S100A4 P26447 2 NAN NAN NAN NAN 20.32 20.84 21.18 20.90 21.20 NAN 
S100A6 P06703 2 NAN NAN NAN NAN 21.61 21.46 22.25 22.25 NAN NAN 
SAE1 Q9UBE0 9 NAN NAN NAN NAN 20.87 20.79 20.59 NAN NAN NAN 
SALL2 Q9Y467 12 24.76 24.01 NAN NAN NAN NAN NAN NAN NAN NAN 
SALL4 Q9UJQ4 18 25.38 24.89 NAN NAN NAN NAN NAN NAN NAN NAN 
SAMHD1 Q9Y3Z3 6 NAN NAN NAN NAN 18.94 NAN 20.07 19.65 NAN 19.99 
SAR1A Q9NR31 4 NAN NAN 21.82 21.87 21.10 21.32 21.72 21.36 22.13 22.45 
SARNP P82979 5 NAN 22.06 NAN 21.75 20.70 21.22 21.20 21.28 NAN 21.93 
SART1 O43290 9 NAN NAN NAN NAN 19.97 19.84 20.36 19.77 NAN 20.17 
SATB2 Q9UPW6 24 NAN NAN 22.82 24.04 24.15 24.30 24.07 23.65 23.42 23.38 
SBDS Q9Y3A5 9 NAN NAN NAN NAN 21.00 20.92 21.61 20.99 21.70 21.75 
SBNO1 A3KN83 10 NAN NAN NAN NAN NAN NAN 19.52 19.22 NAN NAN 
SBNO2 Q9Y2G9 23 NAN NAN NAN 21.40 24.81 24.80 22.03 22.20 20.19 20.25 
SBSN Q6UWP8 23 19.89 20.30 26.38 23.01 19.13 18.53 20.62 21.37 20.99 19.91 
SCAF11 Q99590 4 18.44 NAN NAN NAN 19.06 NAN 18.94 18.63 NAN 18.43 
SCAI Q8N9R8 13 NAN NAN NAN NAN 21.96 22.61 20.37 20.76 NAN NAN 
SCML2 Q9UQR0 4 NAN NAN NAN NAN 18.42 18.73 19.11 NAN NAN NAN 
SCNM1 Q9BWG6 5 NAN NAN NAN NAN 21.12 22.32 NAN 20.15 NAN NAN 
SDAD1 Q9NVU7 6 NAN NAN NAN NAN 19.87 19.85 19.01 NAN NAN NAN 
SDE2 Q6IQ49 4 NAN NAN NAN NAN 19.88 19.69 19.37 NAN NAN NAN 
SEC13 P55735 2 NAN NAN NAN NAN 20.29 NAN 19.77 20.52 NAN NAN 
SEC22B O75396 6 NAN NAN NAN NAN NAN 21.02 21.85 21.21 22.69 22.23 
SEC23A Q15436 7 NAN NAN 21.16 21.67 20.31 20.85 21.41 20.99 21.41 22.00 
SEH1L Q96EE3 4 NAN NAN NAN NAN 20.07 20.15 20.20 19.72 NAN NAN 
SELENOH Q8IZQ5 4 NAN NAN NAN NAN 21.51 21.00 20.54 20.28 NAN NAN 
SEPHS1 P49903 6 NAN NAN NAN NAN 20.16 19.97 NAN 20.18 NAN NAN 
SEPT7 Q16181 6 NAN NAN NAN NAN NAN 21.16 21.16 NAN 22.34 22.18 
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SERBP1 Q8NC51 7 22.85 22.89 NAN NAN 20.02 18.91 20.18 NAN 20.05 21.57 
SERPINB2 P05120 5 NAN NAN 20.53 19.84 19.69 19.61 19.87 21.11 NAN 19.98 
SERPINH1 P50454 11 NAN NAN NAN 21.18 19.89 19.98 21.15 21.16 21.93 22.85 
SESN2 P58004 6 NAN NAN NAN NAN 19.29 19.54 19.40 NAN NAN NAN 
SET Q01105 8 25.87 25.03 23.69 24.78 24.41 24.61 25.13 24.79 24.73 24.66 
SF1 Q15637 20 21.33 23.42 25.12 25.35 26.33 26.35 26.19 26.38 24.43 24.64 
SF3A2 Q15428 2 NAN NAN NAN NAN NAN NAN 18.38 18.27 NAN NAN 
SF3B1 O75533 13 NAN NAN NAN NAN NAN 20.16 20.98 20.78 20.71 20.87 
SF3B2 Q13435 14 NAN NAN NAN 21.08 20.57 21.25 20.97 20.70 NAN 20.32 
SF3B3 Q15393 13 20.67 21.57 NAN 21.05 21.63 21.70 22.38 21.84 21.23 21.56 
SF3B4 Q15427 4 NAN NAN 21.93 NAN 20.79 21.61 21.84 21.25 20.55 20.54 
SF3B6 Q9Y3B4 4 NAN NAN NAN NAN 20.96 20.86 20.80 21.01 NAN 20.65 
SFPQ P23246 33 26.97 28.43 29.43 29.81 30.01 30.30 29.01 29.75 28.69 28.78 
SFRS4 Q08170 4 22.56 21.29 NAN 21.39 NAN NAN 21.14 NAN NAN NAN 
SH3BGRL3 Q9H299 3 NAN NAN 21.57 NAN 22.07 21.69 21.97 22.10 21.83 21.61 
SIN3A Q96ST3 8 NAN NAN NAN NAN 18.91 19.14 19.98 19.07 NAN NAN 
SIN3B O75182 5 NAN NAN NAN NAN 19.06 18.82 NAN NAN NAN 18.86 
SIRT6 Q8N6T7 9 NAN NAN NAN 21.76 21.55 20.93 21.31 20.92 NAN 20.36 
SKI P12755 30 NAN NAN 23.90 24.45 25.96 26.27 24.67 24.71 23.52 23.99 
SKIL P12757 19 NAN NAN NAN 22.02 23.32 24.01 21.90 22.35 19.84 21.28 
SKP1 P63208 7 NAN 22.20 NAN NAN 21.07 21.24 21.28 20.93 21.08 21.45 
SLBP Q14493 3 NAN NAN NAN NAN 21.00 21.15 20.59 21.00 19.71 20.09 
SLFN5 Q08AF3 18 NAN NAN NAN NAN 23.09 23.37 23.08 22.81 23.52 23.32 
SLU7 O95391 14 NAN NAN NAN 21.06 22.68 22.68 21.41 21.50 NAN 21.09 
SMAD1 Q15797 5 NAN NAN NAN NAN 19.75 19.77 NAN 19.14 NAN NAN 
SMAD2 Q15796 6 NAN NAN NAN NAN 21.55 21.41 21.37 20.91 NAN NAN 
SMAD4 Q13485 15 22.96 NAN 23.53 23.70 25.22 25.35 23.56 23.78 22.25 22.89 
SMARCA2 P51531 17 NAN NAN NAN NAN 20.67 20.50 20.52 21.30 NAN NAN 
SMARCA4 P51532 36 25.17 24.36 23.58 24.36 24.79 24.86 24.56 24.03 22.78 23.36 
SMARCA5 O60264 34 25.15 24.11 22.51 23.92 23.92 23.78 24.42 23.60 23.69 23.29 
SMARCAD1 Q9H4L7 9 NAN NAN NAN NAN 21.04 20.85 21.48 NAN NAN 20.51 
SMARCAL1 Q9NZC9 7 NAN NAN NAN NAN 19.00 20.50 NAN NAN NAN 18.40 
SMARCB1 Q12824 10 22.68 22.81 21.31 22.61 23.35 22.82 22.33 22.21 21.50 NAN 
SMARCC1 Q92922 41 25.54 23.92 22.32 24.48 25.18 25.35 25.29 24.46 23.33 23.55 
SMARCC2 Q8TAQ2 39 21.18 20.66 21.34 22.19 23.16 23.85 23.03 22.42 19.95 21.13 
SMARCD1 Q96GM5 12 22.69 22.20 NAN 20.90 22.10 21.55 20.96 20.37 NAN NAN 
SMARCD2 Q92925 20 22.27 21.75 21.88 23.51 24.86 25.21 24.08 23.65 19.75 22.24 
SMARCD3 Q6STE5 9 NAN NAN NAN NAN 20.23 20.57 20.41 20.16 NAN NAN 
SMARCE1 Q969G3 13 23.30 23.82 23.93 22.90 23.74 23.45 23.74 22.69 21.40 21.67 
SMC1A Q14683 41 23.23 21.71 20.40 23.71 24.86 24.83 24.20 23.17 22.12 22.91 
SMC3 Q9UQE7 39 23.56 22.79 21.47 23.83 24.73 24.89 24.63 23.79 21.36 22.80 
SMC5 Q8IY18 9 NAN NAN NAN NAN 20.66 21.19 20.25 NAN NAN 19.61 
SMC6 Q96SB8 8 NAN NAN NAN NAN 20.76 20.19 19.73 NAN NAN NAN 
SMCHD1 A6NHR9 38 23.33 22.93 23.42 24.55 23.43 23.39 23.99 23.42 24.03 23.94 
SMNDC1 O75940 4 NAN NAN NAN NAN 20.30 20.56 19.74 19.77 NAN 19.85 
SMS P52788 3 NAN NAN NAN NAN 19.14 19.63 NAN 19.06 NAN 19.08 
SMTN P53814 16 NAN NAN 20.94 22.10 20.98 21.29 21.97 22.20 22.25 22.36 
SMU1 Q2TAY7 16 21.84 22.42 NAN 22.83 22.80 22.78 22.73 22.37 22.84 22.68 
SMURF2 Q9HAU4 8 NAN NAN NAN NAN 20.68 20.69 19.97 19.73 NAN 19.73 
SNAI1 O95863 5 NAN NAN NAN NAN 20.15 20.07 20.04 20.30 NAN 19.91 
SND1 Q7KZF4 17 NAN 21.54 NAN 21.16 NAN 20.40 21.24 21.21 22.15 22.61 
SNIP1 Q8TAD8 5 NAN NAN NAN NAN 21.25 21.32 20.56 20.47 NAN NAN 
SNRNP200 O75643 38 21.23 22.94 21.82 21.85 21.97 22.14 23.33 22.19 22.06 22.84 
SNRNP40 Q96DI7 8 NAN NAN NAN NAN 21.48 21.54 21.37 21.72 21.07 21.30 
SNRNP70 P08621 9 23.04 22.32 NAN NAN 21.59 20.92 22.60 21.09 22.25 21.86 
SNRPA P09012 7 NAN NAN NAN NAN 19.77 20.53 19.68 NAN NAN NAN 
SNRPA1 P09661 6 NAN NAN 20.20 20.54 NAN 21.27 NAN NAN NAN NAN 
SNRPC P09234 3 NAN 21.60 21.87 22.41 22.62 23.03 22.16 22.40 21.11 21.17 
SNRPD1 P62314 3 NAN 21.94 20.61 20.89 20.78 20.94 NAN 21.10 21.60 21.16 
SNRPD2 P62316 7 21.50 22.42 NAN NAN 20.53 20.46 21.50 20.68 NAN 21.46 
SNRPD3 P62318 3 21.54 23.15 21.46 NAN 21.13 21.90 21.71 22.04 20.91 21.29 
SNRPN P63162 5 NAN NAN NAN NAN 21.02 20.84 21.20 20.87 21.68 21.45 
SNW1 Q13573 16 20.41 20.90 23.66 24.80 24.97 26.06 24.36 25.07 22.98 24.10 
SNX3 O60493 4 NAN NAN NAN NAN NAN 21.13 21.12 20.70 NAN NAN 
SOX13 Q9UN79 7 NAN NAN NAN NAN 20.38 20.53 NAN NAN NAN NAN 
SOX2 P48431 19 24.99 24.15 30.93 31.52 31.23 31.69 30.63 30.88 30.17 30.44 
SP100 P23497 4 NAN NAN NAN NAN 19.86 19.51 NAN NAN NAN NAN 
SPDL1 Q96EA4 4 NAN NAN NAN NAN 18.71 19.03 19.54 NAN NAN NAN 
SPIN Q9Y657 4 NAN 20.57 NAN NAN 20.30 20.59 20.20 20.04 19.75 19.82 
SPOP O43791 7 NAN NAN NAN NAN 22.64 22.47 22.04 20.33 NAN 23.81 
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SPRR2D P22532 6 22.42 NAN NAN 21.41 20.16 NAN 19.59 26.80 21.17 21.34 
SPTY2D1 Q68D10 18 NAN NAN NAN NAN 22.65 23.01 21.72 21.65 20.11 20.82 
SRBD1 Q8N5C6 19 NAN NAN NAN NAN 23.13 23.21 22.00 21.11 20.79 21.62 
SRI P30626 10 NAN NAN NAN NAN 23.99 24.30 23.12 23.31 22.09 23.09 
SRM P19623 8 NAN NAN 20.92 21.21 21.34 21.12 21.05 21.02 21.41 NAN 
SRP14 P37108 4 NAN NAN NAN NAN NAN 21.38 20.99 NAN 20.97 21.20 
SRP9 P49458 2 NAN NAN NAN NAN 20.09 20.10 NAN 20.01 NAN NAN 
SRRT Q9BXP5 15 22.35 21.45 NAN 22.07 22.17 22.11 22.47 22.26 22.27 21.83 
SRSF1 Q07955 11 24.32 24.72 21.65 23.99 22.01 20.94 23.32 21.45 23.99 22.81 
SRSF10 O75494 5 22.02 NAN NAN NAN 20.86 21.07 21.72 NAN 21.81 21.63 
SRSF2 Q01130 3 NAN 21.96 NAN 21.37 20.17 20.41 21.65 20.70 21.74 21.23 
SRSF3 P84103 6 21.98 21.98 NAN NAN 21.31 21.11 22.75 21.39 22.75 22.62 
SRSF7 Q16629 7 25.13 24.84 21.62 23.42 22.78 21.81 23.79 21.78 23.69 23.53 
SRSF9 Q13242 8 23.54 23.74 20.46 21.63 21.47 20.55 21.36 20.56 21.86 21.34 
SS18 Q15532 6 21.78 NAN NAN NAN 21.82 22.80 21.44 21.78 NAN 20.41 
SS18L1 O75177 3 NAN NAN NAN NAN 19.46 19.45 NAN NAN NAN NAN 
SSB P05455 10 NAN 21.95 NAN 21.18 21.00 20.76 21.78 21.35 22.03 22.21 
SSBP3 Q9BWW4 3 NAN NAN NAN NAN 20.93 21.10 20.84 20.79 NAN NAN 
SSBP4 Q9BWG4 3 NAN NAN NAN NAN 22.74 22.66 22.01 21.44 NAN NAN 
SSR4 P51571 5 NAN NAN 19.66 NAN 18.61 NAN 19.63 21.58 19.83 20.50 
SSRP1 Q08945 21 25.28 24.34 24.35 25.28 27.16 27.18 26.07 25.67 24.81 25.06 
SSU72 Q9NP77 6 NAN NAN NAN 21.40 21.36 21.39 21.00 20.86 20.62 20.78 
STAG1 Q8WVM7 9 NAN NAN NAN 19.75 20.55 21.14 20.19 20.20 NAN NAN 
STAG2 Q8N3U4 7 NAN NAN NAN NAN 19.69 19.87 19.63 NAN NAN NAN 
STAT1 P42224 28 NAN NAN 24.55 24.76 23.91 24.12 25.47 24.86 25.73 25.65 
STAT3 P40763 35 20.09 21.85 25.30 26.50 27.19 27.93 26.30 27.75 25.34 26.47 
STAT5A P42229 18 NAN NAN 19.87 20.91 22.94 23.68 22.72 22.97 NAN 20.13 
STAT5B P51692 15 NAN NAN 20.42 NAN NAN 20.17 19.50 19.75 NAN NAN 
STAT6 P42226 7 NAN NAN NAN NAN 20.62 20.07 20.81 20.48 20.59 20.92 
STIP1 P31948 9 NAN NAN NAN 19.90 21.77 21.98 20.72 20.42 NAN NAN 
STRAP Q9Y3F4 10 NAN NAN NAN 21.39 20.09 20.37 21.53 21.70 20.24 20.99 
STUB1 Q9UNE7 7 NAN NAN NAN 20.27 21.29 20.66 19.88 19.70 NAN 19.71 
SUGP2 Q8IX01 12 NAN 20.55 NAN 20.69 21.38 21.57 21.33 20.68 NAN NAN 
SUGT1 Q9Y2Z0 5 NAN NAN NAN NAN 19.84 19.83 19.15 NAN NAN 19.56 
SUI1 P41567 4 NAN NAN NAN NAN 21.52 21.59 21.77 21.28 21.30 21.15 
SUMO1 P63165 8 24.29 23.79 22.54 23.01 23.90 24.12 22.94 23.21 22.28 22.63 
SUMO2 P61956 2 24.98 23.93 22.30 24.72 21.91 25.99 24.47 24.50 23.13 23.10 
SUMO3 P55854 2 25.63 24.75 24.80 25.75 26.91 27.08 25.91 25.69 24.15 24.62 
SUPT16H Q9Y5B9 49 25.96 25.38 25.33 26.30 27.64 27.78 26.70 26.30 25.46 25.76 
SUPT20H Q8NEM7 2 NAN NAN NAN NAN 18.68 18.82 NAN NAN NAN NAN 
SUPT5H O00267 40 21.00 20.70 23.52 24.98 25.83 26.24 25.65 25.52 24.74 24.30 
SUPT6H Q7KZ85 43 20.28 20.38 19.80 22.62 23.39 24.35 24.52 23.90 24.07 23.11 
SYF2 O95926 4 NAN NAN NAN NAN 21.79 21.72 NAN NAN NAN NAN 
SYNCRIP O60506 21 24.60 24.87 22.71 23.74 23.07 22.97 24.59 23.05 23.88 24.31 
TAF15 Q92804 13 25.23 25.21 25.24 25.87 26.48 26.84 26.03 25.87 24.88 24.67 
TAGLN Q01995 17 NAN NAN 25.20 25.76 25.30 25.36 26.04 25.94 26.41 25.90 
TAGLN2 P37802 10 NAN NAN 22.33 22.96 23.23 23.38 22.88 22.92 23.08 23.01 
TALDO1 P37837 9 NAN 20.96 21.74 21.80 21.61 21.33 21.39 22.82 22.32 22.20 
TAOK2 Q9UL54 15 NAN NAN 21.37 NAN 21.66 21.48 21.43 21.47 NAN NAN 
TBCB Q99426 4 19.37 NAN NAN 19.10 NAN NAN 19.53 19.49 19.46 NAN 
TBL1X O60907 11 NAN NAN NAN NAN 19.61 20.06 19.24 19.28 NAN NAN 
TBL1XR1 Q9BZK7 16 21.78 20.61 22.52 23.55 24.54 24.54 24.29 23.35 22.13 23.09 
TBL3 Q12788 11 NAN NAN NAN NAN 22.18 21.66 21.06 20.91 NAN 21.00 
TBX1 O43435 6 NAN NAN NAN NAN 19.89 20.32 NAN 19.38 NAN NAN 
TBX15 Q96SF7 15 NAN NAN NAN NAN 22.50 22.64 21.20 21.29 NAN 21.60 
TBX18 O95935 6 NAN NAN NAN NAN 20.28 20.18 NAN NAN NAN NAN 
TBX3 O15119 18 NAN NAN 21.43 23.20 23.94 24.06 23.11 23.41 21.91 22.25 
TBX5 Q99593 3 NAN NAN NAN NAN 20.61 20.41 NAN 19.79 NAN NAN 
TCEA1 P23193 8 21.62 20.91 NAN 21.18 21.29 21.24 20.86 20.73 20.90 20.87 
TCEAL4 Q96EI5 3 NAN NAN NAN NAN 18.49 18.57 17.76 NAN NAN NAN 
TCERG1 O14776 9 NAN 21.01 NAN 21.89 21.22 20.87 21.37 20.95 21.46 21.53 
TCF12 Q99081 18 21.42 19.57 NAN 21.74 23.68 23.47 22.56 22.07 20.07 20.68 
TCF19 Q9Y242 3 NAN NAN NAN NAN 19.34 20.27 NAN 20.62 NAN NAN 
TCF20 Q9UGU0 60 19.73 21.51 22.34 23.13 26.41 26.58 25.12 24.72 19.68 22.44 
TCF3 P15923 19 NAN NAN NAN 21.24 24.19 23.80 22.75 22.44 19.38 20.83 
TCF4 P15884 9 21.31 20.71 NAN NAN 21.49 21.77 20.74 20.75 NAN 19.98 
TCP1 P17987 7 NAN NAN NAN NAN NAN 18.60 19.55 21.91 19.89 19.92 
TDP43 Q13148 14 23.69 24.65 23.57 23.39 24.00 24.09 23.99 23.55 23.97 23.75 
TEAD1 P28347 16 NAN NAN 21.82 NAN 24.50 24.35 23.36 22.99 21.72 21.89 
TEAD3 Q9NQB0 18 22.83 21.98 23.43 24.35 25.60 25.25 24.33 24.66 23.20 23.85 
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TEAD4 Q15561 11 NAN NAN NAN NAN 22.36 22.74 21.85 20.86 NAN 19.92 
TELO2 Q9Y4R8 18 NAN NAN NAN 21.21 23.03 23.00 22.74 22.42 21.13 20.44 
TENT2 Q6PIY7 7 NAN NAN NAN NAN 21.98 21.73 20.69 NAN NAN NAN 
TES Q9UGI8 10 NAN NAN NAN 21.23 20.50 20.69 21.02 20.75 NAN 21.56 
TET2 Q6N021 6 NAN NAN NAN NAN 19.39 19.41 NAN NAN NAN NAN 
TEX10 Q9NXF1 5 NAN NAN NAN NAN 20.44 19.55 NAN NAN NAN NAN 
TFAP2C Q92754 5 NAN NAN NAN NAN 20.79 20.88 20.70 NAN NAN NAN 
TFAP4 Q01664 8 NAN NAN 21.17 22.20 23.72 23.65 22.60 21.99 19.89 19.77 
TFCP2 Q12800 6 NAN NAN NAN NAN 19.80 19.83 NAN NAN NAN NAN 
TFE3 P19532 5 NAN NAN NAN NAN 19.96 19.78 NAN 19.29 NAN NAN 
TFEB P19484 5 NAN NAN NAN NAN 20.17 20.96 19.36 19.86 NAN NAN 
TFIP11 Q9UBB9 18 NAN NAN NAN NAN 22.42 22.99 21.91 21.86 20.46 21.42 
TGFB1I1 O43294 7 NAN NAN 21.42 NAN 20.65 20.43 21.17 21.14 20.93 21.50 
TGM2 P21980 10 NAN NAN NAN 20.82 NAN 19.43 20.82 19.76 22.20 20.66 
THAP11 Q96EK4 4 NAN NAN NAN NAN 21.02 20.60 NAN NAN NAN NAN 
THOC5 Q13769 3 NAN NAN NAN NAN 19.52 19.59 NAN NAN NAN NAN 
THOC6 Q86W42 8 NAN NAN NAN NAN 21.41 21.34 20.04 20.75 NAN NAN 
THRAP3 Q9Y2W1 12 20.93 20.94 NAN NAN 19.65 NAN 20.87 NAN 20.46 21.13 
THYN1 Q9P016 6 NAN NAN NAN 19.99 20.44 20.95 20.14 20.08 19.88 20.51 
TIA1 P31483 7 NAN NAN NAN NAN 20.68 20.78 20.44 20.12 NAN NAN 
TIAL1 Q01085 8 21.78 21.96 22.54 22.35 22.82 23.21 22.64 22.50 21.88 21.80 
TIPRL O75663 7 NAN NAN NAN NAN 20.68 20.76 20.46 20.32 20.34 20.65 
TKT P29401 19 25.27 25.13 24.95 24.28 24.20 24.59 24.67 24.76 24.66 24.81 
TLE1 Q04724 21 NAN 21.45 NAN NAN 22.91 23.48 21.43 21.14 NAN 20.56 
TLE3 Q04726 27 22.27 20.59 23.54 25.25 26.43 26.64 25.69 25.38 23.35 23.94 
TLE4 Q04727 25 NAN 21.35 22.47 23.78 25.11 24.99 24.37 24.03 21.91 22.40 
TLN1 Q9Y490 9 NAN NAN NAN NAN NAN NAN 19.72 21.05 21.56 21.13 
TMEM113 Q6UXN9 7 NAN NAN NAN 21.09 20.47 20.77 20.02 20.12 NAN 20.24 
TMEM201 Q5SNT2 7 NAN NAN NAN 20.62 19.61 20.77 21.45 20.51 21.92 22.39 
TMEM43 Q9BTV4 7 NAN NAN NAN NAN NAN NAN 21.68 21.60 22.63 22.53 
TMPO P42167 27 23.91 23.58 23.74 25.32 24.10 24.27 25.80 24.66 25.60 25.78 
TNIP2 Q8NFZ5 13 NAN NAN 22.78 21.91 22.81 23.05 22.00 22.30 NAN NAN 
TNPO1 Q92973 35 21.04 21.26 24.99 25.47 26.32 26.60 25.97 26.25 24.30 24.87 
TNPO2 O14787 27 NAN NAN 20.33 22.30 23.86 24.08 23.75 23.86 22.52 21.98 
TNPO3 Q9Y5L0 18 NAN NAN 21.88 21.02 23.52 22.75 22.48 22.21 20.24 20.39 
TNRC18 O15417 36 22.00 NAN 22.73 24.35 24.63 24.92 23.92 24.45 21.41 22.63 
TOP1 P11387 27 24.33 23.62 24.18 25.09 24.93 25.09 24.77 24.02 24.36 24.63 
TOP2A P11388 38 24.90 24.44 22.03 23.16 21.82 21.92 23.83 22.94 22.75 22.87 
TOP2B Q02880 43 25.29 25.17 24.12 24.72 25.01 24.95 24.98 24.32 24.18 24.77 
TOP3A Q13472 10 NAN NAN NAN NAN 20.74 21.38 20.38 20.16 NAN 19.75 
TPI1 P60174 15 24.07 23.61 24.00 21.72 22.86 22.73 22.14 25.65 23.39 23.12 
TPM3 P06753 11 NAN NAN 21.51 21.97 20.49 22.29 22.02 23.31 22.72 22.34 
TPM4 P67936 9 NAN NAN NAN 20.56 19.66 19.32 21.16 20.46 20.51 21.34 
TPR P12270 9 NAN NAN 20.74 19.66 NAN NAN 19.28 19.15 19.59 19.91 
TRA2A Q13595 5 NAN NAN NAN NAN 19.00 18.75 21.14 NAN 21.75 20.33 
TRA2B P62995 6 22.13 22.65 NAN 21.16 20.57 19.88 22.92 20.50 21.95 22.16 
TRAF3IP2 O43734 20 NAN NAN NAN NAN 24.31 24.61 22.33 21.90 NAN 19.50 
TRAF4 Q9BUZ4 5 NAN NAN NAN NAN 19.12 19.80 19.76 NAN NAN NAN 
TRAPPC2L Q9UL33 2 NAN NAN NAN NAN 19.73 20.12 NAN NAN NAN NAN 
TRAPPC4 Q9Y296 4 NAN NAN NAN NAN 21.25 20.65 NAN 19.90 NAN NAN 
TRERF1 Q96PN7 11 NAN NAN NAN NAN 22.45 22.88 21.31 21.10 NAN NAN 
TRIM11 Q96F44 11 NAN NAN NAN NAN 22.70 22.98 22.17 22.17 NAN 22.40 
TRIM22 Q8IYM9 19 NAN NAN 24.43 24.95 26.56 26.92 25.39 25.24 24.16 24.48 
TRIM24 O15164 25 23.70 23.42 NAN 21.98 23.14 23.82 22.51 22.47 NAN 20.83 
TRIM25 Q14258 12 NAN NAN 19.73 20.87 NAN 19.32 19.87 21.09 20.09 19.53 
TRIM28 Q13263 34 26.65 27.40 24.78 27.01 27.03 26.93 27.38 26.57 27.02 27.09 
TRIM32 Q13049 10 NAN NAN NAN NAN 21.71 21.76 NAN NAN NAN NAN 
TRIM33 Q9UPN9 32 23.66 23.63 23.84 24.41 26.10 25.95 24.62 24.27 22.93 23.06 
TRIM35 Q9UPQ4 8 NAN NAN NAN NAN 21.30 21.86 20.07 20.16 NAN NAN 
TRIM65 Q6PJ69 7 NAN NAN NAN NAN 20.23 20.52 NAN 19.72 NAN NAN 
TRIM8 Q9BZR9 15 NAN NAN NAN 21.52 23.61 23.84 22.14 22.37 20.42 21.80 
TRIP12 Q14669 20 NAN NAN 21.75 22.50 21.22 20.89 22.36 21.21 22.29 22.65 
TRIP6 Q15654 18 NAN NAN 23.68 24.00 24.78 24.98 24.07 24.32 22.91 23.22 
TRIR Q9BQ61 4 NAN NAN NAN NAN 21.73 21.88 21.18 21.38 21.37 20.93 
TRMT1 O75648 9 NAN NAN NAN NAN 20.47 20.27 20.39 20.09 20.55 20.57 
TRPS1 Q9UHF7 15 NAN NAN NAN 21.35 21.49 21.50 21.86 20.86 19.49 20.68 
TRRAP Q9Y4A5 35 NAN NAN NAN 20.52 22.08 23.46 21.92 21.45 NAN 19.67 
TSEN34 Q9BSV6 10 NAN NAN NAN NAN 22.69 22.50 21.42 21.78 NAN 21.06 
TSG101 Q99816 7 NAN NAN NAN NAN 21.31 21.86 20.82 21.24 NAN NAN 
TSR1 Q2NL82 14 NAN NAN NAN 21.77 21.37 21.93 21.78 21.57 21.68 22.14 
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TTLL12 Q14166 10 NAN NAN NAN 21.04 21.30 21.70 21.91 21.58 20.58 20.22 
TUBA1A Q71U36 21 NAN NAN 22.79 NAN NAN NAN 21.69 21.35 23.02 21.88 
TUBA1B P68363 21 25.44 26.34 26.27 26.67 25.34 25.31 26.42 26.50 27.39 26.96 
TUBB P07437 18 22.95 23.92 24.15 23.78 22.99 23.35 22.77 23.10 24.67 24.15 
TUBB2C P68371 19 24.57 25.25 25.85 25.98 24.85 25.08 25.69 26.02 26.77 26.38 
TUBB6 Q9BUF5 15 NAN NAN 22.43 23.08 21.08 21.41 22.36 22.38 23.36 22.72 
TUFM P49411 11 21.76 20.79 NAN NAN NAN 20.12 NAN 20.64 NAN NAN 
TWF2 Q6IBS0 5 NAN NAN NAN NAN 20.54 20.69 21.18 20.60 NAN NAN 
TWIST2 Q8WVJ9 2 NAN NAN NAN NAN 21.75 21.42 NAN NAN NAN NAN 
TXN P10599 8 23.86 23.16 25.21 24.57 24.57 24.96 24.49 25.35 25.18 25.10 
TXNDC5 Q8NBS9 4 NAN NAN NAN NAN NAN NAN 19.49 19.19 NAN 20.00 
TXNL1 O43396 6 NAN NAN NAN NAN 21.14 20.60 20.45 21.31 NAN 20.70 
TXNRD1 Q16881 5 NAN NAN NAN NAN 20.34 19.64 20.27 20.36 20.41 20.65 
U2AF1 Q01081 9 NAN 22.73 22.54 23.48 24.26 24.66 24.63 24.31 23.88 23.82 
U2AF2 P26368 15 23.28 24.16 24.08 23.62 24.44 24.60 24.64 24.31 23.75 23.68 
U2SURP O15042 10 20.78 20.91 NAN 21.76 20.93 20.58 21.51 20.95 21.27 20.97 
UBA1 P22314 17 NAN 20.42 21.50 22.09 21.67 21.42 22.03 22.70 22.83 22.69 
UBE2I P63279 8 21.80 22.06 22.06 22.68 23.93 23.53 22.30 22.37 21.03 21.94 
UBE2L3 P68036 3 NAN NAN NAN NAN 19.13 NAN 19.88 19.23 NAN NAN 
UBE2M P61081 5 NAN NAN NAN NAN 20.09 20.20 19.37 20.02 NAN 19.54 
UBE2N P61088 3 NAN NAN NAN NAN 20.37 20.42 20.28 21.10 NAN 20.74 
UBE2S Q16763 3 NAN NAN NAN NAN 20.91 21.18 21.07 20.85 20.49 20.59 
UBE2V1 Q13404 3 NAN NAN 20.22 NAN 20.35 NAN 20.92 20.68 20.34 NAN 
UBTF P17480 15 22.98 22.15 20.72 22.40 22.98 23.48 23.49 22.74 21.88 22.08 
UBXN1 Q04323 2 NAN NAN NAN NAN NAN 19.34 19.50 19.63 19.46 19.05 
UCHL1 P09936 3 22.17 NAN NAN 20.74 20.81 20.69 21.11 20.68 NAN 20.50 
UCHL3 P15374 4 NAN NAN NAN NAN NAN NAN 18.27 19.76 NAN NAN 
UFD1L Q92890 5 NAN NAN 20.45 20.70 20.66 21.02 21.09 21.10 NAN NAN 
UGDH O60701 8 NAN NAN NAN NAN 19.93 19.78 20.16 20.46 21.76 21.25 
UHMK1 Q8TAS1 16 NAN NAN 20.41 22.61 24.82 24.97 22.64 22.71 21.61 21.80 
UHRF1 Q96T88 26 NAN 21.14 NAN 22.26 21.99 22.54 23.04 22.32 22.02 22.56 
UHRF2 Q96PU4 19 NAN NAN 21.04 22.82 23.87 23.57 23.35 22.70 22.00 22.33 
UIMC1 Q96RL1 3 NAN NAN NAN NAN 18.72 18.13 NAN NAN NAN NAN 
UPF1 Q92900 6 NAN NAN 20.09 20.13 NAN NAN NAN 20.09 NAN NAN 
USF1 P22415 6 NAN NAN NAN NAN 20.97 20.79 20.77 21.11 NAN NAN 
USP11 P51784 10 19.22 NAN NAN NAN 19.42 19.70 20.22 20.16 NAN NAN 
USP15 Q9Y4E8 14 23.04 23.12 NAN 21.45 NAN NAN 21.09 NAN NAN NAN 
USP22 Q9UPT9 4 NAN NAN NAN NAN 20.33 20.39 20.22 NAN NAN NAN 
USP39 Q53GS9 5 NAN NAN 21.86 NAN 20.79 20.55 20.88 20.27 NAN 20.42 
USP48 Q86UV5 14 NAN NAN NAN 20.84 21.03 21.44 21.59 21.17 20.57 21.34 
USP5 P45974 11 NAN NAN NAN 21.27 20.41 21.01 21.46 21.78 20.40 20.96 
USP7 Q93009 14 20.27 21.69 21.83 NAN 20.92 20.95 21.94 20.80 21.18 20.93 
UTP4 Q969X6 7 NAN NAN NAN 20.00 20.14 20.13 19.84 19.84 NAN NAN 
UTP6 Q9NYH9 6 NAN NAN NAN NAN 20.56 20.85 20.27 NAN NAN NAN 
UVSSA Q2YD98 10 NAN NAN NAN NAN 20.38 20.89 20.55 20.76 NAN 20.08 
VCL P18206 33 NAN NAN 24.05 24.11 21.87 21.68 23.38 23.85 23.69 23.88 
VCP P55072 28 NAN NAN 23.73 20.89 21.28 20.56 22.28 24.79 22.31 22.22 
VDR P11473 5 NAN NAN NAN NAN 19.50 19.99 NAN NAN NAN NAN 
VENTX O95231 5 NAN NAN NAN NAN 21.20 20.91 20.78 NAN NAN NAN 
VEZF1 Q14119 6 NAN NAN NAN NAN 19.38 19.62 NAN 19.11 NAN NAN 
VGLL3 A8MV65 3 NAN NAN NAN NAN 21.04 20.59 20.08 NAN NAN NAN 
VGLL4 Q14135 4 NAN NAN NAN NAN 19.33 20.15 NAN NAN NAN NAN 
VPS28 Q9UK41 5 NAN NAN NAN NAN 20.35 20.67 20.41 20.67 NAN 20.16 
VPS37A Q8NEZ2 6 NAN NAN NAN 19.86 19.71 19.62 20.33 20.24 NAN NAN 
VPS37B Q9H9H4 2 NAN NAN NAN NAN NAN 19.42 19.75 19.71 NAN NAN 
VPS4B O75351 8 NAN NAN 21.00 21.05 20.86 21.19 20.78 21.34 20.98 21.01 
VRTN Q9H8Y1 12 24.44 24.61 NAN NAN NAN NAN NAN NAN NAN NAN 
WBP4 O75554 3 NAN NAN NAN NAN NAN 19.02 19.33 19.19 NAN NAN 
WDR12 Q9GZL7 6 NAN NAN NAN NAN 20.69 20.67 20.85 20.22 20.40 20.62 
WDR13 Q9H1Z4 4 NAN NAN NAN NAN 20.05 20.89 NAN NAN NAN NAN 
WDR25 Q64LD2 8 NAN NAN NAN NAN 20.91 21.27 NAN 20.15 NAN NAN 
WDR3 Q9UNX4 12 NAN NAN NAN 19.84 20.87 21.49 20.31 19.73 NAN 19.14 
WDR33 Q9C0J8 8 NAN NAN NAN NAN 19.74 19.89 20.41 19.74 19.78 NAN 
WDR36 Q8NI36 13 21.03 NAN NAN NAN 20.68 21.58 19.72 19.91 20.55 20.53 
WDR5 P61964 14 22.09 22.32 22.90 23.95 25.20 25.06 24.28 24.21 22.98 22.95 
WDR55 Q9H6Y2 12 NAN NAN NAN 22.35 22.93 23.02 22.67 21.41 21.54 21.46 
WDR6 Q9NNW5 4 NAN NAN NAN NAN 19.55 20.05 19.04 18.95 NAN NAN 
WDR61 Q9GZS3 5 NAN NAN NAN NAN NAN 20.54 20.75 21.10 NAN NAN 
WDR70 Q9NW82 6 NAN NAN NAN NAN 21.39 20.99 21.21 20.57 NAN NAN 
WDR74 Q6RFH5 5 NAN NAN NAN NAN 21.16 20.52 NAN 19.47 NAN NAN 
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WIZ O95785 26 23.06 21.91 22.58 23.26 23.00 23.15 22.65 22.33 21.93 21.98 
WRNIP1 Q96S55 9 NAN NAN NAN NAN 20.28 20.37 20.76 20.09 NAN 20.59 
WWTR1 Q9GZV5 11 19.90 NAN 21.04 23.25 23.84 23.70 22.48 22.33 20.29 21.44 
XIAP P98170 4 NAN NAN NAN NAN 20.02 19.68 19.63 19.14 NAN NAN 
XPC Q01831 10 NAN NAN NAN NAN 21.19 21.68 20.68 20.38 21.04 20.95 
XPO1 O14980 38 22.50 23.22 24.19 24.73 25.13 25.17 25.13 24.83 23.84 24.12 
XPO4 Q9C0E2 8 NAN NAN NAN NAN 19.57 19.79 NAN 19.06 NAN NAN 
XPO5 Q9HAV4 19 20.15 NAN 21.37 21.31 21.80 21.86 22.21 21.25 20.95 21.16 
XPO6 Q96QU8 17 NAN NAN 20.68 21.26 22.64 23.51 22.42 22.27 NAN NAN 
XPO7 Q9UIA9 12 NAN NAN NAN NAN 21.34 21.46 21.34 20.64 NAN NAN 
XPOT O43592 22 19.97 NAN 20.88 21.45 23.61 23.24 22.96 22.77 20.20 21.97 
XRCC5 P13010 29 24.15 25.14 23.13 24.36 23.60 23.91 25.27 24.54 24.63 24.84 
XRCC6 P12956 27 25.52 25.63 24.66 24.98 24.97 25.24 25.70 25.19 25.48 25.88 
XRN2 Q9H0D6 31 22.48 23.07 23.26 23.89 24.87 25.20 24.32 23.98 23.20 23.56 
YAP1 P46937 15 22.56 20.52 23.83 24.44 25.30 25.58 24.00 24.70 23.37 23.36 
YBX1 P67809 5 20.74 20.27 NAN 20.87 19.47 19.27 20.36 19.23 19.76 20.54 
YLPM1 P49750 14 20.55 21.02 21.42 21.16 20.20 20.47 20.87 20.94 20.63 20.27 
YWHAB P31946 11 NAN NAN 22.66 23.27 22.62 22.74 22.86 23.26 22.40 22.46 
YWHAE P62258 16 23.62 24.22 23.94 23.88 24.47 24.90 24.62 25.37 23.60 23.96 
YWHAG P61981 12 21.74 NAN NAN 23.35 22.64 22.47 23.00 23.49 22.56 23.02 
YWHAH Q04917 8 NAN NAN NAN NAN 20.39 20.95 21.02 20.87 NAN 20.81 
YWHAQ P27348 14 22.74 22.29 23.20 23.00 22.98 23.58 23.54 23.64 23.21 23.73 
YWHAZ P63104 13 22.31 22.39 23.23 22.77 23.83 23.94 23.87 25.34 23.37 24.08 
YY1 P25490 10 21.99 NAN NAN 21.75 21.58 21.55 21.70 21.42 21.44 21.67 
ZBTB10 Q96DT7 13 NAN NAN NAN NAN 22.01 22.75 21.54 20.96 NAN 20.28 
ZBTB20 Q9HC78 16 NAN NAN 21.50 NAN 23.27 23.99 21.40 21.23 19.95 20.30 
ZBTB33 Q86T24 8 NAN NAN NAN NAN 20.48 20.74 20.38 20.09 NAN NAN 
ZBTB4 Q9P1Z0 16 NAN NAN NAN NAN 23.14 23.22 21.08 20.98 NAN 17.70 
ZBTB40 Q9NUA8 7 NAN NAN NAN NAN 19.90 20.08 20.28 19.77 NAN NAN 
ZBTB43 O43298 7 NAN NAN NAN NAN 21.49 21.64 20.78 20.55 NAN NAN 
ZBTB44 Q8NCP5 4 NAN NAN NAN NAN 19.43 19.88 19.55 18.94 NAN NAN 
ZBTB5 O15062 10 NAN NAN NAN NAN 21.61 22.02 21.11 20.58 NAN NAN 
ZBTB7A O95365 10 NAN NAN NAN 20.56 21.59 22.00 21.67 21.07 NAN 21.00 
ZBTB9 Q96C00 7 NAN NAN NAN 20.99 22.59 22.63 21.41 20.65 NAN 20.76 
ZC3H14 Q6PJT7 10 NAN NAN NAN 20.85 20.85 21.35 21.25 20.87 NAN 19.83 
ZFHX1B O60315 8 NAN NAN NAN NAN 20.10 20.32 20.12 19.78 NAN NAN 
ZFHX3 Q15911 9 NAN NAN NAN NAN 19.63 19.81 19.51 19.40 NAN NAN 
ZFR Q96KR1 13 NAN NAN 20.58 21.83 21.21 21.42 21.67 21.25 20.46 20.58 
ZGPAT Q8N5A5 12 NAN NAN NAN 20.91 20.50 20.92 20.69 20.29 20.04 20.03 
ZIC2 O95409 2 22.31 21.37 NAN NAN NAN NAN NAN NAN NAN NAN 
ZKSCAN1 P17029 9 NAN NAN NAN NAN 21.80 22.18 20.90 21.19 20.19 20.58 
ZKSCAN8 Q15776 4 NAN NAN NAN NAN 19.80 19.31 NAN NAN NAN NAN 
ZMIZ1 Q9ULJ6 25 NAN NAN 23.38 24.98 26.97 26.97 25.81 25.96 23.62 23.87 
ZMIZ2 Q8NF64 17 NAN NAN NAN 23.19 24.31 24.91 22.60 23.13 21.27 21.07 
ZMYM4 Q5VZL5 26 22.43 21.22 20.58 22.13 22.68 23.02 22.98 22.17 21.92 22.76 
ZNF106 Q9H2Y7 21 NAN NAN NAN NAN 22.00 22.37 20.26 19.20 NAN NAN 
ZNF148 Q9UQR1 14 NAN NAN NAN 20.84 21.83 21.44 22.21 21.52 22.14 22.03 
ZNF198 Q9UBW7 14 23.46 22.97 NAN 20.90 20.82 20.72 21.23 19.99 NAN NAN 
ZNF207 O43670 5 21.02 NAN 21.27 22.51 22.03 21.86 22.38 21.63 21.66 21.73 
ZNF217 O75362 10 20.71 20.84 NAN 21.21 20.57 20.71 20.87 20.31 NAN NAN 
ZNF219 Q9P2Y4 7 19.89 19.49 NAN NAN 19.56 19.73 NAN 19.35 NAN NAN 
ZNF239 Q16600 2 NAN NAN NAN NAN 18.62 18.92 NAN NAN NAN NAN 
ZNF24 P17028 13 NAN NAN NAN NAN 22.95 22.90 21.85 22.16 21.23 21.41 
ZNF281 Q9Y2X9 26 21.53 21.91 20.25 20.12 23.58 24.41 21.97 22.37 20.04 20.96 
ZNF282 Q9UDV7 6 NAN NAN NAN NAN 21.37 21.08 20.15 NAN NAN NAN 
ZNF292 O60281 12 NAN NAN NAN NAN 19.91 19.92 19.53 19.51 NAN NAN 
ZNF296 Q8WUU4 11 NAN NAN NAN 22.04 22.77 23.03 22.98 23.09 NAN NAN 
ZNF318 Q5VUA4 9 NAN NAN NAN NAN 20.69 20.53 20.18 20.65 NAN NAN 
ZNF319 Q9P2F9 4 NAN NAN NAN 20.21 20.01 20.53 20.35 19.09 NAN 20.41 
ZNF326 Q5BKZ1 10 21.99 22.16 NAN 21.48 21.26 21.21 21.68 21.14 22.00 21.39 
ZNF362 Q5T0B9 7 NAN NAN NAN NAN 20.71 20.54 20.14 19.67 NAN NAN 
ZNF384 Q8TF68 13 20.94 21.88 22.72 23.17 24.12 25.03 23.73 23.86 22.52 22.87 
ZNF462 Q96JM2 27 23.68 24.45 NAN NAN 20.80 20.31 19.28 21.22 NAN NAN 
ZNF499 Q96K62 13 NAN NAN NAN 20.91 23.51 23.87 21.31 21.20 NAN 20.03 
ZNF503 Q96F45 13 NAN NAN 21.64 22.56 22.86 23.41 23.17 23.63 20.73 21.43 
ZNF512 Q96ME7 14 NAN NAN NAN NAN 22.50 22.36 22.22 21.44 22.16 22.03 
ZNF512B Q96KM6 10 NAN NAN NAN NAN 21.85 21.38 20.66 20.06 NAN NAN 
ZNF516 Q92618 6 NAN NAN NAN NAN 20.20 20.41 20.39 NAN NAN NAN 
ZNF532 Q9HCE3 4 21.14 19.81 NAN NAN NAN NAN NAN NAN NAN NAN 
ZNF581 Q9P0T4 4 NAN NAN NAN NAN 20.03 20.97 19.49 NAN NAN NAN 
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ZNF609 O15014 17 NAN NAN NAN NAN 22.61 23.19 22.06 20.80 NAN 19.85 
ZNF646 O15015 8 NAN NAN NAN NAN 19.32 19.31 18.38 NAN NAN NAN 
ZNF703 Q9H7S9 6 NAN NAN NAN 20.43 20.82 21.23 20.50 20.47 NAN NAN 
ZNF746 Q6NUN9 5 NAN NAN NAN NAN 20.75 21.03 19.33 19.30 NAN NAN 
ZNF770 Q6IQ21 6 19.91 NAN NAN NAN 19.46 20.10 18.67 NAN 19.14 19.65 
ZNF787 Q6DD87 6 NAN NAN NAN NAN 20.31 20.88 20.44 19.60 19.72 19.72 
ZNF827 Q17R98 4 NAN NAN NAN NAN 20.26 21.77 21.39 20.85 NAN NAN 
ZNF865 P0CJ78 12 NAN NAN NAN NAN 22.68 22.53 19.95 20.70 20.19 20.91 
ZRANB2 O95218 12 NAN NAN NAN 21.85 22.51 22.41 22.46 21.99 22.57 22.59 
ZYX Q15942 7 NAN NAN NAN NAN NAN NAN 20.55 19.86 20.89 20.84 
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Table 6.2 Identified Proteins SILAC and differential enrichment analysis 
HF/hES_1 HF/hES_2 HF/hES_3 Signifi Peptides Log T-test p-
value  
T-test Diff  Genename UniProtRev 
1.42266 1.59053 1.5065 yes 13 2.98588 1.50656 ABCD3 P28288 
1.05977 1.06833 1.14039 yes 6 3.25947 1.0895 ABCF2 Q9UG63 
2.12257 2.03012 2.1681 yes 30 3.43066 2.10693 ACADVL P49748 
1.77678 NaN 1.62176 yes 12 1.53733 1.69927 ACOX1 Q15067 
1.4328 1.6931 1.91926 yes 69 2.1604 1.68172 ACTN4 O43707 
1.40218 0.883464 1.18796 yes 13 1.78312 1.15787 ACTR1A P61163 
0.864969 1.10125 1.44239 yes 8 1.67626 1.1362 ADAM9 Q13443 
1.61027 1.59908 1.55528 yes 6 3.95236 1.58821 AFAP1 Q8N556 
4.13824 3.45536 3.98687 yes 223 2.54288 3.86016 AHNAK Q09666 
3.64996 3.18487 3.66562 yes 22 2.6938 3.50015 ALCAM Q13740 
1.56423 1.76922 1.48151 yes 18 2.54867 1.60499 ALDH1B1 P30837 
1.65265 1.28155 1.04124 yes 12 1.75601 1.32515 ALDH1L2 Q3SY69 
2.01888 1.44821 1.73535 yes 10 2.05041 1.73415 ANO10 Q9NW15 
5.78897 3.68437 3.53107 yes 39 1.5671 4.3348 ANPEP P15144 
1.20727 0.899717 1.20552 yes 32 2.07248 1.10417 ANXA2 P07355 
1.16008 0.708408 1.45202 yes 12 1.44208 1.10684 AP1M1 Q9BXS5 
1.63993 1.57119 1.61758 yes 37 3.80093 1.60957 AP2A1 O95782 
1.1161 0.898015 1.06592 yes 47 2.38722 1.02668 AP2B1 P63010 
1.44403 1.33988 1.38449 yes 19 3.3269 1.38947 AP2M1 Q96CW1 
1.10621 1.16446 1.13862 yes 14 3.65798 1.13643 APMAP Q9HDC9 
1.37907 1.33165 1.37557 yes 6 3.90157 1.3621 ARF6 P62330 
1.70306 1.18333 1.38482 yes 9 1.95452 1.42374 ARHGEF2 Q92974 
1.31522 0.887213 1.48269 yes 12 1.69457 1.22837 ARPC1B O15143 
3.66857 2.93766 2.54693 yes 26 1.94274 3.05105 ASPH Q12797 
2.8125 3.47457 2.95786 yes 23 2.37439 3.08164 ATL3 Q6DD88 
3.49902 3.01535 3.66721 yes 38 2.48176 3.39386 ATP2B4 P23634 
2.72467 3.0616 NaN yes 4 1.43147 2.89313 B2M P61769 
1.21257 1.4444 1.17409 yes 13 2.3623 1.27702 BCAP31 P51572 
1.20814 1.27906 1.15218 yes 23 3.0388 1.21313 CALR P27797 
3.79223 3.82385 3.60987 yes 24 3.49836 3.74198 CALU O43852 
1.69095 1.017 1.58914 yes 8 1.6824 1.43236 CAMK2D Q13557 
2.05415 1.10601 1.77589 yes 14 1.55249 1.64535 CAPN2 P17655 
2.04324 1.80896 2.35361 yes 12 2.23925 2.0686 CAV1 Q03135 
4.08398 3.42761 3.50818 yes 30 2.50158 3.67326 CD109 Q6YHK3 
3.46845 3.48736 3.40558 yes 11 4.29058 3.4538 CD44 P16070 
3.68796 2.98162 3.86305 yes 5 2.23381 3.51088 CD59 P13987 
1.90839 1.64741 1.71035 yes 3 2.69886 1.75538 CD63 P08962 
1.2822 1.34051 1.44747 yes 4 2.89624 1.35673 CD81 P60033 
3.02735 3.39451 2.68107 yes 8 2.33945 3.03431 CFL2 Q9Y281 
0.974089 1.1562 0.977023 yes 5 2.47323 1.03577 CIRBP Q14011 
2.07608 2.01607 2.02137 yes 37 4.05265 2.03784 CKAP4 Q07065 
1.3058 1.31168 1.51263 yes 8 2.61445 1.3767 CNP P09543 
1.78831 1.65246 1.7191 yes 48 3.28438 1.71996 COL12A1 Q99715 
3.95726 2.90597 3.22517 yes 33 2.0729 3.3628 COL1A1 P02452 
3.24236 3.14217 3.18856 yes 32 4.08466 3.19103 COL1A2 P08123 
3.56998 3.27196 4.28695 yes 24 2.1852 3.70963 COL6A1 P12109 
3.34028 2.49244 3.02595 yes 14 2.15803 2.95289 COL6A2 P12110 
1.81959 2.94146 2.87434 yes 91 1.70395 2.54513 COL6A3 P12111 
2.41616 2.05106 2.21017 yes 10 2.64841 2.2258 COLGALT1 Q8NBJ5 
2.4493 2.81856 2.38612 yes 15 2.55561 2.55133 COMT P21964 
1.24799 1.21735 1.52396 yes 23 2.27304 1.32977 CORO1C Q9ULV4 
4.09609 3.86691 4.17608 yes 4 3.28079 4.04636 CRIP2 P52943 
1.84358 1.86647 1.74537 yes 13 3.37991 1.81847 CRTAP O75718 
3.6828 3.96421 3.50195 yes 13 2.88369 3.71632 CRYAB P02511 
NaN 1.1167 1.1034 yes 8 2.41864 1.11005 CTBP1 Q13363 
3.04315 2.15678 2.45217 yes 10 1.9882 2.5507 CTSA P10619 
4.63906 3.2878 3.45641 yes 14 1.90937 3.79442 CTSB P07858 
3.03466 2.88899 2.89468 yes 19 3.58082 2.93944 CYB5R3 P00387 
2.74155 2.55046 3.04883 yes 17 2.56623 2.78028 DAB2 P98082 
1.33594 1.01628 1.09484 yes 28 2.15909 1.14902 DCTN1 Q14203 
1.66084 1.77594 1.48393 yes 6 2.5735 1.64024 DECR1 Q16698 
1.65892 1.83374 1.19182 yes 24 1.83195 1.56149 DNAJC13 O75165 
1.94565 2.02343 NaN yes 8 1.904 1.98454 ECE1 P42892 
1.62989 1.74687 1.47933 yes 17 2.64195 1.6187 ECI2 O75521 
3.14117 3.47962 3.9631 yes 26 2.34304 3.52796 EHD2 Q9NZN3 
2.3147 2.54809 2.61181 yes 4 2.88232 2.49153 ELOVL1 Q9BW60 
1.22645 2.0121 1.78425 yes 12 1.724 1.67427 EMD P50402 
2.42715 1.36642 1.31777 yes 13 1.37376 1.70378 ERBB2IP Q96RT1 
1.89185 2.36457 2.21785 yes 9 2.38049 2.15809 ERGIC1 Q969X5 
1.04488 0.974676 NaN yes 6 1.65519 1.00978 ERLEC1 Q96DZ1 
1.78211 1.56311 1.59077 yes 14 2.75778 1.64533 ERLIN1 O75477 
2.09855 2.00906 1.80715 yes 16 2.72005 1.97159 ERO1L Q96HE7 
2.76477 2.37887 2.82028 yes 19 2.56493 2.65464 ESYT2 A0FGR8 
1.73829 1.58919 1.58275 yes 12 3.01674 1.63674 ETFA P13804 
1.55208 1.48342 1.3514 yes 12 2.7911 1.4623 ETFB P38117 
1.67978 1.30422 1.61829 yes 3 2.24426 1.5341 FAHD1 Q6P587 
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0.836813 1.28913 1.49523 yes 18 1.60236 1.20706 FAM120A Q9NZB2 
2.83402 2.43095 3.03164 yes 23 2.39148 2.76554 FAM129B Q96TA1 
1.14522 1.56511 1.26592 yes 13 2.05794 1.32542 FARP1 Q9Y4F1 
3.18558 2.23701 2.86882 yes 21 1.99894 2.7638 FBLN2 P98095 
2.57007 2.1845 2.17916 yes 18 2.50571 2.31124 FHL2 Q14192 
2.1845 2.13606 2.45512 yes 26 2.71528 2.25856 FKBP10 Q96AY3 
1.6658 1.83596 1.76952 yes 3 3.10068 1.75709 FKBP11 Q9NYL4 
1.40037 1.75519 1.49769 yes 3 2.33491 1.55108 FKBP2 P26885 
3.4957 2.70131 3.24041 yes 16 2.26007 3.14581 FKBP9 O95302 
1.17773 0.95017 1.17133 yes 29 2.33767 1.09974 FLII Q13045 
1.22602 0.799336 1.22039 yes 141 1.77905 1.08192 FLNA P21333 
1.79847 0.933799 1.70266 yes 146 1.48677 1.47831 FLNC Q14315 
5.61291 5.014 5.27534 yes 103 2.97149 5.30075 FN1 P02751 
1.67016 1.09038 1.34142 yes 15 1.83149 1.36732 FNDC3B Q53EP0 
1.12174 0.822852 1.40996 yes 4 1.65339 1.11818 FTL P02792 
1.64492 0.975557 1.15523 yes 14 1.6137 1.25857 G6PD P11413 
1.75039 2.13596 2.32328 yes 9 2.18223 2.06988 GBA P04062 
3.12408 2.21801 2.18739 yes 18 1.83392 2.50983 GBE1 Q04446 
1.47659 1.04089 1.29443 yes 21 2.01136 1.27064 GBF1 Q92538 
1.49477 1.18447 1.2225 yes 9 2.25202 1.30058 GLB1 P16278 
1.50213 1.87778 1.59364 yes 23 2.33523 1.65785 GLS O94925 
1.77227 1.38973 0.888695 yes 13 1.46757 1.35023 GNA11 P29992 
1.1141 1.21952 1.30001 yes 15 2.7057 1.21121 GNAS O95467 
1.41841 1.65434 1.68383 yes 6 2.55371 1.58553 GNG12 Q9UBI6 
1.35991 1.10909 0.738206 yes 9 1.56278 1.06907 GNS P15586 
1.60103 1.73946 1.17983 yes 11 1.91204 1.50677 GOLIM4 O00461 
3.3069 4.35304 3.98222 yes 12 2.20976 3.88072 GPC1 P35052 
2.26475 2.46543 2.26261 yes 15 3.08018 2.33093 GSN P06396 
2.24577 2.2578 1.58294 yes 5 1.92576 2.02884 GSTK1 Q9Y2Q3 
2.42108 2.72395 NaN yes 5 1.42675 2.57252 H1F0 P07305 
1.53247 1.20995 1.36244 yes 12 2.337 1.36829 H2AFY O75367 
1.25972 1.18732 1.20232 yes 14 3.4831 1.21645 HADHB P55084 
1.44223 1.49447 1.58818 yes 40 3.09673 1.50829 HDLBP Q00341 
1.31968 1.03196 1.47773 yes 8 1.98763 1.27646 HEXB P07686 
1.10615 NaN 1.12552 yes 9 2.25763 1.11584 HIST1H1E P10412 
2.21356 2.75967 2.57492 yes 14 2.39381 2.51605 HLA-A P01891 
2.2131 1.58559 1.57884 yes 6 1.87008 1.79251 HM13 Q8TCT9 
2.73583 2.22722 2.42167 yes 13 2.44324 2.46157 HMOX1 P09601 
0.947853 1.19912 1.10313 yes 23 2.34344 1.08337 HNRNPUL2 Q1KMD3 
2.78088 2.71644 1.88955 yes 13 1.87574 2.46229 HP1BP3 Q5SSJ5 
1.89313 1.14835 1.62784 yes 14 1.72013 1.55644 HSPB1 P04792 
2.87527 2.60279 2.41622 yes 55 2.59247 2.63143 HSPH1 Q92598 
2.02382 1.97493 1.87129 yes 19 3.27759 1.95668 IDH2 P48735 
1.24147 0.953228 1.08651 yes 13 2.24043 1.09374 IKBIP Q70UQ0 
1.42299 1.90095 1.90203 yes 10 2.08199 1.74199 IKBIP Q70UQ0 
1.1121 0.790105 1.1501 yes 11 1.90785 1.01743 ILK Q13418 
1.43819 1.65526 1.37579 yes 6 2.49261 1.48975 IMPAD1 Q9NX62 
2.87784 2.13836 1.75116 yes 19 1.68197 2.25579 INF2 Q27J81 
1.0966 0.857344 1.20226 yes 84 2.03272 1.05207 IQGAP1 P46940 
2.20267 2.46009 2.287 yes 14 2.97141 2.31659 ITGA3 P26006 
2.58251 1.92809 2.00526 yes 19 2.04977 2.17195 ITGA5 P08648 
1.34307 1.29872 1.46415 yes 29 2.88531 1.36865 ITGB1 P05556 
2.32048 2.16989 2.21863 yes 9 3.40527 2.23633 KDELC2 Q7Z4H8 
0.882134 1.22534 1.07011 yes 1 2.06238 1.05919 KRTCAP2 Q8N6L1 
1.41576 1.35168 1.39226 yes 8 3.73957 1.38657 LAMP1 P11279 
1.0943 1.81709 1.8431 yes 5 1.63557 1.58483 LAMP2 P13473 
1.89848 1.32377 1.67956 yes 21 1.9854 1.63394 LDHA P00338 
2.24132 2.05304 2.3364 yes 15 2.84893 2.21025 LEPREL2 Q8IVL6 
3.40531 2.97878 3.21406 yes 10 2.82884 3.19938 LGALS1 P09382 
1.10091 1.05262 1.04691 yes 14 3.58894 1.06681 LMAN1 P49257 
4.41799 3.88762 4.32128 yes 55 2.82453 4.20896 LMNA P02545 
3.43243 3.19128 4.57996 yes 58 1.88926 3.73456 LMO7 Q8WWI1 
1.65576 1.96761 1.78831 yes 80 2.6021 1.80389 LRP1 Q07954 
1.56793 1.54646 1.56647 yes 16 4.70544 1.56029 LRRC59 Q96AG4 
1.33142 0.970044 1.2112 yes 9 2.0897 1.17089 LRRFIP1 Q32MZ4 
1.32152 1.32671 1.0859 yes 6 2.39293 1.24471 MANF P55145 
NaN 3.24047 3.29256 yes 18 2.29449 3.26652 MAP1A P78559 
1.53107 0.898247 1.4863 yes 86 1.62812 1.30521 MAP1B P46821 
1.31927 1.29331 1.09275 yes 6 2.47609 1.23511 MARCKS P29966 
2.14783 1.82509 1.86005 yes 18 2.55999 1.94432 MFGE8 Q08431 
1.27041 1.14084 1.1877 yes 7 3.00199 1.19965 MGST3 O14880 
1.21481 1.05769 1.73057 yes 11 1.64936 1.33436 MMP14 P50281 
NaN 2.1311 2.2502 yes 10 1.76192 2.19065 MOXD1 Q6UVY6 
3.42962 2.61558 3.0968 yes 35 2.22484 3.04733 MRC2 Q9UBG0 
1.37446 1.0708 1.29378 yes 46 2.27844 1.24635 MSN P26038 
1.59732 1.50238 0.983094 yes 10 1.71867 1.36093 MTDH Q86UE4 
3.38142 3.49812 3.05728 yes 40 2.80098 3.31227 MVP Q14764 
1.92907 2.80983 2.7096 yes 3 1.90869 2.48283 MYDGF Q969H8 
1.24001 0.542109 1.23707 yes 175 1.3071 1.0064 MYH9 P35579 
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1.65402 1.45801 1.58861 yes 12 2.86985 1.56688 MYO1B O43795 
2.45033 2.05679 2.29769 yes 45 2.59503 2.26827 MYO1C O00159 
3.19104 3.02217 3.53506 yes 97 2.66759 3.24942 MYOF Q9NZM1 
1.07738 0.943209 1.10996 yes 6 2.62294 1.04352 NANS Q9NR45 
3.92391 3.23619 2.86213 yes 11 2.06794 3.34074 NCEH1 Q6PIU2 
3.05625 2.33685 1.6663 yes 8 1.55476 2.35313 NEK7 Q8TDX7 
2.39383 1.99143 1.81791 yes 6 2.17156 2.06772 NIPSNAP3A Q9UFN0 
1.98732 2.11043 1.93621 yes 14 3.18033 2.01132 NNT Q13423 
1.41115 1.13632 1.74846 yes 12 1.82566 1.43198 NPC1 O15118 
1.70182 2.04558 1.95736 yes 4 2.5338 1.90159 NPTN Q9Y639 
1.51974 1.98251 1.24823 yes 18 1.74872 1.58349 NSF P46459 
5.426 5.32589 5.72438 yes 26 3.3237 5.49209 NT5E P21589 
2.10212 2.52103 2.50238 yes 9 2.48242 2.37518 NUCB2 P80303 
1.12459 1.02694 0.857503 yes 49 2.22207 1.00301 NUMA1 Q14980 
1.18701 1.20714 1.03823 yes 27 2.66545 1.14413 OGDH Q02218 
1.89325 1.72312 0.971884 yes 10 1.48694 1.52942 OSBPL3 Q9H4L5 
2.60711 2.60628 2.4283 yes 26 3.26396 2.54723 P4HA1 P13674 
4.27008 3.71083 3.34823 yes 17 2.30074 3.77638 P4HA2 O15460 
2.23695 2.09004 2.16553 yes 43 3.4158 2.16417 P4HB P07237 
1.15536 1.15108 1.50223 yes 6 2.08125 1.26956 PARVA Q9NVD7 
1.55075 1.90064 1.62691 yes 15 2.4072 1.69277 PCYOX1 Q9UHG3 
1.89231 1.70186 1.80385 yes 18 3.02972 1.79934 PDLIM7 Q9NR12 
1.39523 1.35671 1.38394 yes 19 4.16264 1.37863 PICALM Q13492 
1.9492 1.56487 1.64289 yes 24 2.33505 1.71899 PITRM1 Q5JRX3 
2.9735 2.72312 3.03385 yes 274 2.97192 2.91016 PLEC Q15149 
2.49226 2.91209 2.73327 yes 26 2.69793 2.71254 PLOD1 Q02809 
2.32987 2.15779 2.39023 yes 21 3.03561 2.29263 PLOD2 O00469 
2.20376 2.24607 2.02606 yes 22 3.01166 2.15863 PLOD3 O60568 
1.47415 1.34721 1.72953 yes 5 2.2638 1.51696 POFUT1 Q9H488 
NaN 2.60466 2.58513 yes 4 2.62057 2.5949 PPAP2B O14495 
1.79539 1.21083 1.62887 yes 11 1.90555 1.54503 PPFIBP1 Q86W92 
1.38305 1.34806 1.42514 yes 14 3.5874 1.38542 PPIB P23284 
1.4453 1.41099 1.37868 yes 9 3.73142 1.41166 PRKACA P17612 
3.85619 2.12005 2.604 yes 7 1.506 2.86008 PRKACA P17252 
2.1173 1.73695 1.97596 yes 10 2.48862 1.9434 PRKAR1A P10644 
2.11673 2.27304 2.81574 yes 5 2.11421 2.40184 PRKCDBP Q969G5 
0.938323 1.20239 1.13934 yes 22 2.27889 1.09335 PTK7 Q13308 
3.17714 2.69797 3.27253 yes 14 2.47088 3.04921 PTRF Q6NZI2 
0.91127 1.11317 1.40218 yes 2 1.81812 1.14221 PTTG1IP P53801 
1.43749 1.2969 1.94107 yes 31 1.813 1.55849 PYGB P11216 
1.42551 1.54473 1.37535 yes 16 2.92067 1.44853 RAB14 P61106 
1.08929 1.28291 1.21064 yes 13 2.65174 1.19428 RAB2 P61019 
2.67399 2.70119 2.79165 yes 8 3.76795 2.72228 RAB3B P20337 
1.22169 0.924404 1.20696 yes 10 2.13033 1.11768 RAB5C P51148 
1.06261 0.975924 0.962068 yes 15 3.0053 1.0002 RAB7A P51149 
1.66776 2.06568 1.569 yes 19 2.13693 1.76748 RAI14 Q9P0K7 
1.33268 1.50833 1.48774 yes 16 2.83183 1.44292 RAP1B P61224 
1.28327 1.13704 1.30439 yes 19 2.74684 1.24157 RCN1 Q15293 
1.42659 1.66653 1.68415 yes 3 2.56697 1.59242 RER1 O15258 
1.95375 1.56686 2.93569 yes 11 1.46829 2.1521 RFTN1 Q14699 
1.84699 1.53968 2.17444 yes 19 2.01621 1.8537 RNH1 O60930 
5.23281 4.55391 5.00342 yes 7 2.78738 4.93005 RPL14 P50914 
1.04299 1.07594 0.933648 yes 31 2.74923 1.01753 RPN1 P04843 
2.32579 3.12153 2.47207 yes 8 2.07199 2.6398 RRAS P10301 
1.66993 1.73223 1.6597 yes 65 3.74379 1.68729 RRBP1 Q9P2E9 
1.64533 1.54587 1.6089 yes 14 3.48212 1.60003 RTN4 Q9NQC3 
4.27068 3.37615 3.92458 yes 3 2.34413 3.85714 S100A6 P06703 
2.3691 2.38006 2.06533 yes 13 2.68718 2.2715 SCARB2 Q14108 
1.91112 1.29048 1.70097 yes 9 1.91329 1.63419 SCCPDH Q8NBX0 
1.67487 2.06361 1.4518 yes 8 1.97849 1.73009 SCP2 O14595 
0.780814 1.33297 1.04852 yes 5 1.65529 1.0541 SDF2 Q99470 
1.66084 2.03569 1.80587 yes 4 2.45328 1.83413 SEC22B O75396 
1.9539 2.12578 2.086 yes 13 3.19499 2.05523 SEC22B O75396 
1.53973 1.32953 1.42546 yes 28 2.74561 1.43157 SEC23A Q15436 
1.22946 1.61245 1.49667 yes 12 2.21518 1.44619 SEC24D O94855 
1.25133 1.0497 1.25936 yes 11 2.47843 1.1868 SEC61A1 P61619 
1.48862 1.35688 NaN yes 10 1.53087 1.42275 SEL1L Q9UBV2 
1.35581 1.12935 1.47643 yes 13 2.23041 1.32053 Sep-11 Q9NVA2 
2.30547 1.83649 1.9813 yes 8 2.33891 2.04109 SERPINE1 P05121 
1.65608 1.31075 1.95877 yes 10 1.89442 1.64187 SH3BP4 Q9P0V3 
2.93452 4.61105 4.12895 yes 9 1.79574 3.89151 SLC1A5 Q15758 
1.76702 1.78676 1.3634 yes 5 2.15435 1.63906 SLC38A2 Q96QD8 
1.76859 1.38278 1.78396 yes 9 2.20038 1.64511 SLC7A1 P30825 
1.5007 1.25629 1.10969 yes 10 2.11134 1.28889 SMARCC2 Q8TAQ2 
1.21829 0.954345 1.11343 yes 11 2.31238 1.09535 SNX9 Q9Y5X1 
1.1447 1.22725 0.915406 yes 4 2.14452 1.09579 SOD2 P04179 
1.46587 1.84611 1.35795 yes 14 2.04942 1.55664 SRPR P08240 
1.24367 1.44424 1.37579 yes 13 2.72513 1.35457 SRPRB Q9Y5M8 
4.26123 4.20469 3.41278 yes 11 2.32328 3.95957 STOM P27105 
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0.947255 1.06488 1.04872 yes 18 2.88632 1.02029 STT3A P46977 
1.07772 1.29243 0.98156 yes 14 2.17414 1.11724 STT3B Q8TCJ2 
1.37857 1.27453 1.16755 yes 8 2.64203 1.27355 STX12 Q86Y82 
1.6532 1.98907 2.71339 yes 10 1.67541 2.11855 SUCLG2 Q96I99 
3.18967 2.55255 1.96584 yes 20 1.73526 2.56935 SUN2 Q9UH99 
2.15196 1.90612 2.0191 yes 7 2.91089 2.02573 TBL2 Q9Y4P3 
NaN 1.55105 1.75587 yes 3 1.40473 1.65346 TEAD1 P28347 
1.24951 1.26303 1.07608 yes 10 2.59821 1.19621 TLDC1 Q6P9B6 
2.0256 1.55243 2.01228 yes 126 2.1614 1.86344 TLN1 Q9Y490 
1.43301 1.57681 1.70783 yes 14 2.59564 1.57255 TMEM214 Q6NUQ4 
2.1398 1.9185 2.10852 yes 19 2.94709 2.05561 TMEM43 Q9BTV4 
2.20135 2.00899 2.22639 yes 8 2.99016 2.14558 TMX3 Q96JJ7 
2.09322 1.45828 3.17239 yes 24 1.33355 2.2413 TOMM20 Q15388 
2.09217 1.8 2.31803 yes 36 2.28348 2.07007 TPM1 P09493 
2.42121 2.55766 2.23863 yes 6 2.83199 2.40583 TRAM2 Q15035 
1.40844 1.45775 1.55812 yes 14 3.05036 1.47477 TRIM25 Q14258 
1.7015 1.53933 1.56613 yes 17 3.00891 1.60232 TXNDC5 Q8NBS9 
2.57606 2.05592 2.23441 yes 12 2.35502 2.2888 UAP1 Q16222 
2.09376 1.72979 1.99237 yes 23 2.50657 1.93864 UGDH O60701 
3.47599 3.02489 3.53767 yes 70 2.63357 3.34618 VIM P08670 
1.4984 0.834064 1.17204 yes 8 1.58651 1.16817 WFS1 O76024 
2.13763 1.57206 1.86568 yes 9 2.1173 1.85846 FAM114A1 Q8IWE2 
1.40076 1.86386 1.69381 yes 20 2.17852 1.65281 P3H1 Q32P28 
-1.68548 -1.94197 -1.82623 yes 38 2.77989 -1.81789 AARS P49588 
-2.40645 -2.70237 -2.36982 yes 25 2.74989 -2.49288 AASS Q9UDR5 
-3.32063 -3.12608 NaN yes 4 1.71656 -3.22336 ABRACL Q9P1F3 
-2.04579 -2.43792 -2.00613 yes 10 2.39438 -2.16328 ACAT2 Q9BWD1 
-1.30465 -1.78996 -1.10628 yes 9 1.69058 -1.4003 ACOT7 O00154 
-2.10569 -1.99286 -1.84492 yes 22 2.83883 -1.98116 ADFP Q99541 
-1.08061 -1.47361 -1.2285 yes 7 2.08833 -1.26091 ADH5 P11766 
-1.6486 -1.92309 -1.78289 yes 9 2.70655 -1.78486 ADSL P30566 
-1.64598 -1.81284 -1.82414 yes 12 2.97143 -1.76099 ADSS P30520 
-1.0949 NaN -1.22482 yes 14 1.44833 -1.15986 AFG3L2 Q9Y4W6 
-1.99798 -2.32402 -1.85481 yes 13 2.34523 -2.05894 AHCY P23526 
NaN -1.2224 -1.25508 yes 7 2.07587 -1.23874 AHSA1 O95433 
-1.71378 -2.31315 -2.06431 yes 10 2.13956 -2.03041 AK4 P27144 
-0.91001 -1.7574 -1.52807 yes 9 1.50561 -1.39849 AKR1A1 P14550 
-0.89183 -1.38048 -1.00058 yes 7 1.74618 -1.09096 AKR1B1 P15121 
-2.03635 -1.87535 -1.60753 yes 13 2.33825 -1.83974 ALDH2 P05091 
-1.49537 -1.26732 -1.54406 yes 15 2.45447 -1.43558 ALDH3A2 P51648 
-0.84285 -1.14321 -1.0185 yes 19 2.12598 -1.00152 ALDH7A1 P49419 
-2.20124 -4.23107 -2.67567 yes 19 1.41525 -3.03599 ANXA3 P12429 
-1.21083 -1.21998 -1.16884 yes 14 3.76412 -1.19988 APEH P13798 
-1.54612 -1.44788 -1.59379 yes 20 3.10344 -1.52926 APP P05067 
-1.56281 NaN -1.79196 yes 5 1.36234 -1.67738 ARFGAP2 Q8N6H7 
-2.16838 -2.39935 -2.43643 yes 18 2.89024 -2.33472 ASNS P08243 
-1.65222 -2.40408 -2.01905 yes 29 1.94713 -2.02512 ATIC P31939 
-1.19525 -1.36053 NaN yes 9 1.38603 -1.27789 BZW2 Q9Y6E2 
-1.11307 -0.9792 -1.19575 yes 6 2.48184 -1.09601 C1QBP Q07021 
-1.22119 -1.32822 -1.17547 yes 50 2.87735 -1.24163 CAD O76075 
-0.9718 -1.23216 -0.95364 yes 35 2.14103 -1.05253 CAND1 Q86VP6 
-1.36792 -2.20656 -1.81472 yes 12 1.75187 -1.7964 CAPG P40121 
-2.74623 -2.4412 -2.09752 yes 13 2.22904 -2.42832 CASP3 P42574 
-1.05919 -1.21957 -1.06389 yes 8 2.65187 -1.11422 CBX5 P45973 
-1.48645 -1.91664 -1.60573 yes 5 2.2331 -1.66961 CD2AP Q9Y5K6 
-1.37494 -1.83357 -1.80692 yes 11 2.10725 -1.67181 CDK1 P06493 
-1.32847 -1.2412 -1.09854 yes 16 2.52429 -1.22274 CEBPZ Q03701 
-1.60301 -1.88769 -1.36268 yes 6 2.06135 -1.61779 CHORDC1 Q9UHD1 
-1.63671 -1.92489 -1.4933 yes 14 2.24991 -1.68497 CKB P12277 
-2.08009 -3.26202 -2.38934 yes 24 1.73664 -2.57715 CNDP2 Q96KP4 
-1.14976 NaN -1.2059 yes 8 1.81904 -1.17783 COTL1 Q14019 
-1.42171 -2.56124 -3.22769 yes 9 1.34768 -2.40355 CRABP1 P29762 
-1.21736 -1.97132 -1.90622 yes 11 1.70817 -1.6983 CSDA P16989 
-1.16809 -1.27415 -1.26618 yes 42 3.11905 -1.23614 CSE1L P55060 
-1.4231 -2.25099 -1.62999 yes 9 1.71609 -1.76803 CSRP2 Q16527 
-2.11572 -2.48261 -2.60735 yes 9 2.42569 -2.40189 CTSC P53634 
-1.33763 -0.99859 -1.14258 yes 14 2.14866 -1.1596 CYP51A1 Q16850 
-1.45194 NaN -1.53337 yes 2 1.76043 -1.49265 DBI P07108 
-1.60942 NaN -1.59732 yes 3 2.6194 -1.60337 DDT P30046 
-1.15056 -0.95741 -1.27509 yes 5 2.17723 -1.12769 DDX52 Q9Y2R4 
-1.33232 -1.08259 -1.3054 yes 10 2.39278 -1.2401 DHCR24 Q15392 
-0.93066 -1.13046 -1.06079 yes 11 2.50156 -1.04063 DNAJA2 O60884 
-4.15889 -2.90703 -3.09764 yes 21 1.88751 -3.38785 DNMT3A Q9Y6K1 
-3.38683 -2.80037 -3.61823 yes 35 2.25965 -3.26848 DNMT3B Q9UBC3 
-1.64165 NaN -1.6385 yes 6 3.21371 -1.64007 DPPA4 Q7L190 
-2.26216 -2.67927 -2.40331 yes 26 2.60315 -2.44825 DPYSL3 Q14195 
-1.29396 -1.41758 -1.20946 yes 33 2.67141 -1.307 ECM29 Q5VYK3 
-1.25677 -1.13074 -1.26896 yes 11 2.88225 -1.21882 EIF4B P23588 
-1.48185 -1.69507 -1.52118 yes 39 2.75813 -1.56603 EZR P15311 
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-3.74346 -3.78958 -3.53977 yes 14 3.36443 -3.69094 FABP5 Q01469 
-2.34249 -1.95607 -2.29039 yes 7 2.51935 -2.19632 FADS2 O95864 
-1.52272 -1.22337 -1.0147 yes 10 1.86805 -1.2536 FAR1 Q8WVX9 
-1.25336 -1.72619 -1.28571 yes 90 1.9465 -1.42175 FASN P49327 
-2.55376 -2.37415 -2.46801 yes 20 3.35426 -2.46531 FDFT1 P37268 
-2.82409 -3.04716 -2.717 yes 25 2.93854 -2.86275 FKBP4 Q02790 
-1.44195 -1.68896 -1.31721 yes 29 2.26892 -1.48271 FSCN1 Q16658 
-1.58225 -1.55152 -1.69404 yes 9 3.14069 -1.60927 GALNT7 Q86SF2 
-2.15117 -2.14388 -1.93821 yes 26 2.94817 -2.07775 GART P22102 
-0.84601 -1.37464 -1.11832 yes 30 1.73778 -1.11299 GDI2 P50395 
-0.83524 -1.36264 -0.97628 yes 26 1.66784 -1.05805 GFPT1 Q06210 
-1.21846 -1.81553 -1.31775 yes 15 1.8005 -1.45058 GFPT2 O94808 
-2.74642 -2.49761 -2.37617 yes 15 2.73628 -2.54007 GJA1 P17302 
-3.94326 -3.2105 -2.66456 yes 23 1.90065 -3.27277 GLDC P23378 
-1.59571 -2.31115 -1.70237 yes 8 1.85671 -1.86974 GLO1 Q04760 
-1.17873 -2.08345 -1.58135 yes 11 1.5972 -1.61451 GLRX3 O76003 
-1.41812 -1.88092 -1.53772 yes 11 2.13551 -1.61225 GOT1 P17174 
-2.90142 -2.99551 -2.64629 yes 16 2.87311 -2.84774 GPC4 O75487 
-2.2133 -3.17762 -2.44796 yes 12 1.9164 -2.61296 GSTP1 P09211 
-1.32869 -2.01019 -1.59872 yes 3 1.84817 -1.64587 HINT1 P49773 
-1.41001 -1.56222 -1.37165 yes 3 2.79282 -1.44796 HMGA1 P17096 
-2.2051 -1.82235 -1.49281 yes 14 1.91079 -1.84009 HMGCS1 Q01581 
-1.49058 -1.89749 -1.56499 yes 54 2.24476 -1.65102 HSP90AB1 P08238 
-1.50226 -1.94442 -1.67853 yes 11 2.25096 -1.7084 HSP90AB2P Q58FF8 
-1.27883 -1.45894 -1.43792 yes 41 2.77872 -1.3919 HSPA4 P34932 
-1.83341 -1.78121 -1.85914 yes 44 3.80181 -1.82459 HSPD1 P10809 
-1.4385 -1.41565 -1.49513 yes 6 3.57604 -1.44976 HSPG2 P98160 
-3.29945 -3.05841 -3.30173 yes 17 3.20202 -3.21986 IDH1 O75874 
-2.95456 -3.57316 -3.78819 yes 21 2.28076 -3.43864 IGF2BP1 Q9NZI8 
-2.31559 -2.7502 -2.78607 yes 19 2.47875 -2.61729 IGF2BP3 O00425 
-1.21669 -1.3407 NaN yes 12 1.5108 -1.27869 IPO9 Q96P70 
-2.03262 -1.65799 -1.53621 yes 7 2.13847 -1.74227 ITM2B Q9Y287 
-2.24797 -2.57355 -2.44938 yes 18 2.81572 -2.42363 KPNA2 P52292 
-4.11299 -3.71867 -3.14573 yes 32 2.23376 -3.65913 KRT18 P05783 
-2.09486 -2.64232 -2.68205 yes 40 2.23526 -2.47308 L1TD1 Q5T7N2 
-0.99821 -1.30632 -0.98542 yes 33 2.04449 -1.09665 LARS Q9P2J5 
-1.35258 -1.57824 -1.38255 yes 8 2.61744 -1.43779 LBR Q14739 
-2.86145 -2.39441 -2.59492 yes 42 2.57491 -2.61693 LCP1 P13796 
-2.24264 -2.7818 -2.44717 yes 19 2.40257 -2.49054 LDHB P07195 
-3.79684 -3.45109 -4.00518 yes 14 2.73272 -3.75104 LIN28A Q9H9Z2 
-2.14784 -2.05625 -2.07339 yes 19 3.74366 -2.09249 LTA4H P09960 
-0.99536 -1.44136 -1.21307 yes 12 1.95795 -1.2166 MAGED2 Q9UNF1 
-1.22695 -1.11594 -1.2127 yes 24 3.06319 -1.1852 MAN2A1 Q16706 
-0.97361 -1.04802 -1.09237 yes 22 2.95379 -1.038 MARS P56192 
-1.75239 -1.49977 -1.28265 yes 12 2.09873 -1.5116 MCAM P43121 
-1.49167 -1.92774 -1.66997 yes 13 2.25798 -1.69646 MDH1 P40925 
-2.35078 -2.77369 -2.00451 yes 96 2.06316 -2.37633 MDN1 Q9NU22 
-1.17615 -1.42449 -1.08776 yes 10 2.17691 -1.22947 MGEA5 O60502 
-1.07039 -0.97457 -1.12208 yes 19 2.77695 -1.05568 MSH6 P52701 
-1.29396 -1.37737 -1.33214 yes 5 3.48655 -1.33449 MSMO1 Q15800 
-1.53458 -2.03115 -1.42217 yes 6 1.90563 -1.66263 MTAP Q13126 
-2.9011 -3.19232 -3.04347 yes 98 3.11852 -3.04563 MYH10 P35580 
-1.00468 -1.19021 -1.08418 yes 5 2.61823 -1.09302 NACA E9PAV3 
-1.27 -1.35255 -1.47827 yes 9 2.70853 -1.36694 NAMPT P43490 
-1.59527 -1.95355 -2.0399 yes 26 2.276 -1.86291 NASP P49321 
-2.4243 -3.15959 -2.51986 yes 70 2.14129 -2.70125 NES P48681 
-1.72991 -1.4467 -1.54806 yes 9 2.55972 -1.57489 NIPSNAP1 Q9BPW8 
-1.4432 -1.64156 -1.66901 yes 14 2.69694 -1.58459 NLN Q9BYT8 
-0.90023 -1.73677 -1.49728 yes 10 1.50771 -1.37809 NME1 P15531 
-1.20307 -1.16424 NaN yes 10 1.98125 -1.18366 NOP2 P46087 
-0.99818 -1.38116 -1.0534 yes 26 1.96917 -1.14425 NPEPPS P55786 
-3.02585 NaN -3.52079 yes 14 1.31841 -3.27332 NUP210 Q8TEM1 
-2.09493 -3.27662 -3.72595 yes 8 1.60599 -3.0325 OCIAD2 Q56VL3 
-1.37868 -1.42233 -1.14685 yes 9 2.37744 -1.31595 OLA1 Q9NTK5 
-1.93126 -2.33665 -1.94358 yes 21 2.38632 -2.0705 PAICS P22234 
-0.98505 -1.64607 -1.12142 yes 10 1.60239 -1.25085 PARK7 Q99497 
-1.01441 -1.1012 -0.93617 yes 45 2.65994 -1.01726 PARP1 P09874 
-1.24619 -1.75511 -1.66974 yes 9 1.99742 -1.55701 PAWR Q96IZ0 
-0.99232 -1.2308 -0.90177 yes 18 2.05755 -1.04163 PDLIM1 O00151 
-1.14184 -1.05523 -0.9352 yes 14 2.4846 -1.04409 PDXDC1 Q6P996 
-2.33548 -2.83136 -2.34256 yes 12 2.3694 -2.50313 PEBP1 P30086 
-1.98707 -2.98245 -2.01136 yes 26 1.71501 -2.32696 PFAS O15067 
-0.92835 -1.34593 -1.3954 yes 10 1.84316 -1.22323 PFKM P08237 
-0.8553 -1.55818 -1.25027 yes 13 1.57444 -1.22125 PFN1 P07737 
-0.92158 -1.61936 -1.31743 yes 17 1.62342 -1.28612 PGAM1 P18669 
-2.03062 -2.46777 -2.04151 yes 20 2.36339 -2.17997 PGD P52209 
-2.47995 -2.80904 -2.68548 yes 26 2.88567 -2.65816 PGDH3 O43175 
-1.11923 -1.73629 -1.16459 yes 6 1.67248 -1.34004 PITPNB P48739 
-0.84487 -1.58217 -1.05865 yes 13 1.47183 -1.1619 PNP P00491 
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-1.15406 -1.51746 -1.29839 yes 14 2.19978 -1.3233 PPIA P62937 
-1.11054 -1.74116 -1.23991 yes 19 1.71428 -1.36387 PRDX1 Q06830 
-2.03558 -2.72843 -2.08964 yes 17 2.02911 -2.28455 PRDX6 P30041 
-3.3645 -3.61084 -3.39443 yes 19 3.29782 -3.45659 PSAT1 Q9Y617 
-1.63953 -1.64052 -1.79361 yes 13 3.03853 -1.69122 PSIP1 O75475 
-1.651 -1.78543 -1.89894 yes 7 2.7906 -1.77846 PTGES3 Q15185 
-1.33126 -1.26538 -1.28062 yes 14 3.62473 -1.29242 PXN P49023 
-1.42857 -1.22307 NaN yes 4 1.30769 -1.32582 PYCARD Q9ULZ3 
-1.21203 -1.36896 -1.01815 yes 20 2.15022 -1.19971 PYGL P06737 
-1.64345 -1.95685 -1.87726 yes 12 2.57793 -1.82585 RAN P62826 
-1.26583 -1.67392 -1.37508 yes 7 2.14784 -1.43828 RANBP1 P43487 
-2.49419 -3.07424 -2.8427 yes 23 2.44422 -2.80371 RCC2 Q9P258 
-2.38752 -2.39676 -2.28405 yes 3 3.62884 -2.35611 RPL38 P63173 
-1.53245 -1.40499 -1.26486 yes 7 2.51863 -1.40077 RRM2 P31350 
-1.24855 -1.32673 -1.39897 yes 14 2.96931 -1.32475 SERBP1 Q8NC51 
-3.24004 -4.58592 -3.41109 yes 25 1.90257 -3.74568 SERPINB9 P50453 
-1.41577 -1.59697 -1.40167 yes 10 2.73964 -1.47147 SET Q01105 
-1.53567 -1.51721 -1.63004 yes 25 3.30042 -1.56097 SHMT2 P34897 
-1.76975 -1.80637 -2.29676 yes 4 2.12797 -1.95763 SLC16A3 O15427 
-2.16566 -2.17377 -2.28335 yes 20 3.52959 -2.20759 SLC25A24 Q6NUK1 
-1.60819 -1.33468 -1.4465 yes 15 2.53292 -1.46312 SLC25A5 P05141 
-3.0607 -2.68845 NaN yes 8 1.38549 -2.87458 SLC2A3 P11169 
-3.02926 -3.198 NaN yes 7 1.7633 -3.11363 SLC35B2 Q8TB61 
-2.63765 -2.24996 -2.20477 yes 27 2.47367 -2.36413 SLC44A2 Q8IWA5 
-1.59933 -1.75735 -1.26878 yes 26 2.06534 -1.54182 SLC4A7 Q9Y6M7 
-3.09369 -2.72671 -2.80783 yes 7 2.8256 -2.87608 SLC9A3R1 O14745 
-1.10222 -1.87287 -1.13743 yes 13 1.49509 -1.37084 SMS P52788 
-1.45012 -1.68812 NaN yes 5 1.31706 -1.56912 SRI P30626 
-1.3873 -0.95982 -1.51325 yes 6 1.78197 -1.28679 SSBP1 Q04837 
-1.0782 -1.1286 -1.04838 yes 6 3.3324 -1.08506 ST13 P50502 
-1.06037 -1.8831 -1.13201 yes 23 1.44945 -1.35849 TAGLN Q01995 
-1.55962 -1.89454 -1.94976 yes 30 2.34221 -1.80131 TARS P26639 
-0.89873 -1.36647 -1.4092 yes 14 1.76051 -1.2248 TES Q9UGI8 
-0.67657 -1.3171 -1.45344 yes 5 1.38933 -1.14904 TFCP2 Q12800 
-1.99493 -2.06921 -2.43846 yes 23 2.40014 -2.16753 TJP2 Q9UDY2 
-1.65731 -2.22817 -1.76675 yes 40 2.07007 -1.88408 TKT P29401 
-1.30055 -1.36286 -1.22415 yes 42 3.01921 -1.29585 TOP2B Q02880 
-1.41469 -1.265 -1.36569 yes 24 2.97224 -1.34846 TRAP1 Q12931 
-1.21581 -1.22546 -1.2345 yes 32 4.71227 -1.22526 TRIM28 Q13263 
-2.68492 -3.64015 -2.1495 yes 27 1.63828 -2.82486 TUBB2B Q9BVA1 
-0.75767 -1.48924 -0.98962 yes 7 1.42279 -1.07884 TXN P10599 
-1.65295 -1.88103 -1.67577 yes 6 2.75957 -1.73658 UBE2N P61088 
-3.9439 -4.50239 -3.67994 yes 16 2.44633 -4.04208 UCHL1 P09936 
-2.72261 -2.74545 -2.77576 yes 18 4.50336 -2.74794 UGP2 Q16851 
-1.62389 -2.08186 -1.4802 yes 70 1.96519 -1.72865 VCL P18206 
-1.13587 -1.73639 -1.18656 yes 15 1.7076 -1.35294 WARS P23381 
-1.04979 -1.76302 -1.34088 yes 13 1.66476 -1.38456 XPNPEP1 Q9NQW7 
-0.98219 -1.09755 -1.07512 yes 40 2.94858 -1.05162 XPO1 O14980 
-1.48286 -1.64697 -1.51548 yes 23 2.97978 -1.54844 XPO5 Q9HAV4 
-1.45795 -1.62932 -1.66319 yes 21 2.79438 -1.58349 XPOT O43592 
-1.3761 -1.74972 -1.29637 yes 25 2.05222 -1.47406 YARS P54577 
-0.84869 -0.62634 -0.72595 no 18 2.11949 -0.733656 ABCE1 P61221 
-0.11524 -0.09769 -0.16668 no 14 1.58941 -0.126535 ABCF1 Q8NE71 
NaN 0.651775 0.448478 no 5 0.934352 0.550127 ABHD10 Q9NUJ1 
0.60027 NaN -0.01409 no 7 0.288242 0.293089 ABHD12 Q8N2K0 
0.348686 0.440314 0.220701 no 16 1.46865 0.336567 ACAA2 P42765 
1.07834 0.900104 0.923339 no 13 2.47777 0.967261 ACAT1 P24752 
0.724563 0.955982 0.732834 no 11 2.05742 0.80446 ACBD3 Q9H3P7 
-0.76665 -0.29678 -0.40234 no 15 1.12268 -0.488589 ACIN1 Q9UKV3 
0.44297 -0.11735 0.281787 no 35 0.458281 0.202469 ACLY P53396 
-0.65804 -0.96576 NaN no 10 0.923616 -0.811897 ACO1 P21399 
0.288181 0.411752 0.231555 no 29 1.55089 0.310496 ACO2 Q99798 
0.790272 0.737168 0.806778 no 14 3.13807 0.778073 ACOT9 Q9Y305 
-0.25677 -0.24845 -0.25005 no 27 3.98932 -0.251755 ACSL3 O95573 
0.364236 0.286763 0.744333 no 29 1.0899 0.465111 ACTB P60709 
0.496207 NaN 0.715718 no 8 0.942822 0.605962 ACTBL2 Q562R1 
0.041664 -0.32744 0.28238 no 24 0.0019644 -0.0011318 ACTC1 P68032 
0.404794 0.309293 0.649661 no 29 1.33449 0.454583 ACTG1 P63261 
0.14991 0.10675 0.106884 no 10 1.86133 0.121181 ACTL6A O96019 
0.80488 0.95211 1.24263 no 68 1.792 0.999873 ACTN1 P12814 
0.665484 0.256045 0.547548 no 13 1.2475 0.489692 ACTR2 P61160 
0.538041 0.292664 0.643394 no 17 1.37756 0.491366 ACTR3 P61158 
-0.89416 -0.99148 -0.96322 no 26 3.03373 -0.949622 ADAR P55265 
-0.72647 -0.88678 -0.75897 no 14 2.41944 -0.790739 ADD1 P35611 
0.103934 -0.00646 0.074368 no 9 0.648414 0.0572797 ADD3 Q9UEY8 
-0.34496 -0.59839 -0.38632 no 7 1.5234 -0.443223 AGK Q53H12 
0.222681 0.481609 0.169027 no 18 1.02427 0.291106 AGPS O00116 
0.599794 0.243669 0.461109 no 10 1.28085 0.434857 AHCYL1 O43865 
0.100978 0.294194 -0.10989 no 16 0.300419 0.0950947 AIFM1 O95831 
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0.466444 0.035202 0.137635 no 8 0.614308 0.213094 AIMP1 Q12904 
-0.17645 -0.14941 -0.08004 no 6 1.37472 -0.135299 AIMP2 Q13155 
0.157303 0.110096 -0.28611 no 9 0.0138348 -0.0062373 AK2 P54819 
-0.41016 -0.44393 -0.5704 no 17 1.98359 -0.47483 AKAP12 Q02952 
1.14633 0.616075 0.987903 no 13 1.55054 0.916769 AKAP2 Q9Y2D5 
0.554638 NaN 0.230572 no 7 0.60348 0.392605 AKR7A2 O43488 
-0.28616 -0.04179 -0.00458 no 26 0.473374 -0.110844 ALDH18A1 P54886 
-0.094 -0.27848 -0.21412 no 13 1.16332 -0.195535 ALDH9A1 P49189 
-0.45378 -1.04946 -0.69162 no 29 1.28661 -0.731617 ALDOA P04075 
0.804136 0.867027 0.884871 no 8 3.08361 0.852011 ALG2 Q9H553 
1.15088 0.825948 NaN no 4 0.984162 0.988414 ALG5 Q9Y673 
-0.01179 0.070939 -0.17945 no 7 0.19333 -0.0401006 ALYREF Q86V81 
0.289008 2.1636 0.254231 no 12 0.539321 0.90228 ANKFY1 Q9P2R3 
0.564232 0.56881 0.569783 no 10 5.04142 0.567608 ANO6 Q4KMQ2 
-0.78724 -0.96207 -1.00694 no 7 2.27747 -0.918751 ANP32A P39687 
0.816395 0.18409 0.472904 no 7 0.939079 0.49113 ANP32B Q92688 
-0.19676 -0.49354 -0.4131 no 7 1.27212 -0.367797 ANP32E Q9BTT0 
-0.42998 -1.04943 -0.38766 no 26 0.997397 -0.622357 ANXA1 P04083 
-0.23455 -0.26519 -0.00771 no 9 0.762818 -0.169149 ANXA11 P50995 
0.116764 -0.42682 -0.00777 no 28 0.232557 -0.105941 ANXA5 P08758 
0.272262 -0.07341 0.263996 no 47 0.511169 0.154283 ANXA6 P08133 
-0.71639 -0.25674 NaN no 10 0.551404 -0.486561 ANXA7 P20073 
0.196229 0.00101 0.188274 no 35 0.741027 0.128504 AP1B1 Q10567 
0.249749 0.170694 0.065159 no 15 1.02694 0.161867 AP1G1 O43747 
0.985646 0.864572 0.976803 no 27 2.76811 0.94234 AP2A2 O94973 
0.825786 0.409798 0.380619 no 8 1.19101 0.538734 AP3B1 O00203 
0.227618 0.06874 0.309293 no 11 0.984262 0.201884 AP3D1 O14617 
0.194591 0.080794 0.263275 no 6 1.10944 0.179553 AP3M1 Q9Y2T2 
-0.08277 -0.02928 0.256286 no 10 0.159507 0.0480776 APEX1 P27695 
-0.23618 -0.27413 -0.17269 no 11 1.78308 -0.227664 API5 Q9BZZ5 
-0.01365 NaN -0.01202 no 7 1.39401 -0.0128395 APLP2 Q06481 
-0.00735 0.004322 NaN no 11 0.0765087 -0.001513 AQR O60306 
0.207143 0.143002 0.162081 no 21 1.91445 0.170742 ARCN1 P48444 
-0.67865 -1.01284 -0.9564 no 10 1.8723 -0.882631 ARF1 P84077 
-0.16009 -0.04351 -0.21262 no 11 0.962837 -0.13874 ARF4 P18085 
-0.19677 -0.04876 -0.61054 no 10 0.635048 -0.285357 ARF5 P84085 
NaN -0.24986 -0.3572 no 5 0.953052 -0.303527 ARFGAP1 Q8N6T3 
NaN -1.2969 -0.57719 no 14 0.631847 -0.937043 ARFGEF1 Q9Y6D6 
-0.41139 -0.84635 -0.23258 no 13 0.949394 -0.496773 ARHGAP1 Q07960 
1.00885 0.013498 0.586885 no 7 0.690346 0.536411 ARHGDIA P52565 
0.174279 0.353436 0.113834 no 7 1.01328 0.21385 ARL1 P40616 
-0.89454 -0.99905 NaN no 12 1.45468 -0.946792 ARPC1B O15143 
0.556993 0.161823 0.536252 no 13 1.08255 0.418356 ARPC2 O15144 
0.346758 0.291721 0.631337 no 4 1.24704 0.423272 ARPC3 O15145 
0.525768 0.233765 0.657091 no 5 1.19675 0.472208 ARPC4 P59998 
0.738984 0.215492 1.00065 no 5 0.975158 0.651709 ARPC5 O15511 
0.0719 -0.27165 NaN no 12 0.177361 -0.0998765 ASCC3 Q8N3C0 
-0.24838 -0.42341 -0.1418 no 7 1.09316 -0.271196 ASNA1 O43681 
0.197362 0.411209 0.460585 no 19 1.32123 0.356385 ATAD3A Q9NVI7 
-0.8132 -0.48795 -0.40863 no 9 1.35585 -0.569922 ATL2 Q8NHH9 
0.532367 0.693855 0.69323 no 12 2.15632 0.639817 ATP13A1 Q9HD20 
-0.33674 -0.02988 -0.17516 no 39 0.74846 -0.180593 ATP1A1 P05023 
-0.40985 0.008917 -0.32198 no 9 0.700447 -0.240973 ATP1B1 P05026 
-0.02712 0.091937 -0.18485 no 11 0.175752 -0.0400102 ATP1B3 P54709 
0.255561 0.437121 0.246469 no 40 1.42992 0.31305 ATP2A2 P16615 
-0.423 -0.28277 -0.47231 no 28 1.69317 -0.392695 ATP5B P06576 
-0.42965 -0.20698 -0.46031 no 14 1.3516 -0.365647 ATP5F1 P24539 
-0.30981 -0.33056 -0.35662 no 32 2.78071 -0.332329 ATP5F1A P25705 
-0.47025 -0.18911 -0.34535 no 11 1.26584 -0.3349 ATP5H O75947 
-0.87319 -0.19489 -0.45851 no 4 0.909072 -0.50886 ATP5L O75964 
-0.44056 -0.22351 -0.43236 no 13 1.44671 -0.365474 ATP5O P48047 
0.258941 0.124461 0.466027 no 19 0.982098 0.283143 ATP6V1A P38606 
0.710261 0.739675 0.859413 no 19 2.45685 0.769783 ATP6V1B2 P21281 
-0.1518 -0.54357 NaN no 4 0.485934 -0.347684 ATP6V1C1 P21283 
NaN 0.416948 0.646808 no 7 0.868125 0.531878 ATP6V1H Q9UI12 
-0.1649 -0.72273 -0.86064 no 11 0.953179 -0.582755 ATXN10 Q9UBB4 
0.934026 0.817705 0.89476 no 10 2.82492 0.882164 BAG2 O95816 
0.093831 0.366476 0.026588 no 6 0.587137 0.162298 BANF1 O75531 
0.440952 0.614569 0.733094 no 10 1.70662 0.596205 BASP1 P80723 
-0.16735 -0.45042 -0.30388 no 1 1.19345 -0.307216 BBS9 Q3SYG4 
-0.26155 -1.09736 NaN no 5 0.45464 -0.679456 BCCIP Q9P287 
-0.72929 -0.2765 NaN no 3 0.569776 -0.502897 BCKDHB P21953 
-0.25957 -0.04475 -0.46759 no 13 0.770598 -0.257302 BCLAF1 Q9NYF8 
-0.79166 -0.39276 -0.71639 no 12 1.45182 -0.633602 BRIX1 Q8TDN6 
-0.38994 -0.21722 -0.58612 no 10 1.18796 -0.397763 BSG P35613 
-0.65547 -0.96993 -0.69881 no 5 1.8027 -0.774736 BTF3 O00478 
-0.10072 -0.12784 -0.1033 no 8 2.21829 -0.11062 BUB3 O43684 
-0.08763 -0.03251 0.052138 no 8 0.198471 -0.022665 BUD31 P41223 
0.299714 -0.1291 0.464773 no 11 0.450945 0.211795 BZW1 Q7L1Q6 
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0.279887 0.372395 0.274292 no 4 1.98125 0.308858 CACNA2D1 P54289 
-0.14079 -0.60964 -0.71236 no 11 0.961588 -0.487599 CACYBP Q9HB71 
-0.60472 -0.88188 -0.46871 no 48 1.48051 -0.65177 CAD,CALD1 Q05682 
0.90512 0.810813 0.821302 no 12 2.90565 0.845745 CALM3 P0DP25 
0.63292 0.836409 0.651959 no 33 2.08005 0.707096 CANX P27824 
0.244522 -0.32938 0.192194 no 33 0.0638889 0.0357797 CAP1 Q01518 
NaN 0.42191 0.586116 no 5 0.988001 0.504013 CAP2 P40123 
-0.27612 -0.72304 -0.40299 no 18 1.141 -0.467382 CAPN1 P07384 
0.593019 0.15769 0.722291 no 10 0.988498 0.491 CAPNS1 P04632 
0.18916 0.205768 0.227618 no 11 2.5425 0.207515 CAPRIN1 Q14444 
0.798175 0.702835 0.82489 no 12 2.64298 0.7753 CAPZA1 P52907 
0.357608 0.311619 0.457542 no 10 1.88948 0.37559 CAPZA2 P47755 
0.610511 0.511266 0.603692 no 15 2.51113 0.575156 CAPZB P47756 
NaN 0.091666 -0.30424 no 6 0.163483 -0.106286 CARM1 Q86X55 
-0.4044 -0.56105 -0.2926 no 19 1.48436 -0.419349 CARS P49589 
0.0782 -0.13594 -0.0165 no 10 0.137743 -0.0247442 CBR1 P16152 
-0.28486 -0.07273 -0.47668 no 9 0.853979 -0.278089 CBX1 P83916 
-0.70188 -0.55393 -0.77594 no 9 2.03822 -0.67725 CBX3 Q13185 
0.304394 0.105946 0.199374 no 21 1.14779 0.203238 CCAR2 Q8N163 
0.018207 0.388024 0.201634 no 11 0.703053 0.202622 CCDC47 Q96A33 
-0.27113 -0.73704 -0.87618 no 2 1.12277 -0.628114 CCDC58 Q4VC31 
-0.45184 -0.67632 -0.41448 no 35 1.61323 -0.514213 CCT2 P78371 
-0.20601 -0.3218 -0.19962 no 31 1.58871 -0.242478 CCT3 P49368 
-0.31674 -0.53921 -0.37081 no 25 1.58836 -0.408919 CCT4 P50991 
-0.15526 -0.438 -0.21157 no 31 1.04598 -0.268274 CCT5 P48643 
-0.09965 -0.40066 0.012354 no 20 0.497639 -0.162653 CCT6A P40227 
-0.08806 -0.37985 -0.18485 no 26 0.89741 -0.217584 CCT7 Q99832 
-0.13316 -0.38981 -0.17241 no 28 0.995952 -0.231794 CCT8 P50990 
0.176195 -0.11361 0.027296 no 10 0.122305 0.0299589 CDC37 Q16543 
0.676899 0.543298 0.768333 no 9 2.01872 0.662843 CDC42 P60953 
-0.37565 -0.5722 -0.13665 no 13 0.987358 -0.361498 CDC5L Q99459 
0.076422 0.084609 0.831472 no 14 0.498635 0.330834 CDH2 P19022 
-0.22629 -0.40662 -0.50613 no 4 1.36139 -0.379679 CDK11B P21127 
NaN 0.937721 0.959548 no 8 2.13527 0.948635 CDK5RAP3 Q96JB5 
-0.54057 NaN -0.37677 no 4 0.948894 -0.458669 CDS2 O75420 
-0.52326 NaN -0.16773 no 3 0.519254 -0.345494 CECR5 Q9BXW7 
0.85583 NaN 0.638954 no 7 1.03751 0.747392 CERS2 Q96G23 
-0.23938 -0.71919 -0.35306 no 15 1.0252 -0.437209 CFL1 P23528 
-0.31518 -0.07222 -0.39855 no 9 0.936146 -0.261986 CHCHD3 Q9NX63 
-0.26493 -0.32673 -0.5303 no 38 1.36646 -0.373988 CHD4 Q14839 
-0.18474 -0.18912 -0.2066 no 9 2.92495 -0.193484 CHERP Q8IWX8 
-0.50678 NaN -0.72535 no 4 0.951686 -0.616067 CHTOP Q9Y3Y2 
0.110096 NaN -0.01418 no 4 0.23542 0.0479585 CISD2 Q8N5K1 
0.74123 0.101516 0.405557 no 35 0.815007 0.416101 CKAP5 Q14008 
-0.15301 -0.86373 -0.29198 no 16 0.738263 -0.436241 CLIC1 O00299 
0.586597 0.241962 0.37829 no 13 1.24555 0.402283 CLIC4 Q9Y696 
-0.4166 -0.19639 -0.37806 no 8 1.40076 -0.330351 CLINT1 Q14677 
0.761285 1.0842 0.437334 no 9 1.25747 0.76094 CLPTM1 O96005 
0.887447 1.11016 0.995014 no 3 2.38408 0.99754 CLPTM1L Q96KA5 
1.04921 0.907198 0.974456 no 97 2.75502 0.976955 CLTC Q00610 
-0.27117 -1.17968 -0.7856 no 9 0.977947 -0.745482 CMAS Q8NFW8 
-0.56837 -0.76685 -0.57652 no 8 1.99155 -0.637244 CNBP P62633 
0.048236 -0.30066 0.311852 no 13 0.0356069 0.0198087 CNN1 P51911 
-1.06857 -1.09514 -0.72173 no 15 1.81579 -0.961813 CNN2 Q99439 
0.178492 -0.18518 0.18612 no 13 0.17154 0.059811 CNN3 Q15417 
-0.50359 -0.07151 -0.2986 no 20 0.839358 -0.291234 CNOT1 A5YKK6 
-0.45247 -0.96635 NaN no 9 0.655178 -0.709409 CNPY2 Q9Y2B0 
0.40294 0.186247 0.479024 no 57 1.25449 0.35607 COPA P53621 
0.459222 0.028994 0.283211 no 34 0.755258 0.257142 COPB1 P53618 
0.514905 0.148609 0.538737 no 28 1.06266 0.40075 COPB2 P35606 
0.419647 0.277032 0.276675 no 13 1.68087 0.324451 COPE O14579 
0.887681 0.491391 0.766044 no 30 1.58784 0.715039 COPG1 Q9Y678 
-0.44479 NaN -0.59782 no 16 1.03255 -0.521308 COPG2 Q9UBF2 
0.310224 -0.59527 NaN no 7 0.0937478 -0.142523 COPS2 P61201 
0.303459 -0.13644 0.286999 no 8 0.394216 0.151339 COPS4 Q9BT78 
NaN -0.02822 -0.06291 no 5 0.635318 -0.0455655 COPS5 Q92905 
0.416191 0.292782 NaN no 5 0.959732 0.354487 COPS6 Q7L5N1 
-0.02762 -0.35039 -0.04002 no 7 0.497929 -0.139344 COPZ1 P61923 
-0.8097 -0.46291 -0.20452 no 8 0.971228 -0.492377 CORO1B Q9BR76 
NaN 0.079566 -0.66626 no 2 0.239828 -0.293345 COX1 P23219 
-0.3515 0.352194 2.3407 no 8 0.36141 0.780465 COX2 P00403 
-0.48552 -0.22038 -0.50441 no 9 1.31905 -0.403435 COX4I1 P13073 
-0.47762 -0.3396 -0.58152 no 6 1.66062 -0.466248 COX5A P20674 
-0.26337 -0.02707 -0.22523 no 4 0.843189 -0.17189 COX5B P10606 
0.028569 -0.09953 -0.18241 no 2 0.519143 -0.0844551 COX6C P09669 
-0.53554 -0.51264 -0.6316 no 12 2.37581 -0.559926 CPD O75976 
0.260508 -0.30852 -0.29212 no 14 0.217547 -0.113378 CPNE3 O75131 
0.260146 0.072723 0.177599 no 7 1.05389 0.170156 CPSF7 Q8N684 
0.15069 0.206768 0.223917 no 21 1.89379 0.193792 CPT1A P50416 
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NaN -1.05949 -0.62249 no 5 0.790953 -0.840988 CRKL P46109 
-1.08021 NaN -0.77061 no 6 0.976684 -0.925409 CROP O95232 
-0.11084 -0.05861 -0.29518 no 20 0.78634 -0.154876 CS O75390 
0.037593 0.347212 0.214249 no 23 0.807274 0.199685 CSDE1 O75534 
-0.25993 -0.17215 -0.23145 no 7 1.87317 -0.221174 CSNK1A1 P48729 
-0.51019 -0.65229 -0.71904 no 10 2.02206 -0.627174 CSNK2A1 P68400 
-0.15956 1.73131 -0.60032 no 12 0.157965 0.323813 CSNK2A2 P19784 
NaN -0.29099 -0.51393 no 4 0.764437 -0.402463 CSNK2B P67870 
0.823097 0.274292 0.884246 no 9 1.11666 0.660545 CSRP1 P21291 
-0.79298 NaN -1.10644 no 4 0.982459 -0.949711 CSTB P04080 
-0.60264 -0.31691 -0.55599 no 8 1.51026 -0.491843 CSTF3 Q12996 
-0.54395 -0.59029 NaN no 14 1.58513 -0.56712 CTBP2 P56545 
0.058109 NaN -0.51457 no 6 0.242917 -0.228232 CTCF P49711 
0.298658 0.303459 0.391768 no 12 2.08385 0.331295 CTGF P29279 
-0.4289 -0.42915 -0.30615 no 44 1.96029 -0.388063 CTNNA1 P35221 
-0.41702 NaN 0.170053 no 8 0.126972 -0.123483 CTNNA2 P26232 
-0.66662 -0.29272 -0.36177 no 27 1.20902 -0.440371 CTNNB1 P35222 
-0.38956 -0.42783 -0.36329 no 30 2.64608 -0.393561 CTNND1 O60716 
-0.25717 -0.64575 -0.54994 no 18 1.27078 -0.484285 CTPS1 P17812 
0.697596 0.40414 0.694657 no 14 1.59485 0.598798 CTSD P07339 
0.232661 -0.08709 0.078747 no 24 0.298391 0.0747726 CTTN Q14247 
-0.17059 NaN -0.25488 no 9 0.904814 -0.212732 CUL1 Q13616 
-0.49119 -0.63509 -0.3709 no 12 1.64543 -0.499059 CUL3 Q13618 
0.388245 0.449112 0.374733 no 9 2.49615 0.40403 CUL4A Q13619 
1.54082 -3.06383 -0.92651 no 9 0.220479 -0.816506 CXADR P78310 
0.441377 0.476848 0.602267 no 4 2.0388 0.506831 CYB5B O43169 
-0.68864 -0.6574 -0.79626 no 6 2.46206 -0.714099 CYCS P99999 
0.70496 0.228726 0.414136 no 22 1.07869 0.449274 CYFIP1 Q7L576 
0.354903 NaN 0.77104 no 4 0.647093 0.562972 CYP20A1 Q6UW02 
0.462157 0.519441 NaN no 13 1.43051 0.490799 CYR61 O00622 
0.106482 0.266397 -0.31968 no 6 0.0322237 0.0177343 DAG1 Q14118 
-0.41933 NaN -0.72707 no 5 0.777398 -0.573201 DAP3 O95886 
0.083384 0.025738 -0.10611 no 17 0.0055308 0.00100373 DARS P14868 
-0.17304 -0.24914 -0.39403 no 9 1.28117 -0.27207 DAZAP1 Q96EP5 
-0.34026 -0.03587 0.187261 no 21 0.142412 -0.0629573 DBN1 Q16643 
-0.74758 -0.03787 -0.80816 no 5 0.783164 -0.531205 DBT P11182 
0.799999 1.03259 0.862273 no 2 2.22654 0.898287 DC2 Q96PD6 
0.801573 0.709908 1.41554 no 11 1.31988 0.975674 DCTN2 Q13561 
-0.16639 -0.17707 -0.11877 no 6 1.87758 -0.154076 DDAH2 O95865 
0.068189 0.105008 0.083111 no 28 1.81522 0.0854362 DDB1 Q16531 
0.730923 0.947255 0.949647 no 15 2.16856 0.875942 DDOST P39656 
0.245739 0.208392 0.294547 no 25 2.00686 0.249559 DDX1 Q92499 
-0.36019 -0.25756 -0.23028 no 31 1.72082 -0.282679 DDX17 Q92841 
-0.96968 -0.76168 -0.78545 no 19 2.2159 -0.838936 DDX18 Q9NVP1 
-0.37484 -0.85606 -0.34318 no 11 1.05979 -0.524694 DDX19A Q9NUU7 
-1.05334 -0.79411 -0.75151 no 32 1.93384 -0.86632 DDX21 Q9NY93 
0.660746 0.147176 0.140648 no 10 0.682154 0.31619 DDX23 Q9BUQ8 
-0.5282 -0.25599 -0.23126 no 19 1.15055 -0.338485 DDX39A O00148 
-0.67872 -0.33924 -0.65692 no 29 1.43755 -0.558292 DDX39B Q13838 
-0.11774 -0.0487 -0.2096 no 31 0.939694 -0.125344 DDX3X O00571 
-0.33621 0.211511 -0.49003 no 24 0.359165 -0.20491 DDX3Y O15523 
-0.03955 -0.03958 -0.27539 no 21 0.566001 -0.11817 DDX42 Q86XP3 
-0.16077 -0.22714 -0.32612 no 16 1.41554 -0.238006 DDX46 Q7L014 
-0.76999 -0.18726 -0.84607 no 11 0.992032 -0.601108 DDX47 Q9H0S4 
-0.35723 -0.13709 -0.36312 no 19 1.21084 -0.285816 DDX48 P38919 
-0.69234 -0.53374 -0.74952 no 30 2.02367 -0.658535 DDX5 P17844 
-0.063 -0.3671 -0.16069 no 14 0.798201 -0.196929 DDX6 P26196 
0.176323 -0.56022 -0.18971 no 9 0.334025 -0.191202 DEK P35659 
NaN -0.08896 0.646992 no 2 0.23137 0.279016 DENR O43583 
-0.19152 -0.28997 -0.27083 no 27 1.84968 -0.250775 DHX15 O43143 
0.459117 0.614192 0.396269 no 13 1.76874 0.489859 DHX29 Q7Z478 
0.034357 -0.04524 -0.00069 no 11 0.0543474 -0.003858 DHX30 Q7L2E3 
-0.46646 -0.4504 NaN no 9 1.9528 -0.458429 DHX36 Q9H2U1 
-0.29807 -0.06995 -0.26147 no 58 1.01177 -0.209829 DHX9 Q08211 
NaN -0.71248 -0.78667 no 12 1.50197 -0.749575 DIAPH1 O60610 
0.387693 0.601411 NaN no 5 0.868146 0.494552 DIMT1 Q9UNQ2 
-0.67093 -0.56407 NaN no 7 1.26005 -0.617504 DIS3 Q9Y2L1 
-0.56689 -0.34205 -0.14247 no 12 0.984316 -0.350468 DKC1 O60832 
-0.34826 -0.04533 -0.45886 no 12 0.828957 -0.28415 DLAT P10515 
-0.0836 0.161307 -0.15738 no 10 0.0922524 -0.0265586 DLD P09622 
0.694836 0.886043 0.943884 no 12 2.10234 0.841588 DLST P36957 
-1.07954 -0.56933 -0.91278 no 14 1.52906 -0.853884 DNAJA1 P31689 
1.19156 0.986447 0.793355 no 7 1.87918 0.990454 DNAJB11 Q9UBS4 
-0.39314 -0.23849 -0.23895 no 12 1.52215 -0.290196 DNAJC10 Q8IXB1 
-0.14543 0.295018 -0.226 no 13 0.0508793 -0.025472 DNAJC11 Q9NVH1 
-0.21825 -0.56397 NaN no 7 0.576857 -0.391106 DNAJC7 Q99615 
0.147176 -0.39413 NaN no 4 0.138155 -0.123475 DNAJC8 O75937 
0.435949 0.524164 0.290424 no 6 1.59005 0.416846 DNCL1 P63167 
-0.66404 -1.1279 -0.84908 no 18 1.64478 -0.880338 DNM1L O00429 
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0.454597 0.248292 0.241474 no 18 1.33746 0.314788 DNM2 P50570 
0.134878 0.374733 0.528971 no 13 1.02498 0.346194 DNMT1 P26358 
-0.44426 -0.93379 -0.61874 no 31 1.36323 -0.665598 DPYSL2 Q16555 
-0.1174 -0.3599 -0.3409 no 12 1.13833 -0.27273 DRG1 Q92597 
0.365133 0.233152 0.318693 no 46 1.80638 0.305659 DSP P15924 
1.39917 0.368489 0.126709 no 23 0.607356 0.631456 DST Q03001 
-0.0375 -0.38058 -0.0949 no 10 0.604947 -0.170992 DSTN P60981 
0.362666 -0.12601 0.388465 no 172 0.469536 0.208372 DYNC1H1 Q14204 
0.154583 -0.21267 0.285343 no 9 0.179249 0.0757527 DYNC1I2 Q13409 
0.222681 -0.12077 NaN no 7 0.0881207 0.050958 DYNC1LI1 Q9Y6G9 
0.757109 NaN 0.531968 no 5 0.958303 0.644538 DYNC1LI2 O43237 
NaN 0.305095 0.252173 no 5 1.21985 0.278634 DYNLL2 Q96FJ2 
NaN -0.24876 0.013212 no 4 0.272637 -0.117773 DYNLT1 P63172 
-0.30148 0.095587 -0.51146 no 3 0.506858 -0.239119 EBP Q15125 
-0.00245 -0.07867 -0.12161 no 10 0.716747 -0.067579 ECHS1 P30084 
-0.41517 0.275126 -0.36734 no 6 0.278474 -0.169129 ECI1 P42126 
0.818278 0.226755 0.055751 no 18 0.596644 0.366928 EDC4 Q6P2E9 
-0.74616 -0.15043 NaN no 7 0.427886 -0.448294 EDIL3 O43854 
-0.09673 -0.42237 -0.20605 no 25 0.894764 -0.241714 EEF1A1 P68104 
0.023184 0.244278 0.305095 no 6 0.807719 0.190852 EEF1B2 P24534 
0.80331 0.65104 0.774249 no 12 2.40625 0.742866 EEF1D P29692 
-0.8247 -1.00599 -0.60338 no 5 1.69957 -0.811356 EEF1E1 O43324 
0.156655 0.097476 0.195977 no 23 1.46181 0.150036 EEF1G P26641 
-0.83632 -1.25429 -0.86056 no 53 1.73424 -0.983723 EEF2 P13639 
-0.12551 -0.0023 -0.06903 no 36 0.684591 -0.0656113 EFTUD2 Q15029 
0.326077 0.525367 0.809826 no 14 1.23169 0.553757 EHD4 Q9H223 
-0.08032 -0.05331 -0.09681 no 7 1.58214 -0.0768127 EIF1A P47813 
-0.00646 0.129481 0.077106 no 10 0.630769 0.066708 EIF2A Q9BY44 
0.483261 0.335255 0.545375 no 11 1.73806 0.45463 EIF2S1 P05198 
-0.03115 -0.1859 -0.03844 no 10 0.632221 -0.0851622 EIF2AK2 P19525 
0.183709 -0.50916 -0.65349 no 4 0.47634 -0.326315 EIF2B1 Q14232 
0.569977 0.413594 0.629566 no 11 1.85256 0.537712 EIF2S2 P20042 
0.475604 0.448795 0.544288 no 11 2.47406 0.489562 EIF2S3 P41091 
0.061154 0.135404 0.147958 no 40 1.2892 0.114839 EIF3A Q14152 
-0.0227 -0.12351 -0.1252 no 28 0.934284 -0.0904687 EIF3B P55884 
-0.07245 0.128029 -0.07677 no 20 0.0332626 -0.0070635 EIF3D O15371 
-0.24132 -0.00247 0.082566 no 20 0.197182 -0.0537416 EIF3E P60228 
-0.24734 -0.16965 -0.13981 no 12 1.54443 -0.185597 EIF3F O00303 
-0.34108 -0.21086 -0.37733 no 11 1.59166 -0.309758 EIF3G O75821 
0.139862 0.042084 0.004034 no 13 0.576566 0.0619933 EIF3H O15372 
-0.01025 NaN 0.158208 no 5 0.26665 0.0739787 EIF3J O75822 
-0.15835 -0.15366 -0.23345 no 8 1.70726 -0.181817 EIF3K Q9UBQ5 
0.090176 0.07779 0.084064 no 23 2.74313 0.08401 EIF3L Q9Y262 
-0.14376 -0.26359 -0.23399 no 15 1.56441 -0.21378 EIF3M Q7L2H7 
-0.04476 -0.27127 -0.09291 no 14 0.729438 -0.136314 EIF3S2 Q13347 
0.005328 0.019773 -0.01498 no 27 0.113674 0.00337355 EIF3S8 Q99613 
-0.6414 -0.72685 -0.64948 no 24 2.78621 -0.672578 EIF4A1 P60842 
0.087327 -0.03716 0.038858 no 17 0.302055 0.0296741 EIF4A2 Q14240 
NaN 0.115566 0.434775 no 5 0.475465 0.27517 EIF4E P06730 
0.167358 0.059355 0.092207 no 33 1.09829 0.106307 EIF4G1 Q04637 
-0.02909 -0.13334 -0.03941 no 23 0.745582 -0.0672795 EIF4G2 P78344 
0.065986 -0.05224 0.105678 no 10 0.310152 0.0398091 EIF5 P55010 
-0.33501 -0.67796 -0.53569 no 17 1.45362 -0.516217 EIF5A P63241 
-0.04908 -0.23008 -0.00555 no 11 0.520758 -0.0949035 EIF5B O60841 
-0.30502 -0.43066 -0.17813 no 8 1.27749 -0.304604 EIF6 P56537 
0.241108 0.231432 0.121811 no 16 1.45196 0.198117 ELAVL1 Q15717 
0.380175 0.727703 0.838508 no 20 1.37238 0.648795 EMC1 Q8N766 
0.659742 0.982072 0.78668 no 4 1.88116 0.809498 EMC7 Q9NPA0 
-1.04433 -0.53024 -0.68233 no 5 1.41219 -0.752298 EMG1 Q92979 
0.305329 0.470303 0.280719 no 15 1.56221 0.352117 ENAH Q8N8S7 
-0.07447 -0.60467 -0.24996 no 34 0.731833 -0.309702 ENO1 P06733 
0.973721 0.413161 0.275961 no 11 0.914462 0.554281 ENO2 P09104 
-0.08177 -0.10885 0.032524 no 16 0.458539 -0.0526958 ENPP1 P22413 
-0.62124 -0.49987 -0.56444 no 22 2.41211 -0.56185 EPB41L2 O43491 
-0.43382 -0.30759 -0.38768 no 18 2.02394 -0.376362 EPHX1 P07099 
-0.64564 -0.05992 -0.68826 no 8 0.826881 -0.464606 EPS15 P42566 
0.365021 NaN 0.266876 no 4 1.00835 0.315949 EPS15L1 Q9UBC2 
-0.30016 -0.84058 -0.3154 no 4 0.951101 -0.485379 EPT1 Q9C0D9 
0.776862 1.17938 NaN no 4 0.888777 0.978121 ERGIC2 Q96RQ1 
-0.24756 0.017922 -0.23302 no 6 0.666752 -0.15422 ERH P84090 
-0.04292 0.158466 0.079566 no 14 0.417326 0.0650381 ERLIN2 O94905 
-0.872 -0.76646 -1.01537 no 14 2.18156 -0.884608 ERP29 P30040 
0.78115 0.850159 0.811964 no 10 3.22181 0.814424 ERP44 Q9BS26 
-0.32027 -0.88124 -0.61072 no 8 1.18731 -0.604077 ESD P10768 
0.654711 0.722379 0.70982 no 38 3.04999 0.695637 ESYT1 Q9BSJ8 
-0.26008 -0.53289 -0.51451 no 10 1.41498 -0.435827 ETF1 P62495 
-0.15317 -0.07224 -0.16417 no 6 1.33366 -0.129862 EWSR1 Q01844 
0.51167 0.100709 NaN no 3 0.42449 0.306189 EXOSC9 Q06265 
0.810813 0.717912 0.841329 no 15 2.65764 0.790018 FACL4 O60488 
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0.752149 0.99581 1.03457 no 12 2.04768 0.92751 FAF2 Q96CS3 
NaN -0.08459 -0.0891 no 2 1.78233 -0.0868462 FAM126A Q9BYI3 
NaN 0.431142 0.603312 no 5 0.978836 0.517227 FAM21A Q641Q2 
-0.70043 -0.32409 -0.49826 no 8 1.36698 -0.507594 FAM3C Q92520 
0.83285 1.33319 0.724476 no 9 1.44569 0.963505 FAM98A Q8NCA5 
0.059494 -0.21523 0.777872 no 8 0.254797 0.207379 FAM98B Q52LJ0 
0.153676 0.141564 0.154194 no 15 3.12045 0.149811 FARSB Q9NSD9 
0.077243 0.050328 0.209141 no 3 0.825497 0.112237 FAU P35544 
-0.7714 -0.6291 -0.72759 no 11 2.45593 -0.709363 FBL P22087 
0.111566 -0.13776 -0.01686 no 9 0.065298 -0.0143518 FEN1 P39748 
NaN 0.140648 0.395172 no 7 0.549263 0.26791 FGF2 P09038 
0.537644 0.528871 0.462576 no 14 2.66667 0.509697 FH P07954 
NaN -0.69923 0.005759 no 4 0.296499 -0.346736 FHL1 Q13642 
0.569588 0.705403 0.53037 no 4 2.11486 0.601787 FIS1 Q9Y3D6 
-0.73447 -0.54768 -0.43002 no 9 1.63299 -0.570723 FKBP3 Q00688 
0.15043 0.694746 0.153935 no 11 0.684234 0.333037 FKBP8 Q14318 
0.232906 -0.15463 0.222434 no 145 0.289001 0.100235 FLNB O75369 
0.682573 1.0246 0.947479 no 11 1.87207 0.884884 FLOT1 O75955 
0.130931 0.262914 -0.40922 no 11 0.0077221 -0.0051253 FLOT2 Q14254 
0.446468 0.104605 NaN no 9 0.451627 0.275536 FSTL1 Q12841 
-0.31201 -0.39988 NaN no 6 1.10686 -0.355945 FTH1 P02794 
-0.67992 -0.62022 -0.71468 no 15 2.77407 -0.671608 FTSJ3 Q8IY81 
-0.43872 -0.51951 -0.48024 no 22 2.62746 -0.479487 FUBP1 Q96AE4 
0.1644 0.492315 0.044184 no 14 0.651368 0.233633 FUBP3 Q96I24 
-0.83475 -0.70402 -0.88857 no 10 2.3415 -0.809112 FUS P35637 
0.142479 0.065572 0.123666 no 25 1.38579 0.110572 FXR1 P51114 
-0.07417 -0.15983 -0.11085 no 16 1.36078 -0.114951 G3BP Q13283 
-0.38154 -0.40492 -0.22703 no 11 1.58136 -0.337828 G3BP2 Q9UN86 
-0.70336 NaN -0.88654 no 7 1.13652 -0.79495 GALNT1 Q10472 
0.775261 0.883621 0.887993 no 19 2.72565 0.848958 GALNT2 Q10471 
0.679874 0.765025 0.617204 no 46 2.41327 0.687368 GANAB Q14697 
-0.24243 -0.68131 -0.46124 no 23 1.16911 -0.46166 GAPDH P04406 
-0.8346 -1.22762 -0.91673 no 25 1.8471 -0.99298 GARS P41250 
0.41684 -0.42579 NaN no 19 0.0029472 -0.004476 GDI1 P31150 
NaN -0.39764 -0.48308 no 6 1.21066 -0.440357 GFM1 Q96RP9 
NaN 0.757706 1.00022 no 4 1.05912 0.878963 GGH Q92820 
0.381505 0.572017 0.244156 no 36 1.28159 0.399226 GLG1 Q92896 
0.160662 0.04712 0.166587 no 24 1.07127 0.12479 GLUD1 P00367 
-0.10978 NaN -0.66059 no 5 0.403224 -0.385184 GLYR1 Q49A26 
-0.22965 -0.32108 -0.2188 no 21 1.80641 -0.256511 GMPS P49915 
0.91311 0.819668 0.974382 no 23 2.60631 0.902387 GNAI2 P04899 
NaN -0.52359 -0.30554 no 15 0.785913 -0.414563 GNAI3 P08754 
0.439251 0.565597 0.505484 no 16 2.28303 0.503444 GNB1 P62873 
0.831391 1.01543 1.10279 no 16 2.18354 0.983204 GNB2 P62879 
0.471135 0.807437 0.502738 no 14 1.5073 0.59377 GNB4 Q9HAV0 
-0.83991 -0.85337 NaN no 5 2.29565 -0.846639 GNL2 Q13823 
-0.38726 -1.07741 -0.79411 no 8 1.19354 -0.752926 GNL3 Q9BVP2 
NaN 0.982948 0.814591 no 14 1.22583 0.898769 GOLGA2 Q08379 
1.09633 0.535356 NaN no 6 0.676107 0.815843 GOLGA5 Q8TBA6 
1.04719 0.510354 1.42637 no 21 1.19014 0.994638 GOLGB1 Q14789 
-0.11535 -0.1161 0.183963 no 7 0.0512628 -0.0158273 GOLPH3 Q9H4A6 
-0.86268 -0.92865 -0.88398 no 20 3.32352 -0.89177 GOT2 P00505 
0.849199 0.988048 0.850959 no 22 2.58102 0.896069 GPD2 P43304 
-0.64149 -0.89146 -0.74984 no 19 2.0494 -0.760928 GPI P06744 
0.686254 0.308011 0.697418 no 9 1.32016 0.563894 GPX1 P07203 
-0.55574 NaN -0.42661 no 3 1.07984 -0.491171 GPX4 P36969 
0.74123 1.1396 1.04047 no 10 1.83016 0.973767 GPX8 Q8TED1 
-0.01015 -0.58951 -0.40307 no 7 0.722588 -0.33424 GRHPR Q9UBQ7 
-0.36835 -0.29823 -0.35951 no 11 2.3841 -0.342028 GRSF1 Q12849 
-0.39216 -0.90814 -0.64939 no 10 1.31226 -0.649897 GSPT1 P15170 
0.745711 0.032101 0.479851 no 8 0.74065 0.419221 GSTO1 P78417 
-0.98467 -0.79912 -0.44676 no 20 1.37481 -0.743517 GTF2I P78347 
-1.0399 0.121944 -0.07707 no 10 0.344091 -0.331676 GTPBP4 Q9BZE4 
-0.32249 0.098015 -0.2061 no 6 0.430891 -0.143523 H2AFV Q71UI9 
-0.92068 -0.79413 -1.15248 no 4 1.92673 -0.955764 H3F3B P84243 
0.061431 0.365133 0.037734 no 10 0.553221 0.154766 HACD3 Q9P035 
0.137766 -0.01759 0.005616 no 6 0.321013 0.0419298 HADH Q16836 
0.864176 1.0606 0.942533 no 31 2.44994 0.95577 HADH P40939 
NaN -0.11336 -0.07179 no 5 0.851914 -0.0925746 HAT1 O14929 
0.019915 -0.17505 NaN no 9 0.242513 -0.0775648 HCFC1 P51610 
-0.06258 -0.06318 -0.18784 no 8 0.890083 -0.104534 HDAC1 Q13547 
-0.1707 0.22848 -0.13228 no 11 0.0638955 -0.0248333 HDAC2 Q92769 
0.7376 0.623586 0.74485 no 8 2.50663 0.702012 HDGF P51858 
-0.39017 -0.55911 -0.21053 no 4 1.21058 -0.386603 HDGFRP2 Q7Z4V5 
-0.94442 -0.198 -0.71771 no 28 0.970705 -0.620042 HEATR1 Q9H583 
0.887447 0.774671 0.968791 no 8 2.3879 0.87697 HIBADH P31937 
0.780646 NaN 0.622274 no 9 1.14531 0.70146 HIP1 O00291 
0.45628 0.715806 0.272382 no 11 1.19022 0.481489 HIST1H1B P16401 
0.961549 1.13356 0.640621 no 12 1.61646 0.91191 HIST1H1C P16403 
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-0.03925 0.475707 -0.11671 no 9 0.204597 0.106583 HIST1H1D P16402 
0.190804 0.41045 0.079702 no 9 0.839914 0.226985 HIST1H2AB P04908 
0.126048 0.258459 -0.06055 no 7 0.439473 0.107986 HIST1H2BI P62807 
0.437228 0.718964 0.263635 no 5 1.1525 0.473276 HIST1H3A P68431 
0.319965 0.517225 0.121679 no 12 0.968811 0.319623 HIST1H4H P62805 
0.264837 0.529371 0.082021 no 9 0.814087 0.292076 HIST2H2AA Q6FI13 
0.001874 0.214498 -0.02763 no 5 0.304379 0.0629138 HIST2H3A Q71DI3 
-0.69935 -0.5929 -0.73365 no 38 2.40734 -0.675299 HK1 P19367 
-0.18198 -0.40375 -0.30506 no 12 1.36012 -0.296931 HMGB1 P09429 
0.063365 -0.24816 -0.14893 no 9 0.456341 -0.111241 HMGB2 P26583 
-1.0673 -1.0416 -0.69162 no 6 1.78424 -0.933505 HMGB3 O15347 
0.721241 0.847917 0.653244 no 6 2.23086 0.740801 HMOX2 P30519 
-0.9519 -0.95291 -0.84848 no 12 2.84715 -0.917763 HNRNPA0 Q13151 
-0.02609 0.170438 -0.02982 no 32 0.206123 0.0381756 HNRNPA2B1 P22626 
-0.11718 0.155231 -0.03664 no 27 0.0017897 0.0004699 HNRNPA3 P51991 
-0.43805 -0.29265 -0.42661 no 16 1.84388 -0.38577 HNRNPAB Q99729 
-0.7655 -0.42366 -0.66614 no 19 1.5866 -0.618434 HNRNPC P07910 
-0.11588 0.055751 -0.0286 no 14 0.213868 -0.0295766 HNRNPDL O14979 
-0.49582 -0.28051 -0.36585 no 21 1.58531 -0.380727 HNRNPH1 P31943 
-0.37458 -0.3467 -0.35181 no 26 3.24152 -0.357697 HNRNPK P61978 
-0.20305 -0.11015 -0.18038 no 27 1.5576 -0.164529 HNRNPK P61978 
-0.37001 -0.1904 -0.36673 no 28 1.45675 -0.309045 HNRNPL P14866 
0.275722 -0.50883 0.097611 no 9 0.0621283 -0.045167 HNRNPLL Q8WVV9 
-0.17285 -0.18094 -0.0481 no 39 1.04862 -0.133961 HNRNPM P52272 
0.33308 0.525969 0.38405 no 29 1.7247 0.414366 HNRNPR O43390 
-0.56798 -0.39009 -0.6437 no 44 1.71563 -0.533924 HNRNPU Q00839 
-0.9311 -0.72394 -0.71222 no 29 2.09594 -0.789086 HNRPA1 P09651 
-0.27151 -0.15898 -0.2063 no 20 1.64176 -0.212262 HNRPD Q14103 
-0.10313 0.110898 -0.07532 no 13 0.113847 -0.0225185 HNRPF P52597 
-0.07021 0.226385 -0.13403 no 12 0.0208834 0.00738067 HNRPH3 P31942 
-0.00583 -0.02355 -0.12825 no 22 0.518876 -0.0525417 HNRPUL1 Q9BUJ2 
-0.62449 -0.66745 -0.40272 no 6 1.68951 -0.564886 HPRT1 P00492 
0.746141 0.055751 0.50019 no 8 0.783236 0.434027 HRS O14964 
-0.12004 0.026021 -0.17725 no 6 0.562669 -0.0904223 HRS,SFRS5 Q13243 
-0.1765 -0.03293 -0.18713 no 14 0.9313 -0.132187 HSD17B10 Q99714 
-0.1538 0.022616 -0.23805 no 10 0.601709 -0.123078 HSD17B12 Q53GQ0 
-0.87758 -0.33707 -0.87163 no 29 1.2187 -0.695424 HSD17B4 P51659 
-0.98485 -0.56967 -1.05481 no 21 1.53775 -0.869776 HSD17B4 P51659 
0.706553 0.813196 0.81836 no 8 2.66178 0.77937 HSDL2 Q6YN16 
-0.39787 -0.70198 -0.5679 no 55 1.61708 -0.555912 HSP90AA1 P07900 
0.490365 0.787767 NaN no 4 0.837012 0.639066 HSPA13 P48723 
0.679244 0.544189 0.603312 no 32 2.38771 0.608915 HSPA1A P0DMV8 
0.798092 0.963326 0.738898 no 47 2.19181 0.833439 HSPA5 P11021 
-0.42756 -0.63765 -0.51787 no 43 1.88485 -0.527693 HSPA8 P11142 
-0.73279 -0.38673 -0.64386 no 42 1.52616 -0.587792 HSPA9 P38646 
-0.27441 -0.4648 -0.38045 no 28 1.67583 -0.373219 HTT P31645 
0.273456 -0.44367 -0.50441 no 33 0.334435 -0.224875 HUWE1 Q7Z6Z7 
0.139601 0.226755 0.075327 no 32 1.10508 0.147228 HYOU1 Q9Y4L1 
-0.66349 -0.7618 -0.63971 no 37 2.5325 -0.688334 IARS P41252 
0.743472 NaN 0.922122 no 11 1.16734 0.832797 IARS2 Q9NSE4 
-1.50738 -0.66477 -0.61147 no 3 1.06831 -0.927872 IFITM1 P13164 
-0.19851 -0.1493 -0.12006 no 42 1.68046 -0.155955 IGF2R P11717 
-0.35073 -0.32433 -0.35111 no 24 3.1734 -0.342055 ILF2 Q12905 
-0.32433 -0.11479 -0.13513 no 42 0.986962 -0.191413 ILF3 Q12906 
0.009777 0.096397 0.119024 no 29 0.815764 0.075066 IMMT Q16891 
-0.39409 -0.30399 -0.25063 no 18 1.76758 -0.316235 IMPDH2 P12268 
-0.93421 NaN -0.93686 no 13 3.04513 -0.935531 IPO4 Q8TEX9 
-0.03167 -0.26368 -0.09093 no 45 0.687119 -0.128758 IPO5 O00410 
-0.02104 -0.31018 -0.29331 no 30 0.805798 -0.208177 IPO7 O95373 
-0.36483 0.074779 NaN no 6 0.201553 -0.145026 ISOC2 Q96AB3 
1.29325 0.601887 0.730749 no 10 1.26695 0.875295 ITGA2 P17301 
0.289716 0.115965 0.209391 no 21 1.25918 0.205024 ITGA6 P23229 
0.190425 0.071076 0.424492 no 37 0.800031 0.228664 ITGAV P06756 
-0.45022 0.021053 -0.10305 no 18 0.474449 -0.177408 ITGB5 P18084 
-0.03741 -0.20262 0.116365 no 3 0.155981 -0.0412237 IWS1 Q96ST2 
-0.12513 -0.32708 -0.17454 no 18 1.12372 -0.208916 KARS Q15046 
0.882839 0.817132 0.241718 no 4 1.06367 0.64723 KDELR1 P24390 
-0.45948 -0.1981 -0.90385 no 11 0.894835 -0.520473 KDM1A O60341 
0.087463 0.087734 0.119157 no 11 1.9469 0.0981181 KHDRBS1 Q07666 
-0.13497 -0.14075 -0.22683 no 26 1.52237 -0.167515 KHSRP Q92945 
1.16774 0.469365 0.880098 no 30 1.27023 0.839068 KIF5B P33176 
0.80752 0.253021 NaN no 10 0.513292 0.53027 KPNA1 P52294 
0.336512 0.129349 0.279055 no 13 1.2469 0.248305 KPNA3 O00505 
0.40021 -0.76058 0.07902 no 12 0.0905548 -0.0937824 KPNA4 O00629 
-0.09789 -0.29186 0.181548 no 11 0.178055 -0.0693989 KPNA6 O60684 
-0.33299 -0.44566 -0.28835 no 40 1.77259 -0.355664 KPNB1 Q14974 
-0.40287 0.063779 0.064193 no 8 0.210687 -0.091634 KRAS P01116 
-0.01594 -0.1812 -0.01539 no 27 0.484358 -0.0708436 KRT19 P08727 
0.288772 0.46874 0.359071 no 41 1.71612 0.372194 KTN1 Q86UP2 
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0.116498 0.838831 -0.92355 no 15 0.0064061 0.010593 LAMB1 P07942 
0.228357 0.658737 1.01271 no 32 0.967038 0.633268 LAMB2 P11047 
0.82725 1.00963 NaN no 5 1.20064 0.91844 LAMTOR1 Q6IAA8 
-0.61043 -0.94859 -0.61854 no 12 1.64302 -0.725853 LAP3 P28838 
-0.11374 -0.52758 -0.23218 no 16 0.848854 -0.291163 LARP1 Q6PKG0 
-0.46061 -0.8279 -0.39906 no 11 1.28201 -0.562523 LASP1 Q14847 
NaN -0.20976 0.158725 no 6 0.0398229 -0.0255185 LDLR P01130 
-1.16333 NaN -0.54101 no 10 0.651931 -0.852169 LEMD3 Q9Y2U8 
0.503552 0.528071 0.384381 no 15 2.05926 0.472001 LETM1 O95202 
0.858458 0.907737 1.08699 no 26 2.27669 0.951062 LIMA1 Q9UHB6 
0.600745 0.201006 0.730401 no 8 1.0702 0.510717 LIMS1 P48059 
0.626112 0.510861 0.488001 no 11 2.20982 0.541658 LMAN2 Q12907 
-0.5661 -0.38052 -0.64932 no 45 1.66585 -0.531981 LMNB1 P20700 
0.351515 0.562963 0.398898 no 39 1.68301 0.437792 LMNB2 Q03252 
0.227371 0.363003 0.243182 no 23 1.63949 0.277852 LONP1 P36776 
-0.31786 NaN -0.12759 no 9 0.590079 -0.222724 LPCAT1 Q8NF37 
-0.76557 -1.37363 -0.85207 no 18 1.46322 -0.99709 LPP Q93052 
1.03372 NaN 0.784755 no 8 1.06238 0.909238 LRPAP1 P30533 
-0.56912 -0.49454 -0.58316 no 67 2.60198 -0.548937 LRPPRC P42704 
-0.55894 -0.44942 -0.36131 no 14 1.8148 -0.456554 LRRC47 Q8N1G4 
-0.33787 -0.30306 -0.34815 no 4 2.76753 -0.329694 LSM2 Q9Y333 
-0.36346 -0.54711 -0.44625 no 1 1.86946 -0.452271 LSM5 Q9Y4Y9 
0.796598 0.193583 0.374845 no 13 0.900625 0.455009 LSS P48449 
0.145873 -0.78237 NaN no 8 0.209468 -0.31825 LUC7L2 Q9Y383 
-0.53101 -0.57574 -0.6031 no 82 2.86771 -0.56995 MACF1 Q9UPN3 
-0.43288 -0.21638 -0.32011 no 8 1.45034 -0.323125 MAGOHB Q96A72 
-0.03956 -0.09692 NaN no 10 0.596424 -0.068239 MAP1S Q66K74 
0.579277 0.095857 0.711935 no 38 0.878765 0.462356 MAP4 P27816 
0.309875 0.089227 0.195977 no 12 1.0481 0.19836 MAPK1 P28482 
-0.44118 -0.9601 -0.64151 no 12 1.33845 -0.680934 MAPRE1 Q15691 
-0.5142 -0.82738 -0.37202 no 11 1.2905 -0.571202 MAT2A P31153 
-0.55572 -0.36465 -0.63185 no 34 1.64222 -0.517402 MATR3 P43243 
-0.36418 -0.49344 -0.53648 no 27 1.91414 -0.464701 MCM2 P49736 
-0.46309 -0.37096 -0.48441 no 30 2.20647 -0.439486 MCM7 P33993 
-0.55201 -0.48257 -0.51319 no 31 2.82017 -0.515925 MCM3 P25205 
-0.63182 -0.70313 -0.75553 no 17 2.57902 -0.696826 MCM4 P33991 
-0.4984 -0.46845 -0.66223 no 23 1.91801 -0.543029 MCM5 P33992 
-0.37219 -0.46729 -0.66093 no 26 1.55812 -0.500138 MCM6 Q14566 
-0.4202 -0.30675 0.020627 no 5 0.663993 -0.235442 MCTS1 Q9ULC4 
-0.89765 -0.82823 -0.70355 no 6 2.31149 -0.809809 MCU Q8NE86 
-0.05016 0.099901 -0.10728 no 20 0.104795 -0.0191776 MDH2 P40926 
NaN 0.090447 -0.11821 no 10 0.0382047 -0.0138815 ME2 P23368 
-0.11899 -0.02859 0.069427 no 4 0.167933 -0.026051 MESDC2 Q14696 
-0.36021 -0.35653 -0.62979 no 10 1.41663 -0.448845 METAP1 P53582 
-0.68566 -0.98719 -1.02544 no 11 1.85468 -0.89943 METAP2 P50579 
-0.85603 -0.34949 NaN no 4 0.596475 -0.602763 MFAP1 P55081 
0.342327 0.175173 -0.14213 no 11 0.326634 0.125123 MFN2 O95140 
-0.15098 0.153027 -0.23301 no 8 0.237029 -0.0769857 MGST1 P10620 
-0.06877 0.048097 NaN no 5 0.051326 -0.0103371 MICU2 Q8IYU8 
-0.19116 0.161178 0.115433 no 10 0.0857281 0.028483 MLEC Q14165 
0.594453 1.1001 NaN no 3 0.733746 0.847277 MME P08473 
-0.40055 -0.4354 NaN no 2 1.57636 -0.417974 MOB1A Q9H8S9 
0.19333 0.085289 0.271665 no 23 1.11413 0.183428 MOGS Q13724 
0.581303 1.08182 0.753861 no 3 1.49991 0.805661 MPDU1 O75352 
-0.87668 -0.67574 NaN no 5 1.08648 -0.77621 MPHOS O00566 
-0.3263 -0.5449 NaN no 2 0.805463 -0.435598 MPST P25325 
-0.41854 NaN -0.60415 no 4 0.941976 -0.511345 MRPL1 Q9BYD6 
-0.75156 -0.36704 -0.58999 no 6 1.44083 -0.56953 MRPL12 P52815 
-0.69928 -0.55718 -0.69411 no 6 2.29395 -0.65019 MRPL15 Q9P015 
-0.78354 NaN -0.63399 no 3 1.17448 -0.708766 MRPL28 Q13084 
NaN -0.27788 -0.63666 no 2 0.62342 -0.457272 MRPL3 P09001 
-0.53885 -0.1285 -0.55152 no 10 1.00106 -0.406291 MRPL37 Q9BZE1 
NaN -0.10364 -0.42705 no 3 0.457889 -0.265347 MRPL46 Q9H2W6 
-0.65535 NaN -0.99332 no 7 0.890354 -0.824337 MRPS22 P82650 
NaN -0.58923 -0.08537 no 5 0.388918 -0.3373 MRPS30 Q9NP92 
-0.36505 0.15769 -0.62224 no 5 0.454217 -0.276536 MRPS35 P82673 
-0.99493 NaN -0.99459 no 17 3.95706 -0.994758 MSH2 P43246 
-0.46174 -0.20581 -0.61876 no 7 1.15156 -0.428771 MTA1 Q13330 
0.441696 NaN 0.902961 no 11 0.677005 0.672329 MTA2 O94776 
0.614003 0.851759 0.767316 no 11 2.06415 0.744359 MTCH2 Q9Y6C9 
-0.66077 -0.90066 -0.72266 no 31 2.05544 -0.761364 MTHFD1 P11586 
-0.20784 -0.44015 -0.53544 no 21 1.25351 -0.394475 MTHFD1L Q6UB35 
-0.91743 -0.87952 -1.05278 no 5 2.5156 -0.94991 MTHFD2 P13995 
0.132906 -0.23703 0.085697 no 4 0.0165261 -0.0061425 MTPN P58546 
-0.13976 0.206143 -0.29566 no 7 0.182053 -0.0764253 MTX1 Q13505 
-0.28335 -0.31486 -0.31547 no 33 2.91707 -0.304559 MYBBP1A Q9BQG0 
0.943959 0.514905 1.15698 no 2 1.35821 0.871948 MYL1 P05976 
1.23014 0.567448 1.02162 no 12 1.39029 0.939736 MYL12A P19105 
0.932288 0.379288 0.796515 no 10 1.28607 0.702697 MYL6 P60660 
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0.781318 -0.29632 -0.11901 no 7 0.12514 0.121998 MYO1C Q12965 
-0.85608 -1.07774 -1.01197 no 16 2.3516 -0.981931 NAA15 Q9BXJ9 
NaN -0.15729 -0.88308 no 4 0.411407 -0.520182 NADH1 P03886 
0.945383 0.143785 0.810567 no 8 0.902916 0.633245 NAGK Q9UJ70 
-0.90002 -1.07646 -0.96748 no 16 2.56343 -0.981318 NAP1L1 P55209 
-0.09544 -0.2446 -0.27023 no 10 1.18798 -0.20342 NAP1L4 Q99733 
0.859015 0.871923 0.8614 no 16 4.67658 0.864113 NAPA O96009 
-0.70461 -1.00295 -0.69947 no 24 1.81602 -0.802341 NARS O43776 
-0.54254 -0.1274 -0.64154 no 26 0.962644 -0.437159 NAT10 Q9H0A0 
NaN 0.459956 0.58602 no 13 1.11714 0.522988 NBAS A2RRP1 
-0.36294 -0.38443 -0.25005 no 16 1.81379 -0.332472 NCAPD2 Q15021 
-0.19126 -0.11405 -0.17713 no 16 1.67579 -0.160814 NCBP1 Q09161 
0.194717 0.024036 0.328147 no 21 0.759137 0.1823 NCKAP1 Q9Y2A7 
-0.48132 -0.46877 -0.51587 no 34 3.08119 -0.488656 NCL P19338 
0.504773 0.413919 0.543397 no 12 2.21157 0.487363 NCLN Q969V3 
-0.57671 -0.6532 -0.545 no 5 2.5327 -0.591637 NCSTN Q92542 
-0.20452 0.117429 0.107822 no 8 0.0205273 0.00691167 NDUFA10 O95299 
NaN 0.033934 -0.38073 no 4 0.254463 -0.173397 NDUFA4 O00483 
-0.05282 NaN -0.23094 no 3 0.447508 -0.14188 NDUFA5 Q16718 
-0.23902 -0.08148 -0.32999 no 15 1.01688 -0.21683 NDUFA9 Q16795 
-0.14944 -0.30109 -0.65597 no 5 0.875227 -0.368832 NDUFB10 O96000 
-0.33506 0.027154 -0.41966 no 2 0.659998 -0.242523 NDUFB11 Q9NX14 
-0.08505 0.139993 -0.02853 no 21 0.0417762 0.00880397 NDUFS1 P28331 
-0.33286 0.027579 -0.05795 no 10 0.418656 -0.121077 NDUFS2 O75306 
-0.17849 0.172616 -0.23805 no 11 0.228712 -0.081307 NDUFS3 O75489 
-0.07355 0.168257 -0.01921 no 12 0.116955 0.0251659 NDUFV1 P49821 
-0.12612 NaN -0.22891 no 7 0.746173 -0.177516 NDUFV2 P19404 
-0.65116 -0.43331 -0.49509 no 6 1.82914 -0.526517 NHP2L1 P55769 
-1.04543 -0.77236 -0.93603 no 10 2.13141 -0.917938 NIFK Q9BYG3 
-0.69306 -1.31768 -0.87181 no 16 1.45111 -0.960851 NME2 P22392 
0.024887 -0.15276 0.160404 no 11 0.0382323 0.0108447 NMT1 P30419 
-1.05992 -0.85629 -0.68355 no 13 1.81273 -0.866589 NOC2L Q9Y3T9 
-0.16463 -0.13386 -0.63093 no 5 0.712477 -0.309805 NOC3L Q8WTT2 
NaN -0.26772 -0.67784 no 8 0.58414 -0.472782 NOC4L Q9BVI4 
-0.9798 NaN -0.65039 no 6 0.896424 -0.815093 NOL11 Q9H8H0 
-0.17101 -0.41367 NaN no 6 0.60129 -0.292342 NOL9 Q5SY16 
0.531169 0.721591 0.656908 no 40 2.11778 0.636556 NOMO2 Q5JPE7 
-0.20754 -0.21456 -0.39802 no 25 1.31614 -0.273373 NONO Q15233 
-0.79411 -0.40137 -0.60036 no 26 1.46787 -0.598611 NOP56 O00567 
-0.6512 -0.40545 -0.69647 no 17 1.6362 -0.584374 NOP58 Q9Y2X3 
0.40414 0.011209 0.157173 no 4 0.623472 0.190841 NPC2 P61916 
0.361656 -0.29219 0.18954 no 10 0.153554 0.0863343 NPLOC4 Q8TAT6 
-0.72924 -0.77875 -0.81135 no 15 3.02148 -0.773115 NPM1 P06748 
0.759412 0.282736 1.04509 no 5 1.05179 0.695746 NRBP1 Q9UHY1 
-0.36928 -0.79118 -0.59203 no 11 1.38864 -0.584163 NSUN2 Q08J23 
0.055057 0.216113 -0.15178 no 12 0.128147 0.0397969 NT5DC2 Q9H857 
1.00885 1.1595 0.790939 no 12 1.93708 0.98643 NUCB1 Q02818 
-0.87551 -1.16576 -0.8279 no 7 1.92193 -0.95639 NUDC Q9Y266 
-0.75831 NaN -0.81198 no 8 1.66251 -0.785143 NUDCD1 Q96RS6 
-0.36673 -0.35969 -0.36305 no 11 4.5048 -0.363156 NUDT21 O43809 
-0.42418 -0.59964 -0.52537 no 18 2.01969 -0.516398 NUP133 Q8WUM0 
-0.56388 -0.73596 -0.63722 no 15 2.22851 -0.645686 NUP153 P49790 
-0.52816 -0.39545 -0.57456 no 34 1.94491 -0.499391 NUP155 O75694 
-0.7055 -0.41625 -0.69731 no 17 1.62493 -0.606354 NUP160 Q12769 
-0.7218 -0.69173 -0.70108 no 31 3.79906 -0.704872 NUP205 Q92621 
-0.34362 -0.84866 -0.19747 no 11 0.843604 -0.463251 NUP214 P35658 
NaN -0.76251 -0.85108 no 5 1.45707 -0.806794 NUP37 Q8NFH4 
-0.32236 -0.19278 -0.71615 no 8 0.91749 -0.410429 NUP50 Q9UKX7 
NaN -0.42975 -0.78173 no 6 0.744717 -0.605739 NUP54 Q7Z3B4 
-0.52359 NaN -0.57229 no 17 1.54864 -0.547937 NUP85 Q9BW27 
NaN -0.02565 -0.44236 no 6 0.334296 -0.234003 NUP88 Q99567 
-0.46128 -0.61268 -0.71869 no 20 1.81625 -0.597551 NUP93 Q8N1F7 
-0.59138 -0.23421 -0.33559 no 22 1.16876 -0.387059 NUP98 P52948 
0.013069 NaN -0.18508 no 6 0.2637 -0.086006 NXF1 Q9UBU9 
-0.0897 0.064883 -0.21846 no 21 0.37008 -0.0810928 OAT P04181 
-0.49466 -0.32151 -0.73243 no 5 1.30684 -0.5162 OCIAD1 Q9NX40 
-0.2133 0.111966 -0.22646 no 10 0.368958 -0.109265 OGT O15294 
-0.07741 -0.21076 0.153546 no 20 0.146145 -0.0448744 OPA1 O60313 
0.356482 0.272979 0.24987 no 16 1.92136 0.29311 OSBPL8 Q9BZF1 
0.660381 -0.13252 0.178364 no 2 0.382157 0.23541 OSTF1 Q92882 
-0.0406 -1.94753 NaN no 7 0.312712 -0.994065 OTUB1 Q96FW1 
0.794021 0.60862 0.461738 no 9 1.63631 0.62146 OXCT1 P55809 
-0.49348 -0.59588 -0.42577 no 22 2.02459 -0.505044 PA2G4 Q9UQ80 
0.087734 0.083384 -0.04301 no 30 0.372452 0.0427038 PABPC1 P11940 
-0.26533 -0.06431 -0.02704 no 22 0.603148 -0.118895 PABPC4 Q13310 
-0.2668 -0.07465 -0.4096 no 7 0.909713 -0.250353 PABPN1 Q86U42 
0.647637 -0.18254 NaN no 12 0.170762 0.232549 PACSIN2 Q9UNF0 
0.15549 -0.14132 -0.12598 no 4 0.132826 -0.0372703 PAF1 P28328 
0.207268 -0.36003 -0.6038 no 10 0.393598 -0.252185 PAFAH1B1 P43034 
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-0.11877 -0.28755 NaN no 5 0.600962 -0.203164 PAIP1 Q9H074 
-0.74722 0.044744 NaN no 11 0.269157 -0.351239 PAK2 Q13177 
0.173895 -0.34084 0.318577 no 17 0.0839803 0.050543 PALLD Q8WX93 
-0.46214 -1.30486 -0.59081 no 7 1.01978 -0.785936 PAPSS1 O43252 
NaN -0.6337 -0.7171 no 10 1.40612 -0.6754 PBRM1 Q86U86 
-0.1332 -0.3469 -0.12746 no 4 0.970228 -0.20252 PC4 P53999 
-0.63617 -0.9531 -0.63165 no 14 1.69809 -0.740305 PCBP1 Q15365 
-0.82902 -1.02368 -0.66488 no 14 1.82598 -0.839196 PCBP2 Q15366 
-0.67657 -0.50543 -0.54004 no 20 2.08715 -0.574016 PCK2 Q16822 
-0.69348 NaN -0.78819 no 7 1.39107 -0.740836 PCMT1 P22061 
-0.03093 -0.2853 -0.12906 no 11 0.737633 -0.148429 PCNA P12004 
NaN -0.45595 -0.21213 no 3 0.652138 -0.334041 PDCD10 Q9BUL8 
-1.36082 -0.44256 -0.78729 no 21 1.07466 -0.863557 PDCD11 Q14690 
0.491084 0.302173 0.359409 no 23 1.68746 0.384222 PDCD6IP Q8WUM4 
-0.45336 -0.09744 -0.38263 no 11 0.984674 -0.311142 PDHA1 P08559 
-0.55148 -0.38579 -0.55729 no 14 1.90316 -0.498185 PDHB P11177 
-0.5438 NaN -0.25271 no 7 0.651574 -0.398255 PDHX O00330 
0.986374 0.916094 0.827006 no 39 2.59195 0.909825 PDIA3 P30101 
0.067363 0.075738 0.004897 no 46 0.801376 0.0493327 PDIA4 P13667 
0.393087 0.463936 0.226015 no 17 1.44234 0.361013 PDIA6 Q15084 
0.188021 0.029135 0.084064 no 21 0.78534 0.100407 PDLIM5 Q96HC4 
-0.97682 -0.77589 -1.18998 no 6 1.83765 -0.980894 PDPR Q8NCN5 
0.21661 -0.84236 NaN no 11 0.180303 -0.312875 PDS5B Q9NTI5 
-0.31251 -1.05718 -0.25986 no 5 0.771243 -0.543182 PEA15 Q15121 
-0.7709 -0.92928 NaN no 15 1.22818 -0.850093 PES1 O00541 
-0.71132 -0.33927 NaN no 2 0.664191 -0.525298 PFDN5 Q99471 
0.519039 0.228603 0.606726 no 16 1.23287 0.451456 PFKL P17858 
0.655352 0.239031 0.655169 no 29 1.1859 0.516517 PFKP Q01813 
-0.42165 -1.00422 -0.67213 no 26 1.27106 -0.699333 PGK1 P00558 
-0.29316 NaN -0.4089 no 9 0.982932 -0.35103 PGLS O95336 
-0.29795 -0.71243 -0.51424 no 15 1.29038 -0.508207 PGM1 P36871 
-0.09151 NaN -0.15777 no 3 0.781488 -0.124639 PGM2 Q96G03 
0.61946 0.716069 0.606537 no 7 2.54702 0.647355 PGRMC1 O00264 
-0.92262 -0.73149 -1.0048 no 17 2.08403 -0.886305 PHB P35232 
-1.00532 -0.73293 -0.9571 no 19 2.06487 -0.898452 PHB2 Q99623 
NaN 0.877901 0.742351 no 6 1.27461 0.810126 PIGK Q92643 
0.887603 0.582171 0.674732 no 7 1.80614 0.714835 PIGS Q96S52 
NaN -0.85056 0.00992 no 5 0.294628 -0.420319 PIN1 Q13526 
0.03196 -0.64025 -0.19798 no 51 0.514024 -0.268758 PKM P14618 
-0.70003 -0.94758 -0.96319 no 14 2.02422 -0.870269 PLAA Q9Y263 
0.786178 1.0453 0.787516 no 7 2.01779 0.872998 PLBD2 Q8NHP8 
NaN -0.03681 -0.31687 no 13 0.370202 -0.176838 PLCB3 Q01970 
0.088684 -0.13402 0.146264 no 24 0.135587 0.0336435 PLEKHC1 Q96AC1 
0.45607 0.004322 0.192699 no 16 0.622594 0.217697 PLIN3 O60664 
-0.13139 -0.15737 -0.07458 no 6 1.41557 -0.121112 PLRG1 O43660 
0.363788 -0.34661 0.275603 no 36 0.151783 0.0975937 PLS3 P13797 
NaN -0.16626 -0.43807 no 13 0.570123 -0.302167 PMPCA Q10713 
-0.4852 0.065848 NaN no 8 0.232196 -0.209674 PMPCB O75439 
-0.45056 -0.56544 -0.4112 no 6 2.03022 -0.47573 PNN Q9H307 
-0.45686 NaN -0.03901 no 7 0.350892 -0.247937 PNPT1 Q8TCS8 
-0.81084 -0.96041 -0.64844 no 12 1.91202 -0.806564 PODXL O00592 
-1.21207 -0.65524 -1.12863 no 8 1.53992 -0.998647 POLDIP3 Q9BY77 
-0.45204 NaN -0.45202 no 10 4.85134 -0.452027 POLR2A P24928 
-0.13722 -0.28674 NaN no 16 0.665838 -0.211981 POLR2B P30876 
0.231555 1.38361 NaN no 7 0.404023 0.807583 PON2 Q15165 
0.098015 0.359409 0.040542 no 17 0.633042 0.165989 POR P16435 
0.486972 0.669843 0.326422 no 6 1.4204 0.494412 PPA2 Q9H2U2 
0.344033 0.180912 0.121546 no 5 1.07828 0.215497 PPIF P30405 
-0.83712 -0.69975 -0.76636 no 13 2.57541 -0.767741 PPM1G O15355 
0.1141 -0.55773 NaN no 3 0.201718 -0.221815 PPME1 Q9Y570 
0.664392 0.479438 0.534759 no 21 2.02413 0.55953 PPP1CA P62136 
-0.14084 -0.03435 -0.2905 no 20 0.764837 -0.15523 PPP1CC P36873 
0.942758 0.383276 0.619554 no 22 1.24255 0.648529 PPP1R12A O14974 
-0.29052 -0.44633 -0.41156 no 14 1.82745 -0.3828 PPP2CA P67775 
-0.42845 -0.63673 -0.41321 no 28 1.68314 -0.492796 PPP2R1A P30153 
-0.77994 -1.13018 -0.89478 no 8 1.92306 -0.934967 PPP2R2A P63151 
-0.97194 -0.89422 -0.58886 no 7 1.70319 -0.818337 PPP2R4 Q15257 
-0.12491 -0.31389 -0.04887 no 7 0.756585 -0.162559 PPP2R5D Q14738 
-0.47431 -0.50535 -0.14032 no 8 1.06764 -0.373326 PPP6C O00743 
-0.63294 -1.1805 -0.37279 no 9 1.03537 -0.728742 PRDX2 P32119 
-0.20174 -0.26159 -0.29594 no 8 1.93478 -0.25309 PRDX3 P30048 
0.831958 0.782325 0.644871 no 16 2.26154 0.753051 PRDX4 Q13162 
-0.15833 -0.44363 -0.39276 no 9 1.19664 -0.331576 PRDX5 P30044 
-0.44774 -0.85721 -0.43721 no 13 1.28158 -0.580721 PREP P48147 
NaN 0.427177 0.410341 no 13 1.89293 0.418759 PRKAR2A P13861 
0.604925 0.735955 0.563841 no 17 2.17946 0.634907 PRKCSH P14314 
0.357833 0.126841 0.444349 no 139 1.08482 0.309674 PRKDC P78527 
-0.3808 -0.42502 -0.37019 no 19 2.73775 -0.392004 PRMT1 Q99873 
-0.67438 -0.7567 -0.86997 no 11 2.26606 -0.767015 PRMT5 O14744 
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-0.17881 0.073957 -0.09202 no 15 0.328343 -0.065624 PRPF19 Q9UMS4 
0.101516 0.399882 0.148609 no 12 0.841036 0.216669 PRPF4 O43172 
-0.23708 -0.03795 -0.27584 no 9 0.885022 -0.183622 PRPF40A O75400 
0.509442 0.296076 0.098554 no 22 0.898623 0.301357 PRPF6 O94906 
-0.05868 0.000865 -0.24318 no 73 0.515237 -0.100333 PRPF8 Q6P2Q9 
1.02205 0.824483 1.11063 no 9 2.13777 0.985721 PRPS1 P60891 
-0.58825 -1.10277 NaN no 7 0.725757 -0.845509 PRRC2C Q9Y520 
-0.14981 -0.09031 -0.15721 no 13 1.60874 -0.132442 PSAP P07602 
-0.17082 -0.2699 -0.21836 no 14 1.78149 -0.219691 PSMA1 P25786 
-0.23009 -0.3873 -0.07427 no 9 0.901809 -0.230555 PSMA2 P25787 
-0.10838 -0.70183 NaN no 7 0.395275 -0.405107 PSMA3 P25788 
-0.26913 -0.38815 -0.22336 no 9 1.57075 -0.293545 PSMA4 P25789 
-0.28528 -0.43121 -0.21473 no 7 1.40146 -0.310406 PSMA5 P28066 
-0.14102 -0.39369 -0.08936 no 11 0.802919 -0.208022 PSMA6 P60900 
-0.03851 -0.29933 0.03492 no 9 0.372284 -0.100973 PSMA7 O14818 
-0.15896 -0.2855 -0.17492 no 10 1.45359 -0.206457 PSMB1 P20618 
-0.3485 0.095587 0.420509 no 7 0.0832915 0.055865 PSMB2 P49721 
0.017067 -0.3411 -0.0998 no 8 0.505473 -0.141279 PSMB3 P49720 
-0.1286 -0.36147 -0.02323 no 6 0.640182 -0.171099 PSMB4 P28070 
-0.29343 -0.47923 -0.33956 no 13 1.6585 -0.370742 PSMB5 P28074 
-0.21225 -0.43197 -0.19332 no 8 1.16937 -0.27918 PSMB6 P28072 
-0.32146 -0.45555 -0.0239 no 6 0.765966 -0.266971 PSMB7 Q99436 
0.249506 -0.10745 0.316609 no 13 0.437432 0.15289 PSMC1 P62191 
0.180912 -0.07797 0.262072 no 26 0.447069 0.121671 PSMC2 P35998 
0.149389 -0.1227 0.123269 no 15 0.205953 0.0499877 PSMC3 P17980 
0.133695 -0.11621 0.05589 no 20 0.112426 0.0244593 PSMC4 P43686 
0.092072 -0.15435 0.040121 no 18 0.0312617 -0.007384 PSMC5 P62195 
0.134615 -0.27509 0.058663 no 14 0.071334 -0.0272701 PSMC6 P62333 
0.069427 -0.14089 0.067501 no 30 0.0058486 -0.0013203 PSMD1 Q99460 
-0.0857 -0.14226 0.072175 no 19 0.298156 -0.0519264 PSMD11 O00231 
0.152508 -0.20226 -0.07435 no 14 0.13751 -0.0413663 PSMD12 O00232 
0.06226 -0.13223 0.146264 no 21 0.104042 0.0254313 PSMD13 Q9UNM6 
-0.16282 -0.23683 0.138421 no 4 0.278016 -0.0870737 PSMD14 O00487 
0.409907 0.028428 0.449007 no 37 0.800596 0.295781 PSMD2 Q13200 
-0.03086 -0.24581 0.016924 no 18 0.402209 -0.0865816 PSMD3 O43242 
0.077653 0.032947 0.114367 no 11 1.06536 0.0749891 PSMD4 P55036 
0.404467 0.216734 -0.00759 no 14 0.641921 0.204536 PSMD6 Q15008 
0.112366 -0.21862 0.147307 no 8 0.0374987 0.013686 PSMD7 P51665 
0.109695 0.246469 0.201258 no 9 1.35829 0.185807 PSMD8 P48556 
0.045024 -0.29557 -0.24129 no 9 0.583523 -0.163945 PSME1 Q06323 
0.095182 -0.34931 0.045303 no 7 0.174206 -0.069608 PSME2 Q9UL46 
0.02432 -0.39172 -0.39312 no 7 0.678684 -0.253508 PSME3 P61289 
-0.53606 -0.79789 -0.68064 no 8 1.9039 -0.67153 PSPC1 Q8WXF1 
-0.10447 -0.14505 0.052694 no 24 0.408674 -0.065606 PTBP1 P26599 
-0.8621 -0.32236 -0.97736 no 11 1.15298 -0.720606 PTCD3 Q96EY7 
-0.85165 -0.96931 -0.8958 no 6 2.8438 -0.905587 PTMA P06454 
1.06378 0.519743 0.704429 no 2 1.38539 0.762651 PTMS P20962 
0.705049 0.631244 0.401084 no 10 1.61829 0.579126 PTPN1 P18031 
-0.09202 -0.12175 -0.31795 no 16 0.887552 -0.177239 PUF60 Q9UHX1 
-0.05925 0.321697 -0.02557 no 7 0.234186 0.0789564 PVRL2 Q92692 
-0.36466 0.384381 -0.23067 no 22 0.102791 -0.0703167 PXDN Q92626 
-0.06034 -0.0107 0.120883 no 29 0.103661 0.0166149 QARS P47897 
0.100978 NaN -0.38464 no 5 0.178198 -0.141831 QRICH1 Q2TAL8 
0.535953 0.817951 0.637007 no 12 1.82101 0.663637 RAB10 P61026 
0.179384 0.095722 0.104068 no 11 1.38124 0.126391 RAB11B Q15907 
0.427821 0.572017 0.370164 no 12 1.77357 0.456667 RAB18 Q9NP72 
0.873026 0.997762 1.01228 no 12 2.67605 0.961023 RAB1A P62820 
1.02977 0.919226 0.916629 no 12 2.81804 0.955208 RAB1B Q9H0U4 
0.57056 0.374066 0.5144 no 9 1.84986 0.486342 RAB21 Q9UL25 
0.147567 0.359071 -0.08355 no 10 0.414683 0.141028 RAB34 P0DI83 
NaN 0.127237 0.239154 no 3 0.724159 0.183196 RAB35 Q15286 
NaN 1.30667 0.068189 no 3 0.330862 0.68743 RAB3D O95716 
-0.76795 -0.6444 -0.58292 no 10 2.17879 -0.665091 RAB5A P20339 
0.59703 0.237074 NaN no 7 0.586095 0.417052 RAB5B P61020 
0.330444 0.240375 0.510962 no 10 1.3431 0.360594 RAB6A P20340 
0.145482 0.777283 0.477677 no 6 0.903737 0.466814 RAB8A P61006 
0.866394 0.671565 0.98083 no 9 1.94444 0.839596 RAC1 P63000 
-0.30068 -0.04403 -0.22031 no 19 0.883095 -0.188341 RACK1 P63244 
-0.12227 0.271306 0.147697 no 10 0.314862 0.0989107 RAD21 O60216 
0.254957 -0.29502 -0.16285 no 12 0.141006 -0.0676377 RAD23B P54727 
-0.11563 -0.22965 -0.60819 no 10 0.779066 -0.317823 RAE1 P78406 
0.091124 0.188148 0.283803 no 7 1.10946 0.187692 RALA P11233 
0.306262 0.394404 0.215865 no 8 1.56382 0.30551 RALY Q9UKM9 
-0.9133 -0.63576 -0.59778 no 53 1.72653 -0.715614 RANBP2 P49792 
-0.48048 -0.77947 -0.57229 no 27 1.69194 -0.610746 RANGAP1 P46060 
0.051581 -0.12686 0.088549 no 27 0.0208904 0.00442186 RARS P54136 
-0.16595 -0.27477 -0.25763 no 14 1.69002 -0.232786 RBBP4 Q09028 
0.734048 0.400319 0.390888 no 11 1.33819 0.508418 RBBP7 Q16576 
-0.10516 0.242206 NaN no 12 0.118743 0.0685215 RBM14 Q96PK6 
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-0.24216 -0.35845 -0.16162 no 7 1.32767 -0.254077 RBM25 P49756 
-0.43343 NaN 0.032947 no 7 0.260982 -0.20024 RBM28 Q9NW13 
-0.19298 -0.22896 -0.34004 no 15 1.53686 -0.253991 RBM39 Q14498 
-1.1166 -0.56854 NaN no 12 0.698578 -0.842569 RBM4 Q9BWF3 
-0.43168 -0.27689 -0.48766 no 14 1.61815 -0.398742 RBMX P38159 
0.455229 0.328837 0.477574 no 12 1.92416 0.420547 RCC1 P18754 
-0.05116 0.173895 -0.03483 no 11 0.139647 0.0293032 RCN2 Q14257 
NaN -0.54345 -0.60428 no 8 1.47222 -0.573862 RDH11 Q8TC12 
0.859174 0.99458 1.09417 no 24 2.32162 0.982641 RDX P35241 
0.697329 0.386149 0.954047 no 19 1.26945 0.679175 RECQL P46063 
0.768163 0.951066 0.731009 no 7 2.1635 0.816746 REEP5 Q00765 
NaN 0.952408 1.01378 no 4 1.70192 0.983094 RETSAT Q6NUM9 
0.20364 -0.22085 NaN no 5 0.0113502 -0.008605 REXO2 Q9Y3B8 
-0.47811 -0.19251 NaN no 5 0.591244 -0.335309 RFC4 P35249 
1.05825 0.954122 0.937118 no 12 2.82979 0.983163 RHOA P61586 
-0.11246 0.040682 -0.25749 no 9 0.480952 -0.109757 RHOT2 Q8IXI1 
0.689478 0.93138 0.257252 no 6 1.0629 0.626037 RMDN1 Q96DB5 
0.694033 -0.38792 0.35208 no 7 0.249502 0.219397 RNPEP Q9H4A4 
-0.37666 -0.24351 -0.15007 no 5 1.22361 -0.256743 RNPS1 Q15287 
NaN 0.77762 1.07827 no 9 0.990368 0.927945 ROCK2 O75116 
-0.24869 -1.49484 NaN no 11 0.403349 -0.871766 ROD1 O95758 
-0.98242 -0.59802 -0.4922 no 11 1.36186 -0.69088 RPA1 P27694 
-0.51988 -0.09698 -0.62295 no 4 0.906461 -0.41327 RPF2 Q9H7B2 
0.263635 0.219958 0.235972 no 8 2.55023 0.239855 RPL10 P27635 
0.330673 0.266517 0.312898 no 12 2.40334 0.303363 RPL10A P62906 
0.183074 0.133037 0.261591 no 11 1.44691 0.192567 RPL11 P62913 
0.256407 0.302407 0.484396 no 9 1.42237 0.347737 RPL12 P30050 
-0.04463 -0.09353 -0.13497 no 12 1.13482 -0.0910402 RPL13 P26373 
0.317999 0.363227 0.397255 no 8 2.39226 0.359494 RPL13A P40429 
0.325962 0.288181 0.439783 no 7 1.78497 0.351309 RPL14 P50914 
0.225892 0.325962 0.244156 no 12 1.88006 0.265337 RPL15 P61313 
0.170053 0.089634 0.188401 no 10 1.41062 0.149363 RPL17 P18621 
0.185867 0.281431 0.260387 no 7 1.85431 0.242562 RPL18 Q07020 
0.414893 0.240253 0.423632 no 11 1.57687 0.359593 RPL18A Q02543 
0.225028 0.100709 0.059217 no 7 0.90859 0.128318 RPL19 P84098 
0.253021 0.178874 0.200379 no 6 1.9688 0.210758 RPL21 P46778 
-0.27037 -0.52382 -0.45876 no 6 1.50096 -0.417648 RPL23 P62829 
0.122739 0.100036 0.152118 no 11 1.84636 0.124964 RPL23A P62750 
0.119688 0.094912 0.253626 no 10 1.06073 0.156075 RPL26 P61254 
0.216238 0.191942 0.269392 no 7 1.99578 0.225857 RPL27 P61353 
0.116098 0.109561 0.224658 no 8 1.24698 0.150106 RPL27A P46776 
0.196859 0.304628 0.32987 no 9 1.67814 0.277119 RPL28 P46779 
0.179256 0.237931 0.400319 no 2 1.26656 0.272502 RPL29 P47914 
0.113034 0.219339 0.244644 no 22 1.38463 0.192339 RPL3 P39023 
0.253747 0.244887 0.245739 no 7 3.88829 0.248124 RPL30 P62888 
-0.03164 0.092884 0.040822 no 9 0.351149 0.0340233 RPL31 P62899 
0.316957 0.441802 0.303576 no 8 1.821 0.354112 RPL32 P62910 
0.147176 0.178619 0.086512 no 6 1.43681 0.137436 RPL34 P49207 
0.187388 0.176067 0.182692 no 5 3.48782 0.182049 RPL35 P42766 
0.148739 0.235359 0.307079 no 5 1.42849 0.230392 RPL35A P18077 
0.269033 0.229834 0.329755 no 5 1.96282 0.276207 RPL36 Q9Y3U8 
0.094777 -0.02512 NaN no 6 0.177224 0.0348291 RPL36A P83881 
0.298072 0.079839 -0.21722 no 6 0.122539 0.053563 RPL36AL Q969Q0 
0.260869 0.23352 0.254957 no 6 2.95683 0.249782 RPL37A P61513 
0.128293 0.209391 0.094642 no 25 1.28763 0.144108 RPL4 P36578 
0.082021 0.234869 0.239398 no 18 1.15642 0.185429 RPL5 P46777 
0.068189 0.159113 0.142871 no 16 1.32042 0.123391 RPL6 Q02878 
0.231801 0.189666 0.284159 no 16 1.87829 0.235209 RPL7 P18124 
0.217355 0.180021 0.277152 no 18 1.81071 0.224843 RPL7A P62424 
-0.3198 -0.80125 -0.93379 no 6 1.17509 -0.68495 RPL7L1 Q6DKI1 
0.195348 0.424062 0.36446 no 12 1.38759 0.327957 RPL8 P62917 
0.331705 0.454387 0.284988 no 8 1.71139 0.357027 RPL9 P32969 
0.316378 0.349252 0.276794 no 14 2.3549 0.314141 RPLP0 P05388 
0.299362 0.273934 0.40806 no 5 1.81123 0.327119 RPLP1 P05386 
0.29678 0.154065 0.238298 no 8 1.50851 0.229714 RPLP2 P05387 
0.913569 1.0345 0.813607 no 26 2.32074 0.920559 RPN2 P04844 
-0.15362 -0.28318 -0.24833 no 7 1.55997 -0.228377 RPS10 P46783 
0.230818 -0.24873 0.247077 no 9 0.164447 0.07639 RPS11 P62280 
-0.05334 -0.04729 -0.09436 no 9 1.31849 -0.0649981 RPS12 P25398 
0.172231 0.064331 0.084336 no 11 1.07542 0.106966 RPS13 P62277 
0.129481 0.030972 0.034357 no 10 0.739964 0.0649364 RPS14 P62263 
-0.05301 0.154324 0.148739 no 8 0.460734 0.0833494 RPS15 P62841 
0.170438 0.028286 0.185105 no 10 0.903763 0.127943 RPS15A P62244 
0.743127 0.512581 0.623586 no 8 1.9545 0.626431 RPS15A P62244 
0.009204 0.10017 0.148999 no 11 0.768947 0.0861243 RPS16 P62249 
-0.01822 0.003746 0.141433 no 10 0.31322 0.0423196 RPS17 P08708 
-0.00201 0.056167 0.060601 no 11 0.702569 0.0382538 RPS18 P62269 
0.063917 0.116498 0.181548 no 12 1.14796 0.120654 RPS19 P39019 
0.091531 0.025596 0.165301 no 14 0.839125 0.0941425 RPS2 P15880 
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0.218471 -0.12716 0.024745 no 4 0.133004 0.0386844 RPS20 P60866 
0.081476 -0.01146 0.028994 no 4 0.46254 0.0330041 RPS21 P63220 
-0.06631 -0.08684 -0.2843 no 6 0.767597 -0.145817 RPS23 P62266 
0.233275 -0.21478 0.111699 no 4 0.109911 0.0433993 RPS24 P62847 
0.132379 0.055612 0.041243 no 5 0.942771 0.0764114 RPS25 P62851 
0.125122 0.039279 0.151339 no 3 1.04723 0.105247 RPS26 P62854 
-0.40251 -0.66105 -0.63111 no 5 1.6934 -0.564889 RPS27 P42677 
0.011496 -0.08453 -0.06505 no 7 0.590295 -0.0460301 RPS27A P62979 
NaN 0.128293 0.115433 no 5 1.47418 0.121863 RPS27L Q71UM5 
0.098824 0.14274 0.161436 no 20 1.73157 0.134333 RPS3 P23396 
0.051024 0.121413 0.072586 no 19 1.22715 0.0816743 RPS3A P61247 
0.074094 0.166972 0.097746 no 22 1.25311 0.112937 RPS4X P62701 
1.10862 0.742265 0.927745 no 16 1.89317 0.92621 RPS4Y1 P22090 
0.08134 0.109829 0.034357 no 13 1.119 0.075175 RPS5 P46782 
-0.0063 -0.07508 0.024462 no 13 0.232746 -0.0189739 RPS6 P62753 
0.073957 0.131194 0.164786 no 13 1.36396 0.123312 RPS7 P62081 
0.173895 0.125122 0.206393 no 16 1.71917 0.16847 RPS8 P62241 
0.0297 0.217727 0.204266 no 14 0.883483 0.150564 RPS9 P46781 
-0.14325 -0.01218 -0.16574 no 18 0.810079 -0.107057 RPSA P08865 
0.533165 0.475189 0.209266 no 11 1.25653 0.405873 RRM1 P23921 
-0.54011 -0.57816 -1.0004 no 18 1.38764 -0.706221 RRP12 Q5JTH9 
-1.30216 -0.43817 NaN no 10 0.532603 -0.870165 RRP1B Q14684 
-0.69797 -0.46015 -0.6453 no 15 1.85115 -0.60114 RSL1D1 O76021 
0.49968 0.186754 0.348572 no 9 1.20586 0.345002 RSU1 Q15404 
0.066262 0.12499 0.168129 no 20 1.25412 0.119793 RTCB Q9Y3I0 
0.108357 -0.21162 NaN no 4 0.0962192 -0.051629 RTN3 O95197 
0.240375 0.222928 0.32435 no 12 1.85628 0.262551 RTRAF Q9Y224 
-0.39032 -0.47525 -0.40137 no 17 2.4021 -0.422314 RUVBL1 Q9Y265 
-0.25891 -0.49814 -0.45407 no 18 1.50043 -0.403706 RUVBL2 Q9Y230 
0.521955 0.196481 0.640436 no 3 1.11819 0.452957 S100A10 P60903 
-0.07444 -0.40541 -0.20262 no 5 0.847365 -0.227492 S100A11 P31949 
-0.17483 0.162468 -0.09028 no 13 0.114777 -0.0342152 SACM1L Q9NTJ5 
-0.48447 -0.19431 NaN no 4 0.589781 -0.33939 SAE1 Q9UBE0 
-0.50771 -0.23174 -0.37767 no 15 1.36759 -0.37237 SAFB Q15424 
-0.06252 0.013927 -0.02818 no 14 0.435807 -0.0255895 SAMM50 Q9Y512 
0.231924 0.395721 0.097746 no 9 0.970697 0.241797 SAR1A Q9NR31 
-1.07094 -0.46222 -1.16971 no 6 1.25704 -0.900956 SARNP P82979 
-0.26214 -0.85747 -0.44416 no 16 1.01002 -0.521258 SARS P49591 
-0.41373 -0.48623 -0.39886 no 19 2.41302 -0.432937 SART3 Q15020 
0.703632 1.09633 0.868529 no 5 1.79617 0.889497 SCAMP1 O15126 
0.591201 0.414352 0.487383 no 20 1.98031 0.497645 SCFD1 Q8WVM8 
-0.49415 0.327228 0.15043 no 12 0.006816 -0.0054973 SCRIB Q14160 
0.709732 0.961179 0.10742 no 10 0.841217 0.592777 SCYL1 Q96KG9 
0.468844 -0.11766 0.057138 no 11 0.287623 0.136107 SDCBP O00560 
0.831472 0.739416 0.630219 no 16 2.20576 0.733702 SDHA P31040 
0.38648 0.505688 0.259303 no 10 1.48577 0.383824 SEC13 P55735 
0.314174 0.470407 0.391548 no 13 1.88681 0.392043 SEC24B O95487 
0.773912 0.346758 0.703278 no 15 1.35489 0.607983 SEC24C P53992 
1.08706 0.800248 1.05026 no 26 2.07777 0.979189 SEC31L1 O94979 
1.08114 0.720891 NaN no 5 0.900967 0.901016 SEC62 Q99442 
0.162468 0.478817 0.279412 no 17 1.0977 0.306899 SEC63 Q9UGP8 
-0.67466 -0.69603 -0.57353 no 8 2.47099 -0.648072 Sep-10 Q9P0V9 
0.865365 0.383386 0.980172 no 14 1.2553 0.742974 Sep-02 Q15019 
0.918997 0.459641 1.00331 no 16 1.37252 0.793983 Sep-07 Q16181 
0.683652 0.469886 0.737773 no 22 1.78477 0.630437 Sep-09 Q9UHD8 
0.949273 -0.22937 0.165301 no 9 0.315143 0.29507 SERPINB6 P35237 
0.321004 0.390338 0.234501 no 29 1.70256 0.315281 SERPINH1 P50454 
-0.08464 -0.16019 -0.18123 no 16 1.39694 -0.142019 SF1 Q13285 
-0.13093 0.057832 -0.09687 no 20 0.364301 -0.0566572 SF3A1 Q15459 
0.019488 -0.04142 -0.05864 no 7 0.426322 -0.0268557 SF3A2 Q15428 
0.061154 -0.10474 -0.05038 no 13 0.231434 -0.0313243 SF3A3 Q12874 
-0.1298 -0.03055 -0.15623 no 43 0.958032 -0.105523 SF3B1 O75533 
-0.00812 0.120617 -0.00999 no 19 0.290659 0.0341705 SF3B2 Q13435 
-0.10414 -0.07094 -0.12942 no 33 1.57309 -0.101498 SF3B3 Q15393 
0.06226 NaN -0.03713 no 4 0.0745022 0.0125636 SF3B4 Q15427 
-0.06969 -0.10805 NaN no 4 0.868676 -0.0888731 SF3B5 Q9BWJ5 
NaN 0.017067 0.074779 no 4 0.447146 0.045923 SF3B6 Q9Y3B4 
-0.56672 -0.48096 -0.57237 no 33 2.52496 -0.540018 SFPQ P23246 
-0.33188 NaN -0.23475 no 3 0.966284 -0.283317 SFRS11 Q05519 
0.007913 0.256045 -0.29384 no 6 0.0196562 -0.0099593 SFRS14 Q8IX01 
-0.2424 0.037734 -0.23564 no 7 0.597446 -0.146766 SFRS3 P84103 
0.296076 0.376846 0.448372 no 7 1.86738 0.373765 SFRS4 Q08170 
0.672742 0.174023 NaN no 7 0.469988 0.423383 SFXN1 Q9H9B4 
0.528671 -0.31739 -0.67717 no 10 0.151008 -0.155297 SGPL1 O95470 
-0.0732 -0.84203 NaN no 7 0.351837 -0.45761 SH3GL1 Q99961 
-0.18354 NaN -0.53257 no 8 0.539526 -0.358057 SH3GLB1 Q9Y371 
NaN -0.29161 -0.62 no 3 0.657344 -0.455806 SIN3A Q96ST3 
-0.44697 -0.42159 -0.53579 no 25 2.2656 -0.46812 SKP1 P63208 
-0.61002 -0.97163 -0.54732 no 10 1.48135 -0.709655 SLC12A4 Q9UP95 
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0.244278 0.626112 0.479748 no 11 1.25185 0.450046 SLC25A11 Q02978 
0.194465 0.453017 0.16877 no 13 1.01953 0.272084 SLC25A13 Q9UJS0 
-0.10613 -0.17395 0.051442 no 22 0.429574 -0.0762125 SLC25A3 Q00325 
-0.42134 -0.30936 -0.44146 no 15 1.96334 -0.390719 SLC25A4 P12235 
-0.20124 -0.25617 -0.24001 no 16 2.31176 -0.232473 SLC25A6 P12236 
0.170181 0.164658 0.20389 no 17 2.33447 0.179576 SLC29A1 Q99808 
-0.65831 -0.33186 -0.35832 no 6 1.29938 -0.449499 SLC39A14 Q15043 
0.22848 0.187768 0.366924 no 12 1.39217 0.261057 SLC7A5 Q01650 
0.322851 0.566474 0.531768 no 5 1.60482 0.473698 SLC8A1 P32418 
-0.41881 -0.56314 -0.56409 no 5 2.06255 -0.515347 SMAP Q92845 
-0.35423 -0.11641 -0.30941 no 15 1.15176 -0.260016 SMARCA4 P51532 
-1.07446 -0.85951 -0.90317 no 38 2.32089 -0.945713 SMARCA5 O60264 
-0.95308 -0.90352 NaN no 4 1.76986 -0.928299 SMARCAD1 Q9H4L7 
-0.75096 -1.20899 -0.79736 no 18 1.61661 -0.919103 SMARCC1 Q92922 
0.478092 0.758815 0.697329 no 9 1.76913 0.644745 SMBP Q9HD45 
0.074232 0.243182 0.070527 no 19 0.820595 0.129313 SMC1A Q14683 
0.269392 -0.62839 0.019631 no 10 0.14658 -0.113121 SMC2L1 O95347 
0.164014 0.225398 0.256045 no 25 1.81111 0.215152 SMC3 Q9UQE7 
-0.32249 -0.08867 NaN no 8 0.482566 -0.205578 SMC4 Q9NTJ3 
0.52647 0.44615 NaN no 5 1.28022 0.48631 SMCHD1 A6NHR9 
-0.79063 -0.40631 -0.70986 no 12 1.49147 -0.635602 SMPD4 Q9NXE4 
-0.07587 -0.13546 -0.17074 no 14 1.35511 -0.127355 SMU1 Q2TAY7 
0.655627 0.600555 0.680324 no 52 2.87568 0.645502 SND1 Q7KZF4 
-0.10109 -0.07213 -0.07156 no 61 1.85461 -0.0815928 SNRNP200 O75643 
-0.13719 0.024036 -0.15565 no 14 0.590108 -0.0895997 SNRP70 P08621 
-0.18644 -0.32233 -0.35288 no 8 1.51876 -0.287215 SNRPA P09012 
-0.0184 -0.00977 -0.09675 no 9 0.566619 -0.0416375 SNRPB2 P08579 
-0.26804 -0.00638 -0.36236 no 5 0.734223 -0.212258 SNRPD1 P62314 
-0.20784 -0.33494 -0.3296 no 8 1.70405 -0.290791 SNRPD2 P62316 
0.198746 NaN -0.28842 no 4 0.0534908 -0.0448355 SNRPE P62304 
-0.34617 -0.1909 -0.22471 no 5 1.48434 -0.253924 SNRPN P63162 
-0.55364 -0.46103 -0.3723 no 8 1.90028 -0.462321 SNW1 Q13573 
0.215119 0.301471 0.384934 no 3 1.59183 0.300508 SNX6 Q9UNH7 
-0.07075 0.438612 0.008917 no 15 0.292025 0.125592 SON P18583 
-0.90804 NaN -0.73877 no 7 1.18572 -0.823403 SORT1 Q99523 
1.16253 0.491802 0.785341 no 7 1.27957 0.813224 SPAG9 O60271 
-0.26484 -0.54282 -0.4302 no 8 1.44119 -0.412619 SPATS2L Q9NUQ6 
0.705314 0.855751 0.783079 no 2 2.51204 0.781381 SPCS1 Q9Y6A9 
1.00834 1.20621 0.40621 no 7 1.1664 0.873587 SPCS2 Q15005 
0.637007 0.589763 0.623492 no 2 3.28532 0.616754 SPCS3 P61009 
0.173767 0.262193 0.279887 no 142 1.73513 0.238616 SPTAN1 Q13813 
0.193583 0.211261 0.24123 no 116 2.38261 0.215358 SPTBN1 Q01082 
0.559443 0.792939 0.525367 no 11 1.75512 0.625916 SPTLC1 O15269 
0.799916 0.645241 1.25369 no 12 1.41107 0.899616 SQSTM1 Q13501 
0.153416 0.166073 0.311154 no 7 1.27287 0.210214 SRP14 P37108 
0.368713 0.346191 0.534659 no 7 1.70434 0.416521 SRP54 P61011 
0.503451 0.557091 0.426211 no 19 2.23479 0.495584 SRP68 Q9UHB9 
0.556307 0.470198 0.460481 no 22 2.42559 0.495662 SRP72 O76094 
0.154583 NaN 0.351289 no 4 0.626917 0.252936 SRP9 P49458 
-0.79243 -0.25408 NaN no 5 0.519319 -0.523258 SRPK1 Q96SB4 
-0.2691 0.019773 -0.23756 no 4 0.661404 -0.162293 SRRM1 Q8IYB3 
-0.20975 -0.36047 -0.35187 no 19 1.61329 -0.307361 SRRM2 Q9UQ35 
-0.24076 -0.02903 -0.23419 no 21 0.863596 -0.167994 SRRT Q9BXP5 
-0.16615 0.020769 -0.58033 no 10 0.513832 -0.241903 SRSF1 Q07955 
-0.06935 0.027296 -0.06759 no 10 0.43083 -0.0365471 SRSF6 Q13247 
-0.83872 -0.43948 -0.53456 no 9 1.42613 -0.604252 SRSF9 Q13242 
-0.742 -0.66745 -0.73875 no 21 2.93848 -0.716064 SSB P05455 
1.04201 0.523462 0.69332 no 4 1.41204 0.752931 SSR1 P43307 
0.736648 1.07793 1.16588 no 6 1.77155 0.993486 SSR4 P51571 
-0.74977 -0.55773 -0.63377 no 22 2.13294 -0.647089 SSRP1 Q08945 
-0.47758 NaN -0.08783 no 9 0.415418 -0.282704 STAG2 Q8N3U4 
0.7376 0.860367 0.890486 no 16 2.49997 0.829484 STAT1 P42224 
-0.69972 -0.8329 -0.60841 no 11 2.08418 -0.713677 STAT3 P40763 
-0.33847 -0.27573 -0.24267 no 8 2.02063 -0.285624 STAU1 O95793 
-0.42676 -0.65856 -0.49893 no 24 1.78502 -0.528085 STIP1 P31948 
0.382944 -0.05589 -0.00455 no 8 0.28491 0.1075 STMN1 P16949 
-0.46745 0.077927 -0.41523 no 10 0.580719 -0.268252 STOML2 Q9UJZ1 
-0.42096 -0.50588 -0.40918 no 18 2.33293 -0.445339 STRAP Q9Y3F4 
0.918692 0.968128 NaN no 9 1.77791 0.94341 STX7 O15400 
-0.57456 -0.45194 -0.4552 no 9 2.18008 -0.493899 SUCLA2 Q9P2R7 
0.187894 0.069977 0.227371 no 5 1.12006 0.161747 SUCLG1 P53597 
-0.9001 -1.0648 -0.88617 no 8 2.44086 -0.950355 SUGT1 Q9Y2Z0 
-0.01777 0.073272 0.433387 no 6 0.445698 0.162964 SUI1 P41567 
-0.70851 -0.64896 -0.78665 no 36 2.50904 -0.714707 SUPT16H Q9Y5B9 
-0.78722 -0.46546 NaN no 5 0.795717 -0.626339 SUPT5H O00267 
-0.2106 -1.11425 NaN no 14 0.418984 -0.662423 SUPT6H Q7KZ85 
0.158466 -0.21255 NaN no 6 0.0419879 -0.0270425 SWAP70 Q9UH65 
0.168129 0.208018 0.075327 no 32 1.20797 0.150491 SYNCRIP O60506 
0.658646 0.531968 0.513491 no 4 2.19465 0.568035 SYPL1 Q16563 
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-0.14334 -0.14089 -0.25381 no 8 1.39245 -0.179346 TAF15 Q16514 
0.784588 0.22132 0.893052 no 18 1.03014 0.632987 TAGLN2 P37802 
0.573375 0.15017 0.292428 no 14 0.948847 0.338658 TALDO1 P37837 
-0.81683 -1.08167 -0.64494 no 8 1.66317 -0.847811 TBC1D15 Q8TC07 
-0.37655 -0.56582 -0.62233 no 12 1.70536 -0.521567 TBL3 Q12788 
-0.64219 -0.17007 -0.64505 no 10 1.03926 -0.48577 TBRG4 Q969Z0 
-0.84557 -0.91817 NaN no 8 1.58188 -0.881871 TCEA1 P23193 
0.215865 0.037593 -0.14086 no 5 0.124693 0.0375337 TCEB1 Q15369 
-0.03653 0.090989 0.340619 no 4 0.447983 0.131694 TCEB2 Q15370 
-0.09877 -0.36233 -0.06154 no 31 0.683827 -0.174211 TCP1 P17987 
-0.14025 -0.01812 -0.12631 no 9 0.875557 -0.0948947 TDP43 Q13148 
0.638213 0.890096 0.47892 no 10 1.51506 0.669076 TECR Q9NZ01 
-0.72538 -0.86607 -0.43805 no 14 1.48203 -0.676499 TEX10 Q9NXF1 
0.691266 0.461948 0.421048 no 7 1.60678 0.524754 TFG Q92734 
0.353549 0.652693 0.483468 no 25 1.53617 0.49657 TFRC P02786 
-0.28007 -0.21299 -0.34095 no 16 1.76408 -0.278003 THRAP3 Q9Y2W1 
0.805045 0.603122 0.562865 no 4 1.89428 0.657011 THY1 P04216 
-0.61971 0.059909 -0.02488 no 9 0.338906 -0.194896 TIAL1 Q01085 
-1.18912 -0.5558 -0.84391 no 6 1.3749 -0.862944 TIMM23 O14925 
-0.7428 NaN -1.16582 no 6 0.857438 -0.954308 TIMM44 O43615 
-0.5066 -0.49511 -0.57332 no 9 2.6676 -0.525007 TIMM50 Q3ZCQ8 
-0.96553 -0.82557 -0.9025 no 31 2.69347 -0.897865 TJP1 Q07157 
0.142087 0.269632 0.455965 no 14 1.06254 0.289228 TM9SF2 Q99805 
0.715015 1.07355 0.696083 no 5 1.67201 0.828216 TM9SF4 Q92544 
0.868134 0.994942 0.934781 no 10 2.81292 0.932619 TMED10 P49755 
0.864652 0.71721 0.857583 no 4 2.45989 0.813148 TMED2 Q15363 
0.7554 1.11537 0.972252 no 8 1.92179 0.947674 TMED7 Q9Y3B3 
0.993566 1.01714 0.825297 no 8 2.3917 0.945334 TMED9 Q9BVK6 
0.467905 0.62938 0.621149 no 4 2.08102 0.572811 TMEM165 Q9HC07 
-0.23603 -0.12232 -0.16322 no 9 1.45978 -0.173855 TMEM33 P57088 
-0.89387 -0.59584 -1.15843 no 19 1.49134 -0.882711 TMPO P42166 
-0.33829 -0.55408 -0.94461 no 23 1.12677 -0.612327 TMPO P42167 
-0.01331 -0.18623 -0.5776 no 12 0.583599 -0.259043 TMTC3 Q6ZXV5 
-0.24475 -0.07074 -0.13231 no 7 1.00255 -0.149267 TMX1 Q9H3N1 
-1.041 -0.35225 0.496718 no 20 0.243509 -0.298845 TNKS1BP1 Q9C0C2 
-0.2326 -0.27837 -0.28325 no 26 2.43269 -0.26474 TNPO1 Q92973 
-0.37535 -0.93851 NaN no 15 0.588723 -0.65693 TNPO3 Q9Y5L0 
-0.61006 -0.3246 -0.51862 no 6 1.53938 -0.484426 TOMM40 O96008 
-0.92953 -0.59092 -0.68011 no 12 1.73156 -0.733517 TOMM70A O94826 
-0.2592 0.085425 -0.06005 no 16 0.286598 -0.0779429 TOP1 P11387 
-0.34401 -0.65041 -0.38421 no 14 1.3863 -0.459541 TOP2A P11388 
-0.428 -0.38028 -0.37159 no 31 2.70282 -0.39329 TOR1A O14656 
0.632268 0.898324 0.836813 no 12 1.99029 0.789135 TP53BP1 Q12888 
0.515914 0.125651 0.628447 no 5 0.963448 0.423337 TPI1 P60174 
0.026729 -0.44961 -0.29681 no 21 0.638869 -0.239898 TPM1 P09493 
0.636543 0.21661 0.845751 no 38 1.03535 0.566301 TPM1 P09493 
-0.07671 -0.34125 -0.02725 no 34 0.572958 -0.1484 TPM3 P06753 
1.05991 0.469469 0.913339 no 32 1.35278 0.814239 TPM4 P67936 
0.164014 -0.21366 -0.10838 no 19 0.163823 -0.0526733 TPP2 P29144 
-0.07399 -0.2963 -0.03632 no 43 0.625808 -0.135534 TPR P12270 
-0.13154 -0.64151 -0.25346 no 6 0.806876 -0.342171 TPT1 P13693 
0.402613 0.560813 0.388906 no 62 1.8343 0.450777 TRA1 P14625 
NaN -0.21893 -0.1757 no 7 1.15818 -0.197315 TRA2B P62995 
NaN 0.164014 0.326767 no 15 0.690688 0.24539 TRIP12 Q14669 
0.274411 -0.86397 NaN no 6 0.157524 -0.294777 TRIP13 Q15645 
NaN -0.61048 -0.6192 no 14 2.34505 -0.61484 TRIP6 Q15654 
-0.96255 -0.58005 NaN no 4 0.810417 -0.7713 TRMT10C Q7L0Y3 
-0.61951 -1.12863 -0.62034 no 7 1.36486 -0.789493 TSFM P43897 
0.096127 0.148739 NaN no 4 0.870516 0.122433 TSG101 Q99816 
-0.53016 -0.6655 -0.63149 no 7 2.35408 -0.609048 TSN Q15631 
0.037593 NaN -0.45825 no 9 0.257975 -0.210327 TSR1 Q2NL82 
-0.60619 -1.3709 -0.63142 no 33 1.13033 -0.869503 TUBA1A Q71U36 
-0.50265 -1.07276 -0.728 no 33 1.3606 -0.767803 TUBA1B P68363 
-0.25195 -0.97361 -0.47953 no 25 0.933935 -0.568365 TUBB P07437 
-0.52782 -1.05119 -0.64535 no 27 1.36849 -0.741453 TUBB2C P68371 
0.134089 -0.61684 0.329066 no 23 0.0578137 -0.0512267 TUBB3 Q13509 
0.19333 -0.44743 0.330673 no 25 0.0338881 0.0255257 TUBB6 Q9BUF5 
-0.46019 -1.09225 -0.41089 no 10 1.01599 -0.654443 TUBB8 Q3ZCM7 
-0.53749 -0.36212 -0.53498 no 25 1.8412 -0.478195 TUFM P49411 
0.267236 0.067914 NaN no 8 0.466525 0.167575 TWF2 Q6IBS0 
0.135141 0.039138 0.257252 no 4 0.823063 0.143844 TXNDC12 O95881 
-0.50386 -0.37071 -0.58253 no 10 1.80091 -0.485701 TXNL1 O43396 
1.11517 0.676448 1.16234 no 21 1.6233 0.984653 TXNRD1 Q16881 
0.135798 0.071625 -0.05427 no 10 0.340082 0.0510503 U2AF1 Q01081 
-0.02348 -0.10205 -0.15592 no 15 0.870142 -0.093814 U2AF2 P26368 
-0.20756 -0.20601 -0.48653 no 16 1.07301 -0.300034 U2SURP O15042 
-0.14623 -0.54631 -0.23754 no 35 0.904532 -0.310026 UBA1 P22314 
-0.04127 -0.35613 -0.25612 no 9 0.8427 -0.217836 UBA2 Q9UBT2 
0.004897 -0.38685 -0.50197 no 6 0.710516 -0.294641 UBA3 Q8TBC4 
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-0.45833 -0.80015 -0.77004 no 14 1.59974 -0.676173 UBA6 A0AVT1 
-0.09323 -0.37323 -0.59351 no 16 0.870476 -0.353324 UBAP2L Q14157 
-0.77066 -1.10302 -0.89746 no 6 1.96607 -0.923714 UBE2I P63279 
-0.29922 -0.39369 0.032524 no 11 0.637097 -0.22013 UBQLN1 Q9UMX0 
-0.45247 -0.56154 -0.28365 no 37 1.47893 -0.432553 UBR4 Q5T4S7 
-0.37619 -0.04435 NaN no 12 0.371304 -0.210267 UBTF P17480 
0.414785 0.745452 0.380397 no 5 1.32139 0.513545 UBXN4 Q92575 
0.19774 1.01735 0.637749 no 16 0.917478 0.617613 UFL1 O94874 
1.00303 0.906737 0.824401 no 44 2.49589 0.911389 UGGT1 Q9NYU2 
0.162468 0.123401 0.185486 no 31 1.88466 0.157118 UPF1 Q92900 
-0.2211 -0.36205 -0.19027 no 5 1.4025 -0.257807 UQCRB P14927 
-0.1643 -0.08848 -0.05733 no 22 1.08168 -0.103373 UQCRC1 P31930 
-0.20154 0.056306 -0.03823 no 16 0.299245 -0.0611551 UQCRC2 P22695 
-0.29034 0.185486 -0.07939 no 5 0.155434 -0.0614132 UQCRFS1 P47985 
-0.25849 0.005472 -0.15351 no 3 0.658718 -0.135511 USMG5 Q96IX5 
-0.34342 -0.37544 -0.39199 no 11 2.83011 -0.370283 USP10 Q14694 
-0.39943 -0.72638 -0.33743 no 20 1.25111 -0.487744 USP14 P54578 
0.434988 -0.08108 0.404576 no 8 0.569264 0.252828 USP39 Q53GS9 
-0.68471 -1.00665 -0.63794 no 21 1.66629 -0.776434 USP5 P45974 
-0.13033 -0.21865 -0.38447 no 19 1.08815 -0.244485 USP7 Q93009 
0.193204 -0.6139 -0.26162 no 22 0.363548 -0.227437 USP9X Q93008 
-0.89714 -0.42436 -0.58277 no 29 1.34952 -0.634757 UTP20 O75691 
-0.71362 NaN -0.53475 no 5 1.04287 -0.624181 UTP4 Q969X6 
0.787432 0.853756 0.743644 no 53 2.79122 0.794944 UTRN P46939 
0.857424 1.02389 0.852159 no 10 2.41932 0.911158 VAPA Q9P0L0 
0.395172 0.482022 0.470303 no 9 2.4378 0.449166 VAPB O95292 
0.36614 0.438293 0.267596 no 35 1.72973 0.357343 VARS P26640 
-0.10673 -0.16062 -0.06842 no 15 1.27885 -0.111925 VASP P50552 
-0.10902 -0.08456 -0.07336 no 19 1.86303 -0.0889807 VAT1 P54219 
0.244156 -0.1589 NaN no 3 0.0618364 0.04263 VBP1 P61758 
-0.14927 -0.27129 -0.14847 no 53 1.36346 -0.189672 VCP P55072 
0.170438 0.28629 0.234011 no 19 1.68791 0.230246 VDAC1 P21796 
-0.28418 -0.1804 -0.14712 no 15 1.41324 -0.203899 VDAC2 P45880 
0.250355 0.304044 0.255803 no 10 2.40153 0.270067 VDAC3 Q9Y277 
-0.05257 -0.16248 0.009204 no 29 0.515574 -0.0686127 VDP O60763 
1.10125 0.681224 0.701593 no 3 1.58163 0.828022 VKORC1L1 Q8N0U8 
0.799336 -0.7822 NaN no 8 0.0030063 0.008569 VPS26A O75436 
0.903655 0.888695 1.00087 no 21 2.84669 0.931073 VPS35 Q96QK1 
-0.19301 -0.35161 -0.4197 no 2 1.38738 -0.321439 VTA1 Q9NP79 
0.347099 -0.1407 NaN no 4 0.127744 0.103201 WASF2 Q9Y6W5 
0.182692 0.351402 0.164529 no 10 1.22545 0.232874 WDFY1 Q8IWB7 
0.127897 -0.34161 0.105946 no 28 0.0776916 -0.0359223 WDR1 O75083 
-0.81112 NaN -0.91874 no 6 1.40278 -0.86493 WDR12 Q9GZL7 
-0.40767 NaN -0.61259 no 6 0.898982 -0.510131 WDR18 Q9BV38 
-0.52554 -0.91015 -0.87689 no 13 1.61011 -0.770859 WDR3 Q9UNX4 
-0.7727 -0.69472 NaN no 3 1.47107 -0.73371 WDR33 Q9C0J8 
0.088549 -0.1123 -0.72159 no 11 0.381929 -0.248447 WDR36 Q8NI36 
-0.93266 -0.54317 -0.74994 no 5 1.65303 -0.741924 WDR43 Q15061 
-0.35043 -0.12244 -0.51404 no 6 0.994166 -0.328971 WDR46 O15213 
-0.07913 0.052416 -0.29246 no 9 0.397193 -0.10639 WDR57 Q96DI7 
0.173767 0.036609 0.260026 no 7 0.861733 0.156801 WDR61 Q9GZS3 
-0.92574 NaN -0.5576 no 4 0.810038 -0.741672 WDR75 Q8IWA0 
0.265197 -0.34975 NaN no 3 0.0395233 -0.0422765 WDR82 Q6UXN9 
0.713872 -0.67277 NaN no 9 0.0082707 0.02055 XPO7 Q9UIA9 
-0.06522 -0.20943 0.006334 no 41 0.531561 -0.0894378 XRCC5 P13010 
0.031819 -0.21556 -0.01284 no 37 0.318733 -0.0655279 XRCC6 P12956 
-0.25271 -0.4665 -0.30768 no 19 1.47727 -0.342294 XRN2 Q9H0D6 
0.136191 0.311736 0.04698 no 14 0.774786 0.164969 YBX1 P67809 
-0.8491 -0.46925 -0.02487 no 11 0.697056 -0.44774 YES1 P07947 
NaN 0.611928 0.337197 no 3 0.746246 0.474562 YIPF3 Q9GZM5 
0.504671 NaN -0.24527 no 6 0.103478 0.129702 YLPM1 P49750 
-0.7421 -0.8686 -0.87136 no 9 2.57757 -0.827351 YTHDF2 Q9Y5A9 
-0.40532 -0.15732 NaN no 9 0.577904 -0.281318 YTHDF3 Q7Z739 
-0.1192 -0.59689 -0.52514 no 16 0.964296 -0.413742 YWHAB P31946 
-0.58656 -0.76146 -0.68852 no 26 2.25679 -0.678845 YWHAE P62258 
-0.51044 -0.67006 -0.5332 no 20 2.12324 -0.571233 YWHAG P61981 
-0.06207 -0.3284 -0.09231 no 19 0.707507 -0.160926 YWHAH Q04917 
-0.02315 -0.30018 -0.10513 no 20 0.649192 -0.142822 YWHAQ P27348 
-0.45563 -0.77098 -0.6083 no 23 1.6686 -0.611636 YWHAZ P63104 
NaN -0.63799 -0.39032 no 5 0.822573 -0.514153 ZC3H15 Q8WU90 
-0.1312 -0.49529 -0.28144 no 19 0.985913 -0.302643 ZC3HAV1 Q7Z2W4 
-0.44788 -0.34672 -0.53671 no 5 1.82525 -0.44377 ZCCHC8 Q6NZY4 
0.488926 0.796182 0.460795 no 10 1.4892 0.581968 ZMPSTE24 O75844 
0.007195 -0.38875 NaN no 8 0.290915 -0.190778 ZMYND8 Q9ULU4 
-0.56384 -0.33883 -0.29802 no 10 1.3969 -0.400229 ZNF326 Q5BKZ1 
0.512783 0.410884 0.762391 no 10 1.48378 0.562019 ZW10 O43264 
-0.01553 -0.47503 -0.15013 no 21 0.588611 -0.213566 ZYX Q15942 
-0.49454 -0.16043 -0.33439 no 10 1.11942 -0.329784 ATP5F1C P36542 
-0.39893 -0.21662 NaN no 2 0.736809 -0.307775 MT-COX3 P00414 
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-0.38651 -0.60018 -0.50204 no 52 1.82004 -0.496242 EPRS P07814 
0.491289 0.593784 0.299362 no 7 1.47847 0.461478 HIST1H2B Q8N257 
0.141302 0.217479 0.096262 no 3 1.29825 0.151681 HIST2H3PS2 Q5TEC6 
-0.99303 -0.18961 -0.386 no 10 0.787547 -0.522882 PUM3 Q15397 
0.25532 0.317883 0.449535 no 8 1.56786 0.340913 TMOD3 Q9NYL9 
0.070939 0.372618 0.133564 no 9 0.765916 0.192374 MTCH1 Q9NZJ7 
-0.81774 -0.97858 -0.73555 no 77 2.15023 -0.843955 GCN1 Q92616 
0.135666 -0.09309 0.184471 no 6 0.32818 0.075681 RPL24 P83731 
0.755571 0.599603 NaN no 4 1.13699 0.677587 Sep-15 O60613 
1.98779 1.63069 NaN no 10 1.20326 1.80924 ACAD9 Q9H845 
2.86833 3.47041 NaN no 5 1.21977 3.16937 ACAT1 P35610 
1.31863 1.06191 NaN no 7 1.16501 1.19027 ACTR1B P42025 
NaN 2.33345 3.0431 no 6 1.07808 2.68828 CD97 P48960 
1.039 1.31858 NaN no 2 1.1241 1.17879 CNIH1 O95406 
2.03924 4.31303 1.99172 no 11 1.16635 2.78133 COL5A1 P20908 
2.15225 NaN 1.36014 no 5 0.850142 1.7562 CRAT P43155 
1.80414 1.08882 NaN no 7 0.811587 1.44648 DHRS7 Q9Y394 
0.472072 1.27596 1.30375 no 29 1.18744 1.01726 EEA1 Q15075 
4.23074 2.23159 2.01543 no 10 1.24414 2.82592 ENG P17813 
NaN 1.36272 1.00029 no 5 1.01373 1.18151 F3 P13726 
2.44438 1.90958 NaN no 16 1.10898 2.17698 FAP Q12884 
2.27289 2.3215 0.977023 no 6 1.28508 1.85714 H1FX Q92522 
1.14633 1.37384 NaN no 10 1.24172 1.26008 HEXA P06865 
NaN 1.75134 3.49672 no 4 0.689521 2.62403 HMGCL P35914 
1.01235 NaN 1.27941 no 12 1.13163 1.14588 ILVBL A1L0T0 
2.19944 NaN 1.07526 no 20 0.676703 1.63735 MPRIP Q6WCQ1 
1.20044 0.53057 1.4461 no 6 1.21666 1.05904 NEXN Q0ZGT2 
3.72279 1.6602 3.92343 no 11 1.29846 3.10214 NQO1 P15559 
1.69019 -0.03423 1.53077 no 12 0.713858 1.06224 NRP1 O14786 
1.60815 0.983532 NaN no 14 0.822291 1.29584 PLXNB2 O15031 
2.66403 NaN 1.6683 no 6 0.842177 2.16617 PTGIS Q16647 
2.11912 NaN 1.66093 no 5 1.11469 1.89002 RAB23 Q9ULC3 
1.14183 1.4282 NaN no 4 1.15092 1.28501 RBM3 P98179 
3.85868 2.73747 NaN no 15 0.969855 3.29807 RCN3 Q96D15 
NaN 2.02963 2.9181 no 11 0.946487 2.47387 RHOC P08134 
NaN 1.46801 1.87421 no 6 1.11354 1.67111 RHOG P84095 
0.125519 1.11597 3.8055 no 14 0.57576 1.68233 SLC25A1 P53007 
1.22002 0.996967 NaN no 4 1.19493 1.10849 SLC3A2 P08195 
NaN 1.61504 1.1173 no 8 0.940388 1.36617 SPARC P09486 
3.67061 1.33862 NaN no 9 0.556932 2.50461 SQRDL Q9Y6N5 
2.70383 3.44798 0.661202 no 21 0.949469 2.271 SYNE1 Q8NF91 
2.75363 3.66221 NaN no 9 1.04789 3.20792 SYNPO2 Q9UMS6 
NaN 1.21996 1.51672 no 12 1.16263 1.36834 TPD52L2 O43399 
NaN 1.66125 0.770787 no 5 0.650838 1.21602 TRAM1 Q15629 
NaN 1.92509 1.16169 no 6 0.811502 1.54339 DDR2 Q16832 
NaN -1.20201 -0.8636 no 17 0.985565 -1.0328 ACACA Q13085 
NaN -2.79796 -1.91828 no 7 0.930353 -2.35812 APRT P07741 
-1.37236 -2.7539 NaN no 7 0.686803 -2.06313 ARMT1 Q9H993 
-3.71698 -4.48691 NaN no 12 1.22496 -4.10194 BCAT1 P54687 
NaN -1.37494 -2.05757 no 4 0.903176 -1.71626 CD9 P21926 
NaN -0.76444 -1.61158 no 6 0.661479 -1.18801 DHCR7 Q9UBM7 
-0.9979 -1.24581 NaN no 19 1.15454 -1.12185 DSG2 Q14126 
-1.26143 -1.45593 -0.52406 no 10 1.20349 -1.08047 EIF4H Q15056 
-2.67328 NaN -3.8017 no 9 0.959227 -3.23749 EPCAM P16422 
-3.55947 -2.13924 NaN no 42 0.808296 -2.84935 EPPK1 P58107 
-0.64323 -1.43803 NaN no 8 0.634071 -1.04063 EPS8L2 Q9H6S3 
NaN -2.49322 -4.17546 no 10 0.803239 -3.33434 F11R Q9Y624 
-0.85909 -1.78195 NaN no 8 0.669565 -1.32052 FAM49B Q9NUQ9 
NaN -1.26979 -1.00526 no 6 1.13258 -1.13753 FDPS P14324 
-0.58888 -2.04168 -2.59903 no 5 0.997297 -1.7432 FIP1L1 Q6UN15 
-1.10426 -1.7324 NaN no 4 0.857823 -1.41833 GMFB P60983 
-1.40924 -1.07643 NaN no 8 1.07194 -1.24283 HELLS Q9NRZ9 
-2.8626 NaN -2.16385 no 25 1.05583 -2.51323 JUP P14923 
-3.85895 -1.68659 -2.45593 no 5 1.2805 -2.66716 METTL7A Q9H8H3 
-1.53642 -1.95148 NaN no 9 1.12261 -1.74395 NOLC1 Q14978 
-1.58199 -2.00857 -0.75614 no 7 1.23093 -1.4489 NUDT5 Q9UKK9 
-0.64449 -1.64693 -1.57915 no 4 1.24047 -1.29019 NUTF2 P61970 
-1.74458 -2.2051 NaN no 8 1.13139 -1.97484 OCLN Q16625 
-0.70595 -1.81777 -1.47265 no 12 1.25344 -1.33212 PAK1 Q13153 
NaN -1.55962 -1.88262 no 4 1.22503 -1.72112 PHP14 Q9NRX4 
NaN -1.84477 -1.34132 no 10 1.001 -1.59304 PLD3 Q8IV08 
NaN -0.84858 -1.4231 no 8 0.802177 -1.13584 POU5F1 Q01860 
-1.15602 -1.94792 -0.85831 no 10 1.25492 -1.32075 PPA1 Q15181 
-1.85157 -1.19021 NaN no 6 0.865517 -1.52089 PPAT Q06203 
-0.99746 -1.17853 NaN no 11 1.27694 -1.088 PPM2C Q9P0J1 
-3.88483 NaN -2.10079 no 11 0.734215 -2.99281 PTBP2 Q9UKA9 
NaN -1.05242 -1.46196 no 6 0.988052 -1.25719 RBPMS Q93062 
-2.60639 -1.77443 NaN no 4 0.922714 -2.19041 RRM2B Q7LG56 
-0.35117 NaN -2.09376 no 4 0.404272 -1.22246 SCD O00767 
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-1.73836 NaN -1.13758 no 18 0.882385 -1.43797 SEC23B Q15437 
-1.73322 -2.30707 NaN no 11 1.04663 -2.02014 SEPHS1 P49903 
-1.43788 -1.7826 -0.65488 no 9 1.21683 -1.29179 STK26 Q9P289 
-1.94964 -2.51672 NaN no 4 1.09475 -2.23318 TBCA O75347 
-1.60021 -1.20141 NaN no 7 1.04568 -1.40081 TFAM Q00059 
-1.41935 NaN -1.17912 no 7 1.23144 -1.29923 TIA1 P31483 
-1.72294 NaN -2.80995 no 13 0.824386 -2.26645 TRIM71 Q2Q1W2 
-0.64537 -1.60902 -0.81568 no 32 1.12576 -1.02336 TUBA1C Q9BQE3 
-1.45395 -2.04073 NaN no 8 0.975084 -1.74734 UBE2K P61086 
-1.81909 -1.10315 NaN no 9 0.81543 -1.46112 UBE2O Q9C0C9 
-1.92676 NaN -0.93641 no 5 0.673663 -1.43159 UMPS P11172 
-2.14146 NaN -3.16294 no 9 0.91681 -2.6522 VSNL1 P62760 
-1.68859 -0.82074 NaN no 9 0.673714 -1.25467 YARS2 Q9Y2Z4 
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Table 6.3 Proteins Identified in 3XFLAG immunoprecipitation 
   LFQ Values 3XFLAG OCT4 IP (log2) 
































AAMP Q13685 3 22.78 NAN 23.55 24.70 24.28 24.84 NAN NAN NAN NAN NAN NAN 
AAR2 Q9Y312 4 23.70 NAN 23.72 23.47 23.76 23.71 NAN NAN NAN NAN NAN NAN 
AATF Q9NY61 6 NAN NAN NAN NAN NAN NAN 25.88 24.12 25.95 24.97 25.16 24.56 
ABCB6 Q9NP58 3 NAN NAN NAN NAN 23.51 23.88 NAN NAN NAN NAN NAN NAN 
ABCB7 O75027 6 25.00 25.88 23.39 23.58 NAN 23.36 NAN NAN NAN NAN NAN NAN 
ABCC1 P33527 16 26.10 26.52 25.89 26.17 25.70 26.12 NAN 23.25 23.29 24.97 23.39 24.56 
ABCE1 P61221 31 25.16 28.05 25.95 27.49 28.00 27.73 28.30 29.15 28.96 27.90 28.17 28.71 
ABCF2 Q9UG63 33 26.62 27.17 26.80 26.44 26.23 26.46 29.12 28.50 28.85 27.99 28.55 27.87 
ACAA2 P42765 8 23.24 NAN 24.18 NAN NAN NAN NAN NAN NAN 23.08 22.83 NAN 
ACACA Q13085 31 25.50 27.80 24.44 26.29 26.62 26.83 24.10 24.59 23.86 25.81 24.66 24.98 
ACAD11 Q709F0 7 NAN NAN NAN NAN NAN NAN 24.79 24.54 25.37 24.14 24.54 24.09 
ACAD9 Q9H845 9 24.89 25.31 24.80 25.38 25.19 25.03 23.91 23.75 24.65 23.94 24.44 24.32 
ACADM P11310 2 NAN NAN NAN NAN 22.76 22.52 NAN NAN NAN NAN NAN NAN 
ACAP2 Q15057 22 26.57 27.35 25.77 27.34 27.90 28.15 22.59 25.11 23.54 24.76 24.05 25.19 
ACAT1 P24752 7 NAN 26.21 NAN NAN 24.84 24.17 NAN 23.80 23.57 23.93 23.64 24.72 
ACBD3 Q9H3P7 8 23.49 23.76 23.78 24.87 24.86 25.19 NAN 23.34 22.86 NAN NAN NAN 
ACIN1 Q9UKV3 2 NAN NAN NAN NAN NAN NAN 24.07 NAN 23.53 NAN NAN NAN 
ACO2 Q99798 6 NAN 22.72 NAN NAN 23.33 23.19 NAN NAN NAN NAN NAN NAN 
ACOT7 O00154 7 24.68 24.96 24.57 24.95 25.19 25.30 23.17 23.51 23.11 24.02 23.57 24.40 
ACOX1 Q15067 23 28.42 27.52 28.74 26.76 26.01 26.44 24.61 23.31 23.85 23.37 25.59 25.44 
ACP1 P24666 2 NAN 22.47 NAN NAN 22.88 NAN NAN NAN NAN NAN NAN NAN 
ACSL1 P33121 6 NAN NAN NAN NAN 23.36 23.37 NAN NAN NAN NAN NAN NAN 
ACSL3 O95573 21 25.94 26.29 26.10 26.78 26.79 26.87 25.63 25.66 25.52 26.20 25.84 26.06 
ACTG1 P63261  25 NAN NAN NAN NAN NAN NAN 26.49 NAN 25.39 NAN NAN NAN 
ADAM10 O14672 5 22.11 22.76 21.63 23.79 23.25 23.65 21.97 22.19 NAN NAN NAN NAN 
ADPGK Q9BRR6 6 25.06 24.61 24.78 25.03 24.81 25.16 NAN NAN NAN 24.06 23.96 24.11 
ADSL P30566 5 NAN NAN NAN NAN 23.67 24.32 NAN NAN NAN NAN NAN NAN 
AFAP1 Q8N556 20 NAN 24.54 NAN NAN 23.97 24.26 26.27 25.64 25.72 25.36 25.71 24.80 
AFG3L2 Q9Y4W6 11 23.85 24.47 23.90 24.85 25.31 25.34 22.74 NAN 23.18 NAN NAN NAN 
AGK Q53H12 10 26.17 25.95 26.84 26.50 26.30 26.55 24.71 24.55 25.01 24.93 25.32 25.25 
AGPS O00116 7 25.02 24.13 24.85 25.01 24.51 24.78 24.02 23.93 NAN 23.61 NAN 24.35 
AHCY P23526 9 23.77 24.77 23.98 25.49 26.33 25.74 NAN 23.56 22.88 23.82 23.51 23.56 
AHCYL1 O43865 5 22.93 23.86 23.25 23.65 24.06 23.91 22.97 22.94 23.00 NAN NAN NAN 
AHSA1 O95433 8 25.32 24.41 25.62 26.33 26.34 26.85 NAN NAN NAN NAN NAN NAN 
AIFM1 O95831 21 26.10 25.98 26.23 28.28 27.59 28.24 23.78 24.18 23.66 25.13 24.62 24.87 
AIMP1 Q12904 7 24.73 25.89 24.50 24.49 24.99 24.99 24.41 25.03 24.40 24.43 24.60 24.74 
AKAP1 Q92667 2 NAN 24.46 NAN NAN NAN 23.51 NAN NAN NAN NAN NAN NAN 
AKAP11 Q9UKA4 4 NAN NAN NAN NAN NAN NAN 22.09 22.71 NAN NAN NAN NAN 
AKAP12 Q02952 4 NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.36 NAN 23.12 
AKAP2 Q9Y2D5 18 24.35 24.78 23.94 23.96 24.98 24.47 26.99 27.32 26.75 26.47 26.23 26.44 
AKAP8L Q9ULX6 6 24.73 23.48 25.35 26.72 24.99 24.77 NAN NAN NAN NAN NAN NAN 
AKR7A2 O43488 4 NAN NAN NAN NAN 23.86 23.32 NAN NAN NAN NAN NAN NAN 
AKT1 P31749 6 NAN 24.08 NAN NAN 24.66 24.41 NAN NAN NAN 23.58 22.96 22.99 
AKT2 P31751 6 NAN NAN NAN NAN 23.79 23.92 NAN NAN NAN 22.68 NAN 23.05 
ALCAM Q13740 14 23.98 25.36 24.03 26.11 26.37 26.65 23.51 24.36 23.27 25.03 24.17 24.94 
ALDH18A1 P54886 27 25.66 27.46 25.55 27.30 27.28 26.91 25.58 25.79 25.80 26.05 25.91 26.79 
ALDH1A1 P00352 5 23.30 NAN 23.57 23.18 23.56 23.97 NAN NAN NAN NAN NAN NAN 
ALDH1B1 P30837 16 25.03 26.29 26.25 26.98 26.69 26.73 25.30 24.67 25.50 24.84 25.10 25.45 
ALDH5A1 P51649 13 25.56 23.60 25.89 26.66 25.10 25.26 NAN NAN NAN 23.65 22.80 NAN 
ALDH7A1 P49419 7 NAN 23.86 NAN NAN 24.50 23.75 NAN NAN NAN 24.00 23.67 24.61 
ALDH9A1 P49189 9 23.59 23.39 NAN 24.00 24.36 25.25 NAN NAN NAN NAN NAN NAN 
ALDOC P09972 5 NAN NAN NAN NAN 25.03 24.46 NAN NAN NAN NAN NAN NAN 
ALG1 Q9BT22 8 24.35 25.27 24.58 25.11 25.47 25.52 23.17 23.45 NAN NAN NAN NAN 
ALG2 Q9H553 7 24.97 26.30 24.44 24.93 24.46 24.52 NAN NAN NAN 23.54 23.43 23.54 
AMPD2 Q01433 3 NAN 22.54 NAN NAN 23.00 23.44 NAN NAN NAN NAN NAN NAN 
ANAPC7 Q9UJX3 2 NAN NAN NAN NAN 22.29 22.10 21.45 NAN 21.71 NAN NAN NAN 
ANGEL2 Q5VTE6 3 NAN NAN NAN NAN NAN NAN 24.01 23.91 23.58 NAN NAN NAN 
ANKLE2 Q86XL3 5 NAN 23.33 NAN NAN 23.83 23.98 NAN NAN NAN NAN NAN NAN 
ANP32E Q9BTT0 4 24.14 23.45 23.73 24.96 25.85 25.28 NAN NAN NAN 24.71 24.16 24.64 
ANTXR1 Q9H6X2 7 NAN NAN NAN NAN NAN NAN 26.01 23.91 25.49 NAN NAN NAN 
ANTXR2 P58335 8 NAN 23.29 NAN NAN 23.03 22.37 24.00 23.13 24.64 23.31 23.99 23.47 
ANXA4 P09525 11 23.91 24.59 25.75 25.48 25.33 25.06 24.03 25.35 26.08 25.28 25.65 26.94 
ANXA4 P09525 68 30.43 29.78 30.61 32.37 32.18 32.06 29.86 30.69 30.55 30.88 31.07 31.50 
ANXA6 P08133 67 NAN NAN NAN NAN 23.63 23.31 NAN NAN NAN NAN NAN NAN 
ANXA6 P08133 30 NAN 24.72 NAN NAN 24.99 24.63 24.27 24.61 24.70 NAN NAN NAN 
AP1G1 O43747 11 23.37 24.93 23.20 24.75 24.71 25.14 22.28 23.30 23.53 24.38 23.55 24.18 
AP1M1 Q9BXS5 4 22.11 NAN NAN 22.80 22.89 22.83 NAN NAN NAN 22.89 NAN 22.67 
AP2A1 O95782 50 27.78 27.62 28.00 27.94 28.23 28.09 29.95 29.79 30.09 29.23 29.45 29.12 
AP2A2 O94973 34 25.63 26.62 25.63 25.87 26.11 25.93 28.15 28.07 28.13 26.79 27.87 27.50 
AP2B1 P63010 62 28.17 28.30 28.07 28.48 28.70 28.61 30.12 29.81 30.15 29.37 29.63 29.53 
AP2M1 Q96CW1 23 25.88 25.71 26.01 26.28 26.44 26.30 28.22 27.84 27.90 27.45 27.63 27.32 
AP3M1 Q9Y2T2 10 24.96 24.40 24.85 25.42 25.44 25.60 24.80 25.20 24.46 24.33 24.63 25.03 
AP3S1 Q92572 5 22.07 22.45 22.46 23.61 23.97 24.35 22.32 23.05 22.40 22.19 22.88 22.89 
AP4E1 Q9UPM8 4 24.12 NAN NAN 24.13 23.95 24.17 NAN NAN NAN NAN NAN NAN 
AP4M1 O00189 5 NAN NAN 23.76 23.84 24.46 24.19 NAN NAN NAN NAN NAN NAN 
APEX1 P27695 10 NAN 26.08 NAN NAN 25.71 25.55 25.26 26.32 25.99 25.75 25.98 26.96 
API5 Q9BZZ5 8 NAN 23.35 NAN NAN 25.02 25.04 25.17 24.95 24.82 23.40 24.29 23.69 
APOBEC3C Q9NRW3 6 NAN 24.14 NAN NAN 23.24 NAN 27.09 26.63 26.66 25.55 26.49 25.64 
APOL2 Q9BQE5 8 23.61 25.01 24.08 24.62 24.57 24.73 23.38 22.96 23.52 23.30 23.06 NAN 
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APOOL Q6UXV4 5 23.01 23.00 24.74 23.26 23.17 23.19 22.74 22.51 NAN 23.05 NAN 23.04 
APRT P07741 5 24.22 26.54 24.47 24.37 24.26 24.12 22.34 NAN 24.37 NAN NAN NAN 
AQR O60306 4 NAN 24.24 NAN NAN 23.01 23.14 NAN NAN NAN NAN NAN NAN 
ARF1 P84077 10 26.50 27.68 NAN 24.99 25.28 25.12 NAN NAN NAN NAN NAN NAN 
ARF4 P18085 12 27.61 29.35 27.64 26.99 27.07 27.05 26.21 26.56 26.29 26.49 27.04 27.20 
ARFGEF2 Q9Y6D5 3 NAN NAN NAN NAN 22.79 22.63 NAN NAN NAN NAN NAN NAN 
ARHG P84095 7 23.45 24.97 23.64 24.95 24.39 25.02 NAN NAN NAN NAN NAN NAN 
ARHGAP1 Q07960 7 24.28 24.64 NAN 23.83 24.44 23.55 NAN NAN NAN 23.09 NAN 24.96 
ARHGAP22 Q7Z5H3 3 NAN NAN NAN NAN 24.15 23.89 NAN NAN NAN NAN NAN NAN 
ARHGAP35 Q9NRY4 3 NAN NAN NAN NAN 22.20 22.01 NAN NAN NAN NAN NAN NAN 
ARHGAP42 A6NI28 13 24.89 25.33 25.54 25.93 25.85 25.98 23.30 23.85 NAN 24.13 NAN 23.83 
ARHGDIA P52565 7 24.71 25.01 25.16 25.77 25.84 25.48 23.81 24.64 24.89 24.97 24.62 25.94 
ARHGEF1 Q92888 9 NAN 25.56 NAN NAN 24.18 23.74 NAN NAN NAN NAN NAN NAN 
ARIH1 Q9Y4X5 5 NAN 22.65 NAN NAN 23.34 24.11 NAN NAN NAN NAN NAN NAN 
ARL6IP5 O75915 3 24.32 25.46 NAN 25.52 25.45 25.00 24.02 23.79 24.67 24.08 24.62 24.43 
ARL8B Q9NVJ2 8 25.12 27.70 26.33 24.64 24.61 24.53 NAN NAN NAN 23.36 23.27 NAN 
ARMCX3 Q9UH62 7 NAN 23.04 NAN NAN 24.07 24.09 NAN NAN NAN NAN NAN NAN 
ARPC1A Q92747 12 23.99 24.61 24.30 24.05 24.25 23.88 25.21 24.49 24.88 24.67 24.82 24.56 
ARPC4 P59998 10 25.36 26.52 25.48 26.94 27.22 26.96 26.63 27.02 26.86 27.35 27.46 27.37 
ARPC5 O15511 3 22.10 23.34 22.51 24.01 24.27 23.85 23.61 24.14 23.97 NAN 23.70 24.06 
ARPC5L Q9BPX5 3 NAN 25.14 NAN NAN 23.71 24.05 24.22 23.96 25.14 NAN NAN NAN 
ASAH1 Q13510 3 24.05 NAN 24.09 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
ASCC1 Q8N9N2 6 NAN 23.04 NAN NAN 23.54 NAN 24.26 23.82 23.99 23.81 24.19 23.37 
ASCC2 Q9H1I8 13 24.23 24.86 25.01 23.12 23.02 24.00 25.47 24.83 25.52 24.22 25.31 24.39 
ASCC3 Q8N3C0 56 26.07 27.02 21.64 26.02 26.60 26.65 28.92 28.13 28.86 27.55 27.81 27.15 
ASMTL O95671 8 NAN NAN NAN NAN NAN NAN 24.33 NAN 24.59 NAN NAN NAN 
ASNA1 O43681 9 24.37 25.08 24.23 25.48 25.56 25.59 NAN NAN NAN NAN NAN NAN 
ASS P00966 6 23.96 25.66 NAN 24.13 25.07 25.23 NAN NAN NAN 23.43 NAN 24.06 
ATAD1 Q8NBU5 9 24.28 26.24 23.77 24.11 23.74 23.78 23.75 23.66 24.92 23.99 23.85 23.90 
ATAD3A Q9NVI7 31 27.49 28.38 27.40 27.67 27.60 27.62 28.45 27.57 27.87 27.83 27.63 27.38 
ATAD3B Q5T9A4 21 25.55 27.27 23.26 NAN 23.32 24.31 24.83 NAN 23.73 23.46 23.86 24.42 
ATG3 Q9NT62 6 23.72 NAN 23.41 24.91 24.95 24.74 NAN NAN NAN 23.17 NAN 23.35 
ATIC P31939 10 23.14 25.50 NAN 24.06 24.46 23.92 23.54 24.39 NAN NAN NAN NAN 
ATL3 Q6DD88 24 27.69 29.13 27.59 28.32 28.18 28.22 26.85 27.00 26.79 27.05 27.22 27.47 
ATP13A1 Q9HD20 15 24.66 25.66 23.71 25.51 25.23 25.25 24.04 24.26 23.82 25.12 24.66 24.60 
ATP1A1 P05023 38 29.17 28.91 29.00 29.55 29.12 29.39 26.58 26.85 26.60 27.79 27.20 27.80 
ATP1B3 P54709 8 25.30 26.56 25.87 26.67 26.49 26.49 23.65 24.33 23.29 24.75 24.44 24.91 
ATP2C1 P98194 9 24.41 23.85 24.02 23.92 23.87 24.42 23.22 23.21 22.69 23.68 23.04 23.80 
ATP5H O75947 9 30.49 30.56 31.25 31.17 30.74 30.68 29.60 29.72 29.19 28.59 28.69 29.13 
ATP5I P56385 2 23.53 NAN 23.86 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
ATP5L O75964 4 24.38 25.29 25.04 26.04 25.89 25.57 22.69 24.01 23.13 24.04 23.53 23.30 
ATP6V0A1 Q93050 13 22.91 26.01 NAN 22.55 22.82 NAN 25.89 26.04 24.70 25.85 25.20 26.99 
ATP6V0A2 Q9Y487 6 NAN NAN NAN NAN NAN NAN 23.54 23.54 23.26 23.61 23.33 23.17 
ATP6V0C P27449 2 NAN 24.58 NAN NAN 22.59 22.06 23.14 24.29 22.66 NAN NAN NAN 
ATP6V0D1 P61421 12 22.75 25.70 24.44 24.15 23.92 24.21 26.66 26.66 26.39 27.48 27.50 27.95 
ATP6V1C1 P21283 8 NAN 25.13 NAN NAN 24.89 24.88 NAN NAN NAN NAN NAN NAN 
ATP6V1E1 P36543 5 24.20 24.48 24.78 23.79 24.49 24.31 24.67 25.13 25.30 24.58 24.93 NAN 
ATP6V1G1 O75348 4 NAN NAN NAN NAN 23.39 23.67 NAN NAN NAN NAN NAN NAN 
ATP6V1H Q9UI12 10 24.17 25.08 24.54 24.47 24.79 24.80 NAN NAN NAN NAN NAN NAN 
ATXN10 Q9UBB4 15 24.10 25.86 24.35 25.14 25.40 25.50 24.53 23.80 23.60 23.26 NAN 23.96 
ATXN2 Q99700 5 NAN NAN NAN NAN NAN NAN 23.85 23.12 23.01 23.22 23.73 23.23 
ATXN2L Q8WWM7 8 23.39 22.55 23.78 NAN NAN 22.72 22.96 22.95 23.18 23.77 24.17 23.50 
AUP1 Q9Y679 6 NAN 24.57 23.65 25.10 24.35 24.99 23.26 23.63 NAN 24.39 25.37 24.47 
BAG3 O95817 6 23.90 23.74 23.90 24.29 24.21 23.88 NAN NAN NAN NAN 23.53 23.51 
BAG5 Q9UL15 8 25.36 26.59 25.49 25.27 25.04 25.62 24.19 23.55 24.56 23.57 23.19 23.94 
BASP1 P80723 5 NAN NAN NAN NAN NAN NAN 22.61 23.20 NAN NAN NAN NAN 
BAT3 P46379 11 25.26 26.46 25.45 25.64 25.19 25.83 NAN NAN NAN NAN NAN NAN 
BAX Q07812 6 24.31 23.87 24.19 23.94 24.05 24.12 NAN NAN NAN NAN NAN NAN 
BCCIP Q9P287 4 24.48 25.99 25.40 26.01 26.22 26.08 NAN NAN NAN 24.44 25.16 26.46 
BCS1L Q9Y276 3 NAN NAN NAN NAN 22.54 22.89 NAN NAN NAN NAN NAN NAN 
BGN P21810 6 NAN 25.37 NAN NAN 23.61 NAN 26.29 23.12 24.56 24.40 25.14 24.37 
BICD2 Q8TD16 19 25.17 24.42 24.89 26.95 26.56 25.98 NAN NAN NAN 22.25 22.89 22.93 
BLVRA P53004 3 NAN NAN NAN NAN 22.13 22.35 NAN NAN NAN NAN NAN NAN 
BOLA2 Q9H3K6 4 24.80 25.57 25.07 25.90 26.02 26.21 NAN NAN NAN NAN NAN NAN 
BOP1 Q14137 9 24.20 24.22 NAN 23.11 23.53 23.87 25.95 25.33 25.56 25.02 25.05 25.00 
BRAT1 Q6PJG6 8 NAN 24.87 NAN NAN 23.47 23.16 NAN NAN NAN NAN NAN NAN 
BRIX1 Q8TDN6 18 NAN 24.22 22.52 23.21 24.61 24.07 29.75 29.33 29.43 28.15 29.74 28.17 
BSG P35613 11 26.84 27.08 27.09 28.91 28.24 28.45 25.63 25.80 25.26 26.71 25.64 25.90 
BST1 Q10588 9 NAN NAN NAN NAN NAN NAN 26.16 25.86 25.68 26.08 26.25 26.17 
BTAF1 O14981 3 NAN 23.85 NAN NAN 22.23 21.91 NAN NAN NAN NAN NAN NAN 
BTF3L4 Q96K17 4 NAN NAN NAN NAN NAN NAN NAN 26.87 26.49 NAN 26.39 26.80 
BUB3 O43684 9 23.25 24.86 24.07 25.77 25.66 25.42 25.34 25.28 25.09 25.72 25.66 25.54 
BYSL Q13895 13 23.40 24.02 23.59 24.14 24.71 24.67 26.31 25.76 25.72 25.43 26.36 25.85 
BZW1 Q7L1Q6 11 23.75 26.19 23.87 24.33 25.61 25.40 23.54 24.07 24.24 23.93 24.05 24.52 
BZW2 Q9Y6E2 6 23.33 24.65 NAN 23.43 23.58 23.62 NAN NAN NAN NAN NAN NAN 
C11orf84 Q9BUA3 8 21.68 22.72 24.79 26.13 26.46 25.66 22.49 23.55 22.89 24.03 22.51 22.17 
C14orf166 Q9Y224 19 26.14 27.24 27.03 27.18 26.98 26.90 28.74 28.71 29.04 27.95 28.46 27.98 
C19orf70 Q5XKP0 4 24.63 25.19 25.37 24.43 23.49 23.67 NAN NAN NAN NAN NAN NAN 
C1QBP Q07021 10 28.63 29.82 27.26 28.77 28.35 28.55 26.85 26.60 28.39 25.68 26.22 26.48 
C2orf47 Q8WWC4 3 NAN 23.58 NAN NAN 24.11 24.08 NAN NAN NAN NAN NAN NAN 
C3orf17 Q6NW34 7 NAN NAN NAN NAN NAN NAN 23.83 22.42 23.90 22.24 22.69 21.78 
C6orf120 Q7Z4R8 2 NAN NAN NAN NAN NAN NAN 24.49 22.88 23.91 NAN NAN NAN 
C7orf50 Q9BRJ6 9 NAN NAN NAN NAN NAN NAN 27.15 26.70 27.22 26.75 27.04 26.26 
C8orf33 Q9H7E9 4 NAN NAN NAN NAN NAN NAN 24.52 24.28 24.24 22.96 24.04 23.31 
C9orf114 Q5T280 6 NAN NAN NAN NAN NAN NAN 25.23 24.24 24.80 24.88 24.80 24.69 
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CACNA2D1 P54289 13 NAN NAN NAN NAN NAN NAN 25.69 25.37 25.14 25.86 25.66 26.23 
CACYBP Q9HB71 7 NAN 24.43 23.75 25.17 25.83 25.79 NAN 23.45 23.88 NAN NAN NAN 
CAD O76075 63 28.49 28.48 27.17 28.63 28.61 28.74 27.46 27.34 26.59 27.03 26.94 26.84 
CALD1 Q05682 59 30.06 29.46 29.71 28.60 28.80 28.68 30.91 30.60 30.55 31.00 31.23 30.87 
CALR P27797 21 29.90 29.31 29.98 31.55 31.29 31.23 28.28 29.03 28.93 29.93 29.78 30.44 
CALU O43852 30 29.54 30.77 29.91 31.12 30.53 30.60 27.60 28.18 27.88 28.80 29.06 29.40 
CALU O43852 26 NAN NAN 23.25 25.27 24.44 24.70 NAN NAN NAN NAN NAN NAN 
CAMK2G Q13555 8 NAN NAN NAN NAN 22.90 23.04 NAN 23.09 22.95 23.38 23.34 23.56 
CANX P27824 39 31.69 30.65 31.81 31.13 31.00 31.02 28.56 29.18 28.82 29.78 29.32 29.73 
CAP2 P40123 5 NAN NAN NAN NAN 22.73 22.44 NAN NAN NAN NAN NAN NAN 
CAPN2 P17655 28 27.42 27.53 27.79 28.51 28.46 28.66 26.44 26.93 26.62 27.47 27.18 27.52 
CAPN5 O15484 5 NAN NAN NAN NAN 24.32 24.28 NAN 23.14 23.39 NAN NAN NAN 
CAV1 Q03135 11 NAN NAN NAN NAN NAN NAN 26.57 27.03 26.93 26.89 26.60 27.24 
CAV2 P51636 4 23.46 24.98 23.36 23.54 23.02 22.46 27.00 25.41 25.82 25.87 25.91 25.74 
CBLL1 Q75N03 2 NAN NAN NAN NAN 23.23 23.25 NAN NAN NAN NAN NAN NAN 
CBR1 P16152 15 27.34 27.11 27.85 26.97 27.37 27.56 24.90 26.70 25.79 25.17 23.50 26.69 
CBX3 Q13185 5 22.41 23.66 23.10 24.96 24.63 24.37 23.32 23.01 23.45 23.39 23.20 23.91 
CCT3 P49368 8 24.69 23.84 25.15 24.73 24.95 24.89 NAN 24.67 24.26 NAN NAN NAN 
CCT4 P50991 42 29.69 29.77 29.99 30.16 30.41 30.39 28.03 29.05 28.15 29.04 28.45 28.94 
CCT7 Q99832 35 29.70 29.83 30.00 30.22 30.28 30.25 27.96 28.85 28.13 28.97 28.44 29.03 
CCT8 P50990 47 29.49 29.64 29.89 30.13 30.36 30.42 27.76 28.59 27.80 28.99 28.08 28.75 
CD151 P48509 3 22.86 22.97 23.63 24.56 24.62 24.29 NAN NAN NAN 23.27 NAN 23.75 
CD276 Q5ZPR3 5 23.33 24.48 23.39 24.83 24.66 24.68 NAN NAN NAN NAN NAN NAN 
CD55 P08174 7 NAN 24.01 NAN NAN 23.38 NAN 24.28 24.46 24.34 24.32 24.47 24.98 
CD63 P08962 2 NAN NAN NAN NAN 23.34 22.83 NAN 22.37 22.40 NAN NAN NAN 
CD81 P60033 5 NAN 26.52 NAN NAN 26.11 26.08 NAN NAN NAN 25.55 NAN 26.18 
CD97 P48960 10 24.81 25.50 24.99 25.51 25.13 25.28 NAN 24.19 24.12 24.37 23.83 24.41 
CD99 P14209 2 NAN 22.06 NAN NAN 22.27 22.44 NAN NAN NAN NAN NAN NAN 
CDC2 P06493 5 23.54 23.77 22.96 NAN NAN 23.12 23.71 NAN 24.48 NAN NAN NAN 
CDC27 P30260 5 NAN NAN NAN NAN NAN NAN 24.50 NAN 23.99 NAN NAN NAN 
CDC2L2 Q9UQ88 6 NAN 22.85 NAN NAN NAN 23.56 23.91 23.68 24.02 23.87 23.43 22.36 
CDC37 Q16543 13 24.60 25.59 24.80 27.19 27.40 27.63 24.19 25.45 25.16 25.44 25.79 25.63 
CDC5L Q99459 8 NAN 24.91 24.58 24.62 24.58 24.20 25.33 24.55 24.84 24.62 25.39 24.39 
CDC73 Q6P1J9 9 25.38 23.26 24.65 24.66 24.14 24.63 23.97 24.06 24.83 24.27 23.41 24.13 
CDH13 P55290 6 NAN 24.59 NAN NAN 24.02 23.98 26.79 26.09 26.23 26.81 26.99 27.12 
CDIPT O14735 6 27.64 26.81 27.59 26.38 26.01 26.47 25.25 24.73 25.64 24.69 25.27 24.67 
CDK4 P11802 5 NAN NAN NAN NAN 22.59 23.54 21.95 NAN 22.07 NAN NAN NAN 
CDK5 Q00535 4 NAN 22.82 NAN NAN NAN 22.23 NAN NAN NAN 23.01 NAN 23.59 
CDK5RAP3 Q96JB5 19 22.91 24.71 NAN 25.05 24.72 25.03 25.00 26.69 25.65 26.30 25.25 26.86 
CDK9 P50750 5 NAN NAN NAN NAN NAN NAN 22.44 21.44 NAN NAN NAN NAN 
CDS2 O75420 2 24.19 23.88 24.93 24.40 24.21 24.32 NAN NAN NAN NAN NAN NAN 
CEBPZ Q03701 32 NAN 24.29 NAN NAN 22.47 NAN 28.87 27.77 28.40 27.55 27.91 26.75 
CES2 O00748 7 NAN NAN NAN NAN 24.90 24.64 NAN NAN NAN NAN NAN NAN 
CHCHD3 Q9NX63 13 23.58 NAN 23.62 NAN NAN NAN 25.06 25.07 25.03 25.72 25.55 25.58 
CHD4 Q14839 23 26.04 26.36 23.42 27.24 26.74 26.39 24.78 24.47 24.42 25.32 24.17 24.38 
CHERP Q8IWX8 5 NAN 23.56 NAN NAN 23.62 23.41 24.02 NAN 23.39 NAN NAN NAN 
CHID1 Q9BWS9 5 NAN 23.37 NAN NAN 22.38 NAN NAN NAN NAN NAN NAN NAN 
CHORDC1 Q9UHD1 2 NAN 23.33 NAN NAN 23.22 23.14 NAN NAN NAN NAN NAN NAN 
CHP Q99653 3 NAN NAN 24.15 24.22 23.84 23.76 NAN NAN NAN NAN NAN NAN 
CHPF Q8IZ52 4 23.49 NAN 23.20 22.98 22.70 23.18 NAN NAN NAN NAN NAN NAN 
CHRNA3 P32297 25 25.46 23.96 25.80 26.91 26.45 26.54 23.69 23.11 22.77 23.41 NAN 23.98 
CHST14 Q8NCH0 3 NAN NAN NAN NAN 22.51 22.33 NAN NAN NAN NAN NAN NAN 
CIAO1 O76071 5 22.87 24.50 23.91 24.02 24.60 24.38 23.21 23.28 22.89 NAN 23.52 23.88 
CISD1 Q9NZ45 3 NAN 23.04 NAN NAN NAN 23.57 NAN NAN NAN NAN NAN NAN 
CKAP5 Q14008 32 26.32 26.96 26.61 26.84 27.19 27.27 25.79 26.41 25.89 26.10 26.23 26.78 
CKB P12277 7 NAN 23.98 NAN NAN 24.66 24.08 NAN NAN NAN NAN NAN NAN 
CLINT1 Q14677 6 NAN NAN NAN NAN NAN NAN 23.66 22.83 24.13 22.24 22.54 22.71 
CLN3 Q13286 2 NAN NAN NAN NAN 23.99 25.32 NAN NAN NAN NAN NAN NAN 
CLPB Q9H078 6 NAN 22.57 NAN NAN 23.68 23.68 NAN NAN NAN NAN NAN NAN 
CLPTM1 O96005 12 25.93 26.43 26.48 26.03 25.20 25.93 NAN NAN NAN 23.81 22.90 24.16 
CLPTM1L Q96KA5 4 24.17 23.94 24.54 24.29 24.18 24.16 23.11 23.33 23.54 NAN NAN NAN 
CLPX O76031 10 NAN 24.77 24.14 24.74 24.58 24.88 23.80 23.99 23.88 NAN NAN NAN 
CLTA P09496 4 NAN NAN NAN NAN NAN NAN 22.95 NAN 23.73 NAN NAN NAN 
CLUH O75153 16 23.16 25.51 NAN 25.25 25.44 25.79 NAN NAN NAN NAN NAN NAN 
CMBL Q96DG6 14 26.03 22.53 26.75 26.99 27.25 27.28 23.10 24.39 24.31 23.27 22.19 23.39 
CMSS1 Q9BQ75 5 NAN NAN NAN NAN NAN NAN 25.26 24.07 24.65 23.64 24.14 NAN 
CNBP P62633 8 21.56 24.94 21.64 22.36 22.65 22.50 25.15 24.78 24.73 23.52 25.06 25.24 
CNOT1 A5YKK6 26 25.12 25.58 24.09 25.53 25.42 25.76 26.39 26.05 26.37 25.87 26.78 25.74 
CNOT7 Q9UIV1 4 21.91 23.29 NAN 22.31 23.20 22.61 23.80 22.94 23.69 23.08 23.74 22.38 
CNTNAP1 P78357 18 26.37 26.09 22.93 27.33 27.73 27.86 24.40 23.55 23.06 25.27 24.01 25.16 
COMT P21964 15 28.08 28.90 27.39 27.67 27.43 27.38 26.17 26.78 26.53 26.78 27.08 26.94 
COPS5 Q92905 11 24.62 23.62 24.22 25.94 26.27 26.26 22.59 23.30 22.44 23.34 NAN 23.30 
COPS6 Q7L5N1 11 25.39 25.22 25.71 26.71 26.73 26.59 NAN 25.93 23.94 24.69 NAN 24.71 
COPS7B Q9H9Q2 2 25.82 NAN 25.82 24.62 24.56 24.78 NAN NAN NAN 22.76 22.49 NAN 
COPS8 Q99627 6 25.20 23.37 24.02 26.67 26.54 25.95 NAN 23.47 23.86 23.58 NAN 23.61 
CORO2B Q9UQ03 3 NAN NAN NAN NAN NAN NAN NAN 22.84 23.57 NAN NAN NAN 
COTL1 Q14019 4 NAN 24.71 NAN NAN NAN 23.47 NAN 23.60 24.08 NAN 23.63 23.91 
COX2 P00403 8 25.99 26.28 26.27 26.67 25.86 25.55 28.18 28.38 28.34 27.10 27.06 27.07 
COX4I1 P13073 9 23.78 23.97 24.24 25.46 25.13 25.01 25.64 25.76 25.89 25.35 24.86 24.90 
COX5A P20674 6 NAN 25.64 24.91 24.23 24.18 24.50 25.78 25.73 26.36 24.45 24.32 24.35 
COX5B P10606 2 NAN 22.14 NAN NAN 22.54 22.67 24.23 24.58 24.85 23.66 24.48 24.39 
COX6A1 P12074 2 23.08 NAN 23.64 NAN NAN NAN 24.04 25.49 25.05 NAN NAN NAN 
COX6C P09669 3 21.78 NAN 22.31 NAN NAN NAN 23.61 24.10 23.76 NAN NAN NAN 
CPD O75976 6 24.34 24.77 NAN 23.73 23.00 23.30 NAN NAN NAN NAN NAN NAN 
CPNE1 Q99829 4 24.53 25.17 24.71 23.92 23.37 23.45 23.25 22.67 23.70 23.37 23.08 23.79 
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CPNE2 Q96FN4 5 NAN NAN NAN NAN NAN NAN 23.76 23.81 23.48 23.78 24.20 24.45 
CPNE3 O75131 26 27.21 26.80 27.73 27.44 27.26 27.26 28.94 28.45 28.58 28.50 28.80 28.84 
CPNE8 Q86YQ8 5 NAN NAN NAN NAN NAN NAN 23.20 22.92 22.98 22.75 23.49 23.48 
CPSF1 Q10570 9 NAN NAN NAN NAN 23.59 23.96 NAN NAN NAN NAN NAN NAN 
CPSF2 Q9P2I0 9 NAN NAN NAN NAN 23.07 22.80 NAN NAN NAN NAN NAN NAN 
CPT1A P50416 24 27.58 26.22 27.99 27.71 27.50 27.73 25.75 25.76 26.01 26.74 26.48 26.67 
CRIP2 P52943 4 NAN 25.64 NAN NAN 24.40 24.02 23.77 24.04 23.93 NAN 24.85 25.66 
CROP O95232 12 NAN 23.20 NAN NAN 24.04 NAN 26.10 25.77 26.59 26.07 25.57 25.14 
CRTAP O75718 21 27.04 26.56 27.55 28.85 28.46 28.59 26.23 26.60 26.32 27.35 26.67 27.13 
CRYAB P02511 19 29.78 28.71 30.25 28.06 28.13 28.37 27.00 27.22 26.74 26.79 26.91 27.11 
CRYZL1 O95825 2 22.76 NAN 23.41 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
CS O75390 10 24.44 24.87 24.20 26.42 26.24 25.71 23.94 24.27 24.81 24.62 24.94 25.41 
CSDA P16989 2 NAN 22.34 NAN NAN 22.34 NAN 22.43 22.09 22.26 22.65 22.19 21.99 
CSDE1 O75534 9 NAN NAN NAN NAN NAN NAN 23.19 NAN 23.05 NAN NAN NAN 
CSNK1A1 P48729 41 27.13 28.76 27.43 28.11 28.20 28.33 25.88 27.07 26.96 26.45 25.84 26.69 
CSNK1A1 P48729 6 23.67 23.53 NAN 23.47 23.58 23.85 24.72 24.12 24.36 NAN NAN NAN 
CSNK1E P49674 2 NAN 21.52 NAN NAN 22.40 22.79 NAN NAN NAN NAN NAN NAN 
CSNK2A2 P19784 15 24.79 25.84 24.98 25.49 25.29 25.49 26.55 26.28 26.09 25.44 26.11 25.40 
CSTA P01040 3 23.53 23.37 23.52 23.36 22.46 22.94 NAN NAN NAN NAN NAN NAN 
CSTB P04080 3 23.18 24.02 23.34 25.86 25.54 25.94 NAN 23.90 23.24 NAN 22.93 23.23 
CSTF1 Q05048 4 24.02 23.64 24.27 24.04 24.37 24.19 24.29 24.52 NAN NAN NAN NAN 
CSTF3 Q12996 6 23.12 24.70 NAN 24.02 23.83 23.62 NAN NAN NAN 22.67 22.51 23.23 
CTBP1 Q13363 13 24.00 24.42 24.70 25.88 25.92 25.62 23.45 24.12 23.27 24.48 24.41 24.88 
CTBP2 P56545 11 NAN 24.73 23.50 24.89 24.52 24.99 23.06 24.12 24.01 NAN NAN NAN 
CTNNBL1 Q8WYA6 7 NAN NAN NAN NAN 24.32 24.12 24.37 23.64 23.79 24.15 23.98 24.06 
CTPS1 P17812 17 26.27 26.90 26.62 26.07 26.39 26.19 25.17 25.39 25.00 24.93 25.44 25.57 
CTSB P07858 12 28.17 26.70 28.69 29.34 29.29 29.69 26.86 27.56 27.37 27.96 27.51 27.87 
CUL1 Q13616 4 NAN 22.56 NAN NAN 22.62 22.89 NAN NAN NAN NAN NAN NAN 
CUL3 Q13618 5 NAN 22.81 NAN NAN NAN 23.02 NAN NAN NAN NAN NAN NAN 
CUL5 Q93034 8 NAN NAN 23.55 23.26 23.26 23.05 24.28 23.53 24.22 23.52 23.47 NAN 
CWC22 Q9HCG8 2 NAN NAN NAN NAN NAN NAN NAN 19.96 20.19 NAN NAN NAN 
CYB5B O43169 5 25.16 26.29 25.40 25.89 25.65 25.67 NAN 24.78 24.08 NAN NAN NAN 
CYB5R1 Q9UHQ9 4 NAN NAN NAN NAN NAN NAN 24.99 24.78 NAN NAN 25.43 25.05 
CYB5R3 P00387 20 28.25 30.17 28.56 29.38 29.25 29.17 28.87 29.14 28.98 29.55 29.49 29.99 
CYC1 P08574 7 25.86 24.83 26.41 26.21 26.70 26.69 25.39 25.99 25.90 25.98 25.18 26.08 
CYCS P99999 4 NAN 23.23 NAN NAN 23.34 23.23 NAN NAN NAN NAN NAN NAN 
CYP51A1 Q16850 8 NAN 26.01 22.20 23.24 23.53 23.27 NAN NAN NAN NAN NAN NAN 
CYTSA Q69YQ0 36 23.24 27.30 23.75 22.55 22.26 21.73 28.75 27.70 28.93 26.55 26.38 25.90 
DAB2 P98082 6 NAN NAN NAN NAN NAN NAN 24.71 24.30 24.22 23.81 24.78 23.89 
DAD1 P61803 3 22.81 24.65 23.28 25.68 25.37 24.99 NAN NAN NAN NAN NAN NAN 
DAZAP1 Q96EP5 4 22.75 22.97 22.86 24.35 23.77 23.43 NAN NAN NAN 23.21 23.81 23.70 
DBNL Q9UJU6 6 NAN NAN NAN NAN NAN NAN NAN 23.81 24.39 NAN NAN NAN 
DBT P11182 2 22.98 NAN 23.33 22.53 NAN NAN NAN NAN NAN NAN NAN NAN 
DCAF6 Q58WW2 5 NAN NAN NAN NAN 23.52 23.66 NAN NAN NAN NAN NAN NAN 
DCAF7 P61962 4 23.67 23.15 24.08 24.04 24.28 23.78 NAN NAN NAN NAN NAN NAN 
DCN P07585 6 NAN NAN NAN NAN NAN NAN 23.35 23.04 23.49 25.41 25.06 24.68 
DCPS Q96C86 3 NAN NAN NAN NAN 22.67 22.22 NAN NAN NAN NAN NAN NAN 
DDHD1 Q8NEL9 2 NAN NAN NAN NAN 22.31 22.04 NAN NAN NAN NAN NAN NAN 
DDRGK1 Q96HY6 7 24.16 24.88 24.58 24.99 24.63 24.19 25.36 25.50 25.99 25.48 25.73 26.04 
DDX10 Q13206 14 NAN NAN NAN NAN NAN NAN 25.15 23.68 24.94 23.18 23.78 23.49 
DDX17 Q92841 35 25.41 26.20 25.43 26.77 26.62 26.49 28.56 27.70 27.97 28.06 28.38 27.55 
DDX18 Q9NVP1 26 NAN NAN NAN NAN NAN NAN 28.83 27.42 28.49 26.78 27.76 26.81 
DDX20 Q9UHI6 6 NAN NAN NAN NAN NAN NAN 24.57 NAN 24.30 24.01 24.14 NAN 
DDX21 Q9NR30 63 26.54 28.67 28.01 27.03 28.07 27.33 32.28 31.61 31.99 31.56 32.11 31.34 
DDX24 Q9GZR7 31 23.51 25.73 24.57 21.87 23.97 22.84 29.00 27.01 27.43 27.10 28.10 26.70 
DDX27 Q96GQ7 9 NAN NAN NAN NAN NAN NAN 25.42 24.64 24.75 25.30 25.80 24.98 
DDX31 Q9H8H2 15 NAN NAN NAN NAN NAN NAN 26.57 25.75 25.94 25.10 26.00 25.27 
DDX39A O00148 17 25.59 25.15 25.71 24.85 24.94 24.93 23.98 23.95 NAN NAN NAN NAN 
DDX39B Q13838 19 27.09 27.31 27.07 28.10 27.87 28.00 25.58 26.31 25.75 26.49 26.40 26.87 
DDX41 Q9UJV9 4 NAN NAN NAN NAN NAN NAN NAN 23.15 24.52 NAN NAN NAN 
DDX42 Q86XP3 17 NAN 23.39 24.82 27.46 27.27 27.04 25.91 25.62 25.44 26.04 26.28 26.45 
DDX46 Q7L014 8 NAN NAN NAN NAN NAN NAN 23.93 23.84 24.79 24.75 NAN 23.08 
DDX47 Q9H0S4 10 NAN 25.10 22.30 24.47 24.08 23.62 27.08 25.31 26.30 25.30 26.37 24.75 
DDX48 P38919 23 25.36 25.36 25.84 26.30 26.20 26.37 25.97 25.59 26.02 25.95 25.57 25.69 
DDX49 Q9Y6V7 6 NAN 24.29 23.33 22.68 22.64 22.77 23.36 NAN 23.21 23.02 23.52 NAN 
DDX5 P17844 40 27.53 28.75 28.05 28.89 28.68 28.64 30.60 29.58 29.97 29.88 30.24 29.62 
DDX50 Q9BQ39 30 NAN NAN NAN NAN NAN NAN 28.85 27.72 28.35 28.28 27.86 26.81 
DDX51 Q8N8A6 9 NAN NAN NAN NAN NAN NAN 25.16 24.37 25.71 24.42 24.69 24.26 
DDX52 Q9Y2R4 15 NAN NAN NAN NAN NAN NAN 26.74 25.52 26.74 25.15 26.23 24.53 
DDX54 Q8TDD1 26 NAN NAN NAN NAN NAN NAN 27.43 26.83 27.23 26.40 26.63 25.81 
DDX55 Q8NHQ9 10 NAN NAN NAN NAN NAN NAN 26.60 25.10 26.66 23.71 23.82 23.00 
DDX56 Q9NY93 8 NAN 24.68 NAN NAN 23.50 NAN 25.25 24.77 25.43 24.75 25.02 24.42 
DDX6 P26196 14 24.72 26.22 25.21 26.58 26.75 26.65 27.22 27.17 26.83 26.80 27.55 27.03 
DECR1 Q16698 19 21.88 22.63 21.79 24.19 24.25 23.96 29.84 29.55 30.25 28.63 28.84 28.66 
DEK P35659 6 NAN NAN NAN NAN NAN NAN 26.34 25.29 25.70 24.91 24.87 24.47 
DERL1 Q9BUN8 2 24.41 24.88 24.99 24.79 NAN 24.61 NAN NAN NAN NAN NAN NAN 
DGKA P23743 10 NAN 24.42 24.02 24.09 24.48 24.05 24.88 24.68 24.53 24.50 24.80 25.31 
DHCR24 Q15392 5 NAN 23.41 23.98 24.39 23.60 24.17 23.02 23.06 23.21 22.92 23.58 23.21 
DHCR7 Q9UBM7 3 22.55 NAN 23.16 NAN 22.13 22.22 NAN NAN NAN NAN NAN NAN 
DHPS P49366 9 24.61 NAN 24.53 26.18 25.53 26.51 NAN NAN NAN NAN NAN NAN 
DHRS7 Q9Y394 4 NAN 25.45 NAN NAN 23.64 23.56 NAN NAN NAN NAN NAN NAN 
DHX15 O43143 33 27.39 28.32 27.44 27.44 27.67 27.73 28.45 28.06 28.37 28.23 28.31 27.98 
DHX29 Q7Z478 43 NAN 25.31 NAN NAN 22.26 23.81 28.77 27.99 28.87 27.17 27.89 27.10 
DHX30 Q7L2E3 52 20.49 25.87 23.45 22.98 24.09 24.40 29.90 29.00 29.40 28.92 29.00 28.42 
DHX37 Q8IY37 9 NAN 24.66 NAN NAN NAN 22.63 25.68 24.18 25.32 24.21 24.79 23.93 
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DHX57 Q6P158 25 NAN 23.24 NAN NAN 22.69 22.49 27.96 26.12 27.97 25.91 26.73 25.26 
DHX9 Q08211 58 28.13 29.21 28.03 29.15 29.24 29.12 30.31 29.49 29.76 29.36 29.78 29.17 
DIAPH1 O60610 14 26.35 26.16 24.29 25.34 26.23 25.81 NAN 23.40 22.54 NAN NAN NAN 
DICER1 Q9UPY3 4 NAN NAN NAN NAN 22.11 22.28 NAN NAN NAN NAN NAN NAN 
DIEXF Q68CQ4 7 NAN 23.30 NAN NAN 23.50 23.45 NAN NAN NAN NAN NAN NAN 
DIMT1 Q9UNQ2 12 NAN 23.72 22.75 21.99 23.56 21.74 27.89 26.95 27.07 26.07 26.75 25.63 
DIS3 Q9Y2L1 8 NAN 24.54 22.42 23.46 23.25 23.44 NAN NAN NAN NAN NAN NAN 
DKC1 O60832 17 24.19 25.35 23.64 22.05 23.26 21.26 29.30 28.15 28.75 28.42 28.68 27.85 
DNAJA1 P31689 26 29.78 28.99 29.81 29.68 29.44 29.91 28.13 28.08 28.06 27.42 27.95 27.64 
DNAJA2 O60884 20 28.89 28.01 29.34 28.79 28.89 29.21 26.73 26.84 26.89 27.24 26.91 26.71 
DNAJA3 Q96EY1 10 26.24 26.11 25.07 27.49 26.98 27.15 25.96 25.48 25.97 25.32 25.22 24.91 
DNAJB1 P25685 9 23.45 24.87 23.69 25.70 25.26 25.61 23.40 23.88 NAN 24.51 24.13 23.81 
DNAJB11 Q9UBS4 13 27.24 25.85 27.44 28.29 27.77 27.80 25.37 25.36 24.79 25.95 25.11 25.86 
DNAJB12 Q9NXW2 5 NAN NAN NAN NAN 23.72 23.84 NAN NAN NAN NAN NAN NAN 
DNAJB2 P25686 8 NAN NAN 24.14 24.45 24.18 25.21 NAN NAN NAN 23.75 NAN 23.70 
DNAJB4 Q9UDY4 7 NAN NAN NAN NAN 23.53 23.51 23.94 23.68 23.46 23.96 23.89 23.71 
DNAJB6 O75190 9 23.48 24.06 24.21 25.89 25.82 25.95 23.61 22.41 23.70 NAN 23.61 23.15 
DNAJC11 Q9NVH1 14 25.34 26.05 25.63 25.07 24.76 25.03 26.55 25.77 25.94 26.41 25.99 26.22 
DNAJC16 Q9Y2G8 3 NAN 24.74 NAN NAN 22.76 NAN 22.83 22.29 24.31 23.19 23.81 NAN 
DNAJC21 Q5F1R6 4 NAN NAN NAN NAN NAN NAN 24.13 23.84 23.58 23.63 23.60 23.73 
DNAJC3 Q13217 7 25.49 25.52 24.86 24.60 25.16 24.86 NAN NAN NAN 24.29 24.27 23.62 
DNAJC7 Q99615 34 27.26 25.67 27.34 28.81 28.89 29.05 25.49 26.74 25.41 26.31 25.92 26.28 
DNAJC8 O75937 4 NAN 22.10 NAN NAN 23.81 23.61 NAN NAN NAN NAN NAN NAN 
DNAJC9 Q8WXX5 3 NAN NAN NAN NAN NAN NAN 24.21 23.52 23.85 NAN NAN NAN 
DNAPTP6 Q9NUQ6 23 NAN 20.46 NAN NAN 21.76 NAN 28.23 27.87 28.21 26.84 27.14 26.25 
DND1 Q8IYX4 2 NAN NAN NAN NAN NAN NAN NAN NAN NAN 28.12 NAN 27.84 
DNM1L O00429 8 23.68 24.48 NAN 23.88 23.92 23.80 NAN NAN NAN NAN NAN NAN 
DNM2 P50570 17 NAN 26.60 NAN NAN 24.79 25.22 24.15 24.03 25.23 23.87 24.94 25.43 
DNMT1 P26358 2 NAN 24.60 NAN NAN 22.23 22.17 NAN NAN NAN NAN NAN NAN 
DNPEP Q9ULA0 10 24.33 25.17 24.55 24.35 24.22 24.53 NAN NAN NAN 24.08 NAN 24.11 
DPCD Q9BVM2 3 NAN 22.52 NAN NAN 23.02 23.29 NAN NAN NAN NAN NAN NAN 
DPP7 Q9UHL4 10 22.71 26.55 22.56 23.83 24.00 24.02 21.82 22.95 23.94 23.75 24.03 23.71 
DPY30 Q9C005 2 NAN NAN NAN NAN NAN NAN 22.95 NAN 23.66 NAN NAN NAN 
DPYSL3 Q14195 17 24.81 25.92 25.03 25.86 26.14 26.09 24.93 24.98 25.03 24.47 25.28 25.76 
DRG1 Q92597 14 24.75 26.42 NAN 26.43 26.55 26.34 26.43 25.71 26.79 26.48 26.71 26.71 
DRG2 P55039 5 NAN 23.46 NAN NAN 23.34 23.47 NAN NAN NAN NAN NAN NAN 
DST Q03001 46 NAN NAN NAN NAN NAN NAN 22.57 NAN 22.99 NAN NAN NAN 
EBNA1BP2 Q99848 14 NAN 22.95 NAN NAN 21.73 NAN 28.29 27.32 27.84 26.22 26.80 25.78 
EBP Q15125 2 NAN 23.74 NAN NAN 24.21 24.47 NAN NAN NAN NAN 23.27 23.46 
ECD O95905 5 23.68 24.13 24.04 NAN 23.53 23.57 23.30 23.49 24.55 23.09 24.22 NAN 
ECE1 P42892 8 NAN NAN NAN NAN 25.12 24.63 NAN NAN NAN 24.24 23.73 24.08 
ECHS1 P30084 5 NAN 25.49 24.07 25.29 24.65 24.85 23.23 23.94 24.98 24.04 23.77 24.07 
ECM29 Q5VYK3 16 24.81 25.24 NAN 24.73 25.08 25.35 NAN NAN NAN NAN NAN NAN 
ECM29 Q5VYK3 11 25.41 NAN 23.97 24.07 24.28 24.76 NAN NAN NAN NAN NAN NAN 
EDC4 Q6P2E9 6 NAN NAN NAN NAN 23.30 22.95 24.90 25.21 25.41 25.25 25.05 24.87 
EDEM3 Q9BZQ6 8 24.00 23.83 24.32 26.03 25.50 25.46 NAN NAN NAN 23.95 NAN 24.48 
EEF1A2 Q05639 18 24.29 25.74 24.56 27.12 27.04 26.96 24.21 NAN 23.30 NAN NAN NAN 
EEF2 P13639 61 30.65 30.85 31.04 30.79 30.91 31.01 31.18 31.44 31.73 30.48 31.08 31.31 
EEFSEC P57772 5 NAN NAN NAN NAN NAN NAN 24.80 24.03 24.45 NAN NAN NAN 
EFEMP2 O95967 7 NAN NAN NAN NAN NAN NAN 23.30 23.62 NAN 23.35 23.32 23.33 
EFHD2 Q96C19 11 22.60 27.12 NAN 22.89 22.73 22.67 25.17 23.94 25.35 23.31 24.47 23.63 
EGFR P00533 8 NAN 24.35 NAN NAN 24.70 24.34 NAN NAN NAN NAN NAN NAN 
EHD1 Q9H4M9 19 26.04 27.64 25.96 26.06 26.32 26.34 26.03 25.49 26.26 25.14 26.02 26.20 
EHD4 Q9H223 12 NAN 24.87 22.46 23.19 23.77 23.53 NAN NAN NAN NAN NAN NAN 
EIF2A Q9BY44 10 23.18 25.64 NAN 23.81 24.17 23.68 NAN 23.23 24.51 NAN 24.70 24.05 
EIF2AK2 P19525 5 23.56 23.70 23.61 22.94 23.05 23.03 23.41 23.13 23.15 23.24 23.63 23.38 
EIF2B1 Q14232 4 NAN NAN NAN NAN 22.19 22.69 NAN NAN NAN NAN 22.90 22.72 
EIF2B2 P49770 2 NAN NAN NAN NAN NAN NAN 22.91 23.06 23.10 NAN NAN NAN 
EIF2B3 Q9NR50 6 24.32 24.44 24.89 24.42 25.00 25.25 24.04 24.82 23.71 24.09 24.22 24.13 
EIF2B4 Q9UI10 6 24.18 23.98 24.37 24.19 24.33 23.89 24.30 24.03 24.14 24.03 24.28 NAN 
EIF2B5 Q13144 6 24.84 24.88 23.96 23.91 22.98 22.96 24.59 23.60 24.13 NAN NAN NAN 
EIF2C2 Q9UKV8 11 NAN 23.35 24.53 24.26 24.49 24.22 26.22 25.74 25.96 25.80 26.15 25.74 
EIF2S1 P05198 20 25.34 26.82 25.51 26.95 26.91 26.78 27.65 27.69 27.75 27.05 27.37 27.91 
EIF2S2 P20042 14 24.51 25.94 24.35 25.82 26.11 25.72 24.92 25.59 24.91 25.52 25.30 25.64 
EIF2S3 P41091 22 25.82 27.46 26.07 27.74 27.89 27.79 27.53 27.95 27.54 27.89 27.80 28.06 
EIF3D O15371 27 27.95 28.31 28.37 28.14 27.78 27.84 28.64 28.46 28.32 28.22 28.42 28.41 
EIF3S1 O75822 11 23.72 24.34 24.46 26.41 26.02 25.99 26.48 25.86 26.10 26.01 26.45 25.91 
EIF4A1 P60842 31 28.83 29.46 28.89 29.25 29.41 29.14 29.86 29.65 29.75 29.07 29.74 29.55 
EIF4A2 Q14240 22 24.32 24.58 24.82 25.65 25.91 25.26 25.71 25.85 25.96 25.82 25.66 26.21 
EIF4B P23588 20 26.38 27.07 26.23 27.14 27.40 27.42 27.25 27.52 27.65 27.24 27.28 27.20 
EIF4E2 O60573 4 NAN NAN NAN NAN 23.85 23.87 NAN NAN NAN 24.25 24.58 24.65 
EIF4G1 Q04637 55 27.92 28.38 27.71 28.02 27.99 27.93 29.35 29.06 29.10 28.77 29.22 28.93 
EIF4G2 P78344 17 24.25 26.04 24.99 24.91 25.48 25.48 25.20 24.60 25.44 24.95 25.60 25.31 
EIF4H Q15056 6 24.40 25.35 25.00 24.86 25.28 25.09 23.70 24.33 25.00 24.12 24.82 25.29 
EIF5 P55010 8 NAN 24.39 NAN NAN 25.98 25.84 25.26 25.04 25.21 24.69 25.27 25.59 
EIF5A P63241 14 26.95 27.83 27.56 27.88 27.89 28.10 26.59 26.90 26.78 26.13 26.34 26.76 
EIF6 P56537 12 25.11 25.57 26.44 25.96 26.12 26.28 28.33 28.83 28.91 28.12 28.54 28.17 
ELAC2 Q9BQ52 15 23.15 25.45 NAN 26.60 26.47 26.81 25.22 25.49 25.64 24.81 25.64 25.84 
ELMO2 Q96JJ3 3 23.32 NAN 23.15 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
ELP2 Q6IA86 12 24.45 24.39 25.17 24.90 25.44 25.55 23.77 23.49 23.60 NAN NAN NAN 
ELP3 Q9H9T3 11 25.20 24.58 24.81 25.91 26.12 26.35 NAN NAN NAN 24.51 24.19 NAN 
EMC2 Q15006 9 24.28 24.25 25.00 24.92 25.08 24.78 23.97 23.88 23.87 24.59 24.28 24.63 
EMC3 Q9P0I2 4 NAN NAN 24.23 24.56 24.29 23.87 NAN NAN NAN NAN NAN NAN 
EMC4 Q5J8M3 2 NAN 23.14 NAN NAN 24.27 24.15 NAN NAN NAN NAN NAN NAN 
EMC8 O43402 3 NAN 22.67 NAN NAN 23.87 23.06 NAN NAN NAN NAN NAN NAN 
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EMG1 Q92979 6 NAN 22.92 NAN NAN 24.50 24.09 24.05 24.05 24.50 24.14 23.91 24.20 
ENAH Q8N8S7 11 24.23 25.00 23.20 24.09 24.49 24.33 23.87 24.01 23.92 NAN NAN NAN 
ENDOD1 O94919 15 25.26 NAN 24.42 NAN NAN NAN 25.75 25.60 25.85 25.66 25.38 25.98 
ENDOG Q14249 2 NAN NAN NAN NAN 22.23 22.31 NAN NAN NAN NAN NAN NAN 
ENO1 P06733 29 28.39 29.19 28.71 29.73 30.09 29.82 26.96 28.65 28.73 28.76 28.99 29.48 
EPB41L3 Q9Y2J2 4 NAN NAN NAN NAN 23.50 23.19 NAN NAN NAN NAN NAN NAN 
EPB41L5 Q9HCM4 2 NAN NAN NAN NAN NAN NAN NAN 21.62 21.84 21.69 22.22 NAN 
EPHA2 P29317 8 24.16 24.73 NAN 24.83 24.48 24.64 NAN NAN NAN NAN NAN NAN 
EPHX1 P07099 13 NAN 25.36 24.89 25.16 25.37 24.85 24.54 25.16 24.36 24.90 24.89 24.89 
EPN1 Q9Y6I3 4 NAN NAN NAN NAN NAN NAN 24.46 25.95 25.51 23.36 24.95 26.07 
EPPK1 P58107 15 NAN NAN NAN NAN NAN NAN 23.93 NAN 24.53 NAN NAN NAN 
EPS15 P42566 8 NAN NAN NAN NAN 22.62 22.65 NAN 22.89 22.21 22.79 23.04 23.37 
EPS15L1 Q9UBC2 3 NAN NAN NAN NAN 22.64 22.12 NAN NAN NAN NAN NAN NAN 
ERGIC1 Q969X5 10 27.13 25.96 27.71 27.41 27.25 27.21 24.65 25.32 24.73 26.09 25.46 26.13 
ERLIN2 O94905 21 24.17 26.39 24.36 22.61 22.39 23.28 28.86 26.96 28.40 27.13 27.78 27.27 
ERO1L Q96HE7 9 25.28 24.82 25.46 25.43 25.72 25.31 NAN 24.60 23.99 25.00 25.09 25.64 
ERP29 P30040 8 23.47 24.67 24.21 24.96 25.01 24.26 23.58 24.41 24.36 24.06 24.44 25.28 
ERP44 Q9BS26 11 25.90 24.95 25.70 26.46 26.75 26.90 24.40 25.40 25.13 26.07 25.72 26.90 
ERP70 P13667 39 27.48 26.49 27.59 29.15 28.71 28.62 25.02 26.35 26.00 27.45 27.10 27.86 
ETF1 P62495 30 28.70 26.44 28.89 30.61 30.46 30.65 27.80 28.14 28.10 28.52 28.37 28.28 
ETFA P13804 9 25.18 26.35 25.05 25.89 25.59 25.42 24.60 23.80 25.41 24.61 24.54 25.28 
ETFB P38117 8 NAN 23.39 23.51 24.51 24.03 24.22 22.81 23.37 23.63 23.89 23.07 23.31 
EWSR1 Q01844 6 24.28 24.78 NAN 26.39 26.05 26.24 NAN 24.67 24.18 23.63 24.00 23.91 
EXOC1 Q9NV70 7 NAN NAN NAN NAN NAN NAN 22.93 23.55 23.59 NAN 22.72 22.78 
EXOC3 O60645 3 22.46 NAN 22.78 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
EXOC3L4 Q17RC7 2 NAN NAN NAN NAN 23.55 23.64 NAN NAN NAN 24.47 24.54 24.29 
EXOC4 Q96A65 8 NAN 24.54 NAN NAN 23.33 NAN 24.45 23.88 24.02 23.27 NAN 23.62 
EXOC6B Q9Y2D4 3 22.20 24.71 21.60 NAN 21.63 21.49 NAN NAN NAN NAN NAN NAN 
EXOG Q9Y2C4 2 NAN NAN NAN NAN 22.58 22.69 NAN NAN NAN NAN NAN NAN 
EXOSC10 Q01780 11 NAN 23.71 23.54 24.64 24.31 24.03 24.37 24.10 24.23 24.67 25.19 23.85 
EXOSC2 Q13868 4 NAN NAN NAN NAN 23.86 24.26 23.84 23.81 24.43 23.87 24.33 23.83 
EXOSC3 Q9NQT5 4 NAN NAN NAN NAN 24.20 24.04 24.81 24.00 23.80 24.48 24.69 24.26 
EXOSC4 Q9NPD3 4 23.03 NAN 23.60 23.77 23.37 23.47 24.20 23.89 24.27 24.05 24.11 24.10 
EXOSC5 Q9NQT4 3 NAN NAN NAN NAN 23.87 23.69 NAN NAN NAN NAN NAN NAN 
EXOSC6 Q5RKV6 6 NAN NAN NAN NAN 23.82 23.66 24.35 24.40 23.91 24.34 24.25 24.11 
EXOSC7 Q15024 4 NAN 24.39 NAN NAN NAN 23.47 NAN NAN NAN NAN NAN NAN 
EXOSC7 Q15024 4 NAN NAN NAN NAN 24.58 24.12 24.13 24.24 24.35 NAN NAN NAN 
EXOSC8 Q96B26 3 NAN NAN NAN NAN 22.10 21.98 22.49 NAN 22.62 22.08 23.43 NAN 
EXOSC9 Q06265 4 NAN 23.98 24.81 24.85 24.43 24.58 24.85 24.30 24.24 23.80 24.64 NAN 
FACL4 O60488 11 23.74 26.53 22.86 25.16 25.30 24.55 24.42 24.26 23.03 23.30 24.58 24.23 
FAM114A1 Q8IWE2 3 22.83 NAN NAN 23.30 23.85 23.42 NAN NAN NAN NAN NAN NAN 
FAM126A Q9BYI3 5 NAN 22.85 23.88 23.37 23.98 23.70 23.91 23.76 23.42 23.96 23.89 NAN 
FAM134C Q86VR2 3 22.65 22.36 23.19 24.42 24.24 24.35 22.45 22.85 22.28 22.99 22.26 22.60 
FAM160B1 Q5W0V3 3 NAN NAN NAN NAN 22.37 22.39 NAN NAN NAN NAN NAN NAN 
FAM162A Q96A26 3 NAN NAN NAN NAN 23.99 23.80 NAN NAN NAN NAN NAN NAN 
FAM210A Q96ND0 3 22.91 NAN 23.67 24.57 24.19 24.48 NAN NAN NAN NAN NAN NAN 
FAM26E Q8N5C1 3 NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.91 24.02 23.67 
FAM36A Q5RI15 2 NAN NAN NAN NAN 23.28 23.01 NAN NAN NAN NAN NAN NAN 
FAM3C Q92520 5 NAN 23.40 NAN NAN 23.81 23.89 NAN NAN NAN NAN NAN NAN 
FAM91A1 Q658Y4 12 24.60 24.67 24.46 24.30 24.32 24.43 24.22 24.36 23.73 24.96 25.32 25.02 
FAM98A Q8NCA5 15 24.62 26.07 25.42 26.09 26.05 25.95 27.93 27.31 27.89 27.16 27.82 27.15 
FAR1 Q8WVX9 3 NAN 23.12 NAN NAN 23.12 23.43 NAN NAN NAN NAN NAN NAN 
FARP2 O94887 8 NAN NAN NAN NAN NAN NAN 26.10 25.90 25.15 NAN NAN NAN 
FARSB Q9NSD9 10 23.98 26.06 NAN 25.09 25.07 25.14 25.01 26.14 25.85 25.69 25.57 26.50 
FARSLA Q9Y285 5 23.71 24.31 NAN 23.20 23.57 23.45 23.17 25.24 24.39 23.61 24.25 24.18 
FAS P25445 5 23.33 NAN 24.87 23.28 22.97 22.87 NAN NAN NAN NAN NAN NAN 
FAS,FASN P49327 95 28.91 30.10 28.06 29.59 29.76 29.87 27.39 28.42 28.12 27.83 27.46 28.12 
FAT3 Q8TDW7 2 NAN NAN NAN NAN NAN NAN 24.04 23.90 NAN 24.57 24.46 24.41 
FAU P35544 3 22.19 24.42 24.03 NAN 22.88 22.06 26.57 26.42 27.65 26.65 27.55 25.99 
FBL P22087 16 25.35 25.67 26.15 26.44 26.22 26.03 28.44 27.55 28.23 28.23 27.55 27.30 
FBLIM1 Q8WUP2 5 NAN NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.96 24.08 
FBLN5 Q9UBX5 2 NAN 23.77 NAN NAN 23.83 NAN NAN NAN NAN NAN NAN NAN 
FBXO21 O94952 2 NAN NAN NAN NAN 23.85 24.07 NAN NAN NAN NAN NAN NAN 
FIP1L1 Q6UN15 4 NAN NAN NAN NAN 23.81 23.83 NAN NAN NAN 24.46 NAN 23.72 
FIS1 Q9Y3D6 3 NAN 23.44 NAN NAN 24.63 NAN NAN NAN NAN NAN NAN NAN 
FKBP10 Q96AY3 23 28.38 27.42 28.52 28.43 28.04 28.10 25.94 26.81 26.84 27.03 27.51 28.00 
FKBP4 Q02790 8 NAN 24.52 NAN NAN 25.48 26.00 NAN NAN NAN NAN 23.88 24.26 
FKBP9 O95302 16 25.67 27.32 25.87 27.30 27.43 27.30 24.30 25.71 23.89 26.81 26.31 27.08 
FLOT1 O75955 18 NAN 26.07 24.61 22.67 22.52 20.52 27.73 27.28 27.60 26.23 26.11 26.58 
FLOT2 Q14254 22 23.15 27.79 NAN 22.32 22.70 NAN 27.84 27.09 28.09 26.75 26.59 26.36 
FMNL3 Q8IVF7 5 NAN NAN NAN NAN NAN NAN 24.69 23.73 24.01 NAN NAN NAN 
FMR1 Q06787 14 NAN NAN NAN NAN NAN NAN 26.81 26.56 27.09 25.60 26.18 25.88 
FNDC3A Q9Y2H6 8 NAN 24.29 NAN NAN 24.46 24.00 NAN NAN NAN 24.17 24.29 NAN 
FTSJ3 Q8IY81 18 NAN NAN NAN NAN NAN NAN 28.56 25.19 27.03 25.72 26.93 25.19 
FUBP1 Q96AE4 8 NAN 24.07 NAN NAN 23.73 23.54 NAN NAN NAN 23.64 23.14 23.43 
FUBP3 Q96I24 12 24.43 24.54 24.77 25.46 25.42 25.37 24.41 24.00 24.42 24.37 24.41 24.39 
FVT1 Q06136 3 22.65 22.83 22.78 24.29 23.90 23.82 NAN NAN NAN NAN NAN NAN 
FXR1 P51114 32 26.17 26.94 26.56 24.80 26.19 25.75 29.07 28.75 29.06 28.85 28.87 28.47 
FXR2 P51116 23 NAN 25.24 NAN NAN 23.76 25.14 28.57 27.01 27.73 27.70 26.78 26.23 
G3BP Q13283 12 24.65 24.65 24.77 25.75 25.93 25.47 26.86 26.63 26.80 26.38 26.34 26.47 
G3BP1 Q13283 18 25.31 27.29 25.12 26.97 26.90 26.84 26.95 27.24 27.18 26.99 27.14 27.26 
GAA P10253 4 NAN 23.43 23.29 23.35 23.21 22.92 NAN NAN NAN NAN NAN NAN 
GAF1 Q9BXF6 5 NAN NAN NAN NAN NAN NAN 23.76 23.19 24.15 23.11 23.22 NAN 
GAK O14976 5 23.27 24.65 NAN 24.14 23.97 23.92 22.83 NAN 23.26 23.62 23.51 23.84 
GALK1 P51570 8 24.00 24.02 23.86 24.96 25.11 25.33 23.16 23.69 23.29 23.63 24.21 23.24 
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GALNT2 Q10471 12 25.66 25.06 25.65 26.23 25.93 25.61 24.64 25.33 24.51 25.03 25.62 25.67 
GAPVD1 Q14C86 6 23.73 23.97 23.88 24.12 23.75 23.70 NAN NAN NAN NAN NAN NAN 
GART P22102 19 26.48 27.40 25.70 25.79 26.00 26.51 25.34 25.45 25.72 25.03 25.68 25.55 
GATAD2A Q86YP4 4 NAN NAN 23.00 24.10 23.12 23.16 NAN NAN NAN NAN NAN NAN 
GATAD2B Q8WXI9 4 23.52 NAN 23.37 24.24 24.09 24.04 NAN NAN NAN NAN NAN NAN 
GBA P04062 7 26.06 26.39 26.27 25.36 25.55 25.49 24.37 24.29 24.41 25.05 NAN 25.36 
GDI1 P31150 9 NAN NAN NAN NAN 23.42 22.95 NAN NAN NAN NAN NAN NAN 
GEMIN4 P57678 9 23.05 24.87 23.11 22.41 22.65 22.99 23.43 23.22 22.72 NAN NAN NAN 
GEMIN5 Q8TEQ6 24 24.72 26.40 24.22 25.61 25.71 25.58 25.02 24.15 24.79 23.67 24.28 24.19 
GFM1 Q96RP9 7 23.00 23.52 23.52 25.13 25.17 25.25 NAN NAN NAN NAN NAN NAN 
GFPT2 O94808 20 25.14 25.87 25.13 25.27 25.21 25.58 24.07 25.01 23.86 NAN NAN NAN 
GGT7 Q9UJ14 5 NAN NAN NAN NAN 23.21 23.28 NAN NAN NAN NAN NAN NAN 
GGYF2 Q6Y7W6 8 24.31 25.79 NAN 25.50 25.25 25.56 25.86 26.07 25.74 25.48 25.58 25.47 
GIPC1 O14908 6 NAN 23.29 22.80 23.67 23.60 23.43 24.31 22.78 23.82 23.65 22.24 22.45 
GIT1 Q9Y2X7 2 22.42 NAN 22.55 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
GJA1 P17302 13 NAN 23.16 NAN NAN 22.92 NAN 26.58 25.62 26.30 25.29 25.54 25.24 
GLIPR2 Q9H4G4 4 NAN NAN NAN NAN 22.48 22.19 23.87 24.11 24.08 23.74 24.23 24.52 
GLRX3 O76003 8 NAN 24.74 24.56 26.02 26.67 25.85 NAN NAN NAN 23.94 24.57 25.28 
GLS O94925 18 24.39 27.40 25.44 26.75 26.63 26.40 24.17 25.39 25.46 24.99 25.44 26.32 
GMPPA Q96IJ6 3 NAN 23.65 NAN NAN 23.48 23.73 22.56 NAN 23.30 NAN NAN NAN 
GMPS P49915 10 NAN 24.06 23.29 24.47 24.44 24.82 22.87 23.45 23.12 23.18 23.29 23.60 
GNA11 P29992 17 26.63 27.73 25.27 27.08 26.78 26.69 25.53 24.91 25.89 25.77 25.30 25.58 
GNA13 Q14344 7 NAN 23.42 NAN NAN 23.76 22.88 NAN NAN NAN NAN NAN NAN 
GNAI3 P08754 14 NAN 24.63 24.34 24.86 24.63 24.67 23.31 24.07 23.15 24.03 23.76 24.22 
GNAQ P50148 12 24.15 25.01 23.84 23.69 23.57 23.61 NAN NAN NAN NAN NAN NAN 
GNB2L1 P63244 31 28.48 30.14 30.07 29.43 30.06 29.80 33.37 33.01 33.45 32.74 33.25 32.54 
GNL2 Q13823 11 NAN 23.53 NAN NAN 23.32 23.82 25.57 24.42 25.45 24.76 24.97 24.56 
GNL3 Q9BVP2 20 NAN 24.68 NAN NAN 22.76 22.01 28.93 27.80 28.97 27.72 28.28 27.12 
GNS P15586 7 23.87 24.21 24.00 26.39 26.16 25.89 NAN NAN NAN 24.63 24.60 24.77 
GOLPH3 Q9H4A6 5 NAN 24.66 NAN NAN 23.19 23.24 22.36 23.29 22.80 22.41 22.97 22.97 
GOLT1B Q9Y3E0 4 NAN 26.28 25.79 25.19 24.42 24.54 25.20 24.82 25.58 24.08 24.32 24.43 
GOPC Q9HD26 4 22.13 NAN 22.66 23.40 23.51 23.36 NAN NAN NAN NAN NAN NAN 
GORASP2 Q9H8Y8 5 24.56 24.33 24.80 25.64 25.17 25.28 23.49 24.09 23.90 24.70 24.92 25.48 
GOT2 P00505 9 23.80 24.02 NAN 25.94 26.12 25.88 NAN 24.21 24.31 24.53 24.54 25.59 
GPC1 P35052 18 NAN 23.09 NAN NAN NAN 22.77 27.90 26.10 26.57 26.07 26.34 25.90 
GPC6 Q9Y625 13 NAN NAN NAN NAN NAN NAN 27.62 25.75 26.10 25.27 25.95 25.01 
GPD2 P43304 19 25.37 26.18 25.81 26.40 26.41 26.21 24.01 NAN 24.55 24.65 24.03 25.44 
GPI P06744 11 23.43 25.77 23.87 26.21 26.57 26.67 23.43 24.71 25.09 23.80 25.67 26.02 
GPR89B P0CG08 3 NAN NAN NAN NAN NAN NAN 23.57 NAN 22.97 NAN NAN NAN 
GPS1 Q13098 12 25.30 24.91 25.70 26.61 26.66 26.57 23.62 24.98 22.27 24.53 23.51 24.92 
GPX1 P07203 12 25.82 26.37 25.87 26.24 25.68 25.72 25.33 26.14 24.59 25.83 25.19 25.46 
GRB2 P62993 5 23.63 23.17 23.61 23.52 23.55 23.71 22.31 22.70 22.74 NAN 23.25 23.58 
GRHPR Q9UBQ7 3 NAN 24.27 NAN NAN 24.07 NAN NAN NAN NAN NAN NAN NAN 
GRPEL1 Q9HAV7 4 NAN 24.19 24.14 25.20 24.96 24.83 NAN NAN NAN NAN NAN NAN 
GRSF1 Q12849 14 25.86 25.39 23.80 25.34 25.37 25.18 27.31 27.34 27.71 26.80 26.87 26.91 
GRWD1 Q9BQ67 13 20.93 25.40 22.54 23.07 23.28 24.61 27.61 26.27 27.93 24.49 26.02 24.96 
GSPT1 P15170 16 24.64 26.43 23.83 26.31 26.90 26.30 24.76 25.56 24.98 24.42 25.19 25.60 
GSTK1 Q9Y2Q3 5 NAN NAN NAN NAN NAN NAN NAN NAN NAN 24.09 NAN 24.11 
GSTO1 P78417 3 23.24 23.16 23.59 23.34 23.63 23.45 NAN NAN NAN NAN NAN NAN 
GTF2F1 P35269 2 NAN NAN NAN NAN 23.37 23.38 NAN NAN NAN NAN NAN NAN 
GTF2H4 Q92759 3 NAN NAN NAN NAN NAN NAN 23.49 22.68 NAN 22.68 25.25 NAN 
GTF3C1 Q12789 9 NAN 26.28 25.33 24.74 24.48 24.39 24.39 24.00 24.37 24.42 24.17 24.40 
GTF3C4 Q9UKN8 5 NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.97 25.12 24.61 
GTF3C5 Q9Y5Q8 5 22.18 21.89 23.22 23.96 24.12 24.24 NAN NAN NAN NAN 22.71 22.91 
GTPBP1 O00178 6 NAN 24.07 NAN NAN NAN 23.41 25.05 24.28 24.74 23.47 24.63 24.61 
GTPBP10 A4D1E9 7 NAN NAN NAN NAN NAN NAN 25.17 24.61 25.49 24.45 24.90 25.11 
GTPBP4 Q9BZE4 22 NAN 23.41 NAN NAN 23.81 22.67 28.30 27.28 28.78 26.91 27.56 26.53 
GYS1 P13807 6 23.52 22.74 23.36 22.96 NAN 22.92 NAN NAN NAN NAN NAN NAN 
HABP4 Q5JVS0 6 NAN NAN NAN NAN NAN NAN 24.90 25.20 25.07 24.60 25.62 24.44 
HARS P12081 4 NAN NAN NAN NAN 23.90 24.10 NAN NAN NAN NAN NAN NAN 
HAT1 O14929 11 25.35 22.42 25.55 27.97 27.65 28.63 22.50 23.69 23.22 NAN NAN NAN 
HBS1L Q9Y450 8 NAN 23.94 NAN NAN 23.89 24.72 24.22 23.97 24.18 NAN 23.56 23.49 
HCFC1 P51610 4 23.28 23.21 NAN 22.73 22.44 NAN 22.28 22.62 22.19 22.85 22.90 23.37 
HDGFRP2 Q7Z4V5 3 NAN NAN NAN NAN NAN NAN 22.54 22.37 22.75 NAN NAN NAN 
HEATR1 Q9H583 7 NAN NAN NAN NAN NAN NAN 23.89 NAN 23.04 NAN NAN NAN 
HEATR3 Q7Z4Q2 4 NAN 22.89 NAN NAN 23.13 22.29 23.22 23.14 23.57 22.38 21.92 22.49 
HEXA P06865 5 NAN NAN NAN NAN 23.86 23.91 NAN NAN NAN NAN NAN NAN 
HEXB P07686 7 23.56 22.91 24.22 25.30 25.29 24.90 NAN NAN NAN 23.57 23.22 24.31 
HIGD1A Q9Y241 2 27.75 26.99 27.40 25.22 24.89 25.19 NAN 22.16 20.96 22.81 21.19 22.49 
HIP1 O00291 10 NAN NAN NAN NAN NAN NAN 24.71 25.18 24.54 24.59 23.90 23.59 
HIST1H1E P10412 10 NAN NAN NAN NAN NAN NAN 21.58 22.15 22.26 NAN NAN NAN 
HIST1H2BJ P06899 6 NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.34 23.47 23.19 
HIST1H3A P68431 4 NAN NAN NAN NAN NAN NAN 25.63 25.99 25.88 23.82 23.81 23.07 
HIST2H2AC Q16777 9 NAN NAN NAN NAN NAN NAN 23.62 22.68 23.61 NAN NAN NAN 
HIST2H3A Q71DI3 4 23.66 25.40 23.47 24.79 23.50 24.54 26.54 25.13 26.37 27.15 27.32 25.55 
HK1 P19367 31 27.13 27.48 26.85 28.27 28.19 28.19 25.22 26.36 26.51 27.02 27.48 27.67 
HK2 P52789 29 26.39 27.09 26.48 27.57 27.05 28.20 24.17 25.09 25.16 26.02 25.83 26.09 
HLA-A P01891 14 25.43 24.26 25.85 26.12 26.01 25.91 22.91 23.55 23.06 24.64 23.34 24.66 
HLA-B P30484 8 22.06 NAN NAN 26.03 25.81 25.77 21.74 NAN 21.41 22.03 21.95 21.87 
HLA-C P04222 6 25.43 24.13 25.21 26.21 25.72 26.08 NAN NAN NAN NAN NAN NAN 
HLA-C P10321 12 23.14 21.92 23.36 24.27 22.94 23.08 NAN NAN NAN NAN NAN NAN 
HLTF Q14527 3 NAN NAN NAN NAN NAN NAN 21.69 21.44 23.11 NAN NAN NAN 
HM13 Q8TCT9 9 27.20 27.08 27.08 27.30 26.87 26.89 24.67 24.28 25.03 25.47 24.77 25.24 
HMOX1 P09601 4 NAN NAN NAN NAN 23.20 23.34 NAN NAN NAN 22.73 22.62 23.40 
HMOX2 P30519 6 NAN 24.87 24.33 25.00 24.47 24.64 NAN NAN NAN NAN NAN NAN 
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HNRNPA0 Q13151 10 24.74 25.04 25.25 26.03 25.96 25.73 25.81 25.42 25.13 25.50 25.40 24.85 
HNRNPC P07910 19 26.50 27.10 27.74 27.88 27.85 27.61 28.69 27.98 27.99 28.46 28.46 27.98 
HNRNPDL O14979 8 24.19 24.60 NAN 26.06 25.88 25.92 25.39 24.63 24.56 24.54 25.00 24.09 
HNRNPL P14866 23 26.95 27.93 27.24 27.68 27.53 27.47 28.73 28.24 28.45 28.08 28.31 28.12 
HNRNPLL Q8WVV9 9 NAN 24.29 NAN NAN 25.08 NAN 25.69 25.15 25.77 24.44 25.16 25.14 
HNRNPM P52272 51 27.44 28.35 27.61 27.85 28.03 27.83 30.45 29.49 29.71 29.70 29.95 29.17 
HNRPF P52597 15 27.20 27.36 26.98 28.31 28.03 28.25 28.22 27.80 28.08 27.53 27.60 27.32 
HNRPUL1 Q9BUJ2 25 24.46 26.05 23.49 26.06 26.16 25.07 28.41 27.48 28.14 27.72 27.57 27.56 
HSD17B10 Q99714 17 30.24 28.16 27.64 28.19 27.78 27.79 27.81 28.24 28.14 27.24 27.63 27.80 
HSD17B11 Q8NBQ5 6 23.49 24.09 23.64 23.88 23.65 23.46 23.11 NAN 22.76 NAN NAN NAN 
HSDL2 Q6YN16 5 24.58 23.54 24.96 25.00 23.96 24.73 NAN NAN NAN 23.88 24.77 NAN 
HSP90AA1 P07900 59 30.36 31.02 30.52 32.15 32.16 32.41 29.14 30.22 29.43 30.49 30.09 30.66 
HSP90AB1 P08238 57 29.82 30.73 29.87 31.43 31.43 31.70 28.43 29.45 28.84 29.33 29.29 29.87 
HSPA1B P0DMV9 48 29.66 30.40 29.95 31.47 31.35 31.65 28.38 28.75 28.39 28.60 28.62 29.03 
HSPA2 P54652 23 25.23 24.98 25.53 25.65 25.22 25.88 NAN NAN NAN 24.96 NAN 24.20 
HSPA4 P34932 26 25.90 26.33 23.49 27.75 27.86 27.62 24.67 25.93 24.73 24.55 25.35 25.99 
HSPA4L O95757 10 NAN 24.94 NAN NAN 23.72 23.76 NAN NAN NAN 22.92 23.01 22.97 
HSPA8 P11142 50 31.33 31.55 31.22 32.19 32.33 32.41 30.97 31.29 31.05 31.05 30.84 31.23 
HSPA9 P38646 35 29.27 29.43 29.34 30.28 30.21 30.30 28.19 28.79 28.17 29.20 28.93 29.24 
HSPB1 P04792 21 30.79 31.23 31.15 30.02 30.03 30.11 29.57 30.02 29.51 29.40 29.75 30.12 
HSPB6 O14558 5 25.33 26.52 26.38 25.08 24.95 24.58 24.58 25.26 25.41 24.10 24.56 24.99 
HSPBP1 Q9NZL4 6 NAN 23.99 23.36 24.36 24.40 24.62 NAN NAN NAN 23.13 23.18 23.18 
HSPD1 P10809 44 30.05 30.38 30.46 30.96 30.65 30.66 27.52 28.48 28.16 28.91 28.79 29.36 
HSPE1 P61604 5 NAN 23.75 NAN NAN 25.40 24.32 NAN NAN NAN NAN NAN NAN 
HSPH1 Q92598 38 28.97 28.45 28.71 29.63 29.60 29.95 27.16 27.48 26.93 27.83 27.53 28.01 
HTRA1 Q92743 3 21.71 NAN 22.47 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
IARS2 Q9NSE4 11 24.81 24.99 24.31 25.11 24.50 24.82 NAN NAN NAN 23.34 22.97 22.93 
ICAM1 P05362 8 26.07 25.17 25.82 25.10 25.02 25.22 NAN NAN NAN NAN NAN NAN 
IDH3A P50213 4 23.66 25.12 24.49 24.88 24.45 24.71 NAN NAN NAN NAN NAN NAN 
IFI16 Q16666 21 NAN 24.92 NAN NAN 23.83 23.26 26.81 26.38 27.37 25.63 25.68 25.56 
IFRD2 Q12894 6 NAN NAN NAN NAN NAN NAN 25.45 24.87 26.01 24.24 24.40 23.81 
IGF2BP1 Q9NZI8 11 23.45 24.04 23.80 NAN NAN 22.87 25.97 25.99 25.45 24.76 25.32 25.05 
IGF2BP2 Q9Y6M1 18 24.01 25.38 24.08 22.17 23.46 23.61 27.60 26.85 27.42 26.65 27.24 26.75 
IGF2R P11717 65 27.95 27.64 27.07 28.51 28.40 28.60 26.00 26.55 25.85 27.52 26.39 26.93 
IKBKAP O95163 25 25.38 25.29 23.65 26.64 27.00 27.52 22.00 23.39 22.95 22.53 23.01 22.01 
ILF2 Q12905 20 26.60 27.87 26.95 27.85 28.01 27.78 29.51 28.70 29.14 28.75 29.37 28.68 
ILF3 Q12906 38 25.66 27.42 25.65 27.51 27.30 27.34 29.25 28.62 28.88 28.33 28.53 28.14 
IMMT Q16891 45 26.71 28.41 26.54 25.34 24.84 24.52 29.07 28.35 28.76 28.26 28.56 28.15 
IMP4 Q8TCT7 3 NAN NAN NAN NAN NAN NAN 24.40 23.78 24.09 NAN NAN NAN 
IMPAD1 Q9NX62 3 NAN 23.79 NAN NAN 24.40 24.41 NAN NAN NAN NAN NAN NAN 
IMPDH1 P20839 13 26.14 27.04 25.81 25.64 26.34 26.35 24.61 25.00 25.05 24.47 24.86 23.97 
IMPDH2 P12268 25 29.07 29.72 29.43 29.17 29.30 29.61 28.21 28.58 27.87 28.44 28.66 28.63 
INPP5K Q9BT40 4 23.51 23.03 23.90 24.65 24.38 25.01 23.33 23.00 23.13 23.48 23.53 NAN 
INPPL1 O15357 4 NAN NAN NAN NAN 23.66 23.46 NAN NAN NAN NAN NAN NAN 
IPO11 Q9UI26 7 23.81 26.87 25.26 24.14 NAN 24.43 NAN NAN NAN NAN NAN NAN 
IPO4 Q8TEX9 18 25.88 27.08 26.54 25.46 25.37 25.54 25.28 24.73 25.18 24.21 24.51 24.31 
IPO8 O15397 6 23.62 24.82 NAN 22.96 23.21 23.22 NAN NAN NAN NAN NAN NAN 
ISG15 P05161 4 23.83 NAN 24.42 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
ISLR O14498 4 NAN NAN NAN NAN NAN NAN 23.60 24.18 23.95 NAN 23.77 23.07 
ITCH Q96J02 3 NAN NAN NAN NAN 22.91 23.39 22.79 22.66 NAN NAN NAN NAN 
ITGA2 P17301 13 23.51 25.83 22.83 24.63 24.72 24.24 NAN NAN NAN 24.16 22.89 23.39 
ITGA3 P26006 5 NAN NAN NAN NAN 22.70 22.18 NAN NAN NAN NAN NAN NAN 
ITPA Q9BY32 2 NAN 23.90 NAN NAN NAN 22.70 NAN NAN NAN NAN NAN NAN 
ITPRIP Q8IWB1 4 NAN 22.83 23.23 24.00 24.30 23.95 NAN NAN NAN NAN NAN NAN 
IVNS1ABP Q9Y6Y0 22 27.33 26.75 27.32 27.74 28.18 28.51 25.37 27.24 26.08 26.41 25.42 26.95 
IWS1 Q96ST2 3 23.52 NAN NAN 22.37 22.60 22.55 NAN NAN NAN NAN NAN NAN 
KARS Q15046 14 24.47 26.42 24.10 25.25 25.44 25.97 25.02 25.22 25.25 24.81 24.99 25.34 
KCTD12 Q96CX2 4 NAN 23.46 NAN NAN 23.15 23.47 NAN NAN NAN NAN NAN NAN 
KCTD17 Q8N5Z5 11 26.93 29.25 26.68 27.40 27.81 27.52 24.69 26.08 24.74 24.82 24.22 24.34 
KCTD2 Q14681 10 24.99 26.55 26.03 25.48 26.01 25.83 22.88 23.54 23.49 23.23 NAN 23.86 
KCTD5 Q9NXV2 15 28.94 30.03 29.59 30.17 30.11 30.35 27.14 28.12 27.08 28.16 27.25 27.75 
KDELC2 Q7Z4H8 10 24.10 24.84 NAN 24.68 24.40 24.57 NAN 23.04 23.37 23.73 24.04 24.00 
KDM1A O60341 13 25.26 25.50 25.70 25.94 25.35 25.74 23.35 23.32 NAN 23.66 24.17 23.39 
KEAP1 Q14145 11 23.15 23.65 23.16 24.46 24.57 25.45 22.81 22.99 23.44 NAN NAN NAN 
KHSRP Q92945 10 25.07 25.62 24.90 26.17 25.93 25.98 24.02 24.21 23.96 23.77 24.90 24.12 
KIDINS220 Q9ULH0 20 NAN 24.91 NAN NAN 23.27 21.30 28.75 26.70 28.88 26.56 27.90 25.63 
KIDINS220 Q9ULH0 4 NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.24 NAN 23.52 
KIF23 Q02241 4 NAN NAN NAN NAN NAN NAN 24.26 23.51 24.43 23.68 24.47 22.93 
KIF2A O00139 15 22.87 NAN NAN 23.38 23.84 23.35 26.70 25.69 25.71 24.72 24.94 24.74 
KLC2 Q6P597 10 NAN 22.01 NAN NAN 22.57 22.98 NAN NAN NAN NAN NAN NAN 
KLF4 O43474 6 25.76 26.52 26.20 26.08 25.00 25.48 26.05 24.76 24.98 24.93 25.23 25.70 
KPNA2 P52292 21 27.85 28.95 28.19 28.53 28.42 28.62 28.06 27.99 28.08 27.71 28.32 27.76 
KRI1 Q8N9T8 6 NAN NAN NAN NAN NAN NAN 25.28 24.05 24.53 24.77 25.19 24.81 
KRR1 Q13601 7 NAN 22.80 NAN NAN 24.17 NAN 26.10 25.51 25.73 25.74 26.19 26.07 
LACTB P83111 19 NAN NAN NAN NAN NAN NAN 27.76 26.35 27.74 26.63 26.24 25.66 
LAMB1 P07942 22 26.92 26.80 25.51 26.57 26.26 26.20 NAN 22.50 23.32 NAN NAN NAN 
LAMP1 P11279 8 25.77 26.62 25.42 26.71 26.69 26.67 24.42 25.02 24.28 26.08 25.05 25.98 
LAMP2 P13473 4 23.47 26.10 23.27 25.68 25.61 25.42 23.24 22.49 NAN 23.58 23.78 23.46 
LAMTOR1 Q6IAA8 7 25.14 25.62 NAN 25.73 25.20 25.16 25.08 25.67 24.78 25.46 24.93 25.30 
LAMTOR3 Q9UHA4 2 NAN 24.48 NAN NAN 24.35 24.74 NAN NAN NAN NAN NAN NAN 
LAMTOR4 Q0VGL1 2 NAN NAN NAN NAN 23.47 23.60 NAN NAN NAN NAN NAN NAN 
LANCL1 O43813 2 NAN 24.59 NAN NAN 24.25 24.31 NAN NAN NAN NAN NAN NAN 
LAP3 P28838 8 NAN 24.20 NAN NAN 24.07 23.99 NAN NAN NAN NAN 24.68 24.90 
LARP1 Q6PKG0 48 22.77 26.40 22.86 21.85 24.98 24.09 29.83 29.36 29.83 28.29 29.15 28.12 
LARP1B Q659C4 6 NAN NAN NAN NAN NAN NAN 22.01 NAN 22.87 NAN NAN NAN 
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LARP4 Q71RC2 6 23.45 25.31 NAN 23.89 NAN 24.71 25.57 24.53 25.29 25.04 25.68 24.69 
LARP4B Q92615 10 NAN 24.80 NAN NAN 24.75 24.02 25.64 24.24 25.27 24.74 25.79 24.04 
LARP7 Q4G0J3 15 NAN NAN NAN NAN NAN NAN 26.84 25.71 26.18 25.82 26.07 25.21 
LAS1L Q9Y4W2 7 NAN NAN NAN NAN NAN NAN 25.16 23.82 25.17 NAN 24.85 24.68 
LBR Q14739 2 NAN NAN NAN NAN NAN NAN 22.33 22.59 22.32 22.75 NAN 23.55 
LCLAT1 Q6UWP7 3 22.69 23.99 22.78 24.09 23.74 23.77 NAN NAN NAN NAN NAN NAN 
LDHA P00338 12 24.50 25.66 24.63 26.58 26.80 26.94 24.31 25.30 25.69 25.33 25.43 26.15 
LDHB P07195 3 NAN NAN NAN NAN 23.17 23.29 NAN NAN NAN NAN NAN NAN 
LEMD3 Q9Y2U8 31 28.12 27.08 28.29 29.01 28.59 28.70 26.74 27.26 26.73 27.84 27.42 27.91 
LETM1 O95202 17 25.33 26.62 25.79 26.97 26.33 26.43 NAN 24.53 24.67 24.72 23.97 25.02 
LGALS3 P17931 7 23.85 25.08 24.14 26.93 26.96 26.63 24.60 25.47 25.15 24.90 25.07 25.59 
LGMN Q99538 2 NAN NAN NAN NAN 24.01 24.05 22.08 22.19 21.98 NAN NAN NAN 
LIG3 P49916 6 NAN NAN NAN NAN NAN NAN NAN 24.20 25.22 25.33 24.80 NAN 
LLPH Q9BRT6 3 NAN NAN NAN NAN NAN NAN 26.67 25.46 26.47 NAN NAN NAN 
LMAN1 P49257 20 27.55 28.31 27.96 28.45 28.35 28.22 26.62 27.45 26.66 27.11 26.60 27.17 
LMAN2 Q12907 15 25.69 26.10 26.24 27.09 27.35 26.99 24.57 25.42 24.93 26.38 25.79 26.34 
LNPK Q9C0E8 4 23.07 NAN 23.37 23.43 NAN NAN NAN NAN NAN NAN NAN NAN 
LONP1 P36776 20 25.14 26.68 24.99 26.80 26.46 26.32 23.84 24.30 25.01 25.20 24.96 25.70 
LONP1 P36776 13 NAN 21.60 22.12 21.32 22.39 21.26 27.65 26.16 27.42 26.76 26.78 26.09 
LPCAT1 Q8NF37 8 25.83 25.41 25.88 25.49 25.47 25.49 23.75 24.13 23.70 24.31 24.28 24.59 
LPCAT4 Q643R3 5 NAN 22.72 22.59 23.00 22.95 NAN 22.91 22.32 24.33 22.44 NAN 22.71 
LRPPRC P42704 96 29.38 32.38 28.91 30.42 30.16 30.10 28.79 28.93 28.74 29.29 29.06 29.33 
LRRC15 Q8TF66 7 NAN NAN NAN NAN 23.99 24.92 NAN NAN NAN NAN NAN NAN 
LRRFIP2 Q9Y608 14 NAN 25.75 NAN NAN 23.65 23.34 27.06 25.68 26.98 25.47 25.59 24.90 
LSG1 Q9H089 15 22.13 24.47 23.58 24.24 24.41 24.34 25.62 25.70 26.96 25.20 25.90 25.07 
LSM14A Q8ND56 3 NAN NAN 23.10 24.01 23.91 23.57 NAN NAN NAN NAN NAN NAN 
LSS P48449 5 NAN 23.48 NAN NAN 23.66 23.99 NAN NAN NAN NAN NAN NAN 
LTN1 O94822 4 NAN 22.59 NAN NAN 22.20 22.50 22.90 22.46 24.14 21.96 22.00 NAN 
LTV1 Q96GA3 4 NAN NAN NAN NAN NAN NAN 23.37 23.36 NAN 23.30 23.88 23.40 
LUC7L Q9NQ29 10 NAN NAN NAN NAN NAN NAN 24.92 24.50 24.87 24.54 24.48 24.27 
LUC7L2 Q9Y383 18 23.66 24.84 24.50 25.42 25.37 25.19 27.58 27.02 27.40 27.02 26.76 26.25 
LUZP1 Q86V48 5 NAN NAN NAN NAN NAN NAN 22.79 23.00 22.99 NAN NAN NAN 
LYAR Q9NX58 20 NAN 24.98 23.49 22.71 23.22 NAN 28.80 28.17 28.50 27.06 27.81 27.01 
LYPLA1 O75608 3 23.20 NAN NAN 23.10 23.77 23.84 NAN NAN NAN NAN NAN NAN 
LYRM4 Q9HD34 4 NAN NAN NAN NAN 24.07 23.84 NAN NAN NAN NAN NAN NAN 
M6PR P20645 3 NAN NAN NAN NAN 24.91 24.87 NAN NAN NAN NAN NAN NAN 
MAGED2 Q9UNF1 7 23.60 23.33 24.05 23.85 24.55 24.13 NAN NAN NAN NAN NAN NAN 
MAK16 Q9BXY0 7 NAN NAN NAN NAN NAN NAN 27.37 25.94 26.95 26.62 26.71 26.49 
MAN1A2 O60476 3 NAN 22.75 NAN NAN 23.42 23.07 NAN NAN NAN NAN NAN NAN 
MAN2A1 Q16706 6 NAN 24.27 NAN NAN 24.69 23.78 NAN NAN NAN NAN NAN NAN 
MAN2B1 O00754 4 NAN NAN NAN NAN 22.81 22.95 NAN NAN NAN NAN NAN NAN 
MANF P55145 2 NAN 22.15 NAN NAN NAN 22.96 NAN NAN NAN NAN NAN NAN 
MAP1LC3B Q9GZQ8 2 NAN 24.55 NAN NAN 25.08 25.18 NAN NAN NAN NAN NAN NAN 
MAP1S Q66K74 10 24.33 25.35 NAN 25.04 25.01 25.36 23.77 23.94 24.08 24.46 NAN 24.21 
MAP2K3 P46734 7 24.95 25.75 24.64 24.51 24.39 24.84 23.32 23.99 25.12 NAN NAN NAN 
MAP3K7 O43318 4 23.90 22.56 23.10 23.85 24.33 24.23 NAN NAN NAN NAN NAN NAN 
MAP3K7IP1 Q15750 20 26.42 23.82 26.36 27.04 27.87 27.68 NAN 25.69 24.98 25.97 25.96 26.21 
MAP4 P27816 19 25.61 24.84 25.76 26.01 25.77 25.71 25.25 25.44 24.90 25.77 26.03 26.36 
MAP4K4 O95819 12 NAN 23.79 NAN NAN 23.95 NAN 23.93 23.80 23.90 NAN NAN NAN 
MAP7D1 Q3KQU3 3 NAN NAN NAN NAN NAN NAN 23.52 23.53 23.45 23.21 23.93 22.97 
MAPK1 P28482 18 26.50 25.89 27.25 27.21 27.02 27.57 26.41 26.65 26.25 25.81 26.04 26.44 
MAPK3 P27361 11 23.75 24.15 25.15 23.79 24.32 25.32 23.69 23.41 23.81 23.22 23.46 24.27 
MAPRE1 Q15691 12 24.34 25.25 25.07 27.19 27.26 27.54 24.46 24.72 23.80 24.36 25.06 25.45 
MARS P56192 24 26.84 27.51 26.37 26.32 26.41 26.62 26.12 26.69 26.50 26.11 26.34 26.43 
MAT2A P31153 17 24.83 26.10 25.36 27.32 28.01 27.94 25.27 26.20 24.98 26.36 26.18 26.33 
MAT2B Q9NZL9 4 NAN NAN 23.10 23.20 24.01 23.73 NAN NAN NAN NAN NAN NAN 
MBD2 Q9UBB5 5 NAN NAN 23.58 24.63 NAN NAN NAN NAN NAN NAN NAN NAN 
MBD3 O95983 5 NAN 23.23 NAN NAN 23.10 22.80 NAN NAN NAN 22.62 23.25 NAN 
MBDin Q9HCN4 2 NAN NAN NAN NAN 22.87 23.61 NAN NAN NAN NAN NAN NAN 
MBNL1 Q9NR56 4 NAN NAN NAN NAN NAN NAN 22.91 22.80 22.38 23.28 23.14 23.47 
MCCC2 Q9HCC0 9 24.44 24.82 24.58 25.59 25.21 25.24 NAN NAN NAN NAN NAN NAN 
MCM5 P33992 32 26.64 27.33 26.71 27.95 27.98 28.38 26.73 27.49 26.78 27.67 27.02 27.46 
MCM7 P33993 26 NAN 22.85 NAN NAN 23.40 23.88 23.05 NAN 23.09 23.70 23.45 23.54 
MCM7 P33993 31 26.95 27.63 27.11 28.34 28.44 28.47 27.96 27.49 27.52 27.98 27.91 28.11 
MCMBP Q9BTE3 4 NAN NAN NAN NAN 23.68 23.62 NAN NAN NAN NAN NAN NAN 
MCU Q8NE86 7 25.84 24.38 25.90 24.99 24.81 24.25 25.48 NAN 25.60 23.88 25.92 25.56 
MDH2 P40926 18 27.13 27.04 27.44 28.60 28.16 28.26 24.94 26.58 27.14 27.17 27.48 28.11 
MDN1 Q9NU22 10 NAN 24.17 NAN NAN NAN 23.82 NAN NAN NAN NAN NAN NAN 
ME2 P23368 9 NAN 25.48 NAN NAN 23.73 24.00 NAN 23.73 22.71 23.67 22.73 23.73 
MEPCE Q7L2J0 9 NAN NAN NAN NAN NAN NAN 26.22 25.74 26.03 25.04 26.22 25.61 
MESDC2 Q14696 3 23.92 22.40 24.54 22.74 22.79 22.24 NAN NAN NAN NAN NAN NAN 
METAP1 P53582 13 NAN 24.96 NAN NAN 24.14 23.26 28.69 28.16 27.93 25.06 26.69 26.33 
METTL13 Q8N6R0 5 NAN 24.15 NAN NAN 21.29 NAN NAN NAN NAN NAN NAN NAN 
MGA O43451 2 NAN 22.85 NAN NAN 23.54 23.41 NAN NAN NAN NAN NAN NAN 
MGAT1 P26572 4 NAN NAN NAN NAN 22.28 22.45 NAN NAN NAN NAN NAN NAN 
MGAT2 Q10469 5 23.49 22.73 23.87 24.64 23.98 24.21 NAN NAN NAN NAN NAN NAN 
MGEA5 O60502 6 NAN 23.95 NAN NAN 24.60 24.60 NAN NAN NAN NAN NAN NAN 
MIB1 Q86YT6 2 NAN NAN NAN NAN NAN NAN 20.65 20.60 20.48 NAN NAN NAN 
MICAL1 Q8TDZ2 12 24.22 25.89 25.28 23.78 24.38 NAN 25.22 25.21 25.35 24.68 24.67 25.01 
MICU1 Q9BPX6 3 NAN 24.05 NAN NAN 22.44 22.35 NAN NAN NAN NAN NAN NAN 
MKI67 P46013 5 NAN NAN NAN NAN NAN NAN 23.51 23.56 23.51 23.27 23.88 23.49 
MLEC Q14165 8 26.27 25.96 26.07 27.32 26.93 27.03 24.60 25.15 24.35 25.63 24.53 25.34 
MLF2 Q15773 5 23.16 22.75 NAN 23.24 22.95 23.18 NAN NAN NAN NAN NAN NAN 
MMGT1 Q8N4V1 2 22.56 22.85 22.73 NAN NAN 23.80 NAN NAN NAN NAN NAN NAN 
MMP14 P50281 7 24.17 24.82 24.57 25.03 24.97 25.38 NAN 23.96 23.58 24.68 24.01 NAN 
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MMS19 Q96T76 15 25.19 26.75 25.07 25.69 25.60 25.97 24.05 23.90 24.04 23.98 23.36 23.69 
MOB1A Q9H8S9 3 NAN NAN NAN NAN 24.76 24.81 22.85 22.64 NAN 23.01 24.47 23.56 
MOB2 Q70IA6 9 24.62 26.00 24.38 26.91 26.94 27.03 NAN NAN NAN 25.09 NAN 24.16 
MOB4 Q9Y3A3 6 24.74 23.71 24.45 24.36 24.63 24.52 NAN NAN NAN NAN NAN NAN 
MON2 Q7Z3U7 4 NAN 24.51 22.58 22.86 23.29 23.96 NAN NAN NAN NAN NAN NAN 
MOV10 Q9HCE1 14 22.68 NAN 22.83 NAN NAN NAN 27.18 25.04 25.71 24.74 25.36 25.03 
MOV10L1 Q9BXT6  5 NAN 22.38 22.50 23.37 23.52 23.61 22.10 22.10 22.40 NAN NAN NAN 
MOXD1 Q6UVY6 26 26.39 27.98 25.68 26.20 26.51 26.44 29.05 28.93 28.69 29.15 28.73 29.16 
MPDU1 O75352 2 25.03 26.02 25.27 24.71 24.56 24.27 NAN 22.58 22.04 NAN NAN NAN 
MPHOSPH10 O00566 5 NAN NAN NAN NAN NAN NAN 25.76 24.94 25.47 24.58 24.59 24.27 
MRPL11 Q9Y3B7 2 NAN NAN NAN NAN 22.15 22.34 NAN 22.04 22.26 NAN NAN NAN 
MRPL12 P52815 8 24.15 24.21 25.03 25.74 24.64 24.65 23.23 23.24 NAN NAN NAN NAN 
MRPL38 Q96DV4 5 22.58 NAN 22.74 23.59 23.45 23.21 23.18 23.22 22.80 23.74 23.32 23.30 
MRPL44 Q9H9J2 5 NAN 24.09 NAN NAN 24.55 24.59 24.17 24.83 23.76 23.88 24.49 23.81 
MRPL49 Q13405 3 NAN 22.50 NAN NAN 23.09 22.76 22.08 NAN 22.28 NAN NAN NAN 
MRPS17 Q9Y2R5 4 23.33 23.18 24.11 24.17 24.28 24.21 24.65 24.72 24.07 23.95 23.82 NAN 
MRPS18B Q9Y676 3 NAN NAN NAN NAN NAN NAN 23.12 22.50 NAN NAN 22.97 22.83 
MRPS2 Q9Y399 5 NAN NAN NAN NAN 22.95 23.17 23.62 23.11 23.44 22.76 23.44 22.74 
MRPS23 Q9Y3D9 4 NAN 22.90 23.32 23.67 23.45 23.28 23.22 23.16 22.75 23.31 22.91 23.18 
MRPS30 Q9NP92 4 NAN NAN NAN NAN NAN NAN NAN NAN NAN 21.99 21.61 22.25 
MRPS31 Q92665 3 NAN 23.89 23.35 22.94 23.21 22.86 NAN NAN NAN NAN NAN NAN 
MRPS34 P82930 5 NAN 23.09 23.75 23.93 23.87 23.27 24.58 23.45 24.00 24.91 24.43 24.30 
MRPS5 P82675 5 NAN NAN NAN NAN NAN NAN 23.51 22.99 23.29 NAN NAN NAN 
MRTO4 Q9UKD2 13 NAN NAN NAN NAN NAN NAN 27.20 27.34 27.73 26.66 27.29 26.46 
MSH2 P43246 16 22.48 26.56 23.63 26.06 24.90 26.20 22.12 22.74 22.09 24.07 22.54 21.50 
MSH6 P52701 14 24.58 24.67 24.29 25.41 25.34 25.46 25.03 24.76 25.21 25.14 24.36 24.66 
MTA3 Q9BTC8 11 22.69 NAN 22.45 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
MTCH1 Q9NZJ7 6 23.25 23.71 23.35 23.67 23.68 23.77 24.08 23.63 23.79 23.75 24.51 23.93 
MTCH2 Q9Y6C9 12 26.99 27.00 27.80 27.59 27.15 27.07 27.03 27.38 27.12 27.49 26.86 27.63 
MTDH Q86UE4 25 24.58 25.28 25.22 25.79 25.77 25.53 28.20 28.17 28.35 28.30 28.27 27.63 
MTHFD1 P11586 25 25.01 27.02 25.35 26.40 26.86 26.62 25.60 26.12 25.75 24.69 25.70 26.13 
MTHFD1L Q6UB35 30 26.49 27.35 26.40 27.89 27.77 27.81 26.85 26.87 26.99 27.27 26.99 27.45 
MT-ND1 P03886 3 22.88 NAN 22.93 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
MTOR P42345 3 NAN 22.99 NAN NAN 22.10 22.15 NAN NAN NAN NAN NAN NAN 
MTPAP Q9NVV4 8 NAN NAN NAN NAN NAN NAN 26.54 25.87 26.33 25.23 25.74 25.55 
MTX2 O75431 6 23.98 NAN 24.35 23.80 NAN NAN 26.18 25.43 25.91 25.22 25.60 25.00 
MX1 P20591 12 27.37 NAN 26.57 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
MXRA7 P84157 3 NAN 23.93 NAN NAN 23.92 23.78 22.15 22.68 NAN NAN NAN NAN 
MYADM Q96S97 8 26.07 29.26 25.57 24.56 23.79 23.09 28.87 28.35 28.47 28.51 28.55 28.59 
MYBBP1A Q9BQG0 62 26.82 28.74 26.82 27.48 27.52 27.34 30.58 29.51 30.37 29.67 30.10 29.08 
MYC P01106 17 28.45 27.93 28.93 27.30 26.52 26.59 25.67 24.32 25.40 24.27 24.41 25.47 
MYCBP2 O75592 8 NAN NAN NAN NAN NAN NAN 23.16 22.87 23.68 22.77 22.99 NAN 
MYH10 P35580 195 29.81 31.27 27.00 27.43 28.11 28.22 32.52 31.94 32.52 31.26 31.62 30.77 
MYL1 P05976 2 NAN NAN NAN NAN NAN NAN 28.17 27.28 27.96 24.80 25.93 24.61 
MYL6B P14649 6 NAN NAN NAN NAN NAN NAN 24.59 23.58 25.21 NAN NAN NAN 
MYO10 Q9HD67 5 NAN NAN NAN NAN NAN NAN 23.88 22.24 23.24 NAN NAN NAN 
MYO9A B2RTY4 3 22.58 NAN 22.21 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
MYOM1 P52179 2 NAN NAN NAN NAN NAN NAN 23.29 NAN 23.75 NAN NAN NAN 
NAA10 P41227 5 NAN 23.94 NAN NAN 23.20 23.34 24.20 24.74 24.79 22.84 23.39 23.20 
NAA15 Q9BXJ9 17 NAN 25.17 NAN NAN 25.04 25.19 26.20 26.92 26.73 24.96 26.40 25.98 
NACA E9PAV3 8 24.75 27.25 25.53 26.60 26.89 26.51 28.21 28.41 28.58 27.68 28.41 28.31 
NAGLU P54802 4 NAN NAN NAN NAN 22.44 22.48 NAN NAN NAN 22.91 22.89 22.85 
NAP1L4 Q99733 16 25.66 25.25 25.73 26.15 26.39 26.44 26.44 26.35 26.81 26.00 26.00 26.02 
NAPA O96009 16 25.34 26.35 25.99 26.96 26.93 26.70 24.40 25.78 24.43 25.64 24.09 25.64 
NAPG Q99747 3 NAN 23.25 NAN NAN 23.63 23.57 NAN NAN NAN NAN NAN NAN 
NARS O43776 21 26.40 26.66 24.78 27.18 27.73 27.73 25.27 25.52 23.97 25.41 25.70 26.41 
NASP P49321 7 24.40 23.73 NAN 25.00 25.17 24.99 NAN NAN NAN 23.57 NAN 23.64 
NAT10 Q9H0A0 40 23.07 25.44 NAN 22.18 21.90 22.04 29.38 27.69 28.74 27.71 28.50 27.16 
NCBP1 Q09161 18 25.16 25.69 24.66 26.06 26.11 26.47 25.71 25.84 26.09 25.49 25.54 25.94 
NCEH1 Q6PIU2 9 23.57 24.36 24.02 25.72 25.12 25.02 NAN 23.48 23.23 24.26 23.85 23.99 
NCL P19338 63 29.87 30.82 30.50 30.72 30.56 30.44 33.25 32.49 32.76 32.57 32.88 32.48 
NCSTN Q92542 7 24.22 24.37 24.38 25.35 25.21 25.67 23.70 24.26 23.66 23.56 NAN 23.94 
ND2 P03891 2 NAN NAN NAN NAN NAN NAN 22.87 NAN 23.39 NAN NAN NAN 
ND4 P03905 4 24.34 NAN NAN 23.32 NAN NAN 23.89 24.06 24.77 NAN NAN NAN 
ND5 P03915 3 23.96 22.88 24.21 24.48 23.74 23.93 24.42 24.36 24.80 NAN NAN NAN 
NDUFA11 Q86Y39 3 NAN 23.49 NAN NAN 23.66 23.74 NAN NAN NAN 23.37 NAN 23.70 
NDUFA4 O00483 4 23.97 24.54 23.76 26.20 26.33 26.29 NAN 23.33 23.81 23.94 23.67 NAN 
NDUFA5 Q16718 4 NAN NAN 24.47 24.34 24.06 24.34 24.61 24.07 24.55 23.56 23.71 24.04 
NDUFA8 P51970 6 25.03 24.36 25.72 25.49 25.00 25.12 24.62 24.66 24.68 24.52 24.70 25.24 
NDUFAF4 Q9P032 3 23.80 22.59 22.99 23.60 23.36 23.93 NAN NAN NAN NAN NAN NAN 
NDUFB10 O96000 6 24.86 23.42 24.85 23.88 24.03 24.14 24.43 24.65 24.30 24.45 24.17 24.98 
NDUFB11 Q9NX14 2 NAN NAN NAN NAN 22.78 22.93 22.49 22.64 22.66 NAN NAN NAN 
NDUFB3 O43676 2 22.69 NAN NAN 23.15 NAN NAN NAN NAN NAN NAN NAN NAN 
NDUFB4 O95168 3 23.04 NAN 23.21 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
NDUFB9 Q9Y6M9 6 24.32 23.94 24.19 24.88 24.02 24.28 24.50 24.26 24.37 24.22 24.05 24.24 
NDUFS2 O75306 14 25.71 25.11 25.94 26.19 25.85 25.97 25.65 25.86 25.79 26.04 24.99 25.24 
NDUFS3 O75489 14 25.92 25.68 26.74 26.29 26.12 26.22 25.94 26.26 26.30 26.17 26.10 26.62 
NDUFS5 O43920 4 22.80 23.42 NAN 23.67 22.96 23.05 22.48 NAN 22.79 NAN NAN NAN 
NDUFS7 O75251 4 NAN 23.86 NAN NAN 24.00 24.03 23.88 23.59 24.50 NAN NAN NAN 
NDUFS8 O00217 6 25.29 24.59 NAN 25.35 24.96 24.83 24.83 24.86 25.05 25.02 25.18 25.07 
NDUFV2 P19404 4 NAN 23.55 NAN NAN 23.63 23.64 NAN NAN NAN NAN NAN NAN 
NEDD4 P46934 3 NAN 22.68 NAN NAN 22.16 21.77 NAN NAN NAN 22.02 21.60 NAN 
NELFB Q8WX92 2 NAN 22.54 NAN NAN 23.14 22.49 NAN NAN NAN NAN NAN NAN 
NELFCD Q8IXH7 3 23.51 23.13 22.99 23.06 23.53 22.94 NAN NAN NAN NAN NAN NAN 
NEMF O60524 16 23.25 23.02 22.28 NAN 23.61 NAN 26.70 26.99 27.45 25.17 25.69 25.08 
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NFIX Q14938 2 NAN NAN NAN NAN NAN NAN 22.83 NAN 22.69 NAN NAN NAN 
NFKB2 Q00653 7 23.50 NAN 23.51 23.10 22.99 23.42 NAN NAN NAN NAN NAN NAN 
NFKBIB Q15653 4 24.09 NAN 24.34 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
NFS1 Q9Y697 7 22.65 22.21 22.66 25.33 NAN 23.27 22.97 22.52 22.29 NAN NAN NAN 
NGDN Q8NEJ9 3 NAN NAN NAN NAN NAN NAN 23.43 22.54 23.08 NAN 23.32 23.06 
NHP2 Q9NX24 7 NAN NAN NAN NAN NAN NAN 27.02 25.40 25.55 25.93 25.39 25.58 
NHP2L1 P55769 4 22.48 23.52 22.36 23.16 23.16 23.29 24.62 24.31 24.55 NAN NAN NAN 
NIFK Q9BYG3 8 NAN 23.57 24.29 23.40 23.66 23.25 25.85 24.96 25.31 24.55 25.02 23.74 
NIP7 Q9Y221 5 NAN 24.59 NAN NAN 24.31 24.39 27.57 26.46 26.24 25.46 26.06 25.44 
NKRF O15226 8 NAN NAN NAN NAN NAN NAN 23.57 23.30 23.50 23.63 23.69 23.59 
NMD3 Q96D46 13 24.33 26.49 24.86 24.81 24.73 24.40 26.01 26.51 26.92 25.87 26.71 25.93 
NMNAT1 Q9HAN9 10 NAN NAN NAN NAN NAN NAN 26.73 25.52 26.76 25.86 26.75 25.03 
NNMT P40261 11 24.93 27.69 25.17 24.21 24.81 24.89 24.86 25.09 25.28 24.97 25.36 25.33 
NNT Q13423 8 23.06 24.89 23.81 24.99 24.59 24.43 23.55 23.85 24.01 23.89 NAN 24.06 
NO66 Q9H6W3 5 NAN NAN NAN NAN NAN NAN 21.55 22.18 22.19 NAN NAN NAN 
NOB1 Q9ULX3 10 NAN 24.19 22.28 22.53 23.27 23.45 26.44 25.84 26.25 24.55 25.51 24.36 
NOC2L Q9Y3T9 21 22.50 25.04 24.31 23.34 23.99 24.23 28.13 27.08 27.79 26.93 27.55 26.81 
NOC3L Q8WTT2 13 NAN 23.58 NAN NAN 21.93 21.86 28.05 26.44 27.67 26.23 27.36 26.14 
NOC4L Q9BVI4 28 27.98 28.04 28.36 29.06 28.64 28.46 27.08 27.24 27.14 27.87 27.49 27.00 
NOL10 Q9BSC4 7 NAN NAN NAN NAN NAN NAN 26.05 25.01 26.11 24.30 25.42 24.35 
NOL6 Q9H6R4 38 NAN 25.27 NAN NAN 21.99 21.80 29.30 28.98 29.69 28.02 28.44 27.16 
NOL9 Q5SY16 10 NAN 24.59 25.34 24.03 24.64 NAN 26.67 25.45 26.59 24.88 26.31 25.53 
NOLA1 Q9NY12 7 NAN 24.40 26.32 26.67 26.71 26.30 27.18 26.84 27.08 26.25 27.38 26.14 
NOLC1 Q14978 3 23.26 24.05 23.37 23.23 22.89 22.58 23.82 22.84 24.12 22.55 22.69 22.30 
NOM1 Q5C9Z4 5 NAN NAN NAN NAN NAN NAN 24.14 22.95 23.17 NAN 23.72 23.35 
NOP14 P78316 26 26.22 26.66 26.46 27.93 27.79 27.55 26.03 26.06 25.98 27.28 26.54 26.04 
NOP16 Q9Y3C1 6 NAN NAN NAN NAN NAN NAN 26.18 25.82 26.29 24.95 25.57 24.72 
NOP2 P46087 21 NAN 23.24 NAN NAN 24.07 NAN 28.23 27.42 27.63 27.50 27.69 27.01 
NOP56 O00567 23 22.47 24.92 24.29 23.21 24.79 22.24 28.11 27.15 27.71 27.40 27.36 26.52 
NOP58 Q9Y2X3 16 24.87 25.50 25.02 25.12 24.66 23.96 26.79 26.12 26.83 26.38 26.63 26.14 
NOP9 Q86U38 9 NAN NAN NAN NAN NAN NAN 26.19 24.53 25.87 24.39 25.62 24.22 
NOSIP Q9Y314 2 NAN 23.85 NAN NAN 22.57 NAN NAN NAN NAN NAN NAN NAN 
NPC1 O15118 3 NAN 22.35 NAN NAN 22.91 22.82 NAN NAN NAN NAN NAN NAN 
NPEPPS P55786 9 22.78 23.70 NAN 24.66 24.68 24.58 NAN 23.64 23.95 23.86 24.63 23.90 
NPLOC4 Q8TAT6 14 23.07 23.98 23.32 25.36 27.06 26.65 22.70 21.79 23.29 23.84 22.36 24.56 
NPM1 P06748 21 29.93 30.09 30.24 30.21 29.99 30.07 32.07 31.05 31.31 30.07 31.02 30.03 
NPM3 O75607 3 23.68 24.54 24.07 25.03 24.88 24.82 25.38 24.70 24.78 25.43 25.25 24.86 
NPTN Q9Y639 5 25.38 25.32 25.69 26.57 25.99 26.38 23.78 24.11 23.85 24.74 24.08 24.67 
NQO1 P15559 7 24.43 25.47 24.52 24.98 25.54 25.51 23.58 24.17 24.32 24.61 24.59 25.11 
NRAS P01111 6 NAN 25.18 24.93 25.24 25.45 25.49 24.42 24.62 NAN 24.59 24.11 23.98 
NRBP1 Q9UHY1 4 25.66 26.38 23.86 24.12 24.37 24.39 NAN 23.12 23.29 NAN NAN NAN 
NRD1 O43847 8 22.84 NAN NAN 24.57 24.60 25.20 NAN NAN NAN 23.20 NAN 22.60 
NRP1 O14786 17 23.79 25.03 23.17 25.97 24.57 23.50 27.59 26.25 27.52 26.21 26.67 26.48 
NSDHL Q15738 5 23.13 24.22 23.73 24.19 23.89 23.84 NAN NAN NAN 23.01 23.52 NAN 
NSFL1C Q9UNZ2 18 26.78 24.56 26.13 28.02 28.23 28.20 24.01 26.09 23.95 26.50 25.55 26.34 
NSFL1C Q9UNZ2 18 NAN NAN NAN NAN 24.52 24.49 NAN NAN NAN NAN NAN NAN 
NSUN2 Q08J23 26 26.12 26.95 26.31 26.64 26.45 26.86 27.19 27.22 27.20 26.59 26.84 26.50 
NSUN5 Q96P11 3 NAN NAN NAN NAN NAN NAN NAN NAN NAN 22.15 22.15 NAN 
NT5DC2 Q9H857 7 NAN 24.34 23.28 25.26 24.83 24.48 NAN 23.64 23.14 23.72 NAN 23.85 
NT5E P21589 31 28.49 30.65 28.13 25.94 26.99 25.56 31.31 30.98 31.07 30.99 31.08 31.12 
NTPCR Q9BSD7 5 23.79 24.08 NAN 24.58 24.32 24.81 23.12 23.37 23.26 NAN NAN NAN 
NUBP1 P53384 3 NAN NAN NAN NAN 22.35 22.46 NAN NAN NAN NAN NAN NAN 
NUCB1 Q02818 15 24.55 25.57 24.85 27.55 26.37 26.69 NAN NAN NAN 21.20 NAN 21.38 
NUCB2 P80303 5 23.26 23.75 NAN 25.13 23.73 23.62 NAN NAN NAN NAN NAN NAN 
NUDC Q9Y266 8 22.95 23.52 23.72 25.21 25.42 25.48 23.53 23.67 23.12 23.76 23.23 23.91 
NUDCD1 Q96RS6 7 NAN 23.34 23.92 24.45 24.69 25.23 NAN NAN NAN NAN NAN NAN 
NUDT16L1 Q9BRJ7 2 NAN NAN 22.54 22.93 22.48 22.81 NAN NAN NAN NAN NAN NAN 
NUFIP2 Q7Z417 2 NAN NAN NAN NAN NAN NAN 22.93 23.40 23.20 23.43 NAN 23.45 
NUMA1 Q14980 3 NAN NAN NAN NAN NAN NAN 20.83 20.88 20.92 NAN NAN NAN 
NUMB P49757 3 NAN 23.25 NAN NAN NAN 23.05 23.01 23.28 23.08 NAN NAN NAN 
NUP188 Q5SRE5 12 25.06 25.86 23.06 23.65 23.79 24.10 NAN NAN NAN NAN NAN NAN 
NUP62 P37198 2 NAN 24.68 NAN NAN 22.91 23.57 NAN NAN NAN NAN NAN NAN 
NUP93 Q8N1F7 20 23.28 26.88 23.81 27.31 26.57 26.74 NAN NAN NAN 23.20 23.44 NAN 
NXF1 Q9UBU9 6 NAN NAN NAN NAN NAN NAN 25.36 24.22 24.96 23.97 25.09 24.42 
OAT P04181 11 23.87 25.11 24.00 26.26 25.30 25.95 23.15 24.13 23.83 24.46 25.19 25.31 
OCIAD1 Q9NX40 5 23.58 24.52 24.93 24.99 24.46 24.69 23.60 24.05 24.34 23.68 24.15 24.36 
OCRL Q01968 3 NAN NAN NAN NAN NAN NAN 22.41 22.13 21.74 NAN NAN NAN 
ODR4 Q5SWX8 9 23.59 23.43 24.13 24.97 24.54 25.27 NAN NAN NAN NAN NAN NAN 
OGFOD3 Q6PK18 10 23.06 24.53 NAN 23.23 23.38 23.44 NAN 22.45 22.35 23.26 23.11 22.31 
OGT O15294 6 NAN NAN NAN NAN NAN NAN 24.50 24.21 24.39 24.13 24.93 23.75 
OSTF1 Q92882 2 NAN NAN NAN NAN 21.91 21.71 NAN NAN NAN NAN NAN NAN 
OTUB1 Q96FW1 6 NAN 23.43 23.04 24.22 24.52 24.51 NAN NAN NAN NAN NAN NAN 
OXA1L Q15070 5 NAN 22.75 23.43 24.29 23.78 23.68 22.48 22.28 NAN NAN NAN NAN 
OXSR1 O95747 7 24.14 26.61 NAN 23.48 23.31 23.05 23.11 23.20 23.40 NAN NAN NAN 
P13674 P4HA1 33 26.73 NAN 27.32 NAN 26.08 26.01 25.16 25.49 25.28 NAN 25.90 25.38 
P4HB P07237 54 34.30 31.59 34.36 32.53 32.26 32.38 29.79 30.30 30.12 31.34 30.79 31.51 
PA2G4 Q9UQ80 29 25.04 27.82 25.13 26.46 26.76 26.54 28.31 29.01 28.72 27.67 28.10 28.44 
PABPC1 P11940 33 27.74 29.55 27.54 28.39 28.56 28.42 29.32 29.14 29.10 29.41 29.64 29.41 
PABPC4 Q13310 28 24.85 27.47 24.87 25.71 25.94 25.51 26.93 27.19 26.86 27.01 27.37 26.91 
PAF1 P28328 10 24.06 24.00 24.36 26.14 25.93 25.77 24.26 23.44 23.28 NAN NAN NAN 
PAFAH1B1 P43034 6 22.87 23.85 23.29 23.93 24.30 23.57 NAN NAN NAN NAN NAN NAN 
PAFAH1B2 P68402 2 NAN 24.16 NAN NAN 23.13 23.00 NAN NAN NAN NAN 23.42 23.67 
PAICS P22234 15 26.96 27.15 27.34 26.62 27.05 27.29 26.23 26.02 26.12 25.10 26.12 26.36 
PAK1IP1 Q9NWT1 8 NAN NAN NAN NAN NAN NAN 25.86 23.87 24.95 24.22 24.48 24.03 
PAK2 Q13177 5 NAN NAN NAN NAN 22.77 22.97 NAN NAN NAN NAN NAN NAN 
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PAPSS1 O43252 5 NAN NAN NAN NAN 23.52 23.42 NAN NAN NAN NAN NAN NAN 
PARK7 Q99497 5 23.58 24.91 NAN 23.33 23.59 23.25 NAN NAN NAN NAN NAN NAN 
PARP1 P09874 32 24.18 27.06 NAN 24.18 24.44 23.63 27.58 27.94 28.38 26.30 26.80 26.51 
PARVA Q9NVD7 5 NAN 26.24 NAN NAN 24.00 23.58 24.07 24.43 24.53 23.61 23.77 24.57 
PBRM1 Q86U86 2 NAN NAN NAN NAN 22.75 22.49 NAN NAN NAN NAN NAN NAN 
PBXIP1 Q96AQ6 10 22.81 23.06 24.61 25.82 26.21 26.21 24.00 23.76 23.77 24.56 24.29 24.70 
PC4 P53999 6 NAN NAN NAN NAN NAN NAN 26.96 26.93 27.19 NAN NAN NAN 
PCNA P12004 10 25.46 24.97 26.14 27.46 27.62 27.52 24.60 25.53 24.58 26.25 24.91 26.39 
PCOLCE Q15113 8 NAN NAN NAN NAN NAN NAN 24.71 25.32 24.93 24.46 25.02 26.06 
PCYOX1 Q9UHG3 15 25.64 26.15 25.18 26.83 26.86 26.45 23.40 23.93 24.04 25.64 24.55 25.93 
PDCD11 Q14690 62 NAN 23.82 NAN NAN 20.46 20.76 30.34 29.22 30.03 28.70 29.02 28.24 
PDCD4 Q53EL6 15 NAN 22.20 NAN NAN 22.70 23.54 27.98 26.80 27.80 25.94 26.54 25.94 
PDCD6 O75340 10 25.83 25.18 26.37 26.93 26.87 26.79 26.75 27.10 26.54 26.94 27.07 27.78 
PDCL Q13371 3 22.60 NAN NAN 23.39 22.73 23.49 NAN NAN NAN NAN NAN NAN 
PDCL3 Q9H2J4 5 23.61 23.36 23.86 24.15 24.45 24.16 NAN 23.03 22.72 23.19 NAN 22.98 
PDHB P11177 5 NAN 22.62 22.44 23.72 23.10 NAN NAN NAN NAN NAN NAN NAN 
PDIA3 P30101 7 NAN NAN NAN NAN 26.71 26.95 NAN NAN NAN 25.96 25.91 26.54 
PDIA6 Q15084 24 30.49 30.22 30.59 31.37 31.55 31.48 28.76 29.59 29.54 30.55 30.20 30.94 
PDLIM5 Q96HC4 9 24.36 24.14 24.49 25.13 25.22 25.35 23.78 23.16 24.27 NAN 23.36 23.70 
PDS5A Q29RF7 3 NAN 22.89 NAN NAN 23.33 NAN NAN NAN NAN NAN NAN NAN 
PEBP1 P30086 6 24.12 24.43 24.34 25.17 24.89 25.35 NAN NAN NAN NAN NAN NAN 
PELO Q9BRX2 8 22.66 23.44 NAN 23.13 23.37 23.51 23.04 24.13 23.04 23.34 23.02 23.63 
PELP1 Q8IZL8 17 25.80 NAN NAN 22.75 NAN NAN 27.24 25.53 26.47 26.00 27.55 25.62 
PES1 O00541 9 23.07 23.60 NAN 23.90 23.74 23.48 24.55 23.74 24.47 24.26 24.55 23.56 
PEX5 P50542 7 23.76 23.30 23.71 23.05 23.51 23.28 23.58 23.48 23.59 NAN NAN NAN 
PFDN2 Q9UHV9 2 21.57 22.81 NAN 24.51 24.41 24.48 22.04 22.27 22.03 22.00 21.87 NAN 
PFKFB3 Q16875 28 26.88 27.70 27.51 28.09 28.27 28.55 25.22 26.35 24.88 26.96 26.16 26.81 
PFKM P08237 12 23.61 24.14 23.88 23.85 23.74 23.80 NAN NAN NAN NAN NAN NAN 
PFN1 P07737 13 26.58 27.58 26.67 28.93 28.81 28.60 25.29 27.49 26.98 26.99 27.12 28.29 
PGAM5 Q96HS1 18 26.22 25.95 26.66 26.98 25.87 26.86 27.02 26.49 26.89 26.74 27.04 26.62 
PGD P52209 4 23.03 25.28 NAN 23.73 23.54 23.77 NAN 22.20 22.94 NAN NAN NAN 
PGM1 P36871 5 NAN NAN NAN NAN NAN NAN NAN NAN NAN NAN 21.11 22.12 
PGM3 O95394 4 NAN NAN NAN NAN 22.02 22.39 NAN NAN NAN NAN NAN NAN 
PGRMC1 O00264 11 26.88 26.61 27.68 27.64 27.11 27.32 25.35 25.81 25.57 26.59 26.03 26.50 
PGRMC2 O15173 9 26.19 26.03 26.68 27.15 27.09 26.79 25.36 25.55 25.45 26.69 25.71 26.58 
PHF5A Q7RTV0 5 NAN 22.65 NAN NAN 23.40 23.03 23.23 23.37 22.85 23.99 23.72 23.86 
PHGDH O43175 16 25.88 27.48 26.19 26.64 27.08 26.81 26.79 26.92 26.50 26.70 26.39 27.08 
PHLDA2 Q53GA4 2 22.38 21.92 22.49 NAN NAN 22.68 NAN NAN NAN NAN NAN NAN 
PICALM Q13492 15 25.58 25.32 25.72 24.80 23.30 24.17 27.38 27.03 27.69 25.18 26.54 26.96 
PIGK Q92643 3 23.89 NAN 24.50 24.02 NAN NAN NAN NAN NAN NAN NAN NAN 
PIK3R4 Q99570 7 23.72 24.22 NAN 23.00 23.30 23.55 23.64 NAN 23.36 NAN NAN NAN 
PIP4K2A P48426 3 NAN NAN NAN NAN 24.11 24.07 24.25 NAN 24.20 NAN 25.06 23.58 
PIP4K2C Q8TBX8 4 23.00 NAN 23.25 23.42 23.26 23.83 NAN 22.63 22.40 22.34 22.41 22.67 
PITRM1 Q5JRX3 5 NAN 23.26 NAN NAN 23.91 23.75 NAN NAN NAN NAN NAN NAN 
PLAA Q9Y263 2 NAN NAN NAN NAN 22.83 22.79 NAN NAN NAN NAN NAN NAN 
PLAT P00750 5 NAN NAN NAN NAN 23.20 23.20 24.46 23.83 23.88 23.81 23.94 23.70 
PLAUR Q03405 4 NAN 25.60 NAN NAN 24.66 NAN 25.55 24.34 24.95 25.42 25.41 26.18 
PLEKHO2 Q8TD55 4 NAN NAN NAN NAN 24.17 23.96 23.80 24.08 NAN NAN NAN NAN 
PLIN3 O60664 13 24.82 25.64 24.90 26.72 26.78 26.66 24.59 25.00 24.89 24.97 23.64 25.66 
PLP2 Q04941 2 NAN 23.13 NAN NAN 24.15 23.96 NAN 22.97 22.38 23.62 23.12 23.60 
PLXNB2 O15031 11 23.82 25.38 NAN 25.11 25.08 24.55 NAN NAN NAN 23.79 NAN 24.81 
PMPCA Q10713 3 23.84 25.38 23.93 25.11 24.97 24.70 23.44 23.41 23.90 23.81 23.97 24.83 
PMPCB O75439 6 22.50 22.31 23.03 24.45 23.68 23.17 NAN NAN NAN 22.88 22.57 22.98 
PNN Q9H307 3 NAN NAN NAN NAN NAN NAN 25.92 26.08 NAN NAN NAN NAN 
PNO1 Q9NRX1 8 NAN 24.87 NAN NAN 22.88 NAN 27.00 26.03 26.44 25.40 26.34 24.78 
PNP P00491 6 NAN 24.52 NAN NAN 24.33 24.24 NAN NAN NAN NAN NAN NAN 
PNPT1 Q8TCS8 4 NAN 22.67 NAN NAN 22.94 23.24 NAN NAN NAN NAN NAN NAN 
POLDIP2 Q9Y2S7 3 21.99 23.01 NAN 23.76 23.65 23.73 NAN NAN NAN NAN NAN NAN 
POLR1A O95602 11 NAN 25.03 NAN NAN 23.52 23.60 23.48 23.67 23.99 23.02 23.45 NAN 
POLR1C O15160 8 24.45 25.67 26.40 25.88 25.54 25.72 24.40 24.31 25.38 24.14 24.24 24.71 
POLR1E Q9GZS1 4 NAN NAN NAN NAN NAN NAN 23.24 22.46 23.55 NAN NAN NAN 
POLR3A O14802  6 25.12 24.90 24.58 23.61 23.58 23.62 NAN NAN NAN NAN NAN NAN 
POLRMT O00411 6 NAN NAN NAN NAN NAN NAN 24.70 NAN 24.93 NAN NAN NAN 
PON2 Q15165 9 25.95 25.70 25.74 26.03 25.39 25.27 24.81 24.75 NAN 24.97 24.44 25.02 
POP1 Q8NE79 32 24.41 25.80 24.89 25.38 25.61 25.53 28.05 27.06 27.45 27.16 27.33 27.01 
POP7 O75817 2 NAN NAN NAN NAN NAN NAN 23.94 23.93 NAN NAN NAN NAN 
POR P16435 18 24.46 26.74 24.67 26.14 26.11 26.27 24.36 25.06 24.26 24.80 25.36 23.40 
POU5F1 Q01860 31 36.23 33.71 36.73 35.54 35.47 35.73 32.06 32.54 30.98 31.81 29.90 31.11 
PPA1 Q15181 5 NAN 23.69 NAN NAN 24.24 23.88 NAN NAN NAN NAN NAN NAN 
PPAN Q9NQ55 15 NAN 22.79 NAN NAN 22.63 NAN 28.10 26.59 27.62 26.55 27.24 25.81 
PPFIA1 Q13136 3 22.56 22.73 NAN 22.67 23.37 23.37 NAN NAN NAN NAN NAN NAN 
PPFIBP1 Q86W92 6 NAN NAN NAN NAN 23.18 22.75 NAN NAN NAN NAN NAN NAN 
PPIC P45877 3 23.50 23.30 23.69 24.02 24.58 24.03 22.68 24.06 23.52 24.22 23.70 24.55 
PPM1A P35813 13 23.67 24.47 24.29 25.99 26.60 26.69 NAN NAN NAN 24.22 23.80 24.62 
PPM1B O75688 14 23.99 28.14 25.00 24.43 25.39 25.99 NAN 22.90 21.50 22.76 NAN 22.81 
PPM1G O15355 19 25.56 24.45 25.41 27.05 27.21 27.96 24.74 25.02 25.14 25.51 24.51 24.77 
PPP1R12A O14974 19 26.16 25.98 26.19 26.28 26.45 26.30 27.99 27.68 27.46 27.89 28.07 27.65 
PPP1R18 Q6NYC8 11 NAN NAN NAN NAN NAN NAN 26.23 25.73 26.44 25.75 25.49 25.77 
PPP2CB P62714 16 NAN NAN NAN NAN 23.35 23.41 NAN NAN NAN NAN NAN NAN 
PPP2R1B P30154 10 NAN NAN NAN NAN 22.67 23.33 NAN NAN NAN NAN NAN NAN 
PPP2R2A P63151 11 25.16 25.59 25.63 26.12 26.36 26.49 24.89 24.83 24.89 24.62 24.30 24.37 
PPP2R5C Q13362 5 NAN NAN NAN NAN 23.51 23.45 NAN NAN NAN NAN NAN NAN 
PPP3CA Q08209 7 22.94 23.08 23.96 25.42 25.69 25.37 NAN 23.07 22.63 23.89 23.06 23.80 
PPP4C P60510 9 24.63 NAN 25.11 26.26 26.20 26.39 NAN NAN NAN 24.95 NAN 24.38 
PPP4R1 Q8TF05 7 24.44 24.71 24.09 23.23 23.81 23.60 23.15 23.66 23.29 21.99 23.16 23.15 
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PPP4R2 Q9NY27 6 24.04 NAN 24.74 25.07 24.90 24.81 NAN NAN NAN NAN NAN NAN 
PPP6C O00743 12 26.59 26.42 27.04 27.08 27.30 27.47 25.74 25.73 25.82 25.32 25.54 25.77 
PPP6R1 Q9UPN7 8 23.22 23.47 23.57 23.93 24.67 24.81 NAN NAN NAN NAN NAN NAN 
PPP6R3 Q5H9R7 15 23.17 23.42 23.79 25.53 25.46 26.86 22.85 24.55 22.96 NAN NAN NAN 
PPT1 P50897 2 NAN NAN NAN NAN 22.59 22.53 NAN NAN NAN NAN NAN NAN 
PRDX4 Q13162 19 29.54 29.41 30.14 30.19 29.80 29.90 27.08 28.02 27.04 28.29 27.70 28.11 
PRDX6 P30041 18 27.01 28.53 26.36 28.06 28.55 28.27 24.96 26.67 26.79 26.16 26.92 27.63 
PRKAA1 Q13131 4 NAN 24.30 23.21 24.18 23.56 23.77 NAN NAN NAN NAN 23.52 23.12 
PRKACA P17612 5 22.70 23.40 23.97 24.54 24.68 24.58 23.54 23.53 23.96 23.79 NAN 24.54 
PRKAR1A P10644 10 24.80 25.72 24.81 24.86 25.41 25.30 24.84 25.09 25.21 24.62 24.83 25.08 
PRKAR1A P10644 8 24.72 25.16 24.51 24.39 25.30 24.93 23.36 24.30 24.27 24.47 NAN 24.52 
PRKCD Q05655 5 NAN 23.83 23.42 23.40 NAN 23.69 NAN NAN NAN NAN NAN NAN 
PRKCI P41743 7 24.46 25.71 23.98 23.88 24.08 24.00 24.22 23.50 23.92 NAN 23.81 24.36 
PRKCSH P14314 23 27.44 27.57 27.78 28.53 28.33 28.30 25.40 26.23 25.81 27.03 26.18 26.78 
PRKD1 Q15139 3 NAN NAN NAN NAN NAN NAN 24.35 22.53 24.51 NAN NAN NAN 
PRKRA O75569 12 23.84 25.13 24.44 22.81 22.86 23.41 28.15 27.55 27.90 26.92 27.64 26.89 
PRMT1 Q99873 22 27.79 27.59 28.05 29.18 29.02 29.09 26.79 27.27 26.99 27.31 27.46 27.52 
PRNP F7VJQ1 2 NAN NAN NAN NAN NAN NAN 23.14 23.47 22.91 NAN NAN NAN 
PROCR Q9UNN8 3 NAN NAN NAN NAN 24.28 23.96 NAN NAN NAN NAN NAN NAN 
PRPF19 Q9UMS4 14 26.36 27.36 26.85 27.59 27.40 27.45 27.08 26.89 26.83 27.01 27.26 26.78 
PRPF4 O43172 17 25.47 25.77 24.85 25.44 25.43 25.32 27.15 26.67 26.92 26.71 26.87 26.15 
PRPF40A O75400 7 NAN NAN NAN NAN NAN NAN 26.34 25.03 25.68 25.08 25.54 24.65 
PRPF4B Q13523 6 NAN NAN NAN NAN NAN NAN NAN 24.37 26.02 NAN NAN NAN 
PRPSAP1 Q14558 10 24.71 25.77 24.41 24.99 25.74 25.67 24.04 25.42 24.45 24.72 24.71 24.96 
PRPSAP2 O60256 12 21.89 26.17 22.69 24.13 25.04 24.73 23.52 24.80 23.52 22.08 NAN 22.30 
PSAP P07602 2 22.89 24.30 NAN 23.04 23.60 23.71 22.41 22.29 23.39 NAN NAN NAN 
PSAT1 Q9Y617 5 NAN 22.49 NAN NAN 24.19 23.42 NAN NAN NAN 22.94 23.09 23.30 
PSMA3 P25788 11 25.49 25.18 25.21 26.07 26.30 26.38 23.37 24.46 23.33 24.82 24.31 24.88 
PSMA5 P28066 9 26.35 27.38 27.62 27.58 27.42 27.53 23.88 25.59 24.61 25.70 25.08 25.59 
PSMA7 O14818 14 27.48 27.71 27.68 28.29 28.11 28.27 24.12 26.75 24.93 26.19 26.05 26.42 
PSMB3 P49720 10 26.20 26.61 26.60 27.19 27.42 27.21 24.31 25.30 24.04 25.57 25.21 25.75 
PSMB8 P28062 2 NAN NAN NAN NAN 23.49 23.53 NAN NAN NAN NAN NAN NAN 
PSMD9 O00233 4 23.71 23.72 23.38 24.25 24.48 24.53 NAN NAN NAN 23.05 NAN 23.26 
PSME2 Q9UL46 5 23.98 NAN 24.03 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
PSME3 P61289 7 24.57 24.74 24.01 24.81 24.70 24.73 24.74 24.42 24.62 24.71 25.35 24.92 
PSMF1 Q92530 2 NAN NAN NAN NAN 22.20 21.97 NAN NAN NAN NAN NAN NAN 
PSPC1 Q8WXF1 3 NAN 25.10 NAN NAN 24.61 24.39 NAN NAN NAN NAN 24.13 24.14 
PTBP1 P26599 26 28.31 29.38 28.83 28.87 28.77 28.49 30.25 30.21 30.40 29.90 30.05 29.82 
PTDSS1 P48651 6 25.84 24.69 25.33 25.06 24.53 24.36 25.99 25.54 25.51 26.14 25.78 25.79 
PTGES2 Q9H7Z7 2 NAN NAN NAN NAN 23.25 23.29 NAN NAN NAN NAN NAN NAN 
PTGES3 Q15185 8 24.85 25.25 23.32 27.31 27.58 27.49 24.43 25.02 24.39 23.71 24.73 24.65 
PTPN1 P18031 7 23.33 24.45 NAN 25.39 25.20 25.43 22.52 22.86 22.15 23.03 23.04 23.43 
PTRH2 Q9Y3E5 6 25.24 26.52 25.37 26.63 26.05 25.81 26.70 26.01 26.03 25.54 26.51 26.43 
PTS Q03393 2 NAN NAN NAN NAN 23.42 23.49 NAN NAN NAN NAN NAN NAN 
PUF60 Q9UHX1 17 21.16 24.01 24.66 25.47 25.74 25.24 28.55 27.99 28.58 27.94 27.71 27.81 
PURB Q96QR8 11 22.51 21.48 22.67 23.26 23.34 23.04 27.25 26.29 26.28 25.89 26.28 25.95 
PVRL2 Q92692 3 NAN NAN NAN NAN 23.54 23.16 NAN NAN NAN NAN NAN NAN 
PWP1 Q13610 14 NAN 24.20 NAN NAN NAN 23.21 28.49 27.52 27.54 26.11 26.20 26.20 
PWP2 Q15269 4 NAN NAN NAN NAN NAN NAN 24.38 23.31 23.99 23.66 23.97 23.39 
PXN P49023 2 NAN NAN NAN NAN NAN NAN 23.44 23.32 23.73 NAN NAN NAN 
PYCR1 P32322 6 24.77 24.40 25.80 25.82 25.68 25.72 24.79 24.72 24.49 25.30 25.39 25.59 
PYCR2 Q96C36 6 23.66 23.50 23.79 24.15 24.06 23.97 23.00 23.40 22.47 NAN NAN NAN 
PYCRL Q53H96 4 23.40 NAN 23.63 23.78 23.47 23.48 NAN NAN NAN NAN NAN NAN 
PYGB P11216 26 25.57 26.28 25.93 28.08 28.20 28.12 22.03 23.57 23.23 24.76 24.05 24.85 
Q9Y6K5 OAS3 4 22.61 NAN 22.93 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
QSOX2 Q6ZRP7 16 26.63 26.07 26.98 26.80 26.36 27.09 23.56 23.51 22.69 23.58 23.40 24.24 
RAB10 P61026 12 25.23 26.37 25.26 25.44 25.74 25.71 24.90 25.57 25.26 25.82 26.01 26.32 
RAB11B Q15907 15 25.30 26.49 25.57 26.91 26.98 26.73 25.11 25.70 25.13 26.70 26.19 26.83 
RAB18 Q9NP72 11 24.36 25.53 25.19 26.63 26.26 26.14 25.47 24.93 24.35 25.01 25.02 25.29 
RAB1A P62820 12 27.01 28.34 25.99 27.41 27.86 27.69 26.04 26.93 26.93 27.23 27.13 27.28 
RAB1B Q9H0U4 12 NAN 25.09 NAN NAN 24.56 24.35 24.26 25.01 24.70 23.76 24.63 24.66 
RAB2 P61019 13 25.43 27.25 25.29 27.22 27.31 27.23 25.36 25.96 25.45 26.79 26.25 26.85 
RAB32 Q13637 8 22.75 25.26 22.89 24.24 24.25 24.36 NAN NAN NAN 24.09 23.82 24.31 
RAB34 P0DI83 8 23.40 23.64 23.57 24.61 24.52 24.80 23.52 23.75 NAN 23.57 NAN 23.67 
RAB35 Q15286 4 25.39 24.39 24.89 23.70 23.48 23.32 22.28 22.80 22.44 23.56 22.57 23.68 
RAB5A P20339 7 22.41 23.41 22.53 23.96 24.13 23.95 NAN NAN NAN NAN NAN NAN 
RAB5B P61020 7 NAN 23.59 22.35 24.39 24.02 24.53 23.83 23.04 23.13 23.39 23.82 23.77 
RAB5C P51148 10 26.36 27.12 26.59 27.59 27.46 27.61 26.18 26.87 26.40 27.09 26.60 27.12 
RAB6A P20340 7 NAN 26.68 24.98 27.80 27.75 27.50 25.27 25.52 25.35 26.06 25.48 26.24 
RAB7A P51149 15 25.90 27.82 25.72 27.85 27.61 27.51 25.92 26.60 25.73 27.13 26.73 27.28 
RABL3 Q5HYI8 3 NAN NAN NAN NAN NAN NAN 22.82 NAN 22.43 NAN NAN NAN 
RAC2 P15153 7 22.27 22.43 NAN 24.52 24.47 24.58 22.16 22.47 22.35 22.08 21.91 22.39 
RAD23B P54727 3 NAN 24.24 NAN NAN 24.10 23.95 NAN NAN NAN NAN 22.60 22.71 
RAE1 P78406 4 NAN NAN NAN NAN 23.04 22.93 24.35 23.14 23.40 NAN NAN NAN 
RALA P11233 7 23.15 24.79 24.16 25.91 25.78 25.97 24.07 24.30 24.21 24.44 23.65 24.32 
RAN P62826 12 26.35 26.56 26.99 27.66 27.74 27.66 25.25 26.45 26.12 26.67 26.52 27.13 
RANBP1 P43487 6 NAN 25.30 24.47 25.27 25.14 25.23 23.04 23.79 23.74 NAN NAN NAN 
RANBP2 P49792 22 25.61 26.44 25.93 27.05 26.78 27.04 26.89 25.86 25.79 26.00 26.87 26.16 
RANBP3 Q9H6Z4 2 NAN NAN NAN NAN 22.48 22.58 NAN NAN NAN NAN NAN NAN 
RANGAP1 P46060 21 25.21 26.15 26.20 27.23 26.94 27.84 24.38 25.36 25.04 24.37 25.32 26.12 
RAP1A P62834 13 NAN NAN 23.44 24.17 NAN NAN NAN NAN NAN NAN NAN NAN 
RAP1B P61224 14 27.09 27.46 27.24 28.09 28.06 28.06 26.67 27.13 26.59 27.67 27.27 27.63 
RAP1GDS1 P52306 9 24.79 25.93 24.83 23.50 24.12 24.83 NAN NAN NAN NAN NAN NAN 
RAP2C Q9Y3L5 4 NAN 23.99 NAN NAN 23.02 21.96 NAN NAN NAN NAN NAN NAN 
RB1 P06400 2 NAN NAN NAN NAN NAN NAN 22.80 22.60 22.90 22.51 22.52 22.80 
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RBBP4 Q09028 20 28.51 27.07 28.47 29.27 28.99 29.14 27.23 27.42 27.03 28.01 27.33 27.70 
RBBP5 Q15291 3 NAN NAN NAN NAN 23.09 23.52 NAN NAN NAN NAN NAN NAN 
RBBP7 Q16576 19 27.63 26.38 27.74 28.58 28.18 28.48 23.68 25.48 26.04 25.27 26.17 NAN 
RBM14 Q96PK6 12 23.37 23.54 23.58 24.72 25.09 25.12 25.01 24.16 24.24 24.75 24.65 24.09 
RBM15 Q96T37 2 NAN NAN NAN NAN NAN NAN 23.52 23.08 24.29 NAN 23.35 22.77 
RBM19 Q9Y4C8 12 NAN 21.82 NAN NAN 22.14 22.20 27.10 25.49 26.91 25.62 26.31 25.09 
RBM25 P49756 8 NAN 24.02 23.84 25.05 24.30 24.48 25.14 24.65 24.86 24.77 24.75 24.26 
RBM28 Q9NW13 20 NAN 22.87 NAN NAN 22.10 NAN 28.03 26.29 26.63 25.92 27.16 24.89 
RBM34 P42696 15 NAN NAN NAN NAN NAN NAN 26.56 25.35 26.22 25.93 26.02 25.28 
RBM39 Q14498 18 23.61 26.36 25.02 25.27 25.49 25.32 28.05 27.53 27.82 27.65 27.90 27.23 
RBMS1 P29558 3 NAN NAN NAN NAN NAN NAN 23.00 NAN 22.94 NAN NAN NAN 
RCC1 P18754 3 NAN 22.03 NAN NAN 23.75 23.36 NAN NAN NAN NAN NAN NAN 
RCL1 Q9Y2P8 11 24.26 23.95 24.59 25.84 25.83 25.93 25.98 25.30 25.32 25.97 25.57 24.93 
RCN1 Q15293 17 26.43 28.49 27.63 28.71 27.65 28.24 23.37 23.60 24.34 24.89 26.07 26.01 
RCN3 Q96D15 14 26.87 27.82 27.44 29.18 28.30 28.42 22.41 25.63 24.99 25.54 25.93 26.43 
RCOR1 Q9UKL0 2 NAN NAN NAN NAN 23.30 23.44 NAN NAN NAN NAN NAN NAN 
RDH11 Q8TC12 5 23.31 24.54 23.22 23.73 24.13 23.64 NAN NAN NAN 23.60 23.38 23.67 
RDH13 Q8NBN7 7 NAN 23.57 22.53 23.40 22.56 23.34 NAN 22.65 22.22 NAN NAN NAN 
RETSAT Q6NUM9 9 24.38 24.63 24.15 25.20 25.13 25.11 23.91 23.61 24.15 23.99 24.18 24.00 
REXO2 Q9Y3B8 2 NAN NAN NAN NAN NAN NAN NAN 22.73 22.26 NAN 22.89 22.86 
REXO4 Q9GZR2 3 NAN NAN NAN NAN NAN NAN 23.38 22.80 22.70 22.73 23.52 NAN 
RFC1 P35251 10 NAN NAN NAN NAN NAN NAN 25.98 25.70 25.65 25.02 24.51 24.23 
RFC2 P35250 7 NAN NAN NAN NAN 23.43 23.51 24.76 24.36 25.15 NAN 23.89 24.21 
RFC3 P40938 9 NAN 24.20 23.21 24.62 24.46 24.13 26.17 25.24 26.40 24.58 24.79 23.98 
RFC4 P35249 5 NAN NAN NAN NAN NAN NAN 24.72 24.63 24.59 23.86 24.57 23.56 
RFC5 P40937 10 NAN 24.01 NAN NAN 23.77 23.70 26.57 25.70 26.95 23.88 25.29 25.06 
RHOA P61586 9 NAN NAN NAN NAN 24.19 24.06 22.58 22.50 22.43 NAN NAN NAN 
RHOT1 Q8IXI2 4 21.65 22.12 NAN 22.95 23.44 23.84 21.54 NAN 21.67 NAN NAN NAN 
RHOT2 Q8IXI1 5 NAN 24.49 NAN NAN 23.02 23.50 23.30 22.68 23.65 22.87 22.62 23.48 
RIC8A Q9NPQ8 6 23.28 24.24 NAN 23.12 23.50 23.89 NAN NAN NAN NAN 23.37 23.11 
RILPL1 Q5EBL4 4 NAN NAN NAN NAN 23.01 23.17 NAN NAN NAN NAN NAN NAN 
RIOK1 Q9BRS2 19 27.06 26.51 27.00 26.36 26.34 26.65 24.83 26.32 24.93 24.32 25.27 24.31 
RIOX1 Q9H6W3 5 NAN NAN NAN NAN NAN NAN 24.48 23.87 24.46 23.84 24.32 23.45 
RIOX2 Q8IUF8 4 NAN NAN NAN NAN NAN NAN 23.72 23.54 23.47 NAN NAN NAN 
RNF213 Q63HN8 13 23.55 NAN NAN 23.12 23.21 23.22 NAN NAN NAN NAN NAN NAN 
RNH1 O60930 30 29.46 28.85 29.99 29.93 30.21 30.35 27.92 28.54 28.31 28.54 28.33 28.69 
RNMTL1 Q9HC36 5 NAN NAN NAN NAN 23.05 23.11 26.96 25.07 26.09 24.18 24.93 24.49 
RP2 O75695 3 NAN NAN 23.32 24.11 24.12 24.22 NAN NAN NAN NAN NAN NAN 
RPA2 P15927 3 23.65 NAN 22.66 25.17 24.56 24.95 NAN NAN NAN NAN NAN NAN 
RPAP3 Q9H6T3 4 NAN NAN NAN NAN 24.08 23.71 NAN NAN NAN NAN NAN NAN 
RPF2 Q9H7B2 15 NAN NAN 23.73 23.14 NAN NAN 27.42 25.82 26.07 25.61 27.30 26.25 
RPL10 P27635 18 26.80 27.89 27.97 26.48 27.37 26.94 31.52 31.62 31.76 30.64 30.78 30.42 
RPL10A P62906 23 26.20 27.78 27.63 26.85 27.62 27.40 31.20 31.36 31.76 30.67 31.10 30.55 
RPL11 P62913 19 25.99 28.21 27.97 26.44 27.45 27.44 31.21 30.98 31.34 29.72 30.51 29.67 
RPL12 P30050 14 27.45 28.97 29.04 27.98 28.75 28.39 31.97 31.80 32.08 31.29 31.76 31.39 
RPL13 P26373 24 25.74 27.11 27.63 26.27 27.24 26.86 31.44 31.42 31.66 31.37 31.37 31.07 
RPL13A P40429 20 26.19 27.52 27.73 25.94 27.13 26.81 31.32 31.25 31.20 31.02 30.85 30.57 
RPL14 P50914 10 26.59 27.98 28.26 26.59 27.58 27.06 32.08 31.80 32.05 31.38 31.63 31.17 
RPL15 P61313 17 26.86 27.51 28.19 25.82 27.25 26.66 31.40 30.99 31.20 30.93 30.98 30.52 
RPL17 P18621 19 26.91 29.04 28.76 26.23 27.96 27.09 31.94 31.87 31.90 30.59 31.44 31.07 
RPL18 Q07020 12 26.68 28.03 28.13 26.46 28.08 27.22 32.23 31.78 32.03 31.55 31.82 31.22 
RPL18A Q02543 17 26.06 27.52 27.46 25.19 27.44 26.78 31.23 30.82 31.20 30.32 30.96 29.94 
RPL19 P84098 16 24.70 26.63 26.33 25.91 26.49 26.03 30.23 29.97 30.24 29.80 29.78 29.27 
RPL21 P46778 15 24.98 27.51 26.39 25.67 26.50 25.87 30.76 30.70 31.07 29.81 30.16 29.37 
RPL22 P35268 10 25.46 26.59 26.97 26.44 27.08 26.51 30.65 30.59 30.89 29.95 30.23 29.87 
RPL22L1 Q6P5R6 6 NAN 25.50 NAN NAN 24.12 NAN 27.25 26.78 27.31 25.54 25.86 25.37 
RPL23 P62829 12 27.48 29.16 28.48 27.61 28.03 27.70 31.52 31.71 31.87 30.91 31.28 30.72 
RPL23A P62750 19 27.22 27.00 28.45 27.48 27.67 27.02 30.43 30.37 30.63 30.43 29.90 30.02 
RPL24 P83731 17 26.36 27.73 27.73 26.93 27.55 27.20 31.19 31.23 31.49 30.92 31.11 30.57 
RPL26 P61254 17 23.18 26.17 25.65 24.36 24.76 24.57 30.29 30.65 30.24 29.42 29.43 28.93 
RPL27 P61353 14 25.95 27.44 27.40 26.70 27.60 27.08 31.70 31.16 31.51 30.51 31.29 30.14 
RPL27A P46776 11 26.81 27.99 28.12 25.94 28.33 27.73 31.38 31.28 31.33 30.50 31.11 30.53 
RPL28 P46779 17 24.69 25.95 26.70 24.06 25.91 25.22 30.53 30.28 30.35 29.85 30.03 29.48 
RPL3 P39023 39 27.49 28.83 28.92 27.18 28.47 27.96 32.81 32.35 32.71 32.02 32.03 31.72 
RPL30 P62888 10 26.11 27.16 27.40 26.17 27.30 26.79 31.86 31.30 31.67 30.74 31.12 30.58 
RPL31 P62899 13 24.92 26.35 26.40 23.96 26.07 24.60 30.35 30.07 30.02 29.55 29.95 29.68 
RPL32 P62910 14 25.02 27.51 26.28 25.19 25.96 24.91 31.09 30.33 31.21 28.75 29.08 29.11 
RPL34 P49207 10 24.95 25.52 25.60 24.11 25.75 24.93 29.72 29.58 29.78 29.33 29.52 29.12 
RPL35 P42766 9 24.40 26.57 25.66 24.80 26.28 25.36 30.58 30.43 30.51 29.08 30.42 29.65 
RPL35A P18077 14 24.27 25.36 24.99 23.05 24.95 24.16 29.29 29.41 29.44 28.91 29.12 28.54 
RPL36 Q9Y3U8 7 24.33 25.56 26.21 23.44 24.87 24.21 29.71 29.60 30.23 28.23 28.89 28.24 
RPL36AL Q969Q0 12 NAN NAN NAN NAN NAN NAN 24.88 25.15 25.21 24.53 25.02 24.42 
RPL37 P61927 4 NAN NAN NAN NAN NAN NAN 23.42 25.28 25.51 25.37 24.83 25.74 
RPL37A P61513 6 23.19 25.22 24.68 22.17 24.68 23.82 28.45 28.46 28.43 27.69 27.87 26.90 
RPL38 P63173 7 24.76 28.13 26.49 25.20 26.02 25.59 29.41 29.85 29.91 29.35 29.76 29.24 
RPL4 P36578 40 28.28 30.12 29.84 27.85 29.41 28.79 33.85 33.37 33.80 33.01 33.45 32.69 
RPL5 P46777 30 26.80 28.40 28.40 26.91 28.16 27.67 32.56 32.23 32.44 31.73 31.92 31.19 
RPL6 Q02878 25 27.71 29.20 29.51 27.26 28.84 28.21 33.26 32.82 32.99 32.78 32.99 32.36 
RPL7 P18124 25 27.58 28.77 29.43 27.74 28.66 28.31 33.30 32.87 33.19 32.89 32.91 32.36 
RPL7A P62424 28 27.25 28.62 28.67 27.52 28.66 28.10 32.89 32.38 32.68 31.98 32.52 31.85 
RPL7L1 Q6DKI1 4 NAN NAN NAN NAN NAN NAN 24.94 24.04 24.53 24.03 24.80 23.61 
RPL8 P62917 23 26.95 27.90 28.56 25.93 27.65 26.91 32.21 31.99 32.09 31.20 31.50 31.27 
RPL9 P32969 19 26.82 28.50 28.13 27.56 28.40 28.00 32.15 32.13 32.20 31.27 31.80 31.32 
RPLP0 P05388 22 28.36 29.29 29.69 28.95 29.77 29.45 33.34 32.99 33.29 32.48 33.09 32.55 
RPLP1 P05386 7 24.19 28.14 27.65 26.71 27.54 26.84 32.06 32.23 32.52 30.85 32.31 31.47 
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RPLP2 P05387 11 25.05 27.58 27.12 26.72 27.27 26.32 31.62 31.04 32.07 30.06 30.92 30.62 
RPP14 O95059 2 NAN NAN NAN NAN NAN NAN 22.96 22.70 23.86 22.67 24.72 23.00 
RPP40 O75818 4 NAN 24.79 NAN NAN NAN 23.15 25.28 23.94 25.63 23.18 25.05 23.93 
RPS10 P46783 20 27.37 28.38 29.05 27.05 27.81 27.39 31.71 31.20 31.51 30.94 31.42 30.81 
RPS11 P62280 20 27.52 27.71 28.54 26.84 27.62 27.07 31.66 31.46 31.82 31.18 31.41 30.89 
RPS12 P25398 14 26.80 28.04 28.09 27.51 27.86 27.59 31.28 30.93 31.25 30.39 30.78 29.89 
RPS13 P62277 16 27.24 28.39 28.93 27.06 27.96 27.82 32.62 32.45 32.69 31.94 32.29 31.60 
RPS14 P62263 13 26.68 28.06 28.06 27.05 27.66 27.10 30.91 30.90 31.09 30.21 30.82 30.22 
RPS15A P62244 15 26.24 27.76 27.73 26.72 27.81 27.43 31.18 31.09 31.51 30.30 31.31 30.32 
RPS16 P62249 21 26.78 28.36 28.48 27.49 28.14 27.67 32.10 31.85 32.08 31.62 31.68 31.31 
RPS17 P08708 15 26.10 28.06 27.95 26.05 27.49 27.04 31.50 31.07 31.76 30.18 30.43 30.10 
RPS18 P62269 23 26.79 28.85 28.63 27.66 28.40 27.98 31.82 32.00 32.06 31.62 31.90 31.34 
RPS19 P39019 20 26.20 27.29 28.09 27.09 27.60 27.23 31.38 31.21 31.46 31.00 31.19 30.77 
RPS2 P15880 20 27.40 28.64 29.28 27.55 28.41 27.99 32.12 31.88 32.03 31.62 32.04 31.39 
RPS20 P60866 9 25.79 27.06 27.58 26.03 26.56 26.39 30.35 30.32 30.81 30.10 30.40 29.78 
RPS21 P63220 7 NAN 24.31 24.72 24.57 24.94 24.71 28.20 28.24 28.40 26.53 27.55 26.53 
RPS23 P62266 11 26.31 27.15 27.84 25.55 26.56 25.84 30.42 30.38 30.39 30.26 30.18 29.81 
RPS24 P62847 6 25.38 27.43 27.24 25.25 26.04 25.22 30.50 30.40 30.45 29.18 29.54 29.16 
RPS25 P62851 11 26.10 27.50 27.97 26.86 27.75 27.24 30.78 30.89 30.88 30.79 30.85 30.39 
RPS26 P62854 6 25.92 26.89 27.05 25.27 26.40 25.60 30.07 29.70 29.99 29.56 29.80 29.23 
RPS27 P42677 7 25.14 26.51 25.69 24.97 25.68 24.94 28.88 28.82 28.78 28.47 28.68 28.06 
RPS27L Q71UM5 6 22.28 25.13 NAN 24.12 24.23 23.90 26.62 25.65 26.18 25.45 26.15 25.19 
RPS28 P62857 8 NAN 24.91 24.93 24.57 25.67 27.06 29.37 29.20 29.98 26.91 27.86 27.19 
RPS29 P62273 4 21.73 24.24 23.49 22.46 22.86 21.70 26.59 26.52 26.71 25.63 25.85 25.42 
RPS3 P23396 30 28.04 29.95 29.77 28.95 29.43 29.00 32.89 32.60 32.85 32.52 32.53 32.08 
RPS3A P61247 34 27.64 29.20 29.26 27.92 28.80 28.25 32.86 32.67 32.84 32.06 32.28 31.79 
RPS4X P62701 33 27.92 29.46 29.47 28.30 28.87 28.44 32.76 32.23 32.67 31.84 32.17 31.62 
RPS4Y1 P22090 27 26.31 26.67 26.25 23.64 24.60 22.90 30.46 29.82 30.30 28.75 30.03 28.63 
RPS5 P46782 20 28.31 29.15 30.14 27.92 29.00 28.57 32.63 32.73 32.83 32.58 32.68 32.29 
RPS6 P62753 24 26.68 28.71 27.86 26.97 27.62 27.13 31.41 31.35 31.59 30.73 31.21 30.39 
RPS7 P62081 19 29.02 29.95 30.30 28.17 29.39 28.67 33.75 32.85 33.78 32.18 32.84 32.34 
RPS8 P62241 25 27.49 29.31 28.93 27.94 29.34 28.67 33.07 32.60 32.91 32.60 32.90 32.19 
RPS9 P46781 27 27.27 28.76 28.74 27.74 28.43 27.95 32.22 31.93 32.14 31.80 31.98 31.35 
RPSA P08865 23 28.45 30.46 30.34 29.42 29.88 29.49 34.00 33.60 33.95 32.80 33.74 33.02 
RQCD1 Q92600 6 NAN NAN NAN NAN NAN NAN 24.02 23.77 24.98 24.93 24.62 24.78 
RRAGA Q7L523 5 22.47 24.34 24.38 23.90 23.78 24.05 NAN NAN NAN 22.85 23.76 23.01 
RRAGC Q9HB90 3 NAN 23.35 NAN NAN 24.39 24.14 NAN NAN NAN 23.99 23.73 23.95 
RRM1 P23921 6 NAN 24.39 NAN NAN 23.42 24.22 NAN 23.45 23.23 NAN 23.54 23.45 
RRP1 P56182 6 NAN 22.20 NAN NAN 22.72 22.55 24.53 23.51 24.08 23.77 24.27 23.33 
RRP12 Q5JTH9 48 24.19 27.73 25.65 25.78 26.28 25.87 29.00 28.29 28.75 28.25 28.78 27.83 
RRP15 Q9Y3B9 4 NAN NAN NAN NAN NAN NAN 24.52 23.96 24.16 24.02 24.43 NAN 
RRP1B Q14684 11 NAN NAN NAN NAN NAN NAN 25.63 24.37 24.43 24.85 25.41 24.49 
RRP7A Q9Y3A4 11 NAN NAN NAN NAN NAN NAN 27.04 26.47 27.46 26.63 26.47 25.46 
RRP8 O43159 7 NAN NAN NAN NAN NAN NAN 25.95 25.27 25.66 25.28 26.00 24.88 
RRP9 O43818 12 NAN 25.36 NAN NAN 24.86 24.16 25.71 25.77 26.15 25.57 25.79 25.88 
RRS1 Q15050 12 NAN NAN NAN NAN NAN NAN 27.18 25.68 26.60 25.74 27.15 25.08 
RSL1D1 O76021 34 NAN 26.39 25.04 23.32 26.10 24.37 30.76 29.91 30.21 29.65 30.09 29.30 
RSL24D1 Q9UHA3 2 NAN NAN NAN NAN NAN NAN NAN 23.14 22.77 NAN NAN NAN 
RSU1 Q15404 12 24.77 27.72 26.26 26.11 26.29 26.06 25.04 25.82 26.55 24.58 25.33 26.50 
RTCA O00442 6 NAN NAN NAN NAN NAN NAN 24.73 23.87 24.83 24.44 25.15 24.46 
RTCB Q9Y3I0 28 26.96 28.10 27.42 27.91 27.91 27.56 29.76 29.25 29.70 28.56 29.09 28.69 
RTN3 O95197 4 24.20 NAN NAN 25.22 24.31 24.79 NAN NAN NAN NAN NAN NAN 
RUVBL1 Q9Y265 26 29.09 29.04 29.31 29.65 29.46 29.68 28.03 28.17 27.60 28.27 28.29 28.11 
RUVBL2 Q9Y230 30 28.31 28.17 28.73 29.02 28.84 29.02 26.83 27.26 26.90 27.31 27.10 27.34 
S100A13 Q99584 3 NAN NAN NAN NAN NAN NAN 24.06 25.40 25.25 NAN 25.29 24.31 
S100A4 P26447 6 23.98 25.16 24.59 27.12 27.78 25.12 25.88 26.41 26.30 NAN NAN NAN 
S100A6 P06703 4 26.72 27.85 28.14 27.88 27.99 27.52 27.09 27.63 27.71 26.84 26.98 28.16 
SACS Q9NZJ4 3 NAN NAN NAN NAN NAN NAN 20.86 20.97 22.54 NAN NAN NAN 
SAE1 Q9UBE0 4 NAN 24.81 NAN NAN 23.29 23.14 NAN NAN NAN 22.06 22.29 22.21 
SAMHD1 Q9Y3Z3 7 24.52 24.26 24.33 NAN 23.13 23.35 NAN NAN NAN NAN NAN NAN 
SAMM50 Q9Y512 14 NAN NAN NAN NAN NAN NAN 26.54 25.38 26.34 26.37 26.62 26.12 
SAR1A Q9NR31 9 25.03 27.17 24.56 NAN 23.52 24.19 24.99 25.83 26.48 24.51 24.78 NAN 
SARS P49591 12 23.93 24.98 23.74 25.29 25.79 25.28 22.76 24.52 24.04 24.09 24.27 25.27 
SART1 O43290 2 NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.18 23.85 NAN 
SBDS Q9Y3A5 7 24.30 24.56 24.03 24.18 24.14 23.79 NAN 23.55 24.36 NAN NAN NAN 
SCAMP3 O14828 2 22.77 NAN NAN 24.74 23.70 23.95 NAN NAN NAN NAN NAN NAN 
SCCPDH Q8NBX0 9 25.40 25.32 25.59 26.66 26.45 26.43 24.46 24.35 24.78 24.68 24.60 24.51 
SCO2 O43819 4 NAN NAN NAN NAN 23.85 24.50 NAN NAN NAN NAN NAN NAN 
SCUBE3 Q8IX30 2 NAN NAN NAN NAN NAN NAN 21.10 20.79 20.98 NAN NAN NAN 
SCYL1 Q96KG9 4 NAN NAN NAN NAN 22.72 22.87 NAN NAN NAN NAN NAN NAN 
SDAD1 Q9NVU7 19 NAN NAN NAN NAN NAN NAN 26.69 26.48 27.23 25.00 26.69 25.21 
SDC4 P31431 3 NAN NAN NAN NAN NAN NAN 22.29 21.45 21.64 21.80 NAN 21.24 
SDF4 Q9BRK5 11 25.37 26.03 25.29 26.35 26.17 26.21 23.82 24.42 23.88 24.86 NAN 24.70 
SDHA P31040 19 26.85 26.67 27.55 27.59 27.22 27.21 24.86 25.16 25.96 26.09 25.07 25.62 
SEC16A O15027 8 24.88 25.90 NAN 24.52 24.19 24.54 25.33 24.41 25.46 23.91 23.75 24.37 
SEC23IP Q9Y6Y8 12 25.36 25.98 25.42 26.18 26.18 26.59 25.07 25.27 24.69 25.36 24.55 24.36 
SEC24A O95486 3 21.74 22.90 23.29 21.69 22.44 22.11 21.33 21.13 22.02 21.30 21.55 21.79 
SEC24B O95487 4 NAN 22.53 NAN NAN 23.08 NAN 23.10 22.64 22.58 22.33 22.38 22.72 
SEC24C P53992 8 23.86 24.03 23.57 23.56 24.00 23.84 23.46 23.55 23.70 24.11 24.16 23.87 
SEC24D O94855 3 NAN NAN NAN NAN 23.94 23.92 NAN NAN NAN NAN NAN NAN 
SEC61A2 Q9H9S3 11 NAN NAN NAN NAN NAN NAN NAN 22.20 23.27 21.97 22.02 22.36 
SEL1L Q9UBV2 19 27.29 26.20 26.89 27.57 26.83 27.16 23.00 25.24 23.54 25.19 NAN 26.14 
SEMA3C Q99985 2 NAN NAN NAN NAN NAN NAN 22.58 22.06 22.30 NAN NAN NAN 
SEMA7A O75326 10 NAN NAN NAN NAN NAN NAN 25.37 25.57 25.37 25.42 25.65 25.50 
SERBP1 Q8NC51 22 25.61 27.25 28.34 25.91 26.84 26.73 30.02 30.17 29.83 29.75 29.72 29.57 
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SERPINB1 P30740 9 24.33 NAN 24.69 24.89 25.27 24.95 23.57 23.32 24.06 23.81 24.07 24.31 
SET Q01105 10 28.11 26.60 28.62 28.85 28.83 28.82 26.34 26.25 26.51 27.55 26.89 27.11 
SETD3 Q86TU7 3 NAN NAN NAN NAN NAN NAN NAN NAN NAN NAN 22.90 24.21 
SF1 Q13285 7 23.98 25.40 23.99 24.23 23.90 NAN 23.81 23.46 23.97 NAN NAN NAN 
SF3A1 Q15459 12 24.50 25.75 24.23 26.04 25.64 25.69 24.59 24.00 24.11 24.75 22.95 24.52 
SF3A3 Q12874 16 24.24 25.85 24.22 25.51 25.57 25.25 24.53 24.35 23.71 24.67 24.89 24.86 
SF3B2 Q13435 18 23.80 24.61 24.68 25.71 25.15 25.49 25.95 25.38 26.00 25.15 25.48 24.36 
SFPQ P23246 16 27.21 27.84 27.17 28.22 27.67 27.39 26.84 26.83 26.59 27.26 26.78 26.73 
SFRS11 Q05519 5 NAN 23.61 NAN NAN 24.00 24.20 25.95 25.35 25.60 26.12 24.94 25.59 
SFRS3 P84103 7 NAN 25.56 NAN NAN 24.42 23.74 27.74 27.28 27.96 27.73 27.96 27.45 
SFRS4 Q08170 5 NAN NAN NAN NAN NAN NAN 22.52 22.14 22.17 NAN NAN NAN 
SFXN1 Q9H9B4 8 24.52 25.07 24.85 25.70 25.29 25.21 23.41 24.65 24.04 24.27 23.73 25.17 
SFXN3 Q9BWM7 13 26.80 25.49 27.22 27.17 26.34 26.66 24.26 24.71 24.79 23.76 24.54 24.17 
SFXN4 Q6P4A7 2 NAN NAN NAN NAN 22.98 23.04 NAN NAN NAN NAN NAN NAN 
SGCE O43556 2 NAN NAN NAN NAN NAN NAN 20.28 20.53 20.55 NAN NAN NAN 
SGPL1 O95470 5 NAN NAN NAN NAN 23.20 23.02 23.26 NAN 23.18 NAN NAN NAN 
SH3BP4 Q9P0V3 5 NAN NAN NAN NAN NAN NAN 22.79 22.43 22.85 22.49 22.50 22.17 
SHCBP1 Q8NEM2 5 NAN 22.88 NAN NAN 22.76 23.20 NAN NAN NAN NAN NAN NAN 
SHMT2 P34897 21 25.11 26.87 25.13 27.83 27.65 27.69 27.00 27.50 26.96 26.41 26.81 27.45 
SHOC2 Q9UQ13 5 NAN NAN NAN NAN 22.86 22.84 22.36 22.65 22.75 NAN 22.71 23.11 
SIGMAR1 Q99720 4 23.11 22.95 24.08 25.45 25.00 24.02 NAN NAN NAN NAN NAN NAN 
SIPA1L1 O43166 9 NAN NAN NAN NAN NAN NAN 24.95 24.47 25.00 NAN NAN NAN 
SIRT1 Q96EB6 12 25.79 24.68 26.01 26.01 25.71 26.56 NAN NAN NAN NAN NAN NAN 
SKIV2L Q15477 35 23.81 26.06 22.68 21.77 22.72 22.22 28.65 28.40 28.48 27.31 28.13 27.74 
SLAIN2 Q9P270 6 24.50 24.19 25.68 26.02 26.30 26.05 23.93 23.36 23.79 23.66 NAN 23.64 
SLAIN2 Q9P270 6 23.37 24.47 23.79 25.90 26.23 25.92 NAN NAN NAN 23.53 NAN 23.96 
SLC16A1 P53985 7 27.47 26.30 28.35 26.06 25.11 25.59 24.41 24.23 24.03 24.77 24.95 24.49 
SLC16A7 O60669 3 22.62 NAN 23.77 21.81 21.96 21.77 NAN NAN NAN NAN NAN NAN 
SLC1A4 P43007 4 24.27 NAN 25.11 24.07 24.24 24.47 NAN NAN NAN NAN NAN NAN 
SLC1A5 Q15758 16 28.98 28.60 29.29 29.55 29.30 29.55 26.46 26.66 26.83 27.94 26.87 27.62 
SLC25A11 Q02978 16 28.02 27.11 28.49 28.30 28.04 28.19 26.43 26.70 26.76 27.13 26.89 27.11 
SLC25A12 O75746 23 27.11 25.41 27.48 27.05 25.76 26.84 22.74 23.11 20.90 24.32 22.50 23.58 
SLC25A13 Q9UJS0 28 28.32 27.08 28.25 28.36 27.67 28.10 24.77 25.65 25.13 25.85 25.54 25.67 
SLC25A20 O43772 7 23.26 23.12 23.87 24.47 23.98 23.71 NAN 23.06 22.95 NAN NAN NAN 
SLC25A22 Q9H936 17 26.98 27.44 26.89 28.99 28.47 28.77 25.68 24.84 25.10 24.93 24.40 25.24 
SLC25A24 Q6NUK1 10 NAN 26.58 23.91 24.94 24.51 24.50 23.54 24.63 24.49 23.58 23.56 24.61 
SLC25A3 Q00325 18 30.25 29.51 30.78 30.49 30.15 30.37 28.94 29.27 29.49 28.74 28.53 29.02 
SLC25A4 P12235 21 26.06 25.83 26.70 26.45 25.82 25.86 23.77 23.67 23.89 24.44 24.40 25.05 
SLC25A5 P05141 24 28.82 28.12 28.97 29.13 28.63 28.91 26.67 27.33 27.14 27.65 27.26 27.56 
SLC25A6 P12236 25 31.01 29.84 31.46 31.24 30.80 31.23 29.60 29.64 29.69 30.10 29.65 29.93 
SLC27A3 Q5K4L6 2 NAN 23.64 NAN NAN 22.30 22.33 NAN NAN NAN NAN 21.95 21.99 
SLC27A4 Q6P1M0 8 24.21 24.83 24.67 25.21 24.72 25.14 22.97 23.11 NAN 23.85 23.77 23.04 
SLC30A1 Q9Y6M5 2 NAN 22.94 NAN NAN 22.82 NAN NAN NAN NAN NAN NAN NAN 
SLC30A7 Q8NEW0 3 24.59 24.65 25.31 25.47 25.35 25.25 23.46 23.66 23.02 NAN NAN NAN 
SLC33A1 O00400 4 23.41 NAN 23.58 23.68 23.50 23.90 NAN NAN NAN NAN NAN NAN 
SLC38A5 Q8WUX1 3 23.44 23.25 23.21 24.04 23.38 23.65 NAN NAN NAN NAN NAN NAN 
SLC39A14 Q15043 3 24.01 24.18 25.14 25.26 24.61 24.64 NAN NAN NAN 23.99 NAN 24.35 
SLC3A2 P08195 27 29.20 29.07 29.51 29.38 29.03 29.27 26.93 26.83 26.79 27.92 27.77 28.01 
SLC4A1AP Q9BWU0 4 NAN NAN 25.22 24.82 24.38 24.85 23.35 23.20 NAN 23.33 NAN 23.55 
SLC7A1 P30825 3 24.38 24.80 25.10 24.78 24.57 24.70 NAN 23.44 24.26 NAN 23.63 23.74 
SLC7A5 Q01650 6 25.38 24.79 25.55 25.98 25.59 25.65 NAN NAN NAN 23.22 NAN 24.35 
SLC9A3R2 Q15599 6 NAN NAN NAN NAN 23.84 23.81 NAN NAN NAN NAN NAN NAN 
SLIRP Q9GZT3 7 22.38 27.13 22.83 26.04 25.97 24.37 NAN NAN NAN 22.93 NAN 22.69 
SLIT2 O94813 2 NAN NAN NAN NAN NAN NAN 25.12 NAN 24.51 NAN NAN NAN 
SMBP Q9HD45 9 26.76 25.79 27.34 27.19 26.89 26.84 24.99 24.97 24.77 25.96 25.58 25.52 
SMC1A Q14683 17 24.23 24.61 NAN 26.01 25.31 24.60 23.85 NAN 23.29 22.54 NAN 23.07 
SMC2 O95347 8 NAN 24.85 NAN NAN 24.05 24.50 NAN 23.43 23.88 NAN NAN NAN 
SMEK1 Q6IN85 24 26.32 23.96 26.10 27.34 27.04 27.63 24.38 25.37 24.45 25.73 24.70 25.33 
SMN1 Q16637 3 NAN NAN NAN NAN NAN NAN NAN NAN NAN 23.38 23.97 NAN 
SMTN P53814 4 NAN NAN NAN NAN NAN NAN 24.13 23.56 24.58 23.12 23.28 23.12 
SMU1 Q2TAY7 7 NAN 22.17 22.49 23.74 23.13 23.12 22.86 22.90 22.75 23.36 23.37 23.23 
SND1 Q7KZF4 82 28.57 29.74 28.97 29.78 30.02 29.78 32.44 32.18 32.29 31.99 32.24 31.88 
SNRPC P09234 3 NAN NAN NAN NAN NAN NAN 23.90 23.14 24.23 NAN NAN NAN 
SNRPE P62304 5 25.88 27.21 25.27 25.10 25.34 25.05 26.58 26.62 26.96 25.37 25.73 25.29 
SNRPF P62306 3 NAN 25.43 23.92 24.84 24.45 25.11 26.43 26.78 26.60 NAN 24.95 24.82 
SNRPG P62308 3 23.07 25.07 23.13 NAN 23.43 NAN 26.12 25.56 26.40 24.42 NAN 24.92 
SNX1 Q13596 2 22.26 NAN NAN 23.36 23.32 23.90 NAN NAN NAN NAN NAN NAN 
SNX6 Q9UNH7 6 23.75 23.65 22.91 NAN 23.62 23.68 22.80 NAN 23.55 NAN 24.10 24.00 
SOAT1 P35610 10 24.76 24.41 24.67 24.35 23.21 23.59 26.36 25.95 26.58 25.69 26.63 26.01 
SOD2 P04179 2 NAN NAN NAN NAN 23.17 22.78 NAN NAN NAN NAN NAN NAN 
SOGA1 O94964 5 NAN NAN NAN NAN 23.61 23.23 NAN NAN NAN NAN NAN NAN 
SON P18583 3 NAN NAN NAN NAN NAN NAN 22.45 22.14 23.13 23.15 23.16 NAN 
SOX2 P48431 12 28.02 25.90 28.28 26.29 25.60 26.22 22.65 23.34 23.11 24.85 24.13 23.67 
SPATA5 Q8NB90 6 NAN NAN 23.44 23.89 NAN NAN 23.58 23.52 23.58 NAN NAN NAN 
SPC18 P67812 6 24.93 26.04 25.30 25.87 25.97 25.76 23.67 24.90 24.83 24.62 NAN 24.78 
SPCS3 P61009 3 23.31 24.26 23.76 25.28 25.11 24.28 NAN NAN NAN 23.92 NAN 24.84 
SPFH1 O75477 17 21.84 25.20 NAN 21.91 NAN 20.85 28.49 26.07 28.21 26.75 26.62 25.74 
SPNS1 Q9H2V7 5 26.74 26.65 26.95 25.23 25.15 24.93 NAN NAN NAN 22.12 22.23 22.60 
SPTLC1 O15269 14 25.93 25.66 25.98 26.54 26.40 26.33 24.52 23.98 24.16 24.45 24.62 25.07 
SQRDL Q9Y6N5 12 24.41 24.00 25.02 25.75 25.92 25.81 NAN 23.67 25.00 24.53 NAN 24.65 
SQSTM1 Q13501 7 23.05 23.78 23.54 23.60 23.34 23.41 23.57 23.36 23.41 NAN 23.56 23.68 
SRBD1 Q8N5C6 3 NAN NAN NAN NAN NAN NAN 24.29 23.22 23.66 NAN NAN NAN 
SREK1 Q8WXA9 6 NAN NAN NAN NAN NAN NAN 24.25 23.22 24.03 23.26 23.26 NAN 
SRI P30626 2 NAN NAN NAN NAN 23.00 22.68 NAN NAN NAN NAN NAN NAN 
SRM P19623 8 24.37 25.35 25.16 26.65 26.80 26.73 NAN 23.03 23.39 23.72 24.27 24.40 
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SRP14 P37108 9 25.21 25.21 25.61 25.96 26.15 25.88 27.66 28.20 28.44 26.69 26.69 26.87 
SRP19 P09132 8 NAN NAN NAN NAN NAN NAN 25.30 25.84 26.11 25.32 25.36 25.37 
SRP54 P61011 23 25.93 25.19 24.89 25.24 25.68 25.32 27.22 28.01 28.89 26.41 27.19 26.71 
SRP68 Q9UHB9 33 27.17 27.14 25.61 26.37 26.65 26.79 28.64 28.84 29.28 28.62 28.94 28.65 
SRP72 O76094 38 27.07 26.93 23.23 26.64 26.99 26.47 29.26 29.20 29.32 28.64 29.05 28.84 
SRP9 P49458 4 NAN NAN NAN NAN 24.80 24.63 25.28 24.94 24.87 24.64 24.81 24.58 
SRPK1 Q96SB4 18 NAN NAN NAN NAN NAN NAN 29.01 28.17 27.32 26.91 28.13 26.24 
SRPK2 P78362 12 NAN NAN NAN NAN NAN NAN 26.44 26.33 26.67 25.87 26.04 24.38 
SRPRB Q9Y5M8 20 26.97 26.92 27.28 28.29 28.19 28.06 27.11 26.98 27.09 27.43 27.35 27.64 
SRRM1 Q8IYB3 16 NAN 24.96 NAN NAN 22.98 NAN 26.59 26.34 26.90 26.29 24.91 24.57 
SRRM2 Q9UQ35 9 NAN NAN NAN NAN 22.32 22.55 23.93 23.97 23.71 23.58 23.69 23.63 
SRSF1 Q07955 14 NAN 24.78 NAN NAN 23.41 22.62 27.90 27.20 27.11 27.45 27.37 26.38 
SRSF2 Q01130 7 NAN 24.46 NAN NAN 23.27 22.74 26.59 25.73 26.24 26.50 26.29 25.38 
SRSF5 Q13243 6 NAN NAN NAN NAN NAN NAN 26.40 25.32 26.21 25.13 25.89 24.98 
SRSF6 Q13247 9 NAN 23.57 NAN NAN 23.37 NAN 26.94 26.09 26.28 27.16 26.95 25.85 
SRSF7 Q16629 8 NAN 25.90 NAN NAN 23.74 23.59 26.75 25.33 25.63 26.86 26.13 25.51 
SRSF9 Q13242 9 NAN NAN NAN NAN NAN NAN 26.22 25.42 26.18 25.85 26.05 25.35 
SSBP1 Q04837 6 25.01 24.40 26.09 26.59 25.88 26.28 23.48 24.48 23.66 24.93 24.36 25.01 
SSR1 P43307 4 27.70 26.80 28.37 28.60 27.96 28.24 26.80 27.24 27.18 27.58 27.03 27.06 
SSR3 Q9UNL2 3 27.03 26.59 27.48 26.97 27.16 26.66 26.47 27.10 26.70 26.65 26.99 27.07 
SSR4 P51571 6 28.13 27.24 28.56 29.13 28.55 28.80 27.52 28.16 27.33 28.27 27.58 28.04 
SSRP1 Q08945 25 24.27 26.02 24.59 25.45 24.95 25.00 28.40 27.20 27.64 27.44 27.96 27.46 
ST13 P50502 4 NAN 24.27 NAN NAN 25.30 25.58 NAN NAN NAN NAN NAN NAN 
STAG2 Q8N3U4 6 22.72 23.37 22.90 23.34 23.12 22.78 NAN NAN NAN NAN NAN NAN 
STAT3 P40763 21 26.54 27.84 27.06 26.38 26.27 26.70 24.34 25.18 25.42 24.35 24.37 24.52 
STAU1 O95793 26 NAN 25.14 23.11 23.82 24.88 23.54 28.95 27.72 28.28 27.70 28.50 27.69 
STAU2 Q9NUL3 8 NAN NAN NAN NAN NAN NAN 23.59 22.81 23.16 22.90 23.29 NAN 
STIP1 P31948 22 24.07 25.64 24.20 27.64 27.86 28.56 19.26 22.99 22.42 22.97 23.43 23.89 
STK24 Q9Y6E0 6 NAN NAN 23.15 23.38 24.06 23.64 23.09 23.65 NAN NAN NAN NAN 
STK38L Q9Y2H1 16 25.47 27.34 25.23 27.25 27.57 27.65 NAN NAN NAN 24.66 24.34 24.37 
STK39 Q9UEW8 7 NAN 25.34 NAN NAN 23.58 NAN NAN NAN NAN NAN NAN NAN 
STOM P27105 15 29.29 29.58 29.63 26.96 26.95 26.67 29.78 29.06 29.55 29.46 29.42 29.56 
STP1 P50225 6 NAN NAN NAN NAN NAN NAN 24.45 24.30 24.31 24.01 24.08 NAN 
STRAP Q9Y3F4 20 25.78 26.34 26.25 26.74 27.15 27.06 26.19 26.18 26.04 26.23 26.27 26.57 
STRIP1 Q5VSL9 5 25.03 24.82 24.90 23.53 23.43 23.54 NAN 23.92 23.12 23.68 NAN 24.33 
STRN O43815 4 23.77 23.05 24.06 23.76 23.65 23.29 NAN NAN NAN NAN NAN NAN 
STUB1 Q9UNE7 5 22.85 23.36 NAN 24.13 23.59 24.38 NAN NAN NAN NAN NAN NAN 
STX12 Q86Y82 5 22.68 23.78 23.21 25.47 25.25 24.97 22.85 22.96 22.83 23.67 23.08 23.32 
STX16 O14662 2 NAN NAN NAN NAN 22.76 23.09 NAN NAN NAN NAN 22.19 22.39 
STX7 O15400 4 NAN NAN NAN NAN 24.37 23.90 NAN NAN NAN NAN NAN NAN 
STXBP1 P61764 2 NAN 23.28 NAN NAN NAN 22.16 NAN NAN NAN NAN NAN NAN 
STXBP3 O00186 6 23.48 24.88 22.08 22.98 23.57 23.56 21.94 22.57 22.64 23.22 22.08 23.57 
SUFU Q9UMX1 3 NAN NAN NAN NAN 23.57 23.84 NAN NAN NAN NAN NAN NAN 
SUGP2 Q8IX01 9 NAN NAN NAN NAN NAN NAN 24.64 23.87 24.20 24.11 24.57 24.03 
SUI1 P41567 5 NAN NAN NAN NAN NAN NAN 26.55 26.24 NAN 25.54 25.28 26.16 
SUPT16H Q9Y5B9 34 22.60 26.25 21.92 25.16 24.75 24.25 28.83 27.51 28.40 27.37 27.76 26.94 
SUPT5H O00267 14 23.72 23.41 22.81 26.95 26.15 26.63 25.00 24.47 24.38 24.90 24.78 24.47 
SURF6 O75683 9 NAN NAN NAN NAN NAN NAN 25.53 25.15 25.61 24.71 25.85 25.27 
SYNCRIP O60506 34 NAN NAN NAN NAN NAN NAN 23.00 22.83 22.55 NAN NAN NAN 
TAF9 Q16594 3 NAN NAN NAN NAN 23.15 23.41 NAN NAN NAN NAN NAN NAN 
TAP1 Q03518 9 25.31 25.52 25.21 24.39 24.49 24.37 25.01 23.91 24.47 24.47 24.11 23.70 
TAP2 Q03519 6 25.21 24.82 24.79 24.19 23.95 23.92 24.65 22.80 NAN 22.94 22.93 23.71 
TAPBP O15533 3 NAN NAN NAN NAN 23.62 23.80 NAN NAN NAN NAN NAN NAN 
TARS P26639 8 23.85 24.59 NAN 24.46 24.63 24.64 NAN NAN NAN NAN NAN NAN 
TBC1D15 Q8TC07 7 NAN 23.70 NAN NAN 23.47 23.62 23.27 23.11 NAN NAN NAN NAN 
TBC1D9B Q66K14 4 NAN 24.37 NAN NAN 22.24 NAN NAN NAN NAN NAN NAN NAN 
TBCB Q99426 4 NAN NAN NAN NAN 23.18 22.98 NAN NAN NAN NAN NAN NAN 
TBCD Q9BTW9 5 NAN NAN NAN NAN 22.67 22.45 NAN NAN NAN NAN NAN NAN 
TBK1 Q9UHD2 3 NAN 23.67 NAN NAN 22.24 22.32 NAN NAN NAN NAN NAN NAN 
TBL2 Q9Y4P3 30 25.87 26.51 26.72 27.05 26.93 26.81 29.20 28.44 28.82 29.24 29.27 28.73 
TBL3 Q12788 11 NAN NAN NAN NAN NAN NAN 25.97 24.61 25.34 24.67 25.49 24.59 
TBRG4 Q969Z0 6 NAN 24.67 NAN NAN 23.24 NAN NAN NAN NAN NAN NAN NAN 
TCEB1 Q15369 3 22.71 23.00 22.92 24.32 23.55 24.52 NAN NAN NAN NAN NAN NAN 
TCEB2 Q15370 4 NAN NAN NAN NAN NAN NAN 23.12 23.45 23.38 NAN 23.27 23.11 
TCERG1 O14776 6 NAN 23.56 NAN NAN 24.02 23.98 23.36 NAN 23.15 NAN NAN NAN 
TCF25 Q9BQ70 12 NAN 23.10 NAN NAN 23.37 23.31 24.61 24.52 24.50 24.13 24.00 23.85 
TCIRG1 Q13488 20 22.44 26.28 23.72 NAN 22.26 NAN 26.21 26.95 25.71 27.14 27.30 26.74 
TCP1 P17987 35 30.48 30.39 30.78 30.74 30.95 30.97 28.41 29.51 28.72 29.42 28.98 29.29 
TECR Q9NZ01 11 26.06 25.36 26.44 26.43 26.17 26.32 24.02 24.44 24.33 24.70 23.96 23.99 
TEX10 Q9NXF1 9 NAN NAN NAN NAN NAN NAN 26.45 25.37 26.48 25.57 26.16 25.51 
TFB1M Q8WVM0 6 NAN NAN NAN NAN NAN NAN 25.14 23.51 24.62 23.77 NAN 23.78 
TFG Q92734 8 NAN NAN 24.84 25.77 25.89 25.76 24.96 24.72 24.20 NAN NAN NAN 
TFRC P02786 31 28.03 29.29 28.23 28.88 28.80 28.80 27.16 27.40 26.98 28.12 27.61 28.24 
TGM2 P21980 20 25.01 28.27 26.38 NAN NAN 22.83 28.22 26.48 27.73 26.70 27.72 26.66 
TGOLN2 O43493 4 21.74 NAN 22.27 NAN NAN NAN NAN NAN NAN 22.23 NAN 22.07 
THEX1 Q8IV48 7 NAN NAN NAN NAN NAN NAN 25.26 23.81 24.04 23.89 23.85 23.64 
THUMPD1 Q9NXG2 4 NAN NAN NAN NAN 23.02 23.20 23.09 23.77 23.17 23.60 23.76 24.23 
THY1 P04216 4 27.33 28.07 27.15 26.55 26.70 26.25 29.95 29.88 29.77 30.30 29.90 30.10 
TIAL1 Q01085 4 24.22 23.39 24.23 24.55 24.70 24.65 NAN NAN NAN 23.62 NAN 23.18 
TIMM13 Q9Y5L4 3 NAN NAN NAN NAN 25.11 24.41 NAN NAN NAN NAN NAN NAN 
TIMM23 O14925 4 24.44 NAN 24.64 24.50 24.51 25.10 NAN NAN NAN NAN NAN NAN 
TIMM44 O43615 8 27.40 27.66 27.74 28.18 28.67 28.67 24.19 26.98 25.82 26.58 26.67 27.76 
TIMM50 Q3ZCQ8 10 26.56 25.95 26.90 27.39 27.38 27.77 24.75 24.63 24.45 25.36 24.80 25.50 
TIPRL O75663 6 24.25 23.20 25.45 24.71 24.24 24.59 NAN NAN NAN NAN NAN NAN 
TJP2 Q9UDY2 8 NAN NAN NAN NAN NAN NAN 23.85 23.97 23.84 NAN NAN NAN 
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TKT Q16832 20 26.05 27.17 26.53 27.87 27.91 27.67 25.17 26.42 26.35 26.84 26.81 27.59 
TLDC1 Q6P9B6 5 23.37 24.79 24.27 24.28 24.50 24.46 25.08 24.97 NAN 23.91 24.03 25.19 
TM9SF1 O15321 4 23.40 23.36 24.39 24.55 23.60 24.12 NAN NAN NAN NAN NAN NAN 
TM9SF2 Q99805 7 25.02 24.79 25.46 26.02 24.83 25.34 NAN NAN NAN NAN NAN NAN 
TM9SF4 Q92544 5 23.92 23.31 24.09 25.43 24.72 25.06 NAN NAN NAN NAN NAN NAN 
TMA16 Q96EY4 3 NAN NAN NAN NAN NAN NAN 24.54 23.81 24.76 NAN NAN NAN 
TMBIM1 Q969X1 2 NAN 21.86 NAN NAN NAN 23.13 NAN NAN NAN NAN NAN NAN 
TMCO1 Q9UM00 3 26.45 25.40 26.95 25.85 25.25 25.67 25.26 24.67 25.47 25.06 24.87 25.04 
TMED4 Q7Z7H5 6 23.79 23.27 24.21 24.61 24.07 24.06 NAN NAN NAN NAN NAN NAN 
TMED5 Q9Y3A6 3 NAN 24.49 NAN NAN 22.35 22.55 NAN NAN NAN NAN NAN NAN 
TMED7 Q9Y3B3 8 26.41 25.43 27.06 27.48 27.05 27.20 25.04 25.13 24.58 26.17 25.61 26.16 
TMEM113 Q6UXN9 3 NAN NAN NAN NAN NAN NAN 22.91 23.30 23.26 NAN NAN NAN 
TMEM147 Q9BVK8 2 NAN 22.09 NAN NAN 22.75 NAN NAN NAN NAN NAN NAN NAN 
TMEM165 Q9HC07 6 25.38 24.68 25.70 26.62 25.83 26.13 23.41 23.51 24.05 23.31 24.16 23.31 
TMEM16K Q9NW15 7 23.20 23.80 23.53 NAN 23.05 NAN NAN NAN NAN NAN NAN NAN 
TMEM214 Q6NUQ4 9 NAN 23.50 NAN NAN 23.95 NAN 23.79 24.18 24.07 24.31 24.13 NAN 
TMEM259 Q4ZIN3 3 NAN 21.98 NAN NAN NAN 22.45 NAN NAN NAN NAN NAN NAN 
TMEM33 P57088 10 27.08 27.17 27.24 27.45 27.27 27.46 25.96 26.23 25.78 25.85 25.68 26.17 
TMEM43 Q9BTV4 29 28.28 29.36 28.62 26.38 25.92 26.37 30.49 30.20 30.35 30.10 30.06 30.16 
TMPO P42166 8 23.80 24.30 24.58 25.76 25.08 24.67 24.08 24.50 25.23 24.87 24.79 24.47 
TMTC3 Q6ZXV5 7 24.71 24.50 25.01 24.23 24.25 24.44 NAN NAN NAN NAN NAN NAN 
TMX1 Q9H3N1 7 25.13 24.82 25.76 25.50 25.57 25.58 23.32 24.11 23.85 24.60 24.81 25.04 
TMX2 Q9Y320 3 24.28 24.52 25.15 21.87 21.67 21.98 23.57 22.96 23.36 22.48 22.67 22.14 
TMX3 Q96JJ7 19 27.90 26.79 28.53 28.82 28.63 28.86 24.54 25.73 25.55 26.71 25.85 26.19 
TMX4 Q9H1E5 4 23.86 NAN 25.08 24.78 24.81 24.53 NAN NAN NAN 23.63 NAN 23.98 
TNPO2 O14787 17 NAN 26.42 NAN NAN 22.90 24.87 NAN NAN NAN NAN NAN NAN 
TNPO3 Q9Y5L0 7 23.15 26.43 NAN 22.32 22.77 22.96 NAN NAN NAN 21.78 21.57 21.54 
TOE1 Q96GM8 4 NAN NAN NAN NAN NAN NAN 25.32 NAN 24.21 23.31 23.79 NAN 
TOLLIP Q9H0E2 3 23.61 24.22 23.74 23.73 23.59 23.70 24.71 23.55 23.99 24.16 25.10 23.90 
TOM1 O60784 7 NAN NAN 23.73 22.77 NAN NAN 24.00 23.87 24.42 23.82 24.42 23.92 
TOM1L2 Q6ZVM7 7 NAN NAN NAN NAN NAN NAN 24.57 23.98 25.30 23.70 25.45 24.29 
TOMM22 Q9NS69 6 23.89 25.42 24.59 25.46 24.82 24.92 24.97 25.92 NAN 24.07 24.92 24.76 
TOMM40 O96008 13 25.81 26.73 26.07 25.81 25.41 25.53 26.93 26.94 26.79 25.66 26.55 26.52 
TOMM70A O94826 12 23.33 26.26 23.54 27.08 26.63 26.81 23.78 23.90 23.73 24.41 24.08 24.72 
TOP2A P11388 31 NAN NAN NAN NAN NAN NAN 28.08 25.56 26.25 25.63 26.11 25.11 
TOR1A O14656 5 23.22 23.30 25.12 23.74 23.76 23.83 NAN 22.06 21.97 23.16 22.29 23.22 
TOR1AIP1 Q5JTV8 9 24.39 24.45 24.60 25.67 25.10 25.64 23.09 NAN 24.08 24.51 24.17 24.38 
TOR1AIP2 Q8NFQ8 3 NAN 23.31 NAN NAN 24.03 23.69 NAN NAN NAN 21.71 22.85 22.60 
TP53 P04637 5 26.32 24.58 26.88 25.31 24.08 24.51 NAN NAN NAN NAN NAN NAN 
TPM1 P09493 41 NAN NAN NAN NAN NAN NAN 24.11 23.73 24.27 23.82 23.92 23.71 
TPM1 P09493 43 NAN NAN NAN NAN NAN NAN 24.71 NAN 24.64 28.63 27.90 28.92 
TPM2 P07951 50 NAN NAN NAN NAN NAN NAN NAN NAN NAN 24.48 NAN 25.58 
TPP1 O14773 7 25.94 26.39 26.60 27.62 27.24 27.39 25.27 25.81 25.28 26.15 25.69 26.17 
TPP2 P29144 13 24.69 25.12 24.65 25.06 24.78 24.51 NAN NAN NAN 24.06 24.49 24.47 
TRA2B P62995 8 NAN NAN NAN NAN NAN NAN 24.11 23.86 24.19 24.63 24.42 23.69 
TRAP1 Q12931 17 23.72 25.14 23.57 26.86 26.50 26.63 NAN 23.03 23.30 NAN 22.62 23.11 
TRAPPC3 O43617 4 NAN NAN 22.79 22.98 23.24 23.29 NAN 22.23 22.61 NAN NAN NAN 
TRAPPC5 Q8IUR0 4 NAN 23.32 NAN NAN 23.25 23.43 NAN NAN NAN NAN NAN NAN 
TRIM22 Q8IYM9 6 NAN NAN NAN NAN NAN NAN 23.42 23.84 24.40 NAN 22.49 22.21 
TRIM28 Q13263 37 27.63 28.35 28.01 28.63 28.34 28.55 27.61 27.60 27.46 28.12 27.70 27.84 
TRIM32 Q13049 7 24.00 24.91 23.80 24.06 24.19 24.04 25.12 NAN 24.47 NAN NAN NAN 
TRIM56 Q9BRZ2 14 NAN NAN NAN NAN NAN NAN 28.34 26.95 27.45 26.01 27.06 26.08 
TRIO O75962 12 NAN 24.61 NAN NAN 23.31 23.92 24.33 23.98 24.02 NAN NAN NAN 
TRIP12 Q14669 19 25.76 26.25 23.69 24.77 25.04 24.65 26.63 24.88 25.84 25.27 25.66 25.61 
TRIP13 Q15645 6 NAN 23.97 NAN NAN 23.97 24.43 23.58 23.43 23.71 NAN 23.66 23.72 
TRIP4 Q15650 6 NAN NAN NAN NAN NAN NAN 24.53 22.73 24.30 23.68 23.83 23.71 
TRMT10C Q7L0Y3 22 28.06 26.87 25.99 27.48 27.42 27.64 27.99 27.19 27.86 26.48 27.10 26.70 
TRMT112 Q9UI30 3 NAN 23.98 NAN NAN 23.98 24.04 NAN NAN NAN NAN NAN NAN 
TRMT1L Q7Z2T5 6 NAN NAN NAN NAN NAN NAN 25.06 23.45 24.79 23.47 22.90 22.86 
TROVE2 P10155 12 25.00 24.75 24.97 24.56 24.72 24.89 25.65 25.70 26.07 25.10 25.67 25.60 
TRPM2 O94759 33 NAN NAN NAN NAN 23.21 22.18 NAN NAN NAN NAN NAN NAN 
TRPT1 Q86TN4 2 NAN NAN NAN NAN NAN NAN 22.65 22.84 23.16 NAN NAN NAN 
TSG101 Q99816 7 NAN NAN NAN NAN 23.94 23.97 23.54 24.36 23.67 23.68 23.96 24.03 
TSPYL1 Q9H0U9 4 NAN NAN NAN NAN NAN NAN 23.18 22.22 22.42 NAN NAN NAN 
TSR1 Q2NL82 28 22.45 25.57 24.03 24.07 24.95 24.90 28.87 28.30 28.79 27.81 28.47 27.67 
TTC37 Q6PGP7 52 22.72 24.97 21.78 NAN 24.40 22.53 28.95 29.23 28.90 27.91 28.53 28.14 
TTLL12 Q14166 9 NAN 25.40 23.51 24.51 24.56 24.62 NAN NAN NAN 23.64 NAN 23.88 
TTN Q8WZ42 4 23.68 NAN 23.09 NAN NAN NAN NAN NAN NAN NAN NAN NAN 
TUBA4A P68366 32 26.26 26.52 26.46 26.52 26.31 26.52 24.31 24.07 25.12 24.98 25.12 24.93 
TUBB8 Q3ZCM7 12 30.80 31.92 30.36 29.74 29.77 29.97 29.28 29.72 29.65 27.73 27.44 28.75 
TUBG2 Q9NRH3 6 23.87 24.21 24.04 24.39 25.05 24.86 24.65 24.04 23.63 NAN NAN NAN 
TUFM P49411 28 28.33 28.77 28.85 29.81 29.55 29.76 28.13 28.15 27.98 28.78 28.11 28.28 
TXLNA P40222 9 23.53 24.22 24.10 24.30 24.41 24.48 23.82 24.22 23.75 NAN NAN NAN 
TXNDC12 O95881 2 22.39 NAN 22.80 23.63 22.74 23.15 NAN NAN NAN NAN NAN NAN 
TXNDC9 O14530 2 NAN 22.40 NAN NAN 23.45 23.20 NAN NAN NAN NAN NAN NAN 
TXNL1 O43396 12 24.73 25.41 24.17 26.77 26.87 26.85 24.48 24.92 24.58 24.86 25.28 25.35 
U2AF1 Q01081 15 25.48 27.53 26.62 26.66 26.79 26.35 29.68 28.78 29.40 28.70 29.34 28.69 
U2AF2 P26368 22 23.69 28.69 25.39 28.12 28.41 27.52 31.57 30.38 31.30 29.67 30.88 30.26 
U2SURP O15042 8 NAN NAN NAN NAN NAN NAN 24.81 24.75 24.58 24.67 24.75 24.35 
UACA Q9BZF9 11 NAN NAN NAN NAN NAN NAN 25.25 24.79 25.21 23.52 24.98 24.29 
UAP1 Q16222 5 22.90 25.33 23.25 23.52 24.45 23.64 22.44 NAN 23.10 NAN 22.73 23.56 
UBA2 Q9UBT2 2 NAN NAN NAN NAN 22.91 23.03 NAN NAN NAN NAN NAN NAN 
UBAP2L Q14157 10 24.48 24.60 24.30 24.48 24.30 23.73 25.47 25.20 24.76 25.27 25.48 25.45 
UBE2D2 P62837 3 24.48 25.31 NAN 24.66 24.63 24.85 24.02 23.14 NAN NAN NAN NAN 
UBE2I P63279 3 NAN 23.36 NAN NAN 23.47 23.79 NAN NAN NAN NAN NAN NAN 
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UBE2N P61088 4 NAN 23.06 NAN NAN 23.19 22.86 NAN NAN NAN NAN NAN NAN 
UBE3A Q05086 4 NAN NAN NAN NAN 23.46 24.02 NAN NAN NAN NAN NAN NAN 
UBE3C Q15386 12 23.59 25.79 24.29 24.30 24.14 24.43 22.26 22.71 22.78 23.91 22.80 NAN 
UBTF P17480 12 NAN 22.72 NAN NAN 23.55 NAN 26.86 25.54 25.96 25.55 26.07 24.80 
UBXN4 Q92575 4 NAN 24.43 NAN NAN 24.98 NAN NAN NAN NAN 23.97 NAN 24.16 
UCHL1 P09936 4 NAN NAN NAN NAN 24.52 25.36 NAN 24.45 24.22 NAN 24.69 24.62 
UCK2 Q9BZX2 5 23.08 25.39 NAN 24.27 24.23 25.00 24.24 24.13 NAN NAN NAN NAN 
UFD1L Q92890 4 22.47 22.51 NAN 25.38 24.71 25.36 NAN NAN NAN NAN NAN NAN 
UFL1 O94874 27 25.41 27.07 24.20 27.06 27.00 27.06 27.45 28.04 28.50 27.76 27.59 28.14 
UFSP2 Q9NUQ7 5 NAN 23.62 NAN NAN 23.94 24.18 NAN NAN NAN NAN NAN NAN 
UGGT1 Q9NYU2 74 29.52 29.92 28.69 30.41 30.28 30.29 28.81 29.06 28.63 29.51 29.21 29.81 
UGP2 Q16851 8 24.99 25.05 24.56 25.26 25.97 25.66 24.28 24.41 24.68 24.50 24.73 25.59 
UHRF1 Q96T88 3 NAN NAN NAN NAN NAN NAN 22.68 22.44 22.18 22.32 22.48 22.41 
UMPS P11172 10 23.81 26.42 NAN 24.02 23.98 24.69 23.73 23.98 23.87 23.85 NAN 24.80 
UPF1 Q92900 34 25.76 26.91 25.71 26.69 27.00 26.93 26.62 26.60 26.27 26.92 26.84 27.04 
UQCRFS1 P47985 7 25.49 23.94 25.03 25.77 25.56 25.45 24.28 25.11 24.98 24.99 23.88 25.52 
UQCRQ O14949 3 23.48 21.87 23.75 23.84 23.44 23.42 NAN NAN NAN NAN NAN NAN 
URB1 O60287 34 NAN NAN NAN NAN NAN NAN 27.80 26.32 27.99 25.88 26.98 25.34 
URB2 Q14146 18 NAN NAN NAN NAN NAN NAN 27.63 26.05 26.86 25.58 26.67 25.59 
UROD P06132 14 23.40 23.88 25.22 27.23 27.24 27.12 NAN NAN NAN 23.69 NAN 24.36 
USMG5 Q96IX5 3 NAN NAN NAN NAN 23.91 23.98 NAN NAN NAN NAN NAN NAN 
USP11 P51784 11 NAN NAN 23.93 25.56 25.22 26.04 NAN NAN NAN 23.25 NAN 22.39 
USP14 P54578 5 NAN 24.48 NAN NAN 24.52 24.34 NAN NAN NAN NAN NAN NAN 
USP24 Q9UPU5 2 NAN 22.17 NAN NAN 22.83 NAN NAN NAN NAN NAN NAN NAN 
USP47 Q96K76 6 23.22 23.12 NAN 22.79 23.02 23.38 NAN NAN NAN NAN NAN NAN 
USP5 P45974 22 24.57 26.21 25.05 26.10 26.34 26.56 23.07 24.07 23.81 24.56 24.42 25.32 
UTP18 Q9Y5J1 4 NAN NAN NAN NAN NAN NAN 23.73 22.93 23.60 NAN NAN NAN 
UTP20 O75691 29 NAN NAN NAN NAN NAN NAN 27.62 25.73 26.55 24.59 25.77 23.11 
UTP23 Q9BRU9 2 NAN NAN NAN NAN NAN NAN 23.97 NAN 23.79 NAN NAN NAN 
UTP3 Q9NQZ2 7 23.45 25.84 23.11 22.57 22.81 22.78 25.64 24.38 24.17 22.61 23.65 23.13 
VAC14 Q08AM6 6 25.16 24.51 25.62 24.04 23.56 23.44 NAN NAN NAN NAN NAN NAN 
VAMP2 P63027 3 NAN 23.44 NAN NAN 24.48 24.10 NAN NAN NAN NAN NAN NAN 
VAT1 P54219 15 25.18 26.71 25.25 26.36 26.81 26.87 22.89 25.24 25.35 25.40 25.19 26.05 
VBP1 P61758 2 NAN NAN NAN NAN NAN NAN NAN 22.94 23.30 NAN NAN NAN 
VDAC1 P21796 22 28.32 29.57 28.71 29.41 29.27 29.07 29.40 29.31 29.17 29.74 29.49 29.78 
VDAC2 P45880 17 28.32 28.99 28.68 28.56 28.25 28.23 29.03 28.96 28.68 29.41 29.39 29.32 
VDAC3 Q9Y277 13 25.93 27.25 26.52 26.65 26.34 26.49 27.65 27.34 27.09 27.55 27.56 27.69 
VPS16 Q9H269 8 25.66 25.26 24.00 24.81 24.56 24.77 NAN NAN NAN NAN NAN NAN 
VPS18 Q9P253 12 24.71 25.36 24.73 25.86 25.19 24.90 23.43 23.08 NAN 23.99 23.83 23.54 
VPS26A O75436 7 23.83 NAN NAN 24.73 24.60 24.56 NAN NAN NAN 23.80 24.09 23.93 
VPS29 Q9UBQ0 5 NAN NAN NAN NAN 24.56 24.15 NAN NAN NAN NAN NAN NAN 
VPS33A Q96AX1 10 25.57 25.59 25.33 23.98 23.93 24.13 22.75 22.55 23.18 NAN NAN NAN 
VPS41 P49754 5 24.11 NAN 24.02 23.36 23.45 23.33 NAN NAN NAN NAN NAN NAN 
VPS4B O75351 5 23.27 24.69 23.85 24.22 24.27 24.13 23.45 NAN 23.49 23.34 23.97 NAN 
VPS53 Q5VIR6 3 22.98 24.41 NAN 22.91 22.57 22.42 NAN NAN NAN NAN NAN NAN 
VTA1 Q9NP79 2 NAN NAN NAN NAN 24.29 24.02 23.98 23.87 23.65 23.98 24.40 24.91 
VTI1B Q9UEU0 4 NAN NAN NAN NAN 22.61 22.53 22.30 22.79 21.64 NAN NAN NAN 
WARS P23381 21 27.25 26.56 27.04 27.15 27.81 27.54 24.62 25.65 26.06 25.80 26.31 26.26 
WASH4P A8MWX3 2 NAN NAN NAN NAN 23.70 23.19 NAN NAN NAN NAN NAN NAN 
WDR12 Q9GZL7 6 NAN 23.77 NAN NAN NAN 23.26 24.77 23.36 24.78 NAN 23.52 23.46 
WDR18 Q9BV38 6 NAN NAN NAN NAN NAN NAN 25.27 23.57 24.50 23.08 23.73 23.49 
WDR3 Q9UNX4 14 NAN NAN NAN NAN NAN NAN 25.77 24.60 25.52 25.17 24.96 24.74 
WDR36 Q8NI36 11 NAN 23.33 NAN NAN NAN 23.43 25.66 23.97 24.73 24.14 25.31 NAN 
WDR47 O94967 2 NAN NAN NAN NAN 22.60 22.43 NAN NAN NAN NAN NAN NAN 
WDR6 Q9NNW5 4 NAN NAN NAN NAN 23.56 23.41 23.32 23.32 23.95 NAN NAN NAN 
WDR61 Q9GZS3 12 25.75 25.72 26.11 26.12 25.95 25.72 26.55 27.00 26.73 26.50 26.89 27.00 
WFS1 O76024 3 NAN NAN 22.76 22.66 22.52 22.69 NAN NAN NAN NAN NAN NAN 
WRN Q14191 2 NAN NAN NAN NAN NAN NAN 21.52 20.86 21.37 NAN NAN NAN 
WRNIP1 Q96S55 6 23.78 23.30 23.46 24.13 23.68 23.62 NAN NAN NAN NAN NAN NAN 
XPO1 O14980 35 26.89 28.01 27.32 27.75 27.72 27.98 26.02 26.39 26.90 26.35 26.44 26.49 
XPO5 Q9HAV4 21 24.47 27.07 25.37 24.93 24.70 25.58 NAN NAN NAN 22.48 22.91 22.68 
XPOT O43592 16 25.91 27.25 25.65 25.96 26.23 26.35 24.42 23.84 24.81 23.97 24.04 24.45 
XRCC5 P13010 44 29.83 29.95 28.10 29.48 29.44 29.30 27.52 27.90 28.14 28.24 27.73 28.00 
XRCC6 P12956 36 29.44 29.52 27.57 29.19 29.20 29.11 27.46 27.49 28.22 28.00 27.58 27.98 
XRN2 Q9H0D6 11 24.68 24.00 24.11 25.00 25.10 25.05 24.71 24.40 24.67 25.23 25.44 25.04 
YARS P54577 15 23.97 26.75 23.71 23.96 24.95 24.28 22.73 NAN 23.95 23.51 24.48 24.72 
YES1 P07947 8 23.96 25.12 23.35 24.15 NAN 24.30 24.16 NAN 23.81 NAN NAN NAN 
YIF1A O95070 4 NAN 24.30 NAN NAN NAN 24.16 NAN NAN NAN NAN NAN NAN 
YIF1B Q5BJH7 3 NAN NAN NAN NAN 23.63 23.76 NAN NAN NAN NAN NAN NAN 
YME1L1 Q96TA2 12 23.96 25.20 24.49 25.75 25.73 25.56 25.44 23.58 24.00 NAN 24.70 24.36 
YTHDC2 Q9H6S0 11 NAN NAN NAN NAN NAN NAN 26.67 24.75 25.49 23.44 24.76 22.69 
YTHDF1 Q9BYJ9 5 NAN NAN NAN NAN NAN NAN 24.08 NAN 22.90 NAN 22.82 22.75 
YTHDF2 Q9Y5A9 7 23.00 23.42 NAN 23.31 23.94 23.32 24.03 23.63 23.74 23.76 24.36 23.56 
YTHDF3 Q7Z739 5 NAN NAN NAN NAN NAN NAN 24.05 23.48 23.60 23.29 23.58 23.48 
ZC3H18 Q86VM9 3 NAN NAN NAN NAN NAN NAN 22.20 NAN 21.82 NAN NAN NAN 
ZC3H4 Q9UPT8 4 NAN NAN NAN NAN NAN NAN 24.07 23.03 23.17 NAN NAN NAN 
ZC3H7A Q8IWR0 11 NAN NAN NAN NAN NAN NAN 24.87 24.52 24.74 24.45 24.56 24.27 
ZC3H7B Q9UGR2 10 NAN NAN NAN NAN NAN NAN 24.18 24.28 24.14 NAN 23.98 23.86 
ZC3HAV1 Q7Z2W4 29 22.94 25.22 22.91 22.95 23.84 24.33 27.94 27.15 27.19 27.37 27.66 26.59 
ZFPL1 O95159 2 NAN NAN NAN NAN 22.94 23.03 NAN NAN NAN NAN NAN NAN 
ZFR Q96KR1 15 NAN 23.94 NAN NAN 24.86 24.15 26.46 25.60 26.30 25.48 26.30 25.35 
ZMPSTE24 O75844 8 23.81 24.97 22.80 24.86 24.89 24.69 NAN NAN NAN 23.51 22.54 23.62 
ZNF622 Q969S3 23 NAN NAN NAN NAN NAN NAN 27.75 25.72 27.76 26.76 25.96 26.26 
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